

**MINUTES OF 349TH MEETING OF REGISTRATION BOARD
HELD ON 14TH JULY, 2025**

Item No.	Detail of Item	Page No
I.	Division of Pharmaceutical Evaluation & Registration	
	Miscellaneous -----	03 – 10
	RRR Section -----	11 – 45
	Import & Vet-II Section/Human Import -----	45 – 55
	Applications submitted on e-App (PE&R) -----	56 – 126
II.	Division of Biological Evaluation & Research -----	127 – 465
III.	Additional/Supplementary Minutes:	
	Applications submitted on e-App (PE&R) -----	466 – 473
	Import & Vet-II Section/Human Import -----	474 – 475
	Export Facilitation Desk -----	475
	Division of Biological Evaluation & Research -----	476 – 543

DRUG REGULATORY AUTHORITY OF PAKISTAN
PRIME MINISTER'S NATIONAL HEALTH COMPLEX,
CHAK SHEHZAD, PARK ROAD,
-----ISLAMABAD -----

349th meeting of Registration Board was held on 14th July, 2025 in the Committee Room, Drug Regulatory Authority of Pakistan, Prime Minister's National Health Complex Park Road, Chak Shehzad, Islamabad.

The meeting was chaired by Mr. Sayyad Hussain Khan, Director, Pharmaceutical Evaluation & Registration Division, DRAP / Chairman, Registration Board, DRAP. The meeting started with recitation of the Holy Verses.

The meeting was attended by the following:

1.	Malik Muhammad Saleem, Ex Deputy Manager Production. Rhone Poulenc Rorer Pakistan. Rawalpindi.	Member (Online)
2.	Dr. Syed Asad Ali Shah, Principal Animal Husbandry In-Service Training Institute, Peshawar.	Member
3.	Dr. Tehseen Fatima, Dow College of Biotechnology, Dow University of Health Sciences, Karachi.	Member (Online)
4.	Mr. Iftikhar Ahmed Choudhury, Ex-Chief Pharmacist, Hospital Pharmacist, Government of Punjab, Lahore.	Member
5.	Mr. Syed Adnan Rizvi, Director, Drugs Testing Laboratory, Govt. of Sindh, Karachi.	Member (Online)
6.	Dr. Ali Jan, Director, Drugs Testing Laboratory, Govt. of Baluchistan Quetta.	Member
7.	Mr. Asad Abrar, Director DTL, Govt. of Punjab, Bahawalpur.	Member (Online)
8.	Mr. Muhammad Aslam, Additional Draftsman, Law & Justice Division, Islamabad.	Member
9.	Mr. Ghulam Mujtaba, Deputy Director, Representative of IPO, Islamabad.	Member
10.	Ch. Zeeshan Nazir Bajar, Director, Quality Assurance & Lab Testing Division, DRAP.	Member
11.	Mr. Muneeb Ahmed Cheema, Representative of Biological Evaluation & Research Division, DRAP.	Member
12.	Miss Sadaf Ahmad, Deputy Director, Representative of MD&MC Division, DRAP.	Member
13.	Hafiz M. Ali Tayyab, Additional Director, Pharmaceutical Evaluation & Registration Division, DRAP.	Member/ Secretary

Mr. Nadeem Alamgir and Mr. Saqib Zia (Pharma Bureau), Mr. Arif Bilal and Dr. Laila Mughal (PPMA) and Mr. Shah Nawaz (PCDA) attended the meeting as observers.

Item No. I: Division of Pharmaceutical Evaluation & Registration**Miscellaneous****Case No. 01: Registration of Sildenafil, Tadalafil & Vardenafil Tablets**

Registration Board in its 345th and 347th meeting approved various products containing Sildenafil, Tadalafil & Vardenafil Tablets. The Board in its 347th meeting direction to conduct product specific inception of all drug products containing Sildenafil, Tadalafil & Vardenafil in Tablet dosage, which are approved in said meetings, before issuance of registration letter by the panel constituted by Chairman Registration Board.

In light of above decision of the Board, panel has submitted product specific inspection reports which are being presented for consideration of the Registration Board.

Proceeding of 348th Meeting:

Following report has been Presented before Registration Board:

Status of Product Specific Inspections of Sildenafil, Tadalafil, Vardenafil for the Registration Board.			
I	II	III	IV
Names of firms whose data has been verified against the data submitted to DRAP.	Names of firms that performed stability testing but whose data could not be verified due to changes in area, retention time of chromatograms etc.	Names of the firms having data other than the data submitted to DRAP.	Names of firms whose data could not be verified due to malfunctioning/ out-of-order HPLC system
M/s Crystolite Pharmaceuticals Plot # 1 & 2 Street S-2 National Industrial Zone, Rawat (000778).	M/s Focus & Rulz Pharmaceuticals (Pvt.) Ltd., Plot No. 44, industrial triangle, Kahuta Road, Islamabad (000628).	M/s Shaigan Pharmaceuticals (Pvt.) Ltd., 14-km Adyala Road, Post Office Dahgal, Rawalpindi (000333).	Pacific Pharmaceutical Ltd 30 km Multan Road Lahore (000295)
M/s Solaris Life Sciences (Pvt.) Ltd., Plot No. 08, Street No. S-1, RCCI, Industrial Estate, Rawat (000992).	M/s NovaMed pharmaceuticals (Pvt.) Ltd 28-KM Ferozepur Road Lahore (000590)	M/s Wimits Pharmaceuticals Pvt. Limited, Plot No. 129, Sunder Industrial Estate Raiwind Road, Lahore (000789) .	M/s Fynk Pharmaceuticals, 19-km G. T. Road, kalaShah Kaku, Lahore (000494) .
M/s Gray's Pharmaceuticals, Plot No.2, Street No. N-3, National Industrial Zone, Rawat (000518).	M/s Bio-Labs(Pvt.) Ltd Plot 145, Industrial Triangle, Kahuta Road (000296)	M/s Macter International Ltd., F-216, S.I.T.E., Karachi (000141).	M/s Vision Pharmaceuticals Pvt. Ltd Plot#22-23, Industrial Triangle, Kahuta Road, Islamabad. (000517)
M/s Highnoon Laboratories Ltd., 17.5 Km Multan Road, Lahore (000155).	M/s Quaper (Pvt.) Ltd., 26-A, Small Industrial Estate, Lahore Road, Sargodha (000609).		M/s Caliph Pharmaceuticals Plot 17, Special Industrial Zone Risalpur, KPK (000748)

	Data of one Strength of Sildenafil tablet i.e. 50mg, was not verified.		
M/s Quaper (Pvt.) Ltd., 26-A, Small Industrial Estate, Lahore Road, Sargodha (000609). Data of one Strength of Sildenafil tablet i.e. 100mg, was verified.	M/s Medizan Laboratories (Pvt.) Ltd Plot No. 313 Industrial Triangle Kahuta Road Islamabad (000572)		
M/s Hilton Pharma (Pvt.) Ltd, Plot No. 13-14 & 43, Sector 15, Korangi Industrial Area Karachi (000136).			
M/s AGP Limited B-23-C, S.I.T.E., Karachi (000348).			
M/s Nabiqasim Industries Private Limited., 17/24, Korangi Industrial Area, Karachi (000105).			
M/s S.J & G Fazul Ellahie (Pvt.) Ltd., E-46, S.I.T.E, Karachi (000083).			
M/s Orbis Pharmaceuticals, Plot No. K/138, Phase-II, S.I.T.E., Karachi (000979).			
M/s Genix Pharma (Pvt.) Ltd., Plot No. 44-45-B, Korangi Creek Road, Karachi (000351).			
M/s Platinum Pharmaceuticals A-20, North Western Industrial Zone Bin Qasim, Karachi (000415)			

Decision of 348th Meeting of RB:

Registration Board after through deliberation decided as under:

- i. To issued registration letters to firms mentioned in Column-I without waiting for finalization of minutes.
- ii. To issue show cause / personal hearing notices to all firms mentioned in Column-II-IV and give them personal hearing in the forthcoming meeting i.e., 349th scheduled to be held on 14th July, 2025.

Accordingly, personal hearing letters were issued to the firm in column II to IV of the above mentioned table.

Proceedings of 349th meeting.

i. M/s Pacific Pharmaceutical Ltd 30 km Multan Road Lahore.

On behalf of M/s Pacific Pharma, M. Rizwan Umer (QCM) and Mr. Ghazi Mustansar Riaz appeared before the Board. They informed the Board that they have shifted their R&D. Their software of HPLC was crashed. They were informed about the inspection very late in Eid days and they have no time to recover their software. Now they have recovered their data and is in the server which has real time back up. They informed that Board they requested the inspection panel to check the data in the server, which was not accepted. They further requested the Board for re-inspection of same data from the server.

The inspection panel appraised the Board that at the time of inspection they requested to inspect the data in PDF form only and not the server with real time back up as per statement of firm.

ii. M/s Fynk Pharmaceuticals, 19-km G. T. Road, KalaShah Kaku, Lahore.

On behalf of M/s Fynk Pharmaceuticals, Mr. Kashif Liaquat (Director) and Mr. Yasir Liaquat (Director) appeared before the Board. They stated that 35 points of the PSI questionnaire were fulfilled by them, while only one point was not qualified. Software of Kanur HPLC was corrupted in March 2025. They tried to recover the data. However, only initial and 03rd month time data was recovered in PDF format. They also informed the Board that had they also run a parallel data and requested to verify the same.

iii. M/s Vision Pharmaceuticals Pvt. Ltd Plot#22-23, Industrial Triangle, Kahuta Road, Islamabad.

On behalf of M/s Vision pharma, Mr. Yasir Yaqoob (Head of Regulatory Affairs) & Mr. Rizwan Ali (Director Quality Operation) appeared before the Board. They informed the Board that drive of the computer was corrupted. They sent system to the Water's but data could not be retrieved. The data was available in hard copy and software based data was not shown to the panel. They further stated that they generated CAPA to prevent such type of inconvenience in future and now data is also stored on server on real time basis.

iv. M/s Caliph Pharmaceuticals Plot 17, Special Industrial Zone Risalpur.

On behalf of M/s Caliph Pharma, Mr. Waqas Ali (Director) & Hammad Elahi (Senior analyst) appeared before the Board. They stated that before the inspection their software was corrupted and they sent the system to the vendor for repairing. They informed the Board that at the same time they had also run the data on parallel system and requested to verify the same.

v. M/s Shaigan Pharmaceuticals (Pvt.) Ltd., 14-km Adyala Road, Post Office Dahgal, Rawalpindi.

On behalf of M/s Shaigan Pharma, Mr. Babar Ali (Director Plant) & Mehfooz Ur Rehman appeared before the Board. They informed the Board that during inspection all the 36 points of PSI checklist were verified. However, during data verification the data available in software and the data submitted to DRAP could not be cross-matched. They further stated that their R&D and Regulatory Affairs division are two separate divisions. During uploading of data on Regulatory Division, an error occurred and instead of R&D data of software some other data was uploaded which was not in line with the data submitted in DRAP. They also requested to verify the new data available in the software.

vi. M/s Wimits Pharmaceuticals Pvt. Limited, Plot No. 129, Sunder Industrial Estate Raiwind Road, Lahore.

On behalf of M/s Wimits Pharma, Mr. Atta Ullah Malik (Director Technical) & Mr. Misbah Ul Islam (DD PD) appeared before the Board. They submitted that they got license in 2014 and also have PNAC accreditation. They are manufacturing different products for reputable companies on contract manufacturing. Real time data is available with the firm and even they performed 09th month time point stability studies. However, during uploading of data to DRAP by the IT section, some error occurred. They further stated that after this error now the data will be uploaded by the R&D team instead of the IT section.

vii. M/s Macter International Ltd., F-216, S.I.T.E., Karachi.

On behalf of M/s Macter International, Dr. Azhar Hussain (Head of R&D), Dr. Jibrin (Head of Regulatory Affairs) & Dr. Fida (MD) appeared before the Board. They stated that due to cyber-attack on 17-02-2025, their security was breached. They have taken steps to improve their security. They further stated that new data is available on another HPLC and requested to verify the same.

viii. M/s Focus & Rulz Pharmaceuticals (Pvt.) Ltd., Plot No. 44, industrial triangle, Kahuta Road, Islamabad.

On behalf of M/s Focus & Rulz pharmaceuticals, Dr. Lubna (HOD of Technical team) & Anjum Arif (QC manager) appeared before the Board. They submitted before the Board that 06th month time point data was not verifiable due to changes in peak area. However, results were within 97% to 103%. They requested for substitutino of data available in the software with submitted data. They further submitted that during transfer data may have changed.

ix. M/s NovaMed pharmaceuticals (Pvt.) Ltd 28-KM Ferozepur Road Lahore.

On behalf of M/s NovaMed Pharmaceuticals, Mr. Shoaib Shafiq (Director), Amir Hayat (R&D Manager) & Rehan Ahmad (Head of QC) appeared before the Board. They stated that they are exporting to different countries. They submitted that most of their chromatograms were verified during the inspection, however, few were not verified. The reason may be due to variability in the integration parameters. They have done RCA and CAPA is generated.

- All stability data has been reviewed and verified again.
- Analysts counselling and training is performed.
- Restricted rights authorization has been implemented on all HPLCs.

x. M/s Bio-Labs(Pvt.) Ltd Plot 145, Industrial Triangle, Kahuta Road, Islamabad.

On behalf of M/s Bio-Labs, Hafiz Muhammad Tariq Khalil (Head of Quality) & Muhammad Ijaz (R&D Manager) appeared before the Board. They submitted that their system was initially not 21 CFR compliant, however, later they got certified. They informed that manual integration was done in chromatograms to correct the peak symmetry, due to which difference in area was observed between data submitted in DRAP and available with them. They added that manual integration is not prohibited, but must be used exceptionally and only when scientifically justified as stated in:

- WHO Guidance – WHO TRS 1025, Annex 3.
- USP <621> & <1058>
- BP Appendix III. Chromatographic separation technique.

xi. M/s Quaper (Pvt.) Ltd., 26-A, Small Industrial Estate, Lahore Road, Sargodha.

On behalf of M/s Quaper, Mr. Muhammad Iftikhar (Director) appeared before the Board. He stated that their QCM is not available. There may be a software issue. He further stated that they already purchased a new HPLC for smooth functioning.

xii. M/s Medizan Laboratories (Pvt.) Ltd Plot No. 313 Industrial Triangle Kahuta Road Islamabad.

On behalf of M/s Medizan Laboratories, Mr. Qasim Farooq (MD), Mr. Faisal (QCM) & Mr. Naeem (R&D manager) appeared before the Board. They informed the Board that they have performed actual testing, Audit trial and 09th month testing data is also available. Initially their software was slowed, for which they took the help of third party. However, later their system was not working and hard drive got corrupted. They took the help of Derma technologies to retrieve the data. Fortunately, the data was retrieved, however, changes in time and date occurred due to region change. At the same time due to malware, peak area was also changed. They also brought a consultant, who helped in data retrieval. The consultant reiterated the same narrative as above.

Decision of 349th Meeting:

The Board after considering the above mentioned positions and arguments of the firm and PSI reports of the inspection panel made thorough deliberations that;

- **Data shown by the firms to the inspection panel was not the same as submitted along with application for registration on Form 5F to the DRAP.**
- **Area under the curve (AUC) on the chromatograms cannot be changed due to manual integrations after submitting the data for regulatory approval.**
- **As recommended in 21 CFR part 11, the firms has not achieved their data on real time basis.**
- **If due to any malfunctioning, data is lost and is recovered, area under the curve (AUC) will not be changed in the recovered data. There can be the possibility of overlapping, missing time points but change in area is not possible.**

Therefore, the Registration Board unanimously decided to reject the application for registration of Sildenafil, Tadalafil and Vardenafil of the following firms for reasons mentioned against each;

- i. **M/s Pacific Pharmaceutical Ltd 30 km Multan Road Lahore (Revivor tablet (sildenafil) 25mg, 50mg, and 100mg) on following grounds:-**

The Applicant firm, during the course of panel inspection, was not able to demonstrate the availability of software based HPLC data of stability and analytical testing of sildenafil citrate tablets that have been submitted in the DRAP in the Form 5-F. It was admitted during personal hearing that their software was crashed and its under retrieval at the time of panel inspection.

- ii. **M/s Fynk Pharmaceuticals, 19-km G. T. Road, Kala Shah Kaku, Lahore (Silafil tablet (sildenafil) 25mg, 50mg, and 100mg):-**

The Applicant firm, during the course of panel inspection, was not able to demonstrate the availability of software based HPLC data of stability and analytical testing of sildenafil citrate tablets that have been submitted in the DRAP in the Form 5-F. It was admitted during personal hearing that their software was crashed and complete data could be retrieved.

- iii. **M/s Vision Pharmaceuticals Pvt. Ltd Plot#22-23, Industrial Triangle, Kahuta Road, Islamabad (Reviso tablet (sildenafil) 50mg):-**

The Applicant firm, during the course of panel inspection, was not able to demonstrate the availability of software based HPLC data of stability and analytical testing of sildenafil citrate tablets that have been submitted in the DRAP in the Form 5-F. It was admitted during personal hearing that due to corruption in their software and its non-retrieval, they were not able to show software based data to the panel members.

- iv. **M/s Caliph Pharmaceuticals Plot 17, Special Industrial Zone Risalpur (Sildenacal tablet (Sildenafil) 20mg, 25mg, 50mg, and 100mg):-**

The Applicant firm, during the course of panel inspection, was not able to demonstrate the availability of software based HPLC data of stability and analytical testing of sildenafil citrate tablets that have been submitted in the DRAP in the Form 5-F. It was admitted during personal hearing that due to a corruption of their software, they were not able to demonstrate the availability of software based data to the panel members.

- v. **M/s Shaigan Pharmaceuticals (Pvt.) Ltd., 14-km Adyala Road, Post Office Dahgal, Rawalpindi (Silden tablet (sildenafil) 25mg, 50mg and 100mg):-**

The Applicant firm, during the course of panel inspection, was not able to demonstrate the availability of software based HPLC data of stability and analytical testing of sildenafil citrate tablets that have been submitted in the DRAP in the Form 5-F. It was admitted during personal that uploading of data in the server of Regulatory Affairs Division by Research & Development Division, some error occurred resulted in variable data available in DRAP and their Regulatory Affairs Division.

- vi. M/s Wimits Pharmaceuticals Pvt. Limited, Plot No. 129, Sunder Industrial Estate Raiwind Road, Lahore (Neogra tablet (Sildenafil) 25mg, 50mg, 100mg, Procial tablet (tadalafil) 2.5mg, 5mg, 10mg, and 20mg):-

The Applicant firm, during the course of panel inspection, was not able to demonstrate the availability of software based HPLC data of stability and analytical testing of sildenafil citrate and Tadalafil tablets that have been submitted in the DRAP in the Form 5-F. It was admitted during personal hearing that while submitting data to the DRAP by their IT team, some error occurred which resulted in change of data submitted in DRAP and available with them.

- vii. M/s Macter International Ltd., F-216, S.I.T.E., Karachi (Vigoril tablet (Sildenafil) 25mg, 50 and 100mg).

The Applicant firm, during the course of panel inspection, was not able to demonstrate the availability of software based HPLC data of stability and analytical testing of sildenafil citrate tablets that have been submitted in the DRAP in the Form 5-F. It was admitted during personal hearing that due to cyber-attack on 17-02-2025, their security was breached due to which they were not able to demonstrate the availability their software based data to the panel members.

- viii. M/s Focus & Rulz Pharmaceuticals (Pvt.) Ltd., Plot No. 44, industrial triangle, Kahuta Road, Islamabad (Silpah tablet (sildenafil) 50mg and 100mg):-

The Applicant firm, during the course of panel inspection, was not able to demonstrate the availability of software based HPLC data of stability and analytical testing of sildenafil citrate tablets that have been submitted in the DRAP in the Form 5-F. It was admitted during personal hearing that data stability data at 06-month time point was not cross matched with the data submitted in DRAP on Form 5 F.

- ix. M/s NovaMed pharmaceuticals (Pvt.) Ltd 28-KM Ferozepur Road Lahore (Panagra tablet (Sildenafil) 25 mg, 50 mg, and 100 mg):-

The Applicant firm, during the course of panel inspection, was not able to demonstrate the availability of software based HPLC data of stability and analytical

testing of sildenafil citrate tablets that have been submitted in the DRAP in the Form 5-F. It was admitted during personal hearing that their data at some time points was not cross matched with the data submitted in DRAP on Form 5 F.

- x. M/s Bio-Labs(Pvt.) Ltd Plot 145, Industrial Triangle, Kahuta Road, Islamabad (Enafil tablet (Sildenafil) 100 mg).

The Applicant firm, during the course of panel inspection, was not able to demonstrate the availability of software based HPLC data of stability and analytical testing of sildenafil citrate tablets that have been submitted in the DRAP in the Form 5-F. It was admitted during personal hearing that after submission of data to DRAP some manual integrations were made to correct peak symmetry which resulted in variance between data submitted in DRAP in Form 5 F and available with them.

- xi. M/s Quaper (Pvt.) Ltd., 26-A, Small Industrial Estate, Lahore Road, Sargodha (Veige tablet (Sildenafil) 50mg):-

The Applicant firm, during the course of panel inspection, was not able to demonstrate the availability of software based HPLC data of stability and analytical testing of sildenafil citrate tablets that have been submitted in the DRAP in the Form 5-F. It was admitted during personal hearing that data available with them was not cross matched with the data submitted in DRAP on Form 5 F due to some software issue.

- xii. M/s Medizan Laboratories (Pvt.) Ltd Plot No. 313 Industrial Triangle Kahuta Road Islamabad (Silda tablet (Sildenafil) 25mg, 50mg, 100mg, Zealus/Tadalafil tablet (Tadalafil) 05mg, 10mg, 20mg, Vardil tablet (Vardenafil) 10mg and 20mg):-

The Applicant firm, during the course of panel inspection, was not able to demonstrate the availability of software based HPLC data of stability and analytical testing of sildenafil citrate tablets, Tadalafil Tablets and Vardenafil Tablehts that have been submitted in the DRAP in the Form 5-F. It was admitted during personal hearing that after retrieval of data, at some time points area under curve and timelines are not cross matched with the data submitted in DRAP in Form 5 F.

2. Registration Board under rule 29 sub rule (10) of the Drugs (LICENSING, REGISTRING & ADVERTIZING) Rules, 1976 further decided that rejection of an application for the registration of a drug shall not debar an applicant from submitting a fresh application under rule 26 of the said rules.

Case No.01: M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660)

DML No. 000660 was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.

The Central Licensing Board, 307th meeting held on 20 March 2025, considered the application for approval of Regrant the DML (by way of formulation) and DML has been received with issuance dated is. 09-04-2025. Now As per 199th meeting of DRAP Authority, held on 31 January, 3rd and 4th February 2025, after thorough deliberation and in continuation of its previous decision in the 180th meeting, exempted the requirement of Form 5F for those products that were cancelled due to the cancellation of the DML on account of late or non-submission of renewal applications.

M/s Aventek Pharmaceuticals (Pvt.) Ltd, submit the Form 5 Application with requisite fee and documents of already registered products of the previously under DML No. 000660, as per the following details:-

1.	Brand Name + Dosage Form and Strength	Avetek Injection 1gm
	Composition	Each Vial contains: Cefotaxime Sodium eq. to Cefotaxime 1gm
	Tracking ID and fee details	BEQ-U28-L9N8 Rs.37,000/-dated: : 21.04.2025, (215629807)
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, 1's
	GMP Status	Regrant DML issuance date 09-04-2025.
	RRA status	MHRA Approved.
	Remark of the Renewal section	Cephalosporin injection is not found approved by CLB. As per last inspection report dated 16-01-2025 firm is under process of upgrading cephalosporin injection section.
	Remarks:	Avetek Injection 1gm (059597) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal
Decision: Deferred for manufacturing facility for Dry powder injection (Cephalosporin).		
2.	Brand Name + Dosage Form and Strength	Avetek Injection 250mg
	Composition	Each Vial contains: Cefotaxime Sodium eq. to Cefotaxime.....250mg
	Tracking ID and fee details	V4R-6UG-6WL8 Rs.37,000/-dated: 21.04.2025, (13536931946)
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, 1's
	GMP Status	Regrant DML issuance date 09-04-2025.
	RRA status	MHRA Approved.

	Remark of the Renewal section	Cephalosporin injection is not found approved by CLB. As per last inspection report dated 16-01-2025 firm is under process of upgrading cephalosporin injection section. .
	Remarks:	Avetek Injection 250mg (059598) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal
	Decision: Deferred for manufacturing facility for Dry powder injection (Cephalosporin).	
3.	Brand Name + Dosage Form and Strength	Avetek Injection 500mg
	Composition	Each Vial contains: Cefotaxime Sodium eq. to Cefotaxime.....500mg (USP Specifications)
	Tracking ID and fee details	GGU-BTA-SXJL Rs.37,000/-dated: : 21.04.2025, (43907369)
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, 1's
	GMP Status	Regrant DML issuance date 09-04-2025.
	RRA status	MHRA Approved.
	Remark of the Renewal section	Cephalosporin injection is not found approved by CLB. As per last inspection report dated 16-01-2025 firm is under process of upgrading cephalosporin injection section.
	Remarks:	Avetek Injection 500mg (059599) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Deferred for manufacturing facility for Dry powder injection (Cephalosporin).	
4.	Brand Name + Dosage Form and Strength	Avetron Injection 1gm
	Composition	Each Vial contains: Ceftriaxone Sodium eq. to Ceftriaxone 1gm
	Tracking ID and fee details	WVJ-77W-UWQ6 Rs.37,000/-dated: 21.04.2025 (215629807)
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, 1's
	GMP Status	Regrant DML issuance date 09-04-2025.
	RRA status	MHRA Approved.
	Remark of the Renewal section	Cephalosporin injection is not found approved by CLB. As per last inspection report dated 16-01-2025 firm is under process of upgrading cephalosporin injection section.

	Remarks:	Avetron Injection 1gm (059611) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal
	Decision: Deferred for manufacturing facility for Dry powder injection (Cephalosporin).	
5.	Brand Name + Dosage Form and Strength	Avetron Injection 250mg
	Composition	Each Vial contains: Ceftriaxone Sodium eq. to Ceftriaxone 250mg. (USP Specifications)
	Tracking ID and fee details	S2G-2RL-R4A7 Rs.37,000/-dated: : 21.04.2025, (981082583)
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, 1's
	GMP Status	Regrant DML issuance date 09-04-2025.
	RRA status	MHRA Approved.
	Remark of the Renewal section	Cephalosporin injection is not found approved by CLB. As per last inspection report dated 16-01-2025 firm is under process of upgrading cephalosporin injection section.
	Remarks:	Avetron Injection 250mg (059612) M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal
	Decision: Deferred for manufacturing facility for Dry powder injection (Cephalosporin).	
6.	Brand Name + Dosage Form and Strength	Avetron Injection 500mg
	Composition	Each Vial contains: Ceftriaxone Sodium eq. to Ceftriaxone 500mg
	Tracking ID and fee details	J1W-EU6-2D5Q Rs.37,000/-dated: : 21.04.2025, (8333360393)
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, 1's
	GMP Status	Regrant DML issuance date 09-04-2025.
	RRA status	MHRA Approved.
	Remark of the Renewal section	Cephalosporin injection is not found approved by CLB. As per last inspection report dated 16-01-2025 firm is under process of upgrading cephalosporin injection section.
	Remarks:	Avetron Injection 500mg (059613) M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal

	Decision: Deferred for manufacturing facility for Dry powder injection (Cephalosporin).	
7.	Brand Name + Dosage Form and Strength	Avonil Injection 1 gm
	Composition	Each vial contains: Cephazolin sodium eq. to cephazolin 1 gm (USP Specifications)
	Tracking ID and fee details	X9T-5Q3-HT37 Rs.37,000/-dated: : 21.04.2025, (2384092682)
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, l's
	GMP Status	Regrant DML issuance date 09-04-2025.
	RRA status	USFDA Approved.
	Remark of the Renewal section	Cephalosporin injection is not found approved by CLB. As per last inspection report dated 16-01-2025 firm is under process of upgrading cephalosporin injection section.
	Remarks:	Avonil Injection 1 gm (059570) M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal
	Decision: Deferred for manufacturing facility for Dry powder injection (Cephalosporin).	
8.	Brand Name + Dosage Form and Strength	Avonil Injection 250mg
	Composition	Each vial contains: Cephazolin sodium eq. to cephazolin 250 mg
	Tracking ID and fee details	SLQ-D2U-X7ZS Rs.37,000/-dated: : 21.04.2025, (43393601220)
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, l's
	GMP Status	Regrant DML issuance date 09-04-2025.
	RRA status	USFDA Approved.
	Remark of the Renewal section	Cephalosporin injection is not found approved by CLB. As per last inspection report dated 16-01-2025 firm is under process of upgrading cephalosporin injection section.
	Remarks:	Avonil Injection 250mg (059571) M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal
	Decision: Deferred for manufacturing facility for Dry powder injection (Cephalosporin).	
9.	Brand Name + Dosage Form and Strength	Avonil Injection 500mg
	Composition	Each vial contains: Cephazolin sodium eq. to cephazolin 500 mg
	Tracking ID and fee details	PNX-MHL-GWQW Rs.37,000/-dated: : 21.04.2025, (4287881450)
	Type of form	Fom-5

	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, 1's
	GMP Status	Regrant DML issuance date 09-04-2025.
	RRA status	USFDA Approved.
	Remark of the Renewal section	Cephalosporin injection is not found approved by CLB. As per last inspection report dated 16-01-2025 firm is under process of upgrading cephalosporin injection section.
10.	Remarks:	Avonil Injection 500mg (059572) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal
	Decision: Deferred for manufacturing facility for Dry powder injection (Cephalosporin).	
	Brand Name + Dosage Form and Strength	Alosef Injection 1gm
10.	Composition	Each Vial contains Sterile Cephradine (with sterile Arginine).....1gm
	Tracking ID and fee details	QWY-2GE-GESP Rs.37,000/-dated: 21.04.2025, (82461567)
	Type of form	Fom-5
	Finished product specifications	BP
	Pack size and Demand Price	As per SRO, 1's
	GMP Status	Regrant DML issuance date 09-04-2025.
	RRA status	USFDA approved
	Remark of the Renewal section	Cephalosporin injection is not found approved by CLB. As per last inspection report dated 16-01-2025 firm is under process of upgrading cephalosporin injection section.
	Remarks:	Alosef Injection 1gm (059577) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Deferred for manufacturing facility for Dry powder injection (Cephalosporin).	
11.	Brand Name + Dosage Form and Strength	Alosef Injection 250mg
	Composition	Each Vial contains: Sterile Cephradine (with sterile Arginine)....250mg
	Tracking ID and fee details	1UZ-MPX-NZHH Rs.37,000/-dated: : 21.04.2025, (9603497933)
	Type of form	Fom-5
	Finished product specifications	BP
	Pack size and Demand Price	As per SRO, 1's
	GMP Status	Regrant DML issuance date 09-04-2025.
	RRA status	USFDA Approved.

	Remark of the Renewal section	Cephalosporin injection is not found approved by CLB. As per last inspection report dated 16-01-2025 firm is under process of upgrading cephalosporin injection section.
	Remarks:	Alosef Injection 250mg (059578) M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Deferred for manufacturing facility for Dry powder injection (Cephalosporin).	
12.	Brand Name + Dosage Form and Strength	Avepime Injection 1gm
	Composition	Each Vial contains: Cefepime HCL eq. to Cefepime (with L-Arginine)....1gm
	Tracking ID and fee details	6RN-RRL-L1MG Rs.37,000/-dated: : 21.04.2025, (12826464501)
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, 1's
	GMP Status	Regrant DML issuance date 09-04-2025.
	RRA status	USFDA Approved.
	Remark of the Renewal section	Cephalosporin injection is not found approved by CLB. As per last inspection report dated 16-01-2025 firm is under process of upgrading cephalosporin injection section.
	Remarks:	Avepime Injection 1gm (059585) M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Deferred for manufacturing facility for Dry powder injection (Cephalosporin).	
13.	Brand Name + Dosage Form and Strength	Avepime Injection 500mg
	Composition	Each Vial contains: Cefepime HCL eq. to Cefepime (with L-Arginine) 500mg
	Tracking ID and fee details	U1Z-QQU-P37A Rs.37,000/-dated: : 21.04.2025, (8301371528)
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, 1's
	GMP Status	Re-grant DML issuance date 09-04-2025.
	RRA status	USFDA Approved.
	Remark of the Renewal section	Cephalosporin injection is not found approved by CLB. As per last inspection report dated 16-01-2025 firm is under process of upgrading cephalosporin injection section.
	Remarks:	Avepime Injection 500mg (059586) M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar

		Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Deferred for manufacturing facility for Dry powder injection (Cephalosporin).	
14.	Brand Name + Dosage Form and Strength	Averom Injection 1gm
	Composition	Each Vial contains: Cefpirome Sodium eq. to Cefpirome 1gm
	Tracking ID and fee details	838-MWJ-LVBP Rs.37,000/-dated: : 21.04.2025, (8403714777)
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, 1's
	GMP Status	Regrant DML issuance date 09-04-2025.
	RRA status	
	Remark of the Renewal section	RRA approval status not found. Applied formulation is not available in USP. Cephalosporin injection is not found approved by CLB. As per last inspection report dated 16-01-2025 firm is under process of upgrading cephalosporin injection section.
	Remarks:	Averom Injection 1gm (059590) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Deferred for manufacturing facility for Dry powder injection (Cephalosporin).	
15.	Brand Name + Dosage Form and Strength	Averom Injection 500mg
	Composition	Each Vial contains: Cefpirome Sodium eq. to Cefpirome 500mg (USP Specifications)
	Tracking ID and fee details	993-RPA-6MHU Rs.37,000/-dated: : 21.04.2025, (11057959228)
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, 1's
	GMP Status	Regrant DML issuance date 09-04-2025.
	RRA status	
	Remark of the Renewal section	RRA approval status not found. Applied formulation is not available in USP. Cephalosporin injection is not found approved by CLB. As per last inspection report dated 16-01-2025 firm is under process of upgrading cephalosporin injection section.
	Remarks:	Averom Injection 500mg (059591) M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared

		invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Deferred for manufacturing facility for Dry powder injection (Cephalosporin).	
16.	Brand Name + Dosage Form and Strength	Avefro Injection 1.5gm
	Composition	Each ml contains: Cefuroxime Sodium eq. to Cefuroxime 1.5g
	Tracking ID and fee details	D37-BA9-MJMG Rs.37,000/-dated: : 21.04.2025, (581938349)
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, 1's
	GMP Status	Re-grant DML issuance date 09-04-2025.
	RRA status	MHRA Approved.
	Remark of the Renewal section	Cephalosporin injection is not found approved by CLB. As per last inspection report dated 16-01-2025 firm is under process of upgrading cephalosporin injection section.
	Remarks:	Avefro Injection 1.5gm (059593) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Deferred for manufacturing facility for Dry powder injection (Cephalosporin).	
17.	Brand Name + Dosage Form and Strength	Avefro Injection 250mg
	Composition	Each ml contains: Cefuroxime Sodium eq. to Cefuroxime 250mg
	Tracking ID and fee details	YPS-U2W-S8AD Rs.37,000/-dated: 21.04.2025, (713122936059)
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, 1's
	GMP Status	Regrant DML issuance date 09-04-2025.
	RRA status	MHRA Approved.
	Remark of the Renewal section	Cephalosporin injection is not found approved by CLB. As per last inspection report dated 16-01-2025 firm is under process of upgrading cephalosporin injection section.
	Remarks:	Avefro Injection 250mg (059594) M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Deferred for manufacturing facility for Dry powder injection (Cephalosporin).	
	Brand Name + Dosage Form and Strength	Avefro Injection 750mg

18.	Composition	Each ml contains: Cefuroxime Sodium eq. to Cefuroxime 750mg
	Tracking ID and fee details	JYV-3A6-3MTX Rs.37,000/-dated: : 21.04.2025, (96816888492)
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, 1's
	GMP Status	Regrant DML issuance date 09-04-2025.
	RRA status	MHRA Approved.
	Remark of the Renewal section	Cephalosporin injection is not found approved by CLB. As per last inspection report dated 16-01-2025 firm is under process of upgrading cephalosporin injection section.
	Remarks:	Avefro Injection 750mg (059595) M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
Decision: Deferred for manufacturing facility for Dry powder injection (Cephalosporin).		
19.	Brand Name + Dosage Form and Strength	Avesulzone Injection 1gm
	Composition	Each Vial contains: Ceforerazone as Sodium.... 500mg Sulbactam as Sodium 500mg
	Tracking ID and fee details	P24-P6U-R78X Rs.37,000/-dated: : 21.04.2025, (08506937333)
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, 1's
	GMP Status	Regrant DML issuance date 09-04-2025.
	RRA status	USFDA Approved.
	Remark of the Renewal section	Cephalosporin injection is not found approved by CLB. As per last inspection report dated 16-01-2025 firm is under process of upgrading cephalosporin injection section.
	Remarks:	Avesulzone Injection 1gm (059596) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
Decision: Deferred for manufacturing facility for Dry powder injection (Cephalosporin).		
20.	Brand Name + Dosage Form and Strength	Avetaz Injection 1gm
	Composition	Each Vial contains: Ceftazidime Pentahydrate with Sodium carbonate eq. to Ceftazidime (anhydrous) 1gm
	Tracking ID and fee details	DY8-V1S-66EN Rs.37,000/-dated: : 21.04.2025, (7724706578)
	Type of form	Fom-5

	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, 1's
	GMP Status	Regrant DML issuance date 09-04-2025.
	RRA status	USFDA Approved.
	Remark of the Renewal section	Cephalosporin injection is not found approved by CLB. As per last inspection report dated 16-01-2025 firm is under process of upgrading cephalosporin injection section.
	Remarks:	Avetaz Injection 1gm (059600) M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Deferred for manufacturing facility for Dry powder injection (Cephalosporin).	
21.	Brand Name + Dosage Form and Strength	Avetaz Injection 250mg
	Composition	Each Vial contains: Ceftazidime Pentahydrate with Sodium carbonate eq. to Ceftazidime (anhydrous) 250mg
	Tracking ID and fee details	GQR-H3Z-SR92 Rs.37,000/-dated: : 21.04.2025, (11607731)
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, 1's
	GMP Status	Regrant DML issuance date 09-04-2025.
	RRA status	USFDA Approved.
	Remark of the Renewal section	Cephalosporin injection is not found approved by CLB. As per last inspection report dated 16-01-2025 firm is under process of upgrading cephalosporin injection section.
	Remarks:	Avetaz Injection 250mg (059601) M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
22.	Decision: Deferred for manufacturing facility for Dry powder injection (Cephalosporin).	
	Brand Name + Dosage Form and Strength	Avetaz Injection 500mg
	Composition	Each Vial contains: Ceftazidime Pentahydrate with Sodium carbonate eq. to Ceftazidime (anhydrous) 500mg
	Tracking ID and fee details	B9S-53W-7UE2 Rs.37,000/-dated: : 21.04.2025, (2651042173)
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, 1's
	GMP Status	Regrant DML issuance date 09-04-2025.
	RRA status	USFDA Approved.

	Remark of the Renewal section	Cephalosporin injection is not found approved by CLB. As per last inspection report dated 16-01-2025 firm is under process of upgrading cephalosporin injection section.
	Remarks:	Avetaz Injection 500mg (059602) M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Deferred for manufacturing facility for Dry powder injection (Cephalosporin).	
23.	Brand Name + Dosage Form and Strength	Avezone Injection 1gm
	Composition	Each Vial contains: Cefoperazone Sodium eq. to Cefoperazone 1gm
	Tracking ID and fee details	D5P-D4J-MPL1 Rs.37,000/-dated: : 21.04.2025, (15329974744)
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, 1's
	GMP Status	Regrant DML issuance date 09-04-2025.
	RRA status	USFDA Approved.
	Remark of the Renewal section	Cephalosporin injection is not found approved by CLB. As per last inspection report dated 16-01-2025 firm is under process of upgrading cephalosporin injection section.
	Remarks:	Avezone Injection 1gm (059614) M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Deferred for manufacturing facility for Dry powder injection (Cephalosporin).	
24.	Brand Name + Dosage Form and Strength	Avezone Injection 500mg
	Composition	Each Vial contains: Cefoperazone Sodium eq. to Cefoperazone 500mg
	Tracking ID and fee details	422-AHR-XX9U Rs.37,000/-dated: : 21.04.2025, (0590598716)
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, 1's
	GMP Status	Regrant DML issuance date 09-04-2025.
	RRA status	USFDA Approved.
	Remark of the Renewal section	Cephalosporin injection is not found approved by CLB. As per last inspection report dated 16-01-2025 firm is under process of upgrading cephalosporin injection section.
	Remarks:	Avezone Injection 500mg (059615) M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared

		invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Deferred for manufacturing facility for Dry powder injection (Cephalosporin).	
25.	Brand Name + Dosage Form and Strength	Alocef Injection 500mg
	Composition	Each Vial contains: Cephadrine (with sterile Arginine).....500mg
	Tracking ID and fee details	75W-D75-YQ37 Rs.37,000/-dated: : 21.04.2025, (3303650948)
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, 1's
	GMP Status	Re-grant DML issuance date 09-04-2025.
	RRA status	USFDA Approved.
	Remark of the Renewal section	Cephalosporin injection is not found approved by CLB. As per last inspection report dated 16-01-2025 firm is under process of upgrading cephalosporin injection section.
25.	Remarks:	Alocef Injection 500mg (059618) M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Deferred for manufacturing facility for Dry powder injection (Cephalosporin).	
26.	Brand Name + Dosage Form and Strength	Avecol Capsules 200mg
	Composition	Each Capsule contains: Cefixime as Trihydrate.... 200mg
	Tracking ID and fee details	285-4QR-Y6TU Rs.37,000/-dated: : 21.04.2025, (718850755173)
	Type of form	Fom-5
	Finished product specifications	Manufacturer Specs.
	Pack size and Demand Price	As per SRO, 5's
	GMP Status	Regrant DML issuance date 09-04-2025.
	RRA status	USFDA Approved.
	Remark of the Renewal section	Cephalosporin capsule is approved by CLB. As per last inspection report dated 16-01-2025
26.	Remarks:	Avecol Capsules 200mg (059608) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Approved	
27.	Brand Name + Dosage Form and Strength	Avecol Capsules 400mg
	Composition	Each Capsule contains: Cefixime as Trihydrate 400mg

	Tracking ID and fee details	H4Y-9HW-N6D7 Rs.37,000/-dated: : 21.04.2025, (626937469327)
	Type of form	Fom-5
	Finished product specifications	Manufacturer Specs.
	Pack size and Demand Price	As per SRO, 5's
	GMP Status	Regrant DML issuance date 09-04-2025.
	RRA status	USFDA Approved.
	Remark of the Renewal section	Cephalosporin capsule is approved by CLB. As per last inspection report dated 16-01-2025
	Remarks:	Avecol Capsules 400mg (059609) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Approved	
28.	Brand Name + Dosage Form and Strength	Alosef Capsule 250mg
	Composition	Each Capsule contains: Cephadrine.....250 mg
	Tracking ID and fee details	DN2-YLQ-WNES Rs.37,000/-dated: : 21.04.2025, (3919160382)
	Type of form	Fom-5
	Finished product specifications	USP Specs.
	Pack size and Demand Price	As per SRO, 12's
	GMP Status	Re-grant DML issuance date 09-04-2025.
	RRA status	MHRA Approved.
	Remark of the Renewal section	Cephalosporin capsule is approved by CLB. As per last inspection report dated 16-01-2025 Instant formulation has been obsoleted from latest edition of USP hence BP specification to be granted Label claim to be standardized in line with RRA approved product as under: Cefradine monohydrate equivalent to cefradine.....250mg
	Remarks:	Alosef Capsule 250mg (059573) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Approved with BP specification.	
	Formulation to be standardized in line with RRA as under: Each Capsule contains: Cefradine monohydrate equivalent to cefradine.....250mg	

29.	Brand Name + Dosage Form and Strength	Alosef Capsule 500mg
	Composition	Each Capsule contains: Cephadrine..... 500 mg
	Tracking ID and fee details	MYB-L4D-YRSG Rs.37,000/-dated: 21.04.2025, (371658617)
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, 12's
	GMP Status	Re-grant DML issuance date 09-04-2025.
	RRA status	MHRA Approved.
	Remark of the Renewal section	Cephalosporin capsule is approved by CLB. As per last inspection report dated 16-01-2025 Label claim to be standardized in line with innovator's product as under: Cefradine monohydrate equivalent to cefradine.....500mg
30.	Remarks:	Alosef Capsule 500mg (059574) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Approved with BP specification.	
	Formulation to be standardized in line with RRA as under: Each Capsule contains: Cefradine monohydrate equivalent to cefradine.....500mg	
30.	Brand Name + Dosage Form and Strength	Aveclor Capsules 250mg
	Composition	Each Capsule contains: Cefaclor Monohydrate eq. to Cefaclor....250mg
	Tracking ID and fee details	5VN-M7Y-9Z1V Rs.37,000/-dated: : 21.04.2025, (4108968921)
	Type of form	Fom-5
	Finished product specifications	USP Specs.
	Pack size and Demand Price	As per SRO, 12's
	GMP Status	Regrant DML issuance date 09-04-2025.
	RRA status	USFDA Approved.
	Remark of the Renewal section	Cephalosporin capsule is approved by CLB. As per last inspection report dated 16-01-2025
30.	Remarks:	Aveclor Capsules 250mg (059579) M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Approved	
	Brand Name + Dosage Form and Strength	Aveclor Capsules 500mg

31.	Composition	Each Capsule contains: Cefaclor Monohydrate eq. to Cefaclor....500mg
	Tracking ID and fee details	1TS-LHZ-V66N Rs.37,000/-dated: : 21.04.2025, (0721881374)
	Type of form	Fom-5
	Finished product specifications	USP Specs.
	Pack size and Demand Price	As per SRO, 12's
	GMP Status	Regrant DML issuance date 09-04-2025.
	RRA status	USFDA Approved.
	Remark of the Renewal section	Cephalosporin capsule is approved by CLB. As per last inspection report dated 16-01-2025
	Remarks:	Aveclor Capsules 500mg (059574) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Approved	
32.	Brand Name + Dosage Form and Strength	Avelex Capsule 250mg
	Composition	Each Capsule contains: Cephalexin Monohydrate eq. to Cephalexin....250mg
	Tracking ID and fee details	Y1Q-3SB-MAX5 Rs.37,000/-dated: 21.04.2025, (882806028942)
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, 12's
	GMP Status	Re-grant DML issuance date 09-04-2025.
	RRA status	MHRA Approved.
	Remark of the Renewal section	Cephalosporin capsule is approved by CLB. As per last inspection report dated 16-01-2025
	Decision: Approved	
33.	Brand Name + Dosage Form and Strength	Avelex Capsule 500mg
	Composition	Each Capsule contains: Cephalexin Monohydrate eq. to Cephalexin....500mg
	Tracking ID and fee details	DJ9-GN9-L4ZP Rs.37,000/-dated: 21.04.2025, (1254888913)
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, 12's
	GMP Status	Re-grant DML issuance date 09-04-2025.
	RRA status	MHRA Approved.
	Remark of the Renewal section	Cephalosporin capsule is approved by CLB.

		As per last inspection report dated 16-01-2025
	Remarks:	Avelex Capsule 500mg (059584) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Approved	
34.	Brand Name + Dosage Form and Strength	Avexil Capsules 1gm
	Composition	Each Capsule contains: Cefadroxil as monohydrate.....1gm
	Tracking ID and fee details	4WX-8LR-BYV7 Rs.37,000/-dated: 21.04.2025, (334696553911)
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, 12's
	GMP Status	Re-grant DML issuance date 09-04-2025.
	RRA status	MHRA Approved.
	Remark of the Renewal section	Cephalosporin capsule is approved by CLB. As per last inspection report dated 16-01-2025
	Remarks:	Avexil Capsules 1gm (059603) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Approved	
35.	Brand Name + Dosage Form and Strength	Avecol – DS susp. 200mg
	Composition	Each 5ml contains: Cefixime as Trihydrate.....200mg
	Tracking ID and fee details	LAY-JQD-6GGL Rs.37,000/-dated: 21.04.2025, (684126389)
	Type of form	Fom-5
	Finished product specifications	USP Specs.
	Pack size and Demand Price	As per SRO, 30ml
	GMP Status	Re-grant DML issuance date 09-04-2025.
	RRA status	USFDA Approved.
	Remark of the Renewal section	Cephalosporin suspension is approved by CLB. As per last inspection report dated 16-01-2025
	Remarks:	Avecol – DS susp. 200mg (059607) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Approved	
36.	Brand Name + Dosage Form and Strength	Avecol Dry susp. 100mg
	Composition	Each 5ml contains: Cefixime as Trihydrate...100mg

	Tracking ID and fee details	QN4-G8Y-D5JR Rs.37,000/-dated: 21.04.2025, (726392307392)
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, 30ml
	GMP Status	Re-grant DML issuance date 09-04-2025.
	RRA status	USFDA Approved.
	Remark of the Renewal section	Cephalosporin suspension is approved by CLB. As per last inspection report dated 16-01-2025
37.	Remarks:	Avecol Dry susp. 100mg (059610) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Approved	
37.	Brand Name + Dosage Form and Strength	Alosef Dry Susp. 125mg
	Composition	Each 5ml contains, Cephadrine.....125 mg
	Tracking ID and fee details	9RQ-X33-MHTT Rs.37,000/-dated: 21.04.2025, (0965698144)
	Type of form	Fom-5
	Finished product specifications	USP Specs.
	Pack size and Demand Price	As per SRO, 60ml
	GMP Status	Regrant DML issuance date 09-04-2025.
	RRA status	MHRA Approved.
	Remark of the Renewal section	Cephalosporin suspension is approved by CLB. As per last inspection report dated 16-01-2025 Instant formulation has been obsoleted from latest edition of USP hence BP specification to be granted Approval status in RRA not found
	Remarks:	Alosef Dry Susp. 125mg (059575) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
38.	Decision: Deferred for approval status in RRA.	
	Brand Name + Dosage Form and Strength	Alosef Dry Susp. 250mg
	Composition	Each 5ml contains, Cephadrine.....250 mg
	Tracking ID and fee details	DU3-3V2-TMU9 Rs.37,000/-dated: : 21.04.2025, (2318438366)
	Type of form	Fom-5
	Finished product specifications	USP Specs.
	Pack size and Demand Price	As per SRO, 60ml
	GMP Status	Re-grant DML issuance date 09-04-2025.

	RRA status	MHRA Approved.
	Remark of the Renewal section	Cephalosporin suspension is approved by CLB. As per last inspection report dated 16-01-2025 Instant formulation has been obsoleted from latest edition of USP hence BP specification to be granted Approval status in RRA not found
	Remarks:	Alosef Dry Susp. 250mg (059576) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Approved.	
39.	Brand Name + Dosage Form and Strength	Aveclor Dry Susp. 125mg
	Composition	Each 5ml contains: Cefaclor Monohydrate eq. to Cefaclor.....125mg
	Tracking ID and fee details	48J-BYT-8YEB Rs.37,000/-dated: : 21.04.2025, (8726297597)
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, 60ml
	GMP Status	Re-grant DML issuance date 09-04-2025.
	RRA status	MHRA Approved.
	Remark of the Renewal section	Cephalosporin suspension is approved by CLB. As per last inspection report dated 16-01-2025
	Remarks:	Aveclor Dry Susp. 125mg (059581) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Approved	
40.	Brand Name + Dosage Form and Strength	Aveclor Dry Susp. 250mg
	Composition	Each 5ml contains: Cefaclor Monohydrate eq. to Cefaclor.....250mg
	Tracking ID and fee details	ERR-8P4-6A89 Rs.37,000/-dated: : 21.04.2025, (59444598018)
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, 60ml
	GMP Status	Re-grant DML issuance date 09-04-2025.
	RRA status	MHRA Approved.

	Remark of the Renewal section	Cephalosporin suspension is approved by CLB. As per last inspection report dated 16-01-2025
	Remarks:	Aveclor Dry Susp. 250mg (059582) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Approved	
41.	Brand Name + Dosage Form and Strength	Avedoxim Dry Susp.40mg
	Composition	Each 5ml contains: Cefpodoxime Proxtil....40mg
	Tracking ID and fee details	JSR-JJP-7BNV Rs.37,000/-dated: : 21.04.2025, (85850806)
	Type of form	Fom-5
	Finished product specifications	USP Specs.
	Pack size and Demand Price	As per SRO, 50ml
	GMP Status	Re-grant DML issuance date 09-04-2025.
	RRA status	HPRA Approved.
	Remark of the Renewal section	Formulation to be standardized as : Each 5ml contains: Cefpodoxime proxetil equivalent to cefpodoxime....40mg Cephalosporin suspension is approved by CLB. As per last inspection report dated 16-01-2025
	Remarks:	Avedoxim Dry Susp.40mg (059587) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Approved . Formulation to be standardized in line with RRA along with fee.	
42.	Brand Name + Dosage Form and Strength	Avemrol Dry Susp.125mg
	Composition	Each 5ml contains: Cefprozil as Monohydrate 125mg
	Tracking ID and fee details	DJB-UVB-N1QV Rs.37,000/-dated 21.04.2025, (7416711273)
	Type of form	Fom-5
	Finished product specifications	USP Specs.
	Pack size and Demand Price	As per SRO, 50ml
	GMP Status	Re-grant DML issuance date 09-04-2025.
	RRA status	USFDA Approved.
	Remark of the Renewal section	Cephalosporin suspension is approved by CLB. As per last inspection report dated 16-01-2025

	Remarks:	Avemrol Dry Susp.125mg (059588) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Approved	
43.	Brand Name + Dosage Form and Strength	Avexil Dry Susp. 125mg
	Composition	Each 5ml contains: Cefadroxil as monohydrate....125mg
	Tracking ID and fee details	PZG-LZS-MX7B Rs.37,000/-dated: : 21.04.2025, (972977253106)
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, 60ml
	GMP Status	Re-grant DML issuance date 09-04-2025.
	RRA status	USFDA Approved.
	Remark of the Renewal section	Cephalosporin suspension is approved by CLB. As per last inspection report dated 16-01-2025
	Remarks:	Avexil Dry Susp. 125mg (059605) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Approved	
44.	Brand Name + Dosage Form and Strength	Avexil Dry Susp. 250mg
	Composition	Each 5ml contains: Cefadroxil as monohydrate.....250mg
	Tracking ID and fee details	EJ6-YW9-VWNN Rs.37,000/-dated 21.04.2025, (01523963)
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, 60ml
	GMP Status	Re-grant DML issuance date 09-04-2025.
	RRA status	FDA Approved.
	Remark of the Renewal section	Cephalosporin suspension is approved by CLB. As per last inspection report dated 16-01-2025
	Remarks:	Avexil Dry Susp. 250mg (059606) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Approved	
	Brand Name + Dosage Form and Strength	Avefro Dry Susp.125mg

45.	Composition	Each 5ml contains: Cefuroxime....125mg
	Tracking ID and fee details	71H-EWU-281D Rs.37,000/-dated: : 21.04.2025, (3181038766)
	Type of form	Fom-5
	Finished product specifications	USP Specs.
	Pack size and Demand Price	As per SRO, 60ml
	GMP Status	Re-grant DML issuance date 09-04-2025.
	RRA status	FDA Approved.
	Remark of the Renewal section	Formulation to be standardized as : Each 5ml contains: Cefuroxime axetil equivalent to Cefuroxime.....40mg Cephalosporin suspension is approved by CLB. As per last inspection report dated 16-01-2025
	Remarks:	Avefro Dry Susp. 125mg (059592) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
Decision: Approved . Formulation to be standardized in line with RRA along with fee.		
46.	Brand Name + Dosage Form and Strength	Avelot Dry Susp. 125mg
	Composition	Each 5ml contains: Cephalexin monohydrate eq. to Cephalexin.....125mg
	Tracking ID and fee details	URS-NW2-D2G4 Rs.37,000/-dated: : 21.04.2025, (1852609836)
	Type of form	Fom-5
	Finished product specifications	USP Specs.
	Pack size and Demand Price	As per SRO, 60ml
	GMP Status	Re-grant DML issuance date 09-04-2025.
	RRA status	USFDA Approved.
	Remark of the Renewal section	Cephalosporin suspension is approved by CLB. As per last inspection report dated 16-01-2025
	Remarks:	Avelot Dry Susp. 125mg (059616) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Approved	
47.	Brand Name + Dosage Form and Strength	Avelot Dry Susp. 250mg
	Composition	Each 5ml contains: Cephalexin monohydrate eq.to Cephalexin 250mg

	Tracking ID and fee details	326-LJ3-LNR9 Rs.37,000/-dated: : 21.04.2025, (475224419984)
	Type of form	Fom-5
	Finished product specifications	USP Specs.
	Pack size and Demand Price	As per SRO, 60ml
	GMP Status	Re-grant DML issuance date 09-04-2025.
	RRA status	USFDA Approved.
	Remark of the Renewal section	Cephalosporin suspension section is approved by CLB. As per last inspection report dated 16-01-2025
	Remarks:	Avelot Dry Susp. 250mg (059617) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Approved	
48.	Brand Name + Dosage Form and Strength	Qortik Tablet 400mg
	Composition	Each Tablet contains: Moxifloxacin (as HCl) 400mg
	Tracking ID and fee details	YGS-EH6-Q6QR Rs.37,000/-dated: : 21.04.2025, (6762483408)
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, 5's
	GMP Status	Re-grant DML issuance date 09-04-2025.
	RRA status	USFDA Approved.
	Remark of the Renewal section	Tablet (General) section is approved by CLB. As per last inspection report dated 16-01-2025
	Remarks:	Qortik Tablet 400mg (080066) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Approved	
49.	Brand Name + Dosage Form and Strength	Levodor Tablet 250mg
	Composition	Each Tablet contains: Levofloxacin (as Hemihydrate) 250mg
	Tracking ID and fee details	VYY-9A9-21PV Rs.37,000/-dated: 21.04.2025, (2807055774)
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, 10's
	GMP Status	Re-grant DML issuance date 09-04-2025.
	RRA status	FDA Approved.

	Remark of the Renewal section	Tablet (General) section is approved by CLB. As per last inspection report dated 16-01-2025
	Remarks:	Levodor Tablet 250mg (080067) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Approved	
50.	Brand Name + Dosage Form and Strength	Levodor Tablet 500mg
	Composition	Each Tablet contains: Levofloxacin (as Hemihydrate).....500mg
	Tracking ID and fee details	QZH-JJ6-RQ94 Rs.37,000/-dated: : 21.04.2025, (323377679236)
	Type of form	Fom-5
	Finished product specifications	USP Specs.
	Pack size and Demand Price	As per SRO, 5's
	GMP Status	Regrant DML issuance date 09-04-2025.
	RRA status	USFDA Approved.
	Remark of the Renewal section	Tablet (General) section is approved by CLB. As per last inspection report dated 16-01-2025
	Remarks:	Levodor Tablet 500mg (080068) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Approved	
51.	Brand Name + Dosage Form and Strength	C-PAC Tablet 500mg
	Composition	Each Tablet contains: Ciprofloxacin (as HCl)..... 500mg
	Tracking ID and fee details	2V7-UBP-UU86 Rs.37,000/-dated: : 21.04.2025, (00131041373)
	Type of form	Fom-5
	Finished product specifications	BP
	Pack size and Demand Price	As per SRO, 10's
	GMP Status	Re-grant DML issuance date 09-04-2025.
	RRA status	USFDA Approved.
	Remark of the Renewal section	Tablet (General) section is approved by CLB. As per last inspection report dated 16-01-2025
	Remarks:	C-PAC Tab. 500mg (080070) M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the

		application for DML renewal.
	Decision: Approved	
52.	Brand Name + Dosage Form and Strength	Arte Tablets
	Composition	Each Tablet contains: Artemether.....80mg Lumefantrine..... 480mg
	Tracking ID and fee details	3H5-356-UQN6 Rs.37,000/-dated: 21.04.2025, (0008873853)
	Type of form	Fom-5
	Finished product specifications	International Pharmacopoeia Specs.
	Pack size and Demand Price	As per SRO, 8's
	GMP Status	Re-grant DML issuance date 09-04-2025.
	RRA status	FDA Approved.
	Remark of the Renewal section	Tablet (General) section is approved by CLB. As per last inspection report dated 16-01-2025
	Remarks:	Arte Tablets (080073) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Approved	
53.	Brand Name + Dosage Form and Strength	Plaqtek Tablet 200mg
	Composition	Each film coated Tablet contain: Hydroxychloroquine Sulfate.....200mg
	Tracking ID and fee details	ND8-WN6-YH9S Rs.37,000/-dated: 21.04.2025, (57289470)
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, 30's,50's
	GMP Status	Re-grant DML issuance date 09-04-2025.
	RRA status	USFDA Approved.
	Remark of the Renewal section	Tablet (General) section is approved by CLB. As per last inspection report dated 16-01-2025
	Remarks:	Plaqtek Tablet 200mg (106108) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Approved	
	Brand Name + Dosage Form and Strength	Asctek-C chewable Tablet 500mg

54.	Composition	Each chewable Tablet contains: Ascorbic Acid 500mg
	Tracking ID and fee details	9AY-WMM-5VQW Rs.37,000/-dated: 21.04.2025, (183485205077)
	Type of form	Fom-5
	Finished product specifications	USP Specs.
	Pack size and Demand Price	As per SRO, 40's
	GMP Status	Re-grant DML issuance date 09-04-2025.
	RRA status	USFDA Approved.
	Remark of the Renewal section	Tablet (General) section is approved by CLB. As per last inspection report dated 16-01-2025
	Remarks:	Asctek-C chewable Tablet 500mg (106111) M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Approved	
55.	Brand Name + Dosage Form and Strength	Aveteose – F Tablet
	Composition	Each Tablet contains: Iron Polymaltose Complex 100mg Folic Acid.....0.35mg (Innovator's Specifications).
	Tracking ID and fee details	M6R-M75-A4S1 Rs.37,000/-dated: 21.04.2025, (2197278414)
	Type of form	Fom-5
	Finished product specifications	Innovator's 's Specs.
	Pack size and Demand Price	As per SRO, 10's
	GMP Status	Re-grant DML issuance date 09-04-2025.
	Remark of the Renewal section	Generic versions already registered in Pakistan are available in chewable form Tablet (General) section is approved by CLB. As per last inspection report dated 16-01-2025
	Remarks:	Aveteose – F Tablet (080072) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Deferred for confirmation of applied formulation (whether chewable or to be swallowed) along with relevant reference (generic version/RRA)	
	Brand Name + Dosage Form and Strength	Entzu Tablet 250mg

56.	Composition	Each Tablet contain: Chloroquine Phosphate which is eq. To 155mg of Chloroquine Base...250mg
	Tracking ID and fee details	9LT-L69-N835 Rs.37,000/-dated: 21.04.2025, (470727374)
	Type of form	Fom-5
	Finished product specifications	USP Specs.
	Pack size and Demand Price	As per SRO, 5's
	GMP Status	Regrant DML issuance date 09-04-2025.
	RRA status	USFDA
	Remark of the Renewal section	Label claim to be standardized as: Each Tablet contain: Chloroquine Phosphate 250mg eq. to Chloroquine Base...150mg Tablet (General) section is approved by CLB. As per last inspection report dated 16-01-2025
	Remarks:	Entzu Tablet 250mg (106109) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Approved. Formulation to be standardized in line with RRA along with fee	
57.	Brand Name + Dosage Form and Strength	Avemeb Sachet
	Composition	Each Sachet contains: Mebeverine HCL.....135mg , Ispaghula Husk.....3.5g
	Tracking ID and fee details	T5S-U4U-Y7ZY Rs.37,000/-dated: 21-04-2025 (279172187)
	Type of form	Fom-5
	Finished product specifications	Manufacturer's Specifications
	Pack size and Demand Price	As per SRO, 10's, 30's
	GMP Status	DML Re-grant Issuance Date 09-04-2025
	RRA status	Reckitt Benckiser Healthcare (UK) Ltd (USA) Approved
	Remark of the Renewal section	Fee for change of specification is required. Sachet (General) section is approved by CLB. As per last inspection report dated 16-01-2025
	Remarks:	Avemeb Sachet (079249) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal
	Decision: Approved. Fee to be submitted for change of specification.	
58.	Brand Name + Dosage Form and Strength	Ditro Sachet
	Composition	Each Sachet contains: Diocetahedral Smectite 3gm

	Tracking ID and fee details	A9B-QYZ-3XBD Rs.37,000/-dated: 21-04-2025 (24576808372)
	Type of form	Fom-5
	Finished product specifications	(Innovator's Specifications)
	Pack size and Demand Price	As per SRO, 10's, 30's
	GMP Status	DML Re-grant Issuance Date 09-04-2025
	RRA status	ANSM Approved Smecta M/s IPSEN Industrie. France
	Remark of the Renewal section	Sachet (General) section is approved by CLB. As per last inspection report dated 16-01-2025
	Remarks:	Ditro Sachet (80413) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Approved	
59.	Brand Name + Dosage Form and Strength	Monbro Sachet
	Composition	Each Sachet contains: Montelukast Sodium eq. to Montelukast.....4mg
	Tracking ID and fee details	A3H-NU8-3AL2 Rs.37,000/-dated: 21-04-2025 (60774474269)
	Type of form	Fom-5
	Finished product specifications	USP Specifications
	Pack size and Demand Price	As per SRO 14's
	GMP Status	DML Re-grant Issuance Date 09-04-2025
	RRA status	USFDA Approved
	Remark of the Renewal section	Sachet (General) section is approved by CLB. As per last inspection report dated 16-01-2025
	Remarks:	Monbro Sachet (085497) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Approved	
60.	Brand Name + Dosage Form and Strength	Aveqam Sachet
	Composition	Each Sachet contains: Sodium Chloride.....2.6gm Potassium Chloride.....1.5gm Trisodium Citrate Dihydrate.....2.9gm Glucose Anhydrous... 13.5gm
	Tracking ID and fee details	UXU-MHG-8R37 Rs.37,000/-dated: 21-04-2025 (08021229)
	Type of form	Fom-5
	Finished product specifications	BP Specifications
	Pack size and Demand Price	As per SRO, 10, 20's, 100's
	GMP Status	DML Re-grant Issuance Date 09-04-2025
	RRA status	WHO approved formulation

	Remark of the Renewal section	Sachet (General) section is approved by CLB. As per last inspection report dated 16-01-2025
	Remarks:	Aveqam Sachet (079248) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Approved	
61.	Brand Name + Dosage Form and Strength	Transobiq 500mg Capsule
	Composition	Each Tablet contains: Tranexamic Acid 500mg
	Tracking ID and fee details	UGW-8BB-4WLG Rs.37,000/-dated: 21-04-2025 (634240500976)
	Type of form	Fom-5
	Finished product specifications	manufacturer's Specifications
	Pack size and Demand Price	As per SRO, 10' 20's
	GMP Status	DML Re-grant Issuance Date 09-04-2025
	RRA status	PMDA Approved
	Remark of the Renewal section	Applied formulation is available in Japanese Pharmacopeia. Firm is advised to apply for change of specification Capsule (General) section is approved by CLB. As per last inspection report dated 16-01-2025
	Remarks:	Transobiq Capsule (080074) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Approved. Fee to be submitted for change of specification.	
62.	Brand Name + Dosage Form and Strength	Faxtin Capsule
	Composition	Each Capsule contains: Fluoxetine HCL eq. to Fluoxetine 20mg
	Tracking ID and fee details	TEX-BYU-1V6R Rs.37,000/-dated: 21-04-2025 (145341124)
	Type of form	Fom-5
	Finished product specifications	BP Specifications
	Pack size and Demand Price	As per SRO, 10' 20's
	GMP Status	DML Re-grant Issuance Date 09-04-2025
	RRA status	Prozac 20 mg Capsules (USFDA Approved)
	Remark of the Renewal section	Capsule (General) section is approved by CLB. As per last inspection report dated 16-01-2025
	Remarks:	Faxtin Capsule (080075) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter

		No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Approved	
63.	Brand Name + Dosage Form and Strength	Aveome Capsule. 20mg
	Composition	Each capsule contains: Omeprazole enteric coated pellets eq. to Omeprazole.....20mg
	Tracking ID and fee details	SZZ-BR7-H93E Rs.37,000/-dated: 21-04-2025 (336681484838)
	Type of form	Fom-5
	Finished product specifications	BP Specifications
	Pack size and Demand Price	As per SRO, 10', 14's, 100's
	GMP Status	DML Regrant Issuance Date 09-04-2025
	RRA status	PRILOSEC Capsule (USFDA Approved)
	Remark of the Renewal section	Source of pellets to be provided along with relevant documents. Capsule (General) section is approved by CLB. As per last inspection report dated 16-01-2025
	Remarks:	Aveome Capsule. 20mg (080994) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Deferred for submission of source of pellets along with relevant documents.	
64.	Brand Name + Dosage Form and Strength	Aveome Capsule. 40mg
	Composition	Each capsule contains: Omeprazole enteric coated pellets eq. to Omeprazole.....40mg
	Tracking ID and fee details	X5E-J1V-NM7J Rs.37,000/-dated: 21-04-2025 (32552806164)
	Type of form	Fom-5
	Finished product specifications	BP Specifications
	Pack size and Demand Price	As per SRO, 10', 14's, 100's
	GMP Status	DML Re-grant Issuance Date 09-04-2025
	RRA status	USFDA Approved
	Remark of the Renewal section	Source of pellets to be provided along with relevant documents. Capsule (General) section is approved by CLB. As per last inspection report dated 16-01-2025
	Remarks:	Aveome Cap. 40mg (080995) M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due

		to the late submission of the application for DML renewal.
	Decision: Decision: Deferred for submission of source of pellets along with relevant documents. .	
65.	Brand Name + Dosage Form and Strength	Arozy Capsule 250mg
	Composition	Each Capsule contains: Azithromycin Dihydrate eq. to Azithromycin 250mg
	Tracking ID and fee details	V1M-6HB-P52B Rs.37,000/-dated: 21-04-2025 (8978263779)
	Type of form	Fom-5
	Finished product specifications	BP Specifications
	Pack size and Demand Price	As per SRO, 10', 14's, 100's
	GMP Status	DML Re-grant Issuance Date 09-04-2025
	RRA status	USFDA Approved
	Remark of the Renewal section	Capsule (General) section is approved by CLB. As per last inspection report dated 16-01-2025
	Remarks:	Arozy Capsule 250mg (080076) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Approved	
66.	Brand Name + Dosage Form and Strength	Gabrin Capsule 100mg
	Composition	Each Capsule contains: Pregabalin 100mg
	Tracking ID and fee details	3JT-ZAT-4241 Rs.37,000/-dated: 21-04-2025 (9748791718)
	Type of form	Fom-5
	Finished product specifications	BP Specifications
	Pack size and Demand Price	As per SRO, 10', 14's, 100's
	GMP Status	DML Re-grant Issuance Date 09-04-2025
	RRA status	USFDA Approved
	Remark of the Renewal section	Capsule (General) section is approved by CLB. As per last inspection report dated 16-01-2025
	Remarks:	Gabrin Capsule 100mg (080077) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Approved	
67.	Brand Name + Dosage Form and Strength	A-Lenso Capsule 30mg
	Composition	Each Capsule contains: Enteric coated pellets of Lansoprazole equivalent to

		Lasoprazole 30mg
	Tracking ID and fee details	E7V-QN3-WAHE Rs.37,000/-dated: 21-04-2025 (895397954904)
	Type of form	Fom-5
	Finished product specifications	Innovator's Specifications
	Pack size and Demand Price	As per SRO, 10', 14's, 100's
	GMP Status	DML Re-grant Issuance Date 09-04-2025
	RRA status	USFDA Approved
	Remark of the Renewal section	Applied formulation is available in official monographs. Hence firm is advised to apply for change of specifications along with fee. Source of pellets to be provided along with required documents. Capsule (General) section is approved by CLB. As per last inspection report dated 16-01-2025
	Remarks:	A-Lenso Capsule 30mg (080996) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal. Decision: Deferred for submission of source of pellets along with relevant documents.
68.	Brand Name + Dosage Form and Strength	Esdor Capsule 40mg
	Composition	Each Capsule contains: Delayed release pellets of Esomeprazole Magnesium Trihydrate equivalent to Esomeprazole.....40mg
	Tracking ID and fee details	HQN-VJ4-UXS7 Rs.37,000/-dated: 21-04-2025 (4121270322)
	Type of form	Fom-5
	Finished product specifications	USP Specifications
	Pack size and Demand Price	As per SRO, 10', 14's, 100's
	GMP Status	DML Re-grant Issuance Date 09-04-2025
	RRA status	USFDA Approved
	Remark of the Renewal section	Source of pellets to be provided along with required documents. Capsule (General) section is approved by CLB. As per last inspection report dated 16-01-2025
	Remarks:	Esdor Capsule 40mg (080997) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.

	Decision: Deferred for submission of source of pellets along with relevant documents.	
69.	Brand Name + Dosage Form and Strength	Esdor Capsule 20mg
	Composition	Each Capsule contains: Delayed release pellets of Esomeprazole Magnesium Trihydrate equivalent to Esomeprazole.....20mg
	Tracking ID and fee details	ES2-8MS-WDG4 Rs.37,000/-dated: 21-04-2025 (2037641054)
	Type of form	Fom-5
	Finished product specifications	USP Specifications
	Pack size and Demand Price	As per SRO, 10', 14's, 100's
	GMP Status	DML Re-grant Issuance Date 09-04-2025
	RRA status	USFDA Approved
	Remark of the Renewal section	Source of pellets to be provided along with required documents. Capsule (General) section is approved by CLB. As per last inspection report dated 16-01-2025
	Remarks:	Esdor Capsule 20mg (080998) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Deferred for submission of source of pellets along with relevant documents.	
70.	Brand Name + Dosage Form and Strength	D-OST Capsule 50mg
	Composition	Each Capsule contains: Diacerein 50mg
	Tracking ID and fee details	1RJ-14N-ANYL Rs.37,000/-dated: 21-04-2025 (89617851)
	Type of form	Fom-5
	Finished product specifications	Innovator's Specifications
	Pack size and Demand Price	As per SRO, 10', 14's, 100's
	GMP Status	DML Re-grant Issuance Date 09-04-2025
	RRA status	USFDA Approved
	Remark of the Renewal section	Capsule (General) section is approved by CLB. As per last inspection report dated 16-01-2025
	Remarks:	D-OST Capsule 50mg (103293) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
	Decision: Approved.	
71.	Brand Name + Dosage Form and Strength	AVN-75 Capsule 75mg
	Composition	Each Capsule contains: Oseltamivir (as phosphate) 75 mg

Tracking ID and fee details	9AP-1LV-4T2Q Rs.37,000/-dated: 21-04-2025 (07753985904)
Type of form	Fom-5
Finished product specifications	USP
Pack size and Demand Price	As per SRO, 10', 14's, 100's
GMP Status	DML Re-grant Issuance Date 09-04-2025
RRA status	USFDA Approved
Remark of the Renewal section	Capsule (General) section is approved by CLB. As per last inspection report dated 16-01-2025
Remarks:	AVN-75 Capsule 75mg (106110) by M/s Aventek Pharmaceuticals (Pvt.) Ltd, address Plot No. 44-C, Sundar Industrial Estate, Lahore (DML No. 000660), was declared invalid vide letter No. F.1-70/2022-Lic (Vol-I) dated 11 November 2024, due to the late submission of the application for DML renewal.
Decision: Approved.	

Case No.02: M/s. Libra Pharmaceuticals (Pvt) Ltd. 77 Industrial Estate, Hayatabad Peshawar

1.	Brand Name + Dosage Form and Strength	Libroxime DS Dry Suspension
	Composition	Each 5 ml contains Cefixime (as trihydrate)...200 mg
	Tracking ID and fee details	Rs.37,000/-dated: 24.04.2025, (6283904639)
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO 30ml
	GMP Status	GMP inspection report dated 12.08.2020 Dry powder suspension (Cephalosporin) approved on 28-09-2004
	RRA status	USFDA approved
	Remark of the Renewal section	Updated GMP Status to be verified.
	Remarks:	Firm has applied Registration of Libroxime DS Dry Suspension (060087) a fresh due to non- submission of renewal application
Decision: Deferred for updated GMP status.		
2.	Brand Name + Dosage Form and Strength	Zatax plus 1g Injection
	Composition	Each vial contains Cefoperazone (as sodium) 500 mg Sulbactam(as sodium) 500 mg
	Tracking ID and fee details	Rs.30,000/-dated: 17.04.2024, (895852228351) Rs.7,000/-dated: 11.04.2025, (280885756344) AB3-U1W-4PYJ
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO

		1's
	GMP Status	GMP inspection report dated 12.08.2020 Dry powder injection (Cephalosporin) approved on 25-02-2013
	RRA status	PMDA Approved
	Remark of the Renewal section	Applied formulation is not available in USP Updated GMP Status to be verified.
	Remarks:	Firm has applied a fresh Registration of Zatax plus 1g Injection (076827) due to non- submission of renewal application
	Decision: Deferred for updated GMP status.	
3.	Brand Name + Dosage Form and Strength	Zatax plus 2g Injection
	Composition	Each vial contains Cefoperazone (as sodium) 1000 mg Sulbactam (as sodium).....1000 mg
	Tracking ID and fee details	Rs.30,000/-dated: 17.04.2024, (603598216) Rs.7,000/-dated: 11.04.2025, (75331015) PN8-6B9-UXXQ
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO, 1, s
	GMP Status	GMP inspection report dated 12.08.2020 Dry powder injection (Cephalosporin) approved on 25-02-2013
	RRA status	PMDA approved
	Remark of the Renewal section	Applied formulation is not available in USP Updated GMP Status to be verified.
	Remarks:	Firm has applied a fresh Registration of Zatax plus 2g Injection (076828) due to non- submission of renewal application
	Decision: Deferred for updated GMP status.	
4.	Brand Name + Dosage Form and Strength	Zine syrup
	Composition	Each 5 ml contains Cetirizine dihydrochloride 5 mg
	Tracking ID and fee details	Rs.30,000/-dated: 15.07.2024, (407317573285) Rs.7,000/-dated: 11.04.2025, (5194773011) RZN-RS5-9PP3
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO,60ml
	GMP Status	GMP inspection report dated 12.08.2020
	RRA status	MHRA approved Indoco Remedies UK Limited

	Remark of the Renewal section	Formulation available in USP/BP with hydrochloride salt instead of dihydrochloride form Updated GMP Status to be verified. Evidence for approval of manufacturing facility/ relevant section by CLB is required.
	Remarks:	Firm has applied Registration of Zine syrup (024855) a fresh due to non-submission of renewal application.
	Decision: Deferred for updated GMP status and manufacturing facility (approved by CLB)	
5.	Brand Name + Dosage Form and Strength	Zine tablets
	Composition	Each film coated tablet contains Cetirizine dihydrochloride 10 mg
	Tracking ID and fee details	Rs.7000/-dated: 15.04.2025, (897255717753) Rs. 30,000/-dated: 15.07.2024, (681754363068) T8M-GT3-TBSS
	Type of form	Fom-5
	Finished product specifications	USP
	Pack size and Demand Price	As per SRO,10,s
	GMP Status	GMP inspection report dated 12.08.2020
	RRA status	MHRA approved Flamingo Pharma UK Ltd.
	Remark of the Renewal section	Formulation available in USP/BP with hydrochloride salt instead of dihydrochloride form. Updated GMP Status to be verified. Evidence for approval of manufacturing facility/ relevant section by CLB is required.
	Remarks:	Firm has applied a fresh Registration of Zine tablets (021831) due to non- submission of renewal application
	Decision: Deferred for updated GMP status and manufacturing facility (approved by CLB)	

Import & Vet-II Section/Human Import

Case No: 01 M/S SANOFI-AVENTIS PAKISTAN REQUESTED FOR EXTENSION IN EXEMPTION FROM LABELING TEXT ON – GLUCANTIME 1.5G/5ML SOLUTION FOR INJECTION (REG. NO.088889)

M/s Hoechst Pakistan Limited, Plot No. 23, Sector No. 22, Korangi Industrial Area, Karachi has requested that subject product is being manufactured and primarily packaged in large volume at the source point from where it will be exported / distributed to different countries as per their needs.

In light of the above, the firm requested for extension in labeling exemption of the said product and product import in Standard Export Packs and **locally print the Registration Number, Maximum Retail Price and Urdu Text on the packs once imported** at their licensed premises i.e. M/s Hoechst Pakistan Limited, Plot No. 23, Sector No. 22, Korangi Industrial Area, Karachi (Drug Manufacturing License No.000007 by way of formulation)

Previously competent authority has granted permission on 30th August, 2023 the same subject mentioned as above.

Firm has submitted following supporting documents: -

1. A requisite fee Rs.10,000/-.
2. Copy of previous approval for Urdu labeling exemption.
3. SOP's for "Control of repacking operations"
4. An undertaking.

Decision: Registration Board acceded to the request of firm for extension in labeling exemption of the GLUCANTIME 1.5G/5ML SOLUTION FOR INJECTION (REG. NO.088889) to be imported in Standard Export Packs and locally print the Registration Number, Maximum Retail Price and Urdu Text on the packs once imported at their licensed premises i.e. M/s Hoechst Pakistan Limited, Plot No. 23, Sector No. 22, Korangi Industrial Area, Karachi (Drug Manufacturing License No.000007 by way of formulation) to comply with the requirements as per Drugs (Labelling & Packing) Rules, 1986. This permission shall be valid for one (01) year only. The firm shall submit the future plan regarding the import of Drugs (Labelling & Packing) Rules, 1986 compliant packs.

Case.No.02: **REQUEST OF M/S NOVARTIS PHARMA (PAKISTAN) LIMITED FOR WITHDRAWAL OF REGISTRATION APPLICATION.**

M/s Novartis Pharma (Pakistan) Limited, 15 West Wharf, Dockyard Road, Karachi has submitted request for withdrawal of registration application of following approved imported product in 316th meeting of Registration Board, due to Global Business decision. Details are as under.

Name of Product	Name of Importer, Product License Holder / Manufacturer
Energair Breezhaler Inhalation Powder Hard Capsule 150/50/160mcg Each Capsule contains: Indacaterol as acetate.....150mcg Glycopyrronium as Bromide...50mcg Mometasone Furoate.....160mcg	M/s Novartis Pharma (Pakistan) Limited, 15 West Wharf, Karachi. Product License Holder: M/s Novartis Pharma Schweiz AG, 6343 Risch, Switzerland. Manufacturer M/s Novartis Pharma Stein AG, Schaffhauserstrasse, 4332 Stein, Switzerland.
Decision: Approved as per Policy for inspection of Manufacturer abroad and verification of local storage facility. The Board further advised the P.E&R division to include following information on the registration letter of Dry Powder Inhaler Capsules: i. Label claim for the "Target Delivered Dose". ii. Description of the delivery device (inhaler) intended to be marketed along with the applied formulation.	

Decision: Registration Board acceded the firm's request for withdrawal of registration application of following imported product:

Name of Product	Name of Importer, Product License Holder / Manufacturer
Energair Breezhaler Inhalation Powder Hard Capsule 150/50/160mcg Each Capsule contains:	M/s Novartis Pharma (Pakistan) Limited, 15 West Wharf, Karachi. Product License Holder:

Indacaterol as acetate.....150mcg Glycopyrronium as Bromide...50mcg Mometasone Furoate.....160mcg	M/s Novartis Pharma Schweiz AG, 6343 Risch, Switzerland. Manufacturer M/s Novartis Pharma Stein AG, Schaffhauserstrasse, 4332 Stein, Switzerland.

Case.No.03: REQUEST OF M/S NOVARTIS PHARMA (PAKISTAN) LIMITED FOR WITHDRAWAL OF REGISTRATION APPLICATION.

M/s Novartis Pharma (Pakistan) Limited, 15 West Wharf, Dockyard Road, Karachi has submitted request for withdrawal of registration application of following approved imported product in **316th meeting of Registration Board**, due to Global Business decision. Details are as under.

Name of Product	Name of Importer, Product License Holder / Manufacturer
Ateectura Breezhaler inhalation powder, hard capsule 150/80mcg Each Capsule contains: Indacaterol (as acetate) 150 mcg Mometasone furoate.....80mcg Each delivered dose (the dose that leaves the mouthpiece of the inhaler) contains 125 mcg of Indacaterol (as acetate) and 62.5 mcg of Mometasone furoate	M/s. Novartis Pharma (Pakistan) Limited, 15 West Wharf, Karachi, Pakistan Product License Holder: M/s Novartis Pharma Schweiz AG, 6343 Risch, Switzerland Manufacturer: M/s Novartis Pharma Stein AG, Schaffhauserstrasse, 4332 Stein, Switzerland
Ateectura Breezhaler inhalation powder, hard capsule 150/160mcg Each Capsule contains: Indacaterol (as acetate) 150 mcg Mometasone furoate.....160mcg Each delivered dose (the dose that leaves the mouthpiece of the inhaler) contains 125 mcg of Indacaterol (as acetate) and 127.5 mcg of Mometasone furoate	
Ateectura Breezhaler inhalation powder, hard capsule 150/320mcg Each Capsule contains: Indacaterol (as acetate) 150 mcg Mometasone furoate.....320mcg Each delivered dose (the dose that leaves the mouthpiece of the inhaler) contains 125 mcg of Indacaterol (as acetate) and 260 mcg of Mometasone furoate	
Decision: Approved with Innovator's specifications as per Policy for inspection of Manufacturer abroad and verification of local storage facility. The Board further advised the P.E&R division to include following information on the registration letter of Dry Powder Inhaler Capsules: i. Label claim for the "Target Delivered Dose". ii. Description of the delivery device (inhaler) intended to be marketed along with the applied formulation.	

Decision: Registration Board acceded the firm's request for withdrawal of registration application following imported products:

Name of Product	Name of Importer, Product License Holder / Manufacturer
Aectura Breezhaler inhalation powder, hard capsule 150/80mcg Each Capsule contains: Indacaterol (as acetate) 150 mcg Mometasone furoate.....80mcg Each delivered dose (the dose that leaves the mouthpiece of the inhaler) contains 125 mcg of Indacaterol (as acetate) and 62.5 mcg of Mometasone furoate	M/s. Novartis Pharma (Pakistan) Limited, 15 West Wharf, Karachi, Pakistan Product License Holder: M/s Novartis Pharma Schweiz AG, 6343 Risch, Switzerland Manufacturer: M/s Novartis Pharma Stein AG, Schaffhauserstrasse, 4332 Stein, Switzerland
Aectura Breezhaler inhalation powder, hard capsule 150/160mcg Each Capsule contains: Indacaterol (as acetate) 150 mcg Mometasone furoate.....160mcg Each delivered dose (the dose that leaves the mouthpiece of the inhaler) contains 125 mcg of Indacaterol (as acetate) and 127.5 mcg of Mometasone furoate	
Aectura Breezhaler inhalation powder, hard capsule 150/320mcg Each Capsule contains: Indacaterol (as acetate) 150 mcg Mometasone furoate.....320mcg Each delivered dose (the dose that leaves the mouthpiece of the inhaler) contains 125 mcg of Indacaterol (as acetate) and 260 mcg of Mometasone furoate	

Case.No.04: REQUEST OF M/S PFIZER PAKISTAN LIMITED FOR WITHDRAWAL OF REGISTRATION APPLICATION.

M/s Pfizer Pakistan Limited, 12 Dockyard Road, West Wharf, Karachi has submitted request for withdrawal of registration application of following approved imported product in **330th meeting of Registration Board**, the reason for the withdraw is due solely to a Pfizer business decision and it is not related to any safety, tolerability, efficacy or quality concern. Details are as under.

Name of Product	Name of Importer, Product License Holder / Manufacturer
NURTEC Oral Lyophilisate (Rimegepant) 75mg Each oral lyophilisate contains Rimegepant sulfate, equivalent to 75mg Rimegepant	M/s Pfizer Pakistan Limited 12-Dockyard Road, West Wharf, Karachi, Pakistan Product License Holder Biohaven Pharmaceuticals Ireland DAC, 6 th Floor, South Bank House, Barrow Street, Dublin, D04 TR29, Ireland Manufacture, Quality Control & Primary Packaging by: Catalent UK Swindon Zydis Limited, Frankland Road, Blagrove, Swindon, SN5 8RU UNITED KINGDOM Primary (labelling blister printing): Anderson Brecon (UK) Limited

	Units 2-7, Wye Valley Business Park, Brecon Road, Hay-On-Wye, Hereford, HR3 5PG, United Kingdom Secondary packaging and Batch Release by: Millmount Healthcare Limited, Block 7 City North Business Campus, Stamullen Ireland
Decision: Approved as per policy of inspections of manufacturer abroad.	

Decision: Registration Board acceded the firm's request for withdrawal of registration application following imported products:

Name of Product	Name of Importer, Product License Holder / Manufacturer
NURTEC Oral Lyophilisate (Rimegepant) 75mg Each oral lyophilisate contains Rimegepant sulfate, equivalent to 75mg Rimegepant	M/s Pfizer Pakistan Limited 12-Dockyard Road, West Wharf, Karachi, Pakistan Product License Holder Biohaven Pharmaceuticals Ireland DAC, 6 th Floor, South Bank House, Barrow Street, Dublin, D04 TR29, Ireland Manufacture, Quality Control & Primary Packaging by: Catalent UK Swindon Zydis Limited, Frankland Road, Blagrove, Swindon, SN5 8RU UNITED KINGDOM Primary (labelling blister printing): Anderson Brecon (UK) Limited Units 2-7, Wye Valley Business Park, Brecon Road, Hay-On-Wye, Hereford, HR3 5PG, United Kingdom Secondary packaging and Batch Release by: Millmount Healthcare Limited, Block 7 City North Business Campus, Stamullen Ireland

Case.No.05: REQUEST OF M/S SERVIER RESEARCH AND PHARMACEUTICALS (PAKISTAN) (PVT) LTD, LAHORE FOR DE-REGISTRATION OF REGISTERED PRODUCT.

M/s Servier Research and Pharmaceuticals (Pakistan) (Pvt) Ltd, Office No. 5 & 6, 7th floor, Askari Corporate Tower 75/76D-1, Main Boulevard, Gulberg-III, Lahore has submitted request for de-registration of following registered imported product as per details mentioned alongside.

S. No	Product(s) Name	Reg. No.	Reason for De-Reg. (stated by firm)	Alternative Registered Product
1.	Lonsurf 15mg Tablet Each film coated tablet contains: Trifluridine..... 15mg tipiracil HCL..... 7.065mg (eq. to Tipiracil..... 6.14mg)	094762	I hereby inform you that Les Laboratoires Servier as for a discontinuation of the marketing authorization of	Not provided

	(As Per Innovator's Specifications*)		Lonsurf 15mg/6.14mg & Lonsurf 20mg/8.19mg.	
2.	Lonsurf 20mg Tablet Each film coated tablet contains: Trifluridine..... 20mg Tipiracil hcl..... 9.420mg (eq. To tipiracil..... 8.19mg) (as per innovator's specifications*)	090527		

Firm has submitted following supporting documents:

- Registration letter of Lonsurf 15mg Tablet & Lonsurf 20mg Tablet issued on 06-03-2019.
- Fee of Rs.7500/- for each product.
- Letter for Les Laboratoires Servier, France.

Decision: Registration Board acceded the firm's request for de-registration of following imported products:

S. No	Product(s) Name	Reg. No.
1.	Lonsurf 15mg Tablet Each film coated tablet contains: Trifluridine..... 15mg tipiracil HCL..... 7.065mg (eq. to Tipiracil..... 6.14mg) (As Per Innovator's Specifications*)	094762
2.	Lonsurf 20mg Tablet Each film coated tablet contains: Trifluridine..... 20mg Tipiracil hcl..... 9.420mg (eq. To tipiracil..... 8.19mg) (as per innovator's specifications*)	090527

I&V-I/Veterinary

- SUBJECT: - CORRECTION INFORMULAITON OF APPROVED PRODUCT ACTIMEC DS INJECTION OF M/S. SELMORE PHARMACEUTICALS (PVT) LIMITED, 36 KM, MULTAN ROAD, LAHORE.**

Below mentioned product was approved in 291st meeting and letter was issued vide No. F. 7-5/2019-I&V-I (M-291) (Vet) dated 23rd October, 2020 Now the firm has requested for correction in formulation as per available generic with fee Rs.12000/- details are as under:-

Reg. No.	Name of drug(s) & Composition.	Correction required
105052	Actimec DS Injection Each ml contains:- Ivermectin.....20mg Clorsulon.....10mg (USP Specifications)	Actimec DS Injection Each ml contains:- Ivermectin.....20mg Clorsulon.....100mg (USP Specifications)

Decision: Approved.

2.	Name and address of manufacturer / Applicant	M/s Nawan Laboratories (Pvt) Ltd., 136 sector 15 Korangi Industrial Area Karachi.
	Brand Name + Dosage Form + Strength	Cephicure 500mg Intrauterine Suspension
	Composition	Each 19.5gm Syringe Contains: Cephapirin as Benzathine...500mg
	Diary No. Date of R& I & fee	Dy.No 33290 dated 15-12-2020 Rs.20,000/- dated 15-12-2020
	Pharmacological Group	Antibacterial/ Anti-infective/ Antiseptic
	Type of Form	Form 5
	Finished product Specification	Manufacturer's specifications
	Pack size & Demanded Price	10 x 19.5gm Syringes: Decontrolled
	Me-too status	Metricure white oily homogenous Intra-Uterine suspension of M/s ICI Pakistan Ltd Karachi (Reg. No. 078355)
	GMP status	Last GMP inspection is conducted on 25-01-2022 and the report concludes that firm was considered to be operating at good level of overall GMP compliance
	Remarks of the Evaluator	Shortcomings: • Approval of Relevant section • evidence of applied formulation/drug already approved by DRAP (generic / me-too status) along with registration number, brand name and name of firm.
	Decision of 326th meeting: Deferred for following: • approval of relevant manufacturing facility • evidence of applied formulation/drug already approved by DRAP (generic / me-too status) along with registration number, brand name and name of firm.	
	Updated status: The firm has submitted the following: “that in our Routine GMP Inspection Report which was conducted on 11-01-2021 in which clearly mentioned <i>“the firm has well dedicated facility for sterile Cephalosporin liquid vials for veterinary use and the same is intended to be used for IMM Tubes based on same GMP requirement”</i> . We use Sterile Liquid Injection Section veterinary for preparation of “Cephicure 500mg Intrauterine Suspension” based on same GMP requirement. There's no any difference in manufacturing preparation as manufacturing intramammary only the way of administration is difference like as “The contents of syringe should be introduced into the lumen of the uterus using the disposable catheter through the cervix into the lumen of the uterus and gentle oscillating movements of the cervix and then inject the suspension.”	
	Me-too/ generic status: Metricure white oily homogenous Intra-Uterine suspension of M/s ICI Pakistan Ltd Karachi (Reg. No. 078355)	
	Remarks of the evaluator: The strength of applied formulation is different than that of reference product approved in the Netherland and already registered in DRAP (the applied formulation contains same quantity	

of API as in reference product per 19.5gm instead of 19gm)	
Decision: Deferred for submission of evidence of approval of applied formulation/drug, in the applied strength, already approved by DRAP (generic / me-too status) alongwith registration number, brand name and name of firm or any RRA.	
Firm correct label claim as per generic.	
Decision: Approved. Firm shall submit fee for specification correction before issuance of letter.	
3. Name and address of manufacturer/ Applicant	M/s Nawan Laboratories (Pvt.) Ltd., plots No. 136, sector 15, Korangi Industrial Area Karachi (Dry powder sachet section (General) veterinary).
Brand Name + Dosage Form + Strength	Easy Digest powder.
Composition	Each 1000gm contains: Propionic Acid Calcium 250gm Propionic Acid Sodium 400gm Acetanilide 150gm Magnesium Oxide 125gm Iron II Sulphate 0.400mg Zinc Sulphate 0.100mg Magnesium Sulphate 0.200mg Copper Sulphate 0.450mg Cobalt Sulphate 0.400mg Sodium Molybdate 0.100mg Sodium Chloride 20gm
Diary No. Date of R & I & fee	Dy. No 11444 dated 05-03-2019; Rs.20,000/- dated 04-03-2019.
Pharmacological Group	Appetizing and digestive tonic powder.
Type of Form	Form-5
Finished product Specification	Manufacturer specifications.
Pack size & Demanded Price	100gm sachet & decontrolled.
Approval status of product in Reference Regulatory Authorities	N/A.
Me-too status	Alvegest powder, Star Laboratories, Reg. No. 008029.
GMP status	Firm has submitted routine GMP inspection report dated 25-01-2022 wherein it is concluded that keeping in view the attitude of the management towards continuous improvements and current observations their overall GMP compliance is rated as good.
Remarks of the Evaluator	Firm was asked to revise their label claim as per their demanded pack size. They revised their label claim as follows; Each 100-gm powder contains; Propionic Acid Calcium 25gm Propionic Acid Sodium 40gm Acetanilide 15gm Magnesium Oxide 12.5gm

	Iron II Sulphate 0.040mg Zinc Sulphate 0.010mg Magnesium Sulphate 0.020mg Copper Sulphate 0.045mg Cobalt Sulphate 0.040mg Sodium Molybdate 0.010mg Sodium Chloride 2gm - Firm has submitted me too details as Alvegest powder manufactured by Star Laboratories, Reg. No. 008029. <i>However, the composition of the applied formulation is different from the already approved formulation.</i>
Decision of 307 th meeting of Registration Board;	Deferred for submission evidence of already approved formulation by the Registration Board with brand name, Registration number & manufacturer name. As the composition of the applied formulation is different from submitted me too in concentration of Iron II Sulphate, Zinc, Magnesium Sulphate, Copper Sulphate, Cobalt Sulphate and Sodium Molybdate.
Reply by the firm;	Firm has revised their formulation as per available approved/registered me too formulation without submission of applicable fee for Change of label claim/formulation. Revised label claim is as under; Each 1000-gm powder contains; Propionic Acid Calcium 250gm Propionic Acid Sodium 400gm Acetanilide 150gm Magnesium Oxide 125gm Iron II Sulphate 400mg Zinc Sulphate 100mg Magnesium Sulphate 200mg Copper Sulphate 450mg Cobalt Sulphate 400mg Sodium Molybdate 100mg Sodium Chloride 20gm
Remarks of the Evaluator PEC ^{XIII}	Full fee along with new form 5 and master formulation shall be submitted.
Decision of 324 th meeting of Registration Board:	Deferred for following; - Submission of full fee of 30,000/- for correction/pre-approval change in the label claim, method of manufacture/specifications, as per notification No.F.7-11/2012-B&A/DRAP dated 13-07-2021 along with revised form 5 shall be submitted. - Evidence of testing facility required for conducting testing of the applied formulation.
Reply submitted by the firm:	Firm has submitted 30,000/- fee vide slip no. 999270798078 dated 09-03-2023 along with revised Form 5.

	Firm has also submitted a list of 67 equipments in their quality control laboratory mentioning 2 HPLCs, UV spectrophotometer, FTIR, 02 Atomic absorptions and many more.
Remarks of the Evaluator PEC ^{XIII}	
Decision: Deferred for verification of the testing facility and availability of Atomic absorption spectrophotometer in a panel inspection report. The board also advised the Division of QA/LT to confirm the availability of required testing facilities of all the manufacturers of such formulations and make it part of GMP inspection reports. Firm submit inspection report which shows that “ The firm was found with required testing equipment in place, like HPLC, FTIR, TOC analyser, AA, LPC, etc Decision: Approved. Firm shall submit fee for specification correction before issuance of letter.	

4.	Name and address of Applicant	M/s Prix Pharmaceutica. 26 Abbot Road, Lahore, 54000, Pakistan
	Detail of Drug Sale License	Not provided
	Name and address of manufacturer	M/s Fatro S.P.A. Via Emilia, 285-40064 Ozzano dell’Emilia (Bologna)-Italy
	Name and address of marketing authorization holder	Not clarified
	Name of exporting country	Italy
	Type of Form	Form 5A
	Diary No. & Date of R& I	Dy No. 33989 Dated 29-12-2021
	Fee including differential fee	Rs.150,000 Deposit Slip No. 5566930933
	Brand Name +Dosage Form + Strength	Wondercef Powder & Solvent for Solution for Injection
	Composition	Each Vial Contains: Ceftiofur Sodium Eq. to Ceftiofur (lyophilized powder)...4200mg Solvent: Water for Injection (EP)....80ml Strength after reconstitution: 50mg/ml
	Finished Product Specification	As per Innovator
	Pharmacological Group	Antibacterial for systemic use
	Shelf life	Powder: 2 years Solvent: 4 years
	Demanded Price	Decontrolled
	Pack size	Not specified
	International availability	N/A
	Me-too status	Not confirmed
	Detail of certificates attached	Original or copy of legalized CoPP, Free Sales certificate, GMP of principal manufacturer and sole agency certificate are not attached

	Remarks of the Evaluator ^{xxiii}	- Valid, legalized CoPP, Free Sales Certificate and GMP certificate of the manufacturer are required. - Copy of valid DSL is required. - Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) along with registration number, brand name and name of firm is required. - Finished Product Specifications are required. - Pack size needs to be specified. - Label is not in accordance with The Drugs (Labelling and Packing) Rules, 1986. - Name & details of marketing authorization holder in the country of origin needs to be clarified. - Real time and accelerated stability studies results are required according to Zone IVA.
	Deferred for submission of following: - Valid, legalized CoPP, Free Sales Certificate and GMP certificate of the manufacturer. - Copy of valid DSL - Original, Valid notarized sole agency certificate - Evidence of applied formulation/drug already approved by DRAP (generic / me-too status) along with registration number, brand name and name of firm - Finished Product Specifications - Applied pack size - Revised label in accordance with The Drugs (Labelling and Packing) Rules, 1986. - Name & details of marketing authorization holder in the country of origin - Real time and accelerated stability studies results according to Zone IVA. The Board further decided that the applicant shall submit the response within 1 month after publication of the minutes. Firm has submitted following documents: - Copy of Valid, legalized CoPP, original already submitted - Copy of valid DSL - Copy Original, Valid notarized sole agency certificate - Evidence of applied formulation in RRA - Finished Product Specifications - Applied pack size - Revised label in accordance with The Drugs (Labelling and Packing) Rules, 1986. - Name & details of marketing authorization holder in the country of origin - Real time and accelerated stability studies results according to Zone IVA. Decision: Approved as per current import policy of manufacturer abroad.	



Drug Regulatory Authority of Pakistan
(Pharmaceutical Evaluation & Registration Division)



Applications submitted on e-App (PE&R)

Sr. No	Title	Description		
1	Case Category	Routine (Abdul Mughees)		
	Name, address of Applicant.	Shaigan Pharmaceuticals (Pvt) Ltd 14Km Adyala Road Post office Dahgal Rawalpindi (000333)		
	Application Form Dy. No / Tracking ID & date of submission	(199-918-SUAB, 2024-01-17)		
	Detail of Fee Submitted	30000.0, 2023-11-21,		
	The proposed proprietary name / brand name	LINAMET 2.5/1000mg Tablet		
	Label Claim	Each film coated tablet contains: Linagliptin.....2.5mg Metformin HCl.....1000mg		
	Reference to Finished product specifications	As per Innovators Specification		
	Proposed Pack Size	14's-As per SRO		
	Shelf Life (Unit)	2 Year(s)store in a cool and dry place below 30		
	For generic drugs (me-too Status)	NA		
	Pharmacotherapeutic Group of (API)	Antidiabetic		
	Name, address of Manufacturing site:	Self Manufacturing		
	Name & address of API manufacturer	Exemed Pharmaceuticals India,Fuxin Long Rui Pharmaceuticals		
	Detail of stability batches of drug product	2 batches of 750 tablets each 1 batch of 1500 tablets each		
	Documents for the procurement of API with approval from DRAP (in case of Import)	--		
	Pharmaceutical Equivalence and Comparative Dissolution Profile	PE & CDP submitted against Jentaduetto tablet		
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	As per Zone IV		
	The status in reference regulatory authorities	Jentaduetto 2.5/1000mg Tablet(Boehringer Ingelhum Pharma Germany		
	GMP status of the firm	28-12-2021: GMP certificate issued including tablet general section		
	Evidence of approval of manufacturing facility	28-12-2021: GMP certificate issued including tablet general section		
Evaluation Remarks				
Firm has submitted response to the following shortcomings:				
<table><tr><td>Sr.#</td><td>Observations</td></tr></table>			Sr.#	Observations
Sr.#	Observations			

1.6.5	Submit latest DML/GMP certificate shall be submitted issued by relevant regulatory authority
3.2.S.4	Justification shall be submitted for not including test of "Enantiomeric purity" in drug substance specifications
3.2.P.1	Justification shall be submitted for proposed quantity of Arginine in the formulation.
3.2.P.5	Justification shall be submitted for not including test of Arginine content in drug product specifications
3.2.P.6	COA of reference/working standard shall be submitted.
3.2.P.8	Documents confirming procurement of drug substance issued by DRAP I&E Office shall be submitted
Decision	
Approved	
Case Category	Routine (Abdul Mughees)
Name, address of Applicant.	Shaigan Pharmaceuticals (Pvt) Ltd 14Km Adyala Road Post office Dahgal Rawalpindi (000333)
Application Form Dy. No / Tracking ID & date of submission	(48S-ZAX-D7YT, 2024-02-12)
Detail of Fee Submitted	30000.0, 2023-12-18,
The proposed proprietary name / brand name	E-LINA 25/5mg Tablets
Label Claim	Each film coated tablet contains:Empagliflozin.....25mglinagliptin.....
Reference to Finished product specifications	As per Innovators Specification
Proposed Pack Size	2x7's-As per SRO
Shelf Life (Unit)	2 Year(s)store in a cool and dry place below 30
For generic drugs (me-too Status)	DIAMPA-LT(Getz Pharma)
Pharmaceutical Group of (API)	Antidiabetic
Name, address of Manufacturing site:	Self Manufacturing
Name & address of API manufacturer	Fuxin Long Rui Pharmaceuticals,India,Jiangsu Yongan Pharmaceuticals Co. Ltd. China
Detail of stability batches of drug product	3 batches of 1500 tablets each
Documents for the procurement of API with approval from DRAP (in case of Import)	Commercial invoices not attested by DRAp I&E office have been submitted
Pharmaceutical Equivalence and Comparative Dissolution Profile	PE & CDP performed against Diampa -LT tablet of Getz Pharma
Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	As per Zone IV conditions
The status in reference regulatory authorities	GLYXAMBI Tablets (Boehringer Ingelheim Germany)
GMP status of the firm	GMP certificate issued dated 04-11-2021
Evidence of approval of manufacturing facility	GMP certificate issued dated 04-11-2021 confirms availability of tablet general section
Evaluation Remarks	

Applicant has submitted response to the following shortcomings inter alia: Submit latest GMP inspection report of drug product manufacturer, conducted within last three years. Declaration of solubility of Empagliflozin in water as “practically insoluble” shall be justified with reference to the innovator drug product literature. Details of specific optical rotation of Empagliflozin are not provided in general properties section. Details of the reference material, against which structural characterization studies of Empagliflozin have been performed, shall be submitted. Analytical record shall be submitted in consolidated manner along with relevant raw data sheets and batch analysis report for each time point. Clarification shall be submitted regarding the wavelength applied for analysis of Assay and Dissolution test since submitted chromatograms have been analyzed at varied wavelength of 223nm and 225nm.

Decision

Approved

3	Case Category	Routine (Abdul Mughees)
	Name, address of Applicant.	Werrick Pharmaceuticals Plot No. 216 - 217, I-10/3, Industrial Area Islambad (000340)
	Application Form Dy. No / Tracking ID & date of submission	(VM5-J3R-3GSB, 2024-04-17)
	Detail of Fee Submitted	30000.0, 2024-02-19,
	The proposed proprietary name / brand name	Eziday-DUO 10/100mg Tablets
	Label Claim	Each Film Coated Tablet Contains:- Amlodipine as Besylate.....10mg Losartan Potassium.....100mg
	Reference to Finished product specifications	As per Innovators Specification
	Proposed Pack Size	10's-As per SRO, 14's-As per SRO, 20's-As per SRO, 28's-As per SRO, 30's-As per SRO, 7's-As per SRO
	Shelf Life (Unit)	2 Year 20°C -25°C
	For generic drugs (me-too Status)	Pixiz 10/100mg Tablets By Tabros Pharma, Karachi
	Pharmaceutical Group of (API)	
	Name, address of Manufacturing site:	Self Manufacturing
	Name & address of API manufacturer	
	Detail of stability batches of drug product	
	Documents for the procurement of API with approval from DRAP (in case of Import)	
	Pharmaceutical Equivalence and Comparative Dissolution Profile	
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	
	The status in reference regulatory authorities	Losamlo 10/100mg Tablets TAD Pharma GmbH https://portal.dimdi.de/amguifree/am/docoutput/jpad
	GMP status of the firm	
	Evidence of approval of manufacturing facility	
Evaluation Remarks		
Applicant used six unit for dissolution test in CDP studies instead of 12 units as recommended by WHO guideline for conducting comparative dissolution profiles CDP studies using 12 units as recommended by WHO guideline for conducting comparative dissolution profiles shall be submitted.		

	Decision	
	Deferred Deferred for submission of CDP studies of applied product against innovator/reference/comparator using 12 units as recommended by WHO guideline for conducting comparative dissolution profiles	
4	Case Category	Contract Manufacturing (Adil Saeed)
	Name, address of Applicant.	Welcome Pakistan Trading Pharma (Pvt) Ltd Chakri Interchange, Gangawala (000987)
	Application Form Dy. No / Tracking ID & date of submission	(EDP-EXD-461V, 2024-04-22)
	Detail of Fee Submitted	75000.0, 2024-04-01,
	The proposed proprietary name / brand name	Ferrina 500mg Injection
	Label Claim	Each 10ml Vial Contains: Iron as Ferric Carboxymaltose.....500mg (Product complies Innovator's Specs)
	Reference to Finished product specifications	As per Innovators Specification
	Proposed Pack Size	As per SRO-As per SRO
	Shelf Life (Unit)	2 YearStore below 25c
	For generic drugs (me-too Status)	FERINJECT 500mg/10ml INJECTION by RG Pharmaceuticals
	Pharmacotherapeutic Group of (API)	
	Name, address of Manufacturing site:	Wnsfeild Pharmaceuticals-Plot NO. 122, Block-A, Phase-V, Industrial Estate, Hattar, KPK. -
	The status in reference regulatory authorities	USFDA Approved
	Detail of previous approval	343rd meeting. Ferrina 500mg/10ml Injection
	Evaluation Remarks	
	Decision	
	Approved	
5	Case Category	Contract Manufacturing (Adil Saeed)
	Name, address of Applicant.	Weather Folds Pharmaceuticals Plot no. 69/2, Phase II, Industrial Area, Hattar, Pakistan. (000644)
	Application Form Dy. No / Tracking ID & date of submission	(EAT-QVY-QBBM, 2024-04-18)
	Detail of Fee Submitted	75000.0, 2024-01-10,
	The proposed proprietary name / brand name	Empzoo 5mg + 1000mg XR Tablet
	Label Claim	Each Film Coated Extended Release Tablet contains: Empagliflozin (as immediate release coat).....5mg Metformin Hydrochloride (as extended release Core).....1000mg (Product Complies Innovator's Specs)
	Reference to Finished product specifications	As per Innovators Specification
	Proposed Pack Size	As per SRO-As per SRO
	Shelf Life (Unit)	2 Year(s)Store below 25°C
	For generic drugs (me-too Status)	Erli Plus XR TABLET by PharmEvo
	Pharmacotherapeutic Group of (API)	Antidiabetic

	Name, address of Manufacturing site:	Winbrains Research Laboratories-Plot No. 69/1, Phase I-II, Industrial Estate, hattar, KPK-
	The status in reference regulatory authorities	USFDA Approved
	Detail of previous approval	Winpa 5/1000 mg XR Tablet, Approved in 343rd Meeting of Registration Board.
	Evaluation Remarks	
	Decision	
	Approved	
6	Case Category	Priority As Per 257-M of RB (Adil Saeed)
	Name, address of Applicant.	REVIVE HEALTH CARE 503, 5TH FLOOR EDEN HEIGHTS 6 MAIN GULBERG JAIL ROAD (05-352-0065)
	Application Form Dy. No / Tracking ID & date of submission	(RGZ-2UP-GH9N, 2025-06-30)
	Detail of Fee Submitted	300000.0, 2025-06-30,
	The proposed proprietary name / brand name	REVIBORT Injection 3.5 mg
	Label Claim	Each Vial Contains: Bortezomib..... 3.5mg
	Reference to Finished product specifications	As per Innovators Specification
	Proposed Pack Size	1's Vial-As per SRO
	Shelf Life (Unit)	2 Year(s)Store below 30 degree centigrade
	For generic drugs (me-too Status)	Product Registration No. 090738 by Revive Healthcare
	Pharmacotherapeutic Group of (API)	Proteasome inhibitors, ATC Code: L01XG01
	Name, address of Manufacturing site:	Qilu Pharmaceutical (Hainan) Co., Ltd.-No.273-A, Nanhai Avenue, National High-Tech Zone, Haikou, Hainan, 570314, China-China
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Pharmaceutical Equivalence study performed by Comparison of VELCADE 3.5 mg Injection (Innovator) with QILU's Bortezomib for Injection 3.5 mg, provided in section 3.2.P.2.2.1 (b)
	Name, address of Marketing Authorization Holder:	Qilu Pharmaceutical (Hainan) Co., Ltd., No.273-A, Nanhai Avenue, National High-Tech Zone, Haikou, Hainan, 570314, China, China
	Details of Certificates (CoPP/FSC/cGMP):	Valid Eudra GMP Certificate No. ES/106HV/24
	Details of Authorization Letter :	NA
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Accelerated 2 to 8 C for 6 months Long term: -20 to -25C for 24 months
	The status in reference regulatory authorities	VELCADE 3.5 mg powder for solution for injection, MHRA Approved
	Evaluation Remarks	
	Copy of USFDA issued COPP for Ukraine is uploaded. Valid till March 17, 2027.MA Holder: Qilu Pharmaceutical (Hainan) Co., Ltd., No.273-A, Nanhai Avenue, National High-Tech Zone, Haikou, Hainan 570314 CHINAManufacturer: Qilu Pharmaceutical (Hainan) Co., Ltd., No. 273-A, Nanhai Avenue, National High-Tech Zone, Haikou, Hainan 570314 CHINACOPP states that product is on sale in US market. manufacturer is holder of Eudra GMP also. Copy of letter of Authorization is also attached.	

	Decision	
	Approved	
	As per policy for inspection abroad.	
7	Case Category	Routine (Dr. Farhad Ullah)
	Name, address of Applicant.	Saffron Pharmaceuticals 19-Km Sheikhpura Road (000616)
	Application Form Dy. No / Tracking ID & date of submission	(37N-PY6-4VJD, 2024-03-12)
	Detail of Fee Submitted	30000.0, 2023-08-28,
	The proposed proprietary name / brand name	ERTU-MET 2.5mg/1000mg Tablet
	Label Claim	Each Film Coated Tablet Contains: Ertugliflozin L-Pyroglutamic Acid Eq. to Ertugliflozin 2.5 mg Metformin HCl 1000mg (Manufacturer's Specifications)
	Reference to Finished product specifications	Manufacturer Specification
	Proposed Pack Size	7's-As per SRO
	Shelf Life (Unit)	24 Month(s) Do not store above 30°C.
	For generic drugs (me-too Status)	Ertuvia-M Tablet by Ferozsens Laboratories
	Pharmaceutical Group of (API)	Combinations of oral blood glucose lowering drugs
	Name, address of Manufacturing site:	Self Manufacturing
	Name & address of API manufacturer	Zhejiang Hongyuan Pharmaceutical Co. LTD. Chem & API's Industrial Zone, Linhai, Zhejiang, P.R. China.
	Detail of stability batches of drug product	3 batches having batch size of 750 tablets each
	Documents for the procurement of API with approval from DRAP (in case of Import)	Firm has submitted copy of clearance certificate dated 14-05-2022 specifying 0.25kg Ertugliflozin L-pyroglutamic acid. Firm has submitted copy of clearance certificate dated 26-06-2022 specifying 1000kg Metformin HCl.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	PE studies and CDP performed against Ertuvia-M 2.5mg/1000mg Tablet by M/s Ferozsens Laboratories.
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance as per Zone IV
	The status in reference regulatory authorities	(Segluroet 2.5/1000mg Tablet) USFDA approved
	GMP status of the firm	Firm has submitted copy of cGMP certificate of the firm based on inspection dated 14-02-2024.
	Evidence of approval of manufacturing facility	Firm has submitted copy of letter of renewal of DML dated 16-05-2024 specifying Tablet I Section (General) (Regularization) and Tablet II Section (General) (Regularization)
	Evaluation Remarks	
	Shortcomings	Firm's Response
	Justification shall be submitted for selecting different dissolution parameters (apparatus; II, medium; Phosphate buffer pH 6.8, rpm; 75, time; 30min) than that recommended by innovator's	As the product was non Pharmacopoeial, the Dissolution test was performed as per in house method previously which is now revised as recommended by innovator with Acetate Buffer pH

	product review document (apparatus; I, medium; 50mM Acetate Buffer pH 4.5, rpm;100, time; 15min)	4.5 and results are found satisfactory just as with phosphate buffer pH 6.8. Revised dissolution conditions is submitted
	Decision	
	Deferred	
	Deferred for submission of product development & batch release data wherein dissolution test shall have been performed as per recommendations of innovator drug product. Moreover, firm shall submit applicable fee for revision of data.	
8	Case Category	Priority As Per 257-M of RB (Dr. Farhad Ullah)
	Name, address of Applicant.	Atco Pharma International (Pvt) Ltd B-18, S.I.T.E., Karachi (046)
	Application Form Dy. No / Tracking ID & date of submission	(44T-H3Z-PTY2, 2025-03-27)
	Detail of Fee Submitted	300000.0, 2025-01-15,
	The proposed proprietary name / brand name	Bortezomib for Injection 3.5 mg/vial
	Label Claim	Each vial contains: Bortezomib 3.5mg
	Reference to Finished product specifications	As per Innovators Specification
	Proposed Pack Size	1vial-Controlled
	Shelf Life (Unit)	24 Month(s)Don't store & transport above 30degree centigrade
	For generic drugs (me-too Status)	Cytomib 3.5mg Injection by Helix Pharma
	Pharmacotherapeutic Group of (API)	Proteasome inhibitors WHO ATC code; L01XG
	Name, address of Manufacturing site:	Fresenius Kabi Oncology Limited-Village Kishanpura Baddi, Tehsil Nalagarh Distt. Solan, H.P, 174101, India -India
	Pharmaceutical Equivalence and Comparative Dissolution Profile	PE performed against Velcade 3.5mg powder for solution for injection
	Name, address of Marketing Authorization Holder:	Fresenius Kabi Oncology Limited, Village Kishanpura Baddi, Tehsil Nalagarh Distt. Solan, H.P, 174101, India , India
	Details of Certificates (CoPP/FSC/cGMP):	Certificate of Pharmaceutical Product: Firm has submitted copy of CoPP (Cerificate#HFW-H (Drugs) 488/06 Vol-V/25-48) issued by Health & Family welfare Department Himachal Pradesh, Baddi, Distt. Solan India for Bortezomab for injection, 3.5mg/vial. CoPP
	Details of Authorization Letter :	Firm has submitted legalized copy of letter of authorization from M/s Fresenius Kabi Oncology Limited., India for applied product dated; 24-07-2024 Validity; 23-07-2029
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Stability study data of three batches is submitted Real time (24 months): 30°C ± 2 °C /75% ±5%RH Accelerated (6 months): 40°C±2 °C /75% ±5%RH
	The status in reference regulatory authorities	VELCADE 3.5 mg powder for solution for injection by Janssen-Cilag Ltd MHRA Approved
	Evaluation Remarks	
	Shortcomings	Firm's response

Details of MAH provided in eApp online portal is different than that submitted in Certificate of a Medicinal Product, clarify	We have provided details of MAH on the eApp online portal as Fresenius Kabi Oncology Limited, Village Kishanpura Baddi, Tehsil Nalagarh Distt. Solan, H.P, 174101, India. This is because it is the actual MAH of this product in India for the purpose of export to Pakistan and this context we are submitting CoPP stating MAH as Fresenius Kabi Oncology Limited, Village Kishanpura Baddi, Tehsil Nalagarh Distt. Solan, H.P, 174101, India.
Letter of authorization from manufacturer of drug product (M/s Fresenius Kabi India) is submitted instead of marketing authorization holder as per certificate of medicinal product (M/s Fresenius Kabi Germany)	Initially firm has submitted following cGMP and CoPP certificate; GMP certificate: Firm has submitted copy of Eudra GMP certificate of product manufacturer valid upto 09-11-2025. Certificate of a Medicinal Product: Firm has submitted copy of Certificate of a Medicinal Product 01/23/007346 issued by EMA Netherland dated 10-07-2023 The certificate confirm the free sale status of the product in country of Origin along with GMP of the manufacturing unit. Later on firm submitted clarification and CoPP from drug product manufacturer; We have submitted attached EMA CoPP with dossier in which MAH for EMA is mentioned as “Fresenius Kabi Deutschland GmbH, Else-Kröner-Straße 1, 61352 Bad Homburg v.d.Höhe, Germany as a SRA country CoPP. Firm has submitted relationship letter. The letter states that following companies own their respective manufacturing sites and are affiliates of Fresenius kabi Ag which include “Fresenius Kabi Oncology Limited., India”. The affiliates are or will be regularly audited by Fresenius Kabi Group under European GMP standards. Certificate of Pharmaceutical Product: Firm has submitted copy of CoPP (Cerificate#HFW-H (Drugs) 488/06 Vol-V/25-48) issued by Health & Family welfare Department Himachal Pradesh, Baddi, Distt. Solan India for Bortezomab for injection, 3.5mg/vial. CoPP confirms facilities and operations conforming to GMP as recommended by the World Health Organization. The certificate is valid till upto 28-08-2026. However, the CoPP certificate has mentioned that this product is not actually on the market of the exporting country. Firm has also submitted clarification that currently there is no demand for this product in India which is the primary reason why it has not been marketed in India.
Decision	
Approved	

Registration Board in its 256th meeting decided as, "If an imported drug is not on free sale in its respective country of origin / manufacture, such product will be registered in Pakistan if the product manufactured in the applied facility is approved by any of the regulatory authorities from USFDA, EMA, PMDA Japan, Australia TGA, Health Canada, Switzerland or any of regulatory authority of former erstwhile Westren Europe (United Kingdom, Germany, France, Switzerland, Netherlands, Austria, Belgium, Denmark, Finland, Sweden, Italy, Ireland, Luxemburg, Norway, Scotland and Spain) or three stringent regulatory bodies of former erstwhile Eastren Europe. However, references countries regarding availability of drug / molecule / formulation shall remain the same as specified in 249th meeting of Registration Board.

While considering the above stated decision, Registration Board decided to approve the instant application as per policy for the inspection of the manufacturer abroad.

Registration Board further decided that Registration letter will be issued after submission of;

Original, legalized and valid CoPP from country of origin.

9	Case Category	Routine (Dr. Farhad Ullah)
	Name, address of Applicant.	Pharmedic Laboratories (Pvt.) Ltd Lahore 16-Km Multan Road, Lahore (000228)
	Application Form Dy. No / Tracking ID & date of submission	(4Y7-YGS-E48B, 2024-03-28)
	Detail of Fee Submitted	30000.0, 2024-03-21,
	The proposed proprietary name / brand name	Artu Tablet 5mg
	Label Claim	Each film coated tablet contains: 6.48mg Ertugliflozin L-Pyroglutamic Acid (Equivalent to 5mg of Ertugliflozin)
	Reference to Finished product specifications	As per Innovators Specification
	Proposed Pack Size	A blister pack of 1 -As per SRO
	Shelf Life (Unit)	2 Year(s)Do not store above 30 C, store in the original package in order to protect from moisture.
	For generic drugs (me-too Status)	Ertuvia 5mg tablet by Ferozsans Laboratories
	Pharmacotherapeutic Group of (API)	Sodium glucose co-transporter 2 (SGLT2) inhibitors
	Name, address of Manufacturing site:	Self Manufacturing
	Name & address of API manufacturer	Zhejiang Hongyuan Pharmaceutical Co., Ltd.
	Detail of stability batches of drug product	3 batches having batch size of 1000 tablets each
	Documents for the procurement of API with approval from DRAP (in case of Import)	Firm has submitted copy of commercial invoice cleared dated 04-03-2020 specifying 918gm Ertugliflozin L-pyroglutamic acid.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	PE studies and CDP performed against Steglatro 5mg by Pfizer Manufacturing Deutschland GmbH, Frieburg, Germany..
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance as per Zone IV
	The status in reference regulatory authorities	STEGLATRO® (Ertugliflozin) tablets USFDA Approved. Merck & Co., Inc. USA https://www.accessdata.fda.gov/drugsatfda_d

	GMP status of the firm	Firm has submitted copy of cGMP certificate of the firm based on inspection dated 04-02-2020.
	Evidence of approval of manufacturing facility	Not submitted
	Evaluation Remarks	
	Shortcomings	Firm's Response
	Copy of cGMP certificate / GMP inspection report of applicant conducted within last three years	Firm has submitted copy of letter to additional director DRAP Lahore for issuance of cGMP certificate
	Evidence of approval of required manufacturing facility from Licensing division is required.	Firm has submitted copy of panel inspection report dated 04-06-2025 specifying Tablet section (General). The panel recommends the Renewal of Drug Manufacturing License and Regularization of Layout Plan. Firm has submitted copy of letter of panel constituted for renewal of DML dated 03-03-2025 specifying tablet (General) section. Firm has submitted copy of cGMP certificate of the firm based on inspection dated 04-02-2020 specifying tablet (Non-Antibiotic) section
	Decision	
	Approved	
10	Case Category	Routine (Dr. Farhad Ullah)
	Name, address of Applicant.	Pharmedic Laboratories (Pvt.) Ltd Lahore 16-Km Multan Road, Lahore (000228)
	Application Form Dy. No / Tracking ID & date of submission	(YVT-B89-E2UQ, 2024-03-12)
	Detail of Fee Submitted	30000.0, 2023-12-04,
	The proposed proprietary name / brand name	Pharbion injection
	Label Claim	Each 3 ml of ampoule contains: Vitamin B1 (Thiamine hydrochloride) 100 mg Vitamin B6 (Pyridoxine hydrochloride)..... 100 mg Vitamin B12 (Cyanocobalamin) 1000 mcg
	Reference to Finished product specifications	As per Innovators Specification
	Proposed Pack Size	3ml-As per SRO
	Shelf Life (Unit)	2 Year(s)store below 30C
	For generic drugs (me-too Status)	Neurobion Injection by Martin Dow Marker Ltd
	Pharmacotherapeutic Group of (API)	Vitamin B1 in combination with vitamin B6 and/or vitamin B12
	Name, address of Manufacturing site:	Self Manufacturing
	Name & address of API manufacturer	
	Detail of stability batches of drug product	3 batches having batch size of 1000 ampoules each
	Documents for the procurement of API with approval from DRAP (in case of Import)	Firm has submitted copy of clearance certificate dated 30-04-2022 specifying 100kg Pyridoxin HCl and 100kg Thiamine HCl. Firm has also submitted copy of clearance certificate dated 30-04-2022 specifying 01kg Cyanocobalamin.

Pharmaceutical Equivalence and Comparative Dissolution Profile	PE studies performed against Neurobion Injection by M Martin Dow Marker Ltd.,
Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance as per Zone IV
The status in reference regulatory authorities	Neurobion solution for injection Germany Approved
GMP status of the firm	Firm has submitted copy of cGMP certificate of the firm based on inspection dated 04-06-2025.
Evidence of approval of manufacturing facility	Not submitted
Evaluation Remarks	
Shortcomings	Firm's response
Submit Evidence of approval of required manufacturing facility / Approved Section from Licensing Authority.	Firm has submitted copy of panel inspection report dated 04-06-2025 specifying Injectable Section (General). The panel recommends the Renewal of Drug Manufacturing License and Regularization of Layout Plan.
Justification shall be submitted for using overage in applied formulation	1. Regulatory Compliance • Many pharmacopoeias and regulatory agencies allow or even require overages for unstable compounds. For Example. 1. Individual USP Monographs for Vitamin B6 Injections & Tablets have assay limit of 95%-115%. 2. Individual USP Monograph for Vitamin B12 Injections has assay limit of 90% - 115%. 2. Degradation During Storage • Vitamins (especially B1, B6, B12) are relatively unstable and can degrade over time, especially when exposed to: o Light o Heat o Oxygen • Overages help maintain potency up to the expiration date. Chemical Degradation • Vitamins—especially the B-complex (thiamine B ₁ , pyridoxine B ₆ , cyanocobalamin B ₁₂)—are sensitive to light, heat and oxygen. Over time, a fraction will degrade, so adding, say, 5–15% extra ensures that by the end of the labeled shelf-life the patient still receives the full therapeutic dose. 3. Loss During Manufacturing • Some vitamin loss occurs during: o Sterilization processes o Filling and sealing of ampoules o Transport and handling • The overage ensures the final dose in the vial is accurate. 4. Ensuring Therapeutic Effect • Since Pharbion is often used to treat neuropathies or vitamin B deficiencies, precise dosing is crucial. • Overages help guarantee the patient receives an effective therapeutic amount.
Justification shall be submitted for using UV method for assay test of cyanocobalamin instead of using HPLC method which is more reliable method.	The firm submitted that as applied product is not available in official monographs and USP method of analysis for Cyanocobalamin API and injection is also by UV method, so in-house UV method was developed and validated for analysis of cyanocobalamin. Please note that all pharmacopoeias including BP, USP, EP and JP contain UV method of vitamin B12 and we are

using the same technique. Neither Pharmacopoeia give any HPLC method. Also, our method is validated and its record is available with dossier.

Decision

Deferred

Deferred for submission of clarification for using UV method for assay test of cyanocobalamin instead of HPLC

11	Case Category	New Section (Dr. Farhad Ullah)
	Name, address of Applicant.	Well Care Pharmaceuticals A/7 PSIE (000465)
	Application Form Dy. No / Tracking ID & date of submission	(WVD-361-X5BS, 2025-01-15)
	Detail of Fee Submitted	30000.0, 7500.0 2024-09-04, 2024-11-07
	The proposed proprietary name / brand name	ITRACARE 100mg capsule
	Label Claim	Each Capsule Contains: Itraconazole (as IR Pellets).....100mg (Itraconazole IR 22% Pellets)
	Reference to Finished product specifications	United States Pharmacopeia
	Proposed Pack Size	4'S-Controlled
	Shelf Life (Unit)	24 Year(s)Store at temperature 15 to 30C away from sunlight
	For generic drugs (me-too Status)	Fewnol 100mg Capsule by Dew-Max Pharmaceuticals Islamabad.
	Pharmacotherapeutic Group of (API)	Antimycotic, Triazole derivatives
	Name, address of Manufacturing site:	Self Manufacturing
	Name & address of API manufacturer	VISION PHARMACEUTICALS
	Detail of stability batches of drug product	3 batches having batch size of 1500 capsule each
	Documents for the procurement of API with approval from DRAP (in case of Import)	Firm has submitted copy of invoice dated 11-10-2023 from M/s Vision Pharmaceuticals specifying 2.5kg of Itraconazole 22.0% IR Pellets in name of M/s Well Care Pharmaceuticals.,
	Pharmaceutical Equivalence and Comparative Dissolution Profile	PE and CDP studies performed against ICON 100mg capsule
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance as per Zone IV
	The status in reference regulatory authorities	Mint-Itraconazole 100mg capsule by Mint pharmaceutical Inc. 6575 Davand Drive. Mississauga. Ontario. Health Canada Approved
	GMP status of the firm	Firm has submitted copy of GMP inspection report dated 10-09-2021 in which the panel recommends the resumption of production in all approved sections.
	Evidence of approval of manufacturing facility	Firm has submitted copy of letter for grant of additional section dated 24-11-2021 specifying Capsule (General)-New
Evaluation Remarks		
Shortcomings		Firm's Response
Submit valid copy of cGMP certificate / GMP inspection report of applicant conducted within last		Firm has submitted grant of additional section inspection report dated 10-09-2021 where panel

	three years	recommend grant of additional section capsule general.
	Submit alternative brand name for applied product as the submitted brand name resemble with already registered product	Firm has submitted alternative brand name. 1- Itrawell 2- Itracon 3- Wellcon 4- IT-WC
	Complete batch analysis of all the batches of drug product containing details of each batch shall be submitted	Firm has submitted batch analysis of all three batches of drug product containing details of each batch
	Decision	
	Approved	
12	Case Category	Routine (Dr. Farhad Ullah)
	Name, address of Applicant.	Saffron Pharmaceuticals 19-Km Sheikhpura Road (000616)
	Application Form Dy. No / Tracking ID & date of submission	(Z1R-LJA-EQ69, 2024-03-14)
	Detail of Fee Submitted	30000.0, 2023-08-28,
	The proposed proprietary name / brand name	ERTU-MET 2.5mg/500mg Tablet
	Label Claim	Each Film Coated Tablet Contains: Ertugliflozin L-Pyrogutamic Acid Eq. to Ertugliflozin 2.5 mg Metformin HCl 500mg (Manufacturer's Specifications)
	Reference to Finished product specifications	Manufacturer Specification
	Proposed Pack Size	14's-As per SRO, 20's-As per SRO, 28's-As per SRO, 7's-As per SRO
	Shelf Life (Unit)	24 Month(s) Do not store above 30°C.
	For generic drugs (me-too Status)	Ertuvia-M Tablet by Ferozsans Laboratories
	Pharmaceutical Group of (API)	Combinations of oral blood glucose lowering drugs
	Name, address of Manufacturing site:	Self Manufacturing
	Name & address of API manufacturer	Ipca Laboratories Limited, H-4, M.I.D.C., Waluj Aurangabad (Maharashtra) Pin : 431136, India, Zhejiang Hongyuan Pharmaceutical Co. LTD. Chem & API's Industrial Zone, Linhai, Zhejiang, P.R. China.
	Detail of stability batches of drug product	3 batches having batch size of 800 tablets each
	Documents for the procurement of API with approval from DRAP (in case of Import)	Firm has submitted copy of clearance certificate dated 14-05-2022 specifying 0.25kg Ertugliflozin L-pyrogutamic acid. Firm has submitted copy of clearance certificate dated 26-06-2022 specifying 1000kg Metformin HCl.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	PE studies and CDP performed against Ertuvia-M 2.5mg/500mg Tablet by M/s Ferozsans Laboratories.
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance as per Zone IV
	The status in reference regulatory authorities	Segluroet 2.5/500mg Tablet USFDA Approved

GMP status of the firm	Firm has submitted copy of cGMP certificate of the firm based on inspection dated 14-02-2024.																														
Evidence of approval of manufacturing facility	Firm has submitted copy of letter of renewal of DML dated 16-05-2024 specifying Tablet I Section (General) (Regularization) and Tablet II Section (General) (Regularization)																														
Evaluation Remarks																															
Shortcomings	Firm's Response																														
Justification shall be submitted for selecting different dissolution parameters (apparatus; II, medium; Phosphate buffer pH 6.8, rpm;75, time; 30min) than that recommended by innovator's product review document (apparatus; I, medium; 50mM Acetate Buffer pH 4.5, rpm;100, time; 15min)	As the product was non Pharmacopoeial, the Dissolution test was performed as per in house method previously which is now revised as recommended by innovator with Acetate Buffer pH 4.5 and results are found satisfactory just as with phosphate buffer pH 6.8. Revised dissolution conditions is submitted																														
Decision																															
Deferred																															
Deferred for submission of product development & batch release data wherein dissolution test shall have been performed as per recommendations of innovator drug product. Moreover, firm shall submit applicable fee for revision of data.																															
13	<table> <tr> <td>Case Category</td><td>Routine (Dr. Farhad Ullah)</td></tr> <tr> <td>Name, address of Applicant.</td><td>Saffron Pharmaceuticals 19-Km Sheikhpura Road (000616)</td></tr> <tr> <td>Application Form Dy. No / Tracking ID & date of submission</td><td>(Z6M-6AD-TQ94, 2024-03-15)</td></tr> <tr> <td>Detail of Fee Submitted</td><td>30000.0, 2023-09-13,</td></tr> <tr> <td>The proposed proprietary name / brand name</td><td>ERTU-MET 7.5mg/500mg Tablet</td></tr> <tr> <td>Label Claim</td><td>Each Film Coated Tablet Contains: Ertugliflozin L-Pyroglutamic Acid Eq. to Ertugliflozin 7.5 mg Metformin HCl 500mg (Manufacturer's Specifications)</td></tr> <tr> <td>Reference to Finished product specifications</td><td>Manufacturer Specification</td></tr> <tr> <td>Proposed Pack Size</td><td>14's-As per SRO,20's-As per SRO,28's-As per SRO,7's-As per SRO</td></tr> <tr> <td>Shelf Life (Unit)</td><td>24 Month(s)Do not store above 30°C.</td></tr> <tr> <td>For generic drugs (me-too Status)</td><td>Ertuvia-M Tablet by Ferozsons Laboratories</td></tr> <tr> <td>Pharmacotherapeutic Group of (API)</td><td>Combinations of oral blood glucose lowering drugs</td></tr> <tr> <td>Name, address of Manufacturing site:</td><td>Self Manufacturing</td></tr> <tr> <td>Name & address of API manufacturer</td><td>Ipca Laboratories Limited,H-4, M.I.D.C., Waluj Aurangabad (Maharashtra) Pin : 431136, India,Zhejiang Hongyuan Pharmaceutical Co. LTD. Chem & API's Industrial Zone, Linhai, Zhejiang, P.R. China.</td></tr> <tr> <td>Detail of stability batches of drug product</td><td>3 batches having batch size of 800 tablets each</td></tr> <tr> <td>Documents for the procurement of API with approval from DRAP (in case of Import)</td><td>Firm has submitted copy of clearance certificate dated 14-05-2022 specifying 0.25kg Ertugliflozin L-pyroglutamic acid. Firm has submitted copy of</td></tr> </table>	Case Category	Routine (Dr. Farhad Ullah)	Name, address of Applicant.	Saffron Pharmaceuticals 19-Km Sheikhpura Road (000616)	Application Form Dy. No / Tracking ID & date of submission	(Z6M-6AD-TQ94, 2024-03-15)	Detail of Fee Submitted	30000.0, 2023-09-13,	The proposed proprietary name / brand name	ERTU-MET 7.5mg/500mg Tablet	Label Claim	Each Film Coated Tablet Contains: Ertugliflozin L-Pyroglutamic Acid Eq. to Ertugliflozin 7.5 mg Metformin HCl 500mg (Manufacturer's Specifications)	Reference to Finished product specifications	Manufacturer Specification	Proposed Pack Size	14's-As per SRO,20's-As per SRO,28's-As per SRO,7's-As per SRO	Shelf Life (Unit)	24 Month(s)Do not store above 30°C.	For generic drugs (me-too Status)	Ertuvia-M Tablet by Ferozsons Laboratories	Pharmacotherapeutic Group of (API)	Combinations of oral blood glucose lowering drugs	Name, address of Manufacturing site:	Self Manufacturing	Name & address of API manufacturer	Ipca Laboratories Limited,H-4, M.I.D.C., Waluj Aurangabad (Maharashtra) Pin : 431136, India,Zhejiang Hongyuan Pharmaceutical Co. LTD. Chem & API's Industrial Zone, Linhai, Zhejiang, P.R. China.	Detail of stability batches of drug product	3 batches having batch size of 800 tablets each	Documents for the procurement of API with approval from DRAP (in case of Import)	Firm has submitted copy of clearance certificate dated 14-05-2022 specifying 0.25kg Ertugliflozin L-pyroglutamic acid. Firm has submitted copy of
Case Category	Routine (Dr. Farhad Ullah)																														
Name, address of Applicant.	Saffron Pharmaceuticals 19-Km Sheikhpura Road (000616)																														
Application Form Dy. No / Tracking ID & date of submission	(Z6M-6AD-TQ94, 2024-03-15)																														
Detail of Fee Submitted	30000.0, 2023-09-13,																														
The proposed proprietary name / brand name	ERTU-MET 7.5mg/500mg Tablet																														
Label Claim	Each Film Coated Tablet Contains: Ertugliflozin L-Pyroglutamic Acid Eq. to Ertugliflozin 7.5 mg Metformin HCl 500mg (Manufacturer's Specifications)																														
Reference to Finished product specifications	Manufacturer Specification																														
Proposed Pack Size	14's-As per SRO,20's-As per SRO,28's-As per SRO,7's-As per SRO																														
Shelf Life (Unit)	24 Month(s)Do not store above 30°C.																														
For generic drugs (me-too Status)	Ertuvia-M Tablet by Ferozsons Laboratories																														
Pharmacotherapeutic Group of (API)	Combinations of oral blood glucose lowering drugs																														
Name, address of Manufacturing site:	Self Manufacturing																														
Name & address of API manufacturer	Ipca Laboratories Limited,H-4, M.I.D.C., Waluj Aurangabad (Maharashtra) Pin : 431136, India,Zhejiang Hongyuan Pharmaceutical Co. LTD. Chem & API's Industrial Zone, Linhai, Zhejiang, P.R. China.																														
Detail of stability batches of drug product	3 batches having batch size of 800 tablets each																														
Documents for the procurement of API with approval from DRAP (in case of Import)	Firm has submitted copy of clearance certificate dated 14-05-2022 specifying 0.25kg Ertugliflozin L-pyroglutamic acid. Firm has submitted copy of																														

	clearance certificate dated 26-06-2022 specifying 1000kg Metformin HCl.
Pharmaceutical Equivalence and Comparative Dissolution Profile	PE studies and CDP performed against Ertuvia-M 7.5mg/500mg Tablet by M/s Ferozsans Laboratories.
Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance as per Zone IV
The status in reference regulatory authorities	Segluroet 7.5/500mg Tablet USFDA Approved
GMP status of the firm	Firm has submitted copy of cGMP certificate of the firm based on inspection dated 14-02-2024.
Evidence of approval of manufacturing facility	Firm has submitted copy of letter of renewal of DML dated 16-05-2024 specifying Tablet I Section (General) (Regularization) and Tablet II Section (General) (Regularization)
Evaluation Remarks	
Shortcomings	Firm's Response
Justification shall be submitted for selecting different dissolution parameters (apparatus; II, medium; Phosphate buffer pH 6.8, rpm;75, time; 30min) than that recommended by innovator's product review document (apparatus; I, medium; 50mM Acetate Buffer pH 4.5, rpm;100, time; 15min)	As the product was non Pharmacopoeial, the Dissolution test was performed as per in house method previously which is now revised as recommended by innovator with Acetate Buffer pH 4.5 and results are found satisfactory just as with phosphate buffer pH 6.8. Revised dissolution profile is submitted
Decision	
Deferred	
Deferred for submission of product development & batch release data wherein dissolution test shall have been performed as per recommendations of innovator drug product. Moreover, firm shall submit applicable fee for revision of data.	
Case Category	Contract Manufacturing (Incharge Evaluation Cell)
Name, address of Applicant.	Hicon Pharmaceuticals 131- Industrial estate Hayatabad (000583)
Application Form Dy. No / Tracking ID & date of submission	(1NW-9ZP-97V7, 2025-01-13)
Detail of Fee Submitted	93000.0, 2024-10-25,
The proposed proprietary name / brand name	Con-D3 Injection 5mg/ml
Label Claim	Each ampoule contains: Cholecalciferol 5mg
Reference to Finished product specifications	As per Innovators Specification
Proposed Pack Size	1's, 5's and 10's-As per SRO
Shelf Life (Unit)	2 YearRoom Temperature
For generic drugs (me-too Status)	Manufacturer Name DANAS Pharmaceuticals Islamabad Brand Name Novel-D Injection Oral/ I.M
Pharmacotherapeutic Group of (API)	
Name, address of Manufacturing site:	Biogen Life Sciences-8-km, Chakbeli Road, Rawat, Rawalpindi-

	The status in reference regulatory authorities	Cholecalciferol (5mg) injection (IM/ Oral) by M/s Bouchara Recordate Laboratories DE GAULLE GAL IMMEUBLE LE WILSON GAULLE 70 AVENUE DU GENERAL DE GAULLE.92800, PUTEAUX, ILE-DE-FRANCE
	Detail of previous approval	Applied product is approved for Biogen Life Sciences in Minutes of 323rd meeting of Registration Boa
	Evaluation Remarks	
	In light of Registration Board's decision taken in its 324th meeting and notified vide F.No.1-2/2022-DMC dated 13th June, 2023, the instant application is being presented for consideration of the Board as an application for cross-reference of already approved data on Form 5F. Applicants need to submit a declaration that they will adopt the same source of drug substance, drug product formulation, specifications and container closure and fulfill other conditions mentioned in the above-mentioned notification. Furthermore, quality agreement under Rule 20-A of the Drugs (LR&A) Rules, 1976 is also needed as part of module-1 of Form 5F.	
	Decision	
15	Approved	
	Case Category	Contract Manufacturing (Incharge Evaluation Cell)
	Name, address of Applicant.	Hicon Pharmaceuticals 131- Industrial estate Hayatabad (000583)
	Application Form Dy. No / Tracking ID & date of submission	(34L-38X-D9T7, 2025-01-13)
	Detail of Fee Submitted	93000.0, 2024-10-25,
	The proposed proprietary name / brand name	DEXCON 30MG CAPSULE
	Label Claim	Each capsulecontains; Dextansoprazole dual delayed released (DDR) pellets 22.5% Equivalent to Dextansoprazole 30 mg
	Reference to Finished product specifications	As per Innovators Specification
	Proposed Pack Size	30's-As per SRO
	Shelf Life (Unit)	3 YearRoom Temperature
	For generic drugs (me-too Status)	Brand Name: Registration holder: Razodex Capsule Getz Pharma.
	Pharmacotherapeutic Group of (API)	
	Name, address of Manufacturing site:	Biogen Life Sciences -8-KM, Chak Beli Road, Rawat, Rawalpindi-
	The status in reference regulatory authorities	Brand Name Regulatory Authority: Dexilant capsule USFDA Approved
	Detail of previous approval	Lansogen 30 mg Capsule Minutes for 339th meeting of Registration Board (6th August to 8th August, 20
	Evaluation Remarks	
	In light of Registration Board's decision taken in its 324th meeting and notified vide F.No.1-2/2022-DMC dated 13th June, 2023, the instant application is being presented for consideration of the Board as an application for cross-reference of already approved data on Form 5F. Applicants need to submit a declaration that they will adopt the same source of drug substance, drug product formulation, specifications and container closure and fulfill other conditions mentioned in the above-mentioned	

	notification. Furthermore, quality agreement under Rule 20-A of the Drugs (LR&A) Rules, 1976 is also needed as part of module-1 of Form 5F.	
	Decision	
	Approved	
16	Case Category	Contract Manufacturing (Incharge Evaluation Cell)
	Name, address of Applicant.	Hicon Pharmaceuticals 131- Industrial estate Hayatabad (000583)
	Application Form Dy. No / Tracking ID & date of submission	(B4Z-TWA-53GM, 2025-01-13)
	Detail of Fee Submitted	93000.0, 2024-10-25,
	The proposed proprietary name / brand name	DUXIMA 200mg/5ml Dry Suspension
	Label Claim	Each 5ml of reconstituted suspension Contains: Cefixime as trihydrate.....200mg (USP Specs)
	Reference to Finished product specifications	United States Pharmacopeia
	Proposed Pack Size	30ml & 60ml-As per SRO
	Shelf Life (Unit)	3 YearRoom Temperature
	For generic drugs (me-too Status)	Brand Name: Cefim suspension Registration holder: Hilton Pharma
	Pharmacotherapeutic Group of (API)	
	Name, address of Manufacturing site:	Biogen Life Sciences -8-km, Chakbeli Road, Rawat, Rawalpindi-
	The status in reference regulatory authorities	Brand Name: Cefixime suspension Regulatory Authority: USFDA Approved
	Detail of previous approval	Minutes of 297th meeting of Registration Board, with brand name of CARECEF 200mg/5ml Dry Suspension
	Evaluation Remarks	
	In light of Registration Board's decision taken in its 324th meeting and notified vide F.No.1-2/2022-DMC dated 13th June, 2023, the instant application is being presented for consideration of the Board as an application for cross-reference of already approved data on Form 5F. Applicants need to submit a declaration that they will adopt the same source of drug substance, drug product formulation, specifications and container closure and fulfill other conditions mentioned in the above-mentioned notification. Furthermore, quality agreement under Rule 20-A of the Drugs (LR&A) Rules, 1976 is also needed as part of module-1 of Form 5F.	
	Decision	
	Approved	
17	Case Category	Contract Manufacturing (Incharge Evaluation Cell)
	Name, address of Applicant.	Hicon Pharmaceuticals 131- Industrial estate Hayatabad (000583)
	Application Form Dy. No / Tracking ID & date of submission	(DHE-VYM-RGMU, 2025-01-13)
	Detail of Fee Submitted	93000.0, 2024-10-25,
	The proposed proprietary name / brand name	DUXIMA 100mg/5ml Dry Suspension
	Label Claim	Each 5ml of reconstituted suspension Contains: Cefixime as trihydrate.....100mg

	Reference to Finished product specifications	United States Pharmacopeia
	Proposed Pack Size	1's-As per SRO
	Shelf Life (Unit)	3 YearRoom Temperature
	For generic drugs (me-too Status)	Cefim suspension by Hilton
	Pharmacotherapeutic Group of (API)	
	Name, address of Manufacturing site:	Biogen Life Sciences -8-km, Chakbeli Road, Rawat, Rawalpindi-
	The status in reference regulatory authorities	Cefixime suspension (USFDA Approved)
	Detail of previous approval	CARECEF 100mg/5ml Dry Suspension Minutes of 297th Meeting of Registration Board (12-15th January, 20
	Evaluation Remarks	
	In light of Registration Board's decision taken in its 324th meeting and notified vide F.No.1-2/2022-DMC dated 13th June, 2023, the instant application is being presented for consideration of the Board as an application for cross-reference of already approved data on Form 5F. Applicants need to submit a declaration that they will adopt the same source of drug substance, drug product formulation, specifications and container closure and fulfill other conditions mentioned in the above-mentioned notification. Furthermore, quality agreement under Rule 20-A of the Drugs (LR&A) Rules, 1976 is also needed as part of module-1 of Form 5F.	
	Decision	
	Approved	
18	Case Category	Export Facilitation (Incharge Evaluation Cell)
	Name, address of Applicant.	Atco Laboratories Limited B-18 SITE KARACHI (000188)
	Application Form Dy. No / Tracking ID & date of submission	(HEH-3E9-SQ5Q, 2024-08-20)
	Detail of Fee Submitted	75000.0, 2024-07-19,
	The proposed proprietary name / brand name	LINGLIP-M TABLET
	Label Claim	Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride 850mg
	Reference to Finished product specifications	As per Innovators Specification
	Proposed Pack Size	10's-De-Controlled,14's-De-Controlled,20's-De-Controlled,28's-De-Controlled,30's-De-Controlled,5's-De-Controlled,60's-De-Controlled,7's-De-Controlled,90's-De-Controlled
	Shelf Life (Unit)	2 Year(s)donot store and transport above 30degree centigrade
	For generic drugs (me-too Status)	Linaphage Tablets by High-Q Pharmaceuticals
	Pharmacotherapeutic Group of (API)	
	Name, address of Manufacturing site:	Self Manufacturing
	Name & address of API manufacturer	CTX LIFESCIENCES PVT. LTD ,IPCA Laboratories Limited
	Detail of stability batches of drug product	Performed.
	Documents for the procurement of API with approval from DRAP (in case of Import)	Form-6 are provided.

	Pharmaceutical Equivalence and Comparative Dissolution Profile	CDP performed against Jentaduo
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Performed for Linagliptin by CTX LIFESCIENCES PVT. LTD.. INDIA Performed for Metformin by IPCA, INDIA.
	The status in reference regulatory authorities	JENTADUETO Tablets by Boehringer Ingelheim Pharmaceuticals, USA
	GMP status of the firm	Report submitted.
	Evidence of approval of manufacturing facility	DML and section approvals.
	Evaluation Remarks	
	The application is considered based on letter No.F.1-6/2019-PR-II (EFD) dated 03-03-2025.	
	Decision	
	Approved	
19	Case Category	Contract Manufacturing (Incharge Evaluation Cell)
	Name, address of Applicant.	Hicon Pharmaceuticals 131- Industrial estate Hayatabad (000583)
	Application Form Dy. No / Tracking ID & date of submission	(P8X-QN4-HB8W, 2025-01-13)
	Detail of Fee Submitted	93000.0, 2024-10-25,
	The proposed proprietary name / brand name	DUXIMA 400mg Capsules
	Label Claim	Each capsule Contains: Cefixime as trihydrate.....400mg (JP Specs)
	Reference to Finished product specifications	Any Other
	Proposed Pack Size	28's/14's,-As per SRO
	Shelf Life (Unit)	3 YearRoom Temperature
	For generic drugs (me-too Status)	Brand Name: Cefim capsules Registration holder: Hilton Pharma
	Pharmacotherapeutic Group of (API)	
	Name, address of Manufacturing site:	Biogen Life Sciences -8-km, Chakbeli Road, Rawat, Rawalpindi-
	The status in reference regulatory authorities	Brand Name: Cefixime capsules Regulatory Authority: USFDA Approved
	Detail of previous approval	Minutes of 297th meeting of Registration Board, with brand name of CARECEF 400mg Capsule
	Evaluation Remarks	
	In light of Registration Board's decision taken in its 324th meeting and notified vide F.No.1-2/2022-DMC dated 13th June, 2023, the instant application is being presented for consideration of the Board as an application for cross-reference of already approved data on Form 5F. Applicants need to submit a declaration that they will adopt the same source of drug substance, drug product formulation, specifications and container closure and fulfill other conditions mentioned in the above-mentioned notification. Furthermore, quality agreement under Rule 20-A of the Drugs (LR&A) Rules, 1976 is also needed as part of module-1 of Form 5F.	
	Decision	
	Approved	
20	Case Category	Export Facilitation (Incharge Evaluation Cell)

	Name, address of Applicant.	Atco Laboratories Limited B-18 SITE KARACHI (000188)
	Application Form Dy. No / Tracking ID & date of submission	(S38-AZU-D59B, 2024-08-20)
	Detail of Fee Submitted	75000.0, 2024-07-19,
	The proposed proprietary name / brand name	LINGLIP-M TABLETS
	Label Claim	Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride 1000mg
	Reference to Finished product specifications	As per Innovators Specification
	Proposed Pack Size	10's-De-Controlled,14's-De-Controlled,20's-De-Controlled,28's-De-Controlled,30's-De-Controlled,5's-De-Controlled,60's-De-Controlled,7's-De-Controlled,90's-De-Controlled
	Shelf Life (Unit)	2 Year(s)Do not store and transport above 30 degree centigrade
	For generic drugs (me-too Status)	Linaphage Tablets, High-Q Pharmaceuticals, Karachi (Reg.No. 125306, 125307, 125308)
	Pharmacotherapeutic Group of (API)	Linagliptin belongs to a class of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors). Metformin belongs to a class of medicines called biguanides.
	Name, address of Manufacturing site:	Self Manufacturing
	Name & address of API manufacturer	NA
	Detail of stability batches of drug product	Perofmed.
	Documents for the procurement of API with approval from DRAP (in case of Import)	Form 6 are provided.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	CDP performed against Jentaducto
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Performed for Linagliptin by CTX LIFESCIENCES PVT. LTD.. INDIA Performed for Metformin by IPCA, INDIA.
	The status in reference regulatory authorities	JENTADUCTO Tablets by Boehringer Ingelheim Pharmaceuticals, USA
	GMP status of the firm	Report submitted.
	Evidence of approval of manufacturing facility	DML and section approvals submitted.
	Evaluation Remarks	
	The said application was considered against letter No.F.1-6/2019-PR-II (EFD) dated 03-03-2025. The firm met requirements as per applicable guidelines.	
	Decision	
	Approved	
21	Case Category	Routine (Sabahat Zehra)
	Name, address of Applicant.	Eterna Pharma Pvt Ltd plot no 99,100,101 & 198-c sector D1, Old industrial Estate,Mirpur, Aj&K (000923)
	Application Form Dy. No / Tracking ID & date of submission	(2PM-16B-2LW2, 2024-10-24)

	Detail of Fee Submitted	37000.0, 2024-10-18,
	The proposed proprietary name / brand name	ETER FEN 2.5 ORAL SUSPENSION
	Label Claim	Each 100ml contains:- Fenbendazole 2.5gm
	Reference to Finished product specifications	As per Innovators Specification
	Proposed Pack Size	1 Litre.-De-Controlled,100ml-De-Controlled,500ml -De-Controlled
	Shelf Life (Unit)	2 YearStore below 25 °C. Protect from light
	For generic drugs (me-too Status)	FENAZOLE 2.5 ORAL SUSPENSION. REG.# 033247 (ISLAMABAD PHARMACEUTICALS ISLAMABAD)
	Pharmacotherapeutic Group of (API)	
	Name, address of Manufacturing site:	--
	GMP status of the firm	cGMP compliance (Satisfactory)
	Evidence of approval of manufacturing facility	
	Evaluation Remarks	
	Decision	
	Approved	
22	Case Category	Routine (Sabahat Zehra)
	Name, address of Applicant.	Eterna Pharma Pvt Ltd plot no 99,100,101 & 198-c sector D1, Old industrial Estate,Mirpur, Aj&K (000923)
	Application Form Dy. No / Tracking ID & date of submission	(7J9-P48-TSGQ, 2024-10-24)
	Detail of Fee Submitted	37000.0, 2024-10-18,
	The proposed proprietary name / brand name	ETER FEN-10 ORAL SUSPENSION
	Label Claim	Each 100ml contains:- Fenbendazole 10gm
	Reference to Finished product specifications	As per Innovators Specification
	Proposed Pack Size	1 Ltr-De-Controlled,100ml-De-Controlled,500ml - De-Controlled
	Shelf Life (Unit)	2 YearStore below 25 °C. Protect from light
	For generic drugs (me-too Status)	FENBAK 10 ORAL SUSPENSION. REG.# 034554 (ATTABAK PHARMACEUTICAL INDUSTRIES ISLAMABAD)
	Pharmacotherapeutic Group of (API)	
	Name, address of Manufacturing site:	--
	GMP status of the firm	cGMP compliance (Satisfactory)
	Evidence of approval of manufacturing facility	
	Evaluation Remarks	
	Decision	

	Approved	
23	Case Category	Routine (Sabahat Zehra)
	Name, address of Applicant.	BIORISE PHARMACEUTICALS 19KM, LAHORE ROAD, MULTAN (000934)
	Application Form Dy. No / Tracking ID & date of submission	(86J-P33-85NG, 2024-09-19)
	Detail of Fee Submitted	30000.0, 7000.0 2024-08-02, 2025-06-30
	The proposed proprietary name / brand name	Gumbonil Water Soluble Powder
	Label Claim	Each 100gm contains: Potassium Citrate..... 18g Sodium Citrate.....12g Vitamin B1.....0.03g Vitamin B2.....0.015g Nicotinamide.....0.32g Menadione Bisulfite....0.115g Vitamin C..... 1.10g Innovator's Specs
	Reference to Finished product specifications	As per Innovators Specification
	Proposed Pack Size	10gm, 50g, 100 gm., -De-Controlled
	Shelf Life (Unit)	2 YearStore in a cool and Dry place, away from moisture and direct sunlight.
	For generic drugs (me-too Status)	Anti Gumbo Powder By M/S. LEADS PHARMA, ISLAMABAD Reg No. 046581
	Pharmacotherapeutic Group of (API)	
	Name, address of Manufacturing site:	--
	GMP status of the firm	The panel of inspectors found the premises satisfactory and recommend the grant of DML.
	Evidence of approval of manufacturing facility	
	Evaluation Remarks	
	Decision	
	Approved	
24	Case Category	Routine (Sabahat Zehra)
	Name, address of Applicant.	BIORISE PHARMACEUTICALS 19KM, LAHORE ROAD, MULTAN (000934)
	Application Form Dy. No / Tracking ID & date of submission	(AN9-VEB-32JL, 2024-09-20)
	Detail of Fee Submitted	30000.0, 7000.0 2024-08-02, 2025-06-30
	The proposed proprietary name / brand name	Norquin-25% Oral Liquid
	Label Claim	Each 100ml contain norfloxacin HCL 25g
	Reference to Finished product specifications	As per Innovators Specification
	Proposed Pack Size	100 ml, 150ml, 200, -De-Controlled
	Shelf Life (Unit)	2 Year(s)Store in a cool and Dry place, away from moisture and direct sunlight.

	For generic drugs (me-too Status)	Normak Liquid By M/S A&K PHARMA, FAISALABAD Reg No. 058973
	Pharmacotherapeutic Group of (API)	
	Name, address of Manufacturing site:	--
	GMP status of the firm	The panel of inspectors found the premises satisfactory and recommend the grant of DML.
	Evidence of approval of manufacturing facility	
	Evaluation Remarks	
	Decision	
	Approved	
25	Case Category	Routine (Sabahat Zehra)
	Name, address of Applicant.	BIORISE PHARMACEUTICALS 19KM, LAHORE ROAD, MULTAN (000934)
	Application Form Dy. No / Tracking ID & date of submission	(7U5-BPP-GWBQ, 2024-09-19)
	Detail of Fee Submitted	30000.0, 7000.0 2024-08-02, 2025-06-30
	The proposed proprietary name / brand name	Clover Injection 100ml
	Label Claim	Each ml contains Ivermectin 10mg Closantel (as sodium dihydrate) 125mg As per Innovator's Specifications
	Reference to Finished product specifications	As per Innovators Specification
	Proposed Pack Size	100ml-De-Controlled
	Shelf Life (Unit)	2 YearStore in a cool and Dry place, away from moisture and direct sunlight.
	For generic drugs (me-too Status)	Clomec Injection by M/S. SYMANS PHARMACEUTICALS, LAHORE REG NO. 062112
	Pharmacotherapeutic Group of (API)	
	Name, address of Manufacturing site:	--
	GMP status of the firm	The panel of inspectors found the premises satisfactory and recommend the grant of DML.
	Evidence of approval of manufacturing facility	
	Evaluation Remarks	
	Decision	
	Approved	
26	Case Category	Routine (Sabahat Zehra)
	Name, address of Applicant.	BIORISE PHARMACEUTICALS 19KM, LAHORE ROAD, MULTAN (000934)
	Application Form Dy. No / Tracking ID & date of submission	(AQ3-ZWY-7V2Z, 2024-09-19)

	Detail of Fee Submitted	30000.0, 7000.0 2024-08-02, 2025-06-30
	The proposed proprietary name / brand name	Colitic Water Soluble Powder
	Label Claim	Each gm contains Colistin Sulphate BP 5,000,000 IU (Innovator's Specs)
	Reference to Finished product specifications	As per Innovators Specification
	Proposed Pack Size	10gm, 50g, 100 gm., -De-Controlled
	Shelf Life (Unit)	2 YearStore in a cool and Dry place, away from moisture and direct sunlight.
	For generic drugs (me-too Status)	Colisel-50 Powder By Selmore Pharmaceuticals, Lahore Reg No. 049616
	Pharmacotherapeutic Group of (API)	
	Name, address of Manufacturing site:	--
	GMP status of the firm	The panel of inspectors found the premises satisfactory and recommend the grant of DML.
	Evidence of approval of manufacturing facility	
	Evaluation Remarks	
	Decision	
	Approved	
27	Case Category	Routine (Sabahat Zehra)
	Name, address of Applicant.	Eterna Pharma Pvt Ltd plot no 99,100,101 & 198-c sector D1, Old industrial Estate,Mirpur, Aj&K (000923)
	Application Form Dy. No / Tracking ID & date of submission	(B7Q-4XB-UPYP, 2024-10-23)
	Detail of Fee Submitted	37000.0, 2024-10-18,
	The proposed proprietary name / brand name	FENOX PLUS WATER SOLUBLE POWDER
	Label Claim	Each 100gm contains:- Oxytetracycline HCL 30% Florfenicol 30% (As Per Innovator's specs.)
	Reference to Finished product specifications	As per Innovators Specification
	Proposed Pack Size	100gm-De-Controlled, 1Kg-De-Controlled, 250gm,-De-Controlled, 500gm-De-Controlled
	Shelf Life (Unit)	2 YearStore below 25 °C. Protect from light
	For generic drugs (me-too Status)	Feroline 60% Water Soluble Powder. Reg.# 109140 (Haarolds Pharmaceuticals (Pvt.) Ltd.Bhimber AJ & K.)
	Pharmacotherapeutic Group of (API)	
	Name, address of Manufacturing site:	--
	GMP status of the firm	cGMP compliance (Satisfactory)
	Evidence of approval of manufacturing facility	
	Evaluation Remarks	
	Decision	

	Approved	
28	Case Category	Routine (Sabahat Zehra)
	Name, address of Applicant.	BIORISE PHARMACEUTICALS 19KM, LAHORE ROAD, MULTAN (000934)
	Application Form Dy. No / Tracking ID & date of submission	(EWR-DVH-B3MY, 2024-09-21)
	Detail of Fee Submitted	30000.0, 7000.0 2024-08-02, 2025-06-30
	The proposed proprietary name / brand name	Fosfotad-25 Powder
	Label Claim	Each g Contains: - Fosfomycin calcium 250mg
	Reference to Finished product specifications	As per Innovators Specification
	Proposed Pack Size	10gm, 50g, 100 gm., -De-Controlled
	Shelf Life (Unit)	2 Year(s)Store in a cool and Dry place, away from moisture and direct sunlight.
	For generic drugs (me-too Status)	Fosmium Powder By M/S. LEADS PHARMA, ISLAMABAD Reg No. 118659
	Pharmacotherapeutic Group of (API)	
	Name, address of Manufacturing site:	--
	GMP status of the firm	The panel of inspectors found the premises satisfactory and recommend the grant of DML.
	Evidence of approval of manufacturing facility	
	Evaluation Remarks	
	Decision	
	Approved	
29	Case Category	Routine (Sabahat Zehra)
	Name, address of Applicant.	BIORISE PHARMACEUTICALS 19KM, LAHORE ROAD, MULTAN (000934)
	Application Form Dy. No / Tracking ID & date of submission	(GAV-UBD-QYXV, 2024-09-05)
	Detail of Fee Submitted	30000.0, 7000.0 2024-08-02, 2025-06-30
	The proposed proprietary name / brand name	Biotropin Injection 100ml
	Label Claim	Each 1ml contains: Atropine Sulphate 1mg (USP Specifications)
	Reference to Finished product specifications	United States Pharmacopeia
	Proposed Pack Size	100ml-De-Controlled
	Shelf Life (Unit)	2 YearStore in a cool and Dry place, away from moisture and direct sunlight.
	For generic drugs (me-too Status)	Atropi Injection 100ml By Prix Pharmaceutica Lahore Reg No. 097989
	Pharmacotherapeutic Group of (API)	
	Name, address of Manufacturing site:	--

	GMP status of the firm	The panel of inspectors found the premises satisfactory and recommend the grant of DML.
	Evidence of approval of manufacturing facility	
	Evaluation Remarks	
	Decision	
	Approved	
30	Case Category	Routine (Sabahat Zehra)
	Name, address of Applicant.	BIORISE PHARMACEUTICALS 19KM, LAHORE ROAD, MULTAN (000934)
	Application Form Dy. No / Tracking ID & date of submission	(DPD-1S7-57NU, 2024-09-04)
	Detail of Fee Submitted	30000.0, 7000.0 2024-08-02, 2025-06-30
	The proposed proprietary name / brand name	Bio-Renal Oral Powder
	Label Claim	Each 100 Gram Powder Contains: - Hexamethylene Tetramine....95.5gm Riboflavin.....2.0gm Calcium Pantothenate.....0.50gm Nicotinamide.....1.50gm As per innovator's specs
	Reference to Finished product specifications	As per Innovators Specification
	Proposed Pack Size	10gm, 50g, 100 gm., -De-Controlled
	Shelf Life (Unit)	2 YearStore in a cool and Dry place, away from moisture and direct sunlight.
	For generic drugs (me-too Status)	SOLUBAR WATER SOLUBLE POWDER By M/S. BAARIQ PHARMACEUTICALS, LAHORE Reg No. 080736
	Pharmacotherapeutic Group of (API)	
	Name, address of Manufacturing site:	--
	GMP status of the firm	The panel of inspectors found the premises satisfactory and recommend the grant of DML.
	Evidence of approval of manufacturing facility	
	Evaluation Remarks	
	Decision	
	Approved	
31	Case Category	Routine (Sabahat Zehra)
	Name, address of Applicant.	BIORISE PHARMACEUTICALS 19KM, LAHORE ROAD, MULTAN (000934)
	Application Form Dy. No / Tracking ID & date of submission	(UEY-VSB-P7ZJ, 2024-09-04)
	Detail of Fee Submitted	30000.0, 7000.0 2024-08-02, 2025-06-30

	The proposed proprietary name / brand name	Biotropin Injection 50ml
	Label Claim	Each 1ml contains: Atropine Sulphate 1mg (USP Specifications)
	Reference to Finished product specifications	United States Pharmacopeia
	Proposed Pack Size	50ml-De-Controlled
	Shelf Life (Unit)	2 YearStore in a cool and Dry place, away from moisture and direct sunlight.
	For generic drugs (me-too Status)	Atopin Injection 50ml By Symans Pharmaceuticals (Pvt.) Ltd. Lahore Reg No. 062122
	Pharmacotherapeutic Group of (API)	
	Name, address of Manufacturing site:	--
	GMP status of the firm	The panel of inspectors found the premises satisfactory and recommend the grant of DML.
	Evidence of approval of manufacturing facility	
	Evaluation Remarks	
	Decision	
	Approved	
32	Case Category	Routine (Sabahat Zehra)
	Name, address of Applicant.	BIORISE PHARMACEUTICALS 19KM, LAHORE ROAD, MULTAN (000934)
	Application Form Dy. No / Tracking ID & date of submission	(VT7-327-1MPX, 2024-09-06)
	Detail of Fee Submitted	30000.0, 7000.0 2024-08-02, 2025-06-30
	The proposed proprietary name / brand name	Bioxin-5% Water Soluble Powder
	Label Claim	Each 100gm contains: - Bromhexine HCl.....5gm (As per Innovator's Specs)
	Reference to Finished product specifications	As per Innovators Specification
	Proposed Pack Size	10gm, 50g, 100 gm., -De-Controlled
	Shelf Life (Unit)	2 YearStore in a cool and Dry place, away from moisture and direct sunlight.
	For generic drugs (me-too Status)	Bromo-5% Water Soluble Powder By Cherished Pharmaceuticals, Lahore Reg No. 063512
	Pharmacotherapeutic Group of (API)	
	Name, address of Manufacturing site:	--
	GMP status of the firm	The panel of inspectors found the premises satisfactory and recommend the grant of DML.
	Evidence of approval of manufacturing facility	
	Evaluation Remarks	
	Decision	
	Approved	

33	Case Category	Routine (Sabahat Zehra)
	Name, address of Applicant.	BIORISE PHARMACEUTICALS 19KM, LAHORE ROAD, MULTAN (000934)
	Application Form Dy. No / Tracking ID & date of submission	(YAQ-7H7-VW35, 2024-10-22)
	Detail of Fee Submitted	30000.0, 7000.0 2024-08-02, 2025-06-30
	The proposed proprietary name / brand name	Neotic-72 Water Soluble Powder
	Label Claim	Each 1gm contains: - Neomycin sulphate.....720mg (As per Innovator's Specifications)
	Reference to Finished product specifications	As per Innovators Specification
	Proposed Pack Size	10gm, 50g, 100 gm., -De-Controlled
	Shelf Life (Unit)	2 YearStore in a cool and Dry place, away from moisture and direct sunlight.
	For generic drugs (me-too Status)	Nemobar-72 Water Soluble Powder By M/S. Baariq Pharmaceuticals, Lahore Reg No.071100
	Pharmacotherapeutic Group of (API)	
	Name, address of Manufacturing site:	--
	GMP status of the firm	The panel of inspectors found the premises satisfactory and recommend the grant of DML.
	Evidence of approval of manufacturing facility	
34	Evaluation Remarks	
	Decision	
	Approved	
34	Case Category	Routine (Sabahat Zehra)
	Name, address of Applicant.	BIORISE PHARMACEUTICALS 19KM, LAHORE ROAD, MULTAN (000934)
	Application Form Dy. No / Tracking ID & date of submission	(Z8P-TM6-2YBS, 2024-09-20)
	Detail of Fee Submitted	30000.0, 7000.0 2024-08-02, 2025-06-30
	The proposed proprietary name / brand name	Linco-Plus Water Soluble Powder
	Label Claim	Each 1gm Contains:- Lincomycin HCl (B.P).....100mg Colistin Sulphate (B.P)...8,00,000 I.U
	Reference to Finished product specifications	As per Innovators Specification
	Proposed Pack Size	10gm, 50g, 100 gm., -De-Controlled
	Shelf Life (Unit)	2 YearStore in a cool and Dry place, away from moisture and direct sunlight.
	For generic drugs (me-too Status)	VETCOLLIN POWDER By M/S. VETZ PHARMACEUTICALS, SINDH Reg No. 079294
	Pharmacotherapeutic Group of (API)	
	Name, address of Manufacturing site:	--

	GMP status of the firm	The panel of inspectors found the premises satisfactory and recommend the grant of DML.
	Evidence of approval of manufacturing facility	
	Evaluation Remarks	
	Decision	
	Approved	
35	Case Category	Routine (Sabahat Zehra)
	Name, address of Applicant.	BIORISE PHARMACEUTICALS 19KM, LAHORE ROAD, MULTAN (000934)
	Application Form Dy. No / Tracking ID & date of submission	(MA9-4YB-JPL5, 2024-09-20)
	Detail of Fee Submitted	30000.0, 7000.0 2024-08-02, 2025-06-30
	The proposed proprietary name / brand name	Xinchlor-NC Oral Powder
	Label Claim	Each Kg Contains: - Bromhexine HCl.....5gm Chlortetracyclin HCl.....80gm Neomycin Sulphate.....70gm Colistin Sulphate.....4gm
	Reference to Finished product specifications	As per Innovators Specification
	Proposed Pack Size	10gm, 50g, 100 gm., -De-Controlled
	Shelf Life (Unit)	2 YearStore in a cool and Dry place, away from moisture and direct sunlight.
	For generic drugs (me-too Status)	NEOCOLICIN PLUS POWDER By M/S. LEADS PHARMA, ISLAMABAD Reg No. 044949
	Pharmacotherapeutic Group of (API)	
	Name, address of Manufacturing site:	--
	GMP status of the firm	The panel of inspectors found the premises satisfactory and recommend the grant of DML.
	Evidence of approval of manufacturing facility	
	Evaluation Remarks	
	Decision	
	Approved	
36	Case Category	Routine (Sabahat Zehra)
	Name, address of Applicant.	BIORISE PHARMACEUTICALS 19KM, LAHORE ROAD, MULTAN (000934)
	Application Form Dy. No / Tracking ID & date of submission	(T72-G53-YU7R, 2024-09-04)
	Detail of Fee Submitted	30000.0, 7000.0 2024-08-02, 2025-06-30
	The proposed proprietary name / brand name	Bromolin-2S Oral Powder

	Label Claim	Each 100gm contains: - Lincomycin hcl.....5gm Spectinomycin hcl.....7.5gm Spiramycin adipate.....2.5gm Bromhexine hcl.....0.5gm (As per innovator's Specs)
	Reference to Finished product specifications	As per Innovators Specification
	Proposed Pack Size	10gm, 50g, 100 gm., -De-Controlled
	Shelf Life (Unit)	2 YearStore in a cool and Dry place, away from moisture and direct sunlight.
	For generic drugs (me-too Status)	Speclinx Oral Powder By M/S. Vantage Pharmaceuticals, Faisalabad Reg No. 081714
	Pharmacotherapeutic Group of (API)	
	Name, address of Manufacturing site:	--
	GMP status of the firm	The panel of inspectors found the premises satisfactory and recommend the grant of DML.
	Evidence of approval of manufacturing facility	
	Evaluation Remarks	
	Decision	
	Approved	
37	Case Category	Routine (Sabahat Zehra)
	Name, address of Applicant.	Eterna Pharma Pvt Ltd plot no 99,100,101 & 198-c sector D1, Old industrial Estate,Mirpur, Aj&K (000923)
	Application Form Dy. No / Tracking ID & date of submission	(WHX-XBS-GMBS, 2024-10-23)
	Detail of Fee Submitted	37000.0, 2024-10-18,
	The proposed proprietary name / brand name	FENOX WATER SOLUBLE POWDER
	Label Claim	Each 100gm contains:- Oxytetracycline HCL 15gm Florfenicol 15gm (As Per Innovator's specs.)
	Reference to Finished product specifications	As per Innovators Specification
	Proposed Pack Size	100gm-De-Controlled,1Kg-De-Controlled,250gm-De-Controlled,500gm-De-Controlled
	Shelf Life (Unit)	2 YearStore below 25 °C. Protect from light
	For generic drugs (me-too Status)	Feroline 30% Water Soluble Powder. Reg.# 109257 (Haarolds Pharmaceuticals (Pvt.) Ltd.Bhimber AJ & K.)
	Pharmacotherapeutic Group of (API)	
	Name, address of Manufacturing site:	--
	GMP status of the firm	cGMP compliance (Satisfactory)
	Evidence of approval of manufacturing facility	
	Evaluation Remarks	
	Decision	

Approved

38	Case Category		Routine (Sana Kanwal)	
	Name, address of Applicant.		Shaigan Pharmaceuticals (Pvt) Ltd 14Km Adyala Road Post office Dahgal Rawalpindi (000333)	
	Application Form Dy. No / Tracking ID & date of submission		(4AJ-H57-V2VR, 2024-02-12)	
	Detail of Fee Submitted		30000.0, 2023-12-18,	
	The proposed proprietary name / brand name		Ketowin Shampoo 2% w/w	
	Label Claim		Each ml contains: Ketoconazole.....20mg	
	Reference to Finished product specifications		British Pharmacopeia	
	Proposed Pack Size		60ml (1's)-As per SRO	
	Shelf Life (Unit)		2 Year(s)store below 30	
	For generic drugs (me-too Status)		conaz shampoo	
	Pharmacotherapeutic Group of (API)		Antifungal	
	Name, address of Manufacturing site:		Self Manufacturing	
	Name & address of API manufacturer		Aarti Drugs Limited	
	Detail of stability batches of drug product		3 batches: Batch size: 80 Bottles 060NS01 060NS02 060NS03	
	Documents for the procurement of API with approval from DRAP (in case of Import)		Clearance certificate submitted dated 15.08.2022 confirming import of 300Kg ketoconazole Batch No. KET/12206335	
	Pharmaceutical Equivalence and Comparative Dissolution Profile		PE studies performed against reference product Nizoral shampoo (Batch No. NHB0G00).	
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)		Stability studies of 3 batches is provided as per Zone IV-A Batch No. 01: KET/11009001 Batch No. 02: KET/11009002 Batch No.03: KET/11009003 (long term study up to 60months)	
	The status in reference regulatory authorities		Nizoral Shampoo (MHRA Approved)	
	GMP status of the firm		GMP certificate of product manufacturer is provided based on inspection dated 16-02-2024 GMP certificate of Drug Substance manufacturer i.e Aarti Drugs Limited ,India is valid till 27-02-2025.	
	Evidence of approval of manufacturing facility		DML renewal inspection report is provided dated 04-11-2021 specifies topical section (cream / ointment / gel / lotion section)	
Evaluation Remarks				
S.No	Observations	Reply	Remarks	
1.	The submitted label claim represents that the product contains w/v while applied brand name as well as innovator's product is 2% w/w. Revision of label	Applied product already contains 2% w/w at the time of CTD submission.	Although the strength mentioned along with brand name as well as API as 2%w/w thought out the dossier yet the label claim to be revised and corrected as	

	claim along with fee is required.		under:Each gm contains:Ketoconazole....20mgalong with fee (as per SRO)
2.	BP monograph specifies that assay is to be performed at 230nm, while your various analysis of assay test has been performed at 225nm. clarification is required in this regard.	he product is tested as per British Pharmacopoeia (BP) specifications, with the assay performed at a detector wavelength of 230 nm. Chromatograms obtained at 225 nm correspond to the assay of the Ketoconazole (API), which is conducted in accordance with United States Pharmacopeia (USP) specifications.	Verified
3,	Submit evidence of autosampler with facility to maintain temperature at 4 degree which is required for assay test.	The analysis of Ketoconazole shampoo is performed using an auto sampler equipped with a sample cooling unit. The instrument model is SIL-20AC HT (Shimadzu).	Firm has provided commercial invoice dated 14-01-2022
4.	Provide raw data / CoA / chromatogram against each time point (to be labelled sequence wise) under 3.2.P.8 to review analytical record of each batch and at each time point.	Firm has provided raw data sheet/CoA and chromatograms against each batch at each time point	Complied
5.	Provide updated GMP certificate of Drug Substance manufacture (Original/legalized).	Attested/signed copy of GMP certificate based on inspection dated 21-10-2021 is providedIssued by FDA Maharashtra state.	The GMP certificate is valid till 27-02-2025

Decision

Approved

Approved. Firm shall submit fee (as per SRO) for standardization of label claim as under:

Each gm contains:

Ketoconazole.....20mg

39	Case Category	Priority As Per 257-M of RB (Sana Kanwal)

Name, address of Applicant.	Oncovanz Pharmaceuticals Private Limited C 52 Block 4 Gulshan e Iqbal (0418)		
Application Form Dy. No / Tracking ID & date of submission	(HZM-XRU-99R7, 2025-06-02)		
Detail of Fee Submitted	300000.0, 2025-04-21,		
The proposed proprietary name / brand name	Temovanz 100 Capsule		
Label Claim	Each hard gelatin capsule contains: Temozolomide.....100mg		
Reference to Finished product specifications	United States Pharmacopeia		
Proposed Pack Size	HDPE bottles contai-As per SRO		
Shelf Life (Unit)	36 Month(s)Store below 30°C. Protect from light and moisture		
For generic drugs (me-too Status)	Zolomid 100mg Capsule		
Pharmacotherapeutic Group of (API)	Antineoplastic agent		
Name, address of Manufacturing site:	Zee Laboratories Limited -Behind 47, Industrial Area, Paonta Sahib-173025 (India)-India		
Pharmaceutical Equivalence and Comparative Dissolution Profile	Attached		
Name, address of Marketing Authorization Holder:	Oncovanz Pharmaceuticals (Pvt.) Ltd, Plot# C-52, Block 4,Gulshan-e-Iqbal,Karachi, Pakistan, Pakistan		
Details of Certificates (CoPP/FSC/cGMP):	Valid & Legalized GMP certificate (No. DCA/SLN/DML/86/10) issued by regulatory body of Himachel Pradesh, India (valid till 10.08.2025) Valid Drug Sale License in the name of applicant is provided (valid till 23-08-2028) Free Sale certificate fro		
Details of Authorization Letter :	Not Applicable		
Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Not Applicable		
The status in reference regulatory authorities	APO TEMOZOLOMIDE, HEALTH CANADA		
Evaluation Remarks			
S.No.	Observation	Reply	Remarks
1.	The excipients used in applied formulation are qualitatively different from Reference/innovator's product hence excipient-drug substance compatibility study is required under section. 3.2.P.2.2.1 (formulation development)	Drug excipient compatibility study has been provided as required under section 3.2.P.2.2.1	complied
Decision			
Approved			
Approved.			

40	Case Category		Priority As Per 257-M of RB (Sana Kanwal)	
	Name, address of Applicant.		Lab Diagnostic Systems (SMC) Pvt. Ltd. 36-A, PSIC, SIE, Taxila, Rawalpindi, Pakistan (01-374-0006)	
	Application Form Dy. No / Tracking ID & date of submission		(EPU-6NG-MA3U, 2025-02-17)	
	Detail of Fee Submitted		300000.0, 2025-01-08,	
	The proposed proprietary name / brand name		CYTRAZ-100	
	Label Claim		Each ml contains: Cytrabine 100 mg Sterile water for injection q.s	
	Reference to Finished product specifications		British Pharmacopeia	
	Proposed Pack Size		1's-As per SRO	
	Shelf Life (Unit)		24 Month(s)Store in a cool place below 25°C. Protect from light.	
	For generic drugs (me-too Status)		Registration Number: 038247 Brand name: Cytocin-100 Injection Each vial contains: Cytarabine 100mg MAH: Pharmedic Pharmaceuticals (Pvt) Ltd	
	Pharmacotherapeutic Group of (API)		Pyrimidine analogue	
	Name, address of Manufacturing site:		Zuvius Lifesciences Pvt. Ltd.-At Plot No. 58 to 67, Sector B-1, Umariya - Dungaria, Tehsil- Shahpura, District- Jabalpur (M. P.) India- 482003-India	
	Pharmaceutical Equivalence and Comparative Dissolution Profile		Reference product: Cytrine injection Batch No: C11851 Manufacturer: Omicron Pharma	
	Name, address of Marketing Authorization Holder:		Zuvius Lifesciences Pvt. Ltd., At Plot No. 58 to 67, Sector B-1, Umariya - Dungaria, Tehsil- Shahpura, District- Jabalpur (M. P.) India- 482003, India	
	Details of Certificates (CoPP/FSC/cGMP):		GMP certificate has been granted in the name of M/s Revacure Lifesciences , India (certificate No. 02/2017) valid upto 13.12.2025 issued by FDA Bhopal, Madhya Pradesh CoPP (No 02/2017) provided valid till 09-06-2025	
	Details of Authorization Letter :		Not Applicable	
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)		Not Applicable	
The status in reference regulatory authorities		Cytarabine Injection 100mg/1ml Distributed by: Hospira, Inc., Lake Forest, IL 60045 USA USFDA Approved		
Evaluation Remarks				
S.No	Observations	Reply	Remarks	
1.	Submit original/legalized CoPP (duly signed /stamped by issuing authority).	We, Zuvius Lifesciences Pvt. Ltd., having our manufacturing site at Kharuni-Lodhimajra Road, Vill. Nandpur, Baddi, Distt. Solan (H.P.), India, hereby submit this undertaking regarding the delay in	The list of drug mentioned on clarification letter (01-07-2025) did not include Cytrabine	

		submission of the Legalized Certificates of Pharmaceutical Product (COPPs) and Letters of Authorization (LOAs). We have applied for the COPPs; however, due to an ongoing FDA audit at our facility, the issuance of COPPs has been delayed. We are enclosing the proof of submission for your reference.	
2.	Clarify name of manufacturer/exporter whether its Zuvius Lifesciences Pvt. Ltd or Revacure Lifesciences. The name of Product license holder mentioned on CoPP and Authorisation letter is Zuvius Lifesciences Pvt Ltd while the name mentioned on GMP certificate is Revacure Lifesciences.	This is to clarify that Zuvius Lifesciences Pvt. Ltd., the product license holder and exporter, has manufactured the concerned pharmaceutical products at the manufacturing facility of Revacure Lifesciences, located at Plot No 58 to 67, sector B-1, Umariya - Dungaria, Tehsil Shahpura, District-Jabalpur (M.P.) India-482003.	The name of manufacturer need to be mentioned on CoPP.
3.	Hydrochloric acid has been used for pH adjustment alongside Sodium hydroxide in reference product (USFDA/MHRA approved) https://www.medicines.org.uk/emc/product/1570/smpc#grefwhile in applied formulation only Sodium hydroxide has been used (as pH adjusting agent) as mentioned under section 3.2.P.2.2.1 (Formulation development) the only. Please clarify.	We would like to clarify that Cytarabine injection products are available in multiple formulations globally and the manufacturing processes and excipients may vary across different versions. The reference product (as per USFDA/MHRA) includes both Hydrochloric acid and Sodium hydroxide for pH adjustment; however, this does not necessarily imply that both must be used in all formulations. Our submitted formulation, only Sodium hydroxide is used for pH adjustment, which is scientifically justified and sufficient to achieve the required pH range.	

		This composition is in compliance with pharmacopeia standards and is backed by our formulation development and stability data.	
Decision			
Deferred			
Deferred for above mentioned shortcomings/observations.			
41	Case Category	Priority As Per 257-M of RB (Sana Kanwal)	
	Name, address of Applicant.	Lab Diagnostic Systems (SMC) Pvt. Ltd. 36-A, PSIC, SIE, Taxila, Rawalpindi, Pakistan (01-374-0006)	
	Application Form Dy. No / Tracking ID & date of submission	(TAE-A2Z-EXBM, 2024-06-27)	
	Detail of Fee Submitted	300000.0, 2024-04-08,	
	The proposed proprietary name / brand name	Bratoma 100mg Capsule	
	Label Claim	Temozolomide 100mg	
	Reference to Finished product specifications	Manufacturer Specification	
	Proposed Pack Size	5's-As per SRO	
	Shelf Life (Unit)	24 Month(s)Store below 30°C. Protect from light.	
	For generic drugs (me-too Status)	Temomedac 100mg Capsule Imported and Marketed by: Amgomed	
	Pharmacotherapeutic Group of (API)	Anti Neoplastic	
	Name, address of Manufacturing site:	Actero Middle East -On the corner of 8th Golestan , Sarvestan Blvd. Baharestan Industrial Zone, Karaj, Iran.-Iran	
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Reference Product: Temodal 100mg capsule Manufacturer: Orion Corporation Batch No: 8DZAA40013 Test Product: Bratoma 100mg Capsule Manufacturer: Actero Middle East Batch No: C1902B	
	Name, address of Marketing Authorization Holder:	Actero Middle East , On the corner of 8th Golestan, Sarvestan Blvd., Baharestan Industrial zone, Karaj, Iran., Iran	
	Details of Certificates (CoPP/FSC/cGMP):	GMP certificate in the name of M/s Actero Middle East issued by Islamic Republic of Iran, Ministry of Health and Education. Validity Date: May 2024. CoPP granted by Islamic Republic of Iran, Ministry of Health and Education, FDA (Ref No. 665/32511 dat	
	Details of Authorization Letter :	Not Applicable	
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Not Applicable	
	The status in reference regulatory authorities	Temodal® 100 mg Capsule (Merck Sharp & Dohme (UK) Limited). European Medicine Agency	
Evaluation Remarks			

S.No	Observations	Reply	Remarks
1.	3.2.P.5: Applied formulation is available in BP as well as USP while applied specification are "In house". As per Drug Specification Rules 1978, Pharmacopial specification to be granted (if available in official monograph). Hence Finished product specifications/analytical testing method to be revised in line with Pharmacopia alongwith performance report of next time point of stability studies.	The principle has provided dated 09.07.2025 undertaking that they will update their specifications and will submit all the relevant documentation till 15th July,2025."We are actively in the process of updating and preparing the necessary documents, and we commit to finalizing and submitting all relevant documentation by 15 July 2025."	
2.	Provide valid sole agency agreement since already provided sole agency agreement/distribution certificate was valid till 15-01-2025.	Firm has provided Letter of Authorization/ Distribution certificate (No. 403-60-4-523) dated 29.05.2024 wherein M/s Lab Diagnostics System Pvt Ltd was exclusively authorized for sale/distribution of applied product within territory of Pakistan.	"This certificate is valid and effective for one year from the date of this letter and the validity of the Distribution Agreement automatically renewable unless earlier terminated according to its terms and conditions."
3.	GMP certificate in the name of M/s Actero Middle East issued by Islamic Republic of Iran, Ministry of Health and Education. Validity Date: May 2024.	Updated GMP certificate (No. 665/4353) dated 19.04.2025 in the name of M/s Actero Middle East issued by Islamic Republic of Iran, Ministry of Health and Education is provided.	Complied
4.	DSL of applicant is valid till 30-04-2024.	Updated DSL is provided (No. 01-374-0006-118530D) valid till 15-08-2029	Complied

Decision

Deferred

Deferred for above mentioned Shortcomings/observations.

42	Case Category	Routine (Shahid Nawaz)

Name, address of Applicant.		Nabiqasim Industries (Pvt) Ltd., 17/24, Korangi Industrial Area, Karachi. (000105)
Application Form Dy. No / Tracking ID & date of submission		(1NR-LJA-HJYH, 2024-03-19)
Detail of Fee Submitted		75000.0, 2024-03-13,
The proposed proprietary name / brand name		Topixat 20mg Tablet
Label Claim		Each tablet contains: Topiroxostat.....20mg
Reference to Finished product specifications		As per Innovators Specification
Proposed Pack Size		7s, 10s, 14s, 20s, 2-Controlled
Shelf Life (Unit)		2 Year(s)Below 30° C
For generic drugs (me-too Status)		N/A
Pharmacotherapeutic Group of (API)		Preparations inhibiting uric acid production. ATC code: M04AA.
Name, address of Manufacturing site:		Self Manufacturing
Name & address of API manufacturer		Allastir Private Limited
Detail of stability batches of drug product		02 batches having batch size of 5000 Tablets each.
Documents for the procurement of API with approval from DRAP (in case of Import)		Firm has submitted copy of Form-6 No. K-2188089871748 dated 01-08-2023 mentioning 1.5kg of Topiroxostat (Manufacturer Specifications) from M/s Allastrir Private Limited India. Form 6 is issued by DRAP, Karachi. Firm has also submitted copy of clearance certificate No. E-6713589873597 dated 20-09-2023 mentioning 1.5kg of Topiroxostat, B. No. 2623050801, Mfg. date 01-05-2023 from Allastrir Private Limited India. Clearance certificate is issued by DRAP, Karachi.
Pharmaceutical Equivalence and Comparative Dissolution Profile		CDP and PE studies are performed against innovator product i.e. Uriadec Tablet 20mg, B. No. KY00201, Exp. date 03-2027 manufactured by M/s Sanwa Kagaku Kenkyusho Co., Ltd. Japan and both reference and applied formulation have shown more than 85% release in pH 1.2 medium while in pH 4.5 and pH 6.8 values of F2 are within acceptable range.
Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)		Stability study data of 3 batches of drug substance as per Zone IV-B is submitted. Accelerated 06 months and real time for 36 months.
The status in reference regulatory authorities		Uriadec 20mg, 40mg and 60mg Tablet, PMDA Japan Approved.
GMP status of the firm		Firm has submitted copy of GMP certificate No. 51/2023-DRAP (K) dated 26-07-2023 issued on the basis of inspection conducted on 22-05-2023.
Evidence of approval of manufacturing facility		Firm has submitted copy of letter No. F. 2-20/85-Lic (Vol-V) dated 27-04-2020 mentioning Tablet (General) section.
Evaluation Remarks		
Sr. No.	Observations	Reply by the firm

i.	Stability summary sheets of the drug substance has mentioned NMT 1.0% specifications for loss on drying test, while 3.2.S.4.1 has mentioned NMT 0.5%. clarification shall be submitted.	Firm has submitted revised specifications for the drug substance from drug substance manufacturer wherein the specifications for loss on drying test are NMT 1.0%.
ii.	Complete six-month time point stability data shall be submitted.	Firm has submitted six-month time point stability sheets along with raw data sheets and chromatograms

Decision

Approved

43	Case Category	Routine (Shahid Nawaz)
	Name, address of Applicant.	Martin Dow Marker Limited 7, Jail Road Quetta. (000028)
	Application Form Dy. No / Tracking ID & date of submission	(1P2-472-PB7H, 2024-02-12)
	Detail of Fee Submitted	75000.0, 9000.0 2023-09-15, 2025-07-09
	The proposed proprietary name / brand name	Vortioxetine Tablets
	Label Claim	Each film-coated tablet contains: Vortioxetine as Hydrobromide.....20mg
	Reference to Finished product specifications	As per Innovators Specification
	Proposed Pack Size	14's-As per SRO
	Shelf Life (Unit)	2 Year(s)Real time 30 C
	For generic drugs (me-too Status)	Nil
	Pharmacotherapeutic Group of (API)	Other Anti-depressants. ATC code: N06AX26.
	Name, address of Manufacturing site:	Self Manufacturing
	Name & address of API manufacturer	Synergene Active Ingredients Pvt. Ltd.
	Detail of stability batches of drug product	03 batches having batch size of 10000 Tablets each.
	Documents for the procurement of API with approval from DRAP (in case of Import)	Firm has submitted copy of form 6 No. K-1211940026793 dated 05-Nov-2022 mentioning 1.75 kg of Vortioxetine hydro bromide. Form 6 is issued by DRAP, Karachi dated 05-Nov-2022.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	CDP and PE studies are performed against innovator product i.e. Brintellix 20mg Tablet, Batch No: 2750354, Exp. date 09-2026 manufactured by Lund beck Ltd., UK and both innovator and applied formulation have shown more than 85% release within 15 minutes in 0.1N HCl and Acetate buffer while in Phosphate buffer value of F2 is in acceptable range.
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Stability study data of 3 batches of drug substance as per Zone IV-A is submitted. Accelerated 06 months and real time for 12 months.
	The status in reference regulatory authorities	Trintellix Tablet 5mg, 10mg and 20mg, USFDA approved.
	GMP status of the firm	Firm has submitted copy of GMP certificate No. 015/2021-DRAP (Q)/K dated 10-09-2021 issued on

		the basis of inspection conducted on 26 & 27- 02- 2021.
Evidence of approval of manufacturing facility		Firm has submitted copy of letter No. F. 4-2/86-Lic (Vol-VII) dated 31-05-2021 mentioning Tablet (General) section.
Evaluation Remarks		
Sr. No.	Observations	Reply by the firm.
1.	Valid copy of GMP certificate of the drug substance manufacturer shall be submitted.	Firm has submitted copy of File No. HMF07-14051/229/2024-ADMIN-DCA issued by Drugs Control Administration, Andhra Pradesh India in the name of M/s Synergene Active Ingredients Private Limited, India. Certificate has mentioned "I forward here with World Health Organization Good Manufacturing Practice Certificate for the products Recommended by the Joint Inspection team consisting of the officers of Drugs Control Administration, Andhra Pradesh and CDSCO, Hyderabad for export purpose. This certificate is valid for a period of Three Years from the Date of issue and this certificate is meant for Export of drugs only"
2.	Water content and assay limits provided by drug product manufacturer are different from drug substance manufacturer. Clarification shall be submitted	Firm has submitted revised water Content and assay limit in COA along with API Specification.
3.	Analytical procedures for the drug substance from drug product manufacturer shall be submitted.	Firm has submitted analytical procedure for the drug substance.
4.	Submitted COA from the drug product manufacturer has not performed Bromide content test and polymorphic form by XRPD. Clarification shall be submitted.	Firm has submitted revised COA for the drug substance with inclusion of Bromide content test and polymorphic form by XRPD as required by the drug substance manufacturer.
5.	Stability summary sheets of the drug substance has mentioned water content of NMT 2% while specification provided by the drug substance manufacturer has mentioned NMT 0.5%. clarification shall be submitted.	Firm has submitted a clarification from the drug substance manufacturer i.e. M/s Synergene Active Ingredients Private Limited, India as follows; This is to clarify the discrepancy observed between the stability summary sheets and the drug substance specification regarding the water content limit. The reference to NMT 0.5% in the specification was a typographical error. The correct specification for water content of the drug substance is Not More Than (NMT) 2.0%, as accurately stated in the stability summary sheets. However, revised specification enclosed for your reference." Revised specifications from drug substance manufacturer are also submitted wherein water content of NMT 2% are mentioned.

6.	Justification shall be submitted for using 45-minutes time for dissolution in PE studies and specification of the finished product.	Firm has submitted that product specification has been revised to incorporate dissolution time 20 minutes as per innovator specification. They further stated that dissolution test results found satisfactory as per revised specifications i.e. 99.54% for 5mg tablet, 95.95% for 10mg tablets and 96.16% for 20mg tablet in 20 minutes. Firm has also submitted pre-registration variation fee vide challan No. 55412815660 dated 09-07-2025.
7.	Pictorial evidence of the Innovator product with visible details against which CDP and PE are performed shall be submitted.	Submitted. Brintellix 20mg Tablet, Batch No: 2750354, Exp. date 09-2026 manufactured by Lund beck Ltd., UK
8.	Clearance certificate for import of API with approval from DRAP shall be submitted.	Firm has submitted copy of Form 6 No. K-1211940026793 dated 05-11-2022 mentioning 1.75kg of VORTIOXETINE HYDROBROMIDE (Manufacturer's Specification) from M/s SYNERGENE ACTIVE INGREDIENTS PVT LTD., India. Form 6 is issued by DRAP, Karachi.

Decision

Deferred

Firm will confirm that the results submitted with revised dissolution specifications are from CDP studies or they have submitted new dissolution results of their product as per revised specifications.

44	Case Category	Routine (Shahid Nawaz)
	Name, address of Applicant.	Nabiqasim Industries (Pvt) Ltd., 17/24, Korangi Industrial Area, Karachi. (000105)
	Application Form Dy. No / Tracking ID & date of submission	(6M9-VUX-29SY, 2024-03-19)
	Detail of Fee Submitted	75000.0, 2024-03-13,
	The proposed proprietary name / brand name	Topixat 60mg Tablet
	Label Claim	Each tablet contains: Topiroxostat.....60mg
	Reference to Finished product specifications	As per Innovators Specification
	Proposed Pack Size	7s, 10s, 14s, 20s, 2-Controlled
	Shelf Life (Unit)	2 Year(s)Below 30° C
	For generic drugs (me-too Status)	N/A
	Pharmacotherapeutic Group of (API)	Preparations inhibiting uric acid production. ATC code: M04AA.
	Name, address of Manufacturing site:	Self Manufacturing
	Name & address of API manufacturer	Allastir Private Limited
	Detail of stability batches of drug product	02 batches having batch size of 5000 Tablets each.
	Documents for the procurement of API with approval from DRAP (in case of Import)	Firm has submitted copy of Form-6 No. K-2188089871748 dated 01-08-2023 mentioning 1.5kg of Topiroxostat (Manufacturer Specifications) from M/s Allastir Private Limited India. Form 6 is issued by DRAP, Karachi. Firm has also submitted copy of clearance certificate No.

		E-6713589873597 dated 20-09-2023 mentioning 1.5kg of Topiroxostat, B. No. 2623050801, Mfg. date 01-05-2023 from Allastrir Private Limited India. Clearance certificate is issued by DRAP, Karachi.									
	Pharmaceutical Equivalence and Comparative Dissolution Profile	CDP and PE studies are performed against innovator product i.e. Uriadec Tablet 60mg, B. No. KY00101, Exp. date 03-2027 manufactured by M/s Sanwa Kagaku Kenkyusho Co., Ltd. Japan and both reference and applied formulation have shown more than 85% release in pH 1.2 medium while in pH 4.5 and pH 6.8 values of F2 are within acceptable range.									
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Stability study data of 3 batches of drug substance as per Zone IV-B is submitted. Accelerated 06 months and real time for 36 months.									
	The status in reference regulatory authorities	Uriadec 20mg, 40mg and 60mg Tablet, PMDA Japan Approved.									
	GMP status of the firm	Firm has submitted copy of GMP certificate No. 51/2023-DRAP (K) dated 26-07-2023 issued on the basis of inspection conducted on 22-05-2023.									
	Evidence of approval of manufacturing facility	Firm has submitted copy of letter No. F. 2-20/85-Lic (Vol-V) dated 27-04-2020 mentioning Tablet (General) section.									
	Evaluation Remarks										
	<table border="1"> <thead> <tr> <th>Sr. No.</th><th>Observations</th><th>Reply by the firm</th></tr> </thead> <tbody> <tr> <td>i.</td><td>Stability summary sheets of the drug substance has mentioned NMT 1.0% specifications for loss on drying test, while 3.2.S.4.1 has mentioned NMT 0.5%. clarification shall be submitted.</td><td>Firm has submitted revised specifications for the drug substance from drug substance manufacturer wherein the specifications for loss on drying test are NMT 1.0%.</td></tr> <tr> <td>ii.</td><td>Complete six-month time point stability data shall be submitted.</td><td>Firm has submitted six-month time point stability sheets along with raw data sheets and chromatograms</td></tr> </tbody> </table>	Sr. No.	Observations	Reply by the firm	i.	Stability summary sheets of the drug substance has mentioned NMT 1.0% specifications for loss on drying test, while 3.2.S.4.1 has mentioned NMT 0.5%. clarification shall be submitted.	Firm has submitted revised specifications for the drug substance from drug substance manufacturer wherein the specifications for loss on drying test are NMT 1.0%.	ii.	Complete six-month time point stability data shall be submitted.	Firm has submitted six-month time point stability sheets along with raw data sheets and chromatograms	
Sr. No.	Observations	Reply by the firm									
i.	Stability summary sheets of the drug substance has mentioned NMT 1.0% specifications for loss on drying test, while 3.2.S.4.1 has mentioned NMT 0.5%. clarification shall be submitted.	Firm has submitted revised specifications for the drug substance from drug substance manufacturer wherein the specifications for loss on drying test are NMT 1.0%.									
ii.	Complete six-month time point stability data shall be submitted.	Firm has submitted six-month time point stability sheets along with raw data sheets and chromatograms									
	Decision										
	Approved										
45	Case Category	Routine (Shahid Nawaz)									
	Name, address of Applicant.	Martin Dow Marker Limited 7, Jail Road Quetta. (000028)									
	Application Form Dy. No / Tracking ID & date of submission	(6ZN-12W-9ZJU, 2024-01-22)									
	Detail of Fee Submitted	75000.0, 9000.0 2023-09-15, 2025-07-09									
	The proposed proprietary name / brand name	Vortioxetine Tablets									
	Label Claim	Each film-coated tablet contains: Vortioxetine as hydrobromide....10mg									
	Reference to Finished product specifications	As per Innovators Specification									
	Proposed Pack Size	14's-As per SRO									

Shelf Life (Unit)	2 Year(s)Real time 30 C
For generic drugs (me-too Status)	Nil
Pharmacotherapeutic Group of (API)	Other Anti-depressants. ATC code: N06AX26.
Name, address of Manufacturing site:	Self Manufacturing
Name & address of API manufacturer	Synergene Active Ingredients Pvt. Ltd.
Detail of stability batches of drug product	03 batches having batch size of 10000 Tablets each.
Documents for the procurement of API with approval from DRAP (in case of Import)	Firm has submitted copy of form 6 No. K-1211940026793 dated 05-Nov-2022 mentioning 1.75 kg of Vortioxetine hydro bromide. Form 6 is issued by DRAP, Karachi dated 05-Nov-2022.
Pharmaceutical Equivalence and Comparative Dissolution Profile	CDP and PE studies are performed against innovator product i.e. Brintellix 10mg Tablet, Batch No: 2738181, Exp. date 06-2026 manufactured by Lund beck Ltd., UK and both innovator and applied formulation have shown more than 85% release within 15 minutes in 0.1N HCl and Acetate buffer while in Phosphate buffer value of F2 is in acceptable range.
Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Stability study data of 3 batches of drug substance as per Zone IV-A is submitted. Accelerated 06 months and real time for 12 months.
The status in reference regulatory authorities	Trintellix Tablet 5mg, 10mg and 20mg, USFDA approved.
GMP status of the firm	Firm has submitted copy of GMP certificate No. 015/2021-DRAP (Q)/K dated 10-09-2021 issued on the basis of inspection conducted on 26 & 27- 02- 2021.
Evidence of approval of manufacturing facility	Firm has submitted copy of letter No. F. 4-2/86-Lic (Vol-VII) dated 31-05-2021 mentioning Tablet (General) section.

Evaluation Remarks

Sr. No.	Observations	Reply by the firm.
1.	Valid copy of GMP certificate of the drug substance manufacturer shall be submitted.	Firm has submitted copy of File No. HMF07-14051/229/2024-ADMIN-DCA issued by Drugs Control Administration, Andhra Pradesh India in the name of M/s Synergene Active Ingredients Private Limited, India. Certificate has mentioned "I forward here with World Health Organisation Good Manufacturing Practice Certificate for the products Recommended by the Joint Inspection team consisting of the officers of Drugs Control Administration, Andhra Pradesh and CDSCO, Hyderabad for export purpose. This certificate is valid for a period of Three Years from the Date of issue and this certificate is meant for Export of drugs only"
2.	Water content and assay limits provided by drug product manufacturer are different	Firm has submitted revised water Content and assay limit in COA along with API Specification.

	from drug substance manufacturer. Clarification shall be submitted	
3.	Analytical procedures for the drug substance from drug product manufacturer shall be submitted.	Firm has submitted analytical procedure for the drug substance.
4.	Submitted COA from the drug product manufacturer has not performed Bromide content test and polymorphic form by XRPD. Clarification shall be submitted.	Firm has submitted revised COA for the drug substance with inclusion of Bromide content test and polymorphic form by XRPD as required by the drug substance manufacturer.
5.	Stability summary sheets of the drug substance has mentioned water content of NMT 2% while specification provided by the drug substance manufacturer has mentioned NMT 0.5%. clarification shall be submitted.	Firm has submitted a clarification from the drug substance manufacturer i.e. M/s Synergene Active Ingredients Private Limited, India as follows; This is to clarify the discrepancy observed between the stability summary sheets and the drug substance specification regarding the water content limit. The reference to NMT 0.5% in the specification was a typographical error. The correct specification for water content of the drug substance is Not More Than (NMT) 2.0%, as accurately stated in the stability summary sheets. However, revised specification enclosed for your reference.” Revised specifications from drug substance manufacturer are also submitted wherein water content of NMT 2% are mentioned.
6.	Justification shall be submitted for using 45-minutes time for dissolution in PE studies and specification of the finished product.	Firm has submitted that product specification has been revised to incorporate dissolution time 20 minutes as per innovator specification. They further stated that dissolution test results found satisfactory as per revised specifications i.e. 99.54% for 5mg tablet, 95.95% for 10mg tablets and 96.16% for 20mg tablet in 20 minutes. Firm has also submitted pre-registration variation fee vide challan No. 4135872534 dated 09-07-2025.
7.	Pictorial evidence of the Innovator product with visible details against which CDP and PE are performed shall be submitted.	Submitted. Brintellix 10mg Tablet, Batch No: 2738181, Exp. date 06-2026 manufactured by Lund beck Ltd., UK
8.	Clearance certificate for import of API with approval from DRAP shall be submitted.	Firm has submitted copy of Form 6 No. K-1211940026793 dated 05-11-2022 mentioning 1.75kg of VORTIOXETINE HYDROBROMIDE (Manufacturer's Specification) from M/s SYNERGENE ACTIVE INGREDIENTS PVT LTD., India. Form 6 is issued by DRAP, Karachi.

Decision

Deferred

	Firm will confirm that the results submitted with revised dissolution specifications are from CDP studies or they have submitted new dissolution results of their product as per revised specifications.	
46	Case Category	New Molecule/Formulation (Shahid Nawaz)
	Name, address of Applicant.	Medizan Laboratories (Pvt) Ltd Plot No.313 Industrial Triangle Kahuta Road Islamabad (000572)
	Application Form Dy. No / Tracking ID & date of submission	(3LY-3G5-JLJ9, 2025-01-28)
	Detail of Fee Submitted	75000.0, 2024-11-06,
	The proposed proprietary name / brand name	Resmet-100 Tablets
	Label Claim	Each film-coated tablet contains: Resmetirom 100mg
	Reference to Finished product specifications	As per Innovators Specification
	Proposed Pack Size	14, 20 & 30 Tablets-As per SRO
	Shelf Life (Unit)	2 Year(s)Below 30°C
	For generic drugs (me-too Status)	NA
	Pharmacotherapeutic Group of (API)	Thyroid hormone receptor (THR)-beta agonists
	Name, address of Manufacturing site:	Self Manufacturing
	Name & address of API manufacturer	SHANDONG CHENGHUI SHUANGDA PHARMACEUTICALS CO., LTD
	Detail of stability batches of drug product	3 batches: 1500 Tablet
	Documents for the procurement of API with approval from DRAP (in case of Import)	02-07-2024: Clearance certificate for 0.7Kg API
	Pharmaceutical Equivalence and Comparative Dissolution Profile	REZDIFFRA Tablet: PE and CDP studies performed
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	3 batches as per Zone IV-A
	The status in reference regulatory authorities	REZDIFFRA (Resmetirom) tablets, for oral use Tablets: 60 mg, 80 mg, and 100 mg Initial U.S. Approval: 2024 Madrigal Pharmaceuticals, Inc. West Conshohocken, PA
	GMP status of the firm	11-01-2024: GMP certificate inspection date
	Evidence of approval of manufacturing facility	11-01-2024: GMP certificate specifies Tablet (General) section
47	Evaluation Remarks	
	product was deferred in 345th meeting of Registration Board for Product Specific Inspection. Accordingly, PSI report is being presented before the Board.	
	Decision	
47	Rejected	
	Registration Board while considering the product specific inspection (PSI) report, decided to reject the application as the Applicant firm, during the course of panel inspection, was not able to demonstrate the availability of software based HPLC data of stability and analytical testing of Resmetirom (Resmet 100mg) tablets that have been submitted in the DRAP in the Form 5-F. It was admitted during personal hearing that after retrieval of data, at some time points area under curve and timelines are not cross matched with the data submitted in DRAP in Form 5 F.	
47	Case Category	Routine (Shahid Nawaz)

Name, address of Applicant.		AsianContinental (Pvt.) Ltd. D-32, S.I.T.E II, Super Highway, Karachi (000643)
Application Form Dy. No / Tracking ID & date of submission		(8GU-PTA-BQHR, 2024-03-13)
Detail of Fee Submitted		30000.0, 9000.0 2024-02-21, 2025-07-11
The proposed proprietary name / brand name		VONAC 20MG
Label Claim		Each film coated Tablet contains: Vonoprazan Fumarate equivalent to Vonoprazan 20mg
Reference to Finished product specifications		As per Innovators Specification
Proposed Pack Size		2 x 7 's-As per SRO
Shelf Life (Unit)		2 Year(s)Store below 30 °C
For generic drugs (me-too Status)		Vonopran 20mg tablets, Shaigan Pharmaceuticals, Reg. No. 110801.
Pharmacotherapeutic Group of (API)		Potassium-Competitive Acid Blocker ATC code: A02BC.
Name, address of Manufacturing site:		Self Manufacturing
Name & address of API manufacturer		Enantiotech Corporation Limited
Detail of stability batches of drug product		03 batches having batch size of 4000 tablets each.
Documents for the procurement of API with approval from DRAP (in case of Import)		Firm has submitted copy of form 6 No. K-1293832698319 dated 28-11-2022 mentioning 2kg of Vonoprazan Fumarate issued by DRAP, Karachi dated 28-11-2022.
Pharmaceutical Equivalence and Comparative Dissolution Profile		CDP and PE studies are performed against comparator product i.e. Vonozan 20mg Tablet, Batch No: 056FF9, Mfg. date 06-2023 manufactured by M/s Getz Pharma and both innovator and applied formulation have shown more than 85% release within 15 minutes in all the three mediums of CDP i.e. 0.1N HCl, Acetate buffer and Phosphate buffer.
Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)		Stability study data of 3 batches of drug substance as per Zone IV-A is submitted. Accelerated 06 months and real time for 24 months.
The status in reference regulatory authorities		Voquezna 10mg and 20mg Tablets, USFDA approved.
GMP status of the firm		Copy of GMP certificate No. 196/2022-DRAP (K) dated 16-11-2022 issued on the basis of inspection conducted on 27-09-2022 is submitted.
Evidence of approval of manufacturing facility		Copy of letter No. F. 1-17/2001-Lic (Vol-II) dated 22-06-2019 mentioning Tablet (General) section is submitted by the firm.
Evaluation Remarks		
Sr. No.	Observations	Reply submitted.
1.	Pharmaceutical equivalence report shall be submitted for applied strength.	Submitted. Vonozan 20mg tablet, B. No. 056FF9, Mfg. date 06-2023 manufactured by Getz pharma.

2.	Innovator product has mentioned Acetate buffer as dissolution medium while the applied product has pH 1.2 gastric fluid as dissolution medium. Clarification shall be submitted.	Firm has submitted that in comparative dissolution profile of Vonac 10mg Tablets manufactured at Asian Continental (Pvt.) Ltd. with the competitor product Vonozan 10mg tablet manufactured at Getz Pharma, in three different mediums i.e. Gastric fluid pH 1.2, pH 4.5 & pH 6.8 meets the comparative dissolution criteria i.e. 100% release in 15 minutes. Therefore, they revised the dissolution method with the medium of 0.05M Acetate Buffer same as innovator product. They also submitted pre-registration variation fee of 9000/- vide challan No. 11019115 dated 11-07-2025.
3.	Clearance certificate for import of API with approval from DRAP shall be submitted.	Firm has informed that they imported the raw material just for the development of trial batches in Nov-2022 (not for commercial use) on that time they received form 6 for custom clearance. Firm has also submitted form 6 along with Airway bill & Goods Declaration GD-I mentioning Vonoprazan with same batch number provided in 3.2.S.4.4.
4.	Alternate brand names shall be submitted.	Vonasian.

Decision

Approved

48	Case Category	New Section (Shahid Nawaz)
	Name, address of Applicant.	Care Pharmaceuticals 8-Km Main Thokar Raiwind Road Lahore (000563)
	Application Form Dy. No / Tracking ID & date of submission	(8MT-29A-GGMQ, 2024-06-20)
	Detail of Fee Submitted	30000.0, 2024-04-23,
	The proposed proprietary name / brand name	Ciprocure 500mg
	Label Claim	Each film coated tablet contains: Ciprofloxacin Hydrochloride equivalent to Ciprofloxacin 500mg
	Reference to Finished product specifications	United States Pharmacopeia
	Proposed Pack Size	10's-As per SRO
	Shelf Life (Unit)	2 Year(s)Below 30 degree
	For generic drugs (me-too Status)	Ciproxin Tablet 500mg, M/s Bayer Pakistan (Pvt.)Ltd, Reg. No. 013329.
	Pharmacotherapeutic Group of (API)	Fluoroquinolones. ATC code J01MA02.
	Name, address of Manufacturing site:	Self Manufacturing
	Name & address of API manufacturer	
	Detail of stability batches of drug product	03 batches having batch size of 1500 Tablets each.
	Documents for the procurement of API with approval from DRAP	Locally purchased from City Pharma.

(in case of Import)	
Pharmaceutical Equivalence and Comparative Dissolution Profile	CDP and PE studies are performed against the comparator product i.e. Ciproxin 500mg Tablet batch no: BAD041, Mfg.: 03-2023, and both comparator and applied formulation have shown similar release in in all the three medium and values of F2 are in acceptable range.
Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Not in readable form.
The status in reference regulatory authorities	Cipro 250mg and 500mg tablets, USFDA approved.
GMP status of the firm	Copy of GMP certificate No. 146/2023-DRAP (AD-8890970234) dated 28-08-2023 is submitted.
Evidence of approval of manufacturing facility	Firm has submitted copy of letter No. 1-19/99-Lic (Vol-II) dated 16-12-2024 (Corrigendum) mentioning Tablet (General) (New) section.

Evaluation Remarks

Sr. No.	Observations	
1.	Justification of specifications for applied drug substance shall be submitted.	Firm has submitted revised Specifications of substance as per BP/USP certificate of analysis.
2.	Stability study data of the drug substance in readable form shall be submitted.	Submitted in readable form.
3.	Details of the comparator product i.e. name of the manufacturer of shall be submitted.	Firm has provided details of the comparator product i.e. Ciproxin 500mg tablets, Batch Number BAD041 Mfg. 03-23, Exp. 02-28 manufactured by M/s Bayer.
4.	Justification shall be submitted for not performing Uniformity of dosage units as recommended by USP monograph.	Firm has now submitted Uniformity of dosage units as recommended by USP monograph.
5.	Documents for purchase of material shall be submitted.	Firm has submitted copy of Sales tax invoice No. Invoice No.: CP23-9793 Date: 04-Jun-23 mentioning 5kg of Ciprofloxacin Hydrochloride, B. No. CPH2305061.

Decision

Approved

49	Case Category	Routine (Shahid Nawaz)
	Name, address of Applicant.	Martin Dow Marker Limited 7, Jail Road Quetta. (000028)
	Application Form Dy. No / Tracking ID & date of submission	(DPP-VP5-1NS7, 2024-01-23)
	Detail of Fee Submitted	75000.0, 9000.0 2023-09-15, 2025-07-09
	The proposed proprietary name / brand name	Vortioxetine Tablets
	Label Claim	Each film-coated tablet contains: Vortioxetine as hydrobromide.....5mg
	Reference to Finished product specifications	As per Innovators Specification

Proposed Pack Size	14's-As per SRO	
Shelf Life (Unit)	2 Year(s)Real time 30 C	
For generic drugs (me-too Status)	Nil	
Pharmacotherapeutic Group of (API)	Other Anti-depressants. ATC code: N06AX26.	
Name, address of Manufacturing site:	Self Manufacturing	
Name & address of API manufacturer	Synergene Active Ingredients Pvt. Ltd., India.	
Detail of stability batches of drug product	03 batches having batch size of 10000 Tablets each.	
Documents for the procurement of API with approval from DRAP (in case of Import)	Firm has submitted copy of form 6 No. K-1211940026793 dated 05-Nov-2022 mentioning 1.75 kg of Vortioxetine hydro bromide. Form 6 is issued by DRAP, Karachi dated 05-Nov-2022.	
Pharmaceutical Equivalence and Comparative Dissolution Profile	CDP and PE studies are performed against innovator product i.e. Brintellix 5mg Tablet, Batch No: 2736225, Exp. date 05-2026 manufactured by Lundbeck Ltd., UK and both innovator and applied formulation have shown more than 85% release within 15 minutes in 0.1N HCl and Acetate buffer while in Phosphate buffer value of F2 is in acceptable range.	
Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Stability study data of 3 batches of drug substance as per Zone IV-A is submitted. Accelerated 06 months and real time for 12 months.	
The status in reference regulatory authorities	Trintellix Tablet 5mg, 10mg and 20mg, USFDA approved.	
GMP status of the firm	Firm has submitted copy of GMP certificate No. 015/2021-DRAP (Q)/K dated 10-09-2021 issued on the basis of inspection conducted on 26 & 27- 02- 2021.	
Evidence of approval of manufacturing facility	Firm has submitted copy of letter No. F. 4-2/86-Lic (Vol-VII) dated 31-05-2021 mentioning Tablet (General) section.	
Evaluation Remarks		
Sr. No.	Observations	Reply by the firm.
1.	Valid copy of GMP certificate of the drug substance manufacturer shall be submitted.	Firm has submitted copy of File No. HMF07-14051/229/2024-ADMIN-DCA issued by Drugs Control Administration, Andhra Pradesh India in the name of M/s Synergene Active Ingredients Private Limited, India. Certificate has mentioned “I forward here with World Health Organization Good Manufacturing Practice Certificate for the products Recommended by the Joint Inspection team consisting of the officers of Drugs Control Administration, Andhra Pradesh and CDSCO, Hyderabad for export purpose. This certificate is valid for a period of Three Years from the Date of issue and this certificate is meant for Export of drugs only”
2.	Water content and assay limits provided by drug product manufacturer are different	Firm has submitted revised water Content and assay limit in COA along with API

	from drug substance manufacturer. Clarification shall be submitted	Specification.
3.	Analytical procedures for the drug substance from drug product manufacturer shall be submitted.	Firm has submitted analytical procedure for the drug substance.
4.	Submitted COA from the drug product manufacturer has not performed Bromide content test and polymorphic form by XRPD. Clarification shall be submitted.	Firm has submitted revised COA for the drug substance with inclusion of Bromide content test and polymorphic form by XRPD as required by the drug substance manufacturer.
5.	Stability summary sheets of the drug substance has mentioned water content of NMT 2% while specification provided by the drug substance manufacturer has mentioned NMT 0.5%. clarification shall be submitted.	Firm has submitted a clarification from the drug substance manufacturer i.e. M/s Synergene Active Ingredients Private Limited, India as follows; This is to clarify the discrepancy observed between the stability summary sheets and the drug substance specification regarding the water content limit. The reference to NMT 0.5% in the specification was a typographical error. The correct specification for water content of the drug substance is Not More Than (NMT) 2.0%, as accurately stated in the stability summary sheets. However, revised specification enclosed for your reference.” Revised specifications from drug substance manufacturer are also submitted wherein water content of NMT 2% are mentioned.
6.	Justification shall be submitted for using 45-minutes time for dissolution in PE studies and specification of the finished product.	Firm has submitted that product specification has been revised to incorporate dissolution time 20 minutes as per innovator specification. They further stated that dissolution test results found satisfactory as per revised specifications i.e. 99.54% for 5mg tablet, 95.95% for 10mg tablets and 96.16% for 20mg tablet in 20 minutes. Firm has also submitted pre-registration variation fee vide challan No. 6106476986 dated 09-07-2025.
7.	Pictorial evidence of the Innovator product with visible details against which CDP and PE are performed shall be submitted.	Submitted. Brintellix 5mg, 2736225, 05-2026 manufactured by Lundbeck Limited, United Kingdom.
8.	Clearance certificate for import of API with approval from DRAP shall be submitted.	Firm has submitted copy of Form 6 No. K-1211940026793 dated 05-11-2022 mentioning 1.75kg of VORTIOXETINE HYDROBROMIDE (Manufacturer's Specification) from M/s SYNERGENE ACTIVE INGREDIENTS PVT LTD., India. Form 6 is issued by DRAP, Karachi.

Decision

Deferred

	Firm will confirm that the results submitted with revised dissolution specifications are from CDP studies or they have submitted new dissolution results of their product as per revised specifications.	
50	Case Category	New License (Shahid Nawaz)
	Name, address of Applicant.	Orbis Pharmaceuticals Plot # K-138 , SITE Super Highway Phase 2 , Karachi (000979)
	Application Form Dy. No / Tracking ID & date of submission	(8G3-4MS-E4AT, 2024-09-30)
	Detail of Fee Submitted	37000.0, 2024-09-25,
	The proposed proprietary name / brand name	Belexa
	Label Claim	Each film coated tablet contains: Escitalopram Oxalate Eq. to Escitalopram.....5mg
	Reference to Finished product specifications	United States Pharmacopeia
	Proposed Pack Size	10's,20's,30's,50's,-As per SRO
	Shelf Life (Unit)	2 Year(s)Preserve in well-closed containers. Store at room temperature
	For generic drugs (me-too Status)	ESPRAM 5mg by pharmatec
	Pharmacotherapeutic Group of (API)	
	Name, address of Manufacturing site:	Self Manufacturing
	Name & address of API manufacturer	Shodhana Laboratories Limited Plot No.24, 25 &2, Phase –IDA,Jeedimetla,Hyderabad,Telangana, India -500 055.
	Detail of stability batches of drug product	
	Documents for the procurement of API with approval from DRAP (in case of Import)	
	Pharmaceutical Equivalence and Comparative Dissolution Profile	
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	
	The status in reference regulatory authorities	Medicines and Healthcare Regulatory Agency (MHRA)
	GMP status of the firm	
	Evidence of approval of manufacturing facility	
	Evaluation Remarks	
	Reason for deferment.	Reply submitted by the firm.
	Deferred for clarification of the point that trial batches are manufactured in November, 2023 while clearance certificate is of June 2024. Also the batch number mentioned in 3.2.S.4.4 is different from that mentioned in clearance certificate.	Firm has submitted copy of commercial invoice No. NM/2122/007 mentioning 25 kg of Escitalopram Oxalate with B. No. EO-54/21, manufacturing date March 2021. Invoice is stamped by DRAP, Karachi dated 31-05-2021. Invoice is also attested by Assistant Director, DRAP Karachi dated 04-05-2021. Batch number of the drug substance mentioned on commercial invoice is similar to that provided in 3.2.S.4.4.
	Decision	
	Approved	

51	Case Category		Routine (Shahid Nawaz)
	Name, address of Applicant.		Barrett Hodgson Pakistan (Pvt.) Ltd F/423, Site, Karachi (000457)
	Application Form Dy. No / Tracking ID & date of submission		(JNW-V77-NAN4, 2024-03-19)
	Detail of Fee Submitted		30000.0, 2023-12-15,
	The proposed proprietary name / brand name		Vonotec 20mg Tablet
	Label Claim		Each Film-Coated Tablet contains; Vonoprazan Fumarate equivalent to Vonoprazan.....20mg
	Reference to Finished product specifications		As per Innovators Specification
	Proposed Pack Size		14's-As per SRO,28's-As per SRO,30's-As per SRO,7's-As per SRO
	Shelf Life (Unit)		2 Year(s)Store below 30°C
	For generic drugs (me-too Status)		Vonopran 20mg tablets, Shaigan Pharmaceuticals, Reg. No. 110801.
	Pharmacotherapeutic Group of (API)		Potassium-Competitive Acid Blocker ATC code: A02BC.
	Name, address of Manufacturing site:		Self Manufacturing
	Name & address of API manufacturer		
	Detail of stability batches of drug product		03 batches having batch size of 1000, 2000 and 2000 tablets each.
	Documents for the procurement of API with approval from DRAP (in case of Import)		Firm has submitted copy of form 6 mentioning 0.3kg of Vonoprazan Fumarate issued by DRAP, Karachi dated 06-10-2021.
	Pharmaceutical Equivalence and Comparative Dissolution Profile		CDP and PE studies are performed against comparator product i.e. Vocinti 20mg Tablet, Batch No: C0005, Exp. date 10-2023 manufactured by M/s Searle Pakistan and both innovator and applied formulation have shown more than 85% release within 15 minutes in all the three mediums of CDP i.e. 0.1N HCl, Acetate buffer and Phosphate buffer.
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)		Stability study data of 3 batches of drug substance as per Zone IV-A is submitted. Accelerated 06 months and real time for 24 months.
	The status in reference regulatory authorities		Voquezna 10mg and 20mg Tablets, USFDA approved.
	GMP status of the firm		Firm has submitted copy of GMP certificate No. 73/2023-DRAP (K) dated 02-11-2023 issued on the basis of inspection conducted on 02-11-2023.
	Evidence of approval of manufacturing facility		Firm has submitted copy renewal inspection report wherein they have tablet general section.
Evaluation Remarks			
	Sr. No.	Observation	Reply submitted.
	1.	Innovator product has mentioned 15-minutes time for dissolution while the applied product has 20-minutes. Clarification shall be submitted.	Firm has submitted that Vonoprazan Fumarate is a BCS class III drug, characterized by high solubility across a wide pH range and low permeable. They further stated that CDP studies of both the strengths

		are performed in three different mediums, and results demonstrated more than 85% release within 10 minutes in all the three mediums. This also confirms the rapid dissolution behavior of the applied product. They further revised their dissolution specifications to NLT 85% release within 15 minutes as per innovator specifications with submission of 9000/- fee vide challan No. 6181650328 dated 10-07-2025.	
	2.	Clearance certificate for import of API with approval from DRAP shall be submitted.	Firm has submitted copy of Form 6 dated 06-10-2021 mentioning 0.3kg of Vonoprazan Fumarate from M/s Jiangxi Synergy, China. Form 6 is attested by DRAP, Karachi. They also submitted copy of commercial invoice No. JXSG210929 dated 28-09-2021 mentioning 0.3kg of Vonoprazan Fumarate attested by DRAP, Karachi dated 06-10-2021
Decision			
Approved			
52	Case Category	New Section (Shahid Nawaz)	
	Name, address of Applicant.	Care Pharmaceuticals 8-Km Main Thokar Raiwind Road Lahore (000563)	
	Application Form Dy. No / Tracking ID & date of submission	(LZ7-812-E649, 2024-06-27)	
	Detail of Fee Submitted	30000.0, 2024-04-23,	
	The proposed proprietary name / brand name	Ciprocare 250mg	
	Label Claim	Each film coated tablet contains: Ciprofloxacin Hydrochloride equivalent to Ciprofloxacin 250mg	
	Reference to Finished product specifications	United States Pharmacopeia	
	Proposed Pack Size	10's-As per SRO	
	Shelf Life (Unit)	2 Year(s)Below 30 degree	
	For generic drugs (me-too Status)	Ciproxin Tablet 250mg, M/s Bayer Pakistan (Pvt.)Ltd, Reg. No. 10118.	
	Pharmacotherapeutic Group of (API)	Fluoroquinolones. ATC code J01MA02.	
	Name, address of Manufacturing site:	Self Manufacturing	
	Name & address of API manufacturer	Citi Pharma Limited.	
	Detail of stability batches of drug product	03 batches having batch size of 1500 Tablets each.	
	Documents for the procurement of API with approval from DRAP (in case of Import)	Locally purchased from City Pharma.	
	Pharmaceutical Equivalence and Comparative Dissolution Profile	CDP and PE studies are performed against the comparator product i.e. Ciproxin 250mg Tablet manufactured by Bayer and both comparator and applied formulation have shown similar release in	

	in all the three medium and values of F2 are in acceptable range.
Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Not in readable form.
The status in reference regulatory authorities	Cipro 250mg and 500mg tablets, USFDA approved.
GMP status of the firm	Copy of GMP certificate No. 146/2023-DRAP (AD-8890970234) dated 28-08-2023 is submitted.
Evidence of approval of manufacturing facility	Firm has submitted copy of letter No. 1-19/99-Lic (Vol-II) dated 16-12-2024 (Corrigendum) mentioning Tablet (General) (New) section.

Evaluation Remarks

Sr. No.	Observations	Reply submitted.
1.	Specifications of the drug substance submitted by the drug product manufacturer are completely different from USP. Clarification shall be submitted.	Firm has submitted that manufacturer has provided both of Specifications BP/USP. We have analysis as per COA.
2.	Justification of specifications for applied drug substance shall be submitted.	Firm has submitted revised Specifications of substance as per BP/USP certificate of analysis.
3.	Stability study data of the drug substance in readable form shall be submitted.	Submitted in readable form.
4.	Details of the comparator product i.e. batch number, Mfg. date etc. shall be submitted.	Firm has provided details of the comparator product i.e. Ciproxin 250mg tablets, Batch Number BAC826, Mfg. 01-23, Exp. 12-27 manufactured by M/s Bayer.
5.	Applied product CDP results in pH 1.2 medium indicate less than 80% release till time of 45 minutes, however in batch analysis it is more than 90% within 30 minutes. Both mediums are same and results are contradictory. Clarification shall be submitted.	Firm has provided revised CDP studies at pH 1.2. However, no clarification is submitted by the firm for less than 80% release till time of 45 minutes.
6.	Justification shall be submitted for not performing Uniformity of dosage units as recommended by USP monograph.	Firm has now submitted Uniformity of dosage units as recommended by USP monograph.
7.	Documents for purchase of material shall be submitted.	Firm has submitted copy of Sales tax invoice No. Invoice No.: CP23-9793 Date: 04-Jun-23 mentioning 5kg of Ciprofloxacin Hydrochloride, B. No. CPH2305061.

Decision

Deferred

Registration Board while considering the disparity in the results of comparative dissolution profile submitted by firm decided to defer the instant application for verification of authenticity of submitted data by the panel to be constituted by the Chairman Registration Board.

53	Case Category	New License (Shahid Nawaz)
	Name, address of Applicant.	Orbis Pharmaceuticals Plot # K-138 , SITE Super Highway Phase 2 , Karachi (000979)

Application Form Dy. No / Tracking ID & date of submission		(8ZY-1HR-9DBH, 2024-09-30)
Detail of Fee Submitted		37000.0, 2024-09-19,
The proposed proprietary name / brand name		Belexa
Label Claim		Each film coated tablet contains: Escitalopram Oxalate Eq. to Escitalopram.....20mg
Reference to Finished product specifications		United States Pharmacopeia
Proposed Pack Size		10's,20's,30's,50's,-As per SRO
Shelf Life (Unit)		2 Year(s)Preserve in well-closed containers. Store at room temperature
For generic drugs (me-too Status)		ESPRAM 10mg by pharmatec
Pharmacotherapeutic Group of (API)		
Name, address of Manufacturing site:		Self Manufacturing
Name & address of API manufacturer		Shodhana Laboratories Limited Plot No.24, 25 &2, Phase –IDA,Jeedimetla,Hyderabad,Telangana, India -500 055.
Detail of stability batches of drug product		
Documents for the procurement of API with approval from DRAP (in case of Import)		
Pharmaceutical Equivalence and Comparative Dissolution Profile		
Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)		
The status in reference regulatory authorities		Medicines and Healthcare Regulatory Agency (MHRA)
GMP status of the firm		
Evidence of approval of manufacturing facility		
Evaluation Remarks		
	Reason for deferment.	Reply submitted by the firm.
	Deferred for clarification of the point that trial batches are manufactured in November, 2023 while clearance certificate is of June 2024. Also the batch number mentioned in 3.2.S.4.4 is different from that mentioned in clearance certificate.	Firm has submitted copy of commercial invoice No. NM/2122/007 mentioning 25 kg of Escitalopram Oxalate with B. No. EO-54/21, manufacturing date March 2021. Invoice is stamped by DRAP, Karachi dated 31-05-2021. Invoice is also attested by Assistant Director, DRAP Karachi dated 04-05-2021. Batch number of the drug substance mentioned on commercial invoice is similar to that provided in 3.2.S.4.4.
Decision		
Approved		
54	Case Category	Routine (Shahid Nawaz)
	Name, address of Applicant.	Global Pharmaceuticals Pvt Ltd Plot Number 204-205 Industrial Triangle Kahuta Road (000417)
	Application Form Dy. No / Tracking ID & date of submission	(DHQ-DZQ-HY7A, 2024-03-13)

Detail of Fee Submitted	75000.0, 2024-02-29,	
The proposed proprietary name / brand name	GLONIB 2MG TABLET	
Label Claim	Each Film Coated Tablet Contains: Baricitinib 2mg	
Reference to Finished product specifications	As per Innovators Specification	
Proposed Pack Size	30's-As per SRO	
Shelf Life (Unit)	2 Year(s)Store at 20–25°C (68–77°F); excursions permitted to 15–30°C (59–86°F)	
For generic drugs (me-too Status)	N/A	
Pharmacotherapeutic Group of (API)	Janus-associated kinase (JAK) inhibitors ATC code: L04AF02.	
Name, address of Manufacturing site:	Self Manufacturing	
Name & address of API manufacturer	Shandong Kehui Pharmaceutical Co., Ltd.. ADDRESS: No. 9A1, Tianheng Road, Changjia Town, Gaoqing County, Zibo City, Shandong Province, China.	
Detail of stability batches of drug product	03 batches having batch size of 500 tablets each.	
Documents for the procurement of API with approval from DRAP (in case of Import)	Firm has submitted copy of clearance certificate No. E-7104939649845 dated 30-10-2023 mentioning 27gm of Baricitinib, Batch No. BIB230801 issued to M/s Global Pharma from M/s Shandong Kehui Pharmaceutical Co., Ltd., China. Clearance certificate is issued by DRAP, Islamabad.	
Pharmaceutical Equivalence and Comparative Dissolution Profile	CDP and PE studies are performed against innovator product i.e. Olumiant 2mg Tablets, B. No. D618086, Mfg. date 10-2022 manufactured by Ely Lilly and company. Both test and reference product have shown similar release pattern in all the three mediums i.e. pH 1.2, pH 4.5 & pH 6.8 and value of F2 is in acceptable range.	
Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Stability study data of 3 batches of drug substance as per Zone IV-A is submitted. Accelerated 06 months and real time for 24 months.	
The status in reference regulatory authorities	Olumiant 2mg, 4mg tablets, USFDA approved.	
GMP status of the firm	Firm has submitted copy of GMP Certificate No. 3- 16/2018-Addl. Dir. (QA<-I)-1 dated 04-01-2022 issued on the basis of inspection conducted on 03- 01-2022.	
Evidence of approval of manufacturing facility	Not submitted.	
Evaluation Remarks		
Sr. No.	Observations	Reply submitted by the firm
1.	Valid copy of GMP certificate of the applicant shall be submitted.	Copy of GMP certificate No. 3-16/2018- Addl. Dir. (QA&LT-I)-28 dated 20-05-2024 issued on the basis of inspection conducted on 02-05-2024 is submitted.
2.	Evidence of approval of manufacturing facility shall be submitted.	Copy of letter No. 1-1/96-Lic (Vol-IV) dated 20-08-2024 mentioning Tablet Section I & II general is submitted.

3.	Signed stability sheets of the drug substance from concerned drug substance manufacturer shall be submitted.	Submitted. For three batches of drug substance as per Zone IV-A. Accelerated for 06 months and real time for 24 months.
4.	Complete six-month time point stability data shall be submitted.	Firm has submitted six-month time point data along with chromatograms and raw data sheets.

Decision

Approved

55	Case Category	Routine (Shahid Nawaz)
	Name, address of Applicant.	Barrett Hodgson Pakistan (Pvt.) Ltd F/423, Site, Karachi (000457)
	Application Form Dy. No / Tracking ID & date of submission	(QT5-572-MMS3, 2024-03-19)
	Detail of Fee Submitted	30000.0, 2023-12-15,
	The proposed proprietary name / brand name	Vonotec 10mg Tablet
	Label Claim	Each Film-Coated Tablet contains; Vonoprazan Fumarate equivalent to Vonoprazan.....10mg
	Reference to Finished product specifications	As per Innovators Specification
	Proposed Pack Size	14's-As per SRO,28's-As per SRO,30's-As per SRO,7's-As per SRO
	Shelf Life (Unit)	2 Year(s)Store below 30°C
	For generic drugs (me-too Status)	Vonopran 10mg tablets, Shaigan Pharmaceuticals, Reg. No. 110800.
	Pharmacotherapeutic Group of (API)	Potassium-Competitive Acid Blocker ATC code: A02BC.
	Name, address of Manufacturing site:	Self Manufacturing
	Name & address of API manufacturer	Jiangxi Synergy Pharmaceutical Co., Ltd.
	Detail of stability batches of drug product	03 batches having batch size of 1000, 2000 and 2000 tablets each.
	Documents for the procurement of API with approval from DRAP (in case of Import)	Firm has submitted copy of form 6 mentioning 0.3kg of Vonoprazan Fumarate issued by DRAP, Karachi dated 06-10-2021.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	CDP and PE studies are performed against comparator product i.e. vocinti 10mg Tablet, Batch No: C0004, Exp. date 08-2023 manufactured by M/s Searle Pakistan and both innovator and applied formulation have shown more than 85% release within 15 minutes in all the three mediums of CDP i.e. 0.1N HCl, Acetate buffer and Phosphate buffer.
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Stability study data of 3 batches of drug substance as per Zone IV-A is submitted. Accelerated 06 months and real time for 24 months.
	The status in reference regulatory authorities	Voquezna 10mg and 20mg Tablets, USFDA approved.
	GMP status of the firm	Firm has submitted copy of GMP certificate No. 73/2023-DRAP (K) dated 02-11-2023 issued on the

		basis of inspection conducted on 02-11-2023.
Evidence of approval of manufacturing facility		Firm has submitted copy renewal inspection report wherein they have tablet general section.
Evaluation Remarks		
	Sr. No.	Observation
	1.	Innovator product has mentioned 15-minutes time for dissolution while the applied product has 20-minutes. Clarification shall be submitted.
		Reply submitted.
	1.	Firm has submitted that Vonoprazan Fumarate is a BCS class III drug, characterized by high solubility across a wide pH range and low permeable. They further stated that CDP studies of both the strengths are performed in three different mediums, and results demonstrated more than 85% release within 10 minutes in all the three mediums. This also confirms the rapid dissolution behavior of the applied product. They further revised their dissolution specifications to NLT 85% release within 15 minutes as per innovator specifications with submission of 9000/- fee vide challan No. 1794529609 dated 10-07-2025.
	2.	Clearance certificate for import of API with approval from DRAP shall be submitted.
		Firm has submitted copy of Form 6 dated 06-10-2021 mentioning 0.3kg of Vonoprazan Fumarate from M/s Jiangxi Synergy, China. Form 6 is attested by DRAP, Karachi. They also submitted copy of commercial invoice No. JXSG210929 dated 28-09-2021 mentioning 0.3kg of Vonoprazan Fumarate attested by DRAP, Karachi dated 06-10-2021
Decision		
Approved		
56	Case Category	Routine (Shahid Nawaz)
	Name, address of Applicant.	Shaigan Pharmaceuticals (Pvt) Ltd 14Km Adyala Road Post office Dahgal Rawalpindi (000333)
	Application Form Dy. No / Tracking ID & date of submission	(SG7-613-DQMS, 2024-02-20)
	Detail of Fee Submitted	30000.0, 2024-01-22,
	The proposed proprietary name / brand name	ERYWELL 250mg tab
	Label Claim	Each Film Coated Tablet Contains: Erythromycin stearate equivalent to erythromycin.....250mg
	Reference to Finished product specifications	United States Pharmacopeia
	Proposed Pack Size	10's-As per SRO
	Shelf Life (Unit)	2 Year(s)store in a cool and dry place below 30
	For generic drugs (me-too Status)	Erythrocin 250mg tablets.
	Pharmacotherapeutic Group of (API)	Macrolide antibiotic.
	Name, address of Manufacturing site:	Self Manufacturing

Name & address of API manufacturer	linaria chemicals (Thailand) Ltd
Detail of stability batches of drug product	03 batches having batch size of 1500 Tablets each.
Documents for the procurement of API with approval from DRAP (in case of Import)	Firm has submitted copy of clearance certificate No. E-6928695875169 dated 13-10-2023 mentioning 10kg of Erythromycin (USP Specification), B. No. EB/M-007/23, Mfg. date 01-07-2023 from M/s. Linaria Chemicals (Thailand).
Pharmaceutical Equivalence and Comparative Dissolution Profile	CDP and PE studies are performed against comparator product i.e. Erythrocin 250mg Tablets Batch No. ETS3931 manufactured by Indus Pharma. Both test and reference product have shown similar release pattern and value of F2 is in acceptable range.
Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Stability study data of 3 batches of drug substance as per Zone IV-B is submitted. Accelerated 06 months and real time for 48 months for only one batch.
The status in reference regulatory authorities	MHRA and USFDA approved.
GMP status of the firm	Firm has submitted copy of GMP Certificate No. 3-8/2018-Addl. Dir. (QA<-I)-32 dated 28-12-2021 issued on the basis of inspection conducted on 04-11-2021.
Evidence of approval of manufacturing facility	Firm has submitted copy of panel inspection report for renewal of DML wherein Tablet (General) section is mentioned.

Evaluation Remarks

Sr. No.	Observations.	Reply submitted by the firm.
1.	Valid copy of GMP certificate of the applicant shall be submitted.	Copy of GMP certificate dated 20-02-2024 is submitted.
2.	1.5.2 section has mentioned 500/tablet. Clarification shall be submitted.	Firm has submitted that due to typographic error 500 was typed instead of 250.
3.	Valid copy of GMP certificate of the drug substance manufacturer issued by relevant authority shall be submitted.	Firm has submitted copy of GMDP certificate No. 1-2-07-17-24-00013 dated 20-09-2023 valid till 23-07-2026 issued by Medicine Regulation Division, F&DA, Ministry of Public Health, Thailand.
4.	Specifications and analytical procedures of the drug substance from drug product manufacturer shall be submitted.	Submitted as per USP monograph.
5.	Justification shall be submitted for not determining the content of Erythromycin B and Erythromycin C and Stearic acid as provided by the drug substance manufacturer.	The specifications and method of analysis have been revised to include the content of Erythromycin B and Erythromycin C. Additionally, the limit for free stearic acid has been incorporated, which was previously not included as it is not specified in the USP. This test has been added in accordance with the specifications of the BP. Firm has submitted revised specifications, method of analysis, and COA of Erythromycin Stearate are attached.
6.	Specifications submitted by the drug substance manufacturer for the drug substance has mentioned assay limit of	As the drug substance manufacturer and the finished product manufacturer follow specifications according to the USP, and the

	“Minimum 60.5%” while the COA submitted by both DS manufacturer and FPP has mentioned Minimum of 55%. Clarification shall be submitted.	limit of erythromycin in the USP is NLT 55% the limits described in the DMF are based on the British Pharmacopoeia (BP) 2014. Firm has submitted revised specifications, method of analysis, and COA of Erythromycin Stearate are attached. Firm has also submitted copy of challan No. 9824791342 dated 10-07-2025 for pre-registration variation.
7.	COA of the reference standard/working standard used during the development of trial batches shall be submitted.	Submitted.
8.	Real time stability of three batches for the drug substance shall be submitted.	Real time stability study data of the drug substance for three batches as per Zone IV-B for 60 months is submitted by the firm.
9.	Justify the quantity of 842.588mg of the drug substance per tablet provided in 3.2.P.3.2.	Firm has submitted that 58.98116kg quantity is used instead of 842.588 Updated quantity is attached. No justification is submitted.
10.	Clearance certificate for Erythromycin stearate instead of Erythromycin with approval from DRAP shall be submitted.	Firm has submitted copy of Form 6 No. K-728326662793 dated 22-07-2022 mentioning ERYTHROMYCIN STEARATE (USP Specification) from M/s LINARIA CHEMICALS THAILAND LTD. However, Clearance certificate is not submitted by the firm. Firm has provided airway bill and commercial invoice.

Decision

Approved

57	Case Category	New License (Shahid Nawaz)
	Name, address of Applicant.	Orbis Pharmaceuticals Plot # K-138 , SITE Super Highway Phase 2 , Karachi (000979)
	Application Form Dy. No / Tracking ID & date of submission	(D31-15B-QRW9, 2024-11-05)
	Detail of Fee Submitted	30000.0, 7000.0 2024-08-09, 2024-09-05
	The proposed proprietary name / brand name	Candirid
	Label Claim	Each Capsule contains: Fluconazole BP.....150mg
	Reference to Finished product specifications	British Pharmacopeia
	Proposed Pack Size	1x1's-As per SRO
	Shelf Life (Unit)	2 YearStore bellow 30°C. Protect from heat, sunlight & moisture. Improper storage may deteriorate the medicine.
	For generic drugs (me-too Status)	Brand Name: Flucaton Capsule Strength: 150mg Dosage Form: Oral Capsules Pack Size: 1's Regn No. 086580 Manufacturer: Newton Health Care Pvt. Ltd.
	Pharmacotherapeutic Group of (API)	
	Name, address of Manufacturing site:	Self Manufacturing

Name & address of API manufacturer	N/A
Detail of stability batches of drug product	
Documents for the procurement of API with approval from DRAP (in case of Import)	
Pharmaceutical Equivalence and Comparative Dissolution Profile	
Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	
The status in reference regulatory authorities	Product Name: Fluconazole Capsule 150mg Manufacturer: Ranbaxy (UK) Limited 5th floor, Hyde Park, Hayes 3 11 Millington Road Hayes, UB3 4AZ United Kingdom Reference Regulatory Authority: MHRA Approved drug.
GMP status of the firm	
Evidence of approval of manufacturing facility	
Evaluation Remarks	
Reason for deferment	Reply submitted by the firm.
Deferred for submission of clearance certificate for the import of API with approval from DRAP.	Firm has submitted copy of Goods Declaration GD-1 mentioning Fluconazole USP with B. No. RC/FL/003-22-23, Mfg. date May 2022, Exp. date April 2027. Information provided on GD-I are similar to that provided in 3.2.S.4.4. Form 5 (License to import is also submitted by the firm)
Decision	
Approved	
58	
Case Category	Routine (Shahid Nawaz)
Name, address of Applicant.	AsianContinental (Pvt.) Ltd. D-32, S.I.T.E II, Super Highway, Karachi (000643)
Application Form Dy. No / Tracking ID & date of submission	(E7G-WT2-715T, 2024-03-13)
Detail of Fee Submitted	30000.0, 9000.0 2024-02-21, 2025-07-11
The proposed proprietary name / brand name	VONAC 10mg
Label Claim	Each film coated Tablet contains: Vonoprazan Fumarate equivalent to Vonoprazan 10mg
Reference to Finished product specifications	As per Innovators Specification
Proposed Pack Size	2 x 7 's-As per SRO
Shelf Life (Unit)	2 Year(s)Store below 30 °C
For generic drugs (me-too Status)	Vonopran 10mg tablets, Shaigan Pharmaceuticals, Reg. No. 110800.
Pharmacotherapeutic Group of (API)	Potassium-Competitive Acid Blocker ATC code: A02BC.
Name, address of Manufacturing site:	Self Manufacturing
Name & address of API manufacturer	Enantiotech Corporation Limited

Detail of stability batches of drug product	03 batches having batch size of 5,500, 5000 and 5000 tablets each.
Documents for the procurement of API with approval from DRAP (in case of Import)	Firm has submitted copy of form 6 No. K-1293832698319 dated 28-11-2022 mentioning 2kg of Vonoprazan Fumarate issued by DRAP, Karachi dated 28-11-2022.
Pharmaceutical Equivalence and Comparative Dissolution Profile	CDP and PE studies are performed against comparator product i.e. Vonozan 10mg Tablet, Batch No: 036FF8, Mfg. date 06-2022 manufactured by M/s Getz Pharma and both innovator and applied formulation have shown more than 85% release within 15 minutes in all the three mediums of CDP i.e. 0.1N HCl, Acetate buffer and Phosphate buffer.
Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Stability study data of 3 batches of drug substance as per Zone IV-A is submitted. Accelerated 06 months and real time for 24 months.
The status in reference regulatory authorities	Voquezna 10mg and 20mg Tablets, USFDA approved.
GMP status of the firm	Copy of GMP certificate No. 196/2022-DRAP (K) dated 16-11-2022 issued on the basis of inspection conducted on 27-09-2022 is submitted.
Evidence of approval of manufacturing facility	Copy of letter No. F. 1-17/2001-Lic (Vol-II) dated 22-06-2019 mentioning Tablet (General) section is submitted by the firm.

Evaluation Remarks

Sr. No.	Observations	
1.	Innovator product has mentioned Acetate buffer as dissolution medium while the applied product has pH 1.2 gastric fluid as dissolution medium. Clarification shall be submitted.	Firm has submitted that in comparative dissolution profile of Vonac 10mg Tablets manufactured at Asian Continental (Pvt.) Ltd. with the competitor product Vonozan 10mg tablet manufactured at Getz Pharma, in three different mediums i.e. Gastric fluid pH 1.2, pH 4.5 & pH 6.8 meets the comparative dissolution criteria i.e. 100% release in 15 minutes. Therefore, they revised the dissolution method with the medium of 0.05M Acetate Buffer same as innovator product. They also submitted revised analytical method along with pre-registration variation fee of 9000/- vide challan No. 32649044 dated 11-07-2025.
2.	Clearance certificate for import of API with approval from DRAP shall be submitted.	Firm has informed that they imported the raw material just for the development of trial batches in Nov-2022 (not for commercial use) on that time they received form 6 for custom clearance. Firm has also submitted form 6 along with Airway bill & Goods Declaration GD-I mentioning Vonoprazan with same batch number provided in 3.2.S.4.4.

	3.	Alternate brand names shall be submitted.	Vonasian.
	Decision		
	Approved		
59	Case Category	Routine (Shahid Nawaz)	
	Name, address of Applicant.	Nabiqasim Industries (Pvt) Ltd., 17/24, Korangi Industrial Area, Karachi. (000105)	
	Application Form Dy. No / Tracking ID & date of submission	(WXE-UML-6RLU, 2024-03-18)	
	Detail of Fee Submitted	75000.0, 2024-03-13,	
	The proposed proprietary name / brand name	Topixat 40mg Tablet	
	Label Claim	Each tablet contains: Topiroxostat.....40mg	
	Reference to Finished product specifications	As per Innovators Specification	
	Proposed Pack Size	7s, 10s, 14s, 20s, 2-Controlled	
	Shelf Life (Unit)	2 Year(s)Below 30° C	
	For generic drugs (me-too Status)	N/A	
	Pharmacotherapeutic Group of (API)	Preparations inhibiting uric acid production. ATC code: M04AA.	
	Name, address of Manufacturing site:	Self Manufacturing	
	Name & address of API manufacturer	Allastir Private Limited	
	Detail of stability batches of drug product	02 batches having batch size of 5000 Tablets each.	
	Documents for the procurement of API with approval from DRAP (in case of Import)	Firm has submitted copy of Form-6 No. K-2188089871748 dated 01-08-2023 mentioning 1.5kg of Topiroxostat (Manufacturer Specifications) from M/s Allastrir Private Limited India. Form 6 is issued by DRAP, Karachi. Firm has also submitted copy of clearance certificate No. E-6713589873597 dated 20-09-2023 mentioning 1.5kg of Topiroxostat, B. No. 2623050801, Mfg. date 01-05-2023 from Allastrir Private Limited India. Clearance certificate is issued by DRAP, Karachi.	
	Pharmaceutical Equivalence and Comparative Dissolution Profile	CDP and PE studies are performed against innovator product i.e. Uriadec Tablet 40mg, B. No. KX01001, Exp. date 11-2026 manufactured by M/s Sanwa Kagaku Kenkyusho Co., Ltd. Japan and both reference and applied formulation have shown more than 85% release in pH 1.2 medium while in pH 4.5 and pH 6.8 values of F2 are is within acceptable range.	
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Stability study data of 3 batches of drug substance as per Zone IV-B is submitted. Accelerated 06 months and real time for 36 months.	
	The status in reference regulatory authorities	Uriadec 20mg, 40mg and 60mg Tablet, PMDA Japan Approved.	

GMP status of the firm	Firm has submitted copy of GMP certificate No. 51/2023-DRAP (K) dated 26-07-2023 issued on the basis of inspection conducted on 22-05-2023.
Evidence of approval of manufacturing facility	Firm has submitted copy of letter No. F. 2-20/85-Lic (Vol-V) dated 27-04-2020 mentioning Tablet (General) section.

Evaluation Remarks

Sr. No.	Observations	Reply by the firm
i.	Stability summary sheets of the drug substance has mentioned NMT 1.0% specifications for loss on drying test, while 3.2.S.4.1 has mentioned NMT 0.5%. clarification shall be submitted.	Firm has submitted revised specifications for the drug substance from drug substance manufacturer wherein the specifications for loss on drying test are NMT 1.0%.
ii.	Complete six-month time point stability data shall be submitted.	Firm has submitted six-month time point stability sheets along with raw data sheets and chromatograms

Decision

Approved

60	Case Category	New License (Shahid Nawaz)
	Name, address of Applicant.	Orbis Pharmaceuticals Plot # K-138 , SITE Super Highway Phase 2 , Karachi (000979)
	Application Form Dy. No / Tracking ID & date of submission	(EYW-2JY-V8L9, 2025-06-27)
	Detail of Fee Submitted	75000.0, 2025-03-27,
	The proposed proprietary name / brand name	Sigra
	Label Claim	Each film coated tablet contains: Sildenafil Citrate eq to Sildenafil.....50mg
	Reference to Finished product specifications	United States Pharmacopeia
	Proposed Pack Size	4's, 10's,14's 20's-As per SRO
	Shelf Life (Unit)	2 YearStore in cool & dry place below 30oC
	For generic drugs (me-too Status)	NA
	Pharmaceutical Group of (API)	
	Name, address of Manufacturing site:	Self Manufacturing
	Name & address of API manufacturer	Rakshit Pharmaceuticals Limited by Plot number 68/A,Jawaharlal Nehru Pharma City,Parawada andal,Anakapalli district, Andhra Pradesh,India. 3102
	Detail of stability batches of drug product	
	Documents for the procurement of API with approval from DRAP (in case of Import)	
	Pharmaceutical Equivalence and Comparative Dissolution Profile	
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	
	The status in reference regulatory authorities	vigara by MHRA

	GMP status of the firm										
	Evidence of approval of manufacturing facility										
	Evaluation Remarks										
	<table> <tr> <th>Sr. No.</th><th>Observation</th><th>Reply by the firm.</th></tr> <tr> <td>i.</td><td>Pictorial evidence of the innovator product with visible details of the Batch number, Expiry date and name of manufacturer shall be submitted.</td><td>Firm has submitted pictorial evidence of the innovator product i.e. Viagra 50mg Tablets, B. No. 19686524AH, Exp. Date 04-2027 manufactured by M/s Pfizer.</td></tr> <tr> <td>ii.</td><td>Copies of executed BMRs shall be submitted.</td><td>Firm has submitted copies of BMR.</td></tr> </table>	Sr. No.	Observation	Reply by the firm.	i.	Pictorial evidence of the innovator product with visible details of the Batch number, Expiry date and name of manufacturer shall be submitted.	Firm has submitted pictorial evidence of the innovator product i.e. Viagra 50mg Tablets, B. No. 19686524AH, Exp. Date 04-2027 manufactured by M/s Pfizer.	ii.	Copies of executed BMRs shall be submitted.	Firm has submitted copies of BMR.	
Sr. No.	Observation	Reply by the firm.									
i.	Pictorial evidence of the innovator product with visible details of the Batch number, Expiry date and name of manufacturer shall be submitted.	Firm has submitted pictorial evidence of the innovator product i.e. Viagra 50mg Tablets, B. No. 19686524AH, Exp. Date 04-2027 manufactured by M/s Pfizer.									
ii.	Copies of executed BMRs shall be submitted.	Firm has submitted copies of BMR.									
	Decision										
	Approved										
	Registration letter will be issued after verification of authenticity of submitted data by the panel constituted by the Chairman Registration Board.										
61	Case Category	Routine (Shahid Nawaz)									
	Name, address of Applicant.	Global Pharmaceuticals Pvt Ltd Plot Number 204-205 Industrial Triangle Kahuta Road (000417)									
	Application Form Dy. No / Tracking ID & date of submission	(LJ8-8GP-76J9, 2024-03-20)									
	Detail of Fee Submitted	75000.0, 2024-02-29,									
	The proposed proprietary name / brand name	GLONIB 4MG TABLET									
	Label Claim	Each Film Coated Tablet Contains: Baricitinib 4mg									
	Reference to Finished product specifications	As per Innovators Specification									
	Proposed Pack Size	30's-As per SRO									
	Shelf Life (Unit)	2 Year(s)Store at 20–25°C (68–77°F); excursions permitted to 15–30°C (59–86°F)									
	For generic drugs (me-too Status)	N/A									
	Pharmacotherapeutic Group of (API)	Janus-associated kinase (JAK) inhibitors ATC code: L04AF02.									
	Name, address of Manufacturing site:	Self Manufacturing									
	Name & address of API manufacturer	Shandong Kehui Pharmaceutical Co., Ltd.. ADDRESS: No. 9A1, Tianheng Road, Changjia Town, Gaoqing County, Zibo City, Shandong Province, China.									
	Detail of stability batches of drug product	03 batches having batch size of 500 tablets each.									
	Documents for the procurement of API with approval from DRAP (in case of Import)	Firm has submitted copy of clearance certificate No. E-7104939649845 dated 30-10-2023 mentioning 27gm of Baricitinib, Batch No. BIB230801 issued to M/s Global Pharma from M/s Shandong Kehui Pharmaceutical Co., Ltd., China. Clearance certificate is issued by DRAP, Islamabad.									
	Pharmaceutical Equivalence and Comparative Dissolution Profile	CDP and PE studies are performed against innovator product i.e. Olumiant 2mg Tablets, B.									

	No. D459297, Mfg. date 07-2021 manufactured by Ely Lilly and company. Both test and reference product have shown similar release pattern in all the three mediums i.e. pH 1.2, pH 4.5 & pH 6.8 and value of F2 is in acceptable range.
Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Stability study data of 3 batches of drug substance as per Zone IV-A is submitted. Accelerated 06 months and real time for 24 months.
The status in reference regulatory authorities	Olumiant 2mg, 4mg tablets, USFDA approved.
GMP status of the firm	Firm has submitted copy of GMP Certificate No. 3-16/2018-Addl. Dir. (QA<-I)-1 dated 04-01-2022 issued on the basis of inspection conducted on 03-01-2022.
Evidence of approval of manufacturing facility	not submitted.

Evaluation Remarks

Sr. No.	Observations	Reply submitted by the firm
1.	Valid copy of GMP certificate of the applicant shall be submitted.	Copy of GMP certificate No. 3-16/2018-Addl. Dir. (QA&LT-I)-28 dated 20-05-2024 issued on the basis of inspection conducted on 02-05-2024 is submitted.
2.	Evidence of approval of manufacturing facility shall be submitted.	Copy of letter No. 1-1/96-Lic (Vol-IV) dated 20-08-2024 mentioning Tablet Section I & II general is submitted.
3.	Signed stability sheets of the drug substance from concerned drug substance manufacturer shall be submitted.	Submitted. For three batches of drug substance as per Zone IV-A. Accelerated for 06 months and real time for 24 months.
4.	Complete six-month time point stability data shall be submitted.	Firm has submitted six-month time point data along with chromatograms and raw data sheets.

Decision

Approved

62	Case Category	New Molecule/Formulation (Shahid Nawaz)
	Name, address of Applicant.	Medizan Laboratories (Pvt) Ltd Plot No.313 Industrial Triangle Kahuta Road Islamabad (000572)
	Application Form Dy. No / Tracking ID & date of submission	(NB6-PGY-9GBQ, 2025-01-28)
	Detail of Fee Submitted	75000.0, 2024-11-06,
	The proposed proprietary name / brand name	Resmet-60 Tablets
	Label Claim	Each film-coated tablet contains: Resmetirom 60mg
	Reference to Finished product specifications	As per Innovators Specification
	Proposed Pack Size	14, 20 & 30 Tablets-As per SRO
	Shelf Life (Unit)	2 Year(s)Below 30°C
	For generic drugs (me-too Status)	NA
	Pharmacotherapeutic Group of (API)	Thyroid hormone receptor (THR)-beta agonists

	Name, address of Manufacturing site:	Self Manufacturing
	Name & address of API manufacturer	SHANDONG CHENGHUI SHUANGDA PHARMACEUTICALS CO., LTD
	Detail of stability batches of drug product	3 batches: 1500 Tablet
	Documents for the procurement of API with approval from DRAP (in case of Import)	02-07-2024: Clearance certificate for 0.7Kg API
	Pharmaceutical Equivalence and Comparative Dissolution Profile	REZDIFFRA Tablet: PE and CDP studies performed
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	3 batches as per Zone IV-A
	The status in reference regulatory authorities	USFDA Approved REZDIFFRA
	GMP status of the firm	11-01-2024: GMP certificate inspection date
	Evidence of approval of manufacturing facility	11-01-2024: GMP certificate specifies Tablet (General) section
	Evaluation Remarks	
	product was deferred in 345th meeting of Registration Board for Product Specific Inspection. Accordingly, PSI report is being presented before the Board.	
	Decision	
	Rejected	
	Registration Board while considering the product specific inspection (PSI) report, decided to reject the application as the Applicant firm, during the course of panel inspection, was not able to demonstrate the availability of software based HPLC data of stability and analytical testing of Resmetirom (Resmet 60mg) tablets that have been submitted in the DRAP in the Form 5-F. It was admitted during personal hearing that after retrieval of data, at some time points area under curve and timelines are not cross matched with the data submitted in DRAP in Form 5 F.	
63	Case Category	New License (Shahid Nawaz)
	Name, address of Applicant.	Orbis Pharmaceuticals Plot # K-138 , SITE Super Highway Phase 2 , Karachi (000979)
	Application Form Dy. No / Tracking ID & date of submission	(QNT-ENB-VL36, 2024-09-30)
	Detail of Fee Submitted	37000.0, 2024-09-19,
	The proposed proprietary name / brand name	Belexa
	Label Claim	Each film coated tablet contains:Escitalopram Oxalate Eq. to Escitalopram.....10mg
	Reference to Finished product specifications	United States Pharmacopeia
	Proposed Pack Size	10's,20's,30's,50's,-As per SRO
	Shelf Life (Unit)	2 Year(s)Preserve in well-closed containers. Store at room temperature
	For generic drugs (me-too Status)	ESPRAM 10mg by pharmatec
	Pharmacotherapeutic Group of (API)	
	Name, address of Manufacturing site:	Self Manufacturing
	Name & address of API manufacturer	Shodhana Laboratories Limited Plot No.24, 25 &2, Phase –IDA,Jeedimetla,Hyderabad,Telangana, India -500 055.
	Detail of stability batches of drug product	

	Documents for the procurement of API with approval from DRAP (in case of Import)	
	Pharmaceutical Equivalence and Comparative Dissolution Profile	
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	
	The status in reference regulatory authorities	Medicines and Healthcare Regulatory Agency (MHRA)
	GMP status of the firm	
	Evidence of approval of manufacturing facility	
	Evaluation Remarks	
	Reason for deferment.	Reply submitted by the firm.
	Deferred for clarification of the point that trial batches are manufactured in November, 2023 while clearance certificate is of June 2024. Also the batch number mentioned in 3.2.S.4.4 is different from that mentioned in clearance certificate.	Firm has submitted copy of commercial invoice No. NM/2122/007 mentioning 25 kg of Escitalopram Oxalate with B. No. EO-54/21, manufacturing date March 2021. Invoice is stamped by DRAP, Karachi dated 31-05-2021. Invoice is also attested by Assistant Director, DRAP Karachi dated 04-05-2021. Batch number of the drug substance mentioned on commercial invoice is similar to that provided in 3.2.S.4.4.
	Decision	
	Approved	
64	Case Category	Routine (Shahid Nawaz)
	Name, address of Applicant.	Maxitech Pharma (Pvt) Ltd. E-178, S.I.T.E., Super Highway Phase-II, Karachi (000851)
	Application Form Dy. No / Tracking ID & date of submission	(RUS-S5Y-27ES, 2024-03-14)
	Detail of Fee Submitted	30000.0, 2024-01-11,
	The proposed proprietary name / brand name	EMPA 10mg Tablet
	Label Claim	Each film coated tablet contains: Empagliflozin.....10mg
	Reference to Finished product specifications	As per Innovators Specification
	Proposed Pack Size	14's or as per SRO-As per SRO
	Shelf Life (Unit)	2 Year(s) as per zone IV-A (30oC, 75%)
	For generic drugs (me-too Status)	Truglif Tablets 10mg, M/s AGP Limited, Reg. No. 104201.
	Pharmacotherapeutic Group of (API)	Sodium-glucose co-transporter 2 (SGLT2) inhibitors. ATC code: A10BK03.
	Name, address of Manufacturing site:	Self Manufacturing
	Name & address of API manufacturer	Anhui Haikang Pharmaceutical Co., Ltd
	Detail of stability batches of drug product	03 batches having batch size of 1000 tablets each.
	Documents for the procurement of API with approval from DRAP (in case of Import)	Firm has submitted copy of form 6 mentioning 2kg of Empagliflozin and Form 6 is also attested by DRAP Karachi, dated 17-09-2020. Firm has also

	submitted copy of commercial invoice dated 20-08-2020 mentioning 2kg of Empagliflozin, B. No. 20060201 and is also attested by DRAP Karachi, dated 17-09-2020.
Pharmaceutical Equivalence and Comparative Dissolution Profile	CDP and PE studies are performed against comparator product i.e. Diampa 10mg Tablet, B. No. 040FB5, Mfg. date 10-2022 manufactured by M/s Getz Pharma and both comparator and applied formulation have shown similar release pattern and values of F2 is in acceptable range in all the three mediums of CDP i.e. 0.1N HCl, Acetate buffer and Phosphate buffer.
Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Stability study data of 3 batches of drug substance as per Zone IV-A is submitted. Accelerated 06 months and real time for 24 months.
The status in reference regulatory authorities	Jardiance 10mg & 25mg Tablets, USFDA approved.
GMP status of the firm	Firm has submitted copy of GMP certificate No. 154/2022-DRAP (K) dated 31-08-2022 issued on the basis of inspection conducted on 23rd 24th June & 4th July. 2022.
Evidence of approval of manufacturing facility	Firm has submitted copy of letter No. 2-12/2012-Lic dated 25-11-2026 mentioning tablet (General) section.

Evaluation Remarks

Sr. No.	Observations	Reply by the firm.
1.	Specifications and analytical procedures of the drug substance from drug product manufacturer shall be submitted.	Specifications and analytical procedures of the drug substance from drug product manufacturer are submitted.
2.	COA of the drug substance from drug substance manufacturer with same batch number shall be submitted.	Copy of COA of Empagliflozin with B. No. 20060201, Mfg. date 02-06-2022 is submitted.
3.	3.2.P.5.1 has mentioned 30-minutes dissolution time for the finished product while the innovator product has mentioned 15-minute time for dissolution. Clarification shall be submitted.	Firm has submitted that CDP results have shown more than 80% release in dissolution medium. They further revised their dissolution specifications to NLT 80% (Q) in 15 minutes with submission of 9000/- fee vide challan No. 97171476519 dated 02-07-2025.
4.	Complete six-month time stability data along with raw data sheets and chromatograms shall be submitted.	Submitted. Six-month time point stability data along with raw data sheets and chromatograms submitted.
5.	Alternate brand names shall be submitted for the applied formulation.	Empitec, Glyfo, Empaflox, Zynoglif, Zeflo.

Decision

Approved

65	Case Category	Routine (Shahid Nawaz)
	Name, address of Applicant.	Maxitech Pharma (Pvt) Ltd. E-178, S.I.T.E., Super Highway Phase-II, Karachi (000851)

Application Form Dy. No / Tracking ID & date of submission	(WDU-DEM-3Z4P, 2024-03-14)	
Detail of Fee Submitted	30000.0, 2024-01-11,	
The proposed proprietary name / brand name	EMPA 25mg Tablet	
Label Claim	Each Film coated tablet contains: Empagliflozin.....25mg	
Reference to Finished product specifications	As per Innovators Specification	
Proposed Pack Size	14's or as per SRO-As per SRO	
Shelf Life (Unit)	2 Year(s)as per zone IV-A (30oC, 75%)	
For generic drugs (me-too Status)	Truglif Tablets 20mg, M/s AGP Limited, Reg. No. 104200.	
Pharmacotherapeutic Group of (API)	Sodium-glucose co-transporter 2 (SGLT2) inhibitors. ATC code: A10BK03.	
Name, address of Manufacturing site:	Self Manufacturing	
Name & address of API manufacturer		
Detail of stability batches of drug product	03 batches having batch size of 1000 tablets each.	
Documents for the procurement of API with approval from DRAP (in case of Import)	Firm has submitted copy of form 6 mentioning 2kg of Empagliflozin and Form 6 is also attested by DRAP Karachi, dated 17-09-2020. Firm has also submitted copy of commercial invoice dated 20-08-2020 mentioning 2kg of Empagliflozin, B. No. 20060201 and is also attested by DRAP Karachi, dated 17-09-2020.	
Pharmaceutical Equivalence and Comparative Dissolution Profile	CDP and PE studies are performed against comparator product i.e. Diampa 25mg Tablet, B. No. 063FB6, Mfg. date 10-2022 manufactured by M/s Getz Pharma and both comparator and applied formulation have shown similar release pattern and values of F2 is in acceptable range in all the three mediums of CDP i.e. 0.1N HCl, Acetate buffer and Phosphate buffer.	
Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Stability study data of 3 batches of drug substance as per Zone IV-A is submitted. Accelerated 06 months and real time for 24 months.	
The status in reference regulatory authorities	Jardiance 10mg & 25mg Tablets, USFDA approved.	
GMP status of the firm	Firm has submitted copy of GMP certificate No. 154/2022-DRAP (K) dated 31-08-2022 issued on the basis of inspection conducted on 23rd 24th June & 4th July. 2022.	
Evidence of approval of manufacturing facility	Firm has submitted copy of letter No. 2-12/2012-Lic dated 25-11-2026 mentioning tablet (General) section.	
Evaluation Remarks		
Sr. No.	Observations	Reply by the firm.
1.	Specifications and analytical procedures of the drug substance from drug product manufacturer shall be submitted.	Specifications and analytical procedures of the drug substance from drug product manufacturer are submitted.

2.	COA of the drug substance from drug substance manufacturer with same batch number shall be submitted.	Copy of COA of Empagliflozin with B. No. 20060201, Mfg. date 02-06-2022 is submitted.
3.	3.2.P.5.1 has mentioned 30-minutes dissolution time for the finished product while the innovator product has mentioned 15-minute time for dissolution. Clarification shall be submitted.	Firm has submitted that CDP results have shown more than 80% release in dissolution medium. They further revised their dissolution specifications to NLT 80% (Q) in 15 minutes with submission of 9000/- fee vide challan No. 97171476519 dated 02-07-2025.
4.	Complete six-month time stability data along with raw data sheets and chromatograms shall be submitted.	Submitted. Six-month time point stability data along with raw data sheets and chromatograms submitted.
5.	Alternate brand names shall be submitted for the applied formulation.	Empitec, Glyfo, Empaflox, Zynoglif, Zeflo.

Decision

Approved

Item No. II: Division of Biological Evaluation & Research
Summary of Cases

S. No.	Category	No. of Cases
1.	Registration Applications of Semaglutide Products for Local Manufacturing	30
2.	Post-registration Variation Applications of Semaglutide Products	02
3.	Registration Applications of Semaglutide Products for Contract Manufacturing	18
4.	Registration Applications of Imported Semaglutide Products	04
5.	Registration Applications of Misc. Biological Products	20
6.	Registration Applications of Veterinary Biological Products	24
Total		98

Agenda Item No 1: Registration Applications of Semaglutide Products for Self Local Manufacturing

Source: rDNA
Drug Substance Import Local Manufacturing
Applied Container Closure System: Pre-filled Pen
Biosimilar to Ozempic Injection

Case # 1	
Name, address of Applicant / Marketing Authorization Holder	Macter International Limited. F- 216, S.I.T.E, Karachi 75700, Pakistan.
Name, address of Manufacturing site.	NAME: Macter International Limited. DML NO: 000141 ADDRESS: F- 216, S.I.T.E, Karachi 75700, Pakistan. Date of Renewal 24-11-2019 Renewal slip is required.
GMP status of the firm	GMP certificate issued to Macter International Limited. based on inspection conducted on 01.07.2024
Evidence of approval of manufacturing facility	Firm has submitted copy of section approval letter dated 19-07-2012 which specifies liquid and lyophilized recombinant DNA technology products (biological) section. Firm has also submitted Revision of section approval dated 18 June 2025 under DML 000141 i.e. Prefilled syringe and cartridge pen filling area (in already approved licensed biotech facility.
Status of the applicant	Manufacturer
Status of application	SBP
Intended use of pharmaceutical product	Domestic and Export sales
Dy. No. and date of submission	Tracking ID:LMQ-WAA-RENR Application Number:94482 Date of Receiving:29-06-2025
Details of fee submitted	Challan Number:001815053521 Division:Biological Evaluation & Registration Paid Fee:37000.0 Paid Date:2025-04-14
proposed proprietary name/brand name	SEGLUTIDE 2mg/3ml PFP
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 3 ml pre-filled pen multi dose contains: Semaglutide....2mg
Pharmaceutical form of applied drug	Liquid solution for injection by SC.
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC code: A10BJ06
Reference to Finished product specifications	As per innovator's specification
Proposed Pack size	1's pen
Proposed unit price	As per Drug pricing committee
The status in reference regulatory authorities	Ozempic Semaglutide 2mg/3ml (0.68mg/ml)
For generic drugs (me-too status)	--
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO template.

Module-III Drug Substance:		
Manufacturer of DS	Livzon New North River Pharmaceutical Co., Ltd. No. 8 Shilong Road, Xinji Village Committee, Shijiao Town, Qingcheng District, QingyuanCity, Guangdong Province, P.R. China 511545	
Source	This product is a recombinant glucagon-like peptide-1 (GLP-1) receptor agonist expressed and produced by DNA recombination technology and chemical modification in E. coli.	
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated and real time conditions. The real time stability data is conducted at (-20°C±5°C) for 36 months on 3 batches. Accelerated study is conducted at (5±3°C) for 6 months on 3 batches of API. Registration batches, SM-2101002, SM-2101003, and SM-2103004	
Module-III Drug Product:		
Manufacturing Site	Macter International Limited will be responsible for formulation, filling in cartridge and testing of the product SEGLUTIDE Pen in their dedicated biotech facility.	
Container closure system of the drug product	Packaging for Semaglutide finished products are 3 ml Prefilable Cartridge Barrel Borosilicate USP type – I, clear glass cylindrical cartridge barrel with an open end & other end sealed with aluminum seal and double-disc accompanied with Prefilable Cartridge Plunger Stopper (Bromobutyl) & Needle.	
Stability study data of drug product, shelf life and storage conditions	3 pilot scale batch no. SEMA-C01A PEN, SEMA-C02A PEN & SEMA-C03A PEN Long term stability study data of 3 batches at 5±3°C. Accelerated stability study data is conducted at 25±2°C & 60±5%RH DOM:01-2025 Study Data:3 months.	
Storage Conditions	Store in a refrigerator (2°C to 8°C).	
Module 4	Single dose & repeated dose toxicity studies of Seglutide injection Seglutide Injection 1.34mg/mL versus Reference product conducted in mice at M/s Dow University of Health Sciences, Karachi. Seglutide (34.29ug/0.5mL) as per body weight of mice.	
Module 5	Studies performed by M/s Livzon New North River Pharmaceutical Co.,Ltd. PHASE 1 A single dose, randomized, open label, parallel controlled pharmacokinetic Phase-I Clinical trial of Semaglutide Injection versus reference in 64 healthy subjects. PHASE 3 ; A multicenter randomized open-label, parallel-controlled comparative trial of clinical efficacy and safety in patient with type 2 diabetes.	
Remarks of Evaluator:		
Biosimilar to Ozempic 2 mg/3ml (0.68mg/ml)		
Sr. No	Query	Query response
1.	Propose distinct brand names for biosimilars of Ozempic and Wegovy, as the same brand name is currently used for both products despite differences in strength and clinical indication.	In response to the query received from DRAP, please find below the proposed brand names for Semaglutide Pre-Filled Syringes (PFS): ☐ For strengths 2 mg / 3 ml, 4 mg / 3 ml & 8 mg / 3 ml, the proposed brand name is Seglutide, as these doses correspond to the reference product Ozempic. ☐ For strengths 6.8 mg/ 3 ml and 9.6 mg / 3 ml, our first priority for brand naming is Seglutide-O
2.	Provide evidence that the Management Committee of the Shijiao Town Industrial Park, Qincheng District, Qingyuan City, is authorized by the NMPA to issue GMP certificates.	As of December 1, 2019, China officially abolished the standalone GMP and GSP certification systems Reference link; https://english.nmpa.gov.cn/2019-11/29/c_456284.htm
3.	The applied strength is 0.68mg/ml whereas, the clinical and non-clinical studies are for 1.34/ml. Justification is required in the light of reference guidelines.	The applied strength of 0.68 mg / ml is generic version of 0.68 mg / ml (2 mg per 3 ml) of innovator (Ozempic). Since it is generic version, extrapolation of indication and dose is allowed. The case of generic peptide registration is based on the sameness or bio comparability which is proven in dossier. The clinical trial submitted are the part of the case to prove comparability and justifying the extrapolation. Reference from ICH Q5E – “Comparability of

		Biotechnological/Biological Products” “Determinations of product comparability can be based solely on quality considerations if the manufacturer can provide assurance of comparability through analytical studies as suggested in this document. Additional evidence from nonclinical or clinical studies is considered appropriate when quality data are insufficient to establish comparability”
4.	The specifications do not include identification by peptide mapping, confirmation of preservative identity, determination of phenol content, and dose accuracy in line with the innovator product.	Qualitatively analysis of preservative identification is performed by RP-HPLC. While Peptide mapping test is performed on drug substance only. Although the Finished product specification has been revised as per your recommendation (FTM enclosed). (Annex 1) & Dose Accuracy Report (Annex 1a)
5.	The release specifications for pH and assay should align with those of the innovator product—pH range of 7.1 to 7.7 and assay range of 94.5% to 104.5%—and should be made more stringent accordingly.	Our stability data indicate that product is stable within the innovator range of PH & assay. Your point is well taken and we have revised specification accordingly (FTM enclosed).
6.	High molecular weight proteins, as well as hydrophilic and hydrophobic impurities, are not detected in the drug product; however, they are present in the drug substance and in the innovator product. Justification for their absence in the drug product is required.	Aggregates can be reversible and non-reversible. During formulation and dilution steps, such reversible aggregates may dissociate, especially in the presence of appropriate buffer systems, excipients, or under optimized pH and ionic conditions. • The drug product formulation has been optimized to ensure stabilization of the active substance, minimizing aggregation potential during shelf life. • Absence of detectable HMW impurities or hydrophobic variants in the drug product reflects the improved stability and favorable formulation conditions, and does not indicate degradation or loss of critical quality attributes. In conclusion, this impurity profile is consistent with, or superior to, that of the reference product and supports product quality and comparability. Since the API is in powder form and concentrate in sample preparation provide the condition for the aggregate formation as compare with formulation which inhibit aggregates.
7.	The stability studies do not include content of phenol. Clarification is required.	Stability study of Phenol content data is enclosed. (Annex 2) • Preservative Effectiveness Testing (PET) has been conducted on the final drug product as per pharmacopeia standards and the formulation passed all acceptance criteria, confirming adequate antimicrobial protection throughout shelf life. (Report enclosed) (Annex 3) • Phenol is a chemically stable compound, especially in aqueous solutions with controlled pH and appropriate container-closure systems. Literature and historical experience support that phenol does not degrade significantly under ICH-recommended storage conditions
8.	Provide the details of pen to be used with cartridge	Document Enclosed (Annex 4)
9.	Stability data for six months is required, as only three months of data has been provided. Chromatograms and raw data sheets should also be included.	Document Enclosed (Annex 5)
10.	In-use stability studies for multiple dose is also required.	Document Enclosed (Annex 6)
11.	Submit ADC attested commercial invoice is required.	System generated form 6, good declaration & commercial invoice are enclosed (Annex 7)
12.	Audit trail and data logger data is required.	Enclosed (Annex 8)
13.	Bio similarity studies and justification where Not Applicable. Comparative PK/PD study is mandatory.	No response submitted.
Decision of 349th Meeting: The Registration Board after thorough deliberation deferred the case for the submission of the following documents: • Audit trail and data logger data for accelerated and real time storage condition. • Complete clinical study report for all recommended doses in comparison with reference product/innovator.		

Case # 2		
Name, address of Applicant / Marketing Authorization Holder	Macter International Limited. F- 216, S.I.T.E, Karachi 75700, Pakistan.	
Name, address of Manufacturing site.	NAME: Macter International Limited. DML NO: 000141 ADDRESS: F- 216, S.I.T.E, Karachi 75700, Pakistan. Date of Renewal 24-11-2019 Renewal slip is required.	
GMP status of the firm	GMP certificate issued to Macter International Limited. based on inspection conducted on 01.07.2024	
Evidence of approval of manufacturing facility	Firm has submitted copy of section approval letter dated 19-07-2012 which specifies liquid and lyophilized recombinant DNA technology products (biological) section. Firm has also submitted Revision of section approval dated 18 June 2025 under DML 000141 i.e. Prefilled syringe and cartridge pen filling area (in already approved licensed biotech facility)	
Status of the applicant	☒ Manufacturer	
Status of application	SBP	
Intended use of pharmaceutical product	☒ Domestic and Export sales	
Dy. No. and date of submission	Tracking ID:HTH-MGP-5M1M Application Number:94583	
Details of fee submitted	Challan Number: 121114424674 Division: Biological Evaluation & Registration Paid Fee: 37000.0 Paid Date: 2025-04-14	
proposed proprietary name/brand name	SEGLUTIDE 4mg/3ml PFP	
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 3 ml pre-filled pen multi dose contains: Semaglutide....4mg	
Pharmaceutical form of applied drug	Liquid solution for injection by SC.	
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC code: A10BJ06	
Reference to Finished product specifications	As per innovator's specification	
Proposed Pack size	1's pen	
Proposed unit price	As per Drug pricing committee	
The status in reference regulatory authorities	Ozempic Semaglutide 4mg/3ml (1.34mg/ml)	
For generic drugs (me-too status)	-	
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO template.	
Module-III Drug Substance:		
Manufacturer of DS	Livzon New North River Pharmaceutical Co., Ltd. No. 8 Shilong Road, Xinji Village Committee, Shijiao Town, Qingcheng District, QingyuanCity, Guangdong Province, P.R. China 511545	
Source	This product is a recombinant glucagon-like peptide-1 (GLP-1) receptor agonist expressed and	

	produced by DNA recombination technology and chemical modification in E. coli.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated and real time conditions. The real time stability data is conducted at (-20°C±5°C) for 36 months on 3 batches. Accelerated study is conducted at (5±3°C) for 6 months on 3 batches of API. Registration batches, SM-2101002, SM-2101003, and SM-2103004
Module-III Drug Product:	
Manufacturing Site	Macter International Limited will be responsible for formulation, filling in cartridge and testing of the product SEGLUTIDE Pen in their dedicated biotech facility.
Container closure system of the drug product	Packaging for Semaglutide finished products are 3 ml Prefilable Cartridge Barrel Borosilicate USP type – I, clear glass cylindrical cartridge barrel with an open end & other end sealed with aluminum seal and double-disc accompanied with Prefilable Cartridge Plunger Stopper (Bromobutyl) & Needle.
Stability study data of drug product, shelf life and storage conditions	3 pilot scale batch no. SEMA-C01B PEN, SEMA-C02B PEN & SEMA-C03B PEN Long term stability study data of 3 batches at 5±3°C. Accelerated stability study data is conducted at 25±2°C & 60±5%RH DOM:01-2025 Study Data:3 months.
Storage Conditions	Store in a refrigerator (2°C to 8°C).
Module 4	Single dose & repeated dose toxicity studies of Seglutide injection Seglutide Injection 1.34mg/mL versus Reference product conducted in mice at M/s Dow University of Health Sciences, Karachi. Seglutide (34.29ug/0.5mL) as per body weight of mice.
Module 5	Studies performed by M/s Livzon New North River Pharmaceutical Co.,Ltd. PHASE 1 A single dose, randomized, open label, parallel controlled pharmacokinetic Phase-I Clinical trial of Semaglutide Injection versus reference in 64 healthy subjects. PHASE 3 ; A multicenter randomized open-label, parallel-controlled comparative trial of clinical efficacy and safety in patient with type 2 diabetes.

Remarks of Evaluator:

Biosimilar to Ozempic 4 mg/3ml (1.34mg/ml)

Ozempic 1 mg solution for injection One ml of solution contains 1.34 mg of semaglutide*. One pre-filled pen contains 4 mg semaglutide* in 3 ml solution. Each dose contains 1 mg of semaglutide in 0.74 ml solution

Sr. No	Query	Query response
1.	Propose distinct brand names for biosimilars of Ozempic and Wegovy, as the same brand name is currently used for both products despite differences in strength and clinical indication.	In response to the query received from DRAP, please find below the proposed brand names for Semaglutide Pre-Filled Syringes (PFS): ☐ For strengths 2 mg / 3 ml, 4 mg / 3 ml & 8 mg / 3 ml, the proposed brand name is Seglutide, as these doses correspond to the reference product Ozempic. ☐ For strengths 6.8 mg/ 3 ml and 9.6 mg / 3 ml, our first priority for brand naming is Seglutide-O
2.	Provide evidence that the Management Committee of the Shijiao Town Industrial Park, Qincheng District, Qingyuan City, is authorized by the NMPA to issue GMP certificates.	As of December 1, 2019, China officially abolished the standalone GMP and GSP certification systems Reference link; https://english.nmpa.gov.cn/2019-11/29/c_456284.htm
3.	Clinical study report is required as only information overview has been provided	The purpose of the test To evaluate the clinical equivalence of semaglutide injection with Novotec ® in the hypoglycemic efficacy of multiple administrations in patients with type 2 diabetes mellitus, and to compare the safety.
4.	The specifications do not include identification by peptide mapping, confirmation of preservative	Qualitatively analysis of preservative identification is performed by RP-HPLC. While Peptide mapping test is performed on drug

	identity, determination of phenol content, and dose accuracy in line with the innovator product.	substance only. Although the Finished product specification has been revised as per your recommendation (FTM enclosed). (Annex 1) & Dose Accuracy Report (Annex 1a)
5.	The release specifications for pH and assay should align with those of the innovator product—pH range of 7.1 to 7.7 and assay range of 94.5% to 104.5%—and should be made more stringent accordingly.	Our stability data indicate that product is stable within the innovator range of PH & assay. Your point is well taken and we have revised specification accordingly (FTM enclosed).
6.	High molecular weight proteins, as well as hydrophilic and hydrophobic impurities, are not detected in the drug product; however, they are present in the drug substance and in the innovator product. Justification for their absence in the drug product is required.	Aggregates can be reversible and non-reversible. During formulation and dilution steps, such reversible aggregates may dissociate, especially in the presence of appropriate buffer systems, excipients, or under optimized pH and ionic conditions. • The drug product formulation has been optimized to ensure stabilization of the active substance, minimizing aggregation potential during shelf life. • Absence of detectable HMW impurities or hydrophobic variants in the drug product reflects the improved stability and favorable formulation conditions, and does not indicate degradation or loss of critical quality attributes. In conclusion, this impurity profile is consistent with, or superior to, that of the reference product and supports product quality and comparability. Since the API is in powder form and concentrate in sample preparation provide the condition for the aggregate formation as compare with formulation which inhibit aggregates.
7.	The stability studies do not include content of phenol. Clarification is required.	Stability study of Phenol content data is enclosed. (Annex 2) • Preservative Effectiveness Testing (PET) has been conducted on the final drug product as per pharmacopeia standards and the formulation passed all acceptance criteria, confirming adequate antimicrobial protection throughout shelf life. (Report enclosed) (Annex 3) • Phenol is a chemically stable compound, especially in aqueous solutions with controlled pH and appropriate container-closure systems. Literature and historical experience support that phenol does not degrade significantly under ICH-recommended storage conditions
8.	Provide the details of pen to be used with cartridge	Document Enclosed (Annex 4)
9.	Stability data for six months is required, as only three months of data has been provided. Chromatograms and raw data sheets should also be included.	Document Enclosed (Annex 5)
10.	In-use stability studies for multiple dose is also required.	Document Enclosed (Annex 6)
11.	Submit ADC attested commercial invoice is required.	System generated form 6, good declaration & commercial invoice are enclosed (Annex 7)
12.	Audit trail and data logger data is required.	Enclosed (Annex 8)
13.	Bio similarity studies and justification where Not Applicable. Comparative PK/PD study is mandatory.	No response submitted.
Decision of 349th Meeting: The Registration Board after thorough deliberation deferred the case for the submission of the following documents: • Audit trail and data logger data for accelerated and real time storage condition. • Complete clinical study report for all recommended doses in comparison with reference product/innovator.		

Case # 3		
	Name, address of Applicant / Marketing Authorization Holder	Macter International Limited. F- 216, S.I.T.E, Karachi 75700, Pakistan.
	Name, address of Manufacturing	NAME: Macter International Limited.

site.	DML NO: 000141 ADDRESS: F- 216, S.I.T.E, Karachi 75700, Pakistan. Date of Renewal 24-11-2019 Renewal slip is required.
GMP status of the firm	GMP certificate issued to Macter International Limited. based on inspection conducted on 01.07.2024
Evidence of approval of manufacturing facility	Firm has submitted copy of section approval letter dated 19-07-2012 which specifies liquid and lyophilized recombinant DNA technology products (biological) section. Firm has also submitted Revision of section approval dated 18 June 2025 under DML 000141 i.e. Prefilled syringe and cartridge pen filling area (in already approved licensed biotech facility.
Status of the applicant	Manufacturer
Status of application	SBP
Intended use of pharmaceutical product	Domestic and Export sales
Dy. No. and date of submission	Tracking ID:J64-NDW-4STW Application Number:96358 Receiving:29-06-2025
Details of fee submitted	Challan Number: 8928055946 Division: Biological Evaluation & Registration Paid Fee: 37000.0 Paid Date: 2025-04-14
proposed proprietary name/brand name	SEGLUTIDE 8mg/3ml PFP
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 3 ml pre-filled pen multi dose contains: Semaglutide....8mg
Pharmaceutical form of applied drug	Liquid solution for injection by SC.
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC code: A10BJ06
Reference to Finished product specifications	As per innovator's specification
Proposed Pack size	1's pen
Proposed unit price	As per Drug pricing committee
The status in reference regulatory authorities	Ozempic Semaglutide 8mg/3ml (2.68mg/ml)
For generic drugs (me-too status)	-
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO template.
Module-III Drug Substance:	
Manufacturer of DS	Livzon New North River Pharmaceutical Co., Ltd. No. 8 Shilong Road, Xinji Village Committee, Shijiao Town, Qingcheng District, QingyuanCity, Guangdong Province, P.R. China 511545
Source	This product is a recombinant glucagon-like peptide-1 (GLP-1) receptor agonist expressed and produced by DNA recombination technology and chemical modification in E. coli.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated and real time conditions. The real time stability data is conducted at (-20°C±5°C) for 36 months on 3 batches. Accelerated study is conducted at (5±3°C) for 6 months on 3 batches of API. Registration batches, SM-2101002, SM-2101003, and SM-2103004
Module-III Drug Product:	

Manufacturing Site	Macter International Limited will be responsible for formulation, filling in cartridge and testing of the product SEGLUTIDE Pen in their dedicated biotech facility.
Container closure system of the drug product	Packaging for Semaglutide finished products are 3 ml Prefilable Cartridge Barrel Borosilicate USP type – I, clear glass cylindrical cartridge barrel with an open end & other end sealed with aluminum seal and double-disc accompanied with Prefilable Cartridge Plunger Stopper (Bromobutyl) & Needle.
Stability study data of drug product, shelf life and storage conditions	3 pilot scale batch no. SEMA-C01D PEN, SEMA-C02D PEN & SEMA-C03D PEN Long term stability study data of 3 batches at 5±3°C. Accelerated stability study data is conducted at 25±2°C & 60±5%RH DOM:01-2025 Study Data:3 months.
Storage Conditions	Store in a refrigerator (2°C to 8°C).
Module 4	Single dose & repeated dose toxicity studies of Seglutide injection Seglutide Injection 1.34mg/mL versus Reference product conducted in mice at M/s Dow University of Health Sciences, Karachi. Seglutide (34.29ug/0.5mL) as per body weight of mice.
Module 5	Studies performed by M/s Livzon New North River Pharmaceutical Co.,Ltd. PHASE 1 A single dose, randomized, open label, parallel controlled pharmacokinetic Phase-I Clinical trial of Semaglutide Injection versus reference in 64 healthy subjects. PHASE 3 ; A multicenter randomized open-label, parallel-controlled comparative trial of clinical efficacy and safety in patient with type 2 diabetes.

Remarks of Evaluator:

Biosimilar to Ozempic 8 mg/3ml (2.68mg/ml)

One ml of solution contains 2.68 mg of semaglutide*. One pre-filled pen contains 8 mg semaglutide* in 3 ml solution. Each dose contains 2 mg of semaglutide in 0.74 ml solution

Sr. No	Query	Query response
1.	Propose distinct brand names for biosimilars of Ozempic and Wegovy, as the same brand name is currently used for both products despite differences in strength and clinical indication.	In response to the query received from DRAP, please find below the proposed brand names for Semaglutide Pre-Filled Syringes (PFS): ☐ For strengths 2 mg / 3 ml, 4 mg / 3 ml & 8 mg / 3 ml, the proposed brand name is Seglutide, as these doses correspond to the reference product Ozempic. ☐ For strengths 6.8 mg/ 3 ml and 9.6 mg / 3 ml, our first priority for brand naming is Seglutide-O
2.	Provide evidence that the Management Committee of the Shijiao Town Industrial Park, Qincheng District, Qingyuan City, is authorized by the NMPA to issue GMP certificates.	As of December 1, 2019, China officially abolished the standalone GMP and GSP certification systems Reference link; https://english.nmpa.gov.cn/2019-11/29/c_456284.htm
3.	The applied strength is 2.68mg/ml whereas, the clinical and non-clinical studies are for 1.34mg/ml.	-
4.	The specifications do not include identification by peptide mapping, confirmation of preservative identity, determination of phenol content, and dose accuracy in line with the innovator product.	Qualitatively analysis of preservative identification is performed by RP-HPLC. While Peptide mapping test is performed on drug substance only. Although the Finished product specification has been revised as per your recommendation (FTM enclosed). (Annex 1) & Dose Accuracy Report (Annex 1a)
5.	The release specifications for pH and assay should align with those of the innovator product—pH range of 7.1 to 7.7 and assay range of 94.5% to 104.5%—and should be made more stringent accordingly.	Our stability data indicate that product is stable within the innovator range of PH & assay. Your point is well taken and we have revised specification accordingly (FTM enclosed).
6.	High molecular weight proteins, as well as hydrophilic and hydrophobic impurities, are not detected in the drug product; however, they are	Aggregates can be reversible and non-reversible. During formulation and dilution steps, such reversible aggregates may dissociate, especially in the presence of appropriate

	present in the drug substance and in the innovator product. Justification for their absence in the drug product is required.	buffer systems, excipients, or under optimized pH and ionic conditions. • The drug product formulation has been optimized to ensure stabilization of the active substance, minimizing aggregation potential during shelf life. • Absence of detectable HMW impurities or hydrophobic variants in the drug product reflects the improved stability and favorable formulation conditions, and does not indicate degradation or loss of critical quality attributes. In conclusion, this impurity profile is consistent with, or superior to, that of the reference product and supports product quality and comparability. Since the API is in powder form and concentrate in sample preparation provide the condition for the aggregate formation as compare with formulation which inhibit aggregates.
7.	•Hydrophilic and hydrophobic impurities are not detected in SEMA-C01D Pen. Clarification is required	It was a typo error the results were actually below the limit of detection.
8.	The stability studies do not include content of phenol. Clarification is required.	Stability study of Phenol content data is enclosed. (Annex 2) • Preservative Effectiveness Testing (PET) has been conducted on the final drug product as per pharmacopeia standards and the formulation passed all acceptance criteria, confirming adequate antimicrobial protection throughout shelf life. (Report enclosed) (Annex 3) • Phenol is a chemically stable compound, especially in aqueous solutions with controlled pH and appropriate container-closure systems. Literature and historical experience support that phenol does not degrade significantly under ICH-recommended storage conditions
9.	Provide the details of pen to be used with cartridge	Document Enclosed (Annex 4)
10.	Stability data for six months is required, as only three months of data has been provided. Chromatograms and raw data sheets should also be included.	Document Enclosed (Annex 5)
11.	In-use stability studies for multiple dose is also required.	Document Enclosed (Annex 6)
12.	Submit ADC attested commercial invoice is required.	System generated form 6, good declaration & commercial invoice are enclosed (Annex 7)
13.	Audit trail and data logger data is required.	Enclosed (Annex 8)
14.	Bio similarity studies and justification where Not Applicable. Comparative PK/PD study is mandatory.	No response submitted.
• Decision of 349th Meeting: The Registration Board after thorough deliberation deferred the case for the submission of the following documents: • Audit trail and data logger data for accelerated and real time storage condition. • Complete clinical study report for all recommended doses including 2mg in comparison with reference product/innovator. Decision of 349th Meeting:		

Semaglutide
Source: rDNA
Drug Substance Import Local Manufacturing
Applied Container Closure System: Pre-filled Syringe
Biosimilar to Ozempic Injection

Case # 4		
Name, address of Applicant / Marketing Authorization Holder	Macter International Limited. F- 216, S.I.T.E, Karachi 75700, Pakistan.	
Name, address of Manufacturing site.	NAME: Macter International Limited. DML NO: 000141 ADDRESS: F- 216, S.I.T.E, Karachi 75700, Pakistan. Date of Renewal 24-11-2019 Renewal slip is required.	
GMP status of the firm	GMP certificate issued to Macter International Limited. based on inspection conducted on 01.07.2024	
Evidence of approval of manufacturing facility	Firm has submitted copy of section approval letter dated 19-07-2012 which specifies liquid and lyophilized recombinant DNA technology products (biological) section. Firm has also submitted Revision of section approval dated 18 June 2025 under DML 000141 i.e. Prefilled syringe and cartridge pen filling area (in already approved licensed biotech facility)	
Status of the applicant	☒ Manufacturer	
Status of application	SBP	
Intended use of pharmaceutical product	☒ Domestic and Export sales	
Dy. No. and date of submission	Tracking ID:77P-XV1-UHVQ Application Number:94729 Date of Receiving:29-06-2025	
Details of fee submitted	Challan Number: 70242718865 Division: Biological Evaluation & Registration Paid Fee: 37000.0 Paid Date: 2025-04-14	
proposed proprietary name/brand name	SEGLUTIDE 2mg/0.75ml PFS	
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 0.75 ml pre-filled syringe single dose contains: Semaglutide....2mg	
Pharmaceutical form of applied drug	Liquid solution for injection by SC.	
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC code: A10BJ06	
Reference to Finished product specifications	As per innovator's specification	
Proposed Pack size	1's	
Proposed unit price	As per Drug pricing committee	
The status in reference regulatory authorities	FDA and EMA Internationally it is approved as PFP as multidose. As per EMA Ozempic 2 mg solution for injection One ml of solution contains 2.68 mg of semaglutide*. One pre-filled pen contains 8 mg semaglutide* in 3 ml solution. Each dose contains 2 mg of semaglutide in 0.74 ml solution.	
For generic drugs (me-too status)	New product No Me too available in PFS in applied strength.	
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO template.	
Module-III Drug Substance:		

Manufacturer of DS	Not Submitted.
Source	Not Submitted.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Not Submitted.
Module-III Drug Product:	
Manufacturing Site	Not Submitted.
Container closure system of the drug product	Not Submitted.
Stability study data of drug product, shelf life and storage conditions	Not Submitted.
Storage Conditions	Store in a refrigerator (2°C to 8°C).
Module 4	Single dose & repeated dose toxicity studies of Seglutide injection Seglutide Injection 1.34mg/mL versus Reference product conducted in mice at M/s Dow University of Health Sciences, Karachi. Seglutide (34.29ug/0.5mL) as per body weight of mice.
Module 5	Studies performed by M/s Livzon New North River Pharmaceutical Co.,Ltd. PHASE 1 A single dose, randomized, open label, parallel controlled pharmacokinetic Phase-I Clinical trial of Semaglutide Injection versus reference in 64 healthy subjects. PHASE 3 ; A multicenter randomized open-label, parallel-controlled comparative trial of clinical efficacy and safety in patient with type 2 diabetes.

Remarks of Evaluator:

Biosimilar to Ozempic 8 mg/3ml (2.68mg/ml)

One ml of solution contains 2.68 mg of semaglutide*.

One pre-filled pen contains 8 mg semaglutide* in 3 ml solution. Each dose contains 2 mg of semaglutide in 0.74 ml solution.

Sr. No	Query	Query response
1.	Propose distinct brand names for biosimilars of Ozempic and Wegovy, as the same brand name is currently used for both products despite differences in strength and clinical indication.	No response submitted.
2.	Provide evidence that the Management Committee of the Shijiao Town Industrial Park, Qincheng District, Qingyuan City, is authorized by the NMPA to issue GMP certificates.	No response submitted.
3.	•Evidence of approval of applied formulation in same filled volume 2ml/0.75ml and container closure system in reference regulatory authority or justification is required in the light of reference guidelines.	No response submitted.
4.	5. Module 3 not attached.	No response submitted.
6.	The applied strength is 2.68mg/ml whereas, the clinical and non-clinical studies are for 0.34/ml. Justification is required in the light of reference guidelines.	No response submitted.

7.	Bio similarity studies and justification where Not Applicable. Comparative PK/PD study is mandatory.	No response submitted.

Decision of 349th Meeting:
The Registration Board deferred the case for the submission of the following documents:

- **Module 3 as per CTD guidance document for biological products.**
- **Complete clinical study report for all recommended doses including 2mg in comparison with reference product/innovator.**

Semaglutide Source: rDNA Drug Substance Import Local Manufacturing Applied Container Closure System: Pre-filled Pen Biosimilar to Wegovy Injection		
Case # 5		
Name, address of Applicant / Marketing Authorization Holder	Macter International Limited. F- 216, S.I.T.E, Karachi 75700, Pakistan.	
Name, address of Manufacturing site.	NAME: Macter International Limited. DML NO: 000141 ADDRESS: F- 216, S.I.T.E, Karachi 75700, Pakistan. Date of Renewal 24-11-2019 Renewal slip is required.	
GMP status of the firm	GMP certificate issued to Macter International Limited. based on inspection conducted on 01.07.2024	
Evidence of approval of manufacturing facility	Firm has submitted copy of section approval letter dated 19-07-2012 which specifies liquid and lyophilized recombinant DNA technology products (biological) section. Firm has also submitted Revision of section approval dated 18 June 2025 under DML 000141 i.e. Prefilled syringe and cartridge pen filling area (in already approved licensed biotech facility	
Status of the applicant	☒ Manufacturer	
Status of application	SBP	
Intended use of pharmaceutical product	☒ Domestic and Export sales	
Dy. No. and date of submission	Tracking ID:M3S-B6P-V1LT Application Number:96354 Date of Receiving:29-06-2025	
Details of fee submitted	Challan Number: 71664869 Division: Biological Evaluation & Registration Paid Fee: 37000.0 Paid Date: 2025-04-14	
proposed proprietary name/brand name	SEGLUTIDE 9.6mg/3ml PFP	
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 3 ml pre-filled pen multi dose contains: Semaglutide....9.6mg	
Pharmaceutical form of applied drug	Liquid solution for injection by SC.	
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC code: A10BJ06	
Reference to Finished	As per innovator's specification	

product specifications	
Proposed Pack size	1's pen
Proposed unit price	As per Drug pricing committee
The status in reference regulatory authorities	EMA Approved Pre-filled pen, FlexTouch (0.5 1, 1.7 and 2.4 mg) 3 mL pre-filled pen 3 mL glass cartridge (type I glass) closed at the one end with a rubber plunger (chlorobutyl) and at the other end with an aluminium cap with a laminated rubber sheet (bromobutyl/polyisoprene) inserted. The cartridge is assembled into a disposable pre-filled pen made of polypropylene, polyoxymethylene, polycarbonate and acrylonitrile butadiene styrene
For generic drugs (me-too status)	NA
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO template.
Module-III Drug Substance:	
Manufacturer of DS	Livzon New North River Pharmaceutical Co., Ltd. No. 8 Shilong Road, Xinji Village Committee, Shijiao Town, Qingcheng District, Qingyuan City, Guangdong Province, P.R. China 511545
Source	This product is a recombinant glucagon-like peptide-1 (GLP-1) receptor agonist expressed and produced by DNA recombination technology and chemical modification in E. coli.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated and real time conditions. The real time stability data is conducted at (-20°C±5°C) for 36 months on 3 batches. Accelerated study is conducted at (5±3°C) for 6 months on 3 batches of API. Registration batches, SM-2101002, SM-2101003, and SM-2103004
Module-III Drug Product:	
Manufacturing Site	Macter International Limited will be responsible for formulation, filling in cartridge and testing of the product SEGLUTIDE Pen in their dedicated biotech facility.
Container closure system of the drug product	Packaging for Semaglutide finished products are 3 ml Prefilable Cartridge Barrel Borosilicate USP type – I, clear glass cylindrical cartridge barrel with an open end & other end sealed with aluminum seal and double-disc accompanied with Prefilable Cartridge Plunger Stopper (Bromobutyl) & Needle.
Stability study data of drug product, shelf life and storage conditions	3 pilot scale batch no. SEMA-C01E PEN, SEMA-C02E PEN & SEMA-C03E PEN Long term stability study data of 3 batches at 5±3°C. Accelerated stability study data is conducted at 25±2°C & 60±5%RH DOM:01-2025 Study Data:6 months.
Storage Conditions	Store in a refrigerator (2°C to 8°C).
Module 4	Single dose & repeated dose toxicity studies of Seglutide injection Seglutide Injection 1.34mg/mL versus Reference product conducted in mice at M/s Dow University of Health Sciences, Karachi. Seglutide (34.29ug/0.5mL) as per body weight of mice.
Module 5	Studies performed by M/s Livzon New North River Pharmaceutical Co.,Ltd. PHASE 1 A single dose, randomized, open label, parallel controlled pharmacokinetic Phase-I Clinical trial of Semaglutide Injection versus reference in 64 healthy subjects. PHASE 3 ; A multicenter randomized open-label, parallel-controlled comparative trial of clinical efficacy and safety in patient with type 2 diabetes.

Remarks of Evaluator:

Biosimilar to Wegovy

9.6 mg / 3 ml (3.2 mg / ml) (4 doses of 2.4 mg)

Each pre-filled pen contains 9.6 mg semaglutide* in 3 mL solution. One mL of solution contains 3.2 mg semaglutide*. One pre-filled pen contains 4 doses of 2.4 mg.

Sr. No	Query	Query response
1.	Propose distinct brand names for biosimilars of Ozempic and Wegovy, as the same brand name is currently used for both products despite differences in strength and clinical indication.	In response to the query received from DRAP, please find below the proposed brand names for Semaglutide Pre-Filled Syringes (PFS): ☐ For strengths 2 mg / 3 ml, 4 mg / 3 ml & 8 mg / 3 ml, the

		proposed brand name is Seglutide, as these doses correspond to the reference product Ozempic. ☐ For strengths 6.8 mg/ 3 ml and 9.6 mg / 3 ml, our first priority for brand naming is Seglutide-O
2.	Provide evidence that the Management Committee of the Shijiao Town Industrial Park, Qincheng District, Qingyuan City, is authorized by the NMPA to issue GMP certificates.	As of December 1, 2019, China officially abolished the standalone GMP and GSP certification systems Reference link; https://english.nmpa.gov.cn/2019-11/29/c_456284.htm
3.	Clinical study report for comparability with Wegovy is required	-clinical study report Clinical trial information 1. The purpose of the test To evaluate the clinical equivalence of semaglutide injection with Novotec ® in the hypoglycemic efficacy of multiple administrations in patients with type 2 diabetes mellitus, and to compare the safety
4.	The specifications .do not include identification by peptide mapping, identity of preservative, content of phenol and dose accuracy as per innovator	Qualitatively analysis of preservative identification is performed by RP-HPLC. While Peptide mapping test is performed on drug substance only. Although the Finished product specification has been revised as per your recommendation (FTM enclosed). (Annex 1) & Dose Accuracy Report (Annex 1a)
5.	The specifications of pH and assay should be stringent as per innovator.	Our stability data indicate that product is stable within the innovator range of PH & assay. Your point is well taken and we have revised specification accordingly (FTM enclosed). (Annex 2)
6.	High Molecular Weigh Proteins are not detected in drug product. However, present in drug substance and innovator product. Justification is required.	Aggregates can be reversible and non-reversible. During formulation and dilution steps, such reversible aggregates may dissociate, especially in the presence of appropriate buffer systems, excipients, or under optimized pH and ionic conditions. • The drug product formulation has been optimized to ensure stabilization of the active substance, minimizing aggregation potential during shelf life. • Absence of detectable HMW impurities or hydrophobic variants in the drug product reflects the improved stability and favorable formulation conditions, and does not indicate degradation or loss of critical quality attributes. In conclusion, this impurity profile is consistent with, or superior to, that of the reference product and supports product quality and comparability. Since the API is in powder form and concentrate in sample preparation provide the condition for the aggregate formation as compare with formulation which inhibit aggregates.
7.	The stability studies do not include content of phenol.	☐ Stability study of Phenol content data is enclosed. (Annex 3) ☐ Preservative Effectiveness Testing (PET) has been conducted on the final drug product as per pharmacopeia standards and the formulation passed all acceptance criteria, confirming adequate antimicrobial protection throughout shelf life. (Report enclosed) (Annex 4) ☐ Phenol is a chemically stable compound, especially in aqueous solutions with controlled pH and appropriate container-closure systems. Literature and historical experience support that phenol does not degrade significantly under ICH-recommended storage conditions
8.	Provide the details of pen to be used with	Document Enclosed (Annex 4)

	cartridge.		
9.	In-use stability studies for multiple dose is required.	Document Enclosed (Annex 6)	
10.	ADC attested Commercial invoice, Audit trail and data logger data is required.	Enclosed (Annex 8)	
11.	Bio similarity studies and justification where Not Applicable. Comparative PK/PD study is mandatory	No response submitted.	
Decision of 349th Meeting: The Registration Board after thorough deliberation deferred the case for the submission of the following documents: • Audit trail and data logger data for accelerated and real time storage condition. • Complete clinical study report for all recommended doses including 1.7mg and 2.4mg in comparison with reference product/innovator. • Provide the details of comparator product Novotec ® whether it is innovator product or otherwise.			

Case # 6	
Name, address of Applicant / Marketing Authorization Holder	Macter International Limited. F- 216, S.I.T.E, Karachi 75700, Pakistan.
Name, address of Manufacturing site.	NAME: Macter International Limited. DML NO: 000141 ADDRESS: F- 216, S.I.T.E, Karachi 75700, Pakistan. Date of Renewal 24-11-2019 Renewal slip is required.
GMP status of the firm	GMP certificate issued to Macter International Limited. based on inspection conducted on 01.07.2024
Evidence of approval of manufacturing facility	Firm has submitted copy of section approval letter dated 19-07-2012 which specifies liquid and lyophilized recombinant DNA technology products (biological) section. Firm has also submitted Revision of section approval dated 18 June 2025 under DML 000141 i.e. Prefilled syringe and cartridge pen filling area (in already approved licensed biotech facility
Status of the applicant	☒ Manufacturer
Status of application	SBP
Intended use of pharmaceutical product	☒ Domestic and Export sales
Dy. No. and date of submission	Tracking ID:26P-YZ8-8DQS Application Number:96329 Date of Receiving:11-07-2025
Details of fee submitted	Challan Number: 903861862449 Division: Biological Evaluation & Registration Paid Fee: 37000.0 Paid Date: 2025-04-14
proposed proprietary name/brand name	SEGLUTIDE 6.8mg/3ml PFP
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 3 ml pre-filled pen multi dose contains: Semaglutide....6.8 mg
Pharmaceutical form of applied drug	Liquid solution for injection by SC.

Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC code: A10BJ06	
Reference to Finished product specifications	As per innovator's specification	
Proposed Pack size	1's pen	
Proposed unit price	As per Drug pricing committee	
The status in reference regulatory authorities	EMA Approved Wegovy 1.7 mg FlexTouch solution for injection pre-filled pen Each pre-filled pen contains 6.8 mg semaglutide* in 3 mL solution. One mL of solution contains 2.27 mg semaglutide*. One pre-filled pen contains 4 doses of 1.7 mg.	
For generic drugs (me-too status)	NA	
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO template.	
Module-III Drug Substance:		
Manufacturer of DS	Livzon New North River Pharmaceutical Co., Ltd. No. 8 Shilong Road, Xinji Village Committee, Shijiao Town, Qingcheng District, QingyuanCity, Guangdong Province, P.R. China 511545	
Source	This product is a recombinant glucagon-like peptide-1 (GLP-1) receptor agonist expressed and produced by DNA recombination technology and chemical modification in E. coli.	
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated and real time conditions. The real time stability data is conducted at (-20°C±5°C) for 36 months on 3 batches. Accelerated study is conducted at (5±3°C) for 6 months on 3 batches of API. Registration batches, SM-2101002, SM-2101003, and SM-2103004	
Module-III Drug Product:		
Manufacturing Site	Macter International Limited will be responsible for formulation, filling in cartridge and testing of the product SEGLUTIDE Pen in their dedicated biotech facility.	
Container closure system of the drug product	Packaging for Semaglutide finished products are 3 ml Prefilable Cartridge Barrel Borosilicate USP type – I, clear glass cylindrical cartridge barrel with an open end & other end sealed with aluminum seal and double-disc accompanied with Prefilable Cartridge Plunger Stopper (Bromobutyl) & Needle.	
Stability study data of drug product, shelf life and storage conditions	3 pilot scale batch no. SEMA-C01C PEN, SEMA-C02C PEN & SEMA-C03 PEN Long term stability study data of 3 batches at 5±3°C. Accelerated stability study data is conducted at 25±2°C & 60±5%RH DOM:01-2025 Study Data:6 months.	
Storage Conditions	Store in a refrigerator (2°C to 8°C).	
Module 4	Single dose & repeated dose toxicity studies of Seglutide injection Seglutide Injection 1.34mg/mL versus Reference product conducted in mice at M/s Dow University of Health Sciences, Karachi. Seglutide (34.29ug/0.5mL) as per body weight of mice.	
Module 5	Studies performed by M/s Livzon New North River Pharmaceutical Co.,Ltd. PHASE 1 A single dose, randomized, open label, parallel controlled pharmacokinetic Phase-I Clinical trial of Semaglutide Injection versus reference in 64 healthy subjects. PHASE 3 ; A multicenter randomized open-label, parallel-controlled comparative trial of clinical efficacy and safety in patient with type 2 diabetes.	
Remarks of Evaluator: Consumption record of DS for all the applied semaglutide injection is required. Biosimilar to Wegovy Wegovy 1.7 mg FlexTouch solution for injection pre-filled pen Each pre-filled pen contains 6.8 mg semaglutide* in 3 mL solution. One mL of solution contains 2.27 mg semaglutide*. One pre-filled pen contains 4 doses of 1.7 mg.		
Sr. No	Query	Query response
1.	Propose distinct brand names for biosimilars of	In response to the querv received from DRAP, please find

	Ozempic and Wegovy, as the same brand name is currently used for both products despite differences in strength and clinical indication.	below the proposed brand names for Semaglutide Pre-Filled Syringes (PFS): ☐ For strengths 2 mg / 3 ml, 4 mg / 3 ml & 8 mg / 3 ml, the proposed brand name is Seglutide, as these doses correspond to the reference product Ozempic. ☐ For strengths 6.8 mg/ 3 ml and 9.6 mg / 3 ml, our first priority for brand naming is Seglutide-O
2.	Provide evidence that the Management Committee of the Shijiao Town Industrial Park, Qincheng District, Qingyuan City, is authorized by the NMPA to issue GMP certificates.	As of December 1, 2019, China officially abolished the standalone GMP and GSP certification systems Reference link; https://english.nmpa.gov.cn/2019-11/29/c_456284.htm
3.	Clinical study report for comparability with Wegovy is required	-clinical study report Clinical trial information 1. The purpose of the test To evaluate the clinical equivalence of semaglutide injection with Novotec ® in the hypoglycemic efficacy of multiple administrations in patients with type 2 diabetes mellitus, and to compare the safety
4.	The specifications .do not include identification by peptide mapping, identity of preservative, content of phenol and dose accuracy as per innovator	Qualitatively analysis of preservative identification is performed by RP-HPLC. While Peptide mapping test is performed on drug substance only. Although the Finished product specification has been revised as per your recommendation (FTM enclosed). (Annex 1) & Dose Accuracy Report (Annex 1a)
5.	The specifications of pH and assay should be stringent as per innovator.	Our stability data indicate that product is stable within the innovator range of PH & assay. Your point is well taken and we have revised specification accordingly (FTM enclosed). (Annex 2)
6.	High Molecular Weigh Proteins are not detected in drug product. However, present in drug substance and innovator product. Justification is required.	Aggregates can be reversible and non-reversible. During formulation and dilution steps, such reversible aggregates may dissociate, especially in the presence of appropriate buffer systems, excipients, or under optimized pH and ionic conditions. • The drug product formulation has been optimized to ensure stabilization of the active substance, minimizing aggregation potential during shelf life. • Absence of detectable HMW impurities or hydrophobic variants in the drug product reflects the improved stability and favorable formulation conditions, and does not indicate degradation or loss of critical quality attributes. In conclusion, this impurity profile is consistent with, or superior to, that of the reference product and supports product quality and comparability. Since the API is in powder form and concentrate in sample preparation provide the condition for the aggregate formation as compare with formulation which inhibit aggregates.
7.	The stability studies do not include content of phenol.	☐ Stability study of Phenol content data is enclosed. (Annex 3) ☐ Preservative Effectiveness Testing (PET) has been conducted on the final drug product as per pharmacopeia standards and the formulation passed all acceptance criteria, confirming adequate antimicrobial protection throughout shelf life. (Report enclosed) (Annex 4) ☐ Phenol is a chemically stable compound, especially in aqueous solutions with controlled

		pH and appropriate container-closure systems. Literature and historical experience support that phenol does not degrade significantly under ICH-recommended storage conditions	
8.	Provide the details of pen to be used with cartridge.	Document Enclosed (Annex 4)	
9.	In-use stability studies for multiple dose is required.	Document Enclosed (Annex 6)	
10.	ADC attested Commercial invoice, Audit trail and data logger data is required.	Enclosed (Annex 8)	
11.	Bio similarity studies and justification where Not Applicable. Comparative PK/PD study is mandatory	No response submitted.	
• The Registration Board after thorough deliberation deferred the case for the submission of the following documents: • Audit trail and data logger data for accelerated and real time storage condition. • Complete clinical study report for all recommended doses including 1.7mg in comparison with reference product/innovator. • Provide the details of comparator product Novotec ® whether it is innovator product or otherwise.			

Biological Human Cases Applied Container Closure System: Pre-filled Syringe Biosimilar to Wegovy Injection	
Case # 7	
Name, address of Applicant / Marketing Authorization Holder	Macter International Limited. F- 216, S.I.T.E, Karachi 75700, Pakistan.
Name, address of Manufacturing site.	NAME: Macter International Limited. DML NO: 000141 ADDRESS: F- 216, S.I.T.E, Karachi 75700, Pakistan. Date of Renewal 24-11-2019 Renewal slip is required.
GMP status of the firm	GMP certificate issued to Macter International Limited. based on inspection conducted on 01.07.2024
Evidence of approval of manufacturing facility	Firm has submitted copy of section approval letter dated 19-07-2012 which specifies liquid and lyophilized recombinant DNA technology products (biological) section. Firm has also submitted Revision of section approval dated 18 June 2025 under DML 000141 i.e. Prefilled syringe and cartridge pen filling area (in already approved licensed biotech facility)
Status of the applicant	☒ Manufacturer
Status of application	SBP
Intended use of pharmaceutical product	☒ Domestic and Export sales
Dy. No. and date of submission	Tracking ID:M9N-TDV-WMGV Application Number:95771 Date of Receiving:29-06-2025
Details of fee submitted	Challan Number: 737830431388 Division: Biological Evaluation & Registration Paid Fee: 37000.0

	Paid Date: 2025-04-14
proposed proprietary name/brand name	SEGLUTIDE 2.4 mg/0.75ml PFS
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 0.75 ml pre-filled syringe contains: Semaglutide....2.4mg
Pharmaceutical form of applied drug	Liquid solution for injection by SC.
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC code: A10BJ06
Reference to Finished product specifications	As per innovator's specification
Proposed Pack size	1's
Proposed unit price	As per Drug pricing committee
The status in reference regulatory authorities	Wegovy 2.4 mg solution for injection Each single-dose pre-filled pen contains 2.4 mg semaglutide* in 0.75 mL solution. One mL of solution contains 3.2 mg of semaglutide*. Approved in Pre-filled Pen.
For generic drugs (me-too status)	NA
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO template.
Module-III Drug Substance:	
Manufacturer of DS	Livzon New North River Pharmaceutical Co., Ltd. No. 8 Shilong Road, Xinji Village Committee, Shijiao Town, Qingcheng District, QingyuanCity, Guangdong Province, P.R. China 511545
Source	This product is a recombinant glucagon-like peptide-1 (GLP-1) receptor agonist expressed and produced by DNA recombination technology and chemical modification in E. coli.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated and real time conditions. The real time stability data is conducted at (-20°C±5°C) for 36 months on 3 batches. Accelerated study is conducted at (5±3°C) for 6 months on 3 batches of API. Registration batches, SM-2101002, SM-2101003, and SM-2103004
Module-III Drug Product:	
Manufacturing Site	Macter International Limited will be responsible for formulation, filling in cartridge and testing of the product SEGLUTIDE Pen in their dedicated biotech facility.
Container closure system of the drug product	Packaging for Semaglutide finished products are 1 ml Luer lock USP type 1 clear glass prefilled syringe accompanied with plunger stopper & plunger Rod.
Stability study data of drug product, shelf life and storage conditions	3 pilot scale batch no. SEMA-01E PFS, SEMA-02E PFS & SEMA-03E PFS Long term stability study data of 3 batches at 5±3°C. Accelerated stability study data is conducted at 25±2°C & 60±5%RH DOM:10-2024 Study Data:6 months.
Storage Conditions	Store in a refrigerator (2°C to 8°C).
Module 4	Single dose & repeated dose toxicity studies of Seglutide injection Seglutide Injection 1.34mg/mL versus Reference product conducted in mice at M/s Dow University of Health Sciences, Karachi. Seglutide (34.29ug/0.5mL) as per body weight of mice.
Module 5	Studies performed by M/s Livzon New North River Pharmaceutical Co.,Ltd. PHASE 1 A single dose, randomized, open label, parallel controlled pharmacokinetic Phase-I Clinical trial of Semaglutide Injection versus reference in 64 healthy subjects. PHASE 3 ; A multicenter randomized open-label, parallel-controlled comparative trial of clinical efficacy and safety in patient with type 2 diabetes.
Remarks of Evaluator:	

Wegovy 2.4 mg solution for injection

Each single-dose pre-filled pen contains 2.4 mg semaglutide* in 0.75 mL solution. One mL of solution contains 3.2 mg of semaglutide*.

Sr. No	Query	Query response
1.	Propose distinct brand names for biosimilars of Ozempic and Wegovy, as the same brand name is currently used for both products despite differences in strength and clinical indication.	In response to the query received from DRAP, please find below the proposed brand names for Semaglutide Pre-Filled Syringes (PFS): ☐ For strengths 2 mg / 3 ml, 4 mg / 3 ml & 8 mg / 3 ml, the proposed brand name is Seglutide, as these doses correspond to the reference product Ozempic. ☐ For strengths 6.8 mg/ 3 ml and 9.6 mg / 3 ml, our first priority for brand naming is Seglutide-O
2.	Provide evidence that the Management Committee of the Shijiao Town Industrial Park, Qincheng District, Qingyuan City, is authorized by the NMPA to issue GMP certificates.	As of December 1, 2019, China officially abolished the standalone GMP and GSP certification systems Reference link; https://english.nmpa.gov.cn/2019-11/29/c_456284.htm
3.		
4.	The specifications do not include identification by peptide mapping, and dose accuracy as per innovator	Peptide mapping test is an identity test for analyzing the right amino acid sequence since formulation cannot have an impact of the amino acid sequence so repetition of test in finished formulation have no benefit. Although the Finished product specification has been revised as per your recommendation (FTM enclosed). (Annex 2) please note that dose accuracy is part of our specification and finished product testing
5.	The release specifications for pH and assay should align with those of the innovator product—i.e., pH range of 7.1 to 7.7 and assay range of 94.5% to 104.5%—and should be made more stringent accordingly.	Our stability data indicate that product is stable within the innovator range of PH & assay. Your point is well taken and we have revised specification accordingly (FTM enclosed). (Annex 2)
6.	High molecular weight proteins, as well as hydrophilic and hydrophobic impurities, are not detected in the drug product; however, they are present in the drug substance and in the innovator product. Justification for their absence in the drug product is required.	Aggregates can be reversible and non-reversible. During formulation and dilution steps, such reversible aggregates may dissociate, especially in the presence of appropriate buffer systems, excipients, or under optimized pH and ionic conditions. • The drug product formulation has been optimized to ensure stabilization of the active substance, minimizing aggregation potential during shelf life. • Absence of detectable HMW impurities or hydrophobic variants in the drug product reflects the improved stability and favorable formulation conditions, and does not indicate degradation or loss of critical quality attributes. In conclusion, this impurity profile is consistent with, or superior to, that of the reference product and supports product quality and comparability. Since the API is in powder form and concentrate in sample preparation provide the condition for the aggregate formation as compare with formulation which inhibit aggregates.
7.	ADC attested Commercial invoice, Audit trail and data logger data is required.	Enclosed (Annex 8)
8.	Complete report of Comparative analysis for clinical and non-clinical studies with Wegovy is required as provided one is information overview for 1.34mg/ml.	The case of generic peptide registration is based on the sameness or bio comparability which is proven in dossier. The clinical trial submitted are the part of the case to prove comparability and justifying the

		extrapolation. The applied strength is generic version of 2.4 mg per 0.75 ml of innovator (wegovy). Since it is generic version, extrapolation of indication and dose is allowed. Reference from ICH Q5E – “Comparability of Biotechnological/Biological Products” “Determinations of product comparability can be based solely on quality considerations if the manufacturer can provide assurance of comparability through analytical studies as suggested in this document. Additional evidence from nonclinical or clinical studies is considered appropriate when quality data are insufficient to establish comparability”
9.	Bio similarity studies and justification where Not Applicable. Comparative PK/PD study is mandatory	No response submitted.

Decision of 349th Meeting:

The Registration Board after thorough deliberation deferred the case for the submission of the following documents:

- **Audit trail and data logger data for accelerated and real time storage condition.**
- **Complete clinical study report for all recommended doses including 2.4mg in comparison with reference product/innovator.**
Provide the details of comparator product Novotec ® whether it is innovator product or otherwise.

Case # 8

Name, address of Applicant / Marketing Authorization Holder	Macter International Limited. F- 216, S.I.T.E, Karachi 75700, Pakistan.
Name, address of Manufacturing site.	NAME: Macter International Limited. DML NO: 000141 ADDRESS: F- 216, S.I.T.E, Karachi 75700, Pakistan. Date of Renewal 24-11-2019 Renewal slip is required.
GMP status of the firm	GMP certificate issued to Macter International Limited. based on inspection conducted on 01.07.2024
Evidence of approval of manufacturing facility	Firm has submitted copy of section approval letter dated 19-07-2012 which specifies liquid and lyophilized recombinant DNA technology products (biological) section. Firm has also submitted Revision of section approval dated 18 June 2025 under DML 000141 i.e. Prefilled syringe and cartridge pen filling area (in already approved licensed biotech facility)
Status of the applicant	☒ Manufacturer
Status of application	SBP
Intended use of pharmaceutical product	☒ Domestic and Export sales
Dy. No. and date of submission	Tracking ID:JVW-99W-YT4E Application Number:94715 Date of Receiving:29-06-2025
Details of fee submitted	Challan Number: 1217044523 Division: Biological Evaluation & Registration Paid Fee: 37000.0

	Paid Date: 2025-04-14
proposed proprietary name/brand name	SEGLUTIDE 1.7 mg/0.75ml PFS
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 0.75 ml single dose pre-filled syringe contains: Semaglutide....1.7mg
Pharmaceutical form of applied drug	Liquid solution for injection by SC.
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC code: A10BJ06
Reference to Finished product specifications	As per innovator's specification
Proposed Pack size	1's
Proposed unit price	As per Drug pricing committee
The status in reference regulatory authorities	Wegovy 1.7 mg solution for injection Each single-dose pre-filled pen contains 1.7 mg semaglutide* in 0.75 mL solution. One mL of solution contains 2.27 mg of semaglutide*. Pre-filled pen, single-dose 1 mL glass syringe (type I glass) with attached stainless steel needle, rigid needle shield (type II/polyisoprene) and a rubber plunger (type I/chlorobutyl). EMA
For generic drugs (me-too status)	NA
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO template.
Module-III Drug Substance:	
Manufacturer of DS	Livzon New North River Pharmaceutical Co., Ltd. No. 8 Shilong Road, Xinji Village Committee, Shijiao Town, Qingcheng District, QingyuanCity, Guangdong Province, P.R. China 511545
Source	This product is a recombinant glucagon-like peptide-1 (GLP-1) receptor agonist expressed and produced by DNA recombination technology and chemical modification in E. coli.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated and real time conditions. The real time stability data is conducted at (-20°C±5°C) for 36 months on 3 batches. Accelerated study is conducted at (5±3°C) for 6 months on 3 batches of API. Registration batches, SM-2101002, SM-2101003, and SM-2103004
Module-III Drug Product:	
Manufacturing Site	Macter International Limited will be responsible for formulation, filling in cartridge and testing of the product SEGLUTIDE Pen in their dedicated biotech facility.
Container closure system of the drug product	Packaging for Semaglutide finished products are 1 ml Luer lock USP type 1 clear glass prefilled syringe accompanied with plunger stopper & plunger Rod.
Stability study data of drug product, shelf life and storage conditions	3 pilot scale batch no. SEMA-01E PFS, SEMA-02E PFS & SEMA-03E PFS Long term stability study data of 3 batches at 5±3°C. Accelerated stability study data is conducted at 25±2°C & 60±5%RH DOM:10-2024 Study Data:6 months.
Storage Conditions	Store in a refrigerator (2°C to 8°C).
Module 4	Single dose & repeated dose toxicity studies of Seglutide injection Seglutide Injection 1.34mg/mL versus Reference product conducted in mice at M/s Dow University of Health Sciences, Karachi. Seglutide (34.29ug/0.5mL) as per body weight of mice.
Module 5	Studies performed by M/s Livzon New North River Pharmaceutical Co.,Ltd. PHASE 1 A single dose, randomized, open label, parallel controlled pharmacokinetic Phase-I Clinical trial of Semaglutide Injection versus reference in 64 healthy subjects.

Remarks of Evaluator:

Wegovy 1.7 mg solution for injection
Each single-dose pre-filled pen contains 1.7 mg semaglutide* in 0.75 mL solution. One mL of solution contains 2.27 mg of semaglutide*.*.

Sr. No	Query	Query response
1.	Propose distinct brand names for biosimilars of Ozempic and Wegovy, as the same brand name is currently used for both products despite differences in strength and clinical indication.	In response to the query received from DRAP, please find below the proposed brand names for Semaglutide Pre-Filled Syringes (PFS): ☐ For strengths 2 mg / 3 ml, 4 mg / 3 ml & 8 mg / 3 ml, the proposed brand name is Seglutide, as these doses correspond to the reference product Ozempic. ☐ For strengths 6.8 mg/ 3 ml and 9.6 mg / 3 ml, our first priority for brand naming is Seglutide-O
2.	Provide evidence that the Management Committee of the Shijiao Town Industrial Park, Qincheng District, Qingyuan City, is authorized by the NMPA to issue GMP certificates.	As of December 1, 2019, China officially abolished the standalone GMP and GSP certification systems Reference link; https://english.nmpa.gov.cn/2019-11/29/c_456284.htm
3.	The specifications .do not include identification by peptide mapping, and dose accuracy as per innovator	Peptide mapping test is an identity test for analyzing the right amino acid sequence since formulation cannot have an impact of the amino acid sequence so repetition of test in finished formulation have no benefit. Although the Finished product specification has been revised as per your recommendation (FTM enclosed). (Annex 2) please note that dose accuracy is part of our specification and finished product testing
4.	The release specifications for pH and assay should align with those of the innovator product—i.e., pH range of 7.1 to 7.7 and assay range of 94.5% to 104.5%—and should be made more stringent accordingly.	Our stability data indicate that product is stable within the innovator range of PH & assay. Your point is well taken and we have revised specification accordingly (FTM enclosed). (Annex 2)
5.	High molecular weight proteins, as well as hydrophilic and hydrophobic impurities, are not detected in the drug product; however, they are present in the drug substance and in the innovator product. Justification for their absence in the drug product is required.	Aggregates can be reversible and non-reversible. During formulation and dilution steps, such reversible aggregates may dissociate, especially in the presence of appropriate buffer systems, excipients, or under optimized pH and ionic conditions. • The drug product formulation has been optimized to ensure stabilization of the active substance, minimizing aggregation potential during shelf life. • Absence of detectable HMW impurities or hydrophobic variants in the drug product reflects the improved stability and favorable formulation conditions, and does not indicate degradation or loss of critical quality attributes. In conclusion, this impurity profile is consistent with, or superior to, that of the reference product and supports product quality and comparability. Since the API is in powder form and concentrate in sample preparation provide the condition for the aggregate formation as compare with formulation which inhibit aggregates.
6.	ADC attested Commercial invoice, Audit trail and data logger data is required.	Enclosed (Annex 8)
7.	Complete report of Comparative analysis for clinical and non-clinical studies with Wegovy is required as provided one is information overview	The case of generic peptide registration is based on the sameness or bio comparability which is proven in dossier. The clinical trial submitted are the part of the case to prove

	for 1.34mg/ml.	comparability and justifying the extrapolation. The applied strength is generic version of 1.7 mg per 0.75 ml of innovator (wegovy). Since it is generic version, extrapolation of indication and dose is allowed. Reference from ICH Q5E – “Comparability of Biotechnological/Biological Products” “Determinations of product comparability can be based solely on quality considerations if the manufacturer can provide assurance of comparability through analytical studies as suggested in this document. Additional evidence from nonclinical or clinical studies is considered appropriate when quality data are insufficient to establish comparability
8.	Bio similarity studies and justification where Not Applicable. Comparative PK/PD study is mandatory	No response submitted.

Decision of 349th Meeting:

The Registration Board after thorough deliberation deferred the case for the submission of the following documents:

- **Audit trail and data logger data for accelerated and real time storage condition.**
- **Complete clinical study report for all recommended doses including 1.7 mg in comparison with reference product/innovator.**
- **Provide the details of comparator product Novotec ® whether it is innovator product or otherwise.**

Case # 9	
Name, address of Applicant / Marketing Authorization Holder	Macter International Limited. F- 216, S.I.T.E, Karachi 75700, Pakistan.
Name, address of Manufacturing site.	NAME: Macter International Limited. DML NO: 000141 ADDRESS: F- 216, S.I.T.E, Karachi 75700, Pakistan. Date of Renewal 24-11-2019 Renewal slip is required.
GMP status of the firm	GMP certificate issued to Macter International Limited. based on inspection conducted on 01.07.2024
Evidence of approval of manufacturing facility	Firm has submitted copy of section approval letter dated 19-07-2012 which specifies liquid and lyophilized recombinant DNA technology products (biological) section. Firm has also submitted Revision of section approval dated 18 June 2025 under DML 000141 i.e. Prefilled syringe and cartridge pen filling area (in already approved licensed biotech facility
Status of the applicant	☒ Manufacturer
Status of application	SBP
Intended use of pharmaceutical product	☒ Domestic and Export sales
Dy. No. and date of submission	Tracking ID:79T-D9Q-479Z Application Number:93671Date of Receiving:29-06-2025
Details of fee submitted	Challan Number: 6467405724

	Division: Biological Evaluation & Registration Paid Fee: 37000.0 Paid Date: 2025-04-14
proposed proprietary name/brand name	SEGLUTIDE 1 mg/0.5ml PFS
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 0.5 ml single dose pre-filled syringe contains: Semaglutide....1mg
Pharmaceutical form of applied drug	Liquid solution for injection by SC.
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC code: A10BJ06
Reference to Finished product specifications	As per innovator's specification
Proposed Pack size	1's
Proposed unit price	As per Drug pricing committee
The status in reference regulatory authorities	Wegovy 1 mg solution for injection Each single-dose pre-filled pen contains 1 mg semaglutide* in 0.5 mL solution. One mL of solution contains 2 mg of semaglutide*. Pre-filled pen, single-dose 1 mL glass syringe (type I glass) with attached stainless steel needle, rigid needle shield (type II/polyisoprene) and a rubber plunger (type I/chlorobutyl). EMA
For generic drugs (me-too status)	NA
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO template.
Module-III Drug Substance:	
Manufacturer of DS	Livzon New North River Pharmaceutical Co., Ltd. No. 8 Shilong Road, Xinji Village Committee, Shijiao Town, Qingcheng District, Qingyuan City, Guangdong Province, P.R. China 511545
Source	This product is a recombinant glucagon-like peptide-1 (GLP-1) receptor agonist expressed and produced by DNA recombination technology and chemical modification in E. coli.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated and real time conditions. The real time stability data is conducted at (-20°C±5°C) for 36 months on 3 batches. Accelerated study is conducted at (5±3°C) for 6 months on 3 batches of API. Registration batches, SM-2101002, SM-2101003, and SM-2103004
Module-III Drug Product:	
Manufacturing Site	Macter International Limited will be responsible for formulation, filling in cartridge and testing of the product SEGLUTIDE Pen in their dedicated biotech facility.
Container closure system of the drug product	Packaging for Semaglutide finished products are 1 ml Luer lock USP type 1 clear glass prefilled syringe accompanied with plunger stopper & plunger Rod.
Stability study data of drug product, shelf life and storage conditions	3 pilot scale batch no. SEMA-01F PFS, SEMA-02F PFS & SEMA-03F PFS Long term stability study data of 3 batches at 5±3°C. Accelerated stability study data is conducted at 25±2°C & 60±5%RH DOM:01-2025 Study Data:3 months.
Storage Conditions	Store in a refrigerator (2°C to 8°C).
Module 4	Single dose & repeated dose toxicity studies of Seglutide injection Seglutide Injection 1.34mg/mL versus Reference product conducted in mice at M/s Dow University of Health Sciences, Karachi. Seglutide (34.29ug/0.5mL) as per body weight of mice.
Module 5	Studies performed by M/s Livzon New North River Pharmaceutical Co.,Ltd. PHASE 1 A single dose, randomized, open label, parallel controlled pharmacokinetic Phase-I

	Clinical trial of Semaglutide Injection versus reference in 64 healthy subjects.
	PHASE 3 ; A multicenter randomized open-label, parallel-controlled comparative trial of clinical efficacy and safety in patient with type 2 diabetes.

Remarks of Evaluator:

Wegovy 1 mg solution for injection Each single-dose pre-filled pen contains 1 mg semaglutide* in 0.5 mL solution. One mL of solution contains 2 mg of semaglutide*.

Sr. No	Query	Query response
1.	Propose distinct brand names for biosimilars of Ozempic and Wegovy, as the same brand name is currently used for both products despite differences in strength and clinical indication.	In response to the query received from DRAP, please find below the proposed brand names for Semaglutide Pre-Filled Syringes (PFS): ☐ For strengths 2 mg / 3 ml, 4 mg / 3 ml & 8 mg / 3 ml, the proposed brand name is Seglutide, as these doses correspond to the reference product Ozempic. ☐ For strengths 6.8 mg/ 3 ml and 9.6 mg / 3 ml, our first priority for brand naming is Seglutide-O
2.	Provide evidence that the Management Committee of the Shijiao Town Industrial Park, Qincheng District, Qingyuan City, is authorized by the NMPA to issue GMP certificates.	As of December 1, 2019, China officially abolished the standalone GMP and GSP certification systems Reference link; https://english.nmpa.gov.cn/2019-11/29/c_456284.htm
3.	The specifications .do not include identification by peptide mapping, and dose accuracy as per innovator	Peptide mapping test is an identity test for analyzing the right amino acid sequence since formulation cannot have an impact of the amino acid sequence so repetition of test in finished formulation have no benefit. Although the Finished product specification has been revised as per your recommendation (FTM enclosed). (Annex 2) please note that dose accuracy is part of our specification and finished product testing
4.	The release specifications for pH and assay should align with those of the innovator product—i.e., pH range of 7.1 to 7.7 and assay range of 94.5% to 104.5%—and should be made more stringent accordingly.	Our stability data indicate that product is stable within the innovator range of PH & assay. Your point is well taken and we have revised specification accordingly (FTM enclosed). (Annex 2)
5.	High molecular weight proteins, as well as hydrophilic and hydrophobic impurities, are not detected in the drug product; however, they are present in the drug substance and in the innovator product. Justification for their absence in the drug product is required.	Aggregates can be reversible and non-reversible. During formulation and dilution steps, such reversible aggregates may dissociate, especially in the presence of appropriate buffer systems, excipients, or under optimized pH and ionic conditions. • The drug product formulation has been optimized to ensure stabilization of the active substance, minimizing aggregation potential during shelf life. • Absence of detectable HMW impurities or hydrophobic variants in the drug product reflects the improved stability and favorable formulation conditions, and does not indicate degradation or loss of critical quality attributes. In conclusion, this impurity profile is consistent with, or superior to, that of the reference product and supports product quality and comparability. Since the API is in powder form and concentrate in sample preparation provide the condition for the aggregate formation as compare with formulation which inhibit aggregates.
6.	ADC attested Commercial invoice, Audit	System generated form 6, good declaration & commercial

		trail and data logger data is required.	invoice are enclosed (Annex 1)
	7.	Complete report of Comparative analysis for clinical and non-clinical studies with Wegovy is required as provided one is information overview for 1.34mg/ml.	The case of generic peptide registration is based on the sameness or bio comparability which is proven in dossier. The clinical trial submitted are the part of the case to prove comparability and justifying the extrapolation. The applied strength is generic version of 1 mg per 0.5 ml of innovator (wegovy). Since it is generic version, extrapolation of indication and dose is allowed Reference from ICH Q5E – “Comparability of Biotechnological/Biological Products” “Determinations of product comparability can be based solely on quality considerations if the manufacturer can provide assurance of comparability through analytical studies as suggested in this document. Additional evidence from nonclinical or clinical studies is considered appropriate when quality data are insufficient to establish comparability”
	8.	Bio similarity studies and justification where Not Applicable. Comparative PK/PD study is mandatory	No response submitted.

Decision of 349th Meeting:

The Registration Board after thorough deliberation deferred the case for the submission of the following documents:

- **Audit trail and data logger data for accelerated and real time storage condition.**
- **Complete clinical study report for all recommended doses in comparison with reference product/innovator.**
- **The details of comparator product Novotec ® whether it is innovator product or otherwise.**

Case # 10

Name, address of Applicant / Marketing Authorization Holder	Macter International Limited. F- 216, S.I.T.E, Karachi 75700, Pakistan.
Name, address of Manufacturing site.	NAME: Macter International Limited. DML NO: 000141 ADDRESS: F- 216, S.I.T.E, Karachi 75700, Pakistan. Date of Renewal 24-11-2019 Renewal slip is required.
GMP status of the firm	GMP certificate issued to Macter International Limited. based on inspection conducted on 01.07.2024
Evidence of approval of manufacturing facility	The Central Licensing Board in its 3096 meeting held on 19 th May, 2025 has considered the recommendations of panel of experts and approved the revision of following section in the name of M/s Macter International Limited, F-126, S.I.T.E., Karachi under DML No. 000141, by way of Formulation: - i. pre-Filled Syringe (PFS) and Cartridge Pen Filling Area (in already approved licensed Biotech facility)
Status of the applicant	☒ Manufacturer
Status of application	SBP
Intended use of pharmaceutical product	☒ Domestic and Export sales
Dy. No. and date of submission	Tracking ID:5MD-8XG-8NGH Application Number:93662

	Date of Receiving:29-06-2025
Details of fee submitted	Challan Number: 9614358961 Division: Biological Evaluation & Registration Paid Fee: 37000.0 Paid Date: 2025-04-14
proposed proprietary name/brand name	SEGLUTIDE 0.5 mg/0.5ml PFS
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 0.5 ml single dose pre-filled syringe contains: Semaglutide....0.5mg
Pharmaceutical form of applied drug	Liquid solution for injection by SC.
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC code: A10BJ06
Reference to Finished product specifications	As per innovator's specification
Proposed Pack size	1's
Proposed unit price	As per Drug pricing committee
The status in reference regulatory authorities	Wegovy 0.5 mg solution for injection Each single-dose pre-filled pen contains 0.5 mg semaglutide* in 0.5 mL solution. One mL of solution contains 1 mg of semaglutide Pre-filled pen, single-dose 1 mL glass syringe (type I glass) with attached stainless steel needle, rigid needle shield (type II/polyisoprene) and a rubber plunger (type I/chlorobutyl). EMA
For generic drugs (me-too status)	NA
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO template.
Module-III Drug Substance:	
Manufacturer of DS	Livzon New North River Pharmaceutical Co., Ltd. No. 8 Shilong Road, Xinji Village Committee, Shijiao Town, Qingcheng District, QingyuanCity, Guangdong Province, P.R. China 511545
Source	This product is a recombinant glucagon-like peptide-1 (GLP-1) receptor agonist expressed and produced by DNA recombination technology and chemical modification in E. coli.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated and real time conditions. The real time stability data is conducted at (-20°C±5°C) for 36 months on 3 batches. Accelerated study is conducted at (5±3°C) for 6 months on 3 batches of API. Registration batches, SM-2101002, SM-2101003, and SM-2103004
Module-III Drug Product:	
Manufacturing Site	Macter International Limited will be responsible for formulation, filling in cartridge and testing of the product SEGLUTIDE Pen in their dedicated biotech facility.
Container closure system of the drug product	Packaging for Semaglutide finished products are 1 ml Luer lock USP type 1 clear glass prefilled syringe accompanied with plunger stopper & plunger Rod.
Stability study data of drug product, shelf life and storage conditions	3 pilot scale batch no. SEMA-01B PFS, SEMA-02B PFS & SEMA-03B PFS Long term stability study data of 3 batches at 5±3°C. Accelerated stability study data is conducted at 25±2°C & 60±5%RH DOM:01-2025 Study Data:3 months.
Storage Conditions	Store in a refrigerator (2°C to 8°C).
Module 4	Single dose & repeated dose toxicity studies of Seglutide injection Seglutide Injection 1.34mg/mL versus Reference product conducted in mice at M/s Dow University of Health Sciences, Karachi. Seglutide (34.29ug/0.5mL) as per body weight of mice.

Module 5	Studies performed by M/s Livzon New North River Pharmaceutical Co.,Ltd. PHASE 1 A single dose, randomized, open label, parallel controlled pharmacokinetic Phase-I Clinical trial of Semaglutide Injection versus reference in 64 healthy subjects. PHASE 3 ; A multicenter randomized open-label, parallel-controlled comparative trial of clinical efficacy and safety in patient with type 2 diabetes.

Remarks of Evaluator:

Wegovy 0.5 mg solution for injection
Each single-dose pre-filled pen contains 0.5 mg semaglutide* in 0.5 mL solution. One mL of solution contains 1 mg of semaglutide.

Sr. No	Query	Query response
1.	Propose distinct brand names for biosimilars of Ozempic and Wegovy, as the same brand name is currently used for both products despite differences in strength and clinical indication.	In response to the query received from DRAP, please find below the proposed brand names for Semaglutide Pre-Filled Syringes (PFS): ☐ For strengths 2 mg / 3 ml, 4 mg / 3 ml & 8 mg / 3 ml, the proposed brand name is Seglutide, as these doses correspond to the reference product Ozempic. ☐ For strengths 6.8 mg/ 3 ml and 9.6 mg / 3 ml, our first priority for brand naming is Seglutide-O
2.	Provide evidence that the Management Committee of the Shijiao Town Industrial Park, Qincheng District, Qingyuan City, is authorized by the NMPA to issue GMP certificates.	As of December 1, 2019, China officially abolished the standalone GMP and GSP certification systems Reference link; https://english.nmpa.gov.cn/2019-11/29/c_456284.htm
3.	The specifications .do not include identification by peptide mapping, and dose accuracy as per innovator	Peptide mapping test is an identity test for analyzing the right amino acid sequence since formulation cannot have an impact of the amino acid sequence so repetition of test in finished formulation have no benefit. Although the Finished product specification has been revised as per your recommendation (FTM enclosed). (Annex 2) please note that dose accuracy is part of our specification and finished product testing
4.	The release specifications for pH and assay should align with those of the innovator product—i.e., pH range of 7.1 to 7.7 and assay range of 94.5% to 104.5%—and should be made more stringent accordingly.	Our stability data indicate that product is stable within the innovator range of PH & assay. Your point is well taken and we have revised specification accordingly (FTM enclosed). (Annex 2)
5.	High molecular weight proteins, as well as hydrophilic and hydrophobic impurities, are not detected in the drug product; however, they are present in the drug substance and in the innovator product. Justification for their absence in the drug product is required.	Aggregates can be reversible and non-reversible. During formulation and dilution steps, such reversible aggregates may dissociate, especially in the presence of appropriate buffer systems, excipients, or under optimized pH and ionic conditions. • The drug product formulation has been optimized to ensure stabilization of the active substance, minimizing aggregation potential during shelf life. • Absence of detectable HMW impurities or hydrophobic variants in the drug product reflects the improved stability and favorable formulation conditions, and does not indicate degradation or loss of critical quality attributes. In conclusion, this impurity profile is consistent with, or superior to, that of the reference product and supports product quality and comparability. Since the API is in powder form and concentrate in sample preparation provide the condition for the aggregate formation as compare with formulation which inhibit aggregates.
6.	ADC attested Commercial invoice, Audit	System generated form 6, good declaration & commercial invoice are

	trail and data logger data is required.	enclosed (Annex 1)
7.	Complete report of Comparative analysis for clinical and non-clinical studies with Wegovy is required as provided one is information overview for 1.34mg/ml.	The case of generic peptide registration is based on the sameness or bio comparability which is proven in dossier. The clinical trial submitted are the part of the case to prove comparability and justifying the extrapolation. The applied strength is generic version of 0/5 mg per 0.5 ml of innovator (wegovy). Since it is generic version, extrapolation of indication and dose is allowed Reference from ICH Q5E – “Comparability of Biotechnological/Biological Products” “Determinations of product comparability can be based solely on quality considerations if the manufacturer can provide assurance of comparability through analytical studies as suggested in this document. Additional evidence from nonclinical or clinical studies is considered appropriate when quality data are insufficient to establish comparability”
8.	Bio similarity studies and justification where Not Applicable. Comparative PK/PD study is mandatory	No response submitted.

•

Decision of 349th Meeting:
The Registration Board after thorough deliberation deferred the case for the submission of the following documents:

- **Audit trail and data logger data for accelerated and real time storage condition.**
- **Complete clinical study report for all recommended doses in comparison with reference product/innovator.**
- **The details of comparator product Novotec ® whether it is innovator product or otherwise.**

Case # 11		
Name, address of Applicant / Marketing Authorization Holder	Macter International Limited. F- 216, S.I.T.E, Karachi 75700, Pakistan.	
Name, address of Manufacturing site.	NAME: Macter International Limited. DML NO: 000141 ADDRESS: F- 216, S.I.T.E, Karachi 75700, Pakistan. Date of Renewal 24-11-2019 Renewal slip is required.	
GMP status of the firm	GMP certificate issued to Macter International Limited. based on inspection conducted on 01.07.2024	
Evidence of approval of manufacturing facility	Firm has submitted copy of section approval letter dated 19-07-2012 which specifies liquid and lyophilized recombinant DNA technology products (biological) section. Firm has also submitted Revision of section approval dated 18 June 2025 under DML 000141 i.e. Prefilled syringe and cartridge pen filling area (in already approved licensed biotech facility)	
Status of the applicant	☒ Manufacturer	
Status of application	SBP	
Intended use of pharmaceutical product	☒ Domestic and Export sales	

Dy. No. and date of submission	Tracking ID:W36-XRA-28N9 Application Number:93618 Date of Receiving:29-06-2025
Details of fee submitted	Challan Number: 3767225966 Division: Biological Evaluation & Registration Paid Fee: 37000.0 Paid Date: 2025-04-14
proposed proprietary name/brand name	SEGLUTIDE 0.25 mg/0.5ml PFS
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 0.5 ml single dose pre-filled syringe contains: Semaglutide....0.25mg
Pharmaceutical form of applied drug	Liquid solution for injection by SC.
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC code: A10BJ06
Reference to Finished product specifications	As per innovator's specification
Proposed Pack size	1's
Proposed unit price	As per Drug pricing committee
The status in reference regulatory authorities	Wegovy 0.25 mg solution for injection Each single-dose pre-filled pen contains 0.25 mg semaglutide* in 0.5 mL solution. One mL of solution contains 0.5 mg of semaglutide*. contains 1 mg of semaglutide Pre-filled pen, single-dose glass syringe (type I glass) with attached stainless steel needle, rigid needle shield (type II/polyisoprene) and a rubber plunger (type I/chlorobutyl). EMA
For generic drugs (me-too status)	NA
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO template.
Module-III Drug Substance:	
Manufacturer of DS	Livzon New North River Pharmaceutical Co., Ltd. No. 8 Shilong Road, Xinji Village Committee, Shijiao Town, Qingcheng District, QingyuanCity, Guangdong Province, P.R. China 511545
Source	This product is a recombinant glucagon-like peptide-1 (GLP-1) receptor agonist expressed and produced by DNA recombination technology and chemical modification in E. coli.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated and real time conditions. The real time stability data is conducted at (-20°C±5°C) for 36 months on 3 batches. Accelerated study is conducted at (5±3°C) for 6 months on 3 batches of API. Registration batches, SM-2101002, SM-2101003, and SM-2103004
Module-III Drug Product:	
Manufacturing Site	Macter International Limited will be responsible for formulation, filling in cartridge and testing of the product SEGLUTIDE Pen in their dedicated biotech facility.
Container closure system of the drug product	Packaging for Semaglutide finished products are 1 ml Luer lock USP type 1 clear glass prefilled syringe accompanied with plunger stopper & plunger Rod.
Stability study data of drug product, shelf life and storage conditions	3 pilot scale batch no. SEMA-01A PFS, SEMA-02A PFS & SEMA-03A PFS Long term stability study data of 3 batches at 5±3°C. Accelerated stability study data is conducted at 25±2°C & 60±5%RH DOM:01-2025 Study Data:3 months.
Storage Conditions	Store in a refrigerator (2°C to 8°C).
Module 4	Single dose & repeated dose toxicity studies of Seglutide injection Seglutide Injection 1.34mg/mL versus Reference product conducted in mice at M/s Dow University of Health

	Sciences, Karachi. Seglutide (34.29ug/0.5mL) as per body weight of mice.
Module 5	Studies performed by M/s Livzon New North River Pharmaceutical Co.,Ltd. PHASE 1 A single dose, randomized, open label, parallel controlled pharmacokinetic Phase-I Clinical trial of Semaglutide Injection versus reference in 64 healthy subjects. PHASE 3 ; A multicenter randomized open-label, parallel-controlled comparative trial of clinical efficacy and safety in patient with type 2 diabetes.

Remarks of Evaluator:

Wegovy 0.25 mg solution for injection
Each single-dose pre-filled pen contains 0.25 mg semaglutide* in 0.5 mL solution. One mL of solution contains 0.5 mg of semaglutide*..

Sr. No	Query	Query response
1.	Propose distinct brand names for biosimilars of Ozempic and Wegovy, as the same brand name is currently used for both products despite differences in strength and clinical indication.	In response to the query received from DRAP, please find below the proposed brand names for Semaglutide Pre-Filled Syringes (PFS): ☐ For strengths 2 mg / 3 ml, 4 mg / 3 ml & 8 mg / 3 ml, the proposed brand name is Seglutide, as these doses correspond to the reference product Ozempic. ☐ For strengths 6.8 mg/ 3 ml and 9.6 mg / 3 ml, our first priority for brand naming is Seglutide-O
2.	Provide evidence that the Management Committee of the Shijiao Town Industrial Park, Qincheng District, Qingyuan City, is authorized by the NMPA to issue GMP certificates.	As of December 1, 2019, China officially abolished the standalone GMP and GSP certification systems Reference link; https://english.nmpa.gov.cn/2019-11/29/c_456284.htm
3.	The specifications do not include identification by peptide mapping, and dose accuracy as per innovator	Peptide mapping test is an identity test for analyzing the right amino acid sequence since formulation cannot have an impact of the amino acid sequence so repetition of test in finished formulation have no benefit. Although the Finished product specification has been revised as per your recommendation (FTM enclosed). (Annex 2) please note that dose accuracy is part of our specification and finished product testing
4.	The release specifications for pH and assay should align with those of the innovator product—i.e., pH range of 7.1 to 7.7 and assay range of 94.5% to 104.5%—and should be made more stringent accordingly.	Our stability data indicate that product is stable within the innovator range of PH & assay. Your point is well taken and we have revised specification accordingly (FTM enclosed). (Annex 2)
5.	High molecular weight proteins, as well as hydrophilic and hydrophobic impurities, are not detected in the drug product; however, they are present in the drug substance and in the innovator product. Justification for their absence in the drug product is required.	Aggregates can be reversible and non-reversible. During formulation and dilution steps, such reversible aggregates may dissociate, especially in the presence of appropriate buffer systems, excipients, or under optimized pH and ionic conditions. • The drug product formulation has been optimized to ensure stabilization of the active substance, minimizing aggregation potential during shelf life. • Absence of detectable HMW impurities or hydrophobic variants in the drug product reflects the improved stability and favorable formulation conditions, and does not indicate degradation or loss of critical quality attributes. In conclusion, this impurity profile is consistent with, or superior to, that of the reference product and supports product quality and comparability. Since the API is in

			powder form and concentrate in sample preparation provide the condition for the aggregate formation as compare with formulation which inhibit aggregates.
6.	ADC attested Commercial invoice, Audit trail and data logger data is required.		System generated form 6, good declaration & commercial invoice are enclosed (Annex 1)
7.	Complete report of Comparative analysis for clinical and non-clinical studies with Wegovy is required as provided one is information overview for 1.34mg/ml.		The case of generic peptide registration is based on the sameness or bio comparability which is proven in dossier. The clinical trial submitted are the part of the case to prove comparability and justifying the extrapolation. The applied strength is generic version of 0.25 mg per 0.5 ml of innovator (wegovy). Since it is generic version, extrapolation of indication and dose is allowed Reference from ICH Q5E – “Comparability of Biotechnological/Biological Products” “Determinations of product comparability can be based solely on quality considerations if the manufacturer can provide assurance of comparability through analytical studies as suggested in this document. Additional evidence from nonclinical or clinical studies is considered appropriate when quality data are insufficient to establish comparability”
8.	Bio similarity studies and justification where Not Applicable. Comparative PK/PD study is mandatory		No response submitted.

Decision of 349th Meeting:

The Registration Board after thorough deliberation deferred the case for the submission of the following documents:

- **Audit trail and data logger data for accelerated and real time storage condition.**
- **Complete clinical study report for all recommended doses in comparison with reference product/innovator.**
- **The details of comparator product Novotec ® whether it is innovator product or otherwise.**

Semaglutide Source: rDNA Drug Concentrate Import Local Manufacturing Applied Container Closure System: Cartridge Pre-filled Pen Biosimilar to Ozempic Injection		
Case # 12		
Name, address of Applicant / Marketing Authorization Holder	M/s Getz Pharma (Pvt) Limited Company Address: Plot No. 29-30, Sector 27, Korangi Industrial Area, Karachi	
Name, address of Manufacturing site.	M/s Getz Pharma (Pvt.) Limited Address: Plot No. 29-30, Sector 27, Korangi Industrial Area, Karachi – 74900, Pakistan	
GMP status of the firm	GMP of relevant section not submitted.	
Evidence of approval of manufacturing facility	DML No. 000284 On December 02, 2024, Central Licensing Division of DRAP has granted section approval of liquid Injection Vials and Cartridges (Biotech-rDNA)	
Status of the applicant	☒ Manufacturer	
Status of application	SBP	
Intended use of pharmaceutical product	☒ Domestic and Export sales	
Dy. No. and date of submission	Tracking ID: 7AD-W1A-E48M	

	Application Number: 97262 Date of Receiving:17-06-2025
Details of fee submitted	Challan Number: 001815053521 Division: Biological Evaluation & Registration Paid Fee: 37000.0 Paid Date: 2025-04-14
proposed proprietary name/brand name	Sem-P Solution for Injection in Cartridge with Disposable pen 2mg/1.5mL
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 1.5mL cartridge contains: Semaglutide..... 2mg
Pharmaceutical form of applied drug	Solution for Injection in Cartridge with Disposable pen
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	As per Innovator's Specifications
Proposed Pack size	1's Cartridge in Disposable pen
Proposed unit price	As per SRO 228(I)/2024 dated 19-02-2024
The status in reference regulatory authorities	OZEMPIC (Semaglutide) solution for injection 2 mg/1.5 ml (USFDA APPROVED)
For generic drugs (me-too status)	Ozempic Injection 2mg/1.5ml by Novo Nordisk (Reg.No:107915)
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO template.
Module-III Drug Substance:	
Manufacturer of DS	M/s Hangzhou Jiuyuan Gene Engineering Co., Ltd China Address: East of No. 8th Street, Hangzhou Economic and Technological Development Zone Provided legalized DML valid upto November 08, 2025 by the applicant specifies Semaglutide Injection in its scope.
Source	This product is a recombinant glucagon-like peptide-1 (GLP-1) receptor agonist expressed and produced by DNA recombination technology and chemical modification in E. coli.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated and real time conditions. The real time stability data is conducted at (-20°C±5°C) on 3 batches. Accelerated study is conducted at (5±3°C) .
Module-III Drug Product:	
Manufacturing Site	M/s Getz Pharma (Pvt.) Limited Address: Plot No. 29-30, Sector 27, Korangi Industrial Area, Karachi – 74900, Pakistan
Container closure system of the drug product	Cartridge in Disposable Pen 2mg/1.5mL in glass type 1 cartridge is further fitted in disposable pen, packed in a printed carton
Stability study data of drug product, shelf life and storage conditions	720DS01,720DS02,720DS03 DOM:31-10-2024 3 months stability data submitted by the applicant. Long Term: 5°C± 3°C Accelerated: 25°C ± 2°C and 60% ± 5% R.H
Storage Conditions	Store in a refrigerator (2°C to 8°C).
Module 4	Submitted.
Module 5	Submitted.
• Remarks of Evaluator:	

- SMPC under section 1.5.14 is required.
- Submit complete commitment for section 1.5.22.
- Provide source of concentrate whether synthetic or rDNA.
- The HMWP proteins limit should be less than 0.7% at release.
- The release specs. should be made stringent for impurities as per innovator.
 - Hydrophilic Impurities $\leq 3.8\%$.
 - Hydrophobic Impurities 1 $\leq 3.5\%$
 - Hydrophobic impurities 2 $\leq 0.5\%$
 - Sum of Impurities $\leq 6.3\%$
- The stability data of concentrate is of 18 months. Submit stability data till claimed shelf life.
- Test of dose accuracy and identification test for peptide mapping to be included in finished product specifications and concentrate.
- Evidence of LC MS is required.
- Submit stability data of six months as provided data is of 3 month.
- Submit ADC attested commercial invoice.
- Submit documents in the light of 278th guidelines for concentrate

Sr No.	Query	Response
1.	SMPC under section 1.5.14 is required.	Please refer to Annexure - 1 for Summary of Product Characteristics (SMPC) of Sem-P (Semaglutide) Solution for Injection in Cartridge with Disposable Pen 2mg/1.5mL.
2.	Submit complete commitment for section 1.5.22.	Please refer to Annexure – 2 for signed & stamped commitment.
3.	Provide source of concentrate whether synthetic or rDNA	Please note that the source of Semaglutide Drug Substance manufactured by M/s Hangzhou Jiuyuan Gene Engineering Co., Ltd. China is rDNA i.e., E. Coli. Please refer to Annexure - 3 for source document of Semaglutide. Please note that t
4.	The HMWP proteins limit should be less than 0.7% at release.	Please note that the release limit of HMWP in the already submitted Finished Product Specifications is more stringent i.e., Not more than 0.5%.
5.	The release specs. should be made stringent for impurities as per innovator. Hydrophilic Impurities $\leq 3.8\%$ Hydrophobic Impurities 1 $\leq 3.5\%$ Hydrophobic impurities 2 $\leq 0.5\%$ • Sum of Impurities $\leq 6.3\%$	Please note that the release limit of impurities in the already submitted Finished Product Specifications are more stringent i.e., Hydrophilic Impurities: Not more than 2.0% Hydrophobic Impurities 1: Not more than 2.5% Hydrophobic impurities 2: Not more than 0.3% Total Impurities: Not more than 4.5%
6.	The stability data of concentrate is of 18 months. Submit stability data till claimed shelf life.	Please refer to Annexure - 5 for stability data with updated interval till claimed shelf-life of 24 months.
7.	Test of dose accuracy and identification test for peptide mapping to be included in finished product specifications and concentrate.	Please refer to Annexure - 4 for updated Finished Product Specification wherein we have included test for dose accuracy. 8 Evidence of LC MS is required. 9 Submit stability data of six months as provided data is of 3 months. Further, please note that in biotechnological products, identification by Peptide Mapping is applicable for Drug Substance as evident by official monographs of European Pharmacopoeia & British Pharmacopoeia. In these Pharmacopoeias, peptide mapping is recommended as an identification test for Drug Substance only and not for the corresponding finished products. Official monographs published in Ph. Eur. & BP for Drug Substances (e.g. Human Insulin & Insulin Glargine) & Finished products (e.g. Injectable Insulin Preparations & Insulin Glargine Injection) are attached for reference. Please refer to Annexure -4 for monographs. Furthermore, the reference product Ozempic PQR data shows that the peptide mapping is only performed on drug substance not on the drug product. Similarly for Getz Pharma product (Semaglutide Injection in Cartridge with disposable pen), Drug Substance manufacturer (Hangzhou Jiuyuan Gene Engineering Co., Ltd. Chin.) has performed identification by peptide mapping on each lot of Semaglutide Drug Substance. Please refer to Annexure – 4 for Certificate of Analysis (COA) of Semaglutide drug substance.

8.	Evidence of LC MS is required.	Please refer to Annexure - 6 for evidence of LC MS provided by M/s Hangzhou Jiuyuan Gene Engineering Co., Ltd. China.
9.	Submit stability data of six months as provided data is of 3 months.	Please refer to Annexure - 7 for 06 months accelerated and real time stability study data of 03 batches along with raw data sheets, chromatogram
10.	Submit ADC attested commercial invoice.	This is to inform you that DRAP is now issuing computerized Form 6 instead of attesting it by Assistant Drug Controller. Therefore, we have submitted following documents for your kind consideration; 1- Form 6 2- Airway Bill 3- Good Declaration 4- Invoice Please refer to Annexure - 8 for aforementioned documents.
11.	Submit documents in the light of 278th guidelines for concentrate.	Please refer to Annexure - 9 for the documents in the light of 278th guidelines for concentrate.
12.	Submit bio similarity of finished product as per attached template	Please refer to Annexure - 10 for Bio similarity report as per the format provided by your good office.

Registration Board in its 278 decided to adopt guidelines as regulatory requirements for the registration of rDNA therapeutic proteins. The same guidelines can be applied to rDNA therapeutic peptides on basis of WHO Guidelines on evaluation of biosimilars Replacement of Annex 2 of WHO Technical Report Series, No. 977 which states that

“The Guidelines apply to biological products that can be well characterized, such as recombinant DNA-derived therapeutic peptides and proteins.”

The point (f) of the approved guidelines for therapeutic proteins may be replaced by the following tests for the therapeutic peptide i.e. semaglutide.

For therapeutic proteins

(f)The local manufacturer shall manufacture three trial batches of the finished biological product to finalize the formulation and then perform analytical studies(Physicochemical and biological) including protein content, appearance, pH, Osmolarity, composition of key excipients including stabilizers (if formulation is same), visible/subvisible particles, identity testing to parent molecule, purity testing, in vitro biological activity, sterility, Pyrogen content, safety, potency and toxicity with support of iso-electro focusing data, gel electrophoresis, Western-Blot and other analytical techniques). The firm shall submit the results for processing of registration application.

For therapeutic peptides(semaglutide)

Macroscopy (Visual inspection), Identity of peptide (RP-HPLC),Identification by Peptide Mapping(LC MS) Content of peptide (RP-HPLC), Ph (Potentiometry), High molecular (SE-HPLC), Hydrophobic impurities (RP-HPLC), Hydrophobic impurities 1 (RP-HPLC), Hydrophobic impurities 2 (RP-HPLC), Sum of impurities (RP-HPLC), Bacterial endotoxins (Chromogenic kinetic method), Sterility (Membrane filtration method), Identity of preservative *(RP-HPLC), Preservative* (RP-HPLC),Biological activity(Cell based Assay),(Particulate matter (Light obscuration), Dose accuracy (Weighing)

***for multi-dose container .**

The point 3 of the approved guidelines for therapeutic proteins will be replaced by the following requirement for the therapeutic peptide

For therapeutic proteins

For products where process like PEGylation are performed locally, then complete clinical data shall be required by the manufacturer

For therapeutic peptides

For drug substance import and local manufacturing PK/PD bioequivalence study is mandatory to be performed by local manufacturer(for very simple peptides).

DOCUMENTS IN THE LIGHT OF 278 TH GUIDELINES	GETZ PHARMA RESPONSE
The firm shall provide legalized GMP certificate of biological drug substance manufacturer abroad (who will provide concentrate / ready to fill bulk of biological drug to Pakistani manufacturers for further processing) as an evidence that the manufacturer is an authorized manufacturer of biological drug in the country of origin.	Please note that China has stopped issuing GMP Certificate from 2019. Therefore, in lieu of GMP Certificate, we have submitted legalized DML of M/s Hangzhou Jiuyuan Gene Engineering Co., Ltd China as evidence that the manufacturer is an authorized manufacturer of Semaglutide Injection in China.
The firms shall provide legalized free sale certificate/CoPP either from country of origin or by any reference regulatory authority as adopted by Registration Board of finished product as evidence that the final product has been manufactured by same	This is to inform you that in 343 rd RB Meeting, proceedings of the Registration Board states: <i>The Board was already acquainted with the fact that currently Semaglutide drugs are covered under the patent rules in China, that's why these generic products cannot be registered in NMPA (National Medical Product Administration) China, till the expiry of patent and therefore, COPP cannot be</i>

concentrate/ready to fill bulk after submission of data to the concerned regulatory authority.	issued by the certifying authority. Furthermore, please note that Registration Board in its 336 th RB meeting dated 04 to 06 June, 2024 has approved the product registration of Semaglutide Injection for M/s BF Biosciences Ltd Lahore and M/s Macter International Limited Karachi without submission of CoPP.
The firm shall provide the complete Bio-similarity studies of the finished product of same source (bulk concentrate or ready to fill) manufactured either from country of origin or by any reference regulatory authority as adopted by Registration Board to demonstrate the bio-similarity.	Please refer to Annex – A for Bio similarity studies of Semaglutide by M/s Hangzhou Jiuyuan Gene Engineering Co., Ltd China.
The firm shall provide the lot release certificate of the finished product manufactured by same bulk concentrate / ready to fill from country of export (If applicable).	Not Applicable
The firm shall provide the 6 months accelerated and real time stability studies for drug substance.	Please refer to Annexure – 7 of query response for 6 months accelerated and 24 months real time stability studies for drug substance.
The local manufacturer shall manufacture three trial batches of the finished biological product to finalize the formulation and then perform analytical studies (Physicochemical and biological) including protein content, appearance, pH, Osmolarity, composition of key excipients including stabilizers (if formulation is same), visible subvisible particles, identity testing to parent molecule, purity testing, in vitro biological activity, sterility, Pyrogen content, safety, potency and toxicity with support of iso-electro focusing data, gel electrophoresis, Western-Blot and other analytical techniques). The firm shall submit the results for processing of registration application.	Please note that we have manufactured three stability batches of the finished product and complete test / analysis has been performed as per submitted finished product specification. This is to inform you that isoelectric point is an important structural characterization of protein drugs, which reflects the number and distribution of dissociable groups of acidic and basic amino acids in proteins. The isoelectric points of the self-made sample and the reference product were determined by M/s Hangzhou Jiuyuan Gene Engineering Co., Ltd China on whole column imaging capillary isoelectric focusing electrophoresis. The results showed the isoelectric point was between 4.85 and 4.88, averaging 4.866, the inter-batch relative standard deviation (RSD) was 0.22%, and the relative area was all 100%. The isoelectric point and relative area of the self-made samples had good batch-to-batch consistency and sample-to-sample consistency, and were consistent with that of reference product (Ozempic). The peptide is a well-characterized rDNA-derived molecule with minimal structural variability, and its identity and purity are confirmed by validated orthogonal methods such as RP-HPLC and mass spectrometry which are more precise and advance techniques than gel electrophoresis and Western-Blot. Charge-related characteristics are comprehensively evaluated and controlled at the drug substance stage by the manufacturer. The bulk concentrate is received as a fully purified material with no further purification processing. We performed Analytical testing on bulk concentrate including protein content, appearance, pH, osmolarity, identification, HMWP, Hydrophobic and Hydrophilic Impurities, phenol and Polypropylene glycol content, in vitro biological activity, sterility, pyrogen content, TAMC. However, Peptide mapping, Host cell protein, PCR for residual DNA, Isoelectric pH is performed by manufacturer on Drug Substance.
The manufacturer shall perform all tests locally as detailed on Certificate of analysis.	Please refer to Annex – B for Certificate of Analysis (COA) of API manufacturer and FPP manufacturer.
The firm shall also provide the list of finished products being manufactured from same bulk concentrate or ready to fill form in any country of the world (if available).	Getz Pharma is manufacturing following products using same bulk concentrate; - Sem-P Solution for Injection 2mg/1.5mL (Reg No.: 126126) - Sem-P Solution for Injection 4mg/3mL (Reg No.: 126127)
The firm shall provide the agreement with the source (of bulk concentrate/ready to fill) that if there shall be any critical change in manufacturing process, biological systems used to manufacture, etc. the firm shall inform DRAP immediately along with relevant documents.	Please refer to Annex - C for Agreement.
Regular monitoring through pharmacovigilance reporting system shall be observed through proper pharmacovigilance cell of the manufacturer and report will be forwarded to the National Pharmacovigilance Centre, Division of Pharmacy Services and Biological	Please refer to Annex - D for Undertaking.

Division of DRAP. In case of any severe adverse event, immediate mandatory reporting procedure shall be followed.	
The firm shall inform DRAP if there shall be any adverse event or ADR reporting from the country of manufacture of concentrate/ready to fill bulk and finished product as required vide Rules 30 of Drug (LR&A) Rule.	Please refer to Annex - D for Undertaking.
If any of the conditions is not fulfilled or public health risk reported at any stage, the drug registration shall stand cancelled with immediate effect.	Please refer to Annex - D for Undertaking.
The provisions as contained in the Drugs Act, 1976 and rules made there under including provisions of Lot Release certification from National Control Laboratory for Biological shall be strictly adhered to.	Please refer to Annex - D for Undertaking.

Bio similarity Data	
PART A - ADMINISTRATIVE INFORMATION	
Biosimilar Product Information	
Name of the biosimilar medicinal product	Sem-P (Semaglutide) Solution for Injection in Cartridge with Disposable Pen 2mg/1.5mL
Manufacturer	M/s Getz Pharma (Pvt.) Limited Address: Plot No. 29-30, Sector 27, Korangi Industrial Area, Karachi – 74900, Pakistan Semaglutide Concentrate Manufacturer: Hangzhou Jiuyuan Gene Engineering Co., Ltd Address: East of No. 8th Street, Hangzhou Economic and Technological Development Zone China
Name of the active substance	Semaglutide
Pharmaco-therapeutic group	Glucagon-Like peptide-1 (GLP-1) Analogues
Substance category	A10BJ06
Pharmaceutical form	Solution for Injection
Quantitative composition	Each 1.5ml cartridge contains: Semaglutide.....2mg
Route of administration	Sub-cutaneous
Packaging/material	Sem-P Solution for Injection in Cartridge in Disposable Pen 2mg/1.5mL in glass type 1 cartridge is further fitted in disposable pen, packed in a unit carton along with an insert.
Package size(s)	1's (1.5ml Cartridge) in disposable pen.
Reference of biosimilar guidelines	- Technical Guideline for the Research and Assessment of Biosimilars (for trial implementation) - Registration Classification of Biological Products and Application Dossier Requirements - Technical Guidelines for the Similarity Assessment and Indication Extrapolation of Biosimilars Date: February, 2001 - Guidelines for Clinical Trial Design for Biosimilars of Liraglutide Injection Date: May 2020
Reference Biotherapeutic Product (RBP) Information	

	Name of the RBP	Ozempic Injection 2mg/1.5mL
	Authorized indications for RBP	Ozempic is indicated: - As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. - To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease. - As monotherapy when metformin is considered inappropriate due to intolerance or contraindications. - In addition to other medicinal products for the treatment of diabetes.
	Pharmaceutical form	Solution for Injection
	Quantitative composition	Each 1.5ml cartridge contains: Semaglutide.....2mg
	Route of administration	Sub-cutaneous
	Packaging/material	Ozempic Injection is available in prefilled, disposable, single-patient-use pens
	Package size(s)	1's (disposable, single-patient-use pens)
	License number (of RBP)	MHRA: PLGB 04668/0332 USFDA: 209637
	Date of authorization (of RBP)	MHRA: 01/01/2021 USFDA: 12/05/2017
	Authorization (Licence) Holder (of RBP)	MHRA: Novo Nordisk A/S Novo Allé DK-2880 Bagsvaerd Denmark USFDA: Novo Nordisk A/S DK-2880 Bagsvaerd Denmark
	Source of RBP (or other comparator) for comparability exercise	Saccharomyces cerevisiae cells (Yeast Fermentation)
	Availability of the RBP assessment report (language)/link	MHRA: https://mhraproducts4853.blob.core.windows.net/docs/851066223f7ec7aab00effba53bc55a922cb772e USFDA: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s0251b1.pdf
	Summary of outcomes	
	Comparability exercise to demonstrate similarity to RBP	Firm has submitted quality comparison, non-clinical comparison and clinical comparison with RBP.
	Indications applied for (if different to RBP)	Not Applicable

PART B - SUBMITTED DATA AND REVIEWER SUMMARY

Quality data. Composition of the biosimilar product(s)

Each 1.5ml cartridge contains:
Semaglutide.....2mg

Excipients	Quantity (mg/mL)
Propylene Glycol	14.00
Disodium Hydrogen Phosphate Anhydrous	1.13
Phenol	5.61*
Hydrochloric Acid	QS

Sodium Hydroxide	QS
Water for Injection	1.000

* 2% overage of Phenol will be used due to its volatile in nature.

Quality data. State-of-the-art methods

Sem-P Injection has been compared with. Reference Listed Drug (RLD)

The quality attributes characterize biological products in terms of structural, physicochemical and functional properties.

1. Primary Structure
2. Higher Level Structure
3. Biological Profile

Sameness studies

1. Structural comparison

Following robust characterization of drug substance and drug product proves the sameness of Sem-P with RLD.

Primary Structure:

- Molecular Weight
- Isoelectric Point
- Amino Acid composition
- N-terminal amino acid sequence
- C-terminal amino acid sequence
- Sequence Coverage
- Peptide map consistency
- Peptide mapping peak assignment
- Elucidation of fatty acid chain
- Modification analysis

High Level Structures:

- Circular Dichroism
- Fluorescence Spectroscopy

2. Quality Comparison:

Comparative testing of Sem-P with Ozempic (RLD)

- Quality Attributes and Characteristics Considered in Similarity Assessment

Biological bioactivity:

- Albumin Affinity
- GLP-1 receptor affinity
- Stimulation of cAMP in cells in vitro

Impurity Profile:

- **Process related impurities**
 - Potassium dihydrogen phosphate
 - Disodium hydrogen phosphate
 - Sodium chloride
 - Magnesium sulfate
 - Citric acid
 - Magnesium chloride
 - Ammonium sulfate
 - Sodium hydroxide
 - Hydrochloric acid
 - Calcium chloride
 - Ammonium chloride
 - Ammonium hydroxide
 - Potassium hydroxide
 - Tween-20
 - Tris (hydroxymethyl aminomethane)
 - Glacial acetic acid
 - Anhydrous sodium sulfate
 - Sodium dihydrogen phosphate monohydrate

- Phosphoric acid
- Agar powder
- Tryptone
- Peptone
- Yeast extract powder
- Glucose
- Host cell proteins
- Residual DNA
- Bacterial endotoxins
- Microorganism
- Defoamer (Polyoxypropylene oxyethylene glycerol ether)
- Antibiotic (Kanamycin)
- Antibiotic (Chloramphenicol)

▪ **Product Related Impurity**

- 1) High molecular weight proteins
- 2) Hydrophilic impurities
- 3) Hydrophobic impurities 1
- 4) Hydrophobic impurities 2
- 5) Residual solvents
- 6) Elemental Impurities
- 7) Mutagenic impurities

Mechanism of action

Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. GLP-1 is a physiological hormone that has multiple actions on glucose, mediated by the GLP-1 receptors. The principal mechanism of protraction resulting in the long half-life of semaglutide is albumin binding, which results in decreased renal clearance and protection from metabolic degradation. Furthermore, semaglutide is stabilized against degradation by the DPP-4 enzyme. Semaglutide reduces blood glucose through a mechanism where it stimulates insulin secretion and lowers glucagon secretion, both in a glucose-dependent manner. Thus, when blood glucose is high, insulin secretion is stimulated, and glucagon secretion is inhibited. The mechanism of blood glucose lowering also involves a minor delay in gastric emptying in the early postprandial phase.

Nonclinical data. In vitro studies

Firm has submitted in vitro hemolysis Study of SBP with RBP.

Nonclinical data. In vivo studies

Firm has submitted following in vivo studies;

- ***In vivo pharmacological study***
Single-dose PD study in db/db mice
Repeat-dose PD study in db/db mice
- ***Pharmacokinetics/Toxicokinetics***
Single-dose PK study on JY29-2 injection in cynomolgus monkeys
- ***Toxicity study***
Repeat-dose toxicity study

Clinical data. PK studies

Study Number: Semaglutide injection-JY-2021-01 (Version: 1.2 Version Date: January 17, 2022)

Summary of design: A Single-center, Randomized, Open-label, Single-dose (Fasting), Subcutaneous Administration, Two-preparation, Parallel Pharmacokinetic Comparison Study of Semaglutide Injection and Ozempic® in Healthy Male Chinese Subjects

Objective and primary endpoint:

Primary objective: To compare the pharmacokinetics (PK) of semaglutide injection and Ozempic® following a single subcutaneous injection under fasting conditions in healthy Chinese male subjects and to evaluate the bioequivalence of the two preparations.

Secondary objective: To compare the safety of semaglutide injection and Ozempic® in healthy male Chinese subjects.

Primary Endpoints: Cmax, AUC0-t, AUC0-∞.

Secondary Endpoints:

1) Tmax, t1/2, λz, AUC_%Extrap, Vd, CL, AUC0-t/AUC0-∞.

2) Safety endpoints: physical examination, vital signs, laboratory tests, fingertip blood glucose monitoring, 12-lead ECG, adverse events (AEs), serious adverse events (SAEs), positive rate of anti-drug antibodies (ADAs), positive rate of neutralizing antibodies (Nabs), hypoglycaemia events, and injection site observation.

Dose used :

Group T: On Day 1 of the study, subjects received a 0.25 mg subcutaneous injection of semaglutide injection in the abdomen.

Group R: On Day 1 of the study, subjects received a 0.25 mg subcutaneous injection of Ozempic® in the abdomen.

Length of the study:

Date of First Subject's Signing of Informed Consent: December 06, 2021

Date of Last Subject Completion: January 31, 2022

Clinical data. PD Studies

Study Number: JY-2021-05

Summary of design: A Multi-center, Randomized, Open-Label, Parallel-controlled, Phase III Clinical Study Comparing the Efficacy and Safety of Semaglutide Injection Versus Ozempic® in Combination with Metformin in the Treatment of Type 2 Diabetes (T2DM)

Objective: To compare the similarity in efficacy and safety between semaglutide injection developed by Hangzhou Jiuyuan Gene Engineering Co., Ltd. and semaglutide injection (trade name: Ozempic®) manufactured by Novo Nordisk, Denmark, both in combination with metformin, for the treatment of T2DM.

Dose used:

Study Drug	Control Drug	Combination Drug
0.25 mg once weekly from Week 1 to Week 4, 0.5 mg once weekly from Week 5 to Week 8, and 1 mg once weekly from Week 9 to Week 32	0.25 mg once weekly from Week 1 to Week 4, 0.5 mg once weekly from Week 5 to Week 8, and 1 mg once weekly from Week 9 to Week 32	1000 mg/day, or 1500 mg/day, or 2000 mg/day

Primary Efficacy Endpoint:

Change in HbA1c from baseline after 32 weeks of treatment.

Secondary Efficacy Endpoints:

- (1) Change in HbA1c from baseline after 20 weeks of treatment
- (2) Change in fasting venous blood glucose from baseline after 20 weeks of treatment;
- (3) Change in fasting venous blood glucose from baseline after 32 weeks of treatment;

- (4) The proportion of subjects with HbA1c<7.0% after 32 weeks of treatment;
- (5) The proportion of subjects with HbA1c≤6.5% after 32 weeks of treatment;
- (6) The proportion of subjects with HbA1c<7.0% and without hypoglycaemia after 32 weeks of treatment;
- (7) Change in weight from baseline after 32 weeks of treatment;
- (8) Change in systolic blood pressure and diastolic blood pressure from baseline after 32 weeks of treatment;
- (9) Change in pulse from baseline after 32 weeks of treatment
- (10) Change in blood lipids (total cholesterol, low density lipoprotein, high density lipoprotein and triglycerides) from baseline after 32 weeks of treatment.

Study duration: 464 days

Date of first subject signing the informed consent form: July 25, 2022

Date of last subject completing the study: October 31, 2023

Clinical data. Efficacy studies

Study Number: JY-2021-05

Summary of design: A Multi-center, Randomized, Open-Label, Parallel-controlled, Phase III Clinical Study Comparing the Efficacy and Safety of Semaglutide Injection Versus Ozempic® in Combination with Metformin in the Treatment of Type 2 Diabetes (T2DM)

Objective: To compare the similarity in efficacy and safety between semaglutide injection developed by Hangzhou Jiuyuan Gene Engineering Co., Ltd. and semaglutide injection (trade name: Ozempic®) manufactured by Novo Nordisk, Denmark, both in combination with metformin, for the treatment of T2DM.

Dose used:

Primary
Change in
Secondary

Study Drug	Control Drug	Combination Drug
0.25 mg once weekly from Week 1 to Week 4, 0.5 mg once weekly from Week 5 to Week 8, and 1 mg once weekly from Week 9 to Week 32	0.25 mg once weekly from Week 1 to Week 4, 0.5 mg once weekly from Week 5 to Week 8, and 1 mg once weekly from Week 9 to Week 32	1000 mg/day, or 1500 mg/day, or 2000 mg/day

Efficacy Endpoint:

HbA1c from baseline after 32 weeks of treatment.

Efficacy Endpoints:

Change in HbA1c from baseline after 20 weeks of

(1)
treatment

- (2) Change in fasting venous blood glucose from baseline after 20 weeks of treatment;
- (3) Change in fasting venous blood glucose from baseline after 32 weeks of treatment;
- (4) The proportion of subjects with HbA1c<7.0% after 32 weeks of treatment;
- (5) The proportion of subjects with HbA1c≤6.5% after 32 weeks of treatment;
- (6) The proportion of subjects with HbA1c<7.0% and without hypoglycaemia after 32 weeks of treatment;
- (7) Change in weight from baseline after 32 weeks of treatment;

- (8) Change in systolic blood pressure and diastolic blood pressure from baseline after 32 weeks of treatment;
- (9) Change in pulse from baseline after 32 weeks of treatment
- (10) Change in blood lipids (total cholesterol, low density lipoprotein, high density lipoprotein and triglycerides) from baseline after 32 weeks of treatment.

Study duration: 464 days

Date of first subject signing the informed consent form: July 25, 2022

Date of last subject completing the study: October 31, 2023

Clinical data. Safety/ Immunogenicity studies (specify population, dose used, length of the study and comparability margins)

Study Number: JY-2021-05

Summary of design: A Multi-center, Randomized, Open-Label, Parallel-controlled, Phase III Clinical Study Comparing the Efficacy and Safety of Semaglutide Injection Versus Ozempic® in Combination with Metformin in the Treatment of Type 2 Diabetes (T2DM)

Objective: To compare the similarity in efficacy and safety between semaglutide injection developed by Hangzhou Jiuyuan Gene Engineering Co., Ltd. and semaglutide injection (trade name: Ozempic®) manufactured by Novo Nordisk, Denmark, both in combination with metformin, for the treatment of T2DM.

Dose used:

Study Drug	Control Drug	Combination Drug
0.25 mg once weekly from Week 1 to Week 4, 0.5 mg once weekly from Week 5 to Week 8, and 1 mg once weekly from Week 9 to Week 32	0.25 mg once weekly from Week 1 to Week 4, 0.5 mg once weekly from Week 5 to Week 8, and 1 mg once weekly from Week 9 to Week 32	1000 mg/day, or 1500 mg/day, or 2000 mg/day

Primary

Efficacy Endpoint:

Change in HbA1c from baseline after 32 weeks of treatment.

Secondary Efficacy Endpoints:

- (1) Change in HbA1c from baseline after 20 weeks of treatment
- (2) Change in fasting venous blood glucose from baseline after 20 weeks of treatment;
- (3) Change in fasting venous blood glucose from baseline after 32 weeks of treatment;
- (4) The proportion of subjects with HbA1c < 7.0% after 32 weeks of treatment;
- (5) The proportion of subjects with HbA1c ≤ 6.5% after 32 weeks of treatment;
- (6) The proportion of subjects with HbA1c < 7.0% and without hypoglycaemia after 32 weeks of treatment;
- (7) Change in weight from baseline after 32 weeks of treatment;
- (8) Change in systolic blood pressure and diastolic blood pressure from baseline after 32 weeks of treatment;
- (9) Change in pulse from baseline after 32 weeks of treatment

(10 Change in blood lipids (total cholesterol, low density lipoprotein, high density lipoprotein and triglycerides) from baseline after 32 weeks of treatment.

Study duration: 464 days

Date of first subject signing the informed consent form: July 25, 2022

Date of last subject completing the study: October 31, 2023

Decision of 345th Meeting:

Registration Board decided to approve the product “as per innovator’s Specification”

Additionally, after registration the applicant is responsible to perform and submit the following:

- The manufacturer shall perform identification test for peptide mapping for finished product from any of Government Drug Testing Laboratory for every batch and during the aforesaid period the manufacturer shall install LC/MS in their own facility and inform Registration Board.
- Post-authorization safety and efficacy studies as per Rule 11 of the Pharmacovigilance Rules, 2022 and submission of reports on a quarterly basis.
- Actively collect, assess, and report ADRs as per the timelines defined in the Rule 11(5) of the Pharmacovigilance Rules 2022.
- PBRERs (Periodic Benefit Risk Evaluation Reports) as per Rules 11(10) of the Pharmacovigilance Rules.

Case # 13

Name, address of Applicant / Marketing Authorization Holder	M/s Getz Pharma (Pvt) Limited Company Address: Plot No. 29-30, Sector 27, Korangi Industrial Area, Karachi
Name, address of Manufacturing site.	M/s Getz Pharma (Pvt.) Limited Address: Plot No. 29-30, Sector 27, Korangi Industrial Area, Karachi – 74900, Pakistan
GMP status of the firm	GMP of relevant section not submitted.
Evidence of approval of manufacturing facility	DML No. 000284 On December 02, 2024, Central Licensing Division of DRAP has granted section approval of liquid Injection Vials and Cartridges (Biotech-rDNA)
Status of the applicant	☒ Manufacturer
Status of application	SBP
Intended use of pharmaceutical product	☒ Domestic and Export sales
Dy. No. and date of submission	Tracking ID:A8S-982-NNQ5 Application Number:97231 Date of Receiving:17-06-2025
Details of fee submitted	Challan Number: 425230515462 Division: Biological Evaluation & Registration Paid Fee: 300000.0 Paid Date: 2025-04-17
proposed proprietary name/brand name	Sem-P Solution for Injection in Cartridge with Disposable pen 4mg/3mL
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 3mL cartridge contains: Semaglutide..... 4mg
Pharmaceutical form of applied drug	Solution for Injection in Cartridge with Disposable pen
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product	As per Innovator’s Specifications

specifications			
Proposed Pack size	1's Cartridge in Disposable pen		
Proposed unit price	As per SRO 228(I)/2024 dated 19-02-2024		
The status in reference regulatory authorities	OZEMPIC (Semaglutide) solution for injection 4 mg/3 ml (USFDA APPROVED)		
For generic drugs (me-too status)	Ozempic Injection 4mg/3ml by Novo		
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO template.		
Module-III Drug Substance:			
Manufacturer of DS	M/s Hangzhou Jiuyuan Gene Engineering Co., Ltd China Address: East of No. 8th Street, Hangzhou Economic and Technological Development Zone Provided legalized DML valid upto November 08, 2025 by the applicant specifies Semaglutide Injection in its scope.		
Source	This product is a recombinant glucagon-like peptide-1 (GLP-1) receptor agonist expressed and produced by DNA recombination technology and chemical modification in E. coli.		
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API at accelerated and real time conditions. The real time stability data is conducted at (-20°C±5°C) on 3 batches. Accelerated study is conducted at (5±3°C) .		
Module-III Drug Product:			
Manufacturing Site	M/s Getz Pharma (Pvt.) Limited Address: Plot No. 29-30, Sector 27, Korangi Industrial Area, Karachi – 74900, Pakistan		
Container closure system of the drug product	Cartridge in Disposable Pen 4mg/3mL in glass type 1 cartridge is further fitted in disposable pen, packed in a printed carton		
Stability study data of drug product, shelf life and storage conditions	721DS01,721DS02,721DS03 DOM:31-10-2024 3 months stability data submitted by the applicant. Long Term: 5°C± 3°C Accelerated: 25°C ± 2°C and 60% ± 5% R.H		
Storage Conditions	Store in a refrigerator (2°C to 8°C).		
Module 4	Submitted.		
Module 5	Submitted.		
• Remarks of Evaluator: • SMPC under section 1.5.14 is required. • Submit complete commitment for section 1.5.22. • Provide source of concentrate whether synthetic or rDNA. • The HMWP proteins limit should be less than 0.7% at release. • The release specs. should be made stringent for impurities as per innovator. ▪ Hydrophilic Impurities ≤3.8%. ▪ Hydrophobic Impurities 1≤3.5% ▪ Hydrophobic impurities 2≤0.5% ▪ Sum of Impurities ≤6.3% • The stability data of concentrate is of 18 months. Submit stability data till claimed shelf life. • Test of dose accuracy and identification test for peptide mapping to be included in finished product specifications and concentrate. • Evidence of LC MS is required. • Submit stability data of six months as provided data is of 3 month. Submit ADC attested commercial invoice. • Submit documents in the light of 278th guidelines for concentrate			
Sr No.	Query	Response	Remarks of Assessor
1.	SMPC under section 1.5.14 is required.	Please refer to Annexure - 1 for Summary of Product Characteristics (SMPC) of Sem-P (Semaglutide) Solution for Iniection in Cartridge with Disposable	SMPC attached.

		Pen 2mg/1.5mL.	
2.	Submit complete commitment for section 1.5.22.	Please refer to Annexure – 2 for signed & stamped commitment.	Undertaking provided.
3.	Provide source of concentrate whether synthetic or rDNA	Please note that the source of Semaglutide Drug Substance manufactured by M/s Hangzhou Jiuyuan Gene Engineering Co., Ltd. China is rDNA i.e., E. Coli. Please refer to Annexure - 3 for source document of Semaglutide. Please note that t	Host cell The proposed product and the reference product have different expression systems: the host cell of the proposed product is E.coli, while that of reference product is yeast. As per WHO Biosimilarity guidelines different host cell can be used.
4.	The HMWP proteins limit should be less than 0.7% at release.	Please note that the release limit of HMWP in the already submitted Finished Product Specifications is more stringent i.e., Not more than 0.5%.	Submitted.
5.	The release specs. should be made stringent for impurities as per innovator. Hydrophilic Impurities $\leq 3.8\%$ Hydrophobic Impurities 1 $\leq 3.5\%$ Hydrophobic impurities 2 $\leq 0.5\%$ • Sum of Impurities $\leq 6.3\%$	Please note that the release limit of impurities in the already submitted Finished Product Specifications are more stringent i.e., Hydrophilic Impurities: Not more than 2.0% Hydrophobic Impurities 1: Not more than 2.5% Hydrophobic impurities 2: Not more than 0.3% Total Impurities: Not more than 4.5%	More stringent .
6.	The stability data of concentrate is of 18 months. Submit stability data till claimed shelf life.	Please refer to Annexure - 5 for stability data with updated interval till claimed shelf-life of 24 months.	24 months data attached.
7.	Test of dose accuracy and identification test for peptide mapping to be included in finished product specifications and concentrate.	Please refer to Annexure - 4 for updated Finished Product Specification wherein we have included test for dose accuracy. 8 Evidence of LC MS is required. 9 Submit stability data of six months as provided data is of 3 months. Further, please note that in biotechnological products, identification by Peptide Mapping is applicable for Drug Substance as evident by official monographs of European Pharmacopoeia & British Pharmacopoeia. In these Pharmacopoeias, peptide mapping is recommended as an identification test for Drug Substance only and not for the corresponding finished products. Official monographs published in Ph. Eur. & BP for Drug Substances (e.g. Human Insulin & Insulin Glargine) & Finished products (e.g. Injectable Insulin Preparations & Insulin Glargine Injection) are attached for reference. Please refer to Annexure -4 for monographs. Furthermore, the reference product Ozempic PQR data shows that the peptide mapping is only performed on drug substance not on the drug product. Similarly for Getz Pharma product (Semaglutide Injection in Cartridge with disposable pen), Drug Substance manufacturer (Hangzhou Jiuyuan Gene Engineering Co., Ltd. Chin.) has performed identification by peptide mapping on each lot of Semaglutide Drug Substance. Please refer to Annexure – 4 for Certificate of Analysis (COA) of	Dose accuracy test included. Peptide mapping to be performed on the concentrate in case of concentrate import.

		Semaglutide drug substance.	
8.	Evidence of LC MS is required.	Please refer to Annexure - 6 for evidence of LC MS provided by M/s Hangzhou Jiuyuan Gene Engineering Co., Ltd. China.	LC MS of concentrate manufacturer provided.
9.	Submit stability data of six months as provided data is of 3 months.	Please refer to Annexure - 7 for 06 months accelerated and real time stability study data of 03 batches along with raw data sheets, chromatogram	Stability data of six months submitted.
10.	Submit ADC attested commercial invoice.	This is to inform you that DRAP is now issuing computerized Form 6 instead of attesting it by Assistant Drug Controller. Therefore, we have submitted following documents for your kind consideration; 1- Form 6 2- Airway Bill 3- Good Declaration 4- Invoice Please refer to Annexure - 8 for aforementioned documents.	Computerized Form 6 attached.
11.	Submit documents in the light of 278th guidelines for concentrate.	Please refer to Annexure - 9 for the documents in the light of 278th guidelines for concentrate.	Submitted.
12.	Submit bio similarity of finished product as per attached template	Please refer to Annexure - 10 for Bio similarity report as per the format provided by your good office.	Submitted.

DOCUMENTS IN THE LIGHT OF 278 TH GUIDELINES	GETZ PHARMA RESPONSE
The firm shall provide legalized GMP certificate of biological drug substance manufacturer abroad (who will provide concentrate / ready to fill bulk of biological drug to Pakistani manufacturers for further processing) as an evidence that the manufacturer is an authorized manufacturer of biological drug in the country of origin.	Please note that China has stopped issuing GMP Certificate from 2019. Therefore, in lieu of GMP Certificate, we have submitted legalized DML of M/s Hangzhou Jiuyuan Gene Engineering Co., Ltd China as evidence that the manufacturer is an authorized manufacturer of Semaglutide Injection in China.
The firms shall provide legalized free sale certificate/CoPP either from country of origin or by any reference regulatory authority as adopted by Registration Board of finished product as evidence that the final product has been manufactured by same concentrate/ready to fill bulk after submission of data to the concerned regulatory authority.	This is to inform you that in 343 rd RB Meeting, proceedings of the Registration Board states: <i>The Board was already acquainted with the fact that currently Semaglutide drugs are covered under the patent rules in China, that's why these generic products cannot be registered in NMPA (National Medical Product Administration) China, till the expiry of patent and therefore, COPP cannot be issued by the certifying authority.</i> Furthermore, please note that Registration Board in its 336 th RB meeting dated 04 to 06 June, 2024 has approved the product registration of Semaglutide Injection for M/s BF Biosciences Ltd Lahore and M/s Macter International Limited Karachi without submission of CoPP.
The firm shall provide the complete Bio-similarity studies of the finished product of same source (bulk concentrate or ready to fill) manufactured either from country of origin or by any reference regulatory authority as adopted by Registration Board to demonstrate the bio-similarity.	Please refer to Annex – A for Bio similarity studies of Semaglutide by M/s Hangzhou Jiuyuan Gene Engineering Co., Ltd China.
The firm shall provide the lot release certificate of the finished product manufactured by same bulk concentrate / ready to fill from country of export (If applicable).	Not Applicable
The firm shall provide the 6 months accelerated and real time stability studies for drug substance.	Please refer to Annexure – 7 of query response for 6 months accelerated and 24 months real time stability studies for drug substance.
The local manufacturer shall manufacture three trial batches of the finished biological product to finalize the formulation and then perform analytical studies (Physicochemical and biological) including protein content, appearance, pH, Osmolarity, composition of key excipients including stabilizers (if formulation is same), visible subvisible particles, identity testing to parent molecule, purity testing, in vitro biological activity, sterility, Pyrogen content, safety, potency and toxicity with support of iso-electro focusing data, gel electrophoresis, Western-Blot and other analytical techniques. The firm shall submit the results for processing of registration application.	Please note that we have manufactured three stability batches of the finished product and complete test / analysis has been performed as per submitted finished product specification. This is to inform you that isoelectric point is an important structural characterization of protein drugs, which reflects the number and distribution of dissociable groups of acidic and basic amino acids in proteins. The isoelectric points of the self-made sample and the reference product were determined by M/s Hangzhou Jiuyuan Gene Engineering Co., Ltd China on whole column imaging capillary isoelectric focusing electrophoresis. The results showed the isoelectric point was between 4.85 and 4.88, averaging 4.866, the inter-batch relative standard deviation (RSD) was 0.22%, and the relative area was all 100%. The isoelectric point and relative area of the self-made samples had good batch-to-batch consistency and sample-to-sample consistency, and were consistent with that of reference product (Ozempic). The peptide is a well-characterized rDNA-derived molecule with minimal structural variability, and its identity and purity are confirmed by validated orthogonal methods such as RP-HPLC and mass spectrometry which are more precise and advance techniques than gel electrophoresis and Western-Blot. Charge-related characteristics are comprehensively evaluated and controlled at the drug substance stage by the manufacturer. The bulk concentrate is received as a fully purified material with no further purification processing. We performed Analytical testing on bulk concentrate including protein content, appearance, pH, osmolarity, identity testing to parent molecule, purity testing, in vitro biological activity, sterility, Pyrogen content, safety, potency and toxicity with support of iso-electro focusing data, gel electrophoresis, Western-Blot and other analytical techniques. The firm shall submit the results for processing of registration application.

Product Name	
PART A - ADMINISTRATIVE INFORMATION	
	Biosimilar Product Information
Name of the biosimilar medicinal product	Sem-P (Semaglutide) Solution for Injection in Cartridge with Disposable Pen 4mg/3mL
Manufacturer	M/s Getz Pharma (Pvt.) Limited Address: Plot No. 29-30, Sector 27, Korangi Industrial Area, Karachi – 74900, Pakistan Semaglutide Concentrate Manufacturer: Hangzhou Jiuyuan Gene Engineering Co., Ltd Address: East of No. 8th Street, Hangzhou Economic and Technological Development Zone China
Name of the active substance	Semaglutide
Pharmaco-therapeutic group	Glucagon-Like peptide-1 (GLP-1) Analogues
Substance category	A10BJ06
Pharmaceutical form	Solution for Injection
Quantitative composition	Each 3ml cartridge contains: Semaglutide.....4mg
Route of administration	Sub-cutaneous
Packaging/material	Sem-P Solution for Injection in Cartridge in Disposable Pen 4mg/3mL in glass type 1 cartridge is further fitted in disposable pen, packed in a unit carton along with an insert.
Package size(s)	1's (3ml Cartridge) in disposable pen.
Reference of biosimilar guidelines	- Technical Guideline for the Research and Assessment of Biosimilars (for trial implementation) - Registration Classification of Biological Products and Application Dossier Requirements - Technical Guidelines for the Similarity Assessment and Indication Extrapolation of Biosimilars Date: February, 2001 - Guidelines for Clinical Trial Design for Biosimilars of Liraglutide Injection Date: May 2020
	Reference Biotherapeutic Product (RBP) Information
Name of the RBP	Ozempic Injection 4mg/3mL
Authorized indications for RBP	Ozempic is indicated: - As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. - To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease. - As monotherapy when metformin is considered inappropriate due to intolerance or contraindications. - In addition to other medicinal products for the treatment of diabetes.
Pharmaceutical form	Solution for Injection
Quantitative composition	Each 3ml cartridge contains: Semaglutide.....4mg
Route of administration	Sub-cutaneous
Packaging/material	Ozempic Injection is available in prefilled, disposable, single-patient-use pens

	Package size(s)	1's (disposable, single-patient-use pens)
	License number (of RBP)	MHRA: PLGB 04668/0332 USFDA: 209637
	Date of authorization (of RBP)	MHRA: 01/01/2021 USFDA: 12/05/2017
	Authorization (Licence) Holder (of RBP)	MHRA: Novo Nordisk A/S Novo Allé DK-2880 Bagsvaerd Denmark USFDA: Novo Nordisk A/S DK-2880 Bagsvaerd Denmark
	Source of RBP (or other comparator) for comparability exercise	Saccharomyces cerevisiae cells (Yeast Fermentation)
	Availability of the RBP assessment report (language)/link	MHRA: https://mhraproducts4853.blob.core.windows.net/docs/851066223f7ec7aab00effba53bc55a922cb772e USFDA: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s0251bl.pdf
	Summary of outcomes	
	Comparability exercise to demonstrate similarity to RBP	Firm has submitted quality comparison, non-clinical comparison and clinical comparison with RBP.
	Indications applied for (if different to RBP)	Not Applicable

PART B - SUBMITTED DATA AND REVIEWER SUMMARY

Quality data. Composition of the biosimilar product(s)

Each 3ml cartridge contains:

Semaglutide.....4mg

Excipients	Quantity (mg/mL)
Propylene Glycol	14.00
Disodium Hydrogen Phosphate Anhydrous	1.13
Phenol	5.61*
Hydrochloric Acid	QS
Sodium Hydroxide	QS
Water for Injection	1.000

* 2% overage of Phenol will be used due to its volatile in nature.

Quality data. State-of-the-art methods

Sem-P Injection has been compared with. Reference Listed Drug (RLD)

The quality attributes characterize biological products in terms of structural, physicochemical and functional properties.

4. Primary Structure
5. Higher Level Structure
6. Biological Profile

Sameness studies

2. Structural comparison

Following robust characterization of drug substance and drug product proves the sameness of Sem-P with RLD.

Primary Structure:

- Molecular Weight
- Isoelectric Point
- Amino Acid composition
- N-terminal amino acid sequence
- C-terminal amino acid sequence
- Sequence Coverage
- Peptide map consistency

- Peptide mapping peak assignment
- Elucidation of fatty acid chain
- Modification analysis

High Level Structures:

- Circular Dichroism
- Fluorescence Spectroscopy

3. Quality Comparison:

Comparative testing of Sem-P with Ozempic (RLD)

- Quality Attributes and Characteristics Considered in Similarity Assessment

Biological bioactivity:

- Albumin Affinity
- GLP-1 receptor affinity
- Stimulation of cAMP in cells in vitro

Impurity Profile:

- **Process related impurities**
 - Potassium dihydrogen phosphate
 - Disodium hydrogen phosphate
 - Sodium chloride
 - Magnesium sulfate
 - Citric acid
 - Magnesium chloride
 - Ammonium sulfate
 - Sodium hydroxide
 - Hydrochloric acid
 - Calcium chloride
 - Ammonium chloride
 - Ammonium hydroxide
 - Potassium hydroxide
 - Tween-20
 - Tris (hydroxymethyl aminomethane)
 - Glacial acetic acid
 - Anhydrous sodium sulfate
 - Sodium dihydrogen phosphate monohydrate
 - Phosphoric acid
 - Agar powder
 - Tryptone
 - Peptone
 - Yeast extract powder
 - Glucose
 - Host cell proteins
 - Residual DNA
 - Bacterial endotoxins
 - Microorganism
 - Defoamer (Polyoxypropylene oxyethylene glycerol ether)
 - Antibiotic (Kanamycin)
 - Antibiotic (Chloramphenicol)
- **Product Related Impurity**
 - 1) High molecular weight proteins
 - 2) Hydrophilic impurities
 - 3) Hydrophobic impurities 1
 - 4) Hydrophobic impurities 2
 - 5) Residual solvents
 - 6) Elemental Impurities
 - 7) Mutagenic impurities

Mechanism of action

	Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. GLP-1 is a physiological hormone that has multiple actions on glucose, mediated by the GLP-1 receptors. The principal mechanism of protraction resulting in the long half-life of semaglutide is albumin binding, which results in decreased renal clearance and protection from metabolic degradation. Furthermore, semaglutide is stabilized against degradation by the DPP-4 enzyme. Semaglutide reduces blood glucose through a mechanism where it stimulates insulin secretion and lowers glucagon secretion, both in a glucose-dependent manner. Thus, when blood glucose is high, insulin secretion is stimulated, and glucagon secretion is inhibited. The mechanism of blood glucose lowering also involves a minor delay in gastric emptying in the early postprandial phase.
	<u>Nonclinical data. In vitro studies</u>
	Firm has submitted in vitro hemolysis Study of SBP with RBP.
	<u>Nonclinical data. In vivo studies</u>
	Firm has submitted following in vivo studies; • <i>In vivo pharmacological study</i> Single-dose PD study in db/db mice Repeat-dose PD study in db/db mice • <i>Pharmacokinetics/Toxicokinetics</i> Single-dose PK study on JY29-2 injection in cynomolgus monkeys • <i>Toxicity study</i> Repeat-dose toxicity study
	<u>Clinical data. PK studies</u>
	Study Number: Semaglutide injection-JY-2021-01 (Version: 1.2 Version Date: January 17, 2022) Summary of design: A Single-center, Randomized, Open-label, Single-dose (Fasting), Subcutaneous Administration, Two-preparation, Parallel Pharmacokinetic Comparison Study of Semaglutide Injection and Ozempic® in Healthy Male Chinese Subjects Objective and primary endpoint: <i>Primary objective:</i> To compare the pharmacokinetics (PK) of semaglutide injection and Ozempic® following a single subcutaneous injection under fasting conditions in healthy Chinese male subjects and to evaluate the bioequivalence of the two preparations. <i>Secondary objective:</i> To compare the safety of semaglutide injection and Ozempic® in healthy male Chinese subjects. Primary Endpoints: Cmax, AUC0-t, AUC0-∞. Secondary Endpoints: 1) Tmax, t1/2, λz, AUC_%Extrap, Vd, CL, AUC0-t/AUC0-∞. 2) Safety endpoints: physical examination, vital signs, laboratory tests, fingertip blood glucose monitoring, 12-lead ECG, adverse events (AEs), serious adverse events (SAEs), positive rate of anti-drug antibodies (ADAs), positive rate of neutralizing antibodies (Nabs), hypoglycaemia events, and injection site observation. Dose used : Group T: On Day 1 of the study, subjects received a 0.25 mg subcutaneous injection of semaglutide injection in the abdomen. Group R: On Day 1 of the study, subjects received a 0.25 mg subcutaneous injection of Ozempic® in the abdomen. Length of the study: Date of First Subject's Signing of Informed Consent: December 06, 2021 Date of Last Subject Completion: January 31, 2022
	<u>Clinical data. PD Studies</u> Study Number: JY-2021-05 Summary of design: A Multi-center, Randomized, Open-Label, Parallel-controlled, Phase III Clinical Study Comparing the Efficacy and Safety of Semaglutide Injection Versus Ozempic® in Combination with Metformin in the Treatment of Type 2 Diabetes (T2DM)

Objective: To compare the similarity in efficacy and safety between semaglutide injection developed by Hangzhou Jiuyuan Gene Engineering Co., Ltd. and semaglutide injection (trade name: Ozempic®) manufactured by Novo Nordisk, Denmark, both in combination with metformin, for the treatment of T2DM.

Dose used:

Study Drug	Control Drug	Combination Drug
0.25 mg once weekly from Week 1 to Week 4, 0.5 mg once weekly from Week 5 to Week 8, and 1 mg once weekly from Week 9 to Week 32	0.25 mg once weekly from Week 1 to Week 4, 0.5 mg once weekly from Week 5 to Week 8, and 1 mg once weekly from Week 9 to Week 32	1000 mg/day, or 1500 mg/day, or 2000 mg/day

Clinical data. Efficacy studies

Study Number: JY-2021-05

Summary of design: A Multi-center, Randomized, Open-Label, Parallel-controlled, Phase III Clinical Study Comparing the Efficacy and Safety of Semaglutide Injection Versus Ozempic® in Combination with Metformin in the Treatment of Type 2 Diabetes (T2DM)

Objective: To compare the similarity in efficacy and safety between semaglutide injection developed by Hangzhou Jiuyuan Gene Engineering Co., Ltd. and semaglutide injection (trade name: Ozempic®) manufactured by Novo Nordisk, Denmark, both in combination with metformin, for the treatment of T2DM.

Dose used:

Study Drug	Control Drug	Combination Drug
0.25 mg once weekly from Week 1 to Week 4, 0.5 mg once weekly from Week 5 to Week 8, and 1 mg once weekly from Week 9 to Week 32	0.25 mg once weekly from Week 1 to Week 4, 0.5 mg once weekly from Week 5 to Week 8, and 1 mg once weekly from Week 9 to Week 32	1000 mg/day, or 1500 mg/day, or 2000 mg/day

Primary Efficacy Endpoint:

Change in HbA1c from baseline after 32 weeks of treatment.

Secondary Efficacy Endpoints:

- (1) Change in HbA1c from baseline after 20 weeks of treatment
- (2) Change in fasting venous blood glucose from baseline after 20 weeks of treatment;
- (3) Change in fasting venous blood glucose from baseline after 32 weeks of treatment;
- (4) The proportion of subjects with HbA1c<7.0% after 32 weeks of treatment;
- (5) The proportion of subjects with HbA1c≤6.5% after 32 weeks of treatment;
- (6) The proportion of subjects with HbA1c<7.0% and without hypoglycaemia after 32 weeks of treatment;
- (7) Change in weight from baseline after 32 weeks of treatment;
- (8) Change in systolic blood pressure and diastolic blood pressure from baseline after 32 weeks of treatment;
- (9) Change in pulse from baseline after 32 weeks of treatment
- (10) Change in blood lipids (total cholesterol, low density lipoprotein, high density lipoprotein and triglycerides) from baseline after 32 weeks of treatment.

Study duration: 464 days

Date of first subject signing the informed consent form: July 25, 2022

Date of last subject completing the study: October 31, 2023

Clinical data. Safety/ Immunogenicity studies (specify population, dose used, length of the study and comparability margins)

Study Number: JY-2021-05

Summary of design: A Multi-center, Randomized, Open-Label, Parallel-controlled, Phase III Clinical Study Comparing the Efficacy and Safety of Semaglutide Injection Versus Ozempic® in Combination with Metformin in the Treatment of Type 2 Diabetes (T2DM)

Objective: To compare the similarity in efficacy and safety between semaglutide injection developed by Hangzhou Jiuyuan Gene Engineering Co., Ltd. and semaglutide injection (trade name: Ozempic®) manufactured by Novo Nordisk, Denmark, both in combination with metformin, for the treatment of T2DM.

Dose used:

Study Drug	Control Drug	Combination Drug
0.25 mg once weekly from Week 1 to Week 4, 0.5 mg once weekly from Week 5 to Week 8, and 1 mg once weekly from Week 9 to Week 32	0.25 mg once weekly from Week 1 to Week 4, 0.5 mg once weekly from Week 5 to Week 8, and 1 mg once weekly from Week 9 to Week 32	1000 mg/day, or 1500 mg/day, or 2000 mg/day

Primary

Change in treatment.

Secondary

(1)

weeks of

Efficacy Endpoint:

HbA1c from baseline after 32 weeks of

Efficacy Endpoints:

Change in HbA1c from baseline after 20 weeks of treatment

- (2) Change in fasting venous blood glucose from baseline after 20 weeks of treatment;
- (3) Change in fasting venous blood glucose from baseline after 32 weeks of treatment;
- (4) The proportion of subjects with HbA1c<7.0% after 32 weeks of treatment;
- (5) The proportion of subjects with HbA1c≤6.5% after 32 weeks of treatment;
- (6) The proportion of subjects with HbA1c<7.0% and without hypoglycaemia after 32 weeks of treatment;

- (7) Change in weight from baseline after 32 weeks of treatment;
- (8) Change in systolic blood pressure and diastolic blood pressure from baseline after 32 weeks of treatment;
- (9) Change in pulse from baseline after 32 weeks of treatment
- (10) Change in blood lipids (total cholesterol, low density lipoprotein, high density lipoprotein and triglycerides) from baseline after 32 weeks of treatment.

Study duration: 464 days

Date of first subject signing the informed consent form: July 25, 2022

Date of last subject completing the study: October 31, 2023

Safety and immunogenicity data collected from all clinical study.

Study Numbers:

Decision of 345th Meeting:

Registration Board decided to approve product “as per innovator’s Specification”

Additionally, after registration the applicant is responsible to perform and submit the following:

- **The manufacturer shall perform identification test for peptide mapping for finished product from any of Government Drug Testing Laboratory for every batch and during the aforesaid period the manufacturer shall install LC/MS in their own facility and inform Registration Board.**
- **Post-authorization safety and efficacy studies as per Rule 11 of the Pharmacovigilance Rules, 2022 and submission of reports on a quarterly basis.**
- **Actively collect, assess, and report ADRs as per the timelines defined in the Rule 11(5) of the Pharmacovigilance Rules 2022. PBRERs (Periodic Benefit Risk Evaluation Reports) as per Rules 11(10) of the Pharmacovigilance Rules.**

Semaglutide Source: Synthetic Drug Substance Import Local Manufacturing Applied Container Closure System: Alu-Alu Blister Generic of RYBELSUS Tablet	
Case # 14	
Name, address of Applicant / Marketing Authorization Holder	M/s Getz Pharma (Pvt) Limited Company Address: Plot No. 29-30, Sector 27, Korangi Industrial Area, Karachi
Name, address of Manufacturing site.	M/s Getz Pharma (Pvt.) Limited Address: Plot No. 29-30, Sector 27, Korangi Industrial Area, Karachi – 74900, Pakistan
GMP status of the firm	GMP of relevant section not submitted.
Evidence of approval of manufacturing facility	Grant of Additional/Revised Sections Tablet (Biotech) Section New. 12-06-2025
Status of the applicant	☒ Manufacturer
Status of application	SBP
Intended use of pharmaceutical product	☒ Domestic and Export sales
Dy. No. and date of submission	Tracking ID:EZ6-SEG-7YAD Application Number:90468 Date of Receiving:25-06-2025
Details of fee submitted	Challan Number: 8676686211 Division: Biological Evaluation & Registration Paid Fee: 37000.0

	Paid Date: 2024-10-04
proposed proprietary name/brand name	Sem-O Tablets 3mg
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Semaglutide.....3mg
Pharmaceutical form of applied drug	Alu- ALu Blister
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	As per Innovator's Specifications
Proposed Pack size	10's, 14's, 28's, 30's , Alu-Alu blister
Proposed unit price	As per SRO 228(I)/2024 dated 19-02-2024
The status in reference regulatory authorities	RYBELSUS USFDA Approved.
For generic drugs (me-too status)	-
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO template.
Module-III Drug Substance:	
Manufacturer of DS	Manufacturer: Hubei JXBio Pharmaceutical Co.,Ltd (Hubei JXBio) Address: No. 09 Lushan Road, Xian'an Economic Development District, Xianning City, Hubei Province, China DMF Holder: JYMed Technology Co., Limited. Address: 1#-8/F, biomedicine Innovation Industrial Park No. 14 Jinhui road, pingshan District, Shenzhen, GD China.
Source	Synthetic
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Three batches of Semaglutide (Batch number: C005-D210101, C005-D210201 and C005-D210401, Hubei JXBio Pharmaceutical Co., Ltd.) were used in stability study. Accelerated Condition: 2-8C Long term Condition: -20±C
Module-III Drug Product:	
Manufacturing Site	M/s Getz Pharma (Pvt.) Limited Address: Plot No. 29-30, Sector 27, Korangi Industrial Area, Karachi – 74900, Pakistan
Container closure system of the drug product	Alu- ALu blister
Stability study data of drug product, shelf life and storage conditions	Alu- ALu Blister Real time: 30°C ± 2°C / 75% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH Real time: 6 months Accelerated: 6 months Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6, 9, 12, 18, 24 (Months) 657DS04 657DS05 657DS06 590 Tablets 590 Tablets 590 Tablets 05-2024 05-2024 05-2024 05-2026 05-2026 05-2026
Storage Conditions	Do not store above 30°C. Protect from sunlight and moisture.
Module 4	NA
Module 5	NA
Remarks of Evaluator:	

- The manufacturing of tablets is before the grant of section. Clarification is required.
- SMPC under section 1.5.14 is required.
- Submit complete commitment for section 1.5.22.
- The GMP certificate issuing authority is “Pharmaceutical Profession Association of Hubei Province”. Clarification is required whether it is authorized to issue GMP certificate.
- The specification of drug substance does not include identification test by peptide mapping, particle size distribution and biological activity.
- Content of sodium has been determined in the drug substance. Clarification is required for the presence of sodium in the drug substance.
- Clarification is required for Manufacturer and DMF holder as mentioned in section 3.2.S.2.1.
- The COA of semaglutide is from M/s Shenzhen JYMed Technology whereas, the API manufacturer is “Hubei JXBio Pharmaceutical Co.,Ltd (Hubei JXBio)”.
- Provide source of concentrate whether synthetic or rDNA.
- The specification does not include identification by peptide mapping.
- The dissolution specs should be made stringent as per innovator is Q=75% at 30 min and conduct dissolution, accordingly.
- The related substances (A,B,C,D,E) in drug substance part are not included in drug product specification at release and stability.
- The lyophilized powder is used in the manufacturing of tablet and all ingredient are mixed together whereas. Innovator product uses separate granulation of semaglutide and salcaprozoate sodium granules. Clarification/justification is required for the use of lyophilized powder in tablet formulation.
- Submit complete protocol and supporting documents for CDP.CDP at pH 1.2 not performed. Clarification is required.
- Surfactant is used in CDP. Clarification is required and justification is required in the light of reference guidelines.
- The CDP profile for both media i.e. water and pH 6.8 is same. Clarification is required.
- CDP should include both content of semaglutide and SNAC.
- The limits of dissolution are not as per innovator i.e. Q=75% at 30minutes.
- Provide the source of SNAC.
- Bioequivalence studies is required.
- The drug product should include the following specifications uniformity of dosage units, water content, identity by peptide mapping, impurities as mentioned in drug substance part(A,B,C,D,E).
- The comparability of applied product with innovator shall contain all the tests (uniformity of dosage units, water content, identity by peptide mapping, impurities)
- Evidence of LC MS is required.
- Submit ADC attested commercial invoice.
- The manufacturer mentioned on Form 6 is different than as mentioned in dossier.
- Sameness studies as per “ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin” in a tabulated form.

S. No.	Query Items	Getz Pharma Response
1	The manufacturing of tablets is before the grant of section. Clarification is required.	Please note that we have manufactured stability batches of Sem-O (Semaglutide) Tablets 3mg in our R&D Laboratory.
2	SMPC under section 1.5.14 is required.	Please refer to Annexure – 1 for Summary of Product Characteristics (SMPC) of Sem-O (Semaglutide) Tablets 3mg.
3	Submit complete commitment for section 1.5.22.	Please refer to Annexure – 2 for signed & stamped commitment.
4	The GMP certificate issuing authority is “Pharmaceutical Profession Association of Hubei Province”. Clarification is required whether it is authorized to issue GMP certificate.	Please note that China has stopped issuing GMP Certificate from 2019. Therefore, we have submitted GMP certificate issued by Pharmaceutical Profession Association of Hubei Province valid till Jan 08, 2026 China duly apostille by MOFA China. Getz Pharma has also submitted apostilled DML of M/s Hubei JXBio

		Pharmaceutical Co., Ltd (License No.: E 20200336, valid till 02-12-2029) as evidence that the manufacturer is an authorized manufacturer of Semaglutide Drug Substance in China. Furthermore, we are submitting written confirmation certificate issued by Hubei Medical Products Administration (Provincial Regulatory Authority of NMPA) as evidence that the manufacturer is an authorized manufacturer of Semaglutide Drug Substance and complies with the requirements of the Chinese Good Manufacturing Practice. Please refer to Annexure – 3 for DML & GMP Certificate.
5	The specification of drug substance does not include identification test by peptide mapping, particle size distribution and biological activity.	Please note that Getz Pharma has submitted the Drug Substance specification by Drug Substance manufacturer and FPP manufacturer which already includes the tests of identification by peptide mapping & particle size distribution. Moreover, we have updated the Drug Substance specification wherein test of biological activity has been included. Please refer to Annexure – 4 for updated Drug Substance specifications.
6	Content of sodium has been determined in the drug substance. Clarification is required for the presence of sodium in the drug substance.	Please note that there is residual sodium ion due to the sodium ion present in the mobile phase used in the salt forming step for purification. Therefore, test for content of sodium is part of Drug Substance Specifications. Said justification is already provided in Module 3 - section 3.2.S.4.5 of the dossier.
7	Clarification is required for Manufacturer and DMF holder as mentioned in section 3.2.S.2.1.	Please note that the manufacturer of Semaglutide Drug Substance is Hubei JXBio (Jianxiang Biopharmaceutical) Co., Ltd China while Shenzhen JYMed (Jianyuan Medical) Technology Co., Limited China is the DMF Holder and hold 100% share of JXBio i.e.: JYMed owns JXBio. Please refer to Annexure – 5 for article of association confirming ownership of JYMed and declaration letter confirming that M/s Shenzhen JYMed Technology Co., Limited China is the DMF Holder. Please note that all the supplies of Semaglutide to Getz Pharma will be from Hubei JXBio Pharmaceutical Co., Ltd China.
8	The COA of semaglutide is from M/s Shenzhen JYMed Technology whereas, the API manufacturer is “Hubei JXBio Pharmaceutical Co.,Ltd (Hubei JXBio)”.	In continuation to the above justification, please note that at the time of import of Semaglutide Drug Substance the documents were supplied through Shenzhen JYMed Technology Co., Limited China manufactured by Hubei JXBio Pharmaceutical Co., Ltd China. Therefore, COA of Semaglutide is in the name of Shenzhen JYMed Technology. However, all the commercial COAs of Semaglutide will be from M/s Hubei JXBio Pharmaceutical Co., Ltd China. Please refer to Annexure - 6 for COA issued by M/s Hubei JXBio Pharmaceutical Co., Ltd China. Assesor Provide COA of same batch by M/s Hubei JXBio Pharmaceutical Co.,

		Ltd China used in manufacturing of drug product.
9	Provide source of concentrate whether synthetic or rDNA.	Please note that the source of Semaglutide manufactured by M/s Hubei JXBio Pharmaceutical Co., Ltd. is synthetic.
10	The specification does not include identification by peptide mapping.	Please note that in biotechnological products, identification by Peptide Mapping is generally part of Drug Substance specification as evident by official monographs of European Pharmacopoeia & British Pharmacopoeia. In these Pharmacopoeias, peptide mapping is recommended as an identification test for Drug Substance only and not for the corresponding finished products. Official monographs published in Ph. Eur. & BP for APIs (e.g. Human Insulin, & Insulin Glargine) & Finished products (e.g. Injectable Insulin Preparations & Insulin Glargine Injection) are attached for reference. Please refer to Annexure – 7 for monographs. Similarly for Getz Pharma product (Semaglutide Tablet), both Hubei JXBio Pharmaceutical Co. Ltd.) and Getz Pharma are performing identification by peptide mapping at each lot of Drug Substance i.e. Semaglutide. Furthermore, peptide mapping is used primarily for confirming the amino acid sequence, identity, and structural integrity of the peptide or protein. Peptide mapping is performed at the drug substance by manufacturer to confirm the sequence, integrity, and post-translational modifications. Since we are not processing drug substance any further and only formulating it to drug product, therefore, peptide mapping on FPP was not performed In drug product, we perform HMWP and product related impurities as these are sensitive and stability-indicating parameters capable of detecting degradation, aggregation that may occur during formulation or storage.
11	The dissolution specs should be made stringent as per innovator is Q=75% at 30 min and conduct dissolution, accordingly.	Please note that specification limit & dissolution time point (i.e., 45 minutes) have been established as per British Pharmacopoeia general chapter “Appendix XII Recommendations on Dissolution Testing”. Please refer to Annexure – 8a (Page 144 of the attachment) for reference. In the subject general chapter, it is recommended to withdraw samples at 45 minutes and the acceptance criteria should be “Not less than 75% (Q) of the prescribed or stated amount”. As requested, we are submitting updated Finished Product Specification wherein we have incorporated dissolution specs Q=75% at 30 min and we commit that we will implement said specs from next stability interval. Please refer to Annexure – 8b. Furthermore, in USFDA product quality review document of innovator product, sampling time of 45 minutes is recommended in dissolution test. Please note that in dissolution specification, we have finalized more stringent Q value than innovator i.e., Q=80%.

		Please refer to Annexure - 9 (Page 170 of the attachment) for reference.
12	The related substances (A,B,C,D,E) in drug substance part are not included in drug product specification at release and stability.	Please note that in the US-FDA Product Quality Review (PQR) document of the innovator product, the innovator has categorized impurities based on their physicochemical nature as follows: - Hydrophilic Impurities: These impurities elute before the principal peak, as hydrophilic compounds have lower retention capacity in reverse-phase chromatography. - Hydrophobic Impurities: These impurities elute after the principal peak, as hydrophobic compounds exhibit longer retention times in reverse-phase chromatography. Please refer to Annexure - 9 (Page 144 of the attachment) for reference. It is evident from the innovator's PQR data that no individual impurity has been separately identified or specified. To align the reporting pattern of impurities in our finished product specification with that of the innovator, we have revised our specification to include two impurity categories: Hydrophilic Impurities and Hydrophobic Impurities. Please refer to Annexure – 8b for updated Finished Product Specifications. Furthermore, there are multiple official API monographs (Valsartan, Telmisartan, Tadalafil) in which the impurity profile comprises of known impurities but impurity profile of the corresponding finished product (Valsartan Tablet, Telmisartan Tablet, Tadalafil Tablet) only comprises of Individual Unknown Impurity & Total Impurities Please refer to Annexure – 10 for monographs.
13	The lyophilized powder is used in the manufacturing of tablet and all ingredient are mixed together whereas. Innovator product uses separate granulation of Semaglutide and salcaprozate sodium granules. Clarification/justification is required for the use of lyophilized powder in tablet formulation.	Please note that manufacturing process for Sem-O Tablets has been developed using the single dry granulation method, as outlined in the innovator's patent WO 2013/189988 AI – "Tablet Formulation Comprising A Peptide And A Delivery Agent". Link is given below: WO2013189988 TABLET FORMULATION COMPRISING A PEPTIDE AND A DELIVERY AGENT Please note that we have used Semaglutide (Spray Dried) in the manufacturing of Sem-O Tablets as mentioned in the COA of Drug Substance Module 3 – Section 3.2.S.4.4 of dossier. This is further clarify that M/s Hubei JXBio Pharmaceutical Co., Ltd. has established two manufacturing processes for development of Semaglutide Drug Substance while Getz Pharma has received Semaglutide manufactured through spray dried process. Please refer to Annexure - 11 for updated manufacturing process of Semaglutide by spray drying method.
14	Submit complete protocol and supporting documents for CDP. CDP at pH 1.2 not performed. Clarification is required.	Please note that Semaglutide has a low solubility and stability below pH 6. Please refer to Annexure - 9 (Page 140, 167-170 of the attachment) for reference. We have performed the analysis of Rybelsus Tablet 7mg in pH 1.2 medium with 0.05% Brij 35, the dissolution profile (in below table) shows poor/incomplete release of the drug.

			<table><tr><th rowspan="2">Time points</th><th>Rybelsus Tablet 7mg (Dissolution Profile in pH 1.2 with 0.05% Brij 35)</th></tr><tr><th>%Results</th></tr><tr><td>05 minutes</td><td>9.71</td></tr><tr><td>10 minutes</td><td>16.75</td></tr><tr><td>15 minutes</td><td>19.50</td></tr><tr><td>20 minutes</td><td>19.72</td></tr><tr><td>30 minutes</td><td>20.96</td></tr><tr><td>45 minutes</td><td>21.71</td></tr><tr><td>60 minutes</td><td>22.06</td></tr></table>	Time points	Rybelsus Tablet 7mg (Dissolution Profile in pH 1.2 with 0.05% Brij 35)	%Results	05 minutes	9.71	10 minutes	16.75	15 minutes	19.50	20 minutes	19.72	30 minutes	20.96	45 minutes	21.71	60 minutes	22.06
Time points	Rybelsus Tablet 7mg (Dissolution Profile in pH 1.2 with 0.05% Brij 35)																			
	%Results																			
05 minutes	9.71																			
10 minutes	16.75																			
15 minutes	19.50																			
20 minutes	19.72																			
30 minutes	20.96																			
45 minutes	21.71																			
60 minutes	22.06																			
		Therefore, in pH 1.2, the release profile of Innovator and Test Product is insignificant for comparison. Furthermore, purified water was used as an additional medium, as referred in the guideline (WHO TRS 1003 Annex 6). Please refer to Annexure – 12 (Page 264 of the attachment) for reference. for reference. Please refer to Annexure – 13 for Comparative Dissolution Profile Study.																		
15	Surfactant is used in CDP. Clarification is required and justification is required in the light of reference guidelines.	Please note that as per USFDA product quality review document of innovator product, Semaglutide is a BCS Class IV molecule having low solubility profile in all physiological pH range. Furthermore, the innovator’s recommended dissolution method as well as the FDA Dissolution Method Database states the medium with 0.05% Brij 35. Therefore, in order to have release profile of the drug in each pH and appropriate comparison with the innovator, surfactant is used for CDP analysis. Please refer to Annexure - 9 (Page 140, 169-170 of the attachment) for reference.																		
16	The CDP profile for both media i.e., water and pH 6.8 is same. Clarification is required.	This is to bring to your kind information that the pH of purified water is around 6.00 – 7.00 which is approximately similar to the pH of phosphate buffer i.e., 6.8. Due to the similarity in the pH range of purified water and phosphate buffer, Semaglutide has shown similar dissolution profile upon analysis in both mediums.																		
17	CDP should include both content of semaglutide and SNAC.	Please refer to Annexure – 13 for protocol & report of Comparative																		

		Dissolution Profile Study of both content i.e., Semaglutide and SNAC.
18	The limits of dissolution are not as per innovator i.e. Q = 75% at 30minutes.	Please note that specification limit & dissolution time point (i.e., 45 minutes) have been established as per British Pharmacopoeia general chapter "Appendix XII Recommendations on Dissolution Testing". Please refer to Annexure – 8a (Please refer to Annexure – 8a (Page 144 of the attachment) for reference. In the subject general chapter, it is recommended to withdraw samples at 45 minutes and the acceptance criteria should be "Not less than 75%(Q) of the prescribed or stated amount". As requested, we are submitting updated Finished Product Specification wherein we have incorporated dissolution specs Q=75% at 30 min and we commit that we will implement said specs from next stability interval. Please refer to Annexure – 8b. Furthermore, in USFDA product quality review document of innovator product, sampling time of 45 minutes is recommended in dissolution test. Please note that in dissolution specification, we have finalized more stringent Q value than innovator i.e., Q=80%. Please refer to Annexure - 9 (Page 170) for reference.
19	Provide the source of SNAC.	Please refer to Annexure - 14 for the source of SNAC.
20	Bioequivalence studies is required.	We, Getz Pharma (Pvt.) Ltd., commit that we will submit the Bioequivalence studies within 12 months after receiving the product registration certificate from DRAP.
21	The drug product should include the following specifications uniformity of dosage units, water content, identity by peptide mapping, impurities as mentioned in substance part (A, B, C, D, E).	Please refer to aforementioned Point no.: 10 and 12 for justification related to inclusion of peptide mapping and impurities A, B, C, D, E) in drug product specifications. Furthermore, please note that submitted drug product specifications already include uniformity of dosage units and loss of drying.
22	The comparability of applied product with innovator shall contain all the tests (uniformity of dosage units, water content, identity by peptide mapping, impurities)	Please refer to Annexure – 15 for updated Pharmaceutical Equivalence Study.
23	Evidence of LC MS is required.	This is to inform you that that we are performing Identification of Peptide Mapping through HPLC. Please refer to Annexure – 4. For evidence of LC MS from JXBio's contract laboratory, please refer to Annexure – 16.
24	Submit ADC attested commercial invoice.	This is to inform you that DRAP is now issuing computerized Form 6 instead of attesting it by Assistant Drug Controller. Therefore, we have submitted Form 6, Airway Bill and Good Declaration for your kind

		consideration; Please refer to Annexure – 17 for aforementioned documents.
24	The manufacturer mentioned on Form 6 is different than as mentioned in dossier.	In continuation to justification provided in Point no.: 7, please note that at the time of import of Semaglutide Drug Substance the documents were supplied through Shenzhen JYMed Technology Co., Limited China. Therefore, Form 6 is in the name of M/s Shenzhen JYMed Technology.
25	Sameness studies as per “ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin” in a tabulated form.	Please refer to Annexure – 18 for sameness studies in accordance with ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin. Assessor remarks The characterization studies are of lyophilized powder. The sameness studies are required as per “ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin” A. Active Ingredient Sameness Primary sequence and physicochemical properties • Secondary structure • Oligomer/aggregation states • Biological activities (by in vitro or animal studies) B. Impurities
26	The recommended column for peptide analysis C18 whereas, you have used C8. Justification is required in the light of reference guidelines.	Please note that there is no official monograph (i.e. USP, BP, Ph. Eur. JP, Ph. Int.) intended to be followed by drug product manufacturers for analysis of Semaglutide Tablet. Analytical procedure employed in Getz Pharma for analysis of Semaglutide Tablet is an in-house method which has been established by using C8 HPLC column and the subjected method has been adequately validated as per recommendations of ICH guidelines Q2 (R2) “Validation of Analytical Procedures” & USP general chapter <1225> “Validation of Compendial Procedures”.

Decision of 349th Meeting:

The Registration Board deferred the case for the submission of the following documents:

- Certificate of analysis of drug substance by M/s Hubei JXBio Pharmaceutical Co., Ltd China used in manufacturing of drug product.
- Performance of dissolution at 30 minutes’ time interval as per innovator specifications and submission of report.
- Drug substance part of spray dried semaglutide 3.2.S.2 by M/s M/s Hubei JXBio Pharmaceutical Co., Ltd China
- Performance of CDP without surfactant and submission of report.
- Sameness studies in accordance with guidelines for **“Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin”** for spray dried semaglutide including the following tests (Oligomer/aggregation states, Biological activities (by in vitro or animal studies and impurities).

Semaglutide
Source: Synthetic
Drug Substance Import Local Manufacturing
Applied Container Closure System: Alu-Alu Blister
Generic of RYBELSUS Tablet

Case # 15

Name, address of Applicant / Marketing Authorization Holder	M/s Getz Pharma (Pvt) Limited Company Address: Plot No. 29-30, Sector 27, Korangi Industrial Area, Karachi
Name, address of Manufacturing site.	M/s Getz Pharma (Pvt.) Limited Address: Plot No. 29-30, Sector 27, Korangi Industrial Area, Karachi – 74900, Pakistan
GMP status of the firm	GMP of relevant section not submitted.
Evidence of approval of manufacturing facility	Grant of Additional/Revised Sections Tablet (Biotech) Section New. 12-06-2025
Status of the applicant	☒ Manufacturer
Status of application	SBP
Intended use of pharmaceutical product	☒ Domestic and Export sales
Dy. No. and date of submission	Tracking ID:MBU-N1J-EQN7 Application Number:90491 Date of Receiving:25-06-2025
Details of fee submitted	Challan Number: 67276384 Division: Biological Evaluation & Registration Paid Fee: 37000.0 Paid Date: 2024-10-04
proposed proprietary name/brand name	Sem-O Tablets 7mg
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Semaglutide.....7mg
Pharmaceutical form of applied drug	Alu- ALu Blister
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	As per Innovator's Specifications
Proposed Pack size	10's, 14's, 28's, 30's, Alu-Alu blister
Proposed unit price	As per SRO 228(I)/2024 dated 19-02-2024
The status in reference regulatory authorities	RYBELSUS USFDA Approved.
For generic drugs (me-too status)	-
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO template.
Module-III Drug Substance:	
Manufacturer of DS	Manufacturer: Hubei JXBio Pharmaceutical Co.,Ltd (Hubei JXBio) Address: No. 09 Lushan Road, Xian'an Economic Development District, Xianning City, Hubei Province, China DMF Holder: JYMed Technology Co., Limited. Address: 1#-8/F, biomedicine Innovation Industrial Park No. 14 Jinhui road, pingshan District, Shenzhen, GD China.
Source	Synthetic
Stability Studies of Drug Substance (Conditions & duration of	Three batches of Semaglutide (Batch number: C005-D210101, C005-D210201 and C005-D210401, Hubei JXBio Pharmaceutical Co., Ltd.) were used in stability study. Accelerated Condition: 2-8C

Stability studies)	Long term Condition: -20±C
Module-III Drug Product:	
Manufacturing Site	M/s Getz Pharma (Pvt.) Limited Address: Plot No. 29-30, Sector 27, Korangi Industrial Area, Karachi – 74900, Pakistan
Container closure system of the drug product	ALu- ALu blister
Stability study data of drug product, shelf life and storage conditions	Alu- Alu Blister Real time: 30°C ± 2°C / 75% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH Real time: 6 months Accelerated: 6 months Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6, 9, 12, 18, 24 (Months) 657DS01 657DS02 657DS03 DOM :13-05-2024 Data submitted for 6 months.
Storage Conditions	Do not store above 30°C. Protect from sunlight and moisture.
Module 4	NA
Module 5	NA

Remarks of Evaluator:

- The manufacturing of tablets is before the grant of section. Clarification is required.
- SMPC under section 1.5.14 is required.
- Submit complete commitment for section 1.5.22.
- The GMP certificate issuing authority is “Pharmaceutical Profession Association of Hubei Province”. Clarification is required whether it is authorized to issue GMP certificate.
- The specification of drug substance does not include identification test by peptide mapping, particle size distribution and biological activity.
- Content of sodium has been determined in the drug substance. Clarification is required for the presence of sodium in the drug substance.
- Clarification is required for Manufacturer and DMF holder as mentioned in section 3.2.S.2.1.
- The COA of semaglutide is from M/s Shenzhen JYMed Technology whereas, the API manufacturer is “Hubei JXBio Pharmaceutical Co.,Ltd (Hubei JXBio)”.
- Provide source of concentrate whether synthetic or rDNA.
- The specification does not include identification by peptide mapping.
- The dissolution specs should be made stringent as per innovator is Q=75% at 30 min and conduct dissolution, accordingly.
- The related substances (A,B,C,D,E) in drug substance part are not included in drug product specification at release and stability.
- The lyophilized powder is used in the manufacturing of tablet and all ingredient are mixed together whereas. Innovator product uses separate granulation of semaglutide and salcaprozoate sodium granules. Clarification/justification is required for the use of lyophilized powder in tablet formulation.
- Submit complete protocol and supporting documents for CDP.CDP at pH 1.2 not performed. Clarification is required.
- Surfactant is used in CDP. Clarification is required and justification is required in the light of reference guidelines.
- The CDP profile for both media i.e. water and pH 6.8 is same. Clarification is required.
- CDP should include both content of semaglutide and SNAC.
- The limits of dissolution are not as per innovator i.e. Q=75% at 30minutes.
- Provide the source of SNAC.
- Bioequivalence studies is required.
- The drug product should include the following specifications uniformity of dosage units, water content, identity by peptide mapping, impurities as mentioned in drug substance part(A,B,C,D,E).
- The comparability of applied product with innovator shall contain all the tests (uniformity of dosage units, water content, identity by peptide mapping, impurities)
- Evidence of LC MS is required.
- Submit ADC attested commercial invoice.
- The manufacturer mentioned on Form 6 is different than as mentioned in dossier.
- Sameness studies as per “ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin” in a tabulated form.

S. No.	Query Items	Getz Pharma Response
1	The manufacturing of tablets is before the grant of section. Clarification is required.	Please note that we have manufactured stability batches of Sem-O (Semaglutide) Tablets 3mg in our R&D Laboratory.
2	SMPC under section 1.5.14 is required.	Please refer to Annexure – 1 for Summary of Product Characteristics (SMPC) of Sem-O (Semaglutide) Tablets 3mg.
3	Submit complete commitment for section 1.5.22.	Please refer to Annexure – 2 for signed & stamped commitment.
4	The GMP certificate issuing authority is “Pharmaceutical Profession Association of Hubei Province”. Clarification is required whether it is authorized to issue GMP certificate.	Please note that China has stopped issuing GMP Certificate from 2019. Therefore, we have submitted GMP certificate issued by Pharmaceutical Profession Association of Hubei Province valid till Jan 08, 2026 China duly apostille by MOFA China. Getz Pharma has also submitted apostilled DML of M/s Hubei JXBio Pharmaceutical Co., Ltd (License No.: E 20200336, valid till 02-12-2029) as evidence that the manufacturer is an authorized manufacturer of Semaglutide Drug Substance in China. Furthermore, we are submitting written confirmation certificate issued by Hubei Medical Products Administration (Provincial Regulatory Authority of NMPA) as evidence that the manufacturer is an authorized manufacturer of Semaglutide Drug Substance and complies with the requirements of the Chinese Good Manufacturing Practice. Please refer to Annexure – 3 for DML & GMP Certificate.
5	The specification of drug substance does not include identification test by peptide mapping, particle size distribution and biological activity.	Please note that Getz Pharma has submitted the Drug Substance specification by Drug Substance manufacturer and FPP manufacturer which already includes the tests of identification by peptide mapping & particle size distribution. Moreover, we have updated the Drug Substance specification wherein test of biological activity has been included. Please refer to Annexure – 4 for updated Drug Substance specifications.
6	Content of sodium has been determined in the drug substance. Clarification is required for the presence of sodium in the drug substance.	Please note that there is residual sodium ion due to the sodium ion present in the mobile phase used in the salt forming step for purification. Therefore, test for content of sodium is part of Drug Substance Specifications. Said justification is already provided in Module 3 - section 3.2.S.4.5 of the dossier.
7	Clarification is required for Manufacturer and DMF holder as mentioned in section 3.2.S.2.1.	Please note that the manufacturer of Semaglutide Drug Substance is Hubei JXBio (Jianxiang Biopharmaceutical) Co., Ltd China while Shenzhen JYMed (Jianyuan Medical) Technology Co., Limited China is the DMF Holder and hold 100% share of JXBio i.e.: JYMed owns JXBio. Please refer to Annexure – 5 for article of association confirming

		ownership of JYMed and declaration letter confirming that M/s Shenzhen JYMed Technology Co., Limited China is the DMF Holder. Please note that all the supplies of Semaglutide to Getz Pharma will be from Hubei JXBio Pharmaceutical Co., Ltd China.
8	The COA of semaglutide is from M/s Shenzhen JYMed Technology whereas, the API manufacturer is “Hubei JXBio Pharmaceutical Co.,Ltd (Hubei JXBio)”.	In continuation to the above justification, please note that at the time of import of Semaglutide Drug Substance the documents were supplied through Shenzhen JYMed Technology Co., Limited China manufactured by Hubei JXBio Pharmaceutical Co., Ltd China. Therefore, COA of Semaglutide is in the name of Shenzhen JYMed Technology. However, all the commercial COAs of Semaglutide will be from M/s Hubei JXBio Pharmaceutical Co., Ltd China. Please refer to Annexure - 6 for COA issued by M/s Hubei JXBio Pharmaceutical Co., Ltd China.
9	Provide source of concentrate whether synthetic or rDNA.	Please note that the source of Semaglutide manufactured by M/s Hubei JXBio Pharmaceutical Co., Ltd. is synthetic.
10	The specification does not include identification by peptide mapping.	Please note that in biotechnological products, identification by Peptide Mapping is generally part of Drug Substance specification as evident by official monographs of European Pharmacopoeia & British Pharmacopoeia. In these Pharmacopoeias, peptide mapping is recommended as an identification test for Drug Substance only and not for the corresponding finished products. Official monographs published in Ph. Eur. & BP for APIs (e.g. Human Insulin, & Insulin Glargine) & Finished products (e.g. Injectable Insulin Preparations & Insulin Glargine Injection) are attached for reference. Please refer to Annexure – 7 for monographs. Similarly for Getz Pharma product (Semaglutide Tablet), both Hubei JXBio Pharmaceutical Co. Ltd.) and Getz Pharma are performing identification by peptide mapping at each lot of Drug Substance i.e. Semaglutide. Furthermore, peptide mapping is used primarily for confirming the amino acid sequence, identity, and structural integrity of the peptide or protein. Peptide mapping is performed at the drug substance by manufacturer to confirm the sequence, integrity, and post-translational modifications. Since we are not processing drug substance any further and only formulating it to drug product, therefore, peptide mapping on FPP was not performed In drug product, we perform HMWP and product related impurities as these are sensitive and stability-indicating parameters capable of detecting degradation, aggregation that may occur during formulation or storage.
11	The dissolution specs should be made stringent as per innovator is Q=75% at 30 min and conduct dissolution, accordingly.	Please note that specification limit & dissolution time point (i.e., 45 minutes) have been established as per British Pharmacopoeia general chapter “Appendix XII Recommendations on Dissolution Testing”.

		Please refer to Annexure – 8a (Page 144 of the attachment) for reference. In the subject general chapter, it is recommended to withdraw samples at 45 minutes and the acceptance criteria should be “Not less than 75% (Q) of the prescribed or stated amount”. As requested, we are submitting updated Finished Product Specification wherein we have incorporated dissolution specs Q=75% at 30 min and we commit that we will implement said specs from next stability interval. Please refer to Annexure – 8b. Furthermore, in USFDA product quality review document of innovator product, sampling time of 45 minutes is recommended in dissolution test. Please note that in dissolution specification, we have finalized more stringent Q value than innovator i.e., Q=80%. Please refer to Annexure - 9 (Page 170 of the attachment) for reference.
12	The related substances (A,B,C,D,E) in drug substance part are not included in drug product specification at release and stability.	Please note that in the US-FDA Product Quality Review (PQR) document of the innovator product, the innovator has categorized impurities based on their physicochemical nature as follows: • Hydrophilic Impurities: These impurities elute before the principal peak, as hydrophilic compounds have lower retention capacity in reverse-phase chromatography. • Hydrophobic Impurities: These impurities elute after the principal peak, as hydrophobic compounds exhibit longer retention times in reverse-phase chromatography. Please refer to Annexure - 9 (Page 144 of the attachment) for reference. It is evident from the innovator's PQR data that no individual impurity has been separately identified or specified. To align the reporting pattern of impurities in our finished product specification with that of the innovator, we have revised our specification to include two impurity categories: Hydrophilic Impurities and Hydrophobic Impurities. Please refer to Annexure – 8b for updated Finished Product Specifications. Furthermore, there are multiple official API monographs (Valsartan, Telmisartan, Tadalafil) in which the impurity profile comprises of known impurities but impurity profile of the corresponding finished product (Valsartan Tablet, Telmisartan Tablet, Tadalafil Tablet) only comprises of Individual Unknown Impurity & Total Impurities Please refer to Annexure – 10 for monographs.
13	The lyophilized powder is used in the manufacturing of tablet and all ingredient are mixed together whereas. Innovator product uses separate granulation of Semaglutide and salcaprozate sodium	Please note that manufacturing process for Sem-O Tablets has been developed using the single dry granulation method, as outlined in the innovator's patent WO 2013/189988 AI – "Tablet Formulation Comprising A Peptide And A Delivery Agent". Link is given below: WO2013189988 TABLET FORMULATION COMPRISING A

	granules. Clarification/justification is required for the use of lyophilized powder in tablet formulation.	<u>PEPTIDE AND A DELIVERY AGENT</u> Please note that we have we have used Semaglutide (Spray Dried) in the manufacturing of Sem-O Tablets as mentioned in the COA of Drug Substance Module 3 – Section 3.2.S.4.4 of dossier. This is further clarify that M/s Hubei JXBio Pharmaceutical Co., Ltd. has established two manufacturing processes for development of Semaglutide Drug Substance while Getz Pharma has received Semaglutide manufactured through spray dried process. Please refer to Annexure - 11 for updated manufacturing process of Semaglutide by spray drying method.																	
14	Submit complete protocol and supporting documents for CDP. CDP at pH 1.2 not performed. Clarification is required.	Please note that Semaglutide has a low solubility and stability below pH 6. Please refer to Annexure - 9 (Page 140, 167-170 of the attachment) for reference. We have performed the analysis of Rybelsus Tablet 7mg in pH 1.2 medium with 0.05% Brij 35, the dissolution profile (in below table) shows poor/incomplete release of the drug. <table><tr><th rowspan="2">Time points</th><th>Rybelsus Tablet 7mg (Dissolution Profile in pH 1.2 with 0.05% Brij 35)</th></tr><tr><th>%Results</th></tr><tr><td>05 minutes</td><td>9.71</td></tr><tr><td>10 minutes</td><td>16.75</td></tr><tr><td>15 minutes</td><td>19.50</td></tr><tr><td>20 minutes</td><td>19.72</td></tr><tr><td>30 minutes</td><td>20.96</td></tr><tr><td>45 minutes</td><td>21.71</td></tr><tr><td>60 minutes</td><td>22.06</td></tr></table> Therefore, in pH 1.2, the release profile of Innovator and Test Product is insignificant for comparison. Furthermore, purified water was used as an additional medium, as referred in the guideline (WHO TRS 1003 Annex 6). Please refer to Annexure – 12 (Page 264 of the attachment) for reference. for reference. Please refer to Annexure – 13 for Comparative Dissolution Profile Study.	Time points	Rybelsus Tablet 7mg (Dissolution Profile in pH 1.2 with 0.05% Brij 35)	%Results	05 minutes	9.71	10 minutes	16.75	15 minutes	19.50	20 minutes	19.72	30 minutes	20.96	45 minutes	21.71	60 minutes	22.06
Time points	Rybelsus Tablet 7mg (Dissolution Profile in pH 1.2 with 0.05% Brij 35)																		
	%Results																		
05 minutes	9.71																		
10 minutes	16.75																		
15 minutes	19.50																		
20 minutes	19.72																		
30 minutes	20.96																		
45 minutes	21.71																		
60 minutes	22.06																		

15	Surfactant is used in CDP. Clarification is required and justification is required in the light of reference guidelines.	Please note that as per USFDA product quality review document of innovator product, Semaglutide is a BCS Class IV molecule having low solubility profile in all physiological pH range. Furthermore, the innovator's recommended dissolution method as well as the FDA Dissolution Method Database states the medium with 0.05% Brij 35. Therefore, in order to have release profile of the drug in each pH and appropriate comparison with the innovator, surfactant is used for CDP analysis. Please refer to Annexure - 9 (Page 140, 169-170 of the attachment) for reference.
16	The CDP profile for both media i.e., water and pH 6.8 is same. Clarification is required.	This is to bring to your kind information that the pH of purified water is around 6.00 – 7.00 which is approximately similar to the pH of phosphate buffer i.e., 6.8. Due to the similarity in the pH range of purified water and phosphate buffer, Semaglutide has shown similar dissolution profile upon analysis in both mediums.
17	CDP should include both content of semaglutide and SNAC.	Please refer to Annexure – 13 for protocol & report of Comparative Dissolution Profile Study of both content i.e., Semaglutide and SNAC.
18	The limits of dissolution are not as per innovator i.e. Q = 75% at 30minutes.	Please note that specification limit & dissolution time point (i.e., 45 minutes) have been established as per British Pharmacopoeia general chapter “Appendix XII Recommendations on Dissolution Testing”. Please refer to Annexure – 8a (Please refer to Annexure – 8a (Page 144 of the attachment) for reference. In the subject general chapter, it is recommended to withdraw samples at 45 minutes and the acceptance criteria should be “Not less than 75%(Q) of the prescribed or stated amount”. As requested, we are submitting updated Finished Product Specification wherein we have incorporated dissolution specs Q=75% at 30 min and we commit that we will implement said specs from next stability interval. Please refer to Annexure – 8b. Furthermore, in USFDA product quality review document of innovator product, sampling time of 45 minutes is recommended in dissolution test. Please note that in dissolution specification, we have finalized more stringent Q value than innovator i.e., Q=80%. Please refer to Annexure - 9 (Page 170) for reference.
19	Provide the source of SNAC.	Please refer to Annexure - 14 for the source of SNAC.
20	Bioequivalence studies is required.	We, Getz Pharma (Pvt.) Ltd., commit that we will submit the Bioequivalence studies within 12 months after receiving the product registration certificate from DRAP.
21	The drug product should include the following specifications uniformity of dosage	Please refer to aforementioned Point no.: 10 and 12 for justification related to inclusion of peptide mapping and impurities A, B, C, D, E) in

	units, water content, identity by peptide mapping, impurities as mentioned in substance part (A, B, C, D, E).	drug product specifications. Furthermore, please note that submitted drug product specifications already include uniformity of dosage units and loss of drying.
22	The comparability of applied product with innovator shall contain all the tests (uniformity of dosage units, water content, identity by peptide mapping, impurities)	Please refer to Annexure – 15 for updated Pharmaceutical Equivalence Study.
23	Evidence of LC MS is required.	This is to inform you that that we are performing Identification of Peptide Mapping through HPLC. Please refer to Annexure – 4 . For evidence of LC MS from JXBio’s contract laboratory , please refer to Annexure – 16 .
24	Submit ADC attested commercial invoice.	This is to inform you that DRAP is now issuing computerized Form 6 instead of attesting it by Assistant Drug Controller. Therefore, we have submitted Form 6, Airway Bill and Good Declaration for your kind consideration; Please refer to Annexure – 17 for aforementioned documents.
24	The manufacturer mentioned on Form 6 is different than as mentioned in dossier.	In continuation to justification provided in Point no.: 7 , please note that at the time of import of Semaglutide Drug Substance the documents were supplied through Shenzhen JYMed Technology Co., Limited China. Therefore, Form 6 is in the name of M/s Shenzhen JYMed Technology.
25	Sameness studies as per “ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin” in a tabulated form.	Please refer to Annexure – 18 for sameness studies in accordance with ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin.
26	The recommended column for peptide analysis C18 whereas, you have used C8. Justification is required in the light of reference guidelines.	Please note that there is no official monograph (i.e. USP, BP, Ph. Eur. JP, Ph. Int.) intended to be followed by drug product manufacturers for analysis of Semaglutide Tablet. Analytical procedure employed in Getz Pharma for analysis of Semaglutide Tablet is an in-house method which has been established by using C8 HPLC column and the subjected method has been adequately validated as per recommendations of ICH guidelines Q2 (R2) “Validation of Analytical Procedures” & USP general chapter <1225> “Validation of Compendial Procedures”.

Decision of 349th Meeting:

The Registration Board deferred the case for the submission of the following documents:

- Certificate of analysis of drug substance by M/s Hubei JXBio Pharmaceutical Co., Ltd China used in manufacturing of drug product.
- Performance of dissolution at 30 minutes’ time interval as per innovator specifications and submission of report.
- Drug substance part of spray dried semaglutide 3.2.S.2 by M/s M/s Hubei JXBio Pharmaceutical Co., Ltd China
- Performance of CDP without surfactant and submission of report.
- Sameness studies in accordance with guideliness for **“Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin”** for spray dried semaglutide including the following tests (Oligomer/aggregation states, Biological activities (by in vitro or animal studies and impurities).

Semaglutide
Source: Synthetic
Drug Substance Import Local Manufacturing
Applied Container Closure System: Alu-Alu Blister
Generic of RYBELSUS Tablet

Case # 16

Name, address of Applicant / Marketing Authorization Holder	M/s Getz Pharma (Pvt) Limited Company Address: Plot No. 29-30, Sector 27, Korangi Industrial Area, Karachi
Name, address of Manufacturing site.	M/s Getz Pharma (Pvt.) Limited Address: Plot No. 29-30, Sector 27, Korangi Industrial Area, Karachi – 74900, Pakistan
GMP status of the firm	GMP of relevant section not submitted.
Evidence of approval of manufacturing facility	Grant of Additional/Revised Sections Tablet (Biotech) Section New. 12-06-2025
Status of the applicant	☒ Manufacturer
Status of application	SBP
Intended use of pharmaceutical product	☒ Domestic and Export sales
Dy. No. and date of submission	Tracking ID:S2J-1UQ-YP6X Application Number:90520 Date of Receiving:25-06-2025
Details of fee submitted	Challan Number: 86546689173 Division: Biological Evaluation & Registration Paid Fee: 37000.0 Paid Date: 2024-10-04
proposed proprietary name/brand name	Sem-O Tablets 14mg
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Semaglutide.....14mg
Pharmaceutical form of applied drug	Alu- ALu Blister
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	As per Innovator's Specifications
Proposed Pack size	10's, 14's, 28's, 30's , Alu-Alu blister
Proposed unit price	As per SRO 228(I)/2024 dated 19-02-2024
The status in reference regulatory authorities	RYBELSUS USFDA Approved.
For generic drugs (me-too status)	-
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO template.
Module-III Drug Substance:	
Manufacturer of DS	Manufacturer: Hubei JXBio Pharmaceutical Co.,Ltd (Hubei JXBio) Address: No. 09 Lushan Road, Xian'an Economic Development District, Xianning City, Hubei Province, China DMF Holder: JYMed Technology Co., Limited. Address: 1#-8/F, biomedicine Innovation Industrial Park No. 14 Jinhui road, pingshan District,

	Shenzhen, GD China.
Source	Synthetic
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Three batches of Semaglutide (Batch number: C005-D210101, C005-D210201 and C005-D210401, Hubei JXBio Pharmaceutical Co., Ltd.) were used in stability study. Accelerated Condition: 2-8C Long term Condition: -20±C
Module-III Drug Product:	
Manufacturing Site	M/s Getz Pharma (Pvt.) Limited Address: Plot No. 29-30, Sector 27, Korangi Industrial Area, Karachi – 74900, Pakistan
Container closure system of the drug product	ALu- ALu blister
Stability study data of drug product, shelf life and storage conditions	Alu- Alu Blister Real time: 30°C ± 2°C / 75% ± 5%RH Accelerated: 40°C ± 2°C / 75% ± 5%RH Real time: 6 months Accelerated: 6 months Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6, 9, 12, 18, 24 (Months) 670DS01 670DS02 670DS03 DOM :16-05-2024 Data submitted for 6 months.
Storage Conditions	Do not store above 30°C. Protect from sunlight and moisture.
Module 4	NA
Module 5	NA

Remarks of Evaluator:

- The manufacturing of tablets is before the grant of section. Clarification is required.
- SMPC under section 1.5.14 is required.
- Submit complete commitment for section 1.5.22.
- The GMP certificate issuing authority is “Pharmaceutical Profession Association of Hubei Province”. Clarification is required whether it is authorized to issue GMP certificate.
- The specification of drug substance does not include identification test by peptide mapping, particle size distribution and biological activity.
- Content of sodium has been determined in the drug substance. Clarification is required for the presence of sodium in the drug substance.
- Clarification is required for Manufacturer and DMF holder as mentioned in section 3.2.S.2.1.
- The COA of semaglutide is from M/s Shenzhen JYMed Technology whereas, the API manufacturer is “Hubei JXBio Pharmaceutical Co.,Ltd (Hubei JXBio)”.
- Provide source of concentrate whether synthetic or rDNA.
- The specification does not include identification by peptide mapping.
- The dissolution specs should be made stringent as per innovator is Q=75% at 30 min and conduct dissolution, accordingly.
- The related substances (A,B,C,D,E) in drug substance part are not included in drug product specification at release and stability.
- The lyophilized powder is used in the manufacturing of tablet and all ingredient are mixed together whereas. Innovator product uses separate granulation of semaglutide and salcaprozoate sodium granules. Clarification/justification is required for the use of lyophilized powder in tablet formulation.
- Submit complete protocol and supporting documents for CDP.CDP at pH 1.2 not performed. Clarification is required.
- Surfactant is used in CDP. Clarification is required and justification is required in the light of reference guidelines.
- The CDP profile for both media i.e. water and pH 6.8 is same. Clarification is required.
- CDP should include both content of semaglutide and SNAC.
- The limits of dissolution are not as per innovator i.e. Q=75% at 30minutes.
- Provide the source of SNAC.
- Bioequivalence studies is required.
- The drug product should include the following specifications uniformity of dosage units, water content, identity by peptide mapping, impurities as mentioned in drug substance part(A,B,C,D,E).
- The comparability of applied product with innovator shall contain all the tests (uniformity of dosage units, water content, identity by peptide mapping, impurities)

- Evidence of LC MS is required.
- Submit ADC attested commercial invoice.
- The manufacturer mentioned on Form 6 is different than as mentioned in dossier.
- Sameness studies as per “ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin” in a tabulated form.

Conclusion:

S. No.	Query Items	Getz Pharma Response
1	The manufacturing of tablets is before the grant of section. Clarification is required.	Please note that we have manufactured stability batches of Sem-O (Semaglutide) Tablets 3mg in our R&D Laboratory.
2	SMPC under section 1.5.14 is required.	Please refer to Annexure – 1 for Summary of Product Characteristics (SMPC) of Sem-O (Semaglutide) Tablets 3mg.
3	Submit complete commitment for section 1.5.22.	Please refer to Annexure – 2 for signed & stamped commitment.
4	The GMP certificate issuing authority is “Pharmaceutical Profession Association of Hubei Province”. Clarification is required whether it is authorized to issue GMP certificate.	Please note that China has stopped issuing GMP Certificate from 2019. Therefore, we have submitted GMP certificate issued by Pharmaceutical Profession Association of Hubei Province valid till Jan 08, 2026 China duly apostille by MOFA China. Getz Pharma has also submitted apostilled DML of M/s Hubei JXBio Pharmaceutical Co., Ltd (License No.: E 20200336, valid till 02-12-2029) as evidence that the manufacturer is an authorized manufacturer of Semaglutide Drug Substance in China. Furthermore, we are submitting written confirmation certificate issued by Hubei Medical Products Administration (Provincial Regulatory Authority of NMPA) as evidence that the manufacturer is an authorized manufacturer of Semaglutide Drug Substance and complies with the requirements of the Chinese Good Manufacturing Practice. Please refer to Annexure – 3 for DML & GMP Certificate.
5	The specification of drug substance does not include identification test by peptide mapping, particle size distribution and biological activity.	Please note that Getz Pharma has submitted the Drug Substance specification by Drug Substance manufacturer and FPP manufacturer which already includes the tests of identification by peptide mapping & particle size distribution. Moreover, we have updated the Drug Substance specification wherein test of biological activity has been included. Please refer to Annexure – 4 for updated Drug Substance specifications.
6	Content of sodium has been determined in the drug substance. Clarification is required for the presence of sodium in the drug substance.	Please note that there is residual sodium ion due to the sodium ion present in the mobile phase used in the salt forming step for purification. Therefore, test for content of sodium is part of Drug Substance Specifications. Said justification is already provided in Module 3 - section 3.2.S.4.5 of the dossier.

7	Clarification is required for Manufacturer and DMF holder as mentioned in section 3.2.S.2.1.	Please note that the manufacturer of Semaglutide Drug Substance is Hubei JXBio (Jianxiang Biopharmaceutical) Co., Ltd China while Shenzhen JYMed (Jianyuan Medical) Technology Co., Limited China is the DMF Holder and hold 100% share of JXBio i.e.: JYMed owns JXBio. Please refer to Annexure – 5 for article of association confirming ownership of JYMed and declaration letter confirming that M/s Shenzhen JYMed Technology Co., Limited China is the DMF Holder. Please note that all the supplies of Semaglutide to Getz Pharma will be from Hubei JXBio Pharmaceutical Co., Ltd China.
8	The COA of semaglutide is from M/s Shenzhen JYMed Technology whereas, the API manufacturer is “Hubei JXBio Pharmaceutical Co.,Ltd (Hubei JXBio)”.	In continuation to the above justification, please note that at the time of import of Semaglutide Drug Substance the documents were supplied through Shenzhen JYMed Technology Co., Limited China manufactured by Hubei JXBio Pharmaceutical Co., Ltd China. Therefore, COA of Semaglutide is in the name of Shenzhen JYMed Technology. However, all the commercial COAs of Semaglutide will be from M/s Hubei JXBio Pharmaceutical Co., Ltd China. Please refer to Annexure - 6 for COA issued by M/s Hubei JXBio Pharmaceutical Co., Ltd China.
9	Provide source of concentrate whether synthetic or rDNA.	Please note that the source of Semaglutide manufactured by M/s Hubei JXBio Pharmaceutical Co., Ltd. is synthetic.
10	The specification does not include identification by peptide mapping.	Please note that in biotechnological products, identification by Peptide Mapping is generally part of Drug Substance specification as evident by official monographs of European Pharmacopoeia & British Pharmacopoeia. In these Pharmacopoeias, peptide mapping is recommended as an identification test for Drug Substance only and not for the corresponding finished products. Official monographs published in Ph. Eur. & BP for APIs (e.g. Human Insulin, & Insulin Glargine) & Finished products (e.g. Injectable Insulin Preparations & Insulin Glargine Injection) are attached for reference. Please refer to Annexure – 7 for monographs. Similarly for Getz Pharma product (Semaglutide Tablet), both Hubei JXBio Pharmaceutical Co. Ltd.) and Getz Pharma are performing identification by peptide mapping at each lot of Drug Substance i.e. Semaglutide. Furthermore, peptide mapping is used primarily for confirming the amino acid sequence, identity, and structural integrity of the peptide or protein. Peptide mapping is performed at the drug substance by manufacturer to confirm the sequence, integrity, and post-translational modifications. Since we are not processing drug substance any further and only formulating it to drug product, therefore, peptide mapping on FPP was not performed In drug product, we perform HMWP and product related impurities as these are sensitive and stability-indicating parameters capable of

		detecting degradation, aggregation that may occur during formulation or storage.
11	The dissolution specs should be made stringent as per innovator is Q=75% at 30 min and conduct dissolution, accordingly.	Please note that specification limit & dissolution time point (i.e., 45 minutes) have been established as per British Pharmacopoeia general chapter “Appendix XII Recommendations on Dissolution Testing”. Please refer to Annexure – 8a (Page 144 of the attachment) for reference. In the subject general chapter, it is recommended to withdraw samples at 45 minutes and the acceptance criteria should be “Not less than 75% (Q) of the prescribed or stated amount”. As requested, we are submitting updated Finished Product Specification wherein we have incorporated dissolution specs Q=75% at 30 min and we commit that we will implement said specs from next stability interval. Please refer to Annexure – 8b. Furthermore, in USFDA product quality review document of innovator product, sampling time of 45 minutes is recommended in dissolution test. Please note that in dissolution specification, we have finalized more stringent Q value than innovator i.e., Q=80%. Please refer to Annexure - 9 (Page 170 of the attachment) for reference.
12	The related substances (A,B,C,D,E) in drug substance part are not included in drug product specification at release and stability.	Please note that in the US-FDA Product Quality Review (PQR) document of the innovator product, the innovator has categorized impurities based on their physicochemical nature as follows: • Hydrophilic Impurities: These impurities elute before the principal peak, as hydrophilic compounds have lower retention capacity in reverse-phase chromatography. • Hydrophobic Impurities: These impurities elute after the principal peak, as hydrophobic compounds exhibit longer retention times in reverse-phase chromatography. Please refer to Annexure - 9 (Page 144 of the attachment) for reference. It is evident from the innovator's PQR data that no individual impurity has been separately identified or specified. To align the reporting pattern of impurities in our finished product specification with that of the innovator, we have revised our specification to include two impurity categories: Hydrophilic Impurities and Hydrophobic Impurities. Please refer to Annexure – 8b for updated Finished Product Specifications. Furthermore, there are multiple official API monographs (Valsartan, Telmisartan, Tadalafil) in which the impurity profile comprises of known impurities but impurity profile of the corresponding finished product (Valsartan Tablet, Telmisartan Tablet, Tadalafil Tablet) only comprises of Individual Unknown Impurity & Total Impurities Please

		refer to Annexure – 10 for monographs.																	
13	The lyophilized powder is used in the manufacturing of tablet and all ingredient are mixed together whereas. Innovator product uses separate granulation of Semaglutide and salcaprozate sodium granules. Clarification/justification is required for the use of lyophilized powder in tablet formulation.	Please note that manufacturing process for Sem-O Tablets has been developed using the single dry granulation method, as outlined in the innovator's patent WO 2013/189988 AI – "Tablet Formulation Comprising A Peptide And A Delivery Agent". Link is given below: WO2013189988 TABLET FORMULATION COMPRISING A PEPTIDE AND A DELIVERY AGENT Please note that we have we have used Semaglutide (Spray Dried) in the manufacturing of Sem-O Tablets as mentioned in the COA of Drug Substance Module 3 – Section 3.2.S.4.4 of dossier. This is further clarify that M/s Hubei JXBio Pharmaceutical Co., Ltd. has established two manufacturing processes for development of Semaglutide Drug Substance while Getz Pharma has received Semaglutide manufactured through spray dried process. Please refer to Annexure - 11 for updated manufacturing process of Semaglutide by spray drying method.																	
14	Submit complete protocol and supporting documents for CDP. CDP at pH 1.2 not performed. Clarification is required.	Please note that Semaglutide has a low solubility and stability below pH 6. Please refer to Annexure - 9 (Page 140, 167-170 of the attachment) for reference. We have performed the analysis of Rybelsus Tablet 7mg in pH 1.2 medium with 0.05% Brij 35, the dissolution profile (in below table) shows poor/incomplete release of the drug. <table><tr><th rowspan="2">Time points</th><th>Rybelsus Tablet 7mg (Dissolution Profile in pH 1.2 with 0.05% Brij 35)</th></tr><tr><th>%Results</th></tr><tr><td>05 minutes</td><td>9.71</td></tr><tr><td>10 minutes</td><td>16.75</td></tr><tr><td>15 minutes</td><td>19.50</td></tr><tr><td>20 minutes</td><td>19.72</td></tr><tr><td>30 minutes</td><td>20.96</td></tr><tr><td>45 minutes</td><td>21.71</td></tr><tr><td>60 minutes</td><td>22.06</td></tr></table> Therefore, in pH 1.2, the release profile of Innovator and Test Product is insignificant for comparison. Furthermore, purified water was used as an additional medium, as referred in the guideline (WHO TRS 1003 Annex 6).	Time points	Rybelsus Tablet 7mg (Dissolution Profile in pH 1.2 with 0.05% Brij 35)	%Results	05 minutes	9.71	10 minutes	16.75	15 minutes	19.50	20 minutes	19.72	30 minutes	20.96	45 minutes	21.71	60 minutes	22.06
Time points	Rybelsus Tablet 7mg (Dissolution Profile in pH 1.2 with 0.05% Brij 35)																		
	%Results																		
05 minutes	9.71																		
10 minutes	16.75																		
15 minutes	19.50																		
20 minutes	19.72																		
30 minutes	20.96																		
45 minutes	21.71																		
60 minutes	22.06																		

		Please refer to Annexure – 12 (Page 264 of the attachment) for reference. for reference. Please refer to Annexure – 13 for Comparative Dissolution Profile Study.
15	Surfactant is used in CDP. Clarification is required and justification is required in the light of reference guidelines.	Please note that as per USFDA product quality review document of innovator product, Semaglutide is a BCS Class IV molecule having low solubility profile in all physiological pH range. Furthermore, the innovator's recommended dissolution method as well as the FDA Dissolution Method Database states the medium with 0.05% Brij 35. Therefore, in order to have release profile of the drug in each pH and appropriate comparison with the innovator, surfactant is used for CDP analysis. Please refer to Annexure - 9 (Page 140, 169-170 of the attachment) for reference.
16	The CDP profile for both media i.e., water and pH 6.8 is same. Clarification is required.	This is to bring to your kind information that the pH of purified water is around 6.00 – 7.00 which is approximately similar to the pH of phosphate buffer i.e., 6.8. Due to the similarity in the pH range of purified water and phosphate buffer, Semaglutide has shown similar dissolution profile upon analysis in both mediums.
17	CDP should include both content of semaglutide and SNAC.	Please refer to Annexure – 13 for protocol & report of Comparative Dissolution Profile Study of both content i.e., Semaglutide and SNAC.
18	The limits of dissolution are not as per innovator i.e. Q = 75% at 30minutes.	Please note that specification limit & dissolution time point (i.e., 45 minutes) have been established as per British Pharmacopoeia general chapter "Appendix XII Recommendations on Dissolution Testing". Please refer to Annexure – 8a (Please refer to Annexure – 8a (Page 144 of the attachment) for reference. In the subject general chapter, it is recommended to withdraw samples at 45 minutes and the acceptance criteria should be "Not less than 75%(Q) of the prescribed or stated amount". As requested, we are submitting updated Finished Product Specification wherein we have incorporated dissolution specs Q=75% at 30 min and we commit that we will implement said specs from next stability interval. Please refer to Annexure – 8b. Furthermore, in USFDA product quality review document of innovator product, sampling time of 45 minutes is recommended in dissolution test. Please note that in dissolution specification, we have finalized more stringent Q value than innovator i.e., Q=80%. Please refer to Annexure - 9 (Page 170) for reference.

19	Provide the source of SNAC.	Please refer to Annexure - 14 for the source of SNAC.
20	Bioequivalence studies is required.	We, Getz Pharma (Pvt.) Ltd., commit that we will submit the Bioequivalence studies within 12 months after receiving the product registration certificate from DRAP.
21	The drug product should include the following specifications uniformity of dosage units, water content, identity by peptide mapping, impurities as mentioned in substance part (A, B, C, D, E).	Please refer to aforementioned Point no.: 10 and 12 for justification related to inclusion of peptide mapping and impurities A, B, C, D, E) in drug product specifications. Furthermore, please note that submitted drug product specifications already include uniformity of dosage units and loss of drying.
22	The comparability of applied product with innovator shall contain all the tests (uniformity of dosage units, water content, identity by peptide mapping, impurities)	Please refer to Annexure – 15 for updated Pharmaceutical Equivalence Study.
23	Evidence of LC MS is required.	This is to inform you that that we are performing Identification of Peptide Mapping through HPLC. Please refer to Annexure – 4 . For evidence of LC MS from JXBio's contract laboratory , please refer to Annexure – 16 .
24	Submit ADC attested commercial invoice.	This is to inform you that DRAP is now issuing computerized Form 6 instead of attesting it by Assistant Drug Controller. Therefore, we have submitted Form 6, Airway Bill and Good Declaration for your kind consideration; Please refer to Annexure – 17 for aforementioned documents.
24	The manufacturer mentioned on Form 6 is different than as mentioned in dossier.	In continuation to justification provided in Point no.: 7 , please note that at the time of import of Semaglutide Drug Substance the documents were supplied through Shenzhen JYMed Technology Co., Limited China. Therefore, Form 6 is in the name of M/s Shenzhen JYMed Technology.
25	Sameness studies as per “ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin” in a tabulated form.	Please refer to Annexure – 18 for sameness studies in accordance with ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin.
26	The recommended column for peptide analysis C18 whereas, you have used C8. Justification is required in the light of reference guidelines.	Please note that there is no official monograph (i.e. USP, BP, Ph. Eur. JP, Ph. Int.) intended to be followed by drug product manufacturers for analysis of Semaglutide Tablet. Analytical procedure employed in Getz Pharma for analysis of Semaglutide Tablet is an in-house method which has been established by using C8 HPLC column and the subjected method has been adequately validated as per recommendations of ICH guidelines Q2 (R2) “Validation of Analytical Procedures” & USP general chapter <1225> “Validation of Compendial Procedures”.
Decision of 349th Meeting: The Registration Board deferred the case for the submission of the following documents: • Certificate of analysis of drug substance by M/s Hubei JXBio Pharmaceutical Co., Ltd China used in manufacturing of drug product.		

- Performance of dissolution at 30 minutes' time interval as per innovator specifications and submission of report.
- Drug substance part of spray dried semaglutide 3.2.S.2 by M/s M/s Hubei JXBio Pharmaceutical Co., Ltd China
- Performance of CDP without surfactant and submission of report.
- Sameness studies in accordance with guideliness for **“Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin”** for spray dried semaglutide including the following tests (Oligomer/aggregation states, Biological activities (by in vitro or animal studies and impurities).

Semaglutide
Source: rDNA
Drug Substance Import Local Manufacturing
Applied Container Closure System: Vial
Biosimilar to Ozempic Injection

Case # 17

Name, address of Applicant / Marketing Authorization Holder	Company Name: Hilton Pharma (Pvt) Limited. Company Address: Plot No. 13-14 & 43, Sector-15, Korangi Industrial Area
Name, address of Manufacturing site.	Company Address: Plot No. 13-14 & 43, Sector-15, Korangi Industrial Area Date of renewal: 23-10-2024
GMP status of the firm	GMP certificate for inspection conducted on 20, Jan,2025
Evidence of approval of manufacturing facility	Additional section Biotech Facility granted on Feb 2013. Doesnot mention SVP vial.
Status of the applicant	☒ Manufacturer
Status of application	SBP
Intended use of pharmaceutical product	☒ Domestic and Export sales
Dy. No. and date of submission	Tracking ID:JA6-SZ4-ZRQP Application Number:104787 Date of Receiving:10-07-2025
Details of fee submitted	Challan Number: 233621909390 Division: Biological Evaluation & Registration Paid Fee: 75000.0 Paid Date: 2025-05-26
proposed proprietary name/brand name	Semhil Injection 2mg/3ml
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each multi dose vial contains: Semaglutide....2mg/3ml
Pharmaceutical form of applied drug	Liquid solution for injection by SC.
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC code: A10BJ06
Reference to Finished product specifications	As per innovator's specification
Proposed Pack size	1's
Proposed unit price	As per Drug pricing committee
The status in reference regulatory	Ozempic Semaglutide 2mg/3ml (0.68mg/ml)

authorities	
For generic drugs (me-too status)	--
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO template.
Module-III Drug Substance:	
Manufacturer of DS	Release testing, stability testing and storage Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. No. 866 Moganshan Road, Hangzhou, 310011, China Manufacturing, packaging, labeling for Semaglutide and release testing for intermediates of Semaglutide Hangzhou Zhongmei Huadong Pharmaceutical Jiangdong Co., Ltd. No. 7278 Meilin Avenue, Dajiangdong Industrial Cluster Zone, Hangzhou, 311228, China
Source	Semaglutide precursor (S4K) is firstly expressed in Escherichia coli by fermentation culture, followed by digested the precursor by enzyme.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Accelerated study is conducted at (5±3°C) for 6 months on 3 batches of API. Three production batches of Semaglutide (Batch No.: 220503AJ, 220601AJ, 220602AJ) manufactured by current manufacturing process were selected to use for the study of accelerated stability (5 °C±3 °C) and long-term stability (-20 °C±5 °C). All stability samples are packaged in two layers of polyethylene bags and then one layer of aluminum-plastic compound bag. Long term 18 months data submitted.
Module-III Drug Product:	
Manufacturing Site	Hilton Pharma (Pvt.) Ltd. Plot No. 13-14 & 43, Sector 15, Korangi Industrial Area Karachi, Pakistan.
Container closure system of the drug product	USP Type I, 3mL, Glass Vials with rubber stopper and aluminum seal then packed in printed carton along with leaflet
Stability study data of drug product, shelf life and storage conditions	SEM-1283-04/24, SEM-1284-05/24, SEM-1285-06/24 Batch Size: Batch Number: SEM-1283-04/24 Batch size: 600mL (200 Vials) Batch Number: SEM-1284-05/24 Batch size: 600mL (200 Vials) Batch Number: SEM-1285-06/24 Batch size: 600mL (200 Vials) The product was tested under specified limits of physical and chemical parameters under control conditions of temperature and humidity for 6 Months.
Storage Conditions	Store in a refrigerator (2°C to 8°C).
Module 4	NA
Module 5	NA

FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products

[FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products | FDA](#)

Adverse event summary

FDA has received reports of dosing errors involving compounded semaglutide injectable products dispensed in multiple-dose vials. Some patients sought medical attention or required hospitalization. Adverse events included gastrointestinal effects (e.g., nausea, vomiting, abdominal pain), fainting, headache, migraine, dehydration, acute pancreatitis and gallstones.

Errors related to incorrect measurement of intended compounded semaglutide dose

The majority of the reports described patients mistakenly drawing up more than the prescribed dose from a multiple-dose vial during self-administration. In these instances, patients administered five to 20 times more than the intended dose of semaglutide. Most of the reports indicated that patients were unfamiliar with how to measure the intended dose using a syringe.

Remarks of Evaluator:

**. Ozempic Injection: 2 mg/1.5 mL (1.34 mg/mL) available in:
Single-patient-use pen that delivers 0.25 mg or 0.5 mg per injection.
Single-patient-use pen that delivers 1 mg per injection**

- Submit Module 1 as per final guidance document for biological products as attached including all the commitments and SMPC.
- Evidence of approval of applied formulation in “vial” in RRA.
- Approval of manufacturing facility of API by regulatory body of country and validity.
- Expression system is Ecoli whereas, innovator is yeast. Justification is required in the light of reference guidelines that change has not affected product quality, safety and efficacy.
- Section 3.2.S.2.3, 3.2.S.2.4, 3.2.S.2.5 and 3.2.S.2.6 is required.
- Details of reference product used in characterization including brand name.
- The product has been compared with synthetic peptide in characterization studies. Clarification is required.
- The HMWP limit should be made more stringent as per innovator $\leq 3\%$.
- Water content, specific activity tests are not performed on Drug substance by Drug product manufacturer.
- Provide assay of semaglutide on as is basis in percentage in batch analysis.
- Stability data of drug substance till claimed shelf life is required as provided data is of 18 months only.
- Submit composition of semaglutide per ml in section 3.2.P.1.
- Submit comparability report of container closure system of PFP with vial.
- The specification for HMWP should be made more stringent $\leq 0.7\%$.
- The specification of assay at release should be made more stringent 95%-105%.
- Test of dose accuracy to be included in the specifications.
- Commercial invoice is not ADC/DDC attested.
- Provide consumption record of 25 g of semaglutide in all the manufactured 6 batches of injection.
- Inclusion of following tests identification by peptide mapping, bacterial endotoxins and sterility in the stability and next time point of stability testing and submit results.
- Evidence of LC-MS
- Submit in use stability studies of drug product i.e. after first opening.
- Data logger’s data for real time studies at 2-8C for July and August 2024 and for accelerated condition from July 2024 to November 2024 is required.
- Chromatograms for impurity testing is required.
- The source of semaglutide is rDNA , submit bio similarity studies as per “WHO Guidelines on evaluation of biosimilars Replacement of Annex 2 of WHO Technical Report Series, No. 977” on attached format, with PK/PD mandatory study. Provide justification where studies are Not applicable.

Applicant Response:

S.#	Query	Response
1.	Submit Module 1 as per final guidance document for biological products as attached including all the commitments and SMPC.	Attached as <u>Annexure I</u>
2.	Evidence of approval of applied formulation in “vial” in RRA.	The applied formulation is supported with 6-month real-time and accelerated stability data, both of which have been included in the submitted dossier. Furthermore, the same formulation of Semaglutide Injection in vial form is registered and marketed by Macter International under the brand name Seglutide
3.	Approval of manufacturing facility of API by regulatory body of country and validity.	Note: In China, the NMPA officially discontinued the issuance of GMP certificates as of December 1, 2019. Therefore, Chinese API manufacturers no longer possess formal GMP certificates but remain subject to regulatory inspection for GMP compliance. (Source: NMPA Official Announcement)

4.	Expression system is Ecoli whereas, innovator is yeast. Justification is required in the light of reference guidelines that change has not affected product quality, safety and efficacy.	<u>Attached as Annexure II</u>
5.	Section 3.2.S.2.3, 3.2.S.2.4, 3.2.S.2.5 and 3.2.S.2.6 is required.	These sections are part of the restricted (closed) portion of the Drug Master File (DMF). The request has been communicated to the API manufacturer, and the required information will be submitted directly to DRAP by the manufacturer
6.	Details of reference product used in characterization including brand name.	<u>Attached as Annexure III.</u>
7.	The product has been compared with synthetic peptide in characterization studies. Clarification is required.	Comparative characterization of API with innovator has been performed by API manufacturer i.e. Hangzhou Zhongmei Huadong Pharmaceutical Ltd. is enclosed. Batch # of the reference product is 202105AFH1, 202106AGM3, 202106AGN3.
8.	The HMWP limit should be made more stringent as per innovator $\leq 0.3\%$.	The HMWP specification for our product is already more stringent than the innovator's limit. For the drug substance (API), the HMWP limit is set at $\leq 0.7\%$, and for the finished product, it is $\leq 1.5\%$, both of which are well within the innovator's specification of $\leq 3\%$.
9.	Water content, specific activity tests are not performed on Drug substance by Drug product manufacturer.	We commit to including water content and specific activity tests on the drug substance at the drug product manufacturing site. These tests will be incorporated in the revised specification and reflected in future CoAs.
10.	Provide assay of semaglutide on as is basis in percentage in batch analysis.	We commit to providing the assay of Semaglutide on an 'as is' basis in percentage in the batch analysis report prior to marketing the product.
11.	Stability data of drug substance till claimed shelf life is required as provided data is of 18 months only.	We commit to submitting updated stability data at upcoming due time points until the claimed shelf life is covered. The data will be provided to DRAP as it becomes available.
12.	Submit composition of semaglutide per ml in section 3.2.P.1.	Composition per mL is now included in section 3.2.P.1. Updated module attached as <u>Annexure IV</u>
13.	Submit comparability report of container closure system of PFP with vial.	We commit to submitting the comparability report of the container closure system (PFP vs. vial) to demonstrate equivalence prior to marketing the product.
14.	The specification for HMWP should be made more stringent $\leq 0.7\%$.	Our current specification for HMWP is already set at $\leq 0.7\%$, in alignment with the requirement.
15.	The specification of assay at release should be made more stringent 95%-105%.	We commit to updating the assay release specification to 95%–105% and will reflect this in the revised product specifications.
16.	Test of dose accuracy to be included in the specifications.	We commit to including a dose accuracy test in the drug product specification and will submit the updated version accordingly.

17.	Commercial invoice is not ADC/DDC attested.	The online approval Form-6 is attached herewith for your reference in Annexure V . The commercial invoice will be submitted with the required ADC/DDC attestation accordingly.
18.	Provide consumption record of 25 g of semaglutide in all the manufactured 6 batches of injection.	Consumption records for the 25 g of semaglutide used are provided and attached as Annexure V .
19.	Inclusion of following tests identification by peptide mapping, bacterial endotoxins and sterility in the stability and next time point of stability testing and submit results.	We commit to including identification by peptide mapping, bacterial endotoxins, and sterility tests in the stability studies at the next time point
20.	Agenda Evidence of LC-MS	The required LC-MS testing has been performed through a qualified external outsourcing laboratory. We are in the process of procuring our own LC-MS equipment to perform future analyses in-house.
21.	Submit in use stability studies of drug product i.e. after first opening.	We commit to conducting and submitting the in-use stability studies of the drug product prior to marketing.
22.	Data logger's data for real time studies at 2-8C for July and August 2024 and for accelerated condition from July 2024 to November 2024 is required.	Temperature data logs for the required period under both conditions are attached. (no document attached)
23.	Chromatograms for impurity testing is required.	Chromatograms of impurity testing are included in the updated analytical documentation.
24.	The source of semaglutide is rDNA , submit bio similarity studies as per "WHO Guidelines on evaluation of biosimilars Replacement of Annex 2 of WHO Technical Report Series, No. 977" on attached format, with PK/PD mandatory study. Provide justification where studies are Not applicable	We commit to submitting a detailed sameness study of Semaglutide in line with WHO guidelines. Given its low molecular weight (<4 kDa) and well-characterized structure, bio similarity studies including PK/PD may not be required.

Decision of 349th Meeting:

The Registration Board deferred the case for the submission of the following documents:

- Section 3.2.S.2.3, 3.2.S.2.4, 3.2.S.2.5 and 3.2.S.2.6 is required.
- The HMWP limit should be made more stringent as per innovator $\leq 0.3\%$.
- Performance of Water content, specific activity tests on Drug substance by Drug product manufacturer and submission of results.
- Assay of semaglutide on as is basis in percentage in batch analysis.
- Stability data of drug substance till claimed shelf life is required as provided data is of 18 months only.
- Comparability report of container closure system of PFP with vial.
- The specification of assay at release should be made more stringent 95%-105%.
- Test of dose accuracy to be included in the specifications.
- Inclusion of following tests identification by peptide mapping, bacterial endotoxins and sterility in the stability and next time point of stability testing and submission of results.
- In use stability studies of drug product i.e. after first opening.
- Data logger's data for real time studies at 2-8°C for July and August 2024 and for accelerated condition from July 2024 to November 2024.
- Chromatograms for impurity testing is required.
- The source of semaglutide is rDNA , submit bio similarity studies (Quality Comparision and clinical data/equivalence in comparison to innovator product.Provide justification where studies are "Not applicable"

Semaglutide
Source: rDNA
Drug Substance Import Local Manufacturing
Applied Container Closure System: Vial
Biosimilar to Ozempic Injection

Case # 18

Name, address of Applicant / Marketing Authorization Holder	Company Name: Hilton Pharma (Pvt) Limited. Company Address: Plot No. 13-14 & 43, Sector-15, Korangi Industrial Area
Name, address of Manufacturing site.	Company Address: Plot No. 13-14 & 43, Sector-15, Korangi Industrial Area Date of renewal: 23-10-2024
GMP status of the firm	GMP certificate for inspection conducted on 20, Jan,2025
Evidence of approval of manufacturing facility	Additional section Biotech Facility granted on Feb 2013. Doesnot mention SVP vial.
Status of the applicant	☒ Manufacturer
Status of application	SBP
Intended use of pharmaceutical product	☒ Domestic and Export sales
Dy. No. and date of submission	Tracking ID:4JZ-3VQ-5HHB Application Number:104876 Date of Receiving:10-07-2025
Details of fee submitted	Challan Number: 233621909390 Division: Biological Evaluation & Registration Paid Fee: 75000.0 Paid Date: 2025-05-26
proposed proprietary name/brand name	Semhil Injection 4mg/3ml
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each multi dose vial contains: Semaglutide....4mg/3ml
Pharmaceutical form of applied drug	Liquid solution for injection by SC.
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC code: A10BJ06
Reference to Finished product specifications	As per innovator's specification
Proposed Pack size	1's
Proposed unit price	As per Drug pricing committee
The status in reference regulatory authorities	Ozempic Semaglutide 4mg/3ml
For generic drugs (me-too status)	--
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO template.
Module-III Drug Substance:	
Manufacturer of DS	Release testing, stability testing and storage Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

	No. 866 Moganshan Road, Hangzhou, 310011, China Manufacturing, packaging, labeling for Semaglutide and release testing for intermediates of Semaglutide Hangzhou Zhongmeihuadong Pharmaceutical Jiangdong Co., Ltd.No.7278 Meilin Avenue, Dajiangdong Industrial Cluster Zone, Hangzhou, 311228, China
Source	Semaglutide precursor (S4K) is firstly expressed in Escherichia coli by fermentation culture, followed-by digested the precursor by enzyme.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Accelerated study is conducted at ($5\pm 3^{\circ}\text{C}$) for 6 months on 3 batches of API. Three production batches of Semaglutide (Batch No.: 220503AJ, 220601AJ, 220602AJ) manufactured by current manufacturing process were selected to use for the study of accelerated stability ($5^{\circ}\text{C}\pm 3^{\circ}\text{C}$) and long-term stability ($-20^{\circ}\text{C}\pm 5^{\circ}\text{C}$). All stability samples are packaged in two layers of polyethylene bags and then one layer of aluminum-plastic compound bag. Long term 18 months data submitted.
Module-III Drug Product:	
Manufacturing Site	Hilton Pharma (Pvt.) Ltd. Plot No. 13-14 & 43, Sector 15, Korangi Industrial Area Karachi, Pakistan.
Container closure system of the drug product	USP Type I, 3mL, Glass Vials with rubber stopper and aluminum seal then packed in printed carton along with leaflet
Stability study data of drug product, shelf life and storage conditions	4mg per 3mL Batch Number: SEM-1280-04/24, SEM-1281-05/24, SEM-1282-06/24 Batch Size: Batch Number: SEM-1280-04/24 Batch size: 600mL (200 Vials) Batch Number: SEM-1281-05/24 Batch size: 600mL (200 Vials) Batch Number: SEM-1282-06/24 Batch size: 600mL (200 Vials) The product was tested under specified limits of physical and chemical parameters under control conditions of temperature and humidity for 6 Months.
Storage Conditions	Store in a refrigerator (2°C to 8°C).
Module 4	NA
Module 5	NA
Remarks of Evaluator: . Ozempic Injection: 4 mg/3 mL (1.34 mg/mL) available in: Injection: 4 mg/3 mL (1.34 mg/mL) available in: • Single-patient-use pen that delivers 1 mg per injection • Submit Module 1 as per final guidance document for biological products as attached including all the commitments and SMPC. • Evidence of approval of applied formulation in “vial” in RRA. • Approval of manufacturing facility of API by regulatory body of country and validity. • Expression system is Ecoli whereas, innovator is yeast. Justification is required in the light of reference guidelines that change has not affected product quality, safety and efficacy. • Section 3.2.S.2.3,3.2.S.2.4, 3.2.S.2.5 and 3.2.S.2.6 is required. • Details of reference product used in characterization including brand name. • The product has been compared with synthetic peptide in characterization studies. Clarification is required. • The HMWP limit should be made more stringent as per innovator $\leq 3\%$. • Water content, specific activity tests are not performed on Drug substance by Drug product manufacturer. • Provide assay of semaglutide on as is basis in percentage in batch analysis. • Stability data of drug substance till claimed shelf life is required as provided data is of 18 months only. • Submit composition of semaglutide per ml in section 3.2.P.1. • Submit comparability report of container closure system of PFP with vial. • The specification for HMWP should be made more stringent $\leq 0.7\%$. • The specification of assay at release should be made more stringent 95%-105%. • Test of dose accuracy to be included in the specifications. • Commercial invoice is not ADC/DDC attested.	

- Provide consumption record of 25 g of semaglutide in all the manufactured 6 batches of injection.
- Inclusion of following tests identification by peptide mapping, bacterial endotoxins and sterility in the stability and next time point of stability testing and submit results.
- Evidence of LC-MS
- Submit in use stability studies of drug product i.e. after first opening.
- Data logger's data for real time studies at 2-8C for July and August 2024 and for accelerated condition from July 2024 to November 2024 is required.
- Chromatograms for impurity testing is required.
- The source of semaglutide is rDNA , submit bio similarity studies as per "WHO Guidelines on evaluation of biosimilars Replacement of Annex 2 of WHO Technical Report Series, No. 977" on attached format, with PK/PD mandatory study. Provide justification where studies are Not applicable.

Applicant Response

S.#	Query	Response
1.	Submit Module 1 as per final guidance document for biological products as attached including all the commitments and SMPC.	Attached as <u>Annexure I</u>
2.	Evidence of approval of applied formulation in "vial" in RRA.	The applied formulation is supported with 6-month real-time and accelerated stability data, both of which have been included in the submitted dossier. Furthermore, the same formulation of Semaglutide Injection in vial form is registered and marketed by Macter International under the brand name Seglutide
3.	Approval of manufacturing facility of API by regulatory body of country and validity.	Note: In China, the NMPA officially discontinued the issuance of GMP certificates as of December 1, 2019. Therefore, Chinese API manufacturers no longer possess formal GMP certificates but remain subject to regulatory inspection for GMP compliance. (Source: NMPA Official Announcement)
4.	Expression system is Ecoli whereas, innovator is yeast. Justification is required in the light of reference guidelines that change has not affected product quality, safety and efficacy.	<u>Attached as Annexure II</u>
5.	Section 3.2.S.2.3, 3.2.S.2.4, 3.2.S.2.5 and 3.2.S.2.6 is required.	These sections are part of the restricted (closed) portion of the Drug Master File (DMF). The request has been communicated to the API manufacturer, and the required information will be submitted directly to DRAP by the manufacturer
6.	Details of reference product used in characterization including brand name.	<u>Attached as Annexure III.</u>
7.	The product has been compared with synthetic peptide in characterization studies. Clarification is required.	Comparative characterization of API with innovator has been performed by API manufacturer i.e. Hangzhou Zhongmei Huadong Pharmaceutical Ltd. is enclosed. Batch # of the reference product is 202105AFH1, 202106AGM3, 202106AGN3.
8.	The HMWP limit should be made more stringent as per innovator $\leq 0.3\%$.	The HMWP specification for our product is already more stringent than the innovator's limit. For the drug substance (API), the HMWP limit is set at $\leq 0.7\%$, and for the finished product, it is $\leq 1.5\%$, both of which are well within the innovator's specification of $\leq 3\%$.

9.	Water content, specific activity tests are not performed on Drug substance by Drug product manufacturer.	We commit to including water content and specific activity tests on the drug substance at the drug product manufacturing site. These tests will be incorporated in the revised specification and reflected in future CoAs.
10.	Provide assay of semaglutide on as is basis in percentage in batch analysis.	We commit to providing the assay of Semaglutide on an 'as is' basis in percentage in the batch analysis report prior to marketing the product.
11.	Stability data of drug substance till claimed shelf life is required as provided data is of 18 months only.	We commit to submitting updated stability data at upcoming due time points until the claimed shelf life is covered. The data will be provided to DRAP as it becomes available.
12.	Submit composition of semaglutide per ml in section 3.2.P.1.	Composition per mL is now included in section 3.2.P.1. Updated module attached as <u>Annexure IV</u>
13.	Submit comparability report of container closure system of PFP with vial.	We commit to submitting the comparability report of the container closure system (PFP vs. vial) to demonstrate equivalence prior to marketing the product.
14.	The specification for HMWP should be made more stringent $\leq 0.7\%$.	Our current specification for HMWP is already set at $\leq 0.7\%$, in alignment with the requirement.
15.	The specification of assay at release should be made more stringent 95%-105%.	We commit to updating the assay release specification to 95%–105% and will reflect this in the revised product specifications.
16.	Test of dose accuracy to be included in the specifications.	We commit to including a dose accuracy test in the drug product specification and will submit the updated version accordingly.
17.	Commercial invoice is not ADC/DDC attested.	The online approval Form-6 is attached herewith for your reference in <u>Annexure V</u> . The commercial invoice will be submitted with the required ADC/DDC attestation accordingly.
18.	Provide consumption record of 25 g of semaglutide in all the manufactured 6 batches of injection.	Consumption records for the 25 g of semaglutide used are provided and attached as <u>Annexure V</u> .
19.	Inclusion of following tests identification by peptide mapping, bacterial endotoxins and sterility in the stability and next time point of stability testing and submit results.	We commit to including identification by peptide mapping, bacterial endotoxins, and sterility tests in the stability studies at the next time point
20.	Agenda Evidence of LC-MS	The required LC-MS testing has been performed through a qualified external outsourcing laboratory. We are in the process of procuring our own LC-MS equipment to perform future analyses in-house.
21.	Submit in use stability studies of drug product i.e. after first opening.	We commit to conducting and submitting the in-use stability studies of the drug product prior to marketing.
22.	Data logger's data for real time studies at 2-8C for July and August 2024 and for accelerated condition from July 2024 to November 2024 is required.	Temperature data logs for the required period under both conditions are attached. (no document attached)

23.	Chromatograms for impurity testing is required.	Chromatograms of impurity testing are included in the updated analytical documentation.
24.	The source of semaglutide is rDNA , submit bio similarity studies as per “WHO Guidelines on evaluation of biosimilars Replacement of Annex 2 of WHO Technical Report Series, No. 977” on attached format, with PK/PD mandatory study. Provide justification where studies are Not applicable	We commit to submitting a detailed sameness study of Semaglutide in line with WHO guidelines. Given its low molecular weight (<4 kDa) and well-characterized structure, biosimilarity studies including PK/PD may not be required.

Decision of 349th Meeting:
The Registration Board deferred the case for the submission of the following documents:

- Section 3.2.S.2.3, 3.2.S.2.4, 3.2.S.2.5 and 3.2.S.2.6 is required.
- The HMWP limit should be made more stringent as per innovator $\leq 0.3\%$.
- Performance of Water content, specific activity tests on Drug substance by Drug product manufacturer and submission of results.
- Assay of semaglutide on as is basis in percentage in batch analysis.
- Stability data of drug substance till claimed shelf life is required as provided data is of 18 months only.
- Comparability report of container closure system of PFP with vial.
- The specification of assay at release should be made more stringent 95%-105%.
- Test of dose accuracy to be included in the specifications.
- Inclusion of following tests identification by peptide mapping, bacterial endotoxins and sterility in the stability and next time point of stability testing and submission of results.
- In use stability studies of drug product i.e. after first opening.
- Data logger's data for real time studies at 2-8°C for July and August 2024 and for accelerated condition from July 2024 to November 2024.
- Chromatograms for impurity testing is required.
- The source of semaglutide is rDNA , submit bio similarity studies (Quality Comparison and clinical data/equivalence in comparison to innovator product. Provide justification where studies are “Not applicable”.

Source: rDNA Drug Substance Import Local Manufacturing Applied Container Closure System: Pre-filled Pen Biosimilar to Ozempic Injection		
Case # 19		
Name, address of Applicant / Marketing Authorization Holder	Company Name: Weather Folds Pharmaceuticals Company Address: Plot no. 69/2, Phase II, Industrial Area, Hattar, Pakistan. Site Address: Plot No. 69/2, Phase-II, Industrial Area, Hattar.	
Name, address of Manufacturing site.	Company Name: Weather Folds Pharmaceuticals Company Address: Plot no. 69/2, Phase II, Industrial Area, Hattar, Pakistan. Site Address: Plot No. 69/2, Phase-II, Industrial Area, Hattar. Date of renewal 27-09-2013	
GMP status of the firm	NA	
Evidence of approval of manufacturing facility	Grant of Additional Section Biological non-rDNA Liquid Injection Vial and PFS (New)	
Status of the applicant	☒ Manufacturer	
Status of application	SBP	
Intended use of pharmaceutical product	☒ Domestic and Export sales	

Dy. No. and date of submission	Tracking ID: A74-R76-W3BP Application Number:110254 Date of Receiving:10-07-2025
Details of fee submitted	Challan Number: 0821186866 Division: Biological Evaluation & Registration Paid Fee: 75000.0 Paid Date: 2025-07-06
proposed proprietary name/brand name	Semma Pre-Filled Pen 0.25mg/0.19ml
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each pre-filled pen contains: - Semaglutide 2mg in 1.5 ml solution. (Each dose contains 0.25 mg of semaglutide in 0.19 ml solution)
Pharmaceutical form of applied drug	Liquid solution for injection by SC.
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC code: A10BJ06
Reference to Finished product specifications	As per innovator's specification
Proposed Pack size	1's pen
Proposed unit price	As per Drug pricing committee
The status in reference regulatory authorities	Ozempic Semaglutide 2mg/1.5ml
For generic drugs (me-too status)	--
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO template.
Module-III Drug Substance:	
Manufacturer of DS	Fuxin Long Rui Pharmaceutical CO., Ltd Address: Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China
Source	Not submitted.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	ccelerated (5°C ± 3°C) B065C120220804 Equivalent to commercial packaging system 1 month, 2 months, 3 months, and 6 months. B065C120220805 B065C120220806 Storage condition (°C, % RH) Batch number Container closure system Completed (and proposed) testing intervals Long Term (-20°C ± 5°C) B065C120220804 Equivalent to commercial packaging system 3 months, 6 months, 9 months, 12 months, 18months, 24 months
Module-III Drug Product:	
Manufacturing Site	Weather Folds Pharmaceuticals Company Address: Plot no. 69/2, Phase II, Industrial Area, Hattar, Pakistan. Site Address: Plot No. 69/2, Phase-II, Industrial Area, Hattar. Date of renewal 27-09-2013
Container closure system of the drug product	SEMMA Injection are packaged as 1's Prefilled Injections further Packed in Bleech Card board Unit Carton along with Leaflet.
Stability study data of drug product, shelf life and storage conditions	T-37, T-38, T-39 Batch Size. 1500 PFP Dom-07-2024
Storage Conditions	Store below 25.
Module 4	Not Submitted.
Module 5	Not Submitted.
Remarks of Evaluator:	

- Submit Module 1 as per final guidance document for biological products as attached below including all the commitments and SMPC.
- Grant of Additional Section is Biological non-rDNA Liquid Injection Vial and PFS (New). Clarification is required where the sterile batches of biological product of rDNA origin have been manufactured.
- Clarification is required for container closure whether cartridge or PFP.
- The RRA in section 1.5.9 mentions Rybelsus Injection. Clarification is required.
- Approval of manufacturing facility of API by regulatory body of country and validity.
- Submit section 3.2.S.2.2, to 3.2.S.2.3. The description of manufacturing is mandatory to mention. Provide source whether synthetic or rDNA.
- Justification is required for presence of sodium and determination of assay in Drug substance.
- Peptide mapping, related substance, HMWP, specific activity tests are not included in drug substance specifications.
- The USFDA recommends “Maximum Potency per unit dose” of propylene glycol 1.4%w/v whereas, the amount of propylene glycol is 30mg in 1.5ml i.e. 2% Justification is required.
- Provide batch formula per ml instead of per filled volume.
- Provide process flow for the manufacturing of drug-device combination product.
- Include the following tests in drug product specifications identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy. Also mention content of semaglutide per ml and performance of same tests in batch analysis at release and stability (where applicable).
- Submit analytical procedures and method validation report.
- Submit section 3.2.P.5.5 i.e. characterization of impurities.
- COA of reference standard is required.
- Details of container closure is required i.e. primary packaging and PFP.
- The DML attached in section 3.2.P.8.3 is of “Hangzhou Patience Chemical Co., Ltd Registered Address: No. 6 Xiyuan 7th Road, Sandun Town, Xihu District, Hangzhou, Zhejiang, China” whereas, DS manufacturer is “Fuxin Long Rui Pharmaceutical CO., Ltd Address: Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province - 123000, China”.
- Commercial invoice is ADC/DDC attested.
- Provide consumption record of 200 g of semaglutide in tablets and injection.
- Inclusion of following tests identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy in the next time point of stability testing.
- Submit in use stability studies of drug product i.e. after first opening.
- Data logger's data for refrigerated condition real time and accelerated condition is required.
- The source of semaglutide is rDNA, submit bio similarity studies (Quality Comparison and clinical data/equivalence in comparison to innovator product. Provide justification where studies are “Not applicable”.

S.NO	Observation/Document Required	Justification/Status of Documents
01	The innovator product Special precautions for storage is Store in a refrigerator (2 °C–8 °C) whereas, you have recommended store below 25C. Justification is required.	It was typographical mistake. Digital Data Logger indicates 2-8c.
02	In continuation to previous shortcoming also provide evidence of prefilled pen section.	We have attached the Section Approval Letter for Vial and Prefilled Syringe manufacturing sections. As per WHO TRS 999 guidelines, rDNA products may be manufactured in a non-rDNA-dedicated facility, provided that appropriate GMP controls are in place to prevent cross-contamination. Furthermore, the manufacturing process for Prefilled Syringe is the same as that of the Prefilled Pen. Therefore, a separate Section Approval is not required.
03	Submit Module 1 as per final guidance document for biological products as attached below including all the commitments and SMPC.	Rectified Attached.
04	The manufacturing of batches is in 2024, whereas section has been granted on 25th June 2025. Clarification is required where the sterile	6 Month Stability Data attached as per DRAP Requirement.

	batches of biological product have been manufactured.	
05	Clarification is required for container closure whether cartridge or PFP.	1's Prefilled Syringe in Unit Carton along with leaflet.
06	Evidence of section approval in which rDNA PFS has been manufactured, as attached evidence is of non r DNA PFS.	According to WHO TRS 999 guidelines, the rDNA products can be manufactured in Non-rDNA facility, hence no separate section required.
07	The RRA in section 1.5.9 mentions Rybelsus Injection. Clarification is required.	Typographical Mistake, which has been rectified.
08	Approval of manufacturing facility of API by regulatory body of country and validity	Attached.
09	Submit section 3.2.S.2.2, to 3.2.S.2.3. The description of manufacturing is mandatory to mention. Provide source whether synthetic or rDNA. .	The Product origin is China, and this is patent product, hence this cannot be provided.
10	Justification is required for presence of sodium and determination of sodium assay in Drug substance	Sodium determine by API manufacturer and available in DMF.
11	Peptide mapping, related substance, HMWP, specific activity tests are not performed on drug substance by drug product manufacturer. Clarification is required. .	The Tests have been performed by the Drug Substance Manufacturer, hence not required to be performed by drug product manufacturer.
12	The USFDA recommends "Maximum Potency per unit dose" of propylene glycol 1.4%w/v whereas; the amount of propylene glycol is 30mg in 1.5ml. Justification is required along with calculation in % w/v for propylene glycol.	It was typographical mistake. Correct Formulation Attached.
13	Provide batch formula per ml in product development section.	Attached.
14	Provide process flow for the manufacturing of drug-device combination product.	Attached
15		
16	Submit analytical procedures and method validation report.	Attached
17	Submit section 3.2.P.5.5 i.e. characterization of impurities	Impurities are Exempted hence not available.
18	Details of container closure is required i.e. primary packaging and PFP.	1's Prefilled Pen in Unit Carton Along with Leaflet.
19	COA of reference standard is required.	Attached
20	The DML attached in section 3.2.P.8.3 is of "Hangzhou Patience Chemical Co.,Ltd Registered Address: No. 6 Xiyuan7th Road,SandunTown,Xihu District, Hangzhou,Zhejiang,China" whereas, DS manufacturer is "Fuxin Long Rui Pharmaceutical CO., Ltd Address: Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China"	Correct DML Attached.
21	Commercial invoice is not ADC/DDC attested. .	We imported Semaglutide and cleared via Green Channel. For reference, Goods Declaration is attached and also we have officially intimated to DRAP regarding our materials imported without

		Clearance Certificate. The Intimation letter with receiving is attached along with.
22	Provide consumption record of 200 g of semaglutide in tablets and injection.	Attached
23	Inclusion of following tests identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy in the next time point of stability testing. Include the following tests in drug product specifications identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy. Also mention content of of semaglutide per ml and performance of same tests in batch analysis at release and stability (where applicable).	BET has already been performed and is included in the Certificate of Analysis (CoA) and Stability Data Sheets. Phenol testing was not performed by the innovator; however, if recommended by the Board, we shall conduct phenol content testing in the next stability intervals. Furthermore, as per the Board's decision in the 340th DRB Meeting regarding the registration of our Semaglutide Tablet, we confirm that identification testing through peptide mapping shall be performed by a Government Testing Laboratory for every . commercial batch of the injection.
24		
25	Data logger's data for refrigerated condition real time and accelerated condition is required.	Attached
26	The source of semaglutide is rDNA , submit bio similarity studies as per "WHO Guidelines on evaluation of biosimilars Replacement of Annex 2 of WHO Technical Report Series, No. 977" on attached format, with PK/PD mandatory study. Provide justification where studies are Not applicable.	API manufacturer and bio similarity of the API has been the required tests have already been performed by the established at the Drug Substance stage, these tests are not required to be repeated for the Finished Product.
	Submit in use stability studies of drug product i.e. after first opening.	After first opening all parameters were test and found within limits, further store at real and accelerated condition and observe weekly for 6 weeks and checks all parameters (appearance, PH, BET, Assay) and found within limits at all interval.

Decision of 349th Meeting:

The Registration Board deferred the case for the submission of the following documents:

- Fee for correction in typographical error in storage condition for semaglutide injection, the evidence of cold storage/stability chamber for 2-8C is required.
- The manufacturing of batches is in 2024, whereas section has been granted on 25th June 2025. Clarification is required where the sterile batches of biological product have been manufactured, as no response was submitted earlier.
- Evidence of section approval in which rDNA Prefilled pen/cartidge has been manufactured, as attached evidence is of non rDNA Pre-filled syringe and vial.
- Section 3.2.S.2.2, to 3.2.S.2.3. The description of manufacturing is mandatory to mention. Provide source whether synthetic or rDNA.
- Performance of Peptide mapping, related substance, HMWP, biological activity tests on drug substance by drug product manufacturer.
- The USFDA recommends "Maximum Potency per unit dose" of propylene glycol 1.4%w/v whereas; the amount of propylene glycol is 30mg in 1.5ml. Justification is required along with calculation in % w/v for propylene glycol and evidence of BMR .
- Process flow for the manufacturing of drug-device combination product.
- Complete method validation report.
- Details of container closure is required i.e. primary packaging and PFP.
- COA of reference standard is required.
- Inclusion of following tests identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy in the next time point of stability testing. Include the following tests in drug product specifications identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy. Also mention content of of semaglutide per ml and performance of same tests in batch analysis at release and stability (where applicable).
- Data logger's data for refrigerated condition real time and accelerated condition for 6 months is required.
- The source of semaglutide is rDNA , submit bio similarity studies (Quality Comparison and clinical data/equivalence in

comparison to innovator product. Provide justification where studies are “Not applicable”.

- In use stability studies of drug product i.e. after first opening.

Case # 20

Name, address of Applicant / Marketing Authorization Holder	Company Name: Weather Folds Pharmaceuticals Company Address: Plot no. 69/2, Phase II, Industrial Area, Hattar, Pakistan. Site Address: Plot No. 69/2, Phase-II, Industrial Area, Hattar.
Name, address of Manufacturing site.	Company Name: Weather Folds Pharmaceuticals Company Address: Plot no. 69/2, Phase II, Industrial Area, Hattar, Pakistan. Site Address: Plot No. 69/2, Phase-II, Industrial Area, Hattar. Date of renewal 27-09-2013
GMP status of the firm	NA
Evidence of approval of manufacturing facility	Grant of Additional Section Biological non-rDNA Liquid Injection Vial and PFS (New)
Status of the applicant	☒ Manufacturer
Status of application	SBP
Intended use of pharmaceutical product	☒ Domestic and Export sales
Dy. No. and date of submission	Tracking ID:X91-NVT-NYRV Application Number:110255 Date of Receiving:10-07-2025
Details of fee submitted	Challan Number: 01372481920 Division: Biological Evaluation & Registration Paid Fee: 75000.0 Paid Date: 2025-07-06
proposed proprietary name/brand name	Semma Pre-Filled Pen 0.5mg/0.37ml
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each pre-filled pen contains: - Semaglutide 2mg in 1.5 ml solution. (Each dose contains 0.5 mg of semaglutide in 0.37 ml solution)
Pharmaceutical form of applied drug	Liquid solution for injection by SC.
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC code: A10BJ06
Reference to Finished product specifications	As per innovator's specification
Proposed Pack size	1's pen
Proposed unit price	As per Drug pricing committee
The status in reference regulatory authorities	Ozempic 0.25 mg solution for injection One ml of solution contains 1.34 mg of semaglutide*. One pre-filled pen contains 2 mg semaglutide* in 1.5 ml solution. Each dose contains 0.25 mg of semaglutide in 0.19 ml solution. Ozempic 0.5 mg solution for injection 1.5 ml: One ml of solution contains 1.34 mg of semaglutide*. One pre-filled pen contains 2 mg semaglutide* in 1.5 ml solution. Each dose contains 0.5 mg of semaglutide in 0.37 ml solution. 3 ml: One ml of solution contains 0.68 mg of semaglutide*. One pre-filled pen contains 2 mg semaglutide* in 3 ml solution. Each dose contains 0.5 mg of semaglutide in 0.74 ml solution. 3 ml: One ml of solution contains 1.34 mg of semaglutide*. One pre-filled pen contains 4 mg semaglutide* in 3 ml solution. Each dose contains 0.5 mg of semaglutide in 0.37 ml solution. Ozempic 1 mg solution for injection One ml of solution contains 1.34 mg of semaglutide*. One pre-filled pen contains 4 mg semaglutide* in 3 ml solution. Each dose contains 1 mg of semaglutide in 0.74 ml solution. One ml of solution contains 2.68 mg of semaglutide*. One pre-filled pen contains 8 mg semaglutide* in 3 ml solution. Each dose contains 1 mg of semaglutide in

	0.37 ml solution. Ozempic 2 mg solution for injection One ml of solution contains 2.68 mg of semaglutide*. One pre-filled pen contains 8 mg semaglutide* in 3 ml solution. Each dose contains 2 mg of semaglutide in 0.74 ml solution
For generic drugs (me-too status)	--
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO template.
Module-III Drug Substance:	
Manufacturer of DS	Fuxin Long Rui Pharmaceutical CO., Ltd Address: Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China
Source	Not submitted.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Accelerated (5°C ± 3°C) B065C120220804 Equivalent to commercial packaging system 1 month, 2 months, 3 months, and 6 months. B065C120220805 B065C120220806 Storage condition (°C, % RH) Batch number Container closure system Completed (and proposed) testing intervals Long Term (-20°C ± 5°C) B065C120220804 Equivalent to commercial packaging system 3 months, 6 months, 9 months, 12 months, 18months, 24 months
Module-III Drug Product:	
Manufacturing Site	Weather Folds Pharmaceuticals Company Address: Plot no. 69/2, Phase II, Industrial Area, Hattar, Pakistan. Site Address: Plot No. 69/2, Phase-II, Industrial Area, Hattar. Date of renewal 27-09-2013
Container closure system of the drug product	SEMMA Injection are packaged as 1's Prefilled Injections further Packed in Bleech Card board Unit Carton along with Leaflet.
Stability study data of drug product, shelf life and storage conditions	T-40, T-41, T-42 Batch Size. 1500 PFP Dom-07-2024
Storage Conditions	Store below 25
Module 4	Not Submitted.
Module 5	Not Submitted.
Remarks of the evaluator Same filled volume has been applied twice. Clarification is required.	
Applicant Response The Product formulation 2mg/3ml and delivered dose is 0.50mg/0.37ml which is different strength even as per EMA. The formulation is: Each pre-filled pen contains:- Semaglutide 2mg in 1.5 ml solution. (Each dose contains 0.50 mg of semaglutide in 0.37ml solution)	
Decision of 349th Meeting: The Registration Board deferred the case for clarification on submission of same filled volume twice as Prefilled Pen 2mg/1.5ml.	

Case # 21		
Name, address of Applicant / Marketing Authorization Holder	Company Name: Weather Folds Pharmaceuticals Company Address: Plot no. 69/2, Phase II, Industrial Area, Hattar, Pakistan. Site Address: Plot No. 69/2, Phase-II, Industrial Area, Hattar.	
Name, address of Manufacturing site.	Company Name: Weather Folds Pharmaceuticals Company Address: Plot no. 69/2, Phase II, Industrial Area, Hattar, Pakistan. Site Address: Plot No. 69/2, Phase-II, Industrial Area, Hattar. Date of renewal 27-09-2013	
GMP status of the firm	NA	
Evidence of approval of manufacturing facility	Grant of Additional Section Biological non-rDNA Liquid Injection Vial and PFS (New)	

Status of the applicant	☒ Manufacturer
Status of application	SBP
Intended use of pharmaceutical product	☒ Domestic and Export sales
Dy. No. and date of submission	Tracking ID:6DW-RQM-VXAS Application Number:110539 Date of Receiving:10-07-2025
Details of fee submitted	Challan Number: 80555341 Division: Biological Evaluation & Registration Paid Fee: 75000.0 Paid Date: 2025-07-07
proposed proprietary name/brand name	Semma Pre-Filled Pen 0.5mg/0.74ml
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each pre-filled pen contains: - Semaglutide 2mg in 3 ml solution. (Each dose contains 0.5 mg of semaglutide in 0.74 ml solution)
Pharmaceutical form of applied drug	Liquid solution for injection by SC.
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC code: A10BJ06
Reference to Finished product specifications	As per innovator's specification
Proposed Pack size	1's pen
Proposed unit price	As per Drug pricing committee
The status in reference regulatory authorities	Ozempic 0.25 mg solution for injection One ml of solution contains 1.34 mg of semaglutide*. One pre-filled pen contains 2 mg semaglutide* in 1.5 ml solution. Each dose contains 0.25 mg of semaglutide in 0.19 ml solution. Ozempic 0.5 mg solution for injection 1.5 ml: One ml of solution contains 1.34 mg of semaglutide*. One pre-filled pen contains 2 mg semaglutide* in 1.5 ml solution. Each dose contains 0.5 mg of semaglutide in 0.37 ml solution. 3 ml: One ml of solution contains 0.68 mg of semaglutide*. One pre-filled pen contains 2 mg semaglutide* in 3 ml solution . Each dose contains 0.5 mg of semaglutide in 0.74 ml solution. 3 ml: One ml of solution contains 1.34 mg of semaglutide*. One pre-filled pen contains 4 mg semaglutide* in 3 ml solution. Each dose contains 0.5 mg of semaglutide in 0.37 ml solution. Ozempic 1 mg solution for injection One ml of solution contains 1.34 mg of semaglutide*. One pre-filled pen contains 4 mg semaglutide* in 3 ml solution. Each dose contains 1 mg of semaglutide in 0.74 ml solution. One ml of solution contains 2.68 mg of semaglutide*. One pre-filled pen contains 8 mg semaglutide* in 3 ml solution. Each dose contains 1 mg of semaglutide in 0.37 ml solution. Ozempic 2 mg solution for injection One ml of solution contains 2.68 mg of semaglutide*. One pre-filled pen contains 8 mg semaglutide* in 3 ml solution. Each dose contains 2 mg of semaglutide in 0.74 ml solution
For generic drugs (me-too status)	--
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO template.
Module-III Drug Substance:	
Manufacturer of DS	Fuxin Long Rui Pharmaceutical CO., Ltd Address: Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China
Source	Not submitted.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	ccelerated (5°C ± 3°C) B065C120220804 Equivalent to commercial packaging system 1 month, 2 months, 3 months, and 6 months. B065C120220805 B065C120220806 Storage condition (°C, % RH) Batch number Container closure system Completed (and proposed)

	testing intervals Long Term (-20°C ± 5°C) B065C120220804 Equivalent to commercial packaging system 3 months, 6 months, 9 months, 12 months, 18months, 24 months	
Module-III Drug Product:		
Manufacturing Site	Weather Folds Pharmaceuticals Company Address: Plot no. 69/2, Phase II, Industrial Area, Hattar, Pakistan. Site Address: Plot No. 69/2, Phase-II, Industrial Area, Hattar. Date of renewal 27-09-2013	
Container closure system of the drug product	SEMMA Injection are packaged as 1's Prefilled Injections further Packed in Bleech Card board Unit Carton along with Leaflet.	
Stability study data of drug product, shelf life and storage conditions	T-49, T-50, T-51 Batch Size. 1500 PFP Dom-07-2024	
Storage Conditions	Store below 25	
Module 4	Not Submitted.	
Module 5	Not Submitted.	
Remarks of the Evaluator • Submit Module 1 as per final guidance document for biological products as attached below, including all the commitments and SMPC. • Grant of Additional Section is Biological non-rDNA Liquid Injection Vial and PFS (New).Clarification is required where the sterile batches of biological product of rDNA origin have been manufactured. • Clarification is required for container closure whether cartridge or PFP. • The RRA in section 1.5.9 mentions Rybelsus Injection. Clarification is required. • Approval of manufacturing facility of API by regulatory body of country and validity. • Submit section 3.2.S.2.2, to 3.2.S.2.3.The description of manufacturing is mandatory to mention. Provide source whether synthetic or rDNA also provide whether final product is freeze dried or spray dried. • Justification is required for presence of sodium in the drug substance specifications. Peptide mapping, related substance, HMWP, specific activity not performed on drug substance by drug product manufacturer. Clarification is required. • The USFDA recommends “Maximum Potency per unit dose” of propylene glycol 1.4%w/v whereas, the amount of propylene glycol is 60mg in 3ml. Justification is required. • Provide batch formula per ml in composition of drug product. • Provide process flow for the manufacturing of drug-device combination product. • Include the following tests in drug product specifications identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy.Also mention content of semaglutide per ml and performance of same tests in batch analysis at release and stability(where applicable). • Submit analytical procedures and method validation report. • Submit section 3.2.P.5.5 i.e. characterization of impurities. • COA of reference standard is required. • Details of container closure is required i.e. primary packaging and PFP. • The DML attached in section 3.2.P.8.3 is of “Hangzhou Patience Chemical Co.,Ltd Registered Address: No. 6 Xiyuan7th Road,SandunTown,Xihu District, Hangzhou,Zhejiang,China” whereas, DS manufacturer is “Fuxin Long Rui Pharmaceutical CO., Ltd Address: Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China”. • Commercial invoice is not attested by DRAP. • Provide consumption record of 200 g of semaglutide in all manufactured batches tablets and injection(PFP and PFS). • Inclusion of following tests identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy in the next time point of stability testing. • Submit in-use stability studies i.e. after first opening. • Data logger’s data for refrigerated condition real time(2-8C) and accelerated condition(25C/60RH) is required. • The source of semaglutide is rDNA , submit bio similarity studies as per “WHO Guidelines on evaluation of biosimilar Replacement of Annex 2 of WHO Technical Report Series, No. 977” on attached format, with PK/PD mandatory study. Provide justification where studies are not applicable in the light of reference guidelines.		
S.NO	Observation/Document Required	Justification/Status of Documents

01	Submit Module 1 as per final guidance document for biological products as attached below, including all the commitments and SMPC.	Rectified Attached.
02	Evidence of approval of applied formulation in applied strength 1mg/0.74ml in prefilled syringe in RRA is required.	Stability studies indicate no interaction of primary packing with product. As per the decision followed by the DRB 336, against Semaglutide Macter Product.
03	Evidence of section approval in which rDNA PFS has been manufactured, as attached evidence is of non r DNA PFS.	According to WHO WHO TRS 999 guidelines, the rDNA products can be manufactured in Non-rDNA facility, hence no separate section required.
04	· The RRA in section 1.5.9 mentions Rybelsus Injection. Clarification is required.	Typographical Mistake, which has been rectified.
05	Approval of manufacturing facility of API by regulatory body of country and validity.	Attached
06	Submit section 3.2.S.2.2, to 3.2.S.2.3. The description of manufacturing is mandatory to mention. Provide source whether synthetic or rDNA.	The Product origin is China, and this is patent product, hence this cannot be provided.
06	Justification is required for presence of sodium and determination of sodium assay in Drug substance.	Sodium determine by API manufacturer and available in DMF.
07	Peptide mapping, related substance, HMWP, specific activity tests are not performed on drug substance by drug product manufacturer. Clarification is required.	The Tests have been performed by the Drug Substance Manufacturer, hence not required to be performed by drug product manufacturer.
08	· Composition of drug per 0.75ml is required, as provided quantities are per 3 ml.	Composition regarding 3ml attached in Annexure-1
09	The applied syringe is single dose .Justify the use of preservative in the formulation as innovators product is PFP containing preservative.	Attached in Annexure-2
10	The section 3.2.P.2 mentions potency 4mg and volume 3ml clarification is required.	Typographical Mistake
11	Provide the details of reference product against which equivalence studies have been done.	Sematide by BF Biosciences Reg No. 120528
12	Provide batch formula for commercial batches and justify the use of preservative with qty. of Propylene glycol exceeding 1.4%w/v.	Revised Attached in Annexure-3
13	Provide description of manufacturing method for PFS as provided one is of cartridge.	Rectified Attached.
14	Provide batch formula per ml in product development section.	Attached in Annexure-4
15	Submit analytical procedures and method validation report.	Attached in Annexure-5
16	Commercial invoice is not ADC/DDC attested. . . .	We imported Semaglutide and cleared via Green Channel. For reference, Goods Declaration is attached and also we have officially intimated to DRAP regarding our materials

		imported without Clearance Certificate. The Intimation letter with receiving is attached along with
17	COA of reference standard is required.	Attached in Annexure-6

Decision of 349th Meeting:

The Registration Board deferred the case for the submission of the following documents:

- Module 1 as per final guidance document for biological products as attached below, including all the commitments and SMPC.
- Fee for correction in typographical error in storage condition for semaglutide injection, the evidence of cold storage/stability chamber for 2-8C is required.
- The manufacturing of batches is in 2024, whereas section has been granted on 25th June 2025. Clarification is required where the sterile batches of biological product have been manufactured, as no response was submitted earlier.
- Evidence of section approval in which rDNA Prefilled pen/cartridge has been manufactured, as attached evidence is of non r DNA Pre-filled syringe and vial.
- Section 3.2.S.2.2, to 3.2.S.2.3. The description of manufacturing is mandatory to mention. Provide source whether synthetic or rDNA.
- Performance of Peptide mapping, related substance, HMWP, biological activity tests on drug substance by drug product manufacturer.
- The USFDA recommends "Maximum Potency per unit dose" of propylene glycol 1.4%w/v. Justification is required along with calculation in % w/v for propylene glycol and evidence of BMR .
- Process flow for the manufacturing of drug-device combination product.
- Complete method validation report.
- Details of container closure is required i.e. primary packaging and PFP.
- COA of reference standard is required.
- Inclusion of following tests identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy in the next time point of stability testing. Include the following tests in drug product specifications identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy. Also mention content of of semaglutide per ml and performance of same tests in batch analysis at release and stability (where applicable).
- Data logger's data for refrigerated condition real time and accelerated condition for 6 months is required.
- The source of semaglutide is rDNA , submit bio similarity studies (Quality Comparision and clinical data/equivalence in comparison to innovator product. Provide justification where studies are "Not applicable".
- In use stability studies of drug product i.e. after first opening.

Case # 22	
Name, address of Applicant / Marketing Authorization Holder	Company Name: Weather Folds Pharmaceuticals Company Address: Plot no. 69/2, Phase II, Industrial Area, Hattar, Pakistan. Site Address: Plot No. 69/2, Phase-II, Industrial Area, Hattar.
Name, address of Manufacturing site.	Company Name: Weather Folds Pharmaceuticals Company Address: Plot no. 69/2, Phase II, Industrial Area, Hattar, Pakistan. Site Address: Plot No. 69/2, Phase-II, Industrial Area, Hattar. Date of renewal 27-09-2013
GMP status of the firm	NA
Evidence of approval of manufacturing facility	Grant of Additional Section Biological non-rDNA Liquid Injection Vial and PFS (New)
Status of the applicant	☒ Manufacturer

Status of application	SBP
Intended use of pharmaceutical product	☒ Domestic and Export sales
Dy. No. and date of submission	Tracking ID:A7L-79Y-ZGV1 Application Number:110256 Date of Receiving:10-07-2025
Details of fee submitted	Challan Number: 06316025445 Division: Biological Evaluation & Registration Paid Fee: 75000.0 Paid Date: 2025-07-06
proposed proprietary name/brand name	Semma Pre-Filled Pen 1mg/0.74ml
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each pre-filled pen contains: - Semaglutide 4mg in 3 ml solution. (Each dose contains 1 mg of semaglutide in 0.74 ml solution)
Pharmaceutical form of applied drug	Liquid solution for injection by SC.
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC code: A10BJ06
Reference to Finished product specifications	As per innovator's specification
Proposed Pack size	1's pen
Proposed unit price	As per Drug pricing committee
The status in reference regulatory authorities	Ozempic 0.25 mg solution for injection One ml of solution contains 1.34 mg of semaglutide*. One pre-filled pen contains 2 mg semaglutide* in 1.5 ml solution. Each dose contains 0.25 mg of semaglutide in 0.19 ml solution. Ozempic 0.5 mg solution for injection 1.5 ml: One ml of solution contains 1.34 mg of semaglutide*. One pre-filled pen contains 2 mg semaglutide* in 1.5 ml solution. Each dose contains 0.5 mg of semaglutide in 0.37 ml solution. 3 ml: One ml of solution contains 0.68 mg of semaglutide*. One pre-filled pen contains 2 mg semaglutide* in 3 ml solution. Each dose contains 0.5 mg of semaglutide in 0.74 ml solution. 3 ml: One ml of solution contains 1.34 mg of semaglutide*. One pre-filled pen contains 4 mg semaglutide* in 3 ml solution. Each dose contains 0.5 mg of semaglutide in 0.37 ml solution. Ozempic 1 mg solution for injection One ml of solution contains 1.34 mg of semaglutide*. One pre-filled pen contains 4 mg semaglutide* in 3 ml solution. Each dose contains 1 mg of semaglutide in 0.74 ml solution. One ml of solution contains 2.68 mg of semaglutide*. One pre-filled pen contains 8 mg semaglutide* in 3 ml solution. Each dose contains 1 mg of semaglutide in 0.37 ml solution. Ozempic 2 mg solution for injection One ml of solution contains 2.68 mg of semaglutide*. One pre-filled pen contains 8 mg semaglutide* in 3 ml solution. Each dose contains 2 mg of semaglutide in 0.74 ml solution
For generic drugs (me-too status)	--
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO template.
Module-III Drug Substance:	
Manufacturer of DS	Fuxin Long Rui Pharmaceutical CO., Ltd Address: Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China
Source	Not submitted.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Accelerated (5°C ± 3°C) B065C120220804 Equivalent to commercial packaging system 1 month, 2 months, 3 months, and 6 months. B065C120220805 B065C120220806 Storage condition (°C, % RH) Batch number Container closure system Completed (and proposed) testing intervals Long Term (-20°C ± 5°C) B065C120220804 Equivalent to commercial packaging system 3 months, 6 months, 9 months, 12 months, 18months, 24 months

Module-III Drug Product:	
Manufacturing Site	Weather Folds Pharmaceuticals Company Address: Plot no. 69/2, Phase II, Industrial Area, Hattar, Pakistan. Site Address: Plot No. 69/2, Phase-II, Industrial Area, Hattar. Date of renewal 27-09-2013
Container closure system of the drug product	SEMMA Injection are packaged as 1's Prefilled Injections further Packed in Bleech Card board Unit Carton along with Leaflet.
Stability study data of drug product, shelf life and storage conditions	T-43, T-44, T-45 Batch Size. 1500 PFP Dom-07-2024
Storage Conditions	Store below 25
Module 4	Not Submitted.
Module 5	Not Submitted.

Remarks of the Evaluator

- Submit Module 1 as per final guidance document for biological products as attached below, including all the commitments and SMPC.
- Grant of Additional Section is Biological non-rDNA Liquid Injection Vial and PFS (New). Clarification is required where the sterile batches of biological product of rDNA origin have been manufactured.
- Clarification is required for container closure whether cartridge or PFP.
- The RRA in section 1.5.9 mentions Rybelsus Injection. Clarification is required.
- Approval of manufacturing facility of API by regulatory body of country and validity.
- Submit section 3.2.S.2.2, to 3.2.S.2.3. The description of manufacturing is mandatory to mention. Provide source whether synthetic or rDNA also provide whether final product is freeze dried or spray dried.
- Justification is required for presence of sodium in the drug substance specifications. Peptide mapping, related substance, HMWP, specific activity not performed on drug substance by drug product manufacturer. Clarification is required.
- The USFDA recommends "Maximum Potency per unit dose" of propylene glycol 1.4%w/v whereas, the amount of propylene glycol is 60mg in 3ml. Justification is required.
- Provide batch formula per ml in composition of drug product.
- Provide process flow for the manufacturing of drug-device combination product.
- Include the following tests in drug product specifications identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy. Also mention content of semaglutide per ml and performance of same tests in batch analysis at release and stability (where applicable).
- Submit analytical procedures and method validation report.
- Submit section 3.2.P.5.5 i.e. characterization of impurities.
- COA of reference standard is required.
- Details of container closure is required i.e. primary packaging and PFP.
- The DML attached in section 3.2.P.8.3 is of "Hangzhou Patience Chemical Co., Ltd Registered Address: No. 6 Xiyuan 7th Road, Sandun Town, Xihu District, Hangzhou, Zhejiang, China" whereas, DS manufacturer is "Fuxin Long Rui Pharmaceutical CO., Ltd Address: Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China".
- Commercial invoice is not attested by DRAP.
- Provide consumption record of 200 g of semaglutide in all manufactured batches tablets and injection (PFP and PFS).
- Inclusion of following tests identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy in the next time point of stability testing.
- Submit in-use stability studies i.e. after first opening.
- Data logger's data for refrigerated condition real time (2-8C) and accelerated condition (25C/60RH) is required.
- The source of semaglutide is rDNA, submit bio similarity studies as per "WHO Guidelines on evaluation of biosimilar Replacement of Annex 2 of WHO Technical Report Series, No. 977" on attached format, with PK/PD mandatory study. Provide justification where studies are not applicable in the light of reference guidelines.

Applicant Response

Applicant has submitted response of syringe instead of PFP.

Decision of 349th Meeting:

The Registration Board deferred the case for the submission of the following documents:

- Module 1 as per final guidance document for biological products as attached below, including all the commitments and SMPC.

- Fee for correction in typographical error in storage condition for semaglutide injection, the evidence of cold storage/stability chamber for 2-8C is required.
- The manufacturing of batches is in 2024, whereas section has been granted on 25th June 2025. Clarification is required where the sterile batches of biological product have been manufactured, as no response was submitted earlier.
- Evidence of section approval in which rDNA Prefilled pen/cartridge has been manufactured, as attached evidence is of non r DNA Pre-filled syringe and vial.
- Section 3.2.S.2.2, to 3.2.S.2.3. The description of manufacturing is mandatory to mention. Provide source whether synthetic or rDNA.
- Performance of Peptide mapping, related substance, HMWP, biological activity tests on drug substance by drug product manufacturer.
- The USFDA recommends "Maximum Potency per unit dose" of propylene glycol 1.4%w/v. Justification is required along with calculation in % w/v for propylene glycol and evidence of BMR .
- Process flow for the manufacturing of drug-device combination product.
- Complete method validation report.
- Details of container closure is required i.e. primary packaging and PFP.
- COA of reference standard is required.
- Inclusion of following tests identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy in the next time point of stability testing. Include the following tests in drug product specifications identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy. Also mention content of semaglutide per ml and performance of same tests in batch analysis at release and stability (where applicable).
- Data logger's data for refrigerated condition real time and accelerated condition for 6 months is required.
- The source of semaglutide is rDNA , submit bio similarity studies (Quality Comparison and clinical data/equivalence in comparison to innovator product. Provide justification where studies are "Not applicable".
- In use stability studies of drug product i.e. after first opening.

Case # 23	
Name, address of Applicant / Marketing Authorization Holder	Company Name: Weather Folds Pharmaceuticals Company Address: Plot no. 69/2, Phase II, Industrial Area, Hattar, Pakistan. Site Address: Plot No. 69/2, Phase-II, Industrial Area, Hattar.
Name, address of Manufacturing site.	Company Name: Weather Folds Pharmaceuticals Company Address: Plot no. 69/2, Phase II, Industrial Area, Hattar, Pakistan. Site Address: Plot No. 69/2, Phase-II, Industrial Area, Hattar. Date of renewal 27-09-2013
GMP status of the firm	NA
Evidence of approval of manufacturing facility	Grant of Additional Section Biological non-rDNA Liquid Injection Vial and PFS (New)
Status of the applicant	☒ Manufacturer
Status of application	SBP
Intended use of pharmaceutical product	☒ Domestic and Export sales
Dy. No. and date of submission	Tracking ID:5B1-TXW-8W5B Application Number:110258
Details of fee submitted	Challan Number: 06316025445 Division: Biological Evaluation & Registration Paid Fee: 75000.0 Paid Date: 2025-07-06
proposed proprietary name/brand name	Semma Pre-Filled Pen 2mg/0.74ml
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each pre-filled pen contains: - Semaglutide 8mg in 3 ml solution. (Each dose contains 2 mg of semaglutide in 0.74 ml solution)

Pharmaceutical form of applied drug	Liquid solution for injection by SC.
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC code: A10BJ06
Reference to Finished product specifications	As per innovator's specification
Proposed Pack size	1's pen
Proposed unit price	As per Drug pricing committee
The status in reference regulatory authorities	Ozempic 0.25 mg solution for injection One ml of solution contains 1.34 mg of semaglutide*. One pre-filled pen contains 2 mg semaglutide* in 1.5 ml solution. Each dose contains 0.25 mg of semaglutide in 0.19 ml solution. Ozempic 0.5 mg solution for injection 1.5 ml: One ml of solution contains 1.34 mg of semaglutide*. One pre-filled pen contains 2 mg semaglutide* in 1.5 ml solution. Each dose contains 0.5 mg of semaglutide in 0.37 ml solution. 3 ml: One ml of solution contains 0.68 mg of semaglutide*. One pre-filled pen contains 2 mg semaglutide* in 3 ml solution. Each dose contains 0.5 mg of semaglutide in 0.74 ml solution. 3 ml: One ml of solution contains 1.34 mg of semaglutide*. One pre-filled pen contains 4 mg semaglutide* in 3 ml solution. Each dose contains 0.5 mg of semaglutide in 0.37 ml solution. Ozempic 1 mg solution for injection One ml of solution contains 1.34 mg of semaglutide*. One pre-filled pen contains 4 mg semaglutide* in 3 ml solution. Each dose contains 1 mg of semaglutide in 0.74 ml solution. One ml of solution contains 2.68 mg of semaglutide*. One pre-filled pen contains 8 mg semaglutide* in 3 ml solution. Each dose contains 1 mg of semaglutide in 0.37 ml solution. Ozempic 2 mg solution for injection One ml of solution contains 2.68 mg of semaglutide*. One pre-filled pen contains 8 mg semaglutide* in 3 ml solution. Each dose contains 2 mg of semaglutide in 0.74 ml solution
For generic drugs (me-too status)	--
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO template.
Module-III Drug Substance:	
Manufacturer of DS	Fuxin Long Rui Pharmaceutical CO., Ltd Address: Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China
Source	Not submitted.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Accelerated (5°C ± 3°C) B065C120220804 Equivalent to commercial packaging system 1 month, 2 months, 3 months, and 6 months. B065C120220805 B065C120220806 Storage condition (°C, % RH) Batch number Container closure system Completed (and proposed) testing intervals Long Term (-20°C ± 5°C) B065C120220804 Equivalent to commercial packaging system 3 months, 6 months, 9 months, 12 months, 18months, 24 months
Module-III Drug Product:	
Manufacturing Site	Weather Folds Pharmaceuticals Company Address: Plot no. 69/2, Phase II, Industrial Area, Hattar, Pakistan. Site Address: Plot No. 69/2, Phase-II, Industrial Area, Hattar. Date of renewal 27-09-2013
Container closure system of the drug product	SEMMA Injection are packaged as 1's Prefilled Injections further Packed in Bleech Card board Unit Carton along with Leaflet.
Stability study data of drug product, shelf life and storage conditions	T-46, T-47, T-48 Batch Size. 1500 PFP Dom-07-2024
Storage Conditions	Store below 25
Module 4	Not Submitted.
Module 5	Not Submitted.

Remarks of the Evaluator

- Submit Module 1 as per final guidance document for biological products as attached below, including all the commitments and SMPC.
- Grant of Additional Section is Biological non-rDNA Liquid Injection Vial and PFS (New). Clarification is required where the sterile batches of biological product of rDNA origin have been manufactured.
- Clarification is required for container closure whether cartridge or PFP.
- The RRA in section 1.5.9 mentions Rybelsus Injection. Clarification is required.
- Approval of manufacturing facility of API by regulatory body of country and validity.
- Submit section 3.2.S.2.2, to 3.2.S.2.3. The description of manufacturing is mandatory to mention. Provide source whether synthetic or rDNA also provide whether final product is freeze dried or spray dried.
- Justification is required for presence of sodium in the drug substance specifications. Peptide mapping, related substance, HMWP, specific activity not performed on drug substance by drug product manufacturer. Clarification is required.
- The USFDA recommends "Maximum Potency per unit dose" of propylene glycol 1.4%w/v whereas, the amount of propylene glycol is 60mg in 3ml. Justification is required.
- Provide batch formula per ml in composition of drug product.
- Provide process flow for the manufacturing of drug-device combination product.
- Include the following tests in drug product specifications identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy. Also mention content of semaglutide per ml and performance of same tests in batch analysis at release and stability (where applicable).
- Submit analytical procedures and method validation report.
- Submit section 3.2.P.5.5 i.e. characterization of impurities.
- COA of reference standard is required.
- Details of container closure is required i.e. primary packaging and PFP.
- The DML attached in section 3.2.P.8.3 is of "Hangzhou Patience Chemical Co., Ltd Registered Address: No. 6 Xiyuan 7th Road, Sandun Town, Xihu District, Hangzhou, Zhejiang, China" whereas, DS manufacturer is "Fuxin Long Rui Pharmaceutical CO., Ltd Address: Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China".
- Commercial invoice is not attested by DRAP.
- Provide consumption record of 200 g of semaglutide in all manufactured batches tablets and injection (PFP and PFS).
- Inclusion of following tests identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy in the next time point of stability testing.
- Submit in-use stability studies i.e. after first opening.
- Data logger's data for refrigerated condition real time (2-8°C) and accelerated condition (25°C/60RH) is required.
- The source of semaglutide is rDNA, submit bio similarity studies as per "WHO Guidelines on evaluation of biosimilar Replacement of Annex 2 of WHO Technical Report Series, No. 977" on attached format, with PK/PD mandatory study. Provide justification where studies are not applicable in the light of reference guidelines.

Reply received on Case Management query Tracking ID: PMA-ULX-5Y6N, Application Number: 112095, Created on: July 13th, 2025, 10:41 pm.

S.NO	Observation/Document Required	Justification/Status of Documents
01	The innovator product Special precautions for storage is Store in a refrigerator (2 °C–8 °C) whereas, you have recommended store below 25C. Justification is required.	It was typographical mistake. Digital Data Logger indicates 2-8c.
02	In continuation to previous shortcoming also provide evidence of prefilled pen section.	We have attached the Section Approval Letter for Vial and Prefilled Syringe manufacturing sections. As per WHO TRS 999 guidelines, rDNA products may be manufactured in a non-rDNA-dedicated facility, provided that appropriate GMP controls are in place to prevent cross-contamination.

		Furthermore, the manufacturing process for Prefilled Syringe is the same as that of the Prefilled Pen. Therefore, a separate Section Approval is not required.
03	Submit Module 1 as per final guidance document for biological products as attached below including all the commitments and SMPC.	Rectified Attached.
04	The manufacturing of batches is in 2024, whereas section has been granted on 25th June 2025. Clarification is required where the sterile batches of biological product have been manufactured.	6 Month Stability Data attached as per DRAP Requirement.
05	Clarification is required for container closure whether cartridge or PFP.	1's Prefilled Syringe in Unit Carton along with leaflet.
06	Evidence of section approval in which rDNA PFS has been manufactured, as attached evidence is of non r DNA PFS.	According to WHO TRS 999 guidelines, the rDNA products can be manufactured in Non-rDNA facility, hence no separate section required.
07	The RRA in section 1.5.9 mentions Rybelsus Injection. Clarification is required.	Typographical Mistake, which has been rectified.
08	Approval of manufacturing facility of API by regulatory body of country and validity	Attached.
09	Submit section 3.2.S.2.2, to 3.2.S.2.3. The description of manufacturing is mandatory to mention. Provide source whether synthetic or rDNA.	The Product origin is China, and this is patent product, hence this cannot be provided.
10	Justification is required for presence of sodium and determination of sodium assay in Drug substance	Sodium determine by API manufacturer and available in DMF.
11	Peptide mapping, related substance, HMWP, specific activity tests are not performed on drug substance by drug product manufacturer. Clarification is required.	The Tests have been performed by the Drug Substance Manufacturer, hence not required to be performed by drug product manufacturer.
12	The USFDA recommends "Maximum Potency per unit dose" of propylene glycol 1.4%w/v whereas; the amount of propylene glycol is 30mg in 1.5ml. Justification is required along with calculation in % w/v for propylene glycol.	It was typographical mistake. Correct Formulation Attached.
13	Provide batch formula per ml in product development section.	Attached.
14	Provide process flow for the manufacturing of drug-device	Attached

	combination product.	
16	Submit analytical procedures and method validation report.	Attached
17	Submit section 3.2.P.5.5 i.e. characterization of impurities	Impurities are Exempted hence not available.
18	Details of container closure is required i.e. primary packaging and PFP.	1's Prefilled Pen in Unit Carton Along with Leaflet.
19	COA of reference standard is required.	Attached
20	The DML attached in section 3.2.P.8.3 is of "Hangzhou Patience Chemical Co.,Ltd Registered Address: No. 6 Xiyuan7th Road,SandunTown,Xihu District, Hangzhou,Zhejiang,China" whereas, DS manufacturer is "Fuxin Long Rui Pharmaceutical CO., Ltd Address: Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province - 123000, China"	Correct DML Attached.
21	Commercial invoice is not ADC/DDC attested. .	We imported Semaglutide and cleared via Green Channel. For reference, Goods Declaration is attached and also we have officially intimated to DRAP regarding our materials imported without Clearance Certificate. The Intimation letter with receiving is attached along with.
22	Provide consumption record of 200 g of semaglutide in tablets and injection.	Attached
23	Inclusion of following tests identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy in the next time point of stability testing. Include the following tests in drug product specifications identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy. Also mention content of semaglutide per ml and performance of same tests in batch analysis at release and stability (where applicable).	BET has already been performed and is included in the Certificate of Analysis (CoA) and Stability Data Sheets. Phenol testing was not performed by the innovator; however, if recommended by the Board, we shall conduct phenol content testing in the next stability intervals. Furthermore, as per the Board's decision in the 340th DRB Meeting regarding the registration of our Semaglutide Tablet, we confirm that identification testing through peptide mapping shall be performed by a Government Testing Laboratory for every . commercial batch of the injectable dosage form too.
24		
25	Data logger's data for refrigerated condition real time and accelerated condition is required.	Attached

26	The source of semaglutide is rDNA , submit bio similarity studies as per “WHO Guidelines on evaluation of biosimilars Replacement of Annex 2 of WHO Technical Report Series, No. 977” on attached format, with PK/PD mandatory study. Provide justification where studies are Not applicable.	API manufacturer and biosimilarity of the API has been As the required tests have already been performed by the established at the Drug Substance stage, these tests are not required to be repeated for the Finished Product.

Decision of 349th Meeting:

The Registration Board deferred the case for the submission of the following documents:

- Fee for correction in typographical error in storage condition for semaglutide injection, the evidence of cold storage/stability chamber for 2-8C is required.
- The manufacturing of batches is in 2024, whereas section has been granted on 25th June 2025. Clarification is required where the sterile batches of biological product have been manufactured, as no response was submitted earlier.
- Evidence of section approval in which rDNA Prefilled pen/cartidge has been manufactured, as attached evidence is of non r DNA Pre-filled syringe and vial.
- Section 3.2.S.2.2, to 3.2.S.2.3. The description of manufacturing is mandatory to mention. Provide source whether synthetic or rDNA.
- Performance of Peptide mapping, related substance, HMWP, biological activity tests on drug substance by drug product manufacturer.
- The USFDA recommends “Maximum Potency per unit dose” of propylene glycol 1.4%w/v. Justification is required along with calculation in % w/v for propylene glycol and evidence of BMR .
- Process flow for the manufacturing of drug-device combination product.
- Complete method validation report.
- Details of container closure is required i.e. primary packaging and PFP.
- COA of reference standard is required.
- Inclusion of following tests identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy in the next time point of stability testing. Include the following tests in drug product specifications identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy. Also mention content of of semaglutide per ml and performance of same tests in batch analysis at release and stability (where applicable).
- Data logger’s data for refrigerated condition real time and accelerated condition for 6 months is required.
- The source of semaglutide is rDNA , submit bio similarity studies (Quality Comparison and clinical data/equivalence in comparison to innovator product. Provide justification where studies are “Not applicable”.
- In use stability studies of drug product i.e. after first opening.

Source: rDNA Drug Substance Import Local Manufacturing Applied Container Closure System: Pre-filled Syringe Biosimilar to Ozempic Injection		
Case # 24		
Name, address of Applicant / Marketing Authorization Holder	Company Name: Weather Folds Pharmaceuticals Company Address: Plot no. 69/2, Phase II, Industrial Area, Hattar, Pakistan. Site Address: Plot No. 69/2, Phase-II, Industrial Area, Hattar.	
Name, address of Manufacturing site.	Company Name: Weather Folds Pharmaceuticals Company Address: Plot no. 69/2, Phase II, Industrial Area, Hattar, Pakistan. Site Address: Plot No. 69/2, Phase-II, Industrial Area, Hattar. Date of renewal 27-09-2013	

GMP status of the firm	NA
Evidence of approval of manufacturing facility	Grant of Additional Section Biological non-rDNA Liquid Injection Vial and PFS (New)
Status of the applicant	☒ Manufacturer
Status of application	SBP
Intended use of pharmaceutical product	☒ Domestic and Export sales
Dy. No. and date of submission	Tracking ID:RGZ-SVT-3UM1 Application Number:108899 Date of submission: 09-07-2025
Details of fee submitted	Challan Number: 0380618523 Division: Biological Evaluation & Registration Paid Fee: 37000.0 Paid Date: 2025-06-30
proposed proprietary name/brand name	Semma Injection 0.5mg
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each PFS contains: - Semaglutide 2 mg in 1.5 ml solution. (Each dose contains 0.50 mg of semaglutide in 0.37ml solution) (As per Innovator's Specifications)
Pharmaceutical form of applied drug	Liquid solution for injection by SC.
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC code: A10BJ06
Reference to Finished product specifications	As per innovator's specification
Proposed Pack size	1's PFS
Proposed unit price	As per Drug pricing committee
The status in reference regulatory authorities	Ozempic 0.25 mg solution for injection One ml of solution contains 1.34 mg of semaglutide*. One pre-filled pen contains 2 mg semaglutide* in 1.5 ml solution. Each dose contains 0.25 mg of semaglutide in 0.19 ml solution. Ozempic 0.5 mg solution for injection 1.5 ml: One ml of solution contains 1.34 mg of semaglutide*. One pre-filled pen contains 2 mg semaglutide* in 1.5 ml solution. Each dose contains 0.5 mg of semaglutide in 0.37 ml solution. 3 ml: One ml of solution contains 0.68 mg of semaglutide*. One pre-filled pen contains 2 mg semaglutide* in 3 ml solution. Each dose contains 0.5 mg of semaglutide in 0.74 ml solution. 3 ml: One ml of solution contains 1.34 mg of semaglutide*. One pre-filled pen contains 4 mg semaglutide* in 3 ml solution. Each dose contains 0.5 mg of semaglutide in 0.37 ml solution. Ozempic 1 mg solution for injection One ml of solution contains 1.34 mg of semaglutide*. One pre-filled pen contains 4 mg semaglutide* in 3 ml solution. Each dose contains 1 mg of semaglutide in 0.74 ml solution. One ml of solution contains 2.68 mg of semaglutide*. One pre-filled pen contains 8 mg semaglutide* in 3 ml solution. Each dose contains 1 mg of semaglutide in 0.37 ml solution. Ozempic 2 mg solution for injection One ml of solution contains 2.68 mg of semaglutide*. One pre-filled pen contains 8 mg semaglutide* in 3 ml solution. Each dose contains 2 mg of semaglutide in 0.74 ml solution
For generic drugs (me-too status)	--
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO template.
Module-III Drug Substance:	
Manufacturer of DS	Fuxin Long Rui Pharmaceutical CO., Ltd Address: Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China

Source	Not submitted.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Accelerated (5°C ± 3°C) B065C120220804 Equivalent to commercial packaging system 1 month, 2 months, 3 months, and 6 months. B065C120220805 B065C120220806 Storage condition (°C, % RH) Batch number Container closure system Completed (and proposed) testing intervals Long Term (-20°C ± 5°C) B065C120220804 Equivalent to commercial packaging system 3 months, 6 months, 9 months, 12 months, 18 months, 24 months
Module-III Drug Product:	
Manufacturing Site	Weather Folds Pharmaceuticals Company Address: Plot no. 69/2, Phase II, Industrial Area, Hattar, Pakistan. Site Address: Plot No. 69/2, Phase-II, Industrial Area, Hattar. Date of renewal 27-09-2013
Container closure system of the drug product	SEMMA Injection are packaged as 1's Prefilled Injections further Packed in Bleech Card board Unit Carton along with Leaflet.
Stability study data of drug product, shelf life and storage conditions	T-22, T-23, T-24 Batch Size. 1500 PFP Dom-07-2024
Storage Conditions	Store below 25
Module 4	Not Submitted.
Module 5	Not Submitted.

Remarks of the Evaluator

- Submit Module 1 as per final guidance document for biological products as attached below, including all the commitments and SMP.
- Evidence of approval of applied formulation in applied strength 2mg/1.5ml and applied dose filled volume in prefilled syringe in RRA is required.
- Clarification is required whether the applied PFS is of 1.5ml or 0.37ml. In case of 0.37ml, justify the use of preservative.
- Evidence of section approval in which rDNA PFS has been manufactured, as attached evidence is of non rDNA PFS.
- The RRA in section 1.5.9 mentions Rybelsus Injection. Clarification is required.
- Approval of manufacturing facility of API by regulatory body of country and validity.
- Submit section 3.2.S.2.2, to 3.2.S.2.3. The description of manufacturing is mandatory to mention. Provide source whether synthetic or rDNA.
- Justification is required for presence of sodium and determination of sodium assay in Drug substance.
- Clarification is required for the container closure system PFS in 2mg/1.5ml with respect to dose and usage.
- Peptide mapping, related substance, HMWP, specific activity tests are not performed on drug substance by drug product manufacturer. Clarification is required.
- The USFDA recommends "Maximum Potency per unit dose" of propylene glycol 1.4%w/v whereas; the amount of propylene glycol is 30mg in 1.5ml. Justification is required along with calculation in % w/v for propylene glycol.
- Provide batch formula per ml in product development section.
- Submit process validation protocol for applied PFS as attached protocol is of 0.25mg/0.19ml.
- The master formulation is of 0.25mg/0.19ml. Moreover, if single dose is applied justify the use of preservative.
- Submit batch analysis of applied product i.e. 2mg/1.5ml(**0.5 mg of semaglutide in 0.37 ml solution**) as applied data is of **0.25mg/0.19 ml**.
- Include the following tests in drug product specifications identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy. Also mention content of semaglutide per ml and performance of same tests in batch analysis at release and stability(where applicable).
- Submit analytical procedures and method validation report.
- Submit section 3.2.P.5.5 i.e. characterization of impurities.
- COA of reference standard is required.
- Details of container closure is required i.e. primary packaging.
- The DML attached in section 3.2.P.8.3 is of "Hangzhou Patience Chemical Co.,Ltd Registered Address: No. 6 Xiyuan7th Road, Sandun Town, Xihu District, Hangzhou, Zhejiang, China" whereas, DS manufacturer is "Fuxin Long Rui Pharmaceutical CO., Ltd Address: Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China".
- Commercial invoice is not ADC/DDC attested.
- Provide consumption record of 200 g of semaglutide in tablets and injection.
- Clarification is required whether stability has been conducted at long term 2 to 8 or 30C/65 and accelerated at 25C/60rH or 40C/75%.

- Inclusion of following tests identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy in the next time point of stability testing if conducted at 2-8C.
- Justification is required for storage condition "Store below 25C".
- The stability summary sheets and supporting data are of 0.25mg/0.19ml whereas, the applied dose is **0.5 mg of semaglutide in 0.37 ml solution.**
- Submit in use stability studies of drug product i.e. after first opening.
- Data logger's data for refrigerated condition real time and accelerated condition is required.
- The provided BMR is of 0.5mg/0.37ml.
- If the source of semaglutide is rDNA , submit bio similarity studies as per "WHO Guidelines on evaluation of biosimilars Replacement of Annex 2 of WHO Technical Report Series, No. 977" on attached format, with PK/PD mandatory study. Provide justification where studies are Not applicable

Reponse Submitted via Case Management Query [Tracking ID:RRX-ERD-NP99](#)[Application Number:112093](#)[Created on:July 13th, 2025, 10:36 pm](#)

S.NO	Observation/Document Required	Justification/Status of Documents
01	Submit Module 1 as per final guidance document for biological products as attached below, including all the commitments and SMPC.	Attached.
02	Evidence of approval of applied formulation in applied strength 2mg/1.5ml and applied dose filled volume in prefilled syringe in RRA is required.	Stability studies indicate no interaction of primary packing with product. As per the decision followed by the DRB 336, against Semaglutide Macter Product.
03	Clarification is required whether the applied PFS is of 1.5ml or 0.37ml. In case of 0.37ml , justify the use of preservative	PFS is 1.5ml.
04	• Evidence of section approval in which rDNA PFS has been manufactured, as attached evidence is of non r DNA PFS.	According to WHO TRS 999 guidelines, the rDNA products can be manufactured in Non-rDNA facility, hence no separate section required.
05	The RRA in section 1.5.9 mentions Rybelsus Injection. Clarification is required.	Typographical Mistake, which has been rectified.
06	Approval of manufacturing facility of API by regulatory body of country and validity.	Attached
06	Submit section 3.2.S.2.2, to 3.2.S.2.3.The description of manufacturing is mandatory to mention. Provide source whether synthetic or rDNA	The Product origin is China, and this is patent product, hence this cannot be provided.
07	Justification is required for presence of sodium and determination of sodium assay in Drug substance	Sodium determine by API manufacturer and available in DMF.
08	Clarification is required for the container closure system PFS in 2mg/1.5ml with respect to dose and usage.	1's Prefilled Syringe in Unit Carton Along with Leaflet. Each Pre-Filled Syringe contains: Semaglutide 2mg in 1.5 ml solution. (Each dose contains 0.5 mg of semaglutide in 0.37 ml solution) (As per Innovator's Specifications)
09	The USFDA recommends "Maximum Potency	Mistakenly wrong due to calculator error, revised and

	per unit dose” of propylene glycol 1.4%w/v whereas; the amount of propylene glycol is 30mg in 1.5ml. Justification is required along with calculation in % w/v for propylene glycol.	corrected formulation attached in Annexure-1
10	· Provide batch formula per ml in product development section.	Revised BMR attached in Annexure-2
11	Submit process validation protocol for applied PFS as attached protocol is of 0.25mg/0.19ml.	Process validation protocol of applied formulation is Attached in Annexure-3
12	· The master formulation is of 0.5mg/0.37ml. Moreover, if single dose is applied justify the use of preservative.	Attached in Annexure-4
13	Submit batch analysis of applied product i.e. 2mg/1.5ml (0.5 mg of semaglutide in 0.37 ml solution) as applied data is of 0.25mg/0.19 ml. . .	Attached in Annexure-5
15	· Submit analytical procedures and method validation report.	analytical procedures and method validation report attached IN Annexure-6
16	· Submit section 3.2.P.5.5 i.e. characterization of impurities	Impurities are Exempted hence not available.

	COA of reference standard is required.	Attached in Annexure-7
18	Details of container closure is required i.e. primary packaging.	1's Prefilled Syringe in Unit Carton Along with Leaflet.
19	The DML attached in section 3.2.P.8.3 is of "Hangzhou Patience Chemical Co.Ltd Registered Address: No. 6 Xiyuan7th Road,SandunTown,Xihu District, Hangzhou, Zhejiang, China" whereas, DS manufacturer is "Fuxin Long Rui Pharmaceutical CO., Ltd Address: Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province - 123000, China".	Correct DML attached.
20	Commercial invoice is not ADC/DDC attested.	We imported Semaglutide and cleared via Green Channel. For reference, Goods Declaration is attached and also we have officially intimated to DRAP regarding our materials imported without Clearance Certificate. The Intimation letter with receiving is attached along with.
21	Provide consumption record of 200 g of semaglutide in tablets and injection	Attached in Annexure-8
22	Clarification is required whether stability has been conducted at long term 2to 8 or 30C/65 and accelerated at 25C/60rH or 40C/75%.	stability has been conducted at long term 2°C to 8°C and accelerated at 25°C/60%RH
23	· Inclusion of following tests identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy in the next time point of stability testing if conducted at 2-8C.	BET has already been performed and is included in the Certificate of Analysis (CoA) and Stability Data Sheets. Phenol testing was not performed by the innovator; however, if recommended by the Board, we shall conduct phenol content testing in the next stability intervals. Furthermore, as per the Board's decision in the 340th DRB Meeting regarding the registration of our Semaglutide Tablet, we confirm that identification testing through peptide mapping shall be performed by a Government Testing Laboratory for every commercial batch of the injectable dosage form too.
24	Include the following tests in drug product specifications identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy. Also mention content of semaglutide per ml and performance of same tests in batch analysis at release and stability (where applicable).	
25	Justification is required for storage condition	Store at condition 2°C to 8°C
26	Data logger's data for refrigerated condition real time and accelerated condition is required.	Attached in Annexure-9
27	The provided BMR is of 0.5mg/0.37ml.	Revised BMR according to complete pack attached in Annexure-10
28	· If the source of semaglutide is rDNA, submit bio similarity studies as per "WHO Guidelines on evaluation of biosimilars Replacement of Annex 2 of WHO Technical Report Series, No. 977" on attached format, with PK/PD mandatory	As the required tests have already been performed by the API manufacturer and biosimilarity of the API has been established at the Drug Substance stage, these

	study. Provide justification where studies are Not applicable	tests are not required to be repeated for the Finished Product.
29	Submit in use stability studies of drug product i.e. after first opening. ·	After first opening all parameters were test and found within limits, further store at real and accelerated condition and observe weekly for 6 weeks and checks all parameters (appearance, PH, BET, Assay) and found within limits at all interval.

Decision of 349th Meeting:

The Registration Board deferred the case for the submission of the following documents:

- Evidence of approval of applied formulation in applied strength 2mg/1.5ml and applied dose filled volume in prefilled syringe in RRA is required.
- Justify the use of preservative in PFS.
- Evidence of section approval in which rDNA PFS has been manufactured, as attached evidence is of non r DNA PFS.
- Submit section 3.2.S.2.2, to 3.2.S.2.3. The description of manufacturing is mandatory to mention. Provide source whether synthetic or rDNA.
- Clarification is required for the container closure system PFS in 2mg/1.5ml with respect to dose and usage.
- Peptide mapping, related substance, HMWP, specific activity tests are not performed on drug substance by drug product manufacturer. Clarification is required.
- The master formulation is of 0.25mg/0.19ml. Moreover, if single dose is applied justify the use of preservative.
- Include the following tests in drug product specifications identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy. Also mention content of semaglutide per ml and performance of same tests in batch analysis at release and stability (where applicable).
- Submit analytical procedures and method validation report.
- COA of reference standard is required.
- Details of container closure is required i.e. primary packaging.
- Inclusion of following tests identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy in the next time point of stability testing if conducted at 2-8C.
- Submit in use stability studies of drug product i.e. after first opening.
- Data logger's data for refrigerated condition real time and accelerated condition for 6 months is required.
- If the source of semaglutide is rDNA, submit bio similarity studies as per "WHO Guidelines on evaluation of biosimilars Replacement of Annex 2 of WHO Technical Report Series, No. 977" including clinical equivalence with innovator product. Provide justification where studies are Not applicable

Case # 25		
Name, address of Applicant / Marketing Authorization Holder	Company Name: Weather Folds Pharmaceuticals Company Address: Plot no. 69/2, Phase II, Industrial Area, Hattar, Pakistan. Site Address: Plot No. 69/2, Phase-II, Industrial Area, Hattar.	
Name, address of Manufacturing site.	Company Name: Weather Folds Pharmaceuticals Company Address: Plot no. 69/2, Phase II, Industrial Area, Hattar, Pakistan. Site Address: Plot No. 69/2, Phase-II, Industrial Area, Hattar. Date of renewal 27-09-2013	
GMP status of the firm	NA	
Evidence of approval of manufacturing facility	Grant of Additional Section Biological non-rDNA Liquid Injection Vial and PFS (New)	
Status of the applicant	☒ Manufacturer	
Status of application	SBP	

Intended use of pharmaceutical product	☒ Domestic and Export sales
Dy. No. and date of submission	Tracking ID:V25-Q5E-PU4S Application Number:108897 Date of submission: 09-07-2025
Details of fee submitted	Challan Number: 0998557406 Division: Biological Evaluation & Registration Paid Fee: 37000.0 Paid Date: 2025-06-30
proposed proprietary name/brand name	Semma Injection 0.25mg
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each PFS contains: - Semaglutide 2 mg in 1.5 ml solution. Each dose contains 0.25 mg of semaglutide in 0.19ml solution
Pharmaceutical form of applied drug	Liquid solution for injection by SC.
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC code: A10BJ06
Reference to Finished product specifications	As per innovator's specification
Proposed Pack size	1's PFS
Proposed unit price	As per Drug pricing committee
The status in reference regulatory authorities	Ozempic 0.25 mg solution for injection One ml of solution contains 1.34 mg of semaglutide*. One pre-filled pen contains 2 mg semaglutide* in 1.5 ml solution. Each dose contains 0.25 mg of semaglutide in 0.19 ml solution. Ozempic 0.5 mg solution for injection 1.5 ml: One ml of solution contains 1.34 mg of semaglutide*. One pre-filled pen contains 2 mg semaglutide* in 1.5 ml solution. Each dose contains 0.5 mg of semaglutide in 0.37 ml solution. 3 ml: One ml of solution contains 0.68 mg of semaglutide*. One pre-filled pen contains 2 mg semaglutide* in 3 ml solution. Each dose contains 0.5 mg of semaglutide in 0.74 ml solution. 3 ml: One ml of solution contains 1.34 mg of semaglutide*. One pre-filled pen contains 4 mg semaglutide* in 3 ml solution. Each dose contains 0.5 mg of semaglutide in 0.37 ml solution. Ozempic 1 mg solution for injection One ml of solution contains 1.34 mg of semaglutide*. One pre-filled pen contains 4 mg semaglutide* in 3 ml solution. Each dose contains 1 mg of semaglutide in 0.74 ml solution. One ml of solution contains 2.68 mg of semaglutide*. One pre-filled pen contains 8 mg semaglutide* in 3 ml solution. Each dose contains 1 mg of semaglutide in 0.37 ml solution. Ozempic 2 mg solution for injection One ml of solution contains 2.68 mg of semaglutide*. One pre-filled pen contains 8 mg semaglutide* in 3 ml solution. Each dose contains 2 mg of semaglutide in 0.74 ml solution
For generic drugs (me-too status)	--
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO template.
Module-III Drug Substance:	
Manufacturer of DS	Fuxin Long Rui Pharmaceutical CO., Ltd Address: Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China
Source	Not submitted.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Accelerated (5°C ± 3°C) B065C120220804 Equivalent to commercial packaging system 1 month, 2 months, 3 months, and 6 months. B065C120220805 B065C120220806 Storage condition (°C, % RH) Batch number Container closure system Completed (and proposed) testing intervals Long Term (-20°C ± 5°C) B065C120220804 Equivalent to commercial packaging system 3 months, 6 months, 9 months, 12 months, 18months, 24 months
Module-III Drug Product:	

Manufacturing Site	Weather Folds Pharmaceuticals Company Address: Plot no. 69/2, Phase II, Industrial Area, Hattar, Pakistan. Site Address: Plot No. 69/2, Phase-II, Industrial Area, Hattar. Date of renewal 27-09-2013
Container closure system of the drug product	SEMMA Injection are packaged as 1's Prefilled Injections further Packed in Bleach Card board Unit Carton along with Leaflet.
Stability study data of drug product, shelf life and storage conditions	T-25, T-26, T-27 Batch Size. 1500 PFP Dom-07-2024
Storage Conditions	Store below 25
Module 4	Not Submitted.
Module 5	Not Submitted.

• **Remarks of the Evaluator**

- Submit Module 1 as per final guidance document for biological products as attached below including all the commitments and SMPC.
- Evidence of approval of applied formulation in applied strength 2mg/1.5ml in prefilled syringe in RRA is required.
- Evidence of section approval in which rDNA PFS has been manufactured, as attached evidence is of non r DNA PFS.
- The RRA in section 1.5.9 mentions Rybelsus Injection. Clarification is required.
- Approval of manufacturing facility of API by regulatory body of country and validity.
- Submit section 3.2.S.2.2, to 3.2.S.2.3. The description of manufacturing is mandatory to mention. Provide source whether synthetic or rDNA.
- Justification is required for presence of sodium and determination of sodium assay in Drug substance.
- Clarification is required for the container closure system PFS in 2mg/1.5ml with respect to dose and usage.
- Peptide mapping, related substance, HMWP, specific activity tests are not performed on drug substance by drug product manufacturer. Clarification is required.
- The USFDA recommends "Maximum Potency per unit dose" of propylene glycol 0.14%w/v whereas; the amount of propylene glycol is 30mg in 1.5ml. Justification is required along with calculation in % w/v for propylene glycol.
- Provide batch formula per ml in product development section.
- Submit process validation protocol for applied PFS as attached protocol is of 0.5mg/0.37ml.
- Submit batch analysis of applied product i.e. 2mg/1.5ml(**0.25 mg of semaglutide in 0.19 ml solution**) as applied data is of **0.5mg/0.37 ml**.
- Include the following tests in drug product specifications identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy. Also mention content of semaglutide per ml and performance of same tests in batch analysis at release and stability(where applicable).
- Submit analytical procedures and method validation report.
- Submit section 3.2.P.5.5 i.e. characterization of impurities.
- COA of reference standard is required.
- Details of container closure is required i.e. primary packaging.
- The DML attached in section 3.2.P.8.3 is of "Hangzhou Patience Chemical Co.,Ltd Registered Address: No. 6 Xiyuan7th Road,SandunTown,Xihu District, Hangzhou,Zhejiang,China" whereas, DS manufacturer is "Fuxin Long Rui Pharmaceutical CO., Ltd Address: Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China".
- Commercial invoice is not ADC/DDC attested.
- Provide consumption record of 200 g of semaglutide in tablets and injection.
- Clarification is required whether stability has been conducted at long term 2to 8 or 30C/65 and accelerated at 25C/60rH or 40C/75%.
- Inclusion of following tests identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy in the next time point of stability testing if conducted at 2-8C.
- Justification is required for storage condition "Store below 25C".
- The stability summary sheets are of 0.5mg/0/37ml whereas, the applied dose is **0.25 mg of semaglutide in 0.19 ml solution**.
- Submit in use stability studies of drug product i.e. after first opening.
- Data logger's data for refrigerated condition real time and accelerated condition is required.
- The provided BMR is of 0.5mg/0.37ml.
- If the source of semaglutide is rDNA , submit bio similarity studies as per "WHO Guidelines on evaluation of biosimilars Replacement of Annex 2 of WHO Technical Report Series, No. 977" on attached format, with PK/PD mandatory study. Provide justification where studies are Not applicable

Reply submitted by applicant via case management query Tracking ID: E8J-55Z-UD7S, Application Number:112092, Created on:

July 13th, 2025, 10:34 pm.

S.NO	Observation/Document Required	Justification/Status of Documents
01	Submit Module 1 as per final guidance document for biological products as attached below including all the commitments and SMPC. . .	Attached.
02	Evidence of approval of applied formulation in applied strength 2mg/1.5ml in prefilled syringe in RRA is required	Stability studies indicate no interaction of primary packing with product. As per the decision followed by the DRB 336, against Semaglutide Macter Product.
03	Evidence of section approval in which rDNA PFS has been manufactured, as attached evidence is of non r DNA PFS.	According to WHO WHO TRS 999 guidelines, the rDNA products can be manufactured in Non-rDNA facility, hence no separate section required.
04	The RRA in section 1.5.9 mentions Rybelsus Injection. Clarification is required.	Typographical Mistake, which has been rectified.
05	Approval of manufacturing facility of API by regulatory body of country and validity	Attached
06	Submit section 3.2.S.2.2, to 3.2.S.2.3.The description of manufacturing is mandatory to mention. Provide source whether synthetic or rDNA. .	The Product origin is China, and this is patent product, hence this cannot be provided.
06	Justification is required for presence of sodium and determination of sodium assay in Drug substance	Sodium determine by API manufacturer and available in DMF.
07	Clarification is required for the container closure system PFS in 2mg/1.5ml with respect to dose and usage	1's Prefilled Syringe in Unit Carton Along with Leaflet. Each Pre-Filled Syringe contains:- Semaglutide 2mg in 1.5 ml solution. (Each dose contains 0.25 mg of semaglutide in 0.19 ml solution) (As per Innovator's Specifications)
08	Peptide mapping, related substance, HMWP, specific activity tests are not performed on drug substance by drug product manufacturer. Clarification is required. .	The Tests have been performed by the Drug Substance Manufacturer, hence not required to be performed by drug product manufacturer.
09	· The USFDA recommends "Maximum Potency per unit dose" of propylene glycol 1.4%w/v whereas; the amount of propylene glycol is 30mg in 1.5ml. Justification is required along with calculation in % w/v for propylene glycol.	Mistakenly wrong due to calculator error, revised and corrected formulation attached in Annexure-1
10	Provide batch formula per ml in product development section.	Revised BMR attached in Annexure-2
11	· Submit process validation protocol for applied PFS as attached protocol is of 0.5mg/0.37ml	Process validation protocol of applied formulation is Attached in Annexure-3
12	Submit batch analysis of applied product i.e. 2mg/1.5ml (0.25mg of semaglutide in 0.19 ml solution) as applied data is of 0.5mg/0.37 ml.	Attached in Annexure-4
13 14	Include the following tests in drug product specifications identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy. Also mention content of of semaglutide per ml and performance of same tests in batch analysis at release and stability (where applicable).	BET has already been performed and is included in the Certificate of Analysis (CoA) and Stability Data Sheets. Phenol testing was not performed by the innovator; however, if recommended by the Board, we shall conduct phenol content testing in the next stability intervals. Furthermore, as per the Board's decision in the 340th DRB Meeting regarding the registration of our Semaglutide Tablet, we confirm that identification testing through peptide mapping shall be performed by a Government Testing Laboratory for every commercial batch of the injectable dosage form too.
15	Submit section 3.2.P.5.5 i.e. characterization of impurities	Impurities are Exempted hence not available.
16	Details of container closure is required i.e. primary packaging.	1's Prefilled Syringe in Unit Carton Along with Leaflet.
17	COA of reference standard is required.	Attached in Annexure-6

18	The DML attached in section 3.2.P.8.3 is of “Hangzhou Patience Chemical Co.,Ltd Registered Address: No. 6 Xiyuan7th Road,SandunTown,Xihu District,Hangzhou,Zhejiang,China” whereas, DS manufacturer is “Fuxin Long Rui Pharmaceutical CO., Ltd Address: Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China”	Correct DML Attached.
19	Commercial invoice is not ADC/DDC attested. .	We imported Semaglutide and cleared via Green Channel. For reference, Goods Declaration is attached and also we have officially intimated to DRAP regarding our materials imported without Clearance Certificate. The Intimation letter with receiving is attached along with.
20	Provide consumption record of 200 g of semaglutide in tablets and injection.	Attached in Annexure-7
21	Justification is required for storage condition “Store below 25C”.	Written as mistakenly
22	The stability summary sheets are of 0.5mg/0.37ml whereas, the applied dose is 0.25 mg of semaglutide in 0.19 ml solution.	Attached Annexure-08
23	Submit analytical procedures and method validation report.	Attached in Annexure 5
24	Data logger’s data for refrigerated condition real time and accelerated condition is required.	Attached in Annexure-9
25	The provided BMR is of 0.5mg/0.37ml.	Attached in Annexure-10
26	If the source of semaglutide is rDNA , submit bio similarity studies as per “WHO Guidelines on evaluation of biosimilars Replacement of Annex 2 of WHO Technical Report Series, No. 977” on attached format, with PK/PD mandatory study. Provide justification where studies are Not applicable.	As the required tests have already been performed by the API manufacturer and biosimilarity of the API has been established at the Drug Substance stage, these tests are not required to be repeated for the Finished Product.
27	Submit in use stability studies of drug product i.e. after first opening	After first opening all parameters were test and found within limits, further store at real and accelerated condition and observe weekly for 6 weeks and checks all parameters (appearance, PH, BET, Assay) and found within limits at all interval.

Decision of 349th Meeting:

The Registration Board deferred the case for the submission of the following documents:

- Evidence of approval of applied formulation in applied strength 2mg/1.5ml in prefilled syringe in RRA is required along with clinical usage of applied strength/dose in PFS.
- Clarification for submission of same filled volume of PFS twice 2mg/1.5ml.
- Evidence of section approval in which rDNA PFS has been manufactured, as attached evidence is of non r DNA PFS.
- Submit section 3.2.S.2.2, to 3.2.S.2.3. The description of manufacturing is mandatory to mention. Provide source whether synthetic or rDNA.
- Clarification is required for the container closure system PFS in 2mg/1.5ml with respect to dose and usage.
- Peptide mapping, related substance, HMWP, specific activity tests are not performed on drug substance by drug product manufacturer. Clarification is required.
- The USFDA recommends “Maximum Potency per unit dose” of propylene glycol 1.4%w/v whereas; the amount of propylene glycol is 30mg in 1.5ml. Justification is required along with calculation in % w/v for propylene glycol.
- Provide batch formula per ml in product development section.
- Include the following tests in drug product specifications identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy. Also mention content of semaglutide per ml and

- performance of same tests in batch analysis at release and stability(where applicable).
- Submit analytical procedures and method validation report.
- COA of reference standard is required.
- Clarification is required whether stability has been conducted at long term 2to 8 or 30C/65 and accelerated at 25C/60rH or 40C/75%.

Inclusion of following tests identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy in the next time point of stability testing if conducted at 2-8C.

Submit in use stability studies of drug product i.e. after first opening.

- Data logger's data for 6 months at refrigerated condition real time and accelerated condition is required.
- If the source of semaglutide is rDNA , submit bio similarity studies as per "WHO Guidelines on evaluation of biosimilars Replacement of Annex 2 of WHO Technical Report Series, No. 977" including clinical equivalence with innovator product. Provide justification where studies are Not applicable

Case # 26		
Name, address of Applicant / Marketing Authorization Holder	Company Name: Weather Folds Pharmaceuticals Company Address: Plot no. 69/2, Phase II, Industrial Area, Hattar, Pakistan. Site Address: Plot No. 69/2, Phase-II, Industrial Area, Hattar.	
Name, address of Manufacturing site.	Company Name: Weather Folds Pharmaceuticals Company Address: Plot no. 69/2, Phase II, Industrial Area, Hattar, Pakistan. Site Address: Plot No. 69/2, Phase-II, Industrial Area, Hattar. Date of renewal 27-09-2013	
GMP status of the firm	NA	
Evidence of approval of manufacturing facility	Grant of Additional Section Biological non-rDNA Liquid Injection Vial and PFS (New)	
Status of the applicant	☒ Manufacturer	
Status of application	SBP	
Intended use of pharmaceutical product	☒ Domestic and Export sales	
Dy. No. and date of submission	Tracking ID:13Q-SMZ-8E16 Application Number:108903 Date of submission: 09-07-2025	
Details of fee submitted	Challan Number: 9273994750 Division: Biological Evaluation & Registration Paid Fee: 37000.0 Paid Date: 2025-06-30	
proposed proprietary name/brand name	Semma Injection 0.25mg	
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each PFS contains: - Semaglutide 4 mg in 3 ml solution. Each dose contains 1 mg of semaglutide in 0.74ml solution	
Pharmaceutical form of applied drug	Liquid solution for injection by SC.	
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC code: A10BJ06	
Reference to Finished product specifications	As per innovator's specification	
Proposed Pack size	1's PFS	
Proposed unit price	As per Drug pricing committee	
The status in reference regulatory authorities	Ozempic 0.25 mg solution for injection One ml of solution contains 1.34 mg of semaglutide*. One pre-filled pen contains 2 mg semaglutide* in 1.5 ml solution. Each dose contains 0.25 mg of semaglutide in 0.19 ml solution. Ozempic 0.5 mg solution for injection	

	1.5 ml: One ml of solution contains 1.34 mg of semaglutide*. One pre-filled pen contains 2 mg semaglutide* in 1.5 ml solution. Each dose contains 0.5 mg of semaglutide in 0.37 ml solution. 3 ml: One ml of solution contains 0.68 mg of semaglutide*. One pre-filled pen contains 2 mg semaglutide* in 3 ml solution. Each dose contains 0.5 mg of semaglutide in 0.74 ml solution. 3 ml: One ml of solution contains 1.34 mg of semaglutide*. One pre-filled pen contains 4 mg semaglutide* in 3 ml solution. Each dose contains 0.5 mg of semaglutide in 0.37 ml solution. Ozempic 1 mg solution for injection One ml of solution contains 1.34 mg of semaglutide*. One pre-filled pen contains 4 mg semaglutide* in 3 ml solution. Each dose contains 1 mg of semaglutide in 0.74 ml solution. One ml of solution contains 2.68 mg of semaglutide*. One pre-filled pen contains 8 mg semaglutide* in 3 ml solution. Each dose contains 1 mg of semaglutide in 0.37 ml solution. Ozempic 2 mg solution for injection One ml of solution contains 2.68 mg of semaglutide*. One pre-filled pen contains 8 mg semaglutide* in 3 ml solution. Each dose contains 2 mg of semaglutide in 0.74 ml solution
For generic drugs (me-too status)	--
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO template.
Module-III Drug Substance:	
Manufacturer of DS	Fuxin Long Rui Pharmaceutical CO., Ltd Address: Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China
Source	Not submitted.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Accelerated (5°C ± 3°C) B065C120220804 Equivalent to commercial packaging system 1 month, 2 months, 3 months, and 6 months. B065C120220805 B065C120220806 Storage condition (°C, % RH) Batch number Container closure system Completed (and proposed) testing intervals Long Term (-20°C ± 5°C) B065C120220804 Equivalent to commercial packaging system 3 months, 6 months, 9 months, 12 months, 18 months, 24 months
Module-III Drug Product:	
Manufacturing Site	Weather Folds Pharmaceuticals Company Address: Plot no. 69/2, Phase II, Industrial Area, Hattar, Pakistan. Site Address: Plot No. 69/2, Phase-II, Industrial Area, Hattar. Date of renewal 27-09-2013
Container closure system of the drug product	SEMMA Injection are packaged as 1's Prefilled Injections further Packed in Bleach Card board Unit Carton along with Leaflet.
Stability study data of drug product, shelf life and storage conditions	T-28, T-29, T-30 Batch Size. 2000 PFS Dom-07-2024
Storage Conditions	Store below 25
Module 4	Not Submitted.
Module 5	Not Submitted.
• Remarks of the Evaluator • Submit Module 1 as per final guidance document for biological products as attached below, including all the commitments and SMPC. • Evidence of approval of applied formulation in applied strength 1mg/0.74ml in prefilled syringe in RRA is required. • Evidence of section approval in which rDNA PFS has been manufactured, as attached evidence is of non r DNA PFS. • The RRA in section 1.5.9 mentions Rybelsus Injection. Clarification is required. • Approval of manufacturing facility of API by regulatory body of country and validity. • Submit section 3.2.S.2.2, to 3.2.S.2.3. The description of manufacturing is mandatory to mention. Provide source whether synthetic or rDNA. • Justification is required for presence of sodium and determination of sodium assay in Drug substance. • Peptide mapping, related substance, HMWP, specific activity tests are not performed on drug substance by drug product	

manufacturer. Clarification is required.

- Composition of drug per 0.75ml is required, as provided quantities are per 3 ml.
- The applied syringe is single dose .Justify the use of preservative in the formulation as innovators product is PFP containing preservative.
- The section 3.2.P.2 mentions potency 4mg and volume 3ml clarification is required.
- Provide the details of reference product against which equivalence studies have been done.
- Provide batch formula for commercial batches and justify the use of preservative with qty. of Propylene glycol exceeding 1.4%w/v.
- Provide description of manufacturing method for PFS as provided one is of cartridge.
- Provide batch formula per ml in product development section.
- Provide overfill volume if used in the filling of PFS.
- Include the following tests in drug product specifications identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy. Also mention content of semaglutide per ml and performance of same tests in batch analysis at release and stability(where applicable).
- Submit analytical procedures and method validation report.
- Submit section 3.2.P.5.5 i.e. characterization of impurities.
- COA of reference standard is required.
- Details of container closure is required i.e. primary packaging.
- The DML attached in section 3.2.P.8.3 is of “Hangzhou Patience Chemical Co.,Ltd Registered Address: No. 6 Xiyuan7th Road,SandunTown,Xihu District, Hangzhou,Zhejiang,China” whereas, DS manufacturer is “Fuxin Long Rui Pharmaceutical CO., Ltd Address: Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China”.
- Commercial invoice is not ADC/DDC attested.
- Provide consumption record of 200 g of semaglutide in tablets and injection.
- Clarification is required whether stability has been conducted at long term 2to 8 or 30C/65 and accelerated at 25C/60rH or 40C/75%.
- Inclusion of following tests identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy in the next time point of stability testing if conducted at 2-8C.
- Justification is required for storage condition “Store below 25C”.
- The DOM of batches is 05-2024 .Submit stability data of 12 months, accordingly.
- Submit in use stability studies of drug product i.e. after first opening.
- Data logger’s data for refrigerated condition real time and accelerated condition is required.
- If the source of semaglutide is rDNA , submit bio similarity studies as per “WHO Guidelines on evaluation of biosimilar Replacement of Annex 2 of WHO Technical Report Series, No. 977” on attached format, with PK/PD mandatory study. Provide justification where studies are “Not Applicable”.

The applicant submitted following response via case management query Tracking ID:B2A-WVT-JJRJ,Application Number:112090

Created on:July 13th, 2025, 10:27 pm.

S.NO	Observation/Document Required	Justification/Status of Documents
01	Submit Module 1 as per final guidance document for biological products as attached below, including all the commitments and SMPC.	Rectified Attached.
02	Evidence of approval of applied formulation in applied strength 1mg/0.74ml in prefilled syringe in RRA is required.	Stability studies indicate no interaction of primary packing with product. As per the decision followed by the DRB 336, against Semaglutide Macter Product.
03	Evidence of section approval in which rDNA PFS has been manufactured, as attached evidence is of non r DNA PFS.	According to WHO WHO TRS 999 guidelines, the rDNA products can be manufactured in Non-rDNA facility, hence no separate section required.
04	• The RRA in section 1.5.9 mentions Rybelsus Injection. Clarification is required.	Typographical Mistake, which has been rectified.
05	Approval of manufacturing facility of API by regulatory body of country and validity.	Attached
06	Submit section 3.2.S.2.2, to 3.2.S.2.3.The description of manufacturing is mandatory to mention. Provide source whether synthetic or rDNA.	The Product origin is China, and this is patent product, hence this cannot be provided.
06	Justification is required for presence of sodium and determination of sodium assay in Drug substance.	Sodium determine by API manufacturer and available in DMF.
07	Peptide mapping, related substance, HMWP, specific activity tests are not performed on drug substance by drug product manufacturer. Clarification is required.	The Tests have been performed by the Drug Substance Manufacturer, hence not required to be performed by drug product manufacturer.
08	• Composition of drug per 0.75ml is required, as provided quantities are per 3 ml.	Composition regarding 3ml attachedin Annexure- 1
09	The applied syringe is single dose .Justify the use of preservative in the formulation as innovators product is PFP containing preservative.	Attached in Annexure-2

10	The section 3.2.P.2 mentions potency 4mg and volume 3ml clarification is required.	Typographical Mistake
11	Provide the details of reference product against which equivalence studies have been done.	Sematide by BF Biosciences Reg No. 120528
12	Provide batch formula for commercial batches and justify the use of preservative with qty. of Propylene glycol exceeding 1.4%w/v.	Revised Attached in Annexure-3
13	Provide description of manufacturing method for PFS as provided one is of cartridge.	Rectified Attached.
14	Provide batch formula per ml in product development section.	Attached in Annexure-4
15	Submit analytical procedures and method validation report.	Attached in Annexure-5
16	Commercial invoice is not ADC/DDC attested.	We imported Semaglutide and cleared via Green Channel. For reference, Goods Declaration is attached and also we have officially intimated to DRAP regarding our materials imported without Clearance Certificate. The Intimation letter with receiving is attached along with
17	COA of reference standard is required.	Attached in Annexure-6
18	· Submit section 3.2.P.5.5 i.e. characterization of impurities.	Impurities are Exempted hence not available.
19	· Details of container closure is required i.e. primary packaging.	1's Prefilled Syringe in Unit Carton Along with Leaflet.
20	The DML attached in section 3.2.P.8.3 is of "Hangzhou Patience Chemical Co.,Ltd Registered Address: No. 6 Xiyuan7th Road,SandunTown,Xihu District,Hangzhou,Zhejiang,China" whereas, DS manufacturer is "Fuxin Long Rui Pharmaceutical CO., Ltd Address: Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China".	Correct DML attached.
21	Clarification is required whether stability has been conducted at long term 2to 8 or 30C/65 and accelerated at 25C/60rH or 40C/75%. .	stability has been conducted at long term 2°C to 8°C and accelerated at 25°C/60%RH
22	Provide consumption record of 200 g of semaglutide in tablets and injection.	Attached in Annexure-7
23	· Inclusion of following tests identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy in the next time point of stability testing if conducted at 2-8C.	BET has already been performed and is included in the Certificate of Analysis (CoA) and Stability Data Sheets. Phenol testing was not performed by the innovator; however, if recommended by the Board, we shall conduct phenol content testing in the next stability intervals. Furthermore, as per the Board's decision in the 340th DRB Meeting regarding the registration of our Semaglutide Tablet, we confirm that identification testing through peptide mapping shall be performed by a Government Testing Laboratory for every commercial batch of the injectable dosage form too.
24	Include the following tests in drug product specifications identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy. Also mention content of semaglutide per ml and performance of same tests in batch analysis at release and stability (where applicable).	
25	Justification is required for storage condition "Store below 25C".	Store at condition 2°C to 8°C
26	The DOM of batches is 05-2024 .Submit stability data of 12 months, accordingly.	6 month data attached - 8
27	Submit in use stability studies of drug product i.e. after first opening. .	After first opening all parameters were test and found within limits, further store at real and accelerated condition and observe weekly for 6 weeks and checks all parameters (appearance, PH, BET, Assay) and found within limits at all interval. Details are attached
28	· Data logger's data for refrigerated condition real time and accelerated condition is required.	Attached in Annexure-9
29	If the source of semaglutide is rDNA , submit bio similarity studies as per "WHO Guidelines on evaluation of biosimilars Replacement of Annex 2 of WHO Technical Report Series, No. 977" on attached format, with PK/PD mandatory study. Provide justification where studies are "Not Applicable".	As the required tests have already been performed by the API manufacturer and biosimilarity of the API has been established at the Drug Substance stage, these tests are not required to be repeated for the Finished Product.

Decision of 349th Meeting:

The Registration Board deferred the case for the submission of the following documents:

- Evidence of approval of applied formulation in applied strength 1mg/0.74ml in prefilled syringe in RRA is required.
- Evidence of section approval in which rDNA PFS has been manufactured, as attached evidence is of non r DNA PFS.
- Submit section 3.2.S.2.2, to 3.2.S.2.3. The description of manufacturing is mandatory to mention. Provide source whether synthetic or rDNA.
- Peptide mapping, related substance, HMWP, specific activity tests are not performed on drug substance by drug product manufacturer. Clarification is required.
- The applied syringe is single dose .Justify the use of preservative in the formulation as innovators product is PFP containing preservative.



- Provide the details of reference product against which equivalence studies have been done.
- Provide batch formula for commercial batches and justify the use of preservative with qty. of Propylene glycol exceeding 1.4%w/v.
- Provide description of manufacturing method for PFS as provided one is of cartridge.
- Provide overfill volume if used in the filling of PFS.
- Include the following tests in drug product specifications identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy. Also mention content of semaglutide per ml and performance of same tests in batch analysis at release and stability(where applicable).
- ·Submit analytical procedures and method validation report.
- · COA of reference standard is required.
- Inclusion of following tests identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy in the next time point of stability testing if conducted at 2-8C.
- The DOM of batches is 05-2024 .Submit stability data of 12 months, accordingly.
- Submit in use stability studies of drug product i.e. after first opening.
- If the source of semaglutide is rDNA , submit bio similarity studies as per “WHO Guidelines on evaluation of biosimilars Replacement of Annex 2 of WHO Technical Report Series, No. 977” including clinical equivalence with innovator product. Provide justification where studies are Not applicable.

Semaglutide
Source: Synthetic
Drug Substance Import Local Manufacturing
Applied Container Closure System: Vial

Case#27	
Name, address of Applicant	M/s BF Biosciences Ltd. 5km Sundar Raiwind Road, Raiwind, Lahore-Pakistan.
Status of Applicant	☒ Manufacturer ☐ Importer ☐ Bulk Import & Local Repack ☐ Is involved in none of the above
Name, address of manufacturer(s)	M/s BF Biosciences Ltd. 5km Sundar Raiwind Road, Raiwind, Lahore-Pakistan.
GMP of manufacturer & Evidence of Section	DML No. 000655 Address: 5km Sundar Raiwind Road, Raiwind, Lahore-Pakistan Evidence of section: Parental (Liquid Lyophilized Biotech Section GMP: Valid up to 01-03-2027 issued on the basis of Inspection conducted 01-03-2024 for DML Renewal & Grant of Additional Section
Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
e-app tracking ID and date of receiving	Tracking ID: LZ4-4HU-NM5G / Serial No. 99007 Date of Submission: 15-05-2025
Details of fee submitted	Challan No. 270112448 Amount: 37000/- Date of submission: 02-05-2025
The proposed proprietary name / brand name	Sematide 2mg Injection
Strength / concentration of drug of Active	Each vial Contains

Pharmaceutical ingredient (API) per unit	Semaglutide 2mg/1.5mL
Pharmaceutical form of applied drug	Solution For Injection (For Subcutaneous use only)
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	Manufacturer's Specifications
Proposed Pack size & shelf life	1's vial 24 months (2-8°C)
Proposed unit price	As per SRO
The status in reference regulatory authorities	OZEMPIC (semaglutide) solution for injection 2 mg/1.5 ml (USFDA APPROVED) Reference product Ozempic is Pre-filled pen while the applied product is vial dosage form.
For generic drugs (me-too status)	Seglutide 2mg/1.5mL (Macter International Limited)
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, Elucidation of Structure, impurities specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product are submitted.
Name, address of drug substance manufacturer	Name: Zhejiang Peptides Biotech Co., Ltd Address: No.8 Hengyizhi Road, Sanjie Town, Shengzhou city, Shaoxing City, Zhejiang Province, China
Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, physical form, manufacturers, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted 36 months Real Time Stability data & 6 months accelerated Stability Studies with details as 36 months Real Time Stability Studies (5°C ±3°C) BATCH NO. G06210902 BATCH NO. G06210901 BATCH NO. G06210801

		06 months Accelerated Stability Studies (25°C ±2°C, RH 60% ± 5%) BATCH NO. G06210902 BATCH NO. G06210901 BATCH NO. G06210801												
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, (undertaking for reports), control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures for assay only, batch analysis, working standard COA, container closure system and stability.												
	Analytical method validation/verification of product	Firm has submitted Analytical method validation for assay of Semaglutide injection.												
	Container closure system of the drug product	2ml USP Type 1 Clear Glass vial												
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 03 batches. The accelerated stability study data is conducted at 25°C ± 2°C/RH 60% ±5 for 6 months. The real time stability study data is conducted at 5°C ± 3°C for 6 months. <table> <tr> <td>Batch No.</td><td>Batch Size</td><td>Date of Mfg.</td></tr> <tr> <td>054D01</td><td>166 vials</td><td>June-2024</td></tr> <tr> <td>054D02</td><td>166 vials</td><td>June-2024</td></tr> <tr> <td>054D03</td><td>166 vials</td><td>June-2024</td></tr> </table>	Batch No.	Batch Size	Date of Mfg.	054D01	166 vials	June-2024	054D02	166 vials	June-2024	054D03	166 vials	June-2024
Batch No.	Batch Size	Date of Mfg.												
054D01	166 vials	June-2024												
054D02	166 vials	June-2024												
054D03	166 vials	June-2024												
	MODULE- IV	Detailed in sameness evaluation mentioned below												
	MODULE- V	Detailed in sameness evaluation mentioned below												
<u>DRUG SUBSTANCE:</u> <u>The firm has submitted Sameness data as per USFDA guidelines: ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin Guidance for Industry FDA.</u> Firm has compared Semaglutide API of Zhejiang Peptides Biotech Co. Ltd with Semaglutide reference product Ozempic.														
Parameters		Sameness evaluation Data Submitted by M/s BF Biosciences Ltd												
A. Active Ingredient Sameness (by Orthogonal Method) (specify) 1. Primary sequence and		Firm has performed following in physicochemical characterization; • Appearance • Solubility												

Physicochemical properties	• Hygroscopicity • Specific optical rotation • Clarity and colour of solution • PH • Molecular Weight • Particle size by Malvern Laser Diffraction method • Polymorphism by X-ray powder diffraction method • Isoelectric point by Imaging capillary isoelectric focusing electrophoresis. Primary sequence Firm has conducted Peptide Sequence analysis by mass spectrometer as below; • Amino acid sequence analysis Apparatus: Mass spectrometer XevoG2-XS QToF (Waters) UPLC(Acquity UPLC I-Class) (Waters) Experiment method: Perform primary mass spectra (MS) test, then perform secondary mass spectra test (MS/MS) of target peptide mother ion. Establish data base according to theoretical sequence, search for secondary data to validate accuracy of sequence. Test result: Semaglutide working standard MASCOT secondary mass spectra data match diagram  Semaglutide original product (Ozempic®, Novo Nordisk, batch number: JP54343) MASCOT secondary mass spectra data match diagram 
Secondary structure	Firm has performed Circular dichroism spectrum analysis for study of peptide Secondary structure as below;

	-Secondary structure Circular dichroism spectrum analysis is meaningful for study of peptide secondary structure. Secondary structure are compared between our Semaglutide API and Semaglutide original product with Circular dichroism spectrum analysis. Sample list <table><tr><th>Sample No.</th><th>Name</th><th>Source</th><th>Batch number</th></tr><tr><td>20211111577</td><td>Semaglutide original product</td><td>Novo Nordisk</td><td>KP52701</td></tr><tr><td>20211111578</td><td rowspan="3">Semaglutide API</td><td rowspan="3">Zhejiang peptites</td><td>G06210801</td></tr><tr><td>20211111579</td><td>G06210901</td></tr><tr><td>20211111580</td><td>G06210902</td></tr></table> Apparatus: Chirascan Plus V100 Circular dichroism spectrometer (Applied Photophysics) Apparatus parameter: <table><tr><td>Band width</td><td>1.0nm</td></tr><tr><td>Step</td><td>1.0nm</td></tr><tr><td>Measurement range</td><td>190-260nm(far-UV region scan)</td></tr><tr><td>Time-per-point</td><td>0.5s</td></tr><tr><td>Repeats</td><td>3</td></tr><tr><td>Cell Length</td><td>0.5mm</td></tr><tr><td>Temperature</td><td>Room Temperature</td></tr></table> Far/near UV scan of standard: acquire data of background test and blank test with wavelength 180-340nm, then acquire data of far/near Circular dichroism UV scan with wavelength 180-340nm. Far UV scan: cuvette is soaked with 2M HNO₃, clean with deionized water and dry, acquire data of background and blank. Then add sample into cuvette, acquire data with wavelength 190-260nm. Firm has also performed Thermoanalysis by Differential scanning Calorimeter (DSC) as under; - Thermoanalysis Thermoanalysis is meaningful to stability of protein and polypeptide. With Differential Scanning Calorimeter(DSC) method, melting temperature(T_m) of Semaglutide original product and Semaglutide API samples are tested. Sample list <table><tr><th>Sample No.</th><th>Name</th><th>Source</th><th>Batch number</th></tr><tr><td>20211111582</td><td>Semaglutide original product</td><td>Novo Nordisk</td><td>KP52701</td></tr><tr><td>20211111583</td><td rowspan="3">Semaglutide API</td><td rowspan="3">Zhejiang peptites</td><td>G06210801</td></tr><tr><td>20211111584</td><td>G06210901</td></tr><tr><td>20211111585</td><td>G06210902</td></tr></table> Apparatus: Differential Scanning Calorimeter (Microcal PEAQ-DSC) Apparatus parameter: Temperature: 20-100°C Temperature rising rate: 120°C/h Conclusion: according to above test, T_m of Semaglutide API (G06210801, G06210901, G06210902) and Semaglutide original product (KP52701) are: 66.06 °C, 66.00 °C, 66.16 °C, 65.96°C, which are comparable.	Sample No.	Name	Source	Batch number	20211111577	Semaglutide original product	Novo Nordisk	KP52701	20211111578	Semaglutide API	Zhejiang peptites	G06210801	20211111579	G06210901	20211111580	G06210902	Band width	1.0nm	Step	1.0nm	Measurement range	190-260nm(far-UV region scan)	Time-per-point	0.5s	Repeats	3	Cell Length	0.5mm	Temperature	Room Temperature	Sample No.	Name	Source	Batch number	20211111582	Semaglutide original product	Novo Nordisk	KP52701	20211111583	Semaglutide API	Zhejiang peptites	G06210801	20211111584	G06210901	20211111585	G06210902
Sample No.	Name	Source	Batch number																																												
20211111577	Semaglutide original product	Novo Nordisk	KP52701																																												
20211111578	Semaglutide API	Zhejiang peptites	G06210801																																												
20211111579			G06210901																																												
20211111580			G06210902																																												
Band width	1.0nm																																														
Step	1.0nm																																														
Measurement range	190-260nm(far-UV region scan)																																														
Time-per-point	0.5s																																														
Repeats	3																																														
Cell Length	0.5mm																																														
Temperature	Room Temperature																																														
Sample No.	Name	Source	Batch number																																												
20211111582	Semaglutide original product	Novo Nordisk	KP52701																																												
20211111583	Semaglutide API	Zhejiang peptites	G06210801																																												
20211111584			G06210901																																												
20211111585			G06210902																																												
Oligomer/aggregation states	Firm has performed Polymer (Oligomer/ Aggregates/ High Molecular Weight Proteins) by Size Exclusion Chromatography as below;																																														

Impurities

(Peptide related and non-peptide related impurities)

For each peptide-related impurity that is found in both the proposed generic synthetic peptide and the RLD, the level of such impurity in the proposed product is the same as or lower than that found in the RLD.

Applicants should identify each peptide-related impurity that is 0.10 percent of the drug substance or greater.

Impurities profile

- Peptide related Impurities
- Related Substances I & II (3.2.S.4.1 P 2)
- High molecular weight protein impurities (Polymers 3.2.S.4.1 P 2)
- Process related Impurities (3.2.S.3.2 – P 1)
- Intermediate residue and reaction by products (Restricted Part 3.2.S.2.4 P 1)
- Inorganic and Ion impurities (3.2.S.3.2 – P 8)
- Residual Solvents (3.2.S.3.2 – P 12)
- Elemental Impurities (3.2.S.3.2 – P 8)
- Genotoxic Impurity (3.2.S.3.2 – P 15)
- Nitrosamine Impurities (3.2.S.3.2 – P 36)

Firm has performed Comparison of Semaglutide API with reference product Ozempic in terms of related substance as below:

● Comparison of Semaglutide API and Semaglutide original product -Related substances

Impurity profile are compared between our Semaglutide API and Semaglutide original product with analytical procedures described in chapter 3.2.S.4.2.

Sample list

Name	Source	Batch number	Expiry date
Semaglutide original product, Ozempic	Novo Nordisk	JP54343	2022.07
		KP52701	2023.02
		LP57558	2024.01
Semaglutide API	Zhejiang Peptides	G06210801	2023.09.12
		G06210901	2023.09.25
		G06210902	2023.10.05

Test result

Impurity No.	RRT	Impurity affiliation	Impurity content in Semaglutide API(%)			Impurity content in Semaglutide injection(%)		
			G06210801	G06210901	G06210902	JP54343	KP52701	LP57558
1	0.754	G06-IM01	0.055	0.054	0.053	0.158	0.116	0.059
2	0.839	G06-IM60	0.113	0.075	0.103	0.114	0.107	0.093
3	0.897	G06-IM59	0.105	0.083	0.100	0.032	N.D.	N.D.
4	0.941	Unspecified imp 1	0.034	N.D.	N.D.	N.D.	N.D.	N.D.
5	1.021	G06-IM03	0.042	0.042	0.039	0.073	N.D.	N.D.
6	0.955	G06-IM28	N.D.	0.036	N.D.	N.D.	N.D.	N.D.
7	0.936	Unspecified imp 2	N.D.	N.D.	0.035	N.D.	N.D.	N.D.
8	0.454	Unspecified imp 3	N.D.	N.D.	N.D.	0.038	N.D.	N.D.
9	0.776	Unspecified imp 4	N.D.	N.D.	N.D.	0.081	0.084	0.092
10	0.885	Unspecified imp 5	N.D.	N.D.	N.D.	0.106	0.097	0.085
11	0.913	Unspecified imp 6	N.D.	N.D.	N.D.	0.039	0.040	0.070
12	0.939	Unspecified imp 7	N.D.	N.D.	N.D.	0.519	0.508	0.361
13	1.047	Unspecified imp 8	N.D.	N.D.	N.D.	0.308	0.366	0.293
14	1.064	Unspecified imp 9	N.D.	N.D.	N.D.	0.304	0.343	0.324
15	1.103	Unspecified imp 10	N.D.	N.D.	N.D.	0.043	0.033	N.D.

16	1.129	Unspecified imp 11	N.D.	N.D.	N.D.	0.056	0.054	0.050
17	1.177	Unspecified imp 12	N.D.	N.D.	N.D.	0.123	0.130	0.146
18	1.261	Unspecified imp 13	N.D.	N.D.	N.D.	0.048	0.034	N.D.
19	1.268	Unspecified imp 14	N.D.	N.D.	N.D.	0.449	0.333	0.198
20	0.926	Unspecified imp 15	N.D.	N.D.	N.D.	N.D.	N.D.	0.040
21	1.010	Unspecified imp 16	N.D.	N.D.	N.D.	N.D.	N.D.	0.139
Total impurities			0.349	0.290	0.330	2.491	2.245	1.950

Conclusion:

4 impurities are detected in both API and original formulation: RRT0.754, RRT0.839, RRT0.897, RRT1.021, results of impurity RRT0.754, RRT0.839, RRT1.021 in API are less than results in original formulation. Result of impurity RRT0.897 is comparable with result in original formulation.

For new impurity RRT0.941, RRT0.955 which are not detected in original formulation, results are less than report limit 0.05% defined in ICH Q3A. Result of impurity which is higher than 0.05% is not existed in our Semaglutide API.

Conclusion of sameness studies:

Conclusion

According to comparison of Semaglutide API and Semaglutide original product, impurity level of Semaglutide API is comparable with Semaglutide original product. Total content of polymers in Semaglutide API is much lower than total content of polymers in Semaglutide original product.

For secondary structure comparison, far-UV similarity value of Semaglutide API(G06210801, G06210901, G06210902) and Semaglutide original product (KP52701) is 0.99999, 0.99995, 0.99996. For biological activities, relative activity of samples(G06210801, G06210901, G06210902) comparing with reference are: 0.93, 1.20, 1.08. Samples showed agonist activity on GLP-1 receptor in this study. For Isoelectric point and Thermoanalysis, results of Semaglutide API and Semaglutide original product are comparable. Above all, quality of Semaglutide API manufactured in Zhejiang Peptides is comparable with Semaglutide original product.

DRUG PRODUCT

Firm has compared their product Sematide 2mg/1.5ml vial with Seglutide 2mg/1.5 ml vial of M/s Macter International Limited and following tests are performed;

5. COMPARISON PARAMETERS

Following parameters will be compared according to PD-STP-FG-001 (STP for Semaglutide Injection).

Table-1

Sr. No.	Test	Specifications	Semaglutide 2mg/1.5ml (BF Biosciences)	Seglutide 2mg/1.5ml (Macter International limited)	Significant variation (yes/No)
1.	Appearance	A clear, colourless solution virtually free from particles.	Complies	Complies	No
2.	Identification (HPLC)	The retention time of main peak obtained in sample solution should be in accordance with retention time of main peak obtained in standard solution in chromatograms of assay test.	Complies	Complies	No
3.	pH	7.00 – 7.80	7.52	7.50	No
4.	Assay	90% - 110% of label claim	101.2 %	104.0 %	No
5.	Related substances I	G06-IM60	≤ 1.0 %	N.D	No
		G06-IM01	≤ 1.0 %	0.25 %	No
		G06-IM59	≤ 1.0 %	0.45 %	No
		G06-IM28	≤ 1.0 %	0.14 %	No
		Any other individual impurity	≤ 0.5 %	0.30 %	No
		Total impurities	≤ 7.0 %	1.18 %	No
6.	Related Substances II	G06-IM03	≤ 1.0 %	N.D	No

6. ACCEPTANCE CRITERIA

Semaglutide Injection 2mg/1.5ml manufactured by BF Biosciences and reference product Seglutide Injection 2mg/1.5ml Manufactured by Macter International Limited, meet the specifications as mentioned in Table-1.

7. Conclusion

The results obtained from the comparative study demonstrate Semaglutide Injection 2mg/1.5ml manufactured by BF Biosciences is equivalent to Seglutide Injection 2mg/1.5ml Manufactured by Macter International Limited.

Specifications limit of related substances/impurities is higher than that for API.

Evaluation by BE&R:

- The innovator product Ozempic is available in multi-dose Prefilled Pen only while the applied product is vial dosage form. Evidence of availability of applied product in vial dosage form in any reference country is not provided.
- Drug substance part 3.2.S.2.2 to 3.2.S.2.6 is not provided.
- Complete analytical method validation of drug product is required.
- In-use shelf life is not provided.
- Phenol content is not determined in Finished product testing.
- Firm has performed comparative testing of their product Sematide 2mg/1.5ml vial with Seglutide 2mg/1.5ml vial which is not an innovator product. Comparative studies of the applied product with the innovator product is required.
- Firm has not performed all the tests on applied product as performed by innovator like peptide mapping, biological activity etc.
- Specifications limit of related substances/impurities in drug product is higher than that for API. Justification/clarification is required.

Decision of 349th Meeting:

The Registration Board deferred the case for submission of following requisite documents/clarifications:

- The innovator product Ozempic is available in multi-dose Prefilled Pen only while the applied product is vial dosage form. Evidence of availability of applied product in vial container closure system in any reference

country is required



- Drug substance part 3.2.S.2.2 to 3.2.S.2.6 is required.
- Complete analytical method validation of drug product on all parameters is required.
- In-use shelf-life stability data is required.
- Phenol content is not determined in Finished product testing.
- Firm has performed comparative testing of their product Sematide 2mg/1.5ml vial with Seglutide 2mg/1.5ml vial which is not an innovator product. Comparative studies of the applied product with the innovator product is required.
- Firm has not performed all the tests on applied product as performed by innovator like peptide mapping, biological activity etc.
- Specifications limit of related substances/impurities in drug product is higher than that for API. Justification/clarification is required.

Semaglutide Source: Synthetic Drug Substance Import Local Manufacturing Applied Container Closure System: PFS	
Case # 28	
Name, address of Applicant	M/s Nextar Pharma (Pvt) Ltd Plot No. E-58. North Western, Industrial Zone, Port Qasim Karachi.
Status of the applicant	☒ Manufacturer ☐ Importer ☐ Bulk Import & Local Repack ☐ Is involved in none of the above
Name, address of manufacturer(s)	M/s Nextar Pharma (Pvt) Ltd Plot No. E-58. North Western, Industrial Zone, Port Qasim Karachi.
GMP of manufacturer & Evidence of Section	DML No. 000777 Address: Plot No. E-58. North Western, Industrial Zone, Port Qasim Karachi. Evidence of section: Injectable Ampoules & PFS GMP: Last GMP conducted on 20-03-2024 valid upto 19-03-26
Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
Intended use of pharmaceutical product	☐ Domestic sale Export sale ☒ Domestic and Export sales
E-app tracking ID and Date of submission	Tracking ID: 2A4-X3U-1V8A Application No. 92104 Date of receiving: 21-04-2025
Details of fee submitted	Challan Number: 82461048

	Paid Fee: 37000.0 Paid Date: 2025-04-14 Division: Biological Evaluation & Registration
The proposed proprietary name / brand name	SEMAVI-PFS 1mg/0.75ml
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 0.75mL contains: Semaglutide..... 1mg
Pharmaceutical form of applied drug	Solution for Injection in PFS (For Subcutaneous use only)
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	Innovator's Specifications
Proposed Pack size	1's (PFS)
Proposed unit price	As per SRO
Shelf Life	24 Months
Storage Condition	Store in a refrigerator (2 °C – 8 °C)
The status in reference regulatory authorities	OZEMPIC (semaglutide) solution for injection 2 mg/1.5 ml (USFDA APPROVED) <i>The firm has applied single dose (1mg/0.75ml) pre-filled syringe while the reference product Ozempic is available in multi dose pre-filled pens in different strengths as below;</i> • 0.25 mg or 0.5 mg dose pen (4 doses of 0.25 mg and 2 doses of 0.5 mg, or 4 doses of 0.5 mg) • 1 mg dose pen, (4 doses per pen) • 2 mg dose pen, (4 doses per pen)
For generic drugs (me-too status)	Sematide Prefilled Syringe 1mg/0.75mL Manufactured by M/s BF Biosciences Ltd (Reg.No 120530)
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD. Firm has summarized information related to nomenclature, structure, general properties, physical form, manufacturers, Characterization (Elucidation of Structure and Other Characteristics), impurities, specifications, analytical procedures, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.

Name, address of drug substance manufacturer	M/s Zhejiang Peptides Biotech Co., Ltd No.8 Hengyizhi Road, Sanjie Town, Shengzhou City, Zhejiang Province, China																
Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, physical form, manufacturers, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.																
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of drug substance of following 3 batches at accelerated and real time conditions. The real time stability data is conducted at 5°C ± 3°C for 24 months, and the accelerated stability studies are conducted at 25°C ± 2°C for 6 months. Batch No: G06210801 (Test starting date; 22-10-2021) Batch No: G06210901 (Test starting date; 22-10-2021) Batch No: G06210902 (Test starting date; 22-10-2021)																
Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols (undertaking for reports), control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures for assay only, batch analysis, working standard COA, container closure system and stability.																
Analytical method validation/verification of product	Firm has submitted Analytical method validation for sterility test, bacterial endotoxin test of applied product.																
Container closure system of the drug product	(PFS) 1mL USP Type 1 clear glass/Butyl rubber stopper with plunger rod.																
Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of following 03 batches. The accelerated stability study data is conducted at 25±2°C, 60%±5% RH for 6 months. The real time ongoing stability study data is conducted at 5°C±3°C for 6months. <table><tr><td>Batch No.</td><td>Batch Size</td><td>Manufacturing date</td><td>TSJP001</td></tr><tr><td></td><td>500 PFS</td><td>July-2024</td><td></td></tr><tr><td>TSJP002</td><td>500 PFS</td><td>July-2024</td><td></td></tr><tr><td>TSJP003</td><td>500 PFS</td><td>July-2024</td><td></td></tr></table>	Batch No.	Batch Size	Manufacturing date	TSJP001		500 PFS	July-2024		TSJP002	500 PFS	July-2024		TSJP003	500 PFS	July-2024	
Batch No.	Batch Size	Manufacturing date	TSJP001														
	500 PFS	July-2024															
TSJP002	500 PFS	July-2024															
TSJP003	500 PFS	July-2024															
Module IV	Detailed in sameness evaluation mentioned below																
Module V	Detailed in sameness evaluation mentioned below																
<u>DRUG SUBSTANCE:</u>																	
The firm has submitted Sameness data as per USFDA guidelines: <u>ANDAs for Certain Highly Purified Synthetic</u>																	

Firm has compared Semaglutide API of Zhejiang Peptides Biotech Co. Ltd with Semaglutide reference product Ozempic.

Parameters	Sameness evaluation Data Submitted by the applicant
A. Active Ingredient Sameness (by Orthogonal Method) (specify) 2. Primary sequence and Physicochemical properties	Firm has performed following in physicochemical characterization; • Appearance • Solubility • Hygroscopicity • Specific optical rotation • Clarity and colour of solution • PH • Molecular Weight • Particle size by Malvern Laser Diffraction method • Polymorphism by X-ray powder diffraction method • Isoelectric point by Imaging capillary isoelectric focusing electrophoresis <u>Primary sequence</u> Firm has conducted Peptide Sequence analysis by mass spectrometer as below; • Amino acid sequence analysis Apparatus: Mass spectrometer XevoG2-XS QToF (Waters) UPLC(Acquity UPLC I-Class) (Waters) Experiment method: Perform primary mass spectra (MS) test, then perform secondary mass spectra test (MS/MS) of target peptide mother ion. Establish data base according to theoretical sequence, search for secondary data to validate accuracy of sequence. Test result Semaglutide working standard MASCOT secondary mass spectra data match diagram  Semaglutide original product (Ozempic®, Novo Nordisk, batch number: JP54343) MASCOT secondary mass spectra data match diagram 
Secondary structure	Firm has performed Circular dichroism spectrum analysis for study of peptide Secondary structure as below;

	-Secondary structure Circular dichroism spectrum analysis is meaningful for study of peptide secondary structure. Secondary structure are compared between our Semaglutide API and Semaglutide original product with Circular dichroism spectrum analysis. Sample list <table><tr><th>Sample No.</th><th>Name</th><th>Source</th><th>Batch number</th></tr><tr><td>20211111577</td><td>Semaglutide original product</td><td>Novo Nordisk</td><td>KP52701</td></tr><tr><td>20211111578</td><td rowspan="3">Semaglutide API</td><td rowspan="3">Zhejiang peptites</td><td>G06210801</td></tr><tr><td>20211111579</td><td>G06210901</td></tr><tr><td>20211111580</td><td>G06210902</td></tr></table> Apparatus: Chirascan Plus V100 Circular dichroism spectrometer (Applied Photophysics) Apparatus parameter: <table><tr><td>Band width</td><td>1.0nm</td></tr><tr><td>Step</td><td>1.0nm</td></tr><tr><td>Measurement range</td><td>190-260nm(far-UV region scan)</td></tr><tr><td>Time-per-point</td><td>0.5s</td></tr><tr><td>Repeats</td><td>3</td></tr><tr><td>Cell Length</td><td>0.5mm</td></tr><tr><td>Temperature</td><td>Room Temperature</td></tr></table> Far/near UV scan of standard: acquire data of background test and blank test with wavelength 180-340nm, then acquire data of far/near Circular dichroism UV scan with wavelength 180-340nm. Far UV scan: cuvette is soaked with 2M HNO₃, clean with deionized water and dry, acquire data of background and blank. Then add sample into cuvette, acquire data with wavelength 190-260nm. Firm has also performed Thermoanalysis by Differential scanning Calorimeter (DSC) as under; - Thermoanalysis Thermoanalysis is meaningful to stability of protein and polypeptide. With Differential Scanning Calorimeter(DSC) method, melting temperature(T_m) of Semaglutide original product and Semaglutide API samples are tested. Sample list <table><tr><th>Sample No.</th><th>Name</th><th>Source</th><th>Batch number</th></tr><tr><td>20211111582</td><td>Semaglutide original product</td><td>Novo Nordisk</td><td>KP52701</td></tr><tr><td>20211111583</td><td rowspan="3">Semaglutide API</td><td rowspan="3">Zhejiang peptites</td><td>G06210801</td></tr><tr><td>20211111584</td><td>G06210901</td></tr><tr><td>20211111585</td><td>G06210902</td></tr></table> Apparatus: Differential Scanning Calorimeter (Microcal PEAQ-DSC) Apparatus parameter: Temperature: 20-100°C Temperature rising rate: 120°C/h Conclusion: according to above test, T_m of Semaglutide API (G06210801, G06210901, G06210902) and Semaglutide original product (KP52701) are: 66.06 °C, 66.00 °C, 66.16 °C, 65.96°C, which are comparable.	Sample No.	Name	Source	Batch number	20211111577	Semaglutide original product	Novo Nordisk	KP52701	20211111578	Semaglutide API	Zhejiang peptites	G06210801	20211111579	G06210901	20211111580	G06210902	Band width	1.0nm	Step	1.0nm	Measurement range	190-260nm(far-UV region scan)	Time-per-point	0.5s	Repeats	3	Cell Length	0.5mm	Temperature	Room Temperature	Sample No.	Name	Source	Batch number	20211111582	Semaglutide original product	Novo Nordisk	KP52701	20211111583	Semaglutide API	Zhejiang peptites	G06210801	20211111584	G06210901	20211111585	G06210902
Sample No.	Name	Source	Batch number																																												
20211111577	Semaglutide original product	Novo Nordisk	KP52701																																												
20211111578	Semaglutide API	Zhejiang peptites	G06210801																																												
20211111579			G06210901																																												
20211111580			G06210902																																												
Band width	1.0nm																																														
Step	1.0nm																																														
Measurement range	190-260nm(far-UV region scan)																																														
Time-per-point	0.5s																																														
Repeats	3																																														
Cell Length	0.5mm																																														
Temperature	Room Temperature																																														
Sample No.	Name	Source	Batch number																																												
20211111582	Semaglutide original product	Novo Nordisk	KP52701																																												
20211111583	Semaglutide API	Zhejiang peptites	G06210801																																												
20211111584			G06210901																																												
20211111585			G06210902																																												
Oligomer/aggregation states	Firm has performed Polymer (Oligomer/ Aggregates/ High Molecular Weight Proteins) by Size Exclusion Chromatography as below;																																														

-Polymer

Polymer content are compared between our Semaglutide API and Semaglutide original product with analytical procedures described in chapter 3.2.S.4.2.

Sample list

Name	Source	Batch number	Expiry date
Semaglutide original product, Ozempic	Novo Nordisk	JP54343	2022.07
		KP52701	2023.02
		LP57558	2024.01
Semaglutide API	Zhejiang Peptides	G06210801	2023.09.12
		G06210901	2023.09.25
		G06210902	2023.10.05

Test result

RRT	Name	Impurity content in Semaglutide API(%)	Impurity content in Semaglutide

		injection(%)					
		G06210801	G06210901	G06210902	JP54343	KP52701	LP57558
0.842	Polymer 1	N.D.	N.D.	N.D.	0.070	0.039	N.D.
0.876	Polymer 2	0.062	0.048	0.076	0.510	0.335	0.195
0.967	Polymer 3	N.D.	N.D.	N.D.	N.D.	N.D.	0.037
Total polymer content		0.062	0.048	0.076	0.580	0.374	0.232

Conclusion: there are no new polymers in our Semaglutide API, which are not existed in original formulation. For polymer RRT0.876, which is detected in both Semaglutide API and original formulation, result in Semaglutide API is much lower than result in original formulation.

Biological Activity

Semaglutide Cell Activity Test


Semaglutide cell activity test

Sample list

Name	Source	Batch number	Sample No.
Semaglutide API (reference)	Zhejiang Peptides	G06210801	2021111893
		G06210801	2021111902
Semaglutide sample	Zhejiang Peptides	G06210901	2021111903
		G06210902	2021111904

Test result

Dose-response relationship



Relative activities

Sample batch number	Sample EC ₅₀	Reference EC ₅₀ (G06210801)	Standardization of sample with reference
G06210801	917.3	857.1	0.93
G06210901	715.7	857.1	1.20
G06210902	845.0	915.7	1.08

Analysis: Relative activity of reference=EC₅₀ of reference/EC₅₀ of sample.

Conclusion: according to test results, relative activity of samples(G06210801, G06210901, G06210902) comparing with reference are: 0.93, 1.20, 1.08. Samples showed agonist activity on GLP-1 receptor in this study.

Impurities (Peptide related and non-peptide related impurities)

Impurities profile

- Peptide related Impurities
- Related Substances I & II (3.2.S.4.1 P 2)

For each peptide-related impurity that is found in both the proposed generic synthetic peptide and the RLD, the level of such impurity in the proposed product is the same as or lower than that found in the RLD.

Applicants should identify each peptide-related impurity that is 0.10 percent of the drug substance or greater.

- High molecular weight protein impurities (Polymers 3.2.S.4.1 P 2)
- Process related Impurities (3.2.S.3.2 – P 1)
- Intermediate residue and reaction by products (Restricted Part 3.2.S.2.4 P 1)
- Inorganic and Ion impurities (3.2.S.3.2 – P 8)
- Residual Solvents (3.2.S.3.2 – P 12)
- Elemental Impurities (3.2.S.3.2 – P 8)
- Genotoxic Impurity (3.2.S.3.2 – P 15)
- Nitrosamine Impurities (3.2.S.3.2 – P 36)

Firm has performed Comparison of Semaglutide API with reference product Ozempic in terms of related substance as below:

● **Comparison of Semaglutide API and Semaglutide original product –Related substances**

Impurity profile are compared between our Semaglutide API and Semaglutide original product with analytical procedures described in chapter 3.2.S.4.2.

Sample list

Name	Source	Batch number	Expiry date
Semaglutide original product, Ozempic	Novo Nordisk	JP54343	2022.07
		KP52701	2023.02
		LP57558	2024.01
Semaglutide API	Zhejiang Peptides	G06210801	2023.09.12
		G06210901	2023.09.25
		G06210902	2023.10.05

Test result

Impurity No.	RRT	Impurity affiliation	Impurity content in Semaglutide API(%)			Impurity content in Semaglutide injection(%)		
			G06210801	G06210901	G06210902	JP54343	KP52701	LP57558
1	0.754	G06-IM01	0.055	0.054	0.053	0.158	0.116	0.059
2	0.839	G06-IM60	0.113	0.075	0.103	0.114	0.107	0.093
3	0.897	G06-IM59	0.105	0.083	0.100	0.032	N.D.	N.D.
4	0.941	Unspecified imp 1	0.034	N.D.	N.D.	N.D.	N.D.	N.D.
5	1.021	G06-IM03	0.042	0.042	0.039	0.073	N.D.	N.D.
6	0.955	G06-IM28	N.D.	0.036	N.D.	N.D.	N.D.	N.D.
7	0.936	Unspecified imp 2	N.D.	N.D.	0.035	N.D.	N.D.	N.D.
8	0.454	Unspecified imp 3	N.D.	N.D.	N.D.	0.038	N.D.	N.D.
9	0.776	Unspecified imp 4	N.D.	N.D.	N.D.	0.081	0.084	0.092
10	0.885	Unspecified imp 5	N.D.	N.D.	N.D.	0.106	0.097	0.085
11	0.913	Unspecified imp 6	N.D.	N.D.	N.D.	0.039	0.040	0.070
12	0.939	Unspecified imp 7	N.D.	N.D.	N.D.	0.519	0.508	0.361
13	1.047	Unspecified imp 8	N.D.	N.D.	N.D.	0.308	0.366	0.293
14	1.064	Unspecified imp 9	N.D.	N.D.	N.D.	0.304	0.343	0.324
15	1.103	Unspecified imp 10	N.D.	N.D.	N.D.	0.043	0.033	N.D.

16	1.129	Unspecified imp 11	N.D.	N.D.	N.D.	0.056	0.054	0.050
17	1.177	Unspecified imp 12	N.D.	N.D.	N.D.	0.123	0.130	0.146
18	1.261	Unspecified imp 13	N.D.	N.D.	N.D.	0.048	0.034	N.D.
19	1.268	Unspecified imp 14	N.D.	N.D.	N.D.	0.449	0.333	0.198
20	0.926	Unspecified imp 15	N.D.	N.D.	N.D.	N.D.	N.D.	0.040
21	1.010	Unspecified imp 16	N.D.	N.D.	N.D.	N.D.	N.D.	0.139
Total impurities			0.349	0.290	0.330	2.491	2.245	1.950

Conclusion:

4 impurities are detected in both API and original formulation: RRT0.754, RRT0.839, RRT0.897, RRT1.021, results of impurity RRT0.754, RRT0.839, RRT1.021 in API are less than results in original formulation. Result of impurity RRT0.897 is comparable with result in original formulation.

For new impurity RRT0.941, RRT0.955 which are not detected in original formulation, results are less than report limit 0.05% defined in ICH Q3A. Result of impurity which is higher than 0.05% is not existed in our Semaglutide API.

Conclusion of sameness studies:

Conclusion

According to comparison of Semaglutide API and Semaglutide original product, impurity level of Semaglutide API is comparable with Semaglutide original product. Total content of polymers in Semaglutide API is much lower than total content of polymers in Semaglutide original product.

For secondary structure comparison, far-UV similarity value of Semaglutide API(G06210801, G06210901, G06210902) and Semaglutide original product (KP52701) is 0.99999, 0.99995, 0.99996. For biological activities, relative activity of samples(G06210801, G06210901, G06210902) comparing with reference are: 0.93, 1.20, 1.08. Samples showed agonist activity on GLP-1 receptor in this study. For Isoelectric point and Thermoanalysis, results of Semaglutide API and Semaglutide original product are comparable. Above all, quality of Semaglutide API manufactured in Zhejiang Peptides is comparable with Semaglutide original product.

DRUG PRODUCT

The applicant/manufacturer has performed following tests on drug product in their premises;

S/N	TEST		SPECIFICATIONS	REFERENCE
1.	Appearance		Colorless clear solution free from any foreign particles	As per Manufacturer's Specs.
2.	Particulate matter		"Must be clear"	
	- Visible		$\geq 25\mu\text{m}$ 600, $\geq 10\mu\text{m}$ 6000	
	- Non-visible			
3.	Filling Volume (nominal volume)		The volume of each container should not less than nominal volume (use 05 containers at each interval) 0.750 – 0.825 mL	
4.	Leak test		None of 10 units exhibit leakage	
5.	Identification by HPLC		Examine the chromatograms obtained in the assay. The retention time of main peak obtained in sample solution should be in accordance with retention time of main peak obtained in standard solution.	
6.	pH		7.20-7.60	
7.	Related Substance I	G06-IM60	$\leq 0.2\%$	
		G06-IM01	$\leq 0.2\%$	
		G06-IM59	$\leq 0.2\%$	
		G06-IM28	$\leq 0.2\%$	
		Any other individual impurity	$\leq 0.1\%$	
		Total impurities	$\leq 2.0\%$	
8.	Related Substance II	G06-IM03	$\leq 0.2\%$	
9.	Bacterial endotoxin		< 10 EU/mg	
10.	Assay		(0.900- 1.100) mg/0.75 mL 90.0%~110.0%	
11.	Peptide Content		$\geq 80.0\%$	
12.	Sterility		Meets sterility acceptance criteria	

Firm has submitted safety test report of applied product issued by Pakistan Council of Scientific and Industrial Research Laboratories Complex, Karachi.



GOVERNMENT OF PAKISTAN
Ministry of Science & Technology
Pakistan Council of Scientific & Industrial Research
Laboratories Complex, Karachi
Shahrah-e-Dr. Salimuzzaman Siddiqui, Off University Road, Karachi-75280

Doc No: PSIR/KIC-4500913
Doc Date: May 3, 2017 Doc #01 Doc #01

TEST REPORT

Test Report #. ILD/Ref.Project-2025-37129-3

Date: 27-02-2025

- Name and Address of Client:** M/s. Nextar Pharma (Pvt.) Limited,
Plot No. E-58, North Western Industrial Zone, Port
Qasim, Karachi-Pakistan.
Ref. No: Nil Date of receipt: 19-02-2025
- Description of the Sample:**
Item: Semaqlutide Injection 1mg/0.75ml PFS Make: Nil
Lab. Code No: ILD/Ref.Project-2025-37129-3 Mark if any: Nil
Condition found on receipt: Properly Packed
- Test Performed on:** 20-02-2025 to 27-02-2025
Date of sampling: N.A.
- Environmental Conditions:** Within acceptable limits Temp: 25°C Humidity: 40%
(Where applicable)
- Method Used:** Safety Test USP-43
- Measurements & Results:** Uncertainty: Not Required

Product Name	Test	Result
Semaqlutide Injection 1mg/0.75ml PFS Batch No. TSJP001 Mfg Date : 23-07-2024 Exp Date : 22-07-2026	Safety Test	No signs of acute toxicity & mortality were observed in experimental laboratory animals (Albino mice) during observation period.
- Statement of Compliance:** N.A.
- Opinion/Interpretation (where required):** N.A.

END OF REPORT

Evaluation by BE&R:

Sr.No	Observations /Queries	Response of the firm	Remarks
1	The firm has applied single dose (1mg/0.75ml) pre-filled syringe while the reference product Ozempic is available in multi dose pre-filled	We would like to clarify that the multi-dose presentations of the innovator are dose-proportional, and based on this proportionality, honorable Registration Board has already approved single dose PFS in its 336 Registration Board Meeting held on June 4-6, 2024. This approval was given to M/S BF Biosciences Ltd, 5km Sundar Raiwind Road, Lahore-Pakistan. These single-dose presentations maintain dose accuracy and proportionality, aligning with the innovator's approved dosage regimen. Furthermore, it is worth noting these similar dosage have also been developed and approved by other manufacturers, such as Incepta Pharmaceuticals in Bangladesh, in single-dose formats, reinforcing the International Regulatory acceptance of this approach.	Single dose pre-filled syringe is not available in any reference country.

	pens in different strengths.	Following the same precedent, Nextar has developed three single-dose SKUs, maintaining the same dose and concentration as that of the innovator product.																																																																																																																																																																																				
2	Drug substance part 3.2.S.2.2 to 3.2.S.2.6 is not provided.	Letter of access is attached which states that; We, Zhejiang Peptides Biotech Co., Ltd., located at No. 8, Hengyizhi Road, Sanjie Town, Shengzhou City, Shaoxing City, Zhejiang Province, China, as the holder of the Master File for Semaglutide, hereby confirm our intent to submit the closed part of the Master File in support of the product registration, upon request by the authorized body of the Drug Regulatory Authority of Pakistan (DRAP). Kindly provide the official email address or relevant contact details through which we may securely submit the required documentation.	Not provided yet.																																																																																																																																																																																			
3	Complete analytical method validation of drug product is required.	<u>JUSTIFICATION FOR ANALYTICAL METHOD VALIDATION</u> Date: 11-JUL-2025 In the current product (Semaglutide 1 mg / 0.75 ml), all three strengths i.e Semaglutide 0.25 mg/0.188 ml, Semaglutide 0.5 mg/0.375 ml & Semaglutide 1 mg/0.75 ml contain the same drug-to-excipient ratio i.e 1.33 mg/ml, meaning that the proportion of active pharmaceutical ingredient to inactive ingredient remains constant across different dosage strengths therefore we select 1 mg / 0.75 ml strength for method validation.	Method validation report of only assay is attached.																																																																																																																																																																																			
4	Comparative testing of the applied product with the Innovator product is required.	<table border="1"><thead><tr><th colspan="7">Semaglutide 0.25mg/0.188mL PFS</th></tr><tr><th colspan="3">Reference Product / Innovator Name</th><th colspan="3">Semaglutide 0.25mg/0.188mL</th><th>Ozempic 0.25mg</th></tr><tr><th colspan="3">Batch No.</th><th>TSGP001</th><th>TSGP002</th><th>TSGP003</th><th>NPK/123</th></tr><tr><th>S/N</th><th>TEST</th><th>SPECIFICATIONS</th><th colspan="4">RESULTS</th></tr></thead><tbody><tr><td>1</td><td>Appearance</td><td>Colorless clear solution free from any foreign particles</td><td>Complies</td><td>Complies</td><td>Complies</td><td>Complies</td></tr><tr><td>2</td><td>pH</td><td>7.25-7.60</td><td>7.43</td><td>7.43</td><td>7.43</td><td>7.45</td></tr><tr><td>3</td><td>Identification by HPLC</td><td>Examine the chromatograms obtained in the assay. The retention time of main peak obtained in sample solution should be in accordance with retention time of main peak obtained in standard.</td><td>Complies</td><td>Complies</td><td>Complies</td><td>Complies</td></tr><tr><td>4</td><td>Assay</td><td>(0.225-0.275) mg/0.188 mL, 90.0%-110.0%</td><td>(0.257mg/0.188mL) 102.6 %</td><td>(0.253mg/0.188mL) 101.1 %</td><td>(0.254mg/0.188mL) 101.7 %</td><td>(0.260mg/0.188mL) 103.3 %</td></tr><tr><td>5</td><td>Bacterial endotoxin</td><td>< 10 EU/mg</td><td>Meets</td><td>Meets</td><td>Meets</td><td>Meets</td></tr><tr><td rowspan="5">6</td><td rowspan="5">Related Substance I</td><td>G06-IM06</td><td>≤0.2%</td><td>Not detected</td><td>Not detected</td><td>Not detected</td></tr><tr><td>G06-IM01</td><td>≤0.2%</td><td>Not detected</td><td>Not detected</td><td>Not detected</td></tr><tr><td>G06-IM56</td><td>≤0.2%</td><td>Not detected</td><td>Not detected</td><td>Not detected</td></tr><tr><td>G06-IM28</td><td>≤0.2%</td><td>Not detected</td><td>Not detected</td><td>Not detected</td></tr><tr><td>Any other individual impurity</td><td>≤0.1%</td><td>Not detected</td><td>Not detected</td><td>Not detected</td></tr><tr><td rowspan="2">7</td><td rowspan="2">Related Substance II</td><td>Total Impurities</td><td>≤2.0%</td><td>Not detected</td><td>Not detected</td><td>Not detected</td></tr><tr><td>G06-IM03</td><td>≤0.2%</td><td>Not detected</td><td>Not detected</td><td>Not detected</td></tr><tr><td>8</td><td>Identification by FTIR</td><td>FTIR Spectra of Our Product complies with Innovator</td><td>Meets</td><td>Meets</td><td>Meets</td><td>Meets</td></tr><tr><td>9</td><td>Identification by UV-Visible</td><td>UV-Visible Spectra of Our Product complies with innovator</td><td>Meets</td><td>Meets</td><td>Meets</td><td>Meets</td></tr><tr><td>10</td><td>Identification and Molecular weight</td><td>Same band of Our Product complies with innovator</td><td>Meets</td><td>Meets</td><td>Meets</td><td>Meets</td></tr></tbody></table> Semaglutide 0.5mg/0.375mL PFS <table border="1"><thead><tr><th colspan="7">Semaglutide 0.5mg/0.375mL PFS</th></tr><tr><th colspan="3">Reference Product / Innovator Name</th><th colspan="3">Semaglutide 0.5mg/0.375mL</th><th>Ozempic 0.5mg</th></tr><tr><th colspan="3">Batch No.</th><th>TSGP001</th><th>TSGP002</th><th>TSGP003</th><th>NPK/123</th></tr><tr><th>S/N</th><th>TEST</th><th>SPECIFICATIONS</th><th colspan="4">RESULTS</th></tr></thead><tbody><tr><td>11</td><td>Isosbestic focusing point</td><td>Same band location of Our Product complies with innovator</td><td>Meets</td><td>Meets</td><td>Meets</td><td>Meets</td></tr><tr><td>12</td><td>Polymer</td><td>MMT 3.5%</td><td>Meets</td><td>Meets</td><td>Meets</td><td>Meets</td></tr><tr><td>13</td><td>Particulate matter - Visible</td><td>Conform to standard "Must be clear" <10µm/600,000</td><td>Clear</td><td>Clear</td><td>Clear</td><td>Clear</td></tr><tr><td></td><td>Non-Visible</td><td></td><td>26/0</td><td>22/01</td><td>19/01</td><td>13/0</td></tr></tbody></table> Remarks: Results meet the specification criteria. Analyzed by: <i>Sahil Dutt</i> Date: <i>11/07/25</i> Checked by: <i>NAJ</i> Date: <i>11/07/25</i> Approved by: <i>Abdul</i> Date: <i>11/07/25</i>	Semaglutide 0.25mg/0.188mL PFS							Reference Product / Innovator Name			Semaglutide 0.25mg/0.188mL			Ozempic 0.25mg	Batch No.			TSGP001	TSGP002	TSGP003	NPK/123	S/N	TEST	SPECIFICATIONS	RESULTS				1	Appearance	Colorless clear solution free from any foreign particles	Complies	Complies	Complies	Complies	2	pH	7.25-7.60	7.43	7.43	7.43	7.45	3	Identification by HPLC	Examine the chromatograms obtained in the assay. The retention time of main peak obtained in sample solution should be in accordance with retention time of main peak obtained in standard.	Complies	Complies	Complies	Complies	4	Assay	(0.225-0.275) mg/0.188 mL, 90.0%-110.0%	(0.257mg/0.188mL) 102.6 %	(0.253mg/0.188mL) 101.1 %	(0.254mg/0.188mL) 101.7 %	(0.260mg/0.188mL) 103.3 %	5	Bacterial endotoxin	< 10 EU/mg	Meets	Meets	Meets	Meets	6	Related Substance I	G06-IM06	≤0.2%	Not detected	Not detected	Not detected	G06-IM01	≤0.2%	Not detected	Not detected	Not detected	G06-IM56	≤0.2%	Not detected	Not detected	Not detected	G06-IM28	≤0.2%	Not detected	Not detected	Not detected	Any other individual impurity	≤0.1%	Not detected	Not detected	Not detected	7	Related Substance II	Total Impurities	≤2.0%	Not detected	Not detected	Not detected	G06-IM03	≤0.2%	Not detected	Not detected	Not detected	8	Identification by FTIR	FTIR Spectra of Our Product complies with Innovator	Meets	Meets	Meets	Meets	9	Identification by UV-Visible	UV-Visible Spectra of Our Product complies with innovator	Meets	Meets	Meets	Meets	10	Identification and Molecular weight	Same band of Our Product complies with innovator	Meets	Meets	Meets	Meets	Semaglutide 0.5mg/0.375mL PFS							Reference Product / Innovator Name			Semaglutide 0.5mg/0.375mL			Ozempic 0.5mg	Batch No.			TSGP001	TSGP002	TSGP003	NPK/123	S/N	TEST	SPECIFICATIONS	RESULTS				11	Isosbestic focusing point	Same band location of Our Product complies with innovator	Meets	Meets	Meets	Meets	12	Polymer	MMT 3.5%	Meets	Meets	Meets	Meets	13	Particulate matter - Visible	Conform to standard "Must be clear" <10µm/600,000	Clear	Clear	Clear	Clear		Non-Visible		26/0	22/01	19/01	13/0	Results of Comparative testing of only one strength in tabular form is submitted. Details of comparative tests of all 3 strengths are required.
Semaglutide 0.25mg/0.188mL PFS																																																																																																																																																																																						
Reference Product / Innovator Name			Semaglutide 0.25mg/0.188mL			Ozempic 0.25mg																																																																																																																																																																																
Batch No.			TSGP001	TSGP002	TSGP003	NPK/123																																																																																																																																																																																
S/N	TEST	SPECIFICATIONS	RESULTS																																																																																																																																																																																			
1	Appearance	Colorless clear solution free from any foreign particles	Complies	Complies	Complies	Complies																																																																																																																																																																																
2	pH	7.25-7.60	7.43	7.43	7.43	7.45																																																																																																																																																																																
3	Identification by HPLC	Examine the chromatograms obtained in the assay. The retention time of main peak obtained in sample solution should be in accordance with retention time of main peak obtained in standard.	Complies	Complies	Complies	Complies																																																																																																																																																																																
4	Assay	(0.225-0.275) mg/0.188 mL, 90.0%-110.0%	(0.257mg/0.188mL) 102.6 %	(0.253mg/0.188mL) 101.1 %	(0.254mg/0.188mL) 101.7 %	(0.260mg/0.188mL) 103.3 %																																																																																																																																																																																
5	Bacterial endotoxin	< 10 EU/mg	Meets	Meets	Meets	Meets																																																																																																																																																																																
6	Related Substance I	G06-IM06	≤0.2%	Not detected	Not detected	Not detected																																																																																																																																																																																
		G06-IM01	≤0.2%	Not detected	Not detected	Not detected																																																																																																																																																																																
		G06-IM56	≤0.2%	Not detected	Not detected	Not detected																																																																																																																																																																																
		G06-IM28	≤0.2%	Not detected	Not detected	Not detected																																																																																																																																																																																
		Any other individual impurity	≤0.1%	Not detected	Not detected	Not detected																																																																																																																																																																																
7	Related Substance II	Total Impurities	≤2.0%	Not detected	Not detected	Not detected																																																																																																																																																																																
		G06-IM03	≤0.2%	Not detected	Not detected	Not detected																																																																																																																																																																																
8	Identification by FTIR	FTIR Spectra of Our Product complies with Innovator	Meets	Meets	Meets	Meets																																																																																																																																																																																
9	Identification by UV-Visible	UV-Visible Spectra of Our Product complies with innovator	Meets	Meets	Meets	Meets																																																																																																																																																																																
10	Identification and Molecular weight	Same band of Our Product complies with innovator	Meets	Meets	Meets	Meets																																																																																																																																																																																
Semaglutide 0.5mg/0.375mL PFS																																																																																																																																																																																						
Reference Product / Innovator Name			Semaglutide 0.5mg/0.375mL			Ozempic 0.5mg																																																																																																																																																																																
Batch No.			TSGP001	TSGP002	TSGP003	NPK/123																																																																																																																																																																																
S/N	TEST	SPECIFICATIONS	RESULTS																																																																																																																																																																																			
11	Isosbestic focusing point	Same band location of Our Product complies with innovator	Meets	Meets	Meets	Meets																																																																																																																																																																																
12	Polymer	MMT 3.5%	Meets	Meets	Meets	Meets																																																																																																																																																																																
13	Particulate matter - Visible	Conform to standard "Must be clear" <10µm/600,000	Clear	Clear	Clear	Clear																																																																																																																																																																																
	Non-Visible		26/0	22/01	19/01	13/0																																																																																																																																																																																

5	Firm has not performed all the tests on applied product as performed by innovator like peptide mapping, biological activity etc.	Biological activity has been successfully performed on all three strengths of the applied products (0.25 mg/0.188 mL, 0.5 mg/0.375 mL, and 1 mg/0.75 mL). The results demonstrate that the biological activity of each strength is comparable to that of the innovator (Ozempic®). (BioAssay report by LUMS attached below); cAMP Hunter™ GLP-1 Receptor Bioassay Report for Ozempic® Biosimilars Assay Performed by: Ghulam Hassan Report Prepared by: Ghulam Hassan Report Reviewed and Approved by: Dr. Shaper Mirza Assay Date: 30-04-2025 The DiscoverX cAMP Hunter™ CHO-K1 GLP1R Bioassay Kit is a highly sensitive, cell-based assay designed to measure the activation of the GLP-1 receptor through the detection of cyclic adenosine monophosphate (cAMP) accumulation. This assay employs CHO-K1 cells that are genetically engineered to express the GLP-1 receptor, enabling the monitoring of receptor activation in response to various ligands. Upon activation, the GLP-1 receptor triggers the activation of adenylyl cyclase, leading to increased cAMP production. The assay uses Enzyme Fragment Complementation (EFC) technology to detect cAMP, with a luminescent signal that is directly proportional to the level of cAMP. This assay is well-suited for evaluating the potency and efficacy of GLP-1 receptor agonists, such as Ozempic® and Nextar's different formulations of Semaglutide, by quantitatively measuring their ability to activate the receptor. The cAMP Hunter™ kit provides an accurate and reliable method for comparing the functional activity of these agonists, allowing for direct analysis of their receptor-mediated effects in a controlled, reproducible environment. This serves our purpose by offering a robust platform for assessing the pharmacological properties of GLP-1 receptor agonists. We employed this kit to quantitatively measure activation of the GLP-1 receptor by each formulation, including Ozempic® 4mg/3ml (Novonordisk), Nextar's Semaglutide 0.25mg/0.188mL, Nextar's Semaglutide 0.5mg/0.375mL, and Nextar's Semaglutide 1mg/0.75mL. By analyzing dose-response curves and half-maximal effective concentration (EC₅₀) values, we assessed if Ozempic® biosimilar products induced cAMP signalling with comparable potency to Ozempic®. A rightward shift in EC₅₀ (higher EC₅₀ value) for a test formulation versus Ozempic® indicates lower potency (more ligand required for the same effect), while a similar EC₅₀ suggests equivalent bioactivity. Conclusion: These findings suggest that all Nextar's samples exhibited EC₅₀ values within the acceptable range, indicating that all formulations demonstrate marked similarity with innovator's Ozempic® in the activation of the GLP-1 receptor in this assay. Peptide mapping is currently being conducted on the API as well as higher strength, i.e., 1 mg/0.75 mL, and the results will be shared within one week. This test is used to confirm the protein's structure by breaking it into smaller fragments and comparing the resulting pattern with that of the reference product. As the same raw material and manufacturing process are used across all strengths, and the formulation is dose-proportional, testing only the highest strength i.e., 1 mg/0.75 mL of finished product is technically justified. The obtained results will be considered representative of the lower strengths as well. (Undertaking Attached for Peptide Mapping). Furthermore, we would also like to highlight that we have performed following additional tests from prestigious institutes. These Analysis/Tests includes the following and detailed tests reports were already submitted in dossier.	Bioassay report attached. Undertaking for peptide mapping is attached which states that report will be provided within one month.	

		<table><tr><th>S.NO</th><th>Test Name</th><th>Institute Name</th></tr><tr><td>1</td><td>Peptide Sequence Analysis</td><td>Harvard University, Boston, USA</td></tr><tr><td>2</td><td>Secondary Mass Spectra (MS/MS)" (amino acid sequence)</td><td>Harvard University, Boston, USA</td></tr><tr><td>3</td><td>Molecular Weight Detection</td><td>Harvard University, Boston, USA</td></tr><tr><td>4</td><td>Residual Solvents Test</td><td>IAC-HEJ</td></tr><tr><td>5</td><td>Abnormal Toxicity (Safety) Test</td><td>PCSIR</td></tr></table>	S.NO	Test Name	Institute Name	1	Peptide Sequence Analysis	Harvard University, Boston, USA	2	Secondary Mass Spectra (MS/MS)" (amino acid sequence)	Harvard University, Boston, USA	3	Molecular Weight Detection	Harvard University, Boston, USA	4	Residual Solvents Test	IAC-HEJ	5	Abnormal Toxicity (Safety) Test	PCSIR		
S.NO	Test Name	Institute Name																				
1	Peptide Sequence Analysis	Harvard University, Boston, USA																				
2	Secondary Mass Spectra (MS/MS)" (amino acid sequence)	Harvard University, Boston, USA																				
3	Molecular Weight Detection	Harvard University, Boston, USA																				
4	Residual Solvents Test	IAC-HEJ																				
5	Abnormal Toxicity (Safety) Test	PCSIR																				
Decision of 349th Meeting: The Registration Board deferred the case for submission of following documents/clarifications; • Drug substance part 3.2.S.2.2 to 3.2.S.2.6 • Reports of peptide mapping on drug product • Reports of all the comparative tests performed on the applied strength with that of Innovator product. • Complete analytical method validation of drug product on all parameters .																						

Semaglutide Source: Synthetic Drug Substance Import Local Manufacturing Applied Container Closure System: PFS	
Case # 29	
Name, address of Applicant	M/s Nextar Pharma (Pvt) Ltd Plot No. E-58. North Western, Industrial Zone, Port Qasim Karachi.
Status of the applicant	☒ Manufacturer ☐ Importer ☐ Bulk Import & Local Repack ☐ Is involved in none of the above
Name, address of manufacturer(s)	M/s Nextar Pharma (Pvt) Ltd Plot No. E-58. North Western, Industrial Zone, Port Qasim Karachi.
GMP of manufacturer & Evidence of Section	DML No. 000777 Address: Plot No. E-58. North Western, Industrial Zone, Port Qasim Karachi. Evidence of section: Injectable Ampoules & PFS GMP: Last GMP conducted on 20-03-2024 valid upto 19-03-26
Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
Intended use of pharmaceutical product	☐ Domestic sale Export sale ☒ Domestic and Export sales
E-app tracking ID and Date of submission	Tracking ID: DM4-RY2-RXGG Application No. 92101

	Date of receiving: 21-04-2025
Details of fee submitted	Challan Number: 94197275899 Paid Fee: 37000.0 Paid Date: 2025-04-14 Division: Biological Evaluation & Registration
The proposed proprietary name / brand name	SEMAVI-PFS 0.25mg/0.188ml
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 0.188ml contains: Semaglutide 0.25mg
Pharmaceutical form of applied drug	Solution for Injection in PFS (For Subcutaneous use only)
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	Innovator's Specifications
Proposed Pack size	1's (PFS)
Proposed unit price	As per SRO
Shelf Life	24 Months
Storage Condition	Store in a refrigerator (2 °C – 8 °C)
The status in reference regulatory authorities	OZEMPIC (semaglutide) solution for injection 2 mg/1.5 ml (USFDA APPROVED) <i>The firm has applied single dose (0.25mg/0.188ml) pre-filled syringe while the reference product Ozempic is available in multi dose pre-filled pens in different strengths as below;</i> <i>• 0.25 mg or 0.5 mg dose pen (4 doses of 0.25 mg and 2 doses of 0.5 mg, or 4 doses of 0.5 mg)</i> <i>• 1 mg dose pen, (4 doses per pen)</i> <i>• 2 mg dose pen, (4 doses per pen)</i>
For generic drugs (me-too status)	Sematide Prefilled Syringe 0.25mg/0.188mL Manufactured by M/s BF Biosciences Ltd (Reg.No 120528)

Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD. Firm has summarized information related to nomenclature, structure, general properties, physical form, manufacturers, Characterization (Elucidation of Structure and Other Characteristics), impurities, specifications, analytical procedures, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.												
Name, address of drug substance manufacturer	M/s Zhejiang Peptides Biotech Co., Ltd, No.8 Hengyizhi Road, Sanjie Town, Shengzhou City, Zhejiang Province, China												
Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, physical form, manufacturers, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.												
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of drug substance of following 3 batches at accelerated and real time conditions. The real time stability data is conducted at 5°C ± 3°C for 24 months, and the accelerated stability studies are conducted at 25°C ± 2°C for 6 months. Batch No: G06210801 (Test starting date; 22-10-2021) Batch No: G06210901 (Test starting date; 22-10-2021) Batch No: G06210902 (Test starting date; 22-10-2021)												
Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols (undertaking for reports), control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures for assay only, batch analysis, working standard COA, container closure system and stability.												
Analytical method validation/verification of product	Firm has submitted Analytical method validation for sterility test, bacterial endotoxin test of applied product.												
Container closure system of the drug product	(PFS) 1mL USP Type 1 clear glass/Butyl rubber stopper with plunger rod.												
Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of following 03 batches. The accelerated stability study data is conducted at 25±2°C, 60%±5% RH for 6 months. The real time ongoing stability study data is conducted at 5°C±3°C for 6months. <table><tr><td>Batch No.</td><td>Batch Size</td><td>Manufacturing date</td></tr><tr><td>TSGP001</td><td>500PFS</td><td>July-2024</td></tr><tr><td>TSGP002</td><td>500 PFS</td><td>July-2024</td></tr><tr><td>TSGP003</td><td>500 PFS</td><td>July-2024</td></tr></table>	Batch No.	Batch Size	Manufacturing date	TSGP001	500PFS	July-2024	TSGP002	500 PFS	July-2024	TSGP003	500 PFS	July-2024
Batch No.	Batch Size	Manufacturing date											
TSGP001	500PFS	July-2024											
TSGP002	500 PFS	July-2024											
TSGP003	500 PFS	July-2024											

Module IV	Detailed in sameness evaluation mentioned below
Module V	Detailed in sameness evaluation mentioned below
<u>DRUG SUBSTANCE:</u> The firm has submitted Sameness data as per USFDA guidelines: <u>ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin Guidance for Industry FDA.</u> Firm has compared Semaglutide API of Zhejiang Peptides Biotech Co. Ltd with Semaglutide reference product Ozempic.	
Parameters	Sameness evaluation Data Submitted by the applicant
A. Active Ingredient Sameness (by Orthogonal Method) (specify) 3. Primary sequence and Physicochemical properties	Firm has performed following in physicochemical characterization; • Appearance • Solubility • Hygroscopicity • Specific optical rotation • Clarity and colour of solution • PH • Molecular Weight • Particle size by Malvern Laser Diffraction method • Polymorphism by X-ray powder diffraction method • Isoelectric point by Imaging capillary isoelectric focusing electrophoresis <u>Primary sequence</u> Firm has conducted Peptide Sequence analysis by mass spectrometer as below;

● **Amino acid sequence analysis**

Apparatus: Mass spectrometer XevoG2-XS QToF (Waters)


UPLC(Acquity UPLC I-Class) (Waters)

Experiment method:

Perform primary mass spectra (MS) test, then perform secondary mass spectra test (MS/MS) of target peptide mother ion. Establish data base according to theoretical sequence, search for secondary data to validate accuracy of sequence.


Test result

Semaglutide working standard MASCOT secondary mass spectra data match diagram



Monoisotopic mass of neutral peptide M_r(calc): 4111.1154
Variable modifications:
A2 : Asn (A)
K20 : CysMELI2H3 (K)
Ion Score: 97 Expect: 9.4e-012
Matches (Bold Red): 44/151 fragment ions using 71 most intense peaks

Semaglutide original product (Ozempic®, Novo Nordisk, batch number: JP54343) MASCOT secondary mass spectra data match diagram



Monoisotopic mass of neutral peptide M_r(calc): 4111.1154
Variable modifications:
A2 : Asn (A)
K20 : CysMELI2H3 (K)
Ion Score: 97 Expect: 9.4e-012
Matches (Bold Red): 44/151 fragment ions using 71 most intense peaks

Secondary structure

Firm has performed Circular dichroism spectrum analysis for study of peptide Secondary structure as below;

-Secondary structure

Circular dichroism spectrum analysis is meaningful for study of peptide secondary structure. Secondary structure are compared between our Semaglutide API and Semaglutide original product with Circular dichroism spectrum analysis.

Sample list

Sample No.	Name	Source	Batch number
20211111577	Semaglutide original product	Novo Nordisk	KP52701
20211111578	Semaglutide API	Zhejiang peptides	G06210801
20211111579			G06210901
20211111580			G06210902

Apparatus: Chirascan Plus V100 Circular dichroism spectrometer (Applied Photophysics)

Apparatus parameter:


Band width	1.0nm
Step	1.0nm
Measurement range	190-260nm(far-UV region scan)
Time-per-point	0.5s
Repeats	3
Cell Length	0.5mm
Temperature	Room Temperature

Far/near UV scan of standard: acquire data of background test and blank test with wavelength 180-340nm, then acquire data of far/near Circular dichroism UV scan with wavelength 180-340nm.

Far UV scan: cuvette is soaked with 2M HNO₃, clean with deionized water and dry, acquire data of background and blank. Then add sample into cuvette, acquire data with wavelength 190-260nm.

Firm has also performed Thermoanalysis by Differential scanning Calorimeter (DSC) as under;

	- Thermoanalysis Thermoanalysis is meaningful to stability of protein and polypeptide. With Differential Scanning Calorimeter(DSC) method, melting temperature(Tm) of Semaglutide original product and Semaglutide API samples are tested. Sample list <table><tr><th>Sample No.</th><th>Name</th><th>Source</th><th>Batch number</th></tr><tr><td>20211111582</td><td>Semaglutide original product</td><td>Novo Nordisk</td><td>KP52701</td></tr><tr><td>20211111583</td><td rowspan="3">Semaglutide API</td><td rowspan="3">Zhejiang peptites</td><td>G06210801</td></tr><tr><td>20211111584</td><td>G06210901</td></tr><tr><td>20211111585</td><td>G06210902</td></tr></table> Apparatus: Differential Scanning Calorimeter (Microcal PEAQ-DSC) Apparatus parameter: Temperature: 20-100°C Temperature rising rate: 120°C/h Conclusion: according to above test, Tm of Semaglutide API (G06210801, G06210901, G06210902) and Semaglutide original product (KP52701) are: 66.06 °C, 66.00 °C, 66.16 °C, 65.96°C, which are comparable.	Sample No.	Name	Source	Batch number	20211111582	Semaglutide original product	Novo Nordisk	KP52701	20211111583	Semaglutide API	Zhejiang peptites	G06210801	20211111584	G06210901	20211111585	G06210902																																																								
Sample No.	Name	Source	Batch number																																																																						
20211111582	Semaglutide original product	Novo Nordisk	KP52701																																																																						
20211111583	Semaglutide API	Zhejiang peptites	G06210801																																																																						
20211111584			G06210901																																																																						
20211111585			G06210902																																																																						
Oligomer/aggregation states	Firm has performed Polymer (Oligomer/ Aggregates/ High Molecular Weight Proteins) by Size Exclusion Chromatography as below; -Polymer Polymer content are compared between our Semaglutide API and Semaglutide original product with analytical procedures described in chapter 3.2.S.4.2. Sample list <table><tr><th>Name</th><th>Source</th><th>Batch number</th><th>Expiry date</th></tr><tr><td rowspan="3">Semaglutide original product, Ozempic</td><td rowspan="3">Novo Nordisk</td><td>JP54343</td><td>2022.07</td></tr><tr><td>KP52701</td><td>2023.02</td></tr><tr><td>LP57558</td><td>2024.01</td></tr><tr><td rowspan="3">Semaglutide API</td><td rowspan="3">Zhejiang Peptities</td><td>G06210801</td><td>2023.09.12</td></tr><tr><td>G06210901</td><td>2023.09.25</td></tr><tr><td>G06210902</td><td>2023.10.05</td></tr></table> Test result <table><tr><th>RRT</th><th>Name</th><th>Impurity content in Semaglutide API(%)</th><th>Impurity content in Semaglutide</th></tr></table> <table><tr><th></th><th></th><th colspan="3"></th><th colspan="3">injection(%)</th></tr><tr><th></th><th></th><th>G06210801</th><th>G06210901</th><th>G06210902</th><th>JP54343</th><th>KP52701</th><th>LP57558</th></tr><tr><td>0.842</td><td>Polymer 1</td><td>N.D.</td><td>N.D.</td><td>N.D.</td><td>0.070</td><td>0.039</td><td>N.D.</td></tr><tr><td>0.876</td><td>Polymer 2</td><td>0.062</td><td>0.048</td><td>0.076</td><td>0.510</td><td>0.335</td><td>0.195</td></tr><tr><td>0.967</td><td>Polymer 3</td><td>N.D.</td><td>N.D.</td><td>N.D.</td><td>N.D.</td><td>N.D.</td><td>0.037</td></tr><tr><td colspan="2">Total polymer content</td><td>0.062</td><td>0.048</td><td>0.076</td><td>0.580</td><td>0.374</td><td>0.232</td></tr></table> Conclusion: there are no new polymers in our Semaglutide API, which are not existed in original formulation. For polymer RRT0.876, which is detected in both Semaglutide API and original formulation, result in Semaglutide API is much lower than result in original formulation.	Name	Source	Batch number	Expiry date	Semaglutide original product, Ozempic	Novo Nordisk	JP54343	2022.07	KP52701	2023.02	LP57558	2024.01	Semaglutide API	Zhejiang Peptities	G06210801	2023.09.12	G06210901	2023.09.25	G06210902	2023.10.05	RRT	Name	Impurity content in Semaglutide API(%)	Impurity content in Semaglutide						injection(%)					G06210801	G06210901	G06210902	JP54343	KP52701	LP57558	0.842	Polymer 1	N.D.	N.D.	N.D.	0.070	0.039	N.D.	0.876	Polymer 2	0.062	0.048	0.076	0.510	0.335	0.195	0.967	Polymer 3	N.D.	N.D.	N.D.	N.D.	N.D.	0.037	Total polymer content		0.062	0.048	0.076	0.580	0.374	0.232
Name	Source	Batch number	Expiry date																																																																						
Semaglutide original product, Ozempic	Novo Nordisk	JP54343	2022.07																																																																						
		KP52701	2023.02																																																																						
		LP57558	2024.01																																																																						
Semaglutide API	Zhejiang Peptities	G06210801	2023.09.12																																																																						
		G06210901	2023.09.25																																																																						
		G06210902	2023.10.05																																																																						
RRT	Name	Impurity content in Semaglutide API(%)	Impurity content in Semaglutide																																																																						
					injection(%)																																																																				
		G06210801	G06210901	G06210902	JP54343	KP52701	LP57558																																																																		
0.842	Polymer 1	N.D.	N.D.	N.D.	0.070	0.039	N.D.																																																																		
0.876	Polymer 2	0.062	0.048	0.076	0.510	0.335	0.195																																																																		
0.967	Polymer 3	N.D.	N.D.	N.D.	N.D.	N.D.	0.037																																																																		
Total polymer content		0.062	0.048	0.076	0.580	0.374	0.232																																																																		
Biological Activity	Semaglutide Cell Activity Test																																																																								

	Semaglutide cell activity test Sample list <table><tr><td>Name</td><td>Source</td><td>Batch number</td><td>Sample No.</td></tr><tr><td>Semaglutide API (reference)</td><td>Zhejiang Peptides</td><td>G06210801</td><td>2021111893</td></tr><tr><td rowspan="3">Semaglutide sample</td><td rowspan="3">Zhejiang Peptides</td><td>G06210801</td><td>2021111902</td></tr><tr><td>G06210901</td><td>2021111903</td></tr><tr><td>G06210902</td><td>2021111904</td></tr></table> Test result Dose-response relationship  Relative activities <table><tr><td>Sample batch number</td><td>Sample EC₅₀</td><td>Reference EC₅₀(G06210801)</td><td>Standardization of sample with reference</td></tr><tr><td>G06210801</td><td>917.3</td><td>857.1</td><td>0.93</td></tr><tr><td>G06210901</td><td>715.7</td><td>857.1</td><td>1.20</td></tr><tr><td>G06210902</td><td>845.0</td><td>915.7</td><td>1.08</td></tr></table> Analysis: Relative activity of reference=EC₅₀ of reference/EC₅₀ of sample. Conclusion: according to test results, relative activity of samples(G06210801, G06210901, G06210902) comparing with reference are: 0.93, 1.20, 1.08. Samples showed agonist activity on GLP-1 receptor in this study.	Name	Source	Batch number	Sample No.	Semaglutide API (reference)	Zhejiang Peptides	G06210801	2021111893	Semaglutide sample	Zhejiang Peptides	G06210801	2021111902	G06210901	2021111903	G06210902	2021111904	Sample batch number	Sample EC ₅₀	Reference EC ₅₀ (G06210801)	Standardization of sample with reference	G06210801	917.3	857.1	0.93	G06210901	715.7	857.1	1.20	G06210902	845.0	915.7	1.08
Name	Source	Batch number	Sample No.																														
Semaglutide API (reference)	Zhejiang Peptides	G06210801	2021111893																														
Semaglutide sample	Zhejiang Peptides	G06210801	2021111902																														
		G06210901	2021111903																														
		G06210902	2021111904																														
Sample batch number	Sample EC ₅₀	Reference EC ₅₀ (G06210801)	Standardization of sample with reference																														
G06210801	917.3	857.1	0.93																														
G06210901	715.7	857.1	1.20																														
G06210902	845.0	915.7	1.08																														
Impurities (Peptide related and non-peptide related impurities) For each peptide-related impurity that is found in both the proposed generic synthetic peptide and the RLD, the level of such impurity in the proposed product is the same as or lower than that found in the RLD. Applicants should identify each peptide-related impurity that is 0.10 percent of the drug substance or greater.	Impurities profile ▪ Peptide related Impurities ▪ Related Substances I & II (3.2.S.4.1 P 2) ▪ High molecular weight protein impurities (Polymers 3.2.S.4.1 P 2) ▪ Process related Impurities (3.2.S.3.2 – P 1) ▪ Intermediate residue and reaction by products (Restricted Part 3.2.S.2.4 P 1) ▪ Inorganic and Ion impurities (3.2.S.3.2 – P 8) ▪ Residual Solvents (3.2.S.3.2 – P 12) ▪ Elemental Impurities (3.2.S.3.2 – P 8) ▪ Genotoxic Impurity (3.2.S.3.2 – P 15) ▪ Nitrosamine Impurities (3.2.S.3.2 – P 36) <u>Firm has performed Comparison of Semaglutide API with reference product Ozempic in terms of related substance as below:</u>																																

● **Comparison of Semaglutide API and Semaglutide original product**
-Related substances

Impurity profile are compared between our Semaglutide API and Semaglutide original product with analytical procedures described in chapter 3.2.S.4.2.

Sample list

Name	Source	Batch number	Expiry date
Semaglutide original product, Ozempic	Novo Nordisk	JP54343	2022.07
		KP52701	2023.02
		LP57558	2024.01
Semaglutide API	Zhejiang Peptides	G06210801	2023.09.12
		G06210901	2023.09.25
		G06210902	2023.10.05

Test result

Impurity No.	RRT	Impurity affiliation	Impurity content in Semaglutide API(%)			Impurity content in Semaglutide injection(%)		
			G06210801	G06210901	G06210902	JP54343	KP52701	LP57558
1	0.754	G06-IM01	0.055	0.054	0.053	0.158	0.116	0.059
2	0.839	G06-IM60	0.113	0.075	0.103	0.114	0.107	0.093
3	0.897	G06-IM59	0.105	0.083	0.100	0.032	N.D.	N.D.
4	0.941	Unspecified imp 1	0.034	N.D.	N.D.	N.D.	N.D.	N.D.
5	1.021	G06-IM03	0.042	0.042	0.039	0.073	N.D.	N.D.
6	0.955	G06-IM28	N.D.	0.036	N.D.	N.D.	N.D.	N.D.
7	0.936	Unspecified imp 2	N.D.	N.D.	0.035	N.D.	N.D.	N.D.
8	0.454	Unspecified imp 3	N.D.	N.D.	N.D.	0.038	N.D.	N.D.
9	0.776	Unspecified imp 4	N.D.	N.D.	N.D.	0.081	0.084	0.092
10	0.885	Unspecified imp 5	N.D.	N.D.	N.D.	0.106	0.097	0.085
11	0.913	Unspecified imp 6	N.D.	N.D.	N.D.	0.039	0.040	0.070
12	0.939	Unspecified imp 7	N.D.	N.D.	N.D.	0.519	0.508	0.361
13	1.047	Unspecified imp 8	N.D.	N.D.	N.D.	0.308	0.366	0.293
14	1.064	Unspecified imp 9	N.D.	N.D.	N.D.	0.304	0.343	0.324
15	1.103	Unspecified imp 10	N.D.	N.D.	N.D.	0.043	0.033	N.D.

16	1.129	Unspecified imp 11	N.D.	N.D.	N.D.	0.056	0.054	0.050
17	1.177	Unspecified imp 12	N.D.	N.D.	N.D.	0.123	0.130	0.146
18	1.261	Unspecified imp 13	N.D.	N.D.	N.D.	0.048	0.034	N.D.
19	1.268	Unspecified imp 14	N.D.	N.D.	N.D.	0.449	0.333	0.198
20	0.926	Unspecified imp 15	N.D.	N.D.	N.D.	N.D.	N.D.	0.040
21	1.010	Unspecified imp 16	N.D.	N.D.	N.D.	N.D.	N.D.	0.139
Total impurities			0.349	0.290	0.330	2.491	2.245	1.950

Conclusion:

4 impurities are detected in both API and original formulation: RRT0.754, RRT0.839, RRT0.897, RRT1.021, results of impurity RRT0.754, RRT0.839, RRT1.021 in API are less than results in original formulation. Result of impurity RRT0.897 is comparable with result in original formulation.

For new impurity RRT0.941, RRT0.955 which are not detected in original formulation, results are less than report limit 0.05% defined in ICH Q3A. Result of impurity which is higher than 0.05% is not existed in our Semaglutide API.

Conclusion of sameness studies:

Conclusion

According to comparison of Semaglutide API and Semaglutide original product, impurity level of Semaglutide API is comparable with Semaglutide original product. Total content of polymers in Semaglutide API is much lower than total content of polymers in Semaglutide original product.

For secondary structure comparison, far-UV similarity value of Semaglutide API(G06210801, G06210901, G06210902) and Semaglutide original product (KP52701) is 0.99999, 0.99995, 0.99996. For biological activities, relative activity of samples(G06210801, G06210901, G06210902) comparing with reference are: 0.93, 1.20, 1.08. Samples showed agonist activity on GLP-1 receptor in this study. For Isoelectric point and Thermoanalysis, results of Semaglutide API and Semaglutide original product are comparable. Above all, quality of Semaglutide API manufactured in Zhejiang Peptides is comparable with Semaglutide original product.

DRUG PRODUCT

The applicant/manufacturer has performed following tests on drug product in their premises;

a		TEST	SPECIFICATIONS	REFERENCE
1.		Appearance	Colorless clear solution free from any foreign particles	As per Manufacturer's Specs.
2.		Particulate matter		
		- Visible	"Must be clear"	
		- Non-visible	$\geq 25\mu\text{m}$ 600 $\geq 10\mu\text{m}$ 6000	
3.		Filling Volume (nominal volume)	The volume of each container should not less than nominal volume (use 05 containers at each interval) 0.188 – 0.207 mL	
4.		Leak test	None of 10 units exhibit leakage	
5.		Identification by HPLC	Examine the chromatograms obtained in the assay. The retention time of main peak obtained in sample solution should be in accordance with retention time of main peak obtained in standard solution.	
6.		pH	7.20-7.60	
7.	Related Substance I	G06-IM60	$\leq 0.2\%$	
		G06-IM01	$\leq 0.2\%$	
		G06-IM59	$\leq 0.2\%$	
		G06-IM28	$\leq 0.2\%$	
		Any other individual impurity	$\leq 0.1\%$	
		Total impurities	$\leq 2.0\%$	
8.	Related Substance II	G06-IM03	$\leq 0.2\%$	
9.		Bacterial endotoxin	$< 10 \text{ EU/mg}$	
10.		Assay	(0.225-0.275) mg/0.188 mL 90.0%~110.0%	
11.		Peptide Content	$\geq 80.0\%$	
12.		Sterility	Meets sterility acceptance criteria	

Firm has submitted safety test report of applied product issued by Pakistan Council of Scientific and Industrial Research Laboratories Complex, Karachi.



GOVERNMENT OF PAKISTAN
Ministry of Science & Technology
Pakistan Council of Scientific & Industrial Research
Laboratories Complex, Karachi
Shahrah-e-Dr. Salimuzzaman Siddiqui, Off University Road, Karachi-75280

Sr. No. PC/SIR/KLC-5030477

Doc No. PC/SIR/KLC/5030477
Issue Date: May 1, 2025
Issue # 02
Rev # 01

TEST REPORT

Test Report #. ILD/Ref.Project-2025-37129-1

Date: 27-02-2025

1. Name and Address of Client: M/s. Nextar Pharma (Pvt.) Limited,
Plot No. E-58, North Western Industrial Zone, Port
Qasim, Karachi-Pakistan.

Ref. No: Nil Date of receipt: 19-02-2025

2. Description of the Sample:
Item: Semaglutide Injection 0.25mg/0.188ml PFS Make: Nil
Lab. Code No: ILD/Ref.Project-2025-37129-1 Mark if any: Nil
Condition found on receipt: Properly Packed

3. Test Performed on: 20-02-2025 to 27-02-2025
Date of sampling: N.A.

4. Environmental Conditions: Within acceptable limits Temp: 25°C Humidity: 40%
(Where applicable)

5. Method Used: Safety Test USP-43

6. Measurements & Results: Uncertainty: Not Required

Product Name	Test	Result
Semaglutide Injection 0.25mg/0.188ml PFS Batch No. TSGP001 Mfg Date : 23-07-2024 Exp Date : 22-07-2026	Safety Test	No signs of acute toxicity & mortality were observed in experimental laboratory animals (Albino mice) during observation period.

7. Statement of Compliance: N.A.

8. Opinion/Interpretation (where required): N.A.

END OF REPORT

Evaluation by BE&R:

Sr.No	Observations /Queries	Response of the firm	Remarks
1	The firm has applied single dose (0.25mg/0.188ml) pre-filled syringe while the reference product Ozempic is available in multi dose	We would like to clarify that the multi-dose presentations of the innovator are dose-proportional, and based on this proportionality, honorable Registration Board has already approved single dose PFS in its 336 Registration Board Meeting held on June 4-6, 2024. This approval was given to M/S BF Biosciences Ltd, 5km Sundar Raiwind Road, Lahore-Pakistan. These single-dose presentations maintain dose accuracy and proportionality, aligning with the innovator's approved dosage regimen. Furthermore, it is worth noting these similar dosage have also been developed and approved by other manufacturers, such as Incepta	Single dose pre-filled syringe is not available in any reference country.

	pre-filled pens in different strengths.	Pharmaceuticals in Bangladesh, in single-dose formats, reinforcing the International Regulatory acceptance of this approach. Following the same precedent, Nextar has developed three single-dose SKUs, maintaining the same dose and concentration as that of the innovator product.																																																																																																																												
2	Drug substance part 3.2.S.2.2 to 3.2.S.2.6 is not provided.	Letter of access is attached which states that; We, Zhejiang Peptides Biotech Co., Ltd., located at No. 8, Hengyizhi Road, Sanjie Town, Shengzhou City, Shaoxing City, Zhejiang Province, China, as the holder of the Master File for Semaglutide, hereby confirm our intent to submit the closed part of the Master File in support of the product registration, upon request by the authorized body of the Drug Regulatory Authority of Pakistan (DRAP). Kindly provide the official email address or relevant contact details through which we may securely submit the required documentation.	Not provided yet.																																																																																																																											
3	Complete analytical method validation of drug product is required.	<u>JUSTIFICATION FOR ANALYTICAL METHOD VALIDATION</u> Date: 11-JUL-2025 In the current product (Semaglutide 1 mg / 0.75 ml), all three strengths i.e Semaglutide 0.25 mg/0.188 ml, Semaglutide 0.5 mg/0.375 ml & Semaglutide 1 mg/0.75 ml contain the same drug-to-excipient ratio i.e 1.33 mg/ml, meaning that the proportion of active pharmaceutical ingredient to inactive ingredient remains constant across different dosage strengths therefore we select 1 mg / 0.75 ml strength for method validation.	Method validation report of only assay is attached.																																																																																																																											
4	Comparative testing of the applied product with the Innovator product is required.	<table><tr><th colspan="7">Semaglutide 0.25mg/0.188mL PFS</th></tr><tr><th colspan="3">Reference Product / Innovator Name</th><th colspan="3">Semaglutide 0.25mg/0.188mL</th><th>Ozempic 0.25mg</th></tr><tr><th colspan="3">Batch No</th><th>TSGP001</th><th>TSGP002</th><th>TSGP003</th><th>NPS/123</th></tr><tr><th>S/N</th><th>TEST</th><th>SPECIFICATIONS</th><th colspan="4">RESULTS</th></tr><tr><td>1</td><td>Appearance</td><td>Colorless clear solution free from any foreign particles</td><td>Complies</td><td>Complies</td><td>Complies</td><td>Complies</td></tr><tr><td>2</td><td>pH</td><td>7.16-7.60</td><td>7.43</td><td>7.43</td><td>7.43</td><td>7.45</td></tr><tr><td>3</td><td>Identification by HPLC</td><td>Examine the chromatograms obtained in the assay. The retention time of main peak obtained in sample solution should be in accordance with retention time of main peak obtained in standard</td><td>Complies</td><td>Complies</td><td>Complies</td><td>Complies</td></tr><tr><td>4</td><td>Assay</td><td>(0.225-0.275) mg/0.188 mL, 90.0%-110.0%</td><td>(0.263mg/0.188mL) 102.6 %</td><td>(0.263mg/0.188mL) 101.1 %</td><td>(0.254mg/0.188mL) 101.7 %</td><td>(0.266mg/0.188mL) 103.7 %</td></tr><tr><td>5</td><td>Bacterial endotoxin</td><td>< 10 EU/mg</td><td>Meets</td><td>Meets</td><td>Meets</td><td>Meets</td></tr><tr><td rowspan="6">6</td><td rowspan="6">Related Substance I</td><td>G06-M06</td><td>≤0.2%</td><td>Not detected</td><td>Not detected</td><td>Not detected</td></tr><tr><td>G06-M07</td><td>≤0.2%</td><td>Not detected</td><td>Not detected</td><td>Not detected</td></tr><tr><td>G06-M55</td><td>≤0.2%</td><td>Not detected</td><td>Not detected</td><td>Not detected</td></tr><tr><td>G06-M21</td><td>≤0.2%</td><td>Not detected</td><td>Not detected</td><td>Not detected</td></tr><tr><td>Any other individual impurity</td><td>≤0.1%</td><td>Not detected</td><td>Not detected</td><td>Not detected</td></tr><tr><td>Total Impurities</td><td>≤2.0%</td><td>Not detected</td><td>Not detected</td><td>Not detected</td></tr><tr><td>7</td><td>Related Substance II</td><td>G06-M03</td><td>≤0.2%</td><td>Not detected</td><td>Not detected</td><td>Not detected</td></tr><tr><td>8</td><td>Identification by FTIR</td><td>FT-IR Spectra of Our Product complies with Innovator</td><td>Meets</td><td>Meets</td><td>Meets</td><td>Meets</td></tr><tr><td>9</td><td>Identification by UV-Vis</td><td>UV-Visible Spectra of Our Product complies with Innovator</td><td>Meets</td><td>Meets</td><td>Meets</td><td>Meets</td></tr><tr><td>10</td><td>Identification and Molecular weight</td><td>Same band of Our Product complies with Innovator</td><td>Meets</td><td>Meets</td><td>Meets</td><td>Meets</td></tr></table>	Semaglutide 0.25mg/0.188mL PFS							Reference Product / Innovator Name			Semaglutide 0.25mg/0.188mL			Ozempic 0.25mg	Batch No			TSGP001	TSGP002	TSGP003	NPS/123	S/N	TEST	SPECIFICATIONS	RESULTS				1	Appearance	Colorless clear solution free from any foreign particles	Complies	Complies	Complies	Complies	2	pH	7.16-7.60	7.43	7.43	7.43	7.45	3	Identification by HPLC	Examine the chromatograms obtained in the assay. The retention time of main peak obtained in sample solution should be in accordance with retention time of main peak obtained in standard	Complies	Complies	Complies	Complies	4	Assay	(0.225-0.275) mg/0.188 mL, 90.0%-110.0%	(0.263mg/0.188mL) 102.6 %	(0.263mg/0.188mL) 101.1 %	(0.254mg/0.188mL) 101.7 %	(0.266mg/0.188mL) 103.7 %	5	Bacterial endotoxin	< 10 EU/mg	Meets	Meets	Meets	Meets	6	Related Substance I	G06-M06	≤0.2%	Not detected	Not detected	Not detected	G06-M07	≤0.2%	Not detected	Not detected	Not detected	G06-M55	≤0.2%	Not detected	Not detected	Not detected	G06-M21	≤0.2%	Not detected	Not detected	Not detected	Any other individual impurity	≤0.1%	Not detected	Not detected	Not detected	Total Impurities	≤2.0%	Not detected	Not detected	Not detected	7	Related Substance II	G06-M03	≤0.2%	Not detected	Not detected	Not detected	8	Identification by FTIR	FT-IR Spectra of Our Product complies with Innovator	Meets	Meets	Meets	Meets	9	Identification by UV-Vis	UV-Visible Spectra of Our Product complies with Innovator	Meets	Meets	Meets	Meets	10	Identification and Molecular weight	Same band of Our Product complies with Innovator	Meets	Meets	Meets	Meets	Results of Comparative of only one strength in tabular form is submitted. Details of comparative tests of all 3 strengths are required.
Semaglutide 0.25mg/0.188mL PFS																																																																																																																														
Reference Product / Innovator Name			Semaglutide 0.25mg/0.188mL			Ozempic 0.25mg																																																																																																																								
Batch No			TSGP001	TSGP002	TSGP003	NPS/123																																																																																																																								
S/N	TEST	SPECIFICATIONS	RESULTS																																																																																																																											
1	Appearance	Colorless clear solution free from any foreign particles	Complies	Complies	Complies	Complies																																																																																																																								
2	pH	7.16-7.60	7.43	7.43	7.43	7.45																																																																																																																								
3	Identification by HPLC	Examine the chromatograms obtained in the assay. The retention time of main peak obtained in sample solution should be in accordance with retention time of main peak obtained in standard	Complies	Complies	Complies	Complies																																																																																																																								
4	Assay	(0.225-0.275) mg/0.188 mL, 90.0%-110.0%	(0.263mg/0.188mL) 102.6 %	(0.263mg/0.188mL) 101.1 %	(0.254mg/0.188mL) 101.7 %	(0.266mg/0.188mL) 103.7 %																																																																																																																								
5	Bacterial endotoxin	< 10 EU/mg	Meets	Meets	Meets	Meets																																																																																																																								
6	Related Substance I	G06-M06	≤0.2%	Not detected	Not detected	Not detected																																																																																																																								
		G06-M07	≤0.2%	Not detected	Not detected	Not detected																																																																																																																								
		G06-M55	≤0.2%	Not detected	Not detected	Not detected																																																																																																																								
		G06-M21	≤0.2%	Not detected	Not detected	Not detected																																																																																																																								
		Any other individual impurity	≤0.1%	Not detected	Not detected	Not detected																																																																																																																								
		Total Impurities	≤2.0%	Not detected	Not detected	Not detected																																																																																																																								
7	Related Substance II	G06-M03	≤0.2%	Not detected	Not detected	Not detected																																																																																																																								
8	Identification by FTIR	FT-IR Spectra of Our Product complies with Innovator	Meets	Meets	Meets	Meets																																																																																																																								
9	Identification by UV-Vis	UV-Visible Spectra of Our Product complies with Innovator	Meets	Meets	Meets	Meets																																																																																																																								
10	Identification and Molecular weight	Same band of Our Product complies with Innovator	Meets	Meets	Meets	Meets																																																																																																																								

		prestigious institutes. These Analysis/Tests includes the following and detailed tests reports were already submitted in dossier. <table border="1"> <thead> <tr> <th>S.NO</th> <th>Test Name</th> <th>Institute Name</th> </tr> </thead> <tbody> <tr> <td>1</td> <td>Peptide Sequence Analysis</td> <td>Harvard University, Boston, USA</td> </tr> <tr> <td>2</td> <td>Secondary Mass Spectra (MS/MS)* (amino acid sequence)</td> <td>Harvard University, Boston, USA</td> </tr> <tr> <td>3</td> <td>Molecular Weight Detection</td> <td>Harvard University, Boston, USA</td> </tr> <tr> <td>4</td> <td>Residual Solvents Test</td> <td>IAC-HEJ</td> </tr> <tr> <td>5</td> <td>Abnormal Toxicity (Safety) Test</td> <td>PCSIR</td> </tr> </tbody> </table>	S.NO	Test Name	Institute Name	1	Peptide Sequence Analysis	Harvard University, Boston, USA	2	Secondary Mass Spectra (MS/MS)* (amino acid sequence)	Harvard University, Boston, USA	3	Molecular Weight Detection	Harvard University, Boston, USA	4	Residual Solvents Test	IAC-HEJ	5	Abnormal Toxicity (Safety) Test	PCSIR	
S.NO	Test Name	Institute Name																			
1	Peptide Sequence Analysis	Harvard University, Boston, USA																			
2	Secondary Mass Spectra (MS/MS)* (amino acid sequence)	Harvard University, Boston, USA																			
3	Molecular Weight Detection	Harvard University, Boston, USA																			
4	Residual Solvents Test	IAC-HEJ																			
5	Abnormal Toxicity (Safety) Test	PCSIR																			
Decision: The Registration Board deferred the case for submission of following documents/clarifications; • Drug substance part 3.2.S.2.2 to 3.2.S.2.6 . • Reports of peptide mapping on drug product. • Reports of all the comparative tests performed on the applied strength with that of Innovator product. • Complete analytical method validation of drug product on all parameters.																					

Semaglutide Source: Synthetic Drug Substance Import Local Manufacturing Applied Container Closure System: PFS	
Case # 30	
Name, address of Applicant	M/s Nextar Pharma (Pvt) Ltd Plot No. E-58. North Western, Industrial Zone, Port Qasim Karachi.
Status of the applicant	☒ Manufacturer ☐ Importer ☐ Bulk Import and Local Repack ☐ Is involved in none of the above
Name, address of manufacturer(s)	M/s Nextar Pharma (Pvt) Ltd Plot No. E-58. North Western, Industrial Zone, Port Qasim Karachi.
GMP of manufacturer & Evidence of Section	DML No. 000777 Address: Plot No. E-58. North Western, Industrial Zone, Port Qasim Karachi. Evidence of section: Injectable Ampoules & PFS GMP: Last GMP conducted on 20-03-2024 valid upto 19-03-26
Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
Intended use of pharmaceutical product	☐ Domestic sale Export sale ☒ Domestic and Export sales

E-app tracking ID and Date of submission	Tracking ID: 9YH-BRY-9EGV Application No. 92098 Date of receiving: 21-04-2025
Details of fee submitted	Challan Number: 904535382105 Paid Fee: 37000.0 Paid Date: 2025-04-14 Division: Biological Evaluation & Registration
The proposed proprietary name / brand name	SEMAVI-PFS 0.5mg/0.375ml
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 0.375ml contains: Semaglutide 0.5mg
Pharmaceutical form of applied drug	Solution for Injection in PFS (For Subcutaneous use only)
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	Innovator's Specifications
Proposed Pack size	1's (PFS)
Proposed unit price	As per SRO
Shelf Life	24 Months
Storage Condition	Store in a refrigerator (2 °C – 8 °C)
The status in reference regulatory authorities	OZEMPIC (semaglutide) solution for injection 2 mg/1.5 ml (USFDA APPROVED) <i>The firm has applied single dose (0.5mg/0.375ml) pre-filled syringe while the reference product Ozempic is available in multi dose pre-filled pens in different strengths as below;</i> <i>• 0.25 mg or 0.5 mg dose pen (4 doses of 0.25 mg and 2 doses of 0.5 mg, or 4 doses of 0.5 mg)</i> <i>• 1 mg dose pen, (4 doses per pen)</i> <i>• 2 mg dose pen, (4 doses per pen)</i>
For generic drugs (me-too status)	Sematide Prefilled Syringe 0.5mg/0.375mL Manufactured by M/s BF Biosciences Ltd (Reg.No 120529)

Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD. Firm has summarized information related to nomenclature, structure, general properties, physical form, manufacturers, Characterization (Elucidation of Structure and Other Characteristics), impurities, specifications, analytical procedures, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.												
Name, address of drug substance manufacturer	M/s Zhejiang Peptides Biotech Co., Ltd, No.8 Hengyizhi Road, Sanjie Town, Shengzhou City, Zhejiang Province, China												
Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, physical form, manufacturers, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.												
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of drug substance of following 3 batches at accelerated and real time conditions. The real time stability data is conducted at 5°C ± 3°C for 24 months, and the accelerated stability studies at 25°C ± 2°C for 6 months. Batch No: G06210801 (Test starting date; 22-10-2021) Batch No: G06210901 (Test starting date; 22-10-2021) Batch No: G06210902 (Test starting date; 22-10-2021)												
Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols (undertaking for reports), control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures for assay only, batch analysis, working standard COA, container closure system and stability.												
Analytical method validation/verification of product	Firm has submitted Analytical method validation for sterility test, bacterial endotoxin test of applied product.												
Container closure system of the drug product	(PFS) 1mL USP Type 1 clear glass/Butyl rubber stopper with plunger rod.												
Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of following 03 batches. The accelerated stability study data is conducted at 25±2°C, 60%±5% RH for 6 months. The real time ongoing stability study data is conducted at 5°C±3°C for 6months. <table><tr><td>Batch No.</td><td>Batch Size</td><td>Manufacturing date</td></tr><tr><td>TSHP001</td><td>500PFS</td><td>July-2024</td></tr><tr><td>TSHP002</td><td>500 PFS</td><td>July-2024</td></tr><tr><td>TSHP003</td><td>500 PFS</td><td>July-2024</td></tr></table>	Batch No.	Batch Size	Manufacturing date	TSHP001	500PFS	July-2024	TSHP002	500 PFS	July-2024	TSHP003	500 PFS	July-2024
Batch No.	Batch Size	Manufacturing date											
TSHP001	500PFS	July-2024											
TSHP002	500 PFS	July-2024											
TSHP003	500 PFS	July-2024											

Module IV	Detailed in sameness evaluation mentioned below
Module V	Detailed in sameness evaluation mentioned below
<u>DRUG SUBSTANCE:</u> The firm has submitted Sameness data as per USFDA guidelines: <u>ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin Guidance for Industry FDA.</u> Firm has compared Semaglutide API of Zhejiang Peptides Biotech Co. Ltd with Semaglutide reference product Ozempic.	
Parameters	Sameness evaluation Data Submitted by the applicant
A. Active Ingredient Sameness (by Orthogonal Method) (specify) 4. Primary sequence and Physicochemical properties	Firm has performed following in physicochemical characterization; • Appearance • Solubility • Hygroscopicity • Specific optical rotation • Clarity and colour of solution • PH • Molecular Weight • Particle size by Malvern Laser Diffraction method • Polymorphism by X-ray powder diffraction method • Isoelectric point by Imaging capillary isoelectric focusing electrophoresis <u>Primary sequence</u> Firm has conducted Peptide Sequence analysis by mass spectrometer as below;

● **Amino acid sequence analysis**

Apparatus: Mass spectrometer XevoG2-XS QToF (Waters)


UPLC(Acquity UPLC I-Class) (Waters)

Experiment method:

Perform primary mass spectra (MS) test, then perform secondary mass spectra test (MS/MS) of target peptide mother ion. Establish data base according to theoretical sequence, search for secondary data to validate accuracy of sequence.


Test result

Semaglutide working standard MASCOT secondary mass spectra data match diagram



Monoisotopic mass of neutral peptide M_r(calc): 4111.1154
Variable modifications:
A2 : Asn (A)
K20 : CysMELI2H3 (K)
Ion Score: 97 Expect: 9.4e-012
Matches (Bold Red): 44/151 fragment ions using 71 most intense peaks

Semaglutide original product (Ozempic®, Novo Nordisk, batch number: JP54343) MASCOT secondary mass spectra data match diagram



Monoisotopic mass of neutral peptide M_r(calc): 4111.1154
Variable modifications:
A2 : Asn (A)
K20 : CysMELI2H3 (K)
Ion Score: 97 Expect: 9.4e-012
Matches (Bold Red): 44/151 fragment ions using 71 most intense peaks

Secondary structure

Firm has performed Circular dichroism spectrum analysis for study of peptide Secondary structure as below;

-Secondary structure

Circular dichroism spectrum analysis is meaningful for study of peptide secondary structure. Secondary structure are compared between our Semaglutide API and Semaglutide original product with Circular dichroism spectrum analysis.

Sample list

Sample No.	Name	Source	Batch number
20211111577	Semaglutide original product	Novo Nordisk	KP52701
20211111578	Semaglutide API	Zhejiang peptides	G06210801
20211111579			G06210901
20211111580			G06210902

Apparatus: Chirascan Plus V100 Circular dichroism spectrometer (Applied Photophysics)

Apparatus parameter:


Band width	1.0nm
Step	1.0nm
Measurement range	190-260nm(far-UV region scan)
Time-per-point	0.5s
Repeats	3
Cell Length	0.5mm
Temperature	Room Temperature

Far/near UV scan of standard: acquire data of background test and blank test with wavelength 180-340nm, then acquire data of far/near Circular dichroism UV scan with wavelength 180-340nm.

Far UV scan: cuvette is soaked with 2M HNO₃, clean with deionized water and dry, acquire data of background and blank. Then add sample into cuvette, acquire data with wavelength 190-260nm.

Firm has also performed Thermoanalysis by Differential scanning Calorimeter (DSC) as under;

	- Thermoanalysis Thermoanalysis is meaningful to stability of protein and polypeptide. With Differential Scanning Calorimeter(DSC) method, melting temperature(Tm) of Semaglutide original product and Semaglutide API samples are tested. Sample list <table><tr><th>Sample No.</th><th>Name</th><th>Source</th><th>Batch number</th></tr><tr><td>20211111582</td><td>Semaglutide original product</td><td>Novo Nordisk</td><td>KP52701</td></tr><tr><td>20211111583</td><td rowspan="3">Semaglutide API</td><td rowspan="3">Zhejiang peptites</td><td>G06210801</td></tr><tr><td>20211111584</td><td>G06210901</td></tr><tr><td>20211111585</td><td>G06210902</td></tr></table> Apparatus: Differential Scanning Calorimeter (Microcal PEAQ-DSC) Apparatus parameter: Temperature: 20-100°C Temperature rising rate: 120°C/h Conclusion: according to above test, Tm of Semaglutide API (G06210801, G06210901, G06210902) and Semaglutide original product (KP52701) are: 66.06 °C, 66.00 °C, 66.16 °C, 65.96°C, which are comparable.	Sample No.	Name	Source	Batch number	20211111582	Semaglutide original product	Novo Nordisk	KP52701	20211111583	Semaglutide API	Zhejiang peptites	G06210801	20211111584	G06210901	20211111585	G06210902																																																								
Sample No.	Name	Source	Batch number																																																																						
20211111582	Semaglutide original product	Novo Nordisk	KP52701																																																																						
20211111583	Semaglutide API	Zhejiang peptites	G06210801																																																																						
20211111584			G06210901																																																																						
20211111585			G06210902																																																																						
Oligomer/aggregation states	Firm has performed Polymer (Oligomer/ Aggregates/ High Molecular Weight Proteins) by Size Exclusion Chromatography as below; -Polymer Polymer content are compared between our Semaglutide API and Semaglutide original product with analytical procedures described in chapter 3.2.S.4.2. Sample list <table><tr><th>Name</th><th>Source</th><th>Batch number</th><th>Expiry date</th></tr><tr><td rowspan="3">Semaglutide original product, Ozempic</td><td rowspan="3">Novo Nordisk</td><td>JP54343</td><td>2022.07</td></tr><tr><td>KP52701</td><td>2023.02</td></tr><tr><td>LP57558</td><td>2024.01</td></tr><tr><td rowspan="3">Semaglutide API</td><td rowspan="3">Zhejiang Peptities</td><td>G06210801</td><td>2023.09.12</td></tr><tr><td>G06210901</td><td>2023.09.25</td></tr><tr><td>G06210902</td><td>2023.10.05</td></tr></table> Test result <table><tr><th>RRT</th><th>Name</th><th>Impurity content in Semaglutide API(%)</th><th>Impurity content in Semaglutide</th></tr></table> <table><tr><th></th><th></th><th colspan="3"></th><th colspan="3">injection(%)</th></tr><tr><th></th><th></th><th>G06210801</th><th>G06210901</th><th>G06210902</th><th>JP54343</th><th>KP52701</th><th>LP57558</th></tr><tr><td>0.842</td><td>Polymer 1</td><td>N.D.</td><td>N.D.</td><td>N.D.</td><td>0.070</td><td>0.039</td><td>N.D.</td></tr><tr><td>0.876</td><td>Polymer 2</td><td>0.062</td><td>0.048</td><td>0.076</td><td>0.510</td><td>0.335</td><td>0.195</td></tr><tr><td>0.967</td><td>Polymer 3</td><td>N.D.</td><td>N.D.</td><td>N.D.</td><td>N.D.</td><td>N.D.</td><td>0.037</td></tr><tr><td colspan="2">Total polymer content</td><td>0.062</td><td>0.048</td><td>0.076</td><td>0.580</td><td>0.374</td><td>0.232</td></tr></table> Conclusion: there are no new polymers in our Semaglutide API, which are not existed in original formulation. For polymer RRT0.876, which is detected in both Semaglutide API and original formulation, result in Semaglutide API is much lower than result in original formulation.	Name	Source	Batch number	Expiry date	Semaglutide original product, Ozempic	Novo Nordisk	JP54343	2022.07	KP52701	2023.02	LP57558	2024.01	Semaglutide API	Zhejiang Peptities	G06210801	2023.09.12	G06210901	2023.09.25	G06210902	2023.10.05	RRT	Name	Impurity content in Semaglutide API(%)	Impurity content in Semaglutide						injection(%)					G06210801	G06210901	G06210902	JP54343	KP52701	LP57558	0.842	Polymer 1	N.D.	N.D.	N.D.	0.070	0.039	N.D.	0.876	Polymer 2	0.062	0.048	0.076	0.510	0.335	0.195	0.967	Polymer 3	N.D.	N.D.	N.D.	N.D.	N.D.	0.037	Total polymer content		0.062	0.048	0.076	0.580	0.374	0.232
Name	Source	Batch number	Expiry date																																																																						
Semaglutide original product, Ozempic	Novo Nordisk	JP54343	2022.07																																																																						
		KP52701	2023.02																																																																						
		LP57558	2024.01																																																																						
Semaglutide API	Zhejiang Peptities	G06210801	2023.09.12																																																																						
		G06210901	2023.09.25																																																																						
		G06210902	2023.10.05																																																																						
RRT	Name	Impurity content in Semaglutide API(%)	Impurity content in Semaglutide																																																																						
					injection(%)																																																																				
		G06210801	G06210901	G06210902	JP54343	KP52701	LP57558																																																																		
0.842	Polymer 1	N.D.	N.D.	N.D.	0.070	0.039	N.D.																																																																		
0.876	Polymer 2	0.062	0.048	0.076	0.510	0.335	0.195																																																																		
0.967	Polymer 3	N.D.	N.D.	N.D.	N.D.	N.D.	0.037																																																																		
Total polymer content		0.062	0.048	0.076	0.580	0.374	0.232																																																																		
Biological Activity	Semaglutide Cell Activity Test																																																																								

	Semaglutide cell activity test Sample list <table><tr><td>Name</td><td>Source</td><td>Batch number</td><td>Sample No.</td></tr><tr><td>Semaglutide API (reference)</td><td>Zhejiang Peptides</td><td>G06210801</td><td>2021111893</td></tr><tr><td rowspan="3">Semaglutide sample</td><td rowspan="3">Zhejiang Peptides</td><td>G06210801</td><td>2021111902</td></tr><tr><td>G06210901</td><td>2021111903</td></tr><tr><td>G06210902</td><td>2021111904</td></tr></table> Test result Dose-response relationship  Relative activities <table><tr><td>Sample batch number</td><td>Sample EC₅₀</td><td>Reference EC₅₀(G06210801)</td><td>Standardization of sample with reference</td></tr><tr><td>G06210801</td><td>917.3</td><td>857.1</td><td>0.93</td></tr><tr><td>G06210901</td><td>715.7</td><td>857.1</td><td>1.20</td></tr><tr><td>G06210902</td><td>845.0</td><td>915.7</td><td>1.08</td></tr></table> Analysis: Relative activity of reference=EC₅₀ of reference/EC₅₀ of sample. Conclusion: according to test results, relative activity of samples(G06210801, G06210901, G06210902) comparing with reference are: 0.93, 1.20, 1.08. Samples showed agonist activity on GLP-1 receptor in this study.	Name	Source	Batch number	Sample No.	Semaglutide API (reference)	Zhejiang Peptides	G06210801	2021111893	Semaglutide sample	Zhejiang Peptides	G06210801	2021111902	G06210901	2021111903	G06210902	2021111904	Sample batch number	Sample EC ₅₀	Reference EC ₅₀ (G06210801)	Standardization of sample with reference	G06210801	917.3	857.1	0.93	G06210901	715.7	857.1	1.20	G06210902	845.0	915.7	1.08
Name	Source	Batch number	Sample No.																														
Semaglutide API (reference)	Zhejiang Peptides	G06210801	2021111893																														
Semaglutide sample	Zhejiang Peptides	G06210801	2021111902																														
		G06210901	2021111903																														
		G06210902	2021111904																														
Sample batch number	Sample EC ₅₀	Reference EC ₅₀ (G06210801)	Standardization of sample with reference																														
G06210801	917.3	857.1	0.93																														
G06210901	715.7	857.1	1.20																														
G06210902	845.0	915.7	1.08																														
Impurities (Peptide related and non-peptide related impurities) For each peptide-related impurity that is found in both the proposed generic synthetic peptide and the RLD, the level of such impurity in the proposed product is the same as or lower than that found in the RLD. Applicants should identify each peptide-related impurity that is 0.10 percent of the drug substance or greater.	Impurities profile ▪ Peptide related Impurities ▪ Related Substances I & II (3.2.S.4.1 P 2) ▪ High molecular weight protein impurities (Polymers 3.2.S.4.1 P 2) ▪ Process related Impurities (3.2.S.3.2 – P 1) ▪ Intermediate residue and reaction by products (Restricted Part 3.2.S.2.4 P 1) ▪ Inorganic and Ion impurities (3.2.S.3.2 – P 8) ▪ Residual Solvents (3.2.S.3.2 – P 12) ▪ Elemental Impurities (3.2.S.3.2 – P 8) ▪ Genotoxic Impurity (3.2.S.3.2 – P 15) ▪ Nitrosamine Impurities (3.2.S.3.2 – P 36) <u>Firm has performed Comparison of Semaglutide API with reference product Ozempic in terms of related substance as below:</u>																																

● **Comparison of Semaglutide API and Semaglutide original product**
-Related substances

Impurity profile are compared between our Semaglutide API and Semaglutide original product with analytical procedures described in chapter 3.2.S.4.2.

Sample list

Name	Source	Batch number	Expiry date
Semaglutide original product, Ozempic	Novo Nordisk	JP54343	2022.07
		KP52701	2023.02
		LP57558	2024.01
Semaglutide API	Zhejiang Peptides	G06210801	2023.09.12
		G06210901	2023.09.25
		G06210902	2023.10.05

Test result

Impurity No.	RRT	Impurity affiliation	Impurity content in Semaglutide API(%)			Impurity content in Semaglutide injection(%)		
			G06210801	G06210901	G06210902	JP54343	KP52701	LP57558
1	0.754	G06-IM01	0.055	0.054	0.053	0.158	0.116	0.059
2	0.839	G06-IM60	0.113	0.075	0.103	0.114	0.107	0.093
3	0.897	G06-IM59	0.105	0.083	0.100	0.032	N.D.	N.D.
4	0.941	Unspecified imp 1	0.034	N.D.	N.D.	N.D.	N.D.	N.D.
5	1.021	G06-IM03	0.042	0.042	0.039	0.073	N.D.	N.D.
6	0.955	G06-IM28	N.D.	0.036	N.D.	N.D.	N.D.	N.D.
7	0.936	Unspecified imp 2	N.D.	N.D.	0.035	N.D.	N.D.	N.D.
8	0.454	Unspecified imp 3	N.D.	N.D.	N.D.	0.038	N.D.	N.D.
9	0.776	Unspecified imp 4	N.D.	N.D.	N.D.	0.081	0.084	0.092
10	0.885	Unspecified imp 5	N.D.	N.D.	N.D.	0.106	0.097	0.085
11	0.913	Unspecified imp 6	N.D.	N.D.	N.D.	0.039	0.040	0.070
12	0.939	Unspecified imp 7	N.D.	N.D.	N.D.	0.519	0.508	0.361
13	1.047	Unspecified imp 8	N.D.	N.D.	N.D.	0.308	0.366	0.293
14	1.064	Unspecified imp 9	N.D.	N.D.	N.D.	0.304	0.343	0.324
15	1.103	Unspecified imp 10	N.D.	N.D.	N.D.	0.043	0.033	N.D.

16	1.129	Unspecified imp 11	N.D.	N.D.	N.D.	0.056	0.054	0.050
17	1.177	Unspecified imp 12	N.D.	N.D.	N.D.	0.123	0.130	0.146
18	1.261	Unspecified imp 13	N.D.	N.D.	N.D.	0.048	0.034	N.D.
19	1.268	Unspecified imp 14	N.D.	N.D.	N.D.	0.449	0.333	0.198
20	0.926	Unspecified imp 15	N.D.	N.D.	N.D.	N.D.	N.D.	0.040
21	1.010	Unspecified imp 16	N.D.	N.D.	N.D.	N.D.	N.D.	0.139
Total impurities			0.349	0.290	0.330	2.491	2.245	1.950

Conclusion:

4 impurities are detected in both API and original formulation: RRT0.754, RRT0.839, RRT0.897, RRT1.021, results of impurity RRT0.754, RRT0.839, RRT1.021 in API are less than results in original formulation. Result of impurity RRT0.897 is comparable with result in original formulation.

For new impurity RRT0.941, RRT0.955 which are not detected in original formulation, results are less than report limit 0.05% defined in ICH Q3A. Result of impurity which is higher than 0.05% is not existed in our Semaglutide API.

Conclusion of sameness studies:

Conclusion

According to comparison of Semaglutide API and Semaglutide original product, impurity level of Semaglutide API is comparable with Semaglutide original product. Total content of polymers in Semaglutide API is much lower than total content of polymers in Semaglutide original product.

For secondary structure comparison, far-UV similarity value of Semaglutide API(G06210801, G06210901, G06210902) and Semaglutide original product (KP52701) is 0.99999, 0.99995, 0.99996. For biological activities, relative activity of samples(G06210801, G06210901, G06210902) comparing with reference are: 0.93, 1.20, 1.08. Samples showed agonist activity on GLP-1 receptor in this study. For Isoelectric point and Thermoanalysis, results of Semaglutide API and Semaglutide original product are comparable. Above all, quality of Semaglutide API manufactured in Zhejiang Peptides is comparable with Semaglutide original product.

DRUG PRODUCT

The applicant/manufacturer has performed following tests on drug product in their premises;

S/N	TEST		SPECIFICATIONS	REFERENCE
1.	Appearance		Colorless clear solution free from any foreign particles	As per Manufacturer's Specs.
2.	Particulate matter - Visible - Non-visible		Conform to standard "Must be clear" $\geq 10\mu\text{m}$ 6000, $\geq 25\mu\text{m}$ 600	
3.	Filling Volume (nominal volume)		The volume of each container should not less than nominal volume (use 05 containers at each interval) 0.375 – 0.413 mL	
4.	Leak test		None of 10 units exhibit leakage	
5.	Identification	By HPLC	Examine the chromatograms obtained in the assay. The retention time of main peak obtained in sample solution should be in accordance with retention time of main peak obtained in standard solution.	
6.	pH		7.20-7.60	
7.	Related Substance I	G06-IM60	$\leq 0.2\%$	
		G06-IM01	$\leq 0.2\%$	
		G06-IM59	$\leq 0.2\%$	
		G06-IM28	$\leq 0.2\%$	
		Any other individual impurity	$\leq 0.1\%$	
		Total impurities	$\leq 2.0\%$	
8.	Related Substance II	G06-IM03	$\leq 0.2\%$	
9.	Bacterial endotoxin		< 10 EU/mg	
10.	Assay		(0.450-0.550) mg/0.375 mL 90.0%~110.0%	
11.	Peptide Content		$\geq 80.0\%$	
12.	Sterility		Meets sterility acceptance criteria	

Firm has submitted safety test report of applied product issued by Pakistan Council of Scientific and Industrial Research Laboratories Complex, Karachi.

TEST REPORT

Test Report #. ILD/Ref.Project-2025-37129-2

Date: 27-02-2025

1. **Name and Address of Client:** M/s. Nextar Pharma (Pvt.) Limited,
Plot No. E-58, North Western Industrial Zone, Port
Qasim, Karachi-Pakistan.

Ref. No: Nil Date of receipt: 19-02-2025

2. **Description of the Sample:**
 Item: Semaglutide Injection 0.5mg/0.375ml PFS Make: Nil
 Lab. Code No: ILD/Ref.Project-2025-37129-2 Mark if any: Nil
 Condition found on receipt: Properly Packed

3. **Test Performed on:** 20-02-2025 to 27-02-2025
 Date of sampling: N.A.

4. **Environmental Conditions:** Within acceptable limits Temp: 25°C Humidity: 40%
 (Where applicable)

5. **Method Used:** Safety Test USP-43

6. **Measurements & Results:** Uncertainty: Not Required

Product Name	Test	Result
Semaglutide Injection 0.5mg/0.375ml PFS Batch No. TSHP001 Mfg Date : 23-07-2024 Exp Date : 22-07-2026	Safety Test	No signs of acute toxicity & mortality were observed in experimental laboratory animals (Albino mice) during observation period.

7. **Statement of Compliance:** N.A.

8. **Opinion/Interpretation (where required):** N.A.

END OF REPORT

Evaluation by BE&R:

Sr.No	Observations /Queries	Response of the firm	Remarks
1	The firm has applied single dose (0.5mg/0.375 ml) pre-filled syringe while the reference product Ozempic is available in multi dose pre-filled pens in different	We would like to clarify that the multi-dose presentations of the innovator are dose-proportional, and based on this proportionality, honorable Registration Board has already approved single dose PFS in its 336 Registration Board Meeting held on June 4-6, 2024. This approval was given to M/S BF Biosciences Ltd, 5km Sundar Raiwind Road, Lahore-Pakistan. These single-dose presentations maintain dose accuracy and proportionality, aligning with the innovator's approved dosage regimen. Furthermore, it is worth noting these similar dosage have also been developed and approved by other manufacturers, such as Incepta Pharmaceuticals in Bangladesh, in single-dose formats, reinforcing the International Regulatory acceptance of this approach. Following the same precedent, Nextar has developed three single-dose SKUs, maintaining the same dose and	Single dose pre-filled syringe is not available in any reference country.

	strengths.	concentration as that of the innovator product.																																																																																																																																																																										
2	Drug substance part 3.2.S.2.2 to 3.2.S.2.6 is not provided.	Letter of access is attached which states that; We, Zhejiang Peptides Biotech Co., Ltd., located at No. 8, Hengyizhi Road, Sanjie Town, Shengzhou City, Shaoxing City, Zhejiang Province, China, as the holder of the Master File for Semaglutide, hereby confirm our intent to submit the closed part of the Master File in support of the product registration, upon request by the authorized body of the Drug Regulatory Authority of Pakistan (DRAP). Kindly provide the official email address or relevant contact details through which we may securely submit the required documentation.	Not provided yet.																																																																																																																																																																									
3	Complete analytical method validation of drug product is required.	<u>JUSTIFICATION FOR ANALYTICAL METHOD VALIDATION</u> Date: 11-JUL-2025 In the current product (Semaglutide 1 mg / 0.75 ml), all three strengths i.e Semaglutide 0.25 mg/0.188 ml, Semaglutide 0.5 mg/0.375 ml & Semaglutide 1 mg/0.75 ml contain the same drug-to-excipient ratio i.e 1.33 mg/ml, meaning that the proportion of active pharmaceutical ingredient to inactive ingredient remains constant across different dosage strengths therefore we select 1 mg / 0.75 ml strength for method validation.	Method validation report of only assay is attached.																																																																																																																																																																									
4	Comparative testing of the applied product with the Innovator product is required.	<table border="1"><thead><tr><th colspan="6">Semaglutide 0.25mg/0.188mL PFS</th></tr><tr><th colspan="3">Reference Product / Innovator Name</th><th colspan="2">Semaglutide 0.25mg/0.188mL</th><th>Excipient 0.25mg</th></tr><tr><th colspan="3">Batch No</th><th>TSGP001</th><th>TSGP002</th><th>TSGP003</th><th>NPS/123</th></tr><tr><th>S/N</th><th>TEST</th><th>SPECIFICATIONS</th><th colspan="4">RESULTS</th></tr></thead><tbody><tr><td>1</td><td>Appearance</td><td>Colorless clear solution free from any foreign particles</td><td>Complies</td><td>Complies</td><td>Complies</td><td>Complies</td></tr><tr><td>2</td><td>pH</td><td>7.25-7.60</td><td>7.43</td><td>7.43</td><td>7.43</td><td>7.45</td></tr><tr><td>3</td><td>Identification by HPLC</td><td>Examine the chromatograms obtained in the assay. The retention time of main peak obtained in sample solution should be in accordance with retention time of main peak obtained in standard.</td><td>Complies</td><td>Complies</td><td>Complies</td><td>Complies</td></tr><tr><td>4</td><td>Assay</td><td>(0.225-0.275) mg/0.188 mL 90.0%-110.0%</td><td>(0.257mg/0.188mL) 102.6 %</td><td>(0.253mg/0.188mL) 101.1 %</td><td>(0.254mg/0.188mL) 101.7 %</td><td>(0.260mg/0.188mL) 103.7 %</td></tr><tr><td>5</td><td>Bacterial endotoxin</td><td>< 10 EU/mg</td><td>Meets</td><td>Meets</td><td>Meets</td><td>Meets</td></tr><tr><td rowspan="6">6</td><td rowspan="6">Related Substance I</td><td>G06-AM0</td><td><0.2%</td><td>Not detected</td><td>Not detected</td><td>Not detected</td><td>Not detected</td></tr><tr><td>G06-AM1</td><td><0.2%</td><td>Not detected</td><td>Not detected</td><td>Not detected</td><td>Not detected</td></tr><tr><td>G06-AM5</td><td><0.2%</td><td>Not detected</td><td>Not detected</td><td>Not detected</td><td>Not detected</td></tr><tr><td>G06-AM2</td><td><0.2%</td><td>Not detected</td><td>Not detected</td><td>Not detected</td><td>Not detected</td></tr><tr><td>Any other individual impurity</td><td><0.1%</td><td>Not detected</td><td>Not detected</td><td>Not detected</td><td>Not detected</td></tr><tr><td>Total Impurities</td><td><2.0%</td><td>Not detected</td><td>Not detected</td><td>Not detected</td><td>Not detected</td></tr><tr><td>7</td><td>Related Substance</td><td>G06-AM0</td><td><0.2%</td><td>Not detected</td><td>Not detected</td><td>Not detected</td><td>Not detected</td></tr><tr><td>8</td><td>Identification by FTIR</td><td>FTIR Spectra of Our Product complies with Innovator</td><td>Meets</td><td>Meets</td><td>Meets</td><td>Meets</td></tr><tr><td>9</td><td>Identification by UV-Visible</td><td>UV-Visible Spectra of Our Product complies with Innovator</td><td>Meets</td><td>Meets</td><td>Meets</td><td>Meets</td></tr><tr><td>10</td><td>Identification and Molecular weight</td><td>Same band of Our Product complies with Innovator</td><td>Meets</td><td>Meets</td><td>Meets</td><td>Meets</td></tr></tbody></table> Semaglutide 0.25mg/0.188mL PFS <table border="1"><thead><tr><th colspan="2">determination by SDS PAGE</th><th colspan="4">Semaglutide 0.25mg/0.188mL PFS</th></tr></thead><tbody><tr><td>11</td><td>Isoelectric focusing point</td><td>Same band location of Our Product complies with Innovator</td><td>Meets</td><td>Meets</td><td>Meets</td><td>Meets</td></tr><tr><td>12</td><td>Polymer</td><td>Meets 0.5%</td><td>Meets</td><td>Meets</td><td>Meets</td><td>Meets</td></tr><tr><td>13</td><td>Particulate matter</td><td>Conforms to standard "What be clear"</td><td>Clear</td><td>Clear</td><td>Clear</td><td>Clear</td></tr><tr><td></td><td>- Visible</td><td>≤10µm 6000, 20%µm 600</td><td>26</td><td>22</td><td>19</td><td>13</td></tr><tr><td></td><td>- Non-visible</td><td></td><td>0</td><td>01</td><td>01</td><td>0</td></tr></tbody></table> Remarks: Results meet the specification criteria. Analyzed by: <i>[Signature]</i> Date: <i>11/07/25</i> Checked by: <i>[Signature]</i> Date: <i>11/07/25</i> Approved by: <i>[Signature]</i> Date: <i>11/07/25</i>	Semaglutide 0.25mg/0.188mL PFS						Reference Product / Innovator Name			Semaglutide 0.25mg/0.188mL		Excipient 0.25mg	Batch No			TSGP001	TSGP002	TSGP003	NPS/123	S/N	TEST	SPECIFICATIONS	RESULTS				1	Appearance	Colorless clear solution free from any foreign particles	Complies	Complies	Complies	Complies	2	pH	7.25-7.60	7.43	7.43	7.43	7.45	3	Identification by HPLC	Examine the chromatograms obtained in the assay. The retention time of main peak obtained in sample solution should be in accordance with retention time of main peak obtained in standard.	Complies	Complies	Complies	Complies	4	Assay	(0.225-0.275) mg/0.188 mL 90.0%-110.0%	(0.257mg/0.188mL) 102.6 %	(0.253mg/0.188mL) 101.1 %	(0.254mg/0.188mL) 101.7 %	(0.260mg/0.188mL) 103.7 %	5	Bacterial endotoxin	< 10 EU/mg	Meets	Meets	Meets	Meets	6	Related Substance I	G06-AM0	<0.2%	Not detected	Not detected	Not detected	Not detected	G06-AM1	<0.2%	Not detected	Not detected	Not detected	Not detected	G06-AM5	<0.2%	Not detected	Not detected	Not detected	Not detected	G06-AM2	<0.2%	Not detected	Not detected	Not detected	Not detected	Any other individual impurity	<0.1%	Not detected	Not detected	Not detected	Not detected	Total Impurities	<2.0%	Not detected	Not detected	Not detected	Not detected	7	Related Substance	G06-AM0	<0.2%	Not detected	Not detected	Not detected	Not detected	8	Identification by FTIR	FTIR Spectra of Our Product complies with Innovator	Meets	Meets	Meets	Meets	9	Identification by UV-Visible	UV-Visible Spectra of Our Product complies with Innovator	Meets	Meets	Meets	Meets	10	Identification and Molecular weight	Same band of Our Product complies with Innovator	Meets	Meets	Meets	Meets	determination by SDS PAGE		Semaglutide 0.25mg/0.188mL PFS				11	Isoelectric focusing point	Same band location of Our Product complies with Innovator	Meets	Meets	Meets	Meets	12	Polymer	Meets 0.5%	Meets	Meets	Meets	Meets	13	Particulate matter	Conforms to standard "What be clear"	Clear	Clear	Clear	Clear		- Visible	≤10µm 6000, 20%µm 600	26	22	19	13		- Non-visible		0	01	01	0	Results of Comparative of only one strength in tabular form is submitted. Details of comparative tests along with reports of all 3 strengths are required.
Semaglutide 0.25mg/0.188mL PFS																																																																																																																																																																												
Reference Product / Innovator Name			Semaglutide 0.25mg/0.188mL		Excipient 0.25mg																																																																																																																																																																							
Batch No			TSGP001	TSGP002	TSGP003	NPS/123																																																																																																																																																																						
S/N	TEST	SPECIFICATIONS	RESULTS																																																																																																																																																																									
1	Appearance	Colorless clear solution free from any foreign particles	Complies	Complies	Complies	Complies																																																																																																																																																																						
2	pH	7.25-7.60	7.43	7.43	7.43	7.45																																																																																																																																																																						
3	Identification by HPLC	Examine the chromatograms obtained in the assay. The retention time of main peak obtained in sample solution should be in accordance with retention time of main peak obtained in standard.	Complies	Complies	Complies	Complies																																																																																																																																																																						
4	Assay	(0.225-0.275) mg/0.188 mL 90.0%-110.0%	(0.257mg/0.188mL) 102.6 %	(0.253mg/0.188mL) 101.1 %	(0.254mg/0.188mL) 101.7 %	(0.260mg/0.188mL) 103.7 %																																																																																																																																																																						
5	Bacterial endotoxin	< 10 EU/mg	Meets	Meets	Meets	Meets																																																																																																																																																																						
6	Related Substance I	G06-AM0	<0.2%	Not detected	Not detected	Not detected	Not detected																																																																																																																																																																					
		G06-AM1	<0.2%	Not detected	Not detected	Not detected	Not detected																																																																																																																																																																					
		G06-AM5	<0.2%	Not detected	Not detected	Not detected	Not detected																																																																																																																																																																					
		G06-AM2	<0.2%	Not detected	Not detected	Not detected	Not detected																																																																																																																																																																					
		Any other individual impurity	<0.1%	Not detected	Not detected	Not detected	Not detected																																																																																																																																																																					
		Total Impurities	<2.0%	Not detected	Not detected	Not detected	Not detected																																																																																																																																																																					
7	Related Substance	G06-AM0	<0.2%	Not detected	Not detected	Not detected	Not detected																																																																																																																																																																					
8	Identification by FTIR	FTIR Spectra of Our Product complies with Innovator	Meets	Meets	Meets	Meets																																																																																																																																																																						
9	Identification by UV-Visible	UV-Visible Spectra of Our Product complies with Innovator	Meets	Meets	Meets	Meets																																																																																																																																																																						
10	Identification and Molecular weight	Same band of Our Product complies with Innovator	Meets	Meets	Meets	Meets																																																																																																																																																																						
determination by SDS PAGE		Semaglutide 0.25mg/0.188mL PFS																																																																																																																																																																										
11	Isoelectric focusing point	Same band location of Our Product complies with Innovator	Meets	Meets	Meets	Meets																																																																																																																																																																						
12	Polymer	Meets 0.5%	Meets	Meets	Meets	Meets																																																																																																																																																																						
13	Particulate matter	Conforms to standard "What be clear"	Clear	Clear	Clear	Clear																																																																																																																																																																						
	- Visible	≤10µm 6000, 20%µm 600	26	22	19	13																																																																																																																																																																						
	- Non-visible		0	01	01	0																																																																																																																																																																						
5	Firm has not performed	Biological activity has been successfully performed on all three strengths of the applied products (0.25 mg/0.188 mL,	Bioassay report																																																																																																																																																																									

	all the tests on applied product as performed by innovator like peptide mapping, biological activity etc.	0.5 mg/0.375 mL, and 1 mg/0.75 mL).The results demonstrate that the biological activity of each strength is comparable to that of the innovator (Ozempic®). (BioAssay report by LUMS attached below); cAMP Hunter™ GLP-1 Receptor Bioassay Report for Ozempic® Biosimilars Assay Performed by: Ghulam Hassan Report Prepared by: Ghulam Hassan Report Reviewed and Approved by: Dr. Shaper Mirza Assay Date: 30-04-2025 The DiscoverX cAMP Hunter™ CHO-K1 GLP1R Bioassay Kit is a highly sensitive, cell-based assay designed to measure the activation of the GLP-1 receptor through the detection of cyclic adenosine monophosphate (cAMP) accumulation. This assay employs CHO-K1 cells that are genetically engineered to express the GLP-1 receptor, enabling the monitoring of receptor activation in response to various ligands. Upon activation, the GLP-1 receptor triggers the activation of adenylate cyclase, leading to increased cAMP production. The assay uses Enzyme Fragment Complementation (EFC) technology to detect cAMP, with a luminescent signal that is directly proportional to the level of cAMP. This assay is well-suited for evaluating the potency and efficacy of GLP-1 receptor agonists, such as Ozempic® and Nextar's different formulations of Semaglutide, by quantitatively measuring their ability to activate the receptor. The cAMP Hunter™ kit provides an accurate and reliable method for comparing the functional activity of these agonists, allowing for direct analysis of their receptor-mediated effects in a controlled, reproducible environment. This serves our purpose by offering a robust platform for assessing the pharmacological properties of GLP-1 receptor agonists. We employed this kit to quantitatively measure activation of the GLP-1 receptor by each formulation, including Ozempic® 4mg/3ml (Novonordisk), Nextar's Semaglutide 0.25mg/0.188mL, Nextar's Semaglutide 0.5mg/0.375mL, and Nextar's Semaglutide 1mg/0.75mL. By analyzing dose-response curves and half-maximal effective concentration (EC₅₀) values, we assessed if Ozempic® biosimilar products induced cAMP signalling with comparable potency to Ozempic®. A rightward shift in EC₅₀ (higher EC₅₀ value) for a test formulation versus Ozempic® indicates lower potency (more ligand required for the same effect), while a similar EC₅₀ suggests equivalent bioactivity. Conclusion: These findings suggest that all Nextar's samples exhibited EC50 values within the acceptable range, indicating that all formulations demonstrate marked similarity with innovator's Ozempic® in the activation of the GLP-1 receptor in this assay. Peptide mapping is currently being conducted on the API as well as higher strength, i.e., 1 mg/0.75 mL, and the results will be shared within one week. This test is used to confirm the protein's structure by breaking it into smaller fragments and comparing the resulting pattern with that of the reference product. As the same raw material and manufacturing process are used across all strengths, and the formulation is dose-proportional, testing only the highest strength i.e., 1 mg/0.75 mL of finished product is technically justified. The obtained results will be considered representative of the lower strengths as well. (Undertaking Attached for Peptide Mapping). Furthermore, we would also like to highlight that we have performed following additional tests from prestigious institutes. These Analysis/Tests includes the following and detailed tests reports were already submitted in dossier.	attached. Undertaking for peptide mapping is attached which states that report will be provided within one month.	

		<table><tr><th>S.NO</th><th>Test Name</th><th>Institute Name</th></tr><tr><td>1</td><td>Peptide Sequence Analysis</td><td>Harvard University, Boston, USA</td></tr><tr><td>2</td><td>Secondary Mass Spectra (MS/MS)" (amino acid sequence)</td><td>Harvard University, Boston, USA</td></tr><tr><td>3</td><td>Molecular Weight Detection</td><td>Harvard University, Boston, USA</td></tr><tr><td>4</td><td>Residual Solvents Test</td><td>IAC-HEJ</td></tr><tr><td>5</td><td>Abnormal Toxicity (Safety) Test</td><td>PCSIR</td></tr></table>	S.NO	Test Name	Institute Name	1	Peptide Sequence Analysis	Harvard University, Boston, USA	2	Secondary Mass Spectra (MS/MS)" (amino acid sequence)	Harvard University, Boston, USA	3	Molecular Weight Detection	Harvard University, Boston, USA	4	Residual Solvents Test	IAC-HEJ	5	Abnormal Toxicity (Safety) Test	PCSIR	
S.NO	Test Name	Institute Name																			
1	Peptide Sequence Analysis	Harvard University, Boston, USA																			
2	Secondary Mass Spectra (MS/MS)" (amino acid sequence)	Harvard University, Boston, USA																			
3	Molecular Weight Detection	Harvard University, Boston, USA																			
4	Residual Solvents Test	IAC-HEJ																			
5	Abnormal Toxicity (Safety) Test	PCSIR																			
Decision: The Registration Board deferred the case for submission of following documents/clarifications; • Drug substance part 3.2.S.2.2 to 3.2.S.2.6. • Reports of peptide mapping on drug product. • Reports of all the comparative tests performed on the applied strength with that of Innovator product. • Complete analytical method validation of drug product on all parameters.																					

Agenda Item No. 02: Post-registration Variation Applications of Semaglutide Products

Application for Change of Source of Drug Substance Semaglutide (Local Manufacturing)	
M/s Weather Folds Pharmaceuticals, Plot No. 69/2, Phase-II, Industrial Area, Hattar. (DML No.000644), has applied for “Change of source of Drug Substance” from existing approved source “M/s Livzon New North River Pharmaceutical Co., Ltd.,Renmin One Road, Qingyuan City, Guangdong Province, China” to “M/s Fuxin Long Rui Pharmaceutical Co., Ltd.,Flouride Industrial Park, Fumeng County, Fuxin City, Liaoning Province, China for their already registered product Semma 7mg Tablet (Reg. No. 120557) and Semma 14mg (Reg. No. 120556).	
Case # 01	
Name, address of Applicant / Importer	M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK
Application Details	Tracking ID: DNV-7S3-181E Application Number:95972 Dated: 29-04-2025
Type of Application	Major Variation
Fee Details	Challan Number: 50373969459 Division: Biological Evaluation & Registration Paid Fee: 37000.0 Paid Date: 2025-04-29
Product General Details	Product Name:: Semma 7mg Tablet Registration No.: 120557 Used For: Human Route of Admin: oral Dosage Form: Tablet Product Specification: As per Innovators Specification Shelf Life: 2 years Storage Condition: Store below 25°C Manufacturing Type: Self Manufacturing

	Label Claim: Each Tablet Contains:- Semaglutide.....7mg		
New Source	M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China.		
Approved Source	M/s Livzon New North River Pharmaceutical Co., Ltd., China		
Evaluation by BE&R			
○ The revision of PRVC guidelines for biological products are in process. Therefore, the case has been submitted for the consideration of Board. ○ The Registration Board in its 347th meeting has already approved change of source from existing source “M/s Livzon New North River Pharmaceutical Co., Ltd., China” to “M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China” of semaglutide API for their registered product Semma 3mg Tablet (Reg.No.120558).			
S.No.	Shortcomings communicated	Response of the firm	Remarks by BE&R
01	The proposed change on approved form (appendix-1) comes under MaV-1 instead of MaV-2.	Corrected Attached.	Submitted
02	Evidence that the new drug substance manufacturing facility is GMP compliant.	In China GMP Certificates are not issued any more and DRAP also accepts DML in case of imported by China, which is attached.	DML attached.
03	CTD drug substance part (S1-S7) of new source or in case of same batch you may refer to 3mg strength.	Rectified Attached.	Drug substance part is same as for 3mg tablet.
04	Status of BE studies and plan for new BE studies with new source.	As per decision in DRB 347th Meeting regarding 3mg Tab, we shall perform BE studies within 6 months in this strength too.	Condition will be incorporated in letter.
05	Evidence of installation of LC-MS for performance of peptide mapping along with qualification documents (IQ/OQ/PQ).	We shall outsource the Peptide mapping test of every commercial batch till installation at our own facility as per decision in DRB 347th Meeting	Condition will be incorporated in letter.
06	Detailed analytical procedures used for testing the drug product shall be provided.	Analytical procedures of drug product ATTACHED IN Annexure-2.	Condition will be incorporated in letter.
07	Update section 3.2.P.5.1 as per innovator to include the following tests :for peptide mapping, water content(3.2%),	Revised specifications Attached in Annexure-3	Submitted

	semaglutide assay specs (95%-105%), SNAC assay specs (92%-108%), HPMW (0.5%)(SE-HPLC) and inclusion of hydrophilic and hydrophobic impurities.		
08	Evidence of performance of peptide mapping of previous source and new source.	We shall outsource the Peptide mapping test of every commercial batch till installation at our own facility as per decision in DRB 347th Meeting	No performance record submitted.
09	Clearly Bookmark the raw data of stability for following tests i.e. assay of semaglutide and SNAC, HPMW.	Attached in Annexure-4	Raw data of API attached. Raw data of product required.
10	Real-time stability study data for 18 months, considering the Date of Manufacture (DOM) is 27/07/2023.	Attached	Submitted till 6 months.
11	Audit trails of assay (DP and SNAC) and HMWP for each stability time point.	Attached in Annexure-5	-
12	Commitment to test for impurities in the next stability time point and in commercial production batches.	Attached	Attached.
Decision: The Registration Board approved the “change of source” from existing source “M/s Livzon New North River Pharmaceutical Co., Ltd., China” to “M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China” for their already registered product Semma 7mg Tablet (Reg. No. 120557) with following conditions: ○ The manufacturer shall perform identification test for peptide mapping for finished product from any of Government Drug Testing Laboratory for every batch and during the aforesaid period the manufacturer shall install LC/MS in their own facility and inform Registration Board. ○ The manufacturer shall perform Bioequivalence Studies within six months. ○ The firm shall perform the post marketing surveillance studies. ○ The firm shall make arrangements for the ADR reporting as per Rules. ○ The firm shall submit the quarterly safety Reports to the Registration Board. ○ The firm shall submit evidence of peptide mapping for finished product from any of Government Drug Testing Laboratory for every batch produced with previous source (M/s Livzon New North River Pharmaceutical Co., Ltd., China).			

Case # 02			
Name, address of Applicant / Importer		M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK	
Application Details		Tracking ID: DS2-6L2-JHPE Application Number:95971 Dated: 29-04-2025	
Type of Application		Major Variation	
Fee Details		Challan Number: 0503262943 Division: Biological Evaluation & Registration Paid Fee: 37000.0 Paid Date: 2025-04-29	
Product General Details		Product Name:: Semma 14mg Tablet Registration No.: 120556 Used For: Human Route of Admin: oral Dosage Form: Tablet Product Specification: As per Innovators Specification Shelf Life: 2 years Storage Condition: Store below 25°C Manufacturing Type: Self Manufacturing Label Claim: Each Tablet Contains:- Semaglutide.....14mg	
New Source		M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China.	
Approved Source		M/s Livzon New North River Pharmaceutical Co., Ltd., China	
Evaluation by BE&R - The revision of PRVC guidelines for biological products are in process. Therefore, the case has been submitted for the consideration of Board. The Registration Board in its 347th meeting has already approved change of source from existing source “M/s Livzon New North River Pharmaceutical Co., Ltd., China” to “M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China” of semaglutide API for their registered product Semma 3mg Tablet (Reg.No.120558).			
S.No.	Shortcomings communicated	Response of the firm	Remarks by BE&R
01	The proposed change on approved form (appendix-1) comes under MaV-1 instead of MaV-2.	Corrected Attached.	Submitted
02	Evidence that the new drug substance manufacturing facility is GMP compliant.	In China GMP Certificates are not issued any more and DRAP also accepts DML in case of imported by China, which is attached.	DML attached.
03	CTD drug substance part (S1-S7) of new source or in case of same batch you may refer to 3mg strength.	Rectified Attached.	Drug substance part is same as for 3mg tablet.
04	Status of BE studies and plan for new BE studies with new source.	As per decision in DRB 347th Meeting	Condition will be incorporated in letter.

		regarding 3mg Tab, we shall perform BE studies within 6 months in this strength too.	
05	Evidence of installation of LC-MS for performance of peptide mapping along with qualification documents (IQ/OQ/PQ).	We shall outsource the Peptide mapping test of every commercial batch till installation at our own facility as per decision in DRB 347th Meeting	Condition will be incorporated in letter.
06	Detailed analytical procedures used for testing the drug product shall be provided.	Analytical procedures of drug product ATTACHED IN Annexure-2.	Condition will be incorporated in letter.
07	Update section 3.2.P.5.1 as per innovator to include the following tests :for peptide mapping, water content(3.2%), semaglutide assay specs (95%105%), SNAC assay specs (92%-108%), HMPW (0.5%)(SE-HPLC) and inclusion of hydrophilic and hydrophobic impurities.	Revised specifications Attached in Annexure-3	Submitted
08	Evidence of performance of peptide mapping of previous source and new source.	We shall outsource the Peptide mapping test of every commercial batch till installation at our own facility as per decision in DRB 347th Meeting	No performance record submitted.
09	Clearly Bookmark the raw data of stability for following tests i.e. assay of semaglutide and SNAC , HPMW.	Attached in Annexure-4	Raw data of API attached. Raw data of product required.
10	Real-time stability study data for 18 months, considering the Date of Manufacture (DOM) is 27/07/2023.	Attached	Submitted till 6 months.
11	Audit trails of assay (DP and SNAC) and HMWP for each stability time point.	Attached in Annexure-5	-
12	Commitment to test for impurities in the next stability time point and in commercial	Attached	Attached.

	production batches.			
Decision: The Registration Board approved the “change of source” from existing source “M/s Livzon New North River Pharmaceutical Co., Ltd., China” to “M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China” for their already registered product Semma 14mg Tablet (Reg. No. 120556) with following conditions: ○ The manufacturer shall perform identification test for peptide mapping for finished product from any of Government Drug Testing Laboratory for every batch and during the aforesaid period the manufacturer shall install LC/MS in their own facility and inform Registration Board. ○ The manufacturer shall perform Bioequivalence Studies within six months. ○ The firm shall perform the post marketing surveillance studies. ○ The firm shall make arrangements for the ADR reporting as per Rules. ○ The firm shall submit the quarterly safety Reports to the Registration Board. ○ The firm shall submit evidence of peptide mapping for finished product from any of Government Drug Testing Laboratory for every batch produced with previous source (M/s Livzon New North River Pharmaceutical Co., Ltd., China).				

Agenda Item No. 03. Registration Applications of Semaglutide Products for Contract Manufacturing

The applications of contract manufacturing of semaglutide are evaluated on the basis of DRAP Notification F.No.1-2/2022-DMC dated 13 th June, 2023. However, in the said notification, a word human pharmaceutical drug product is mentioned. The BE&R Division requests to extend the scope of this notification for biological products as well. It is further informed that 27 cases of contract manufacturing of semaglutide by M/s Weather Folds has already been taken up in 345 th meeting of Registration Board on the basis of this notification.	
Decision of 349th meeting of Registration Board: Registration Board extended the scope of DRAP Notification F.No.1-2/2022-DMC dated 13 th June, 2023 for Biological products as well.	
Case # 01	
Name, address of Applicant / Importer	M/s Hoechst Pakistan Limited, Company Address: Plot 23, Sector 22, Korangi Industrial Area, Karachi.
Status of the applicant	Contract Giver
Name, address of manufacturer(s)	M/s BF Biosciences Limited, 5-KM Sunder Raiwind Road, Opposite Ijtima Chowk, Raiwind, Lahore.
GMP of manufacturer & Evidence of Section	DML No. 000655 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan Evidence of section: Injection Pre-filled syringes (Biotech) Section dated 7 th May, 2024 GMP: Last GMP conducted on 01-03-2024 valid up to 28-02-2027
Status of application	Generic Drug Product (GDP)
Intended use of pharmaceutical product	Domestic and Export sales
Dy. No. and Date of submission	Tracking ID: GS1-VJM-1934 Application Number: 105667 Date of Receiving: 07-07-2025
Details of fee submitted	Challan Number: 0159524896

	Division: Biological Evaluation & Registration Paid Fee: Rs 93,000/- Paid Date: 2025-05-23
The proposed proprietary name / brand name	Semagrix 1mg/0.75ml, Solution for Injection in Pre-filled Syringe (For Subcutaneous use only)
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 0.75ml contains: Semaglutide 1mg
Pharmaceutical form of applied drug	Pre-Filled Syringe
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	Manufacturer's Specifications
Proposed Pack size	As per SRO
Proposed unit price	As per SRO
Shelf Life	2 Years
Storage Condition	Store in the refrigerator (2°C to 8°C). Do not freeze.
The status in reference regulatory authorities	OZEMPIC (semaglutide) solution for injection 2 mg/1.5 ml in pre-filled pen (USFDA APPROVED) <i>The firm has applied single dose (1mg/0.75ml) pre-filled syringe while the reference product Ozempic is available in multi dose pre-filled pens in different strengths as below;</i> • 0.25 mg or 0.5 mg dose pen (4 doses of 0.25 mg and 2 doses of 0.5 mg, or 4 doses of 0.5 mg) • 1 mg dose pen, (4 doses per pen) • 2 mg dose pen, (4 doses per pen)
For generic drugs (me-too status)	Ozempic by M/S Novo Nordisk Pharma (Private) Limited Karachi (Registration number : 107915)
Name, address of drug substance manufacturer	M/s Zhejiang Peptides Biotech Co., Ltd No.8 Hengyizhi Road, Sanjie Town, Shengzhou City, Zhejiang Province, China.
Data Already Approved on CTD	Yes
Meeting No.	M-336 (4 th -6 th June,2024)
Remarks of Evaluator: The firm has applied single dose (1mg/0.75ml) pre-filled syringe while the reference product Ozempic is available in multi dose pre-filled pens in different strengths as below; • 0.25 mg or 0.5 mg dose pen (4 doses of 0.25 mg and 2 doses of 0.5 mg, or 4 doses of 0.5 mg) • 1 mg dose pen, (4 doses per pen) • 2 mg dose pen, (4 doses per pen)	
Decision: The Registration Board approved application for contract manufacturing from M/s BF Biosciences Limited, 5-KM Sunder Raiwind Road, Opposite Ijtima Chowk, Raiwind, Lahore with following conditions: • The manufacturer shall perform identification test for peptide mapping for finished product	

from any of Government Drug Testing Laboratory for every batch and during the aforesaid period the manufacturer shall install LC/MS in their own facility and inform Registration Board. The firm shall perform the post marketing surveillance studies. The firm shall make arrangements for the ADR reporting as per Rules. The firm shall submit the quarterly safety Reports to the Registration Board.	
Case # 02	
Name, address of Applicant / Importer	M/s Hoechst Pakistan Limited, Company Address: Plot 23, Sector 22, Korangi Industrial Area, Karachi.
Status of the applicant	Contract Giver
Name, address of manufacturer(s)	M/s BF Biosciences Limited, 5-KM Sunder Raiwind Road, Opposite Ijtima Chowk, Raiwind, Lahore.
GMP of manufacturer & Evidence of Section	DML No. 000655 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan Evidence of section: Injection Pre-filled syringes (Biotech) Section dated 7 th May, 2024 GMP: Last GMP conducted on 01-03-2024 valid up to 28-02-2027
Status of application	Generic Drug Product (GDP)
Intended use of pharmaceutical product	Domestic and Export sales
Dy. No. and Date of submission	Tracking ID: YNS-Z5Y-HJPE Application Number: 105674 Date of Receiving: 10-07-2025
Details of fee submitted	Challan Number: 65459379156 Division: Biological Evaluation & Registration Paid Fee: Rs 93,000/- Paid Date: 2025-05-23
The proposed proprietary name / brand name	Semagrix 0.5mg/0.375ml, Solution for Injection in Pre-filled Syringe (For Subcutaneous use only)
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 0.375ml contains: Semaglutide..... 0.5mg
Pharmaceutical form of applied drug	Pre-Filled Syringe
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	Manufacturer's Specifications
Proposed Pack size	As per SRO
Proposed unit price	As per SRO
Shelf Life	2 Years
Storage Condition	Store in the refrigerator (2°C to 8°C). Do not freeze.
The status in reference regulatory authorities	OZEMPIC (semaglutide) solution for injection 2 mg/1.5 ml in pre-filled pen (USFDA APPROVED) <i>The firm has applied single dose (0.5mg/0.375ml) pre-filled syringe while the reference product Ozempic is available in multi dose pre-filled pens in different strengths as below;</i> <i>0.25 mg or 0.5 mg dose pen (4 doses of 0.25 mg and 2 doses of 0.5 mg,</i>

	<i>or 4 doses of 0.5 mg)</i> • 1 mg dose pen, (4 doses per pen) • 2 mg dose pen, (4 doses per pen)
For generic drugs (me-too status)	Ozempic by M/S Novo Nordisk Pharma (Private) Limited Karachi (Registration number : 107915)
Name, address of drug substance manufacturer	M/s Zhejiang Peptides Biotech Co., Ltd No.8 Hengyizhi Road, Sanjie Town, Shengzhou City, Zhejiang Province, China.
Data Already Approved on CTD	Yes
Meeting No.	M-336 (4 th -6 th June,2024)
Remarks of Evaluator: The firm has applied single dose (0.5mg/0.375ml) pre-filled syringe while the reference product Ozempic is available in multi dose pre-filled pens in different strengths as below; • 0.25 mg or 0.5 mg dose pen (4 doses of 0.25 mg and 2 doses of 0.5 mg, or 4 doses of 0.5 mg) • 1 mg dose pen, (4 doses per pen) • 2 mg dose pen, (4 doses per pen)	
Decision: The Registration Board approved application for contract manufacturing from M/s BF Biosciences Limited, 5-KM Sunder Raiwind Road, Opposite Ijtima Chowk, Raiwind, Lahore with following conditions: • The manufacturer shall perform identification test for peptide mapping for finished product from any of Government Drug Testing Laboratory for every batch and during the aforesaid period the manufacturer shall install LC/MS in their own facility and inform Registration Board. • The firm shall perform the post marketing surveillance studies. • The firm shall make arrangements for the ADR reporting as per Rules. • The firm shall submit the quarterly safety Reports to the Registration Board.	

Case # 03	
Name, address of Applicant / Importer	M/s Hoechst Pakistan Limited, Company Address: Plot 23, Sector 22, Korangi Industrial Area, Karachi.
Status of the applicant	Contract Giver
Name, address of manufacturer(s)	M/s BF Biosciences Limited, 5-KM Sunder Raiwind Road, Opposite Ijtima Chowk, Raiwind, Lahore.
GMP of manufacturer & Evidence of Section	DML No. 000655 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan Evidence of section: Injection Pre-filled syringes (Biotech) Section dated 7 th May, 2024 GMP: Last GMP conducted on 01-03-2024 valid up to 28-02-2027
Status of application	Generic Drug Product (GDP)
Intended use of pharmaceutical product	Domestic and Export sales
Dy. No. and Date of submission	Tracking ID: QH7-JJR-QQLW Application Number: 105682

	Date of Receiving: 07-07-2025
Details of fee submitted	Challan Number: 185819775 Division: Biological Evaluation & Registration Paid Fee: Rs 93,000/- Paid Date: 2025-05-23
The proposed proprietary name / brand name	Semagrix 0.25mg/0.188ml, Solution for Injection in Pre-filled Syringe (For Subcutaneous use only)
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 0.188ml contains: Semaglutide..... 0.25mg
Pharmaceutical form of applied drug	Pre-Filled Syringe
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	Manufacturer's Specifications
Proposed Pack size	As per SRO
Proposed unit price	As per SRO
Shelf Life	2 Years
Storage Condition	Store in the refrigerator (2°C to 8°C). Do not freeze.
The status in reference regulatory authorities	OZEMPIC (semaglutide) solution for injection 2 mg/1.5 ml in pre-filled pen (USFDA APPROVED) <i>The firm has applied single dose (0.25mg/0.188ml) pre-filled syringe while the reference product Ozempic is available in multi dose pre-filled pens in different strengths as below;</i> • 0.25 mg or 0.5 mg dose pen (4 doses of 0.25 mg and 2 doses of 0.5 mg, or 4 doses of 0.5 mg) • 1 mg dose pen, (4 doses per pen) • 2 mg dose pen, (4 doses per pen)
For generic drugs (me-too status)	Ozempic by M/S Novo Nordisk Pharma (Private) Limited Karachi (Registration number : 107915)
Name, address of drug substance manufacturer	M/s Zhejiang Peptides Biotech Co., Ltd No.8 Hengyizhi Road, Sanjie Town, Shengzhou City, Zhejiang Province, China.
Data Already Approved on CTD	Yes
Meeting No.	M-336 (4 th -6 th June,2024)
Remarks of Evaluator: The firm has applied single dose (0.25mg/0.188ml) pre-filled syringe while the reference product Ozempic is available in multi dose pre-filled pens in different strengths as below; • 0.25 mg or 0.5 mg dose pen (4 doses of 0.25 mg and 2 doses of 0.5 mg, or 4 doses of 0.5 mg) • 1 mg dose pen, (4 doses per pen) • 2 mg dose pen, (4 doses per pen)	
Decision: Minutes of 349 th Meeting of Registration Board (14 th July, 2025)	

The Registration Board approved application for contract manufacturing from M/s BF Biosciences Limited, 5-KM Sunder Raiwind Road, Opposite Ijtima Chowk, Raiwind, Lahore with following conditions:

- **The manufacturer shall perform identification test for peptide mapping for finished product from any of Government Drug Testing Laboratory for every batch and during the aforesaid period the manufacturer shall install LC/MS in their own facility and inform Registration Board.**
- **The firm shall perform the post marketing surveillance studies.**
- **The firm shall make arrangements for the ADR reporting as per Rules.**
- **The firm shall submit the quarterly safety Reports to the Registration Board.**

Case # 04	
Name, address of Applicant / Importer	M/s Ferozsons Laboratories Limited, Company Address: P.O. Ferozsons, Nowshera-Pakistan
Status of the applicant	Contract Giver
Name, address of manufacturer(s)	M/s BF Biosciences Limited, 5-KM Sunder Raiwind Road, Opposite Ijtima Chowk, Raiwind, Lahore.
GMP of manufacturer & Evidence of Section	DML No. 000655 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan. Evidence of section: Injection Pre-filled syringes (Biotech) Section dated 7 th May, 2024 GMP: Last GMP conducted on 01-03-2024 valid up to 28-02-2027
Status of application	Generic Drug Product (GDP)
Intended use of pharmaceutical product	Domestic and Export sales
Dy. No. and Date of submission	Tracking ID: MTL-WAH-2PH7 Application Number: 95222 Date of Receiving: 25-04-2025
Details of fee submitted	Challan Number: 36098215245 Division: Biological Evaluation & Registration Paid Fee: Rs 93,000/- Paid Date: 2025-04-25
The proposed proprietary name / brand name	Semagen 1mg/0.75ml (PFS) (For Subcutaneous use only)
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 0.75ml contains: Semaglutide 1mg
Pharmaceutical form of applied drug	Pre-Filled Syringe
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	Manufacturer's Specifications
Proposed Pack size	As per SRO
Proposed unit price	As per SRO
Shelf Life	2 Years
Storage Condition	Store in the refrigerator (2°C to 8°C). Do not freeze.
The status in reference regulatory authorities	OZEMPIC (semaglutide) solution for injection 2 mg/1.5 ml in pre-filled pen (USFDA APPROVED) <i>The firm has applied single dose (1mg/0.75ml) pre-filled syringe while the reference product Ozempic is available in multi dose pre-filled pens in different strengths as below;</i> <i>0.25 mg or 0.5 mg dose pen (4 doses of 0.25 mg and 2 doses of 0.5 mg,</i>

	<i>or 4 doses of 0.5 mg)</i> • 1 mg dose pen, (4 doses per pen) • 2 mg dose pen, (4 doses per pen)
For generic drugs (me-too status)	Ozempic by M/S Novo Nordisk Pharma (Private) Limited Karachi (Registration number : 107915)
Name, address of drug substance manufacturer	M/s Zhejiang Peptides Biotech Co., Ltd No.8 Hengyizhi Road, Sanjie Town, Shengzhou City, Zhejiang Province, China.
Data Already Approved on CTD	Yes
Meeting No.	M-336 (4 th -6 th June,2024)
Remarks of Evaluator: The firm has applied single dose (1mg/0.75ml) pre-filled syringe while the reference product Ozempic is available in multi dose pre-filled pens in different strengths as below; • 0.25 mg or 0.5 mg dose pen (4 doses of 0.25 mg and 2 doses of 0.5 mg, or 4 doses of 0.5 mg) • 1 mg dose pen, (4 doses per pen) • 2 mg dose pen, (4 doses per pen)	
Decision: The Registration Board approved application for contract manufacturing from M/s BF Biosciences Limited, 5-KM Sunder Raiwind Road, Opposite Ijtimia Chowk, Raiwind, Lahore with following conditions: • The manufacturer shall perform identification test for peptide mapping for finished product from any of Government Drug Testing Laboratory for every batch and during the aforesaid period the manufacturer shall install LC/MS in their own facility and inform Registration Board. • The firm shall perform the post marketing surveillance studies. • The firm shall make arrangements for the ADR reporting as per Rules. • The firm shall submit the quarterly safety Reports to the Registration Board.	

Case # 05	
Name, address of Applicant / Importer	M/s Ferozsons Laboratories Limited, Company Address: P.O. Ferozsons, Nowshera-Pakistan
Status of the applicant	Contract Giver
Name, address of manufacturer(s)	M/s BF Biosciences Limited, 5-KM Sunder Raiwind Road, Opposite Ijtimia Chowk, Raiwind, Lahore.
GMP of manufacturer & Evidence of Section	DML No. 000655 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan. Evidence of section: Injection Pre-filled syringes (Biotech) Section dated 7 th May, 2024 GMP: Last GMP conducted on 01-03-2024 valid up to 28-02-2027
Status of application	Generic Drug Product (GDP)
Intended use of pharmaceutical product	Domestic and Export sales

Dy. No. and Date of submission	Tracking ID: 26L-NWA-S147 Application Number: 95220 Date of Receiving: 25-04-2025
Details of fee submitted	Challan Number: 67326742786 Division: Biological Evaluation & Registration Paid Fee: Rs 93,000/- Paid Date: 2025-04-25
The proposed proprietary name / brand name	Semagen 0.5mg/0.375ml (PFS) (For Subcutaneous use only)
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 0.375ml contains: Semaglutide.....0.5mg
Pharmaceutical form of applied drug	Pre-Filled Syringe
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	Manufacturer's Specifications
Proposed Pack size	As per SRO
Proposed unit price	As per SRO
Shelf Life	2 Years
Storage Condition	Store in the refrigerator (2°C to 8°C). Do not freeze.
The status in reference regulatory authorities	OZEMPIC (semaglutide) solution for injection 2 mg/1.5 ml in pre-filled pen (USFDA APPROVED) <i>The firm has applied single dose (0.5mg/0.375ml) pre-filled syringe while the reference product Ozempic is available in multi dose pre-filled pens in different strengths as below;</i> <i>0.25 mg or 0.5 mg dose pen (4 doses of 0.25 mg and 2 doses of 0.5 mg, or 4 doses of 0.5 mg)</i> <i>1 mg dose pen, (4 doses per pen)</i> <i>2 mg dose pen, (4 doses per pen)</i>
For generic drugs (me-too status)	Ozempic by M/S Novo Nordisk Pharma (Private) Limited Karachi (Registration number : 107915)
Name, address of drug substance manufacturer	M/s Zhejiang Peptides Biotech Co., Ltd No.8 Hengyizhi Road, Sanjie Town, Shengzhou City, Zhejiang Province, China.
Data Already Approved on CTD	Yes
Meeting No.	M-336 (4 th -6 th June,2024)
Remarks of Evaluator: The firm has applied single dose (0.5mg/0.375ml) pre-filled syringe while the reference product Ozempic is available in multi dose pre-filled pens in different strengths as below; 0.25 mg or 0.5 mg dose pen (4 doses of 0.25 mg and 2 doses of 0.5 mg, or 4 doses of 0.5 mg)	

• 1 mg dose pen, (4 doses per pen) • 2 mg dose pen, (4 doses per pen)
Decision: The Registration Board approved application for contract manufacturing from M/s BF Biosciences Limited, 5-KM Sunder Raiwind Road, Opposite Ijtima Chowk, Raiwind, Lahore with following conditions: • The manufacturer shall perform identification test for peptide mapping for finished product from any of Government Drug Testing Laboratory for every batch and during the aforesaid period the manufacturer shall install LC/MS in their own facility and inform Registration Board. • The firm shall perform the post marketing surveillance studies. • The firm shall make arrangements for the ADR reporting as per Rules. • The firm shall submit the quarterly safety Reports to the Registration Board.

Case # 06	
Name, address of Applicant / Importer	M/s Ferozsons Laboratories Limited, Company Address: P.O. Ferozsons, Nowshera-Pakistan
Status of the applicant	Contract Giver
Name, address of manufacturer(s)	M/s BF Biosciences Limited, 5-KM Sunder Raiwind Road, Opposite Ijtima Chowk, Raiwind, Lahore.
GMP of manufacturer & Evidence of Section	DML No. 000655 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan. Evidence of section: Injection Pre-filled syringes (Biotech) Section dated 7 th May, 2024 GMP: Last GMP conducted on 01-03-2024 valid up to 28-02-2027
Status of application	Generic Drug Product (GDP)
Intended use of pharmaceutical product	Domestic and Export sales
Dy. No. and Date of submission	Tracking ID: UP7-1B3-EVWL Application Number: 95207 Date of Receiving: 25-04-2025
Details of fee submitted	Challan Number: 9289657162 Division: Biological Evaluation & Registration Paid Fee: Rs 93,000/- Paid Date: 2025-04-25
The proposed proprietary name / brand name	Semagen 0.25mg/0.188ml (PFS) (For Subcutaneous use only)
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 0.188ml contains: Semaglutide.....0.25mg
Pharmaceutical form of applied drug	Pre-Filled Syringe
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06

Reference to Finished product specifications	Manufacturer's Specifications
Proposed Pack size	As per SRO
Proposed unit price	As per SRO
Shelf Life	2 Years
Storage Condition	Store in the refrigerator (2°C to 8°C). Do not freeze.
The status in reference regulatory authorities	OZEMPIC (semaglutide) solution for injection 2 mg/1.5 ml in pre-filled pen (USFDA APPROVED) <i>The firm has applied single dose (0.25mg/0.188ml) pre-filled syringe while the reference product Ozempic is available in multi dose pre-filled pens in different strengths as below;</i> • 0.25 mg or 0.5 mg dose pen (4 doses of 0.25 mg and 2 doses of 0.5 mg, or 4 doses of 0.5 mg) • 1 mg dose pen, (4 doses per pen) • 2 mg dose pen, (4 doses per pen)
For generic drugs (me-too status)	Ozempic by M/S Novo Nordisk Pharma (Private) Limited Karachi (Registration number : 107915)
Name, address of drug substance manufacturer	M/s Zhejiang Peptides Biotech Co., Ltd No.8 Hengyizhi Road, Sanjie Town, Shengzhou City, Zhejiang Province, China.
Data Already Approved on CTD	Yes
Meeting No.	M-336 (4 th -6 th June,2024)
Remarks of Evaluator: The firm has applied single dose (0.25mg/0.188ml) pre-filled syringe while the reference product Ozempic is available in multi dose pre-filled pens in different strengths as below; • 0.25 mg or 0.5 mg dose pen (4 doses of 0.25 mg and 2 doses of 0.5 mg, or 4 doses of 0.5 mg) • 1 mg dose pen, (4 doses per pen) • 2 mg dose pen, (4 doses per pen)	
Decision: The Registration Board approved application for contract manufacturing from M/s BF Biosciences Limited, 5-KM Sunder Raiwind Road, Opposite Ijtim Chowk, Raiwind, Lahore with following conditions: • The manufacturer shall perform identification test for peptide mapping for finished product from any of Government Drug Testing Laboratory for every batch and during the aforesaid period the manufacturer shall install LC/MS in their own facility and inform Registration Board. • The firm shall perform the post marketing surveillance studies. • The firm shall make arrangements for the ADR reporting as per Rules. • The firm shall submit the quarterly safety Reports to the Registration Board.	

Web Publisher
Web Publisher
Monday, 10 November, 2025, 3:19:4 PM

Web Publisher
Web Publisher
Monday, 10 November, 2025, 3:19:4 PM

Case #07	
Name, address of Applicant	M/s Jenner Pharmaceuticals (Pvt) Ltd. Company Address: Plot No. # 3, M2 Pharma Zone 26th KM Lahore Sharaqpur Road, Disst Sheikupura.
Status of the applicant	Contract Giver
Name, address of manufacturer(s)	M/s Weather Folds Pharmaceuticals, Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK
GMP of manufacturer & Evidence of Section	DML No. 000644 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan Evidence of section: Biological tablet products (biological) section dated 25th October, 2023
Status of application	Generic Drug Product (GDP)
Intended use of pharmaceutical product	Domestic and Export sales
Dy. No. and Date of submission	Tracking ID: Q5E-QTD-HHHX Application Number: 65416 Date of Receiving: 23-01-2025
Details of fee submitted	Challan Number: 148875093082 Division: Pharmaceutical Evaluation & Registration Paid Fee: Rs 93,000/- Paid Date: 2024-11-15
The proposed proprietary name / brand name	Nugovy tablet 3mg
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Semaglutide.....3mg
Pharmaceutical form of applied drug	Tablet
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	As per Innovator's Specifications
Proposed Pack size	As approved for Rybelsus
Proposed unit price	As per SRO
Shelf Life	24 months
Storage Condition	Store Below 30°C
The status in reference regulatory authorities	Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark
For generic drugs (me-too status)	Rybelsus by Novo Nordisk
Name, address of drug substance manufacturer	M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One Road, Qingyuan City, Guangdong Province, China.(rDNA origin)
Data Already Approved on CTD	Yes
Meeting No.	340

Remarks of evaluator:

- GMP certificate of M/s Weather Folds Pharmaceuticals is not provided.
- Undertaking by the applicant is required that they will use the same source as approved for M/s Weather Folds (Contract acceptor) by the Registration Board.
- Fee is paid under the Head of PE&R.
- The Registration Board in its 347th meeting has approved “change of source” of semaglutide of M/s Weather Folds Pharmaceuticals (Contract acceptor) from “M/s Livzon New North River Pharmaceutical Co., Ltd., China” to “M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China”. Applicant may be asked to apply for pre-registration variation and submit revised Module-1 with new source of semaglutide.
- The Registration Board in its 347th meeting has approved new source of semaglutide for M/s Weather Folds Pharmaceuticals (Contract acceptor) with following conditions. The conditions will be applicable to the applicant also.
 - The manufacturer shall perform identification test for peptide mapping for finished product from any of Government Drug Testing Laboratory for every batch and during the aforesaid period the manufacturer shall install LC/MS in their own facility and inform Registration Board.
 - The manufacturer shall perform Bioequivalence Studies within six months.
 - The firm will perform the post marketing surveillance studies.
 - The firm will make arrangements for the ADR reporting as per Rules.
 - The firm will submit the quarterly safety Reports to the Registration Board.

Decision:

The Registration Board approved application for contract manufacturing from M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK with new approved source (M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China) with following conditions:

- The manufacturer shall perform identification test for peptide mapping for finished product from any of Government Drug Testing Laboratory for every batch and during the aforesaid period the manufacturer shall install LC/MS in their own facility and inform Registration Board.
- The manufacturer shall perform Bioequivalence Studies within six months.
- The firm shall perform the post marketing surveillance studies.
- The firm shall make arrangements for the ADR reporting as per Rules.
- The firm will submit the quarterly safety Reports to the Registration Board.

Letter shall be issued after submission of following documents;

- A declaration/undertaking that they shall adopt the same source of drug substance, drug product formulation, specifications and container closure as approved for contract acceptor.
- Pre-registration variation fee and revised Module-1 with new approved source of semaglutide.
- Fee for contract manufacturing under the head of BE&R.

Case #08

Name, address of Applicant	M/s Jenner Pharmaceuticals (Pvt) Ltd. Company Address: Plot No. # 3, M2 Pharma Zone 26th KM Lahore Sharaqpur Road, Disst Sheikupura.

Status of the applicant	Contract Giver
Name, address of manufacturer(s)	M/s Weather Folds Pharmaceuticals, Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK
GMP of manufacturer & Evidence of Section	DML No. 000644 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan Evidence of section biological tablet products (biological) section dated 25th October, 2023
Status of application	Generic Drug Product (GDP)
Intended use of pharmaceutical product	Domestic and Export sales
Dy. No. and Date of submission	Tracking ID: 89V-V1L-WQ7A Application Number: 65422 Date of Receiving: 13-01-2025
Details of fee submitted	Challan Number: 58067965539 Division: Pharmaceutical Evaluation & Registration Paid Fee: Rs 93,000/- Paid Date: 2024-11-15
The proposed proprietary name / brand name	Nugovy tablet 7mg
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Semaglutide.....7mg
Pharmaceutical form of applied drug	Tablet
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	As per Innovator's Specifications
Proposed Pack size	As approved for Rybelsus
Proposed unit price	As per SRO
Shelf Life	24 months
Storage Condition	Store Below 30°C
The status in reference regulatory authorities	Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark
For generic drugs (me-too status)	Rybelsus by Novo Nordisk
Name, address of drug substance manufacturer	M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One Road, Qingyuan City, Guangdong Province, China.(rDNA origin)
Data Already Approved on CTD	Yes
Meeting No.	340
Remarks of evaluator: - GMP certificate of M/s Weather Folds Pharmaceuticals is not provided. - Undertaking by the applicant is required that they will use the same source as approved for M/s Weather Folds by the Registration Board.	

	• Fee is paid under the Head of PE&R. • The manufacturer (contract acceptor) has applied for change of source of semaglutide from “M/s Livzon New North River Pharmaceutical Co., Ltd., China” to “M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China” and is not approved by the Registration Board yet. Applicant may be asked to apply for pre-registration variation and submit revised Module-1 with new source of semaglutide after approval of the new source by the Board.
	Decision: The Registration Board approved application for contract manufacturing from M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK with new approved source (M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China) with following conditions: • The manufacturer shall perform identification test for peptide mapping for finished product from any of Government Drug Testing Laboratory for every batch and during the aforesaid period the manufacturer shall install LC/MS in their own facility and inform Registration Board. • The manufacturer shall perform Bioequivalence Studies within six months. • The firm shall perform the post marketing surveillance studies. • The firm shall make arrangements for the ADR reporting as per Rules. • The firm shall submit the quarterly safety Reports to the Registration Board. Letter will be issued after submission of following documents; • A declaration/undertaking that they shall adopt the same source of drug substance, drug product formulation, specifications and container closure as approved for contract acceptor. • Pre-registration variation fee and revised Module-1 with new approved source of semaglutide. • Fee for contract manufacturing under the head of BE&R.

Case # 09	
Name, address of Applicant	M/s Jenner Pharmaceuticals (Pvt) Ltd. Company Address: Plot No. # 3, M2 Pharma Zone 26th KM Lahore Sharaqpur Road, Disst Sheikupura.
Status of the applicant	Contract Giver
Name, address of manufacturer(s)	M/s Weather Folds Pharmaceuticals, Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK
GMP of manufacturer & Evidence of Section	DML No. 000644 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan Evidence of section biological tablet products (biological) section dated 25th October, 2023
Status of application	Generic Drug Product (GDP)
Intended use of pharmaceutical product	Domestic and Export sales
Dy. No. and Date of submission	Tracking ID: ERX-UV7-B2R3 Application Number: 65427 Date of Receiving: 23-01-2025

Details of fee submitted	Challan Number: 6758677025 Division: Pharmaceutical Evaluation & Registration Paid Fee: Rs 93,000/- Paid Date: 2024-11-15
The proposed proprietary name / brand name	Nugovy tablet 14mg
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Semaglutide.....14mg
Pharmaceutical form of applied drug	Tablet
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	As per Innovator's Specifications
Proposed Pack size	As approved for Rybelsus
Proposed unit price	As per SRO
Shelf Life	24 months
Storage Condition	Store Below 30°C
The status in reference regulatory authorities	Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark
For generic drugs (me-too status)	Rybelsus by Novo Nordisk
Name, address of drug substance manufacturer	M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One Road, Qingyuan City, Guangdong Province, China.(rDNA origin)
Data Already Approved on CTD	Yes
Meeting No.	340
Remarks of evaluator: - GMP certificate of M/s Weather Folds Pharmaceuticals is not provided. - Undertaking by the applicant is required that they will use the same source as approved for M/s Weather Folds by the Registration Board. - Fee is paid under the Head of PE&R. - The manufacturer (contract acceptor) has applied for change of source of semaglutide from “M/s Livzon New North River Pharmaceutical Co., Ltd., China” to “M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China” and is not approved by the Registration Board yet. Applicant may be asked to apply for pre-registration variation and submit revised Module-1 with new source of semaglutide after approval of the new source by the Board.	
Decision: The Registration Board approved application for contract manufacturing from M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK with new approved source (M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China) with following conditions: The manufacturer shall perform identification test for peptide mapping for finished product from any of Government Drug Testing Laboratory for every batch and during the aforesaid period the manufacturer shall install LC/MS in their own facility and inform	

	Registration Board. • The manufacturer shall perform Bioequivalence Studies within six months. • The firm shall perform the post marketing surveillance studies. • The firm shall make arrangements for the ADR reporting as per Rules. • The firm shall submit the quarterly safety Reports to the Registration Board. Letter will be issued after submission of following documents; • A declaration/undertaking that they will adopt the same source of drug substance, drug product formulation, specifications and container closure as approved for contract acceptor. • Pre-registration variation fee and revised Module-1 with new approved source of semaglutide. • Fee for contract manufacturing under the head of BE&R.

Case #10	
Name, address of Applicant	M/s McOlson Research Laboratories Pvt. Ltd, Company Address: Plot No. 02, M-2 Pharmazone, 26th Km Lahore Sharikpur Road Sheikhpura Pakistan.
Status of the applicant	Contract Giver
Name, address of manufacturer(s)	M/s Weather Folds Pharmaceuticals, Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK
GMP of manufacturer & Evidence of Section	DML No. 000644 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan Evidence of section: Biological tablet products (biological) section dated 25th October, 2023
Status of application	Generic Drug Product (GDP)
Intended use of pharmaceutical product	Domestic and Export sales
e-app tracking ID and Date of receiving	Tracking ID: PUJ-Y5Q-AYTD Application Number: 65372 Date of Receiving: 23-01-2025
Details of fee submitted	Challan Number: 194522928 Division: Pharmaceutical Evaluation & Registration Paid Fee: Rs 93,000/- Paid Date: 2024-11-12
The proposed proprietary name / brand name	Emalgo 3 mg Tablets
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Tablet Contains: Semaglutide..... 3 mg
Pharmaceutical form of applied drug	Tablet
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	As per Innovator's Specifications
Proposed Pack size	As approved for Rybelsus

Proposed unit price	As per SRO
Shelf Life	24 months
Storage Condition	Store Below 30°C
The status in reference regulatory authorities	Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark
For generic drugs (me-too status)	Rybelsus by Novo Nordisk
Name, address of drug substance manufacturer	M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One Road, Qingyuan City, Guangdong Province, China.(rDNA origin)
Data Already Approved on CTD	Yes
Meeting No.	340

Remarks of evaluator:

- GMP certificate of M/s Weather Folds Pharmaceuticals is not provided.
- Undertaking by the applicant is required that they will use the same source as approved for M/s Weather Folds (Contract acceptor) by the Registration Board.
- Fee is paid under the Head of PE&R.
- The Registration Board in its 347th meeting has approved “change of source” of semaglutide of M/s Weather Folds Pharmaceuticals (Contract acceptor) from “M/s Livzon New North River Pharmaceutical Co., Ltd., China” to “M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China”. Applicant may be asked to apply for pre-registration variation and submit revised Module-1 with new source of semaglutide.
- The Registration Board in its 347th meeting has approved new source of semaglutide for M/s Weather Folds Pharmaceuticals (Contract acceptor) with following conditions. The conditions will be applicable to the applicant also.
 - The manufacturer shall perform identification test for peptide mapping for finished product from any of Government Drug Testing Laboratory for every batch and during the aforesaid period the manufacturer shall install LC/MS in their own facility and inform Registration Board.
 - The manufacturer shall perform Bioequivalence Studies within six months.
 - The firm will perform the post marketing surveillance studies.
 - The firm will make arrangements for the ADR reporting as per Rules.
 - The firm will submit the quarterly safety Reports to the Registration Board.

Decision:

The Registration Board approved application for contract manufacturing from M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK with new approved source (M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China) with following conditions:

- **The manufacturer shall perform identification test for peptide mapping for finished product from any of Government Drug Testing Laboratory for every batch and during the aforesaid period the manufacturer shall install LC/MS in their own facility and inform Registration Board.**
- **The manufacturer shall perform Bioequivalence Studies within six months.**
- **The firm shall perform the post marketing surveillance studies.**
- **The firm shall make arrangements for the ADR reporting as per Rules.**
- **The firm shall submit the quarterly safety Reports to the Registration Board.**

Letter will be issued after submission of following documents;

- **A declaration/undertaking that they shall adopt the same source of drug substance, drug**

product formulation, specifications and container closure as approved for contract acceptor. Pre-registration variation fee and revised Module-1 with new approved source of semaglutide. Fee for contract manufacturing under the head of BE&R.

Case #11	
Name, address of Applicant	M/s McOlson Research Laboratories Pvt. Ltd, Company Address: Plot No. 02, M-2 Pharmazone, 26th Km Lahore Sharikpur Road Sheikhpura Pakistan.
Status of the applicant	Contract Giver
Name, address of manufacturer(s)	M/s Weather Folds Pharmaceuticals, Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK
GMP of manufacturer & Evidence of Section	DML No. 000644 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan Evidence of section: Biological tablet products (biological) section dated 25th October, 2023
Status of application	Generic Drug Product (GDP)
Intended use of pharmaceutical product	Domestic and Export sales
e-app tracking ID and Date of receiving	Tracking ID: XEX-E8P-YZ97 Application Number: 65413 Date of Receiving: 13-01-2025
Details of fee submitted	Challan Number: 65361381812 Division: Pharmaceutical Evaluation & Registration Paid Fee: Rs 93,000/- Paid Date: 2024-11-12
The proposed proprietary name / brand name	Emalgo 7mg Tablets
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Tablet Contains: Semaglutide..... 7 mg
Pharmaceutical form of applied drug	Tablet
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	As per Innovator's Specifications
Proposed Pack size	As approved for Rybelsus
Proposed unit price	As per SRO
Shelf Life	24 months
Storage Condition	Store Below 30°C
The status in reference regulatory authorities	Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark
For generic drugs (me-too status)	Rybelsus by Novo Nordisk

Name, address of drug substance manufacturer	M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One Road, Qingyuan City, Guangdong Province, China.(rDNA origin)
Data Already Approved on CTD	Yes
Meeting No.	340
Remarks of evaluator: - GMP certificate of M/s Weather Folds Pharmaceuticals is not provided. - Undertaking by the applicant is required that they will use the same source as approved for M/s Weather Folds by the Registration Board. - Fee is paid under the Head of PE&R. - The manufacturer (contract acceptor) has applied for change of source of semaglutide from “M/s Livzon New North River Pharmaceutical Co., Ltd., China” to “M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China” and is not approved by the Registration Board yet. Applicant may be asked to apply for pre-registration variation and submit revised Module-1 with new source of semaglutide after approval of the new source of contract acceptor by the Board.	
Decision: The Registration Board approved application for contract manufacturing from M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK with new approved source (M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China) with following conditions: - The manufacturer shall perform identification test for peptide mapping for finished product from any of Government Drug Testing Laboratory for every batch and during the aforesaid period the manufacturer shall install LC/MS in their own facility and inform Registration Board. - The manufacturer shall perform Bioequivalence Studies within six months. - The firm shall perform the post marketing surveillance studies. - The firm shall make arrangements for the ADR reporting as per Rules. - The firm shall submit the quarterly safety Reports to the Registration Board. Letter will be issued after submission of following documents; - A declaration/undertaking that they will adopt the same source of drug substance, drug product formulation, specifications and container closure as approved for contract acceptor. - Pre-registration variation fee and revised Module-1 with new approved source of semaglutide. - Fee for contract manufacturing under the head of BE&R.	

Case #12	
Name, address of Applicant	M/s McOlson Research Laboratories Pvt. Ltd, Company Address: Plot No. 02, M-2 Pharmazone, 26th Km Lahore Sharikpur Road Sheikhpura Pakistan.
Status of the applicant	Contract Giver
Name, address of manufacturer(s)	M/s Weather Folds Pharmaceuticals, Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK
GMP of manufacturer & Evidence of Section	DML No. 000644 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan Evidence of section: Biological tablet products (biological) section dated 25th October, 2023
Status of application	Generic Drug Product (GDP)
Intended use of pharmaceutical product	Domestic and Export sales
e-app tracking ID and Date of receiving	Tracking ID: Y98-5RY-MES1 Application Number: 65424 Date of Receiving: 13-01-2025
Details of fee submitted	Challan Number: 90893265 Division: Pharmaceutical Evaluation & Registration Paid Fee: Rs 93,000/- Paid Date: 2024-11-12
The proposed proprietary name / brand name	Emalgo 14mg Tablets
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Tablet Contains: Semaglutide..... 14mg
Pharmaceutical form of applied drug	Tablet
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	As per Innovator's Specifications
Proposed Pack size	As approved for Rybelsus
Proposed unit price	As per SRO
Shelf Life	24 months
Storage Condition	Store Below 30°C
The status in reference regulatory authorities	Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark
For generic drugs (me-too status)	Rybelsus by Novo Nordisk
Name, address of drug substance manufacturer	M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One Road, Qingyuan City, Guangdong Province, China.(rDNA origin)
Data Already Approved on CTD	Yes
Meeting No.	340
Remarks of evaluator:	

- GMP certificate of M/s Weather Folds Pharmaceuticals is not provided.
- Undertaking by the applicant is required that they will use the same source as approved for M/s Weather Folds by the Registration Board.
- Fee is paid under the Head of PE&R.
- The manufacturer (contract acceptor) has applied for change of source of semaglutide from “M/s Livzon New North River Pharmaceutical Co., Ltd., China” to “M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China” and is not approved by the Registration Board yet. Applicant may be asked to apply for pre-registration variation and submit revised Module-1 with new source of semaglutide after approval of the new source of contract acceptor by the Board.

Decision:

The Registration Board approved application for contract manufacturing from M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK with new approved source (M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China) with following conditions:

- **The manufacturer shall perform identification test for peptide mapping for finished product from any of Government Drug Testing Laboratory for every batch and during the aforesaid period the manufacturer shall install LC/MS in their own facility and inform Registration Board.**
- **The manufacturer shall perform Bioequivalence Studies within six months.**
- **The firm shall perform the post marketing surveillance studies.**
- **The firm shall make arrangements for the ADR reporting as per Rules.**
- **The firm shall submit the quarterly safety Reports to the Registration Board.**

Letter will be issued after submission of following documents;

- **A declaration/undertaking that they shall adopt the same source of drug substance, drug product formulation, specifications and container closure as approved for contract acceptor.**
- **Pre-registration variation fee and revised Module-1 with new approved source of semaglutide.**
- **Fee for contract manufacturing under the head of BE&R.**

Case#13	
Name, address of Applicant / Importer	M/s Winbrains Research Laboratories Company Address: Plot No. 69/1 Block B, Phase I-II Industrial Estate, Hattar, Pakistan
Status of the applicant	Contract Giver
Name, address of manufacturer(s)	M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK
GMP of manufacturer & Evidence of Section	DML No. 000644 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan Evidence of section biological tablet products (biological) section dated 25th October, 2023 GMP: Last GMP conducted on 12-10-2022 valid up to 1-10-2024
Status of application	Generic Drug Product (GDP)
Intended use of pharmaceutical product	Domestic and Export sales
Dy. No. and Date of submission	Tracking ID: 84S-9U3-LMDE

	Application Number: 61092 Date of Receiving: 18-02-2025
Details of fee submitted	Challan Number: 5008721921 Division: Biological Evaluation & Registration Paid Fee: Rs 93,000/- Paid Date: 2024-11-04
The proposed proprietary name / brand name	Semgold tablet 7mg
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Semaglutide...7mg
Pharmaceutical form of applied drug	Tablet
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	As per Innovator's Specifications
Proposed Pack size	As per SRO
Proposed unit price	As per SRO
Shelf Life	2 Years
Storage Condition	Store Below 25°C
The status in reference regulatory authorities	Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark
For generic drugs (me-too status)	Rybelsus by Novo Nordisk
Name, address of drug substance manufacturer	M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One Road, Qingyuan City, Guangdong Province, China.(rDNA origin)
Data Already Approved on CTD	Yes
Meeting No.	340

Evaluation by BE&R

Observations	Applicant Response
- Status of BE studies for already registered product of contract acceptor. - Evidence of installation of LC-MS for performance of peptide mapping along with qualification documents (IQ/OQ/PQ). - Applicant shall submit a declaration that they will adopt the same source of drug substance, drug product formulation, specifications and container closure. - Applicant shall submit a declaration, in case of any post-registration variation by the contract manufacturer, same shall be immediately applied	Regarding the status of BE studies and installation of LC-MS for peptide mapping along with qualification documents, we would like to clarify that we are the Contract Giver for Semaglutide Tablet on basis of Approved Product by Drug Registration Board, and the question should be directed to the registration holder, M/s Weather Folds Pharmaceuticals, as we act solely as the Contract Giver. We reaffirm our commitment to following the same source of drug substance, drug product formulation, specifications, and container closure system as M/s Weather Folds Pharmaceuticals. Additionally, we would like to highlight that the Contract Application of M/s Jupiter Pharmaceuticals has already been approved of the same product from M/s Weather Folds Pharmaceuticals, and the registration letter has been issued.

by the applicant/ registration holder f or requisite approval by Registration Board.	

Proceeding of the Board:
During the meeting the Registration Board was apprised about the following facts and figures pertinent to the drug product manufacturer:

ii.	Performance and submission of bioequivalence studies with new source.	M/s Weather Folds Pharmaceuticals has submitted the application for Change of Source. Upon grant of the approval, Bioequivalence (BE) studies will be conducted using a commercial batch manufactured with the API material from the newly approved source
iii.	Installation of LC/MS in their own facility along with submission of qualification document	M/s Weather Folds Pharmaceuticals have outsourced the LC/MS Facility of every batch like other manufacturers.

Decision of 347th RB meeting:

The Registration Board deferred the case as applicant has not yet applied for “change of source” from “M/s Livzon New North River Pharmaceutical Co., Ltd., China” to “M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China” for Semma 7mg Tablet.

Remarks by BE&R:

The contract acceptor has applied for change of source for their already registered products Semma 7mg and Semma 14mg and both cases are placed above in the instant meeting.

Decision:

The Registration Board approved application for contract manufacturing from M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK with new approved source (M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China) in the instant meeting with following conditions:

- The manufacturer shall perform identification test for peptide mapping for finished product from any of Government Drug Testing Laboratory for every batch and during the aforesaid period the manufacturer shall install LC/MS in their own facility and inform Registration Board.
- The manufacturer shall perform Bioequivalence Studies within six months.
- The firm shall perform the post marketing surveillance studies.
- The firm shall make arrangements for the ADR reporting as per Rules.
- The firm shall submit the quarterly safety Reports to the Registration Board.

Letter will be issued after submission of following documents;

- A declaration/undertaking that they will adopt the same source of drug substance, drug product formulation, specifications and container closure as approved for contract acceptor.
- Pre-registration variation fee and revised Module-1 with new approved source of semaglutide.

Case#14	
Name, address of Applicant / Importer	M/s Winbrains Research Laboratories Company Address: Plot No. 69/1 Block B, Phase I-II Industrial Estate, Hattar, Pakistan
Status of the applicant	Contract Giver

Name, address of manufacturer(s)	M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK				
GMP of manufacturer & Evidence of Section	DML No. 000644 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan Evidence of section biological tablet products (biological) section dated 25th October, 2023 GMP: Last GMP conducted on 12-10-2022 valid up to 1-10-2024				
Status of application	Generic Drug Product (GDP)				
Intended use of pharmaceutical product	Domestic and Export sales				
Dy. No. and Date of submission	Tracking ID: 3XG-BM3-1MBT Application Number: 61098 Date of Receiving: 29-11-2024				
Details of fee submitted	Challan Number: 1201664487 Division: Biological Evaluation & Registration Paid Fee: Rs 93,000/- Paid Date: 2024-11-04				
The proposed proprietary name / brand name	Semgold tablet 14mg				
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Semaglutide...14mg				
Pharmaceutical form of applied drug	Tablet				
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06				
Reference to Finished product specifications	As per Innovator's Specifications				
Proposed Pack size	As per SRO				
Proposed unit price	As per SRO				
Shelf Life	2 Years				
Storage Condition	Store Below 25°C				
The status in reference regulatory authorities	Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark				
For generic drugs (me-too status)	Rybelsus by Novo Nordisk				
Name, address of drug substance manufacturer	M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One Road, Qingyuan City, Guangdong Province, China.(rDNA origin)				
Data Already Approved on CTD	Yes				
Meeting No.	340				
Evaluation by BE&R					
<table border="1"> <thead> <tr> <th>Observations</th><th>Applicant Response</th></tr> </thead> <tbody> <tr> <td> - Status of BE studies for already registered product of contract acceptor. - Evidence of installation of LC-MS for performance of peptide mapping </td><td>Regarding the status of BE studies and installation of LC-MS for peptide mapping along with qualification documents, we would like to clarify that we are the Contract Giver for Semaglutide Tablet on</td></tr> </tbody> </table>		Observations	Applicant Response	- Status of BE studies for already registered product of contract acceptor. - Evidence of installation of LC-MS for performance of peptide mapping	Regarding the status of BE studies and installation of LC-MS for peptide mapping along with qualification documents, we would like to clarify that we are the Contract Giver for Semaglutide Tablet on
Observations	Applicant Response				
- Status of BE studies for already registered product of contract acceptor. - Evidence of installation of LC-MS for performance of peptide mapping	Regarding the status of BE studies and installation of LC-MS for peptide mapping along with qualification documents, we would like to clarify that we are the Contract Giver for Semaglutide Tablet on				

along with qualification documents (IQ/OQ/PQ). • Applicant shall submit a declaration that they will adopt the same source of drug substance, drug product formulation, specifications and container closure. • Applicant shall submit a declaration, in case of any post-registration variation by the contract manufacturer, same shall be immediately applied by the applicant/ registration holder or requisite approval by Registration Board.	basis of Approved Product by Drug Registration Board, and the question should be directed to the registration holder, M/s Weather Folds Pharmaceuticals, as we act solely as the Contract Giver. We reaffirm our commitment to following the same source of drug substance, drug product formulation, specifications, and container closure system as M/s Weather Folds Pharmaceuticals. Additionally, we would like to highlight that the Contract Application of M/s Jupiter Pharmaceuticals has already been approved of the same product from M/s Weather Folds Pharmaceuticals, and the registration letter has been issued.	
Proceeding of the Board: During the meeting the Registration Board was apprised about the following facts and figures pertinent to the drug product manufacturer: The contract acceptor “M/s Weather Folds Pharmaceuticals” has requested for grant of additional source “M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China” in addition to already approved source i.e. “M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One Road, Qingyuan City, Guangdong Province, China (rDNA origin)”. Moreover, the semaglutide tablet of “M/s Weather Folds Pharmaceuticals” was approved in 340th Meeting with following conditions: ✓ The manufacturer shall perform identification test for peptide mapping for finished product from any of Government Drug Testing Laboratory for every batch and during the aforesaid period the manufacturer shall install LC/MS in their own facility and inform Registration Board. ✓ The manufacturer shall perform Bioequivalence Studies within six months. In respect of BE status , the product manufacturer has informed as under: ✓ DRAP Vide letter No. F. No. 2412024-DD(RRR) Dated 08th July 2024 Decided as under: In the Light of S.R.O 713(L)/2015 and Requirements for WHO Listed authorities 1.E, In Particular The Maturity Level-T (ML’I) “The Procedures of Regulatory Approval Related to Registration of Generic Drugs, shall be made in line with the Guidelines of International, Regulatory Agencies, for which implementation of Bio-Equivalence study should be initiated. The board decided the Systematic Implementation of Bo-Equivalence Study in accordance with the WHO and International Guidelines Therefore, keeping in view the complexity and sensitivity of biological product the Board opined to proceed with change of source instead of additional source subject to provision of requisite documents as per deficiencies highlighted by the BE&R Division.		
Decision of 345th Meeting: <i>The Registration Board deferred the case subject to the decision on the contract acceptor request for grant of change of source from M/s Livzon New North River Pharmaceutical Co., Ltd to “M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China”.</i>		
Reply from company With reference to your above mentioned subject, we would like to submit the shortcoming reply, detail of which is given below,		

S.No	Query	Reply from company
i.	Approval of change of source from M/s Livzon New North River Pharmaceutical Co., Ltd to “M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China”.	The Change of Source Application by M/s Weather Folds Pharmaceuticals has been submitted along with all required documents, and any previously conveyed shortcomings have been addressed. We hereby confirm that we shall adopt the same new source, M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China, where M/s Weather Folds Pharmaceuticals is shifting their API procurement from the previous source, M/s Livzon New North River Pharmaceutical Co., Ltd.
ii.	Performance and submission of bioequivalence studies with new source.	M/s Weather Folds Pharmaceuticals has submitted the application for Change of Source. Upon grant of the approval, Bioequivalence (BE) studies will be conducted using a commercial batch manufactured with the API material from the newly approved source
iii.	Installation of LC/MS in their own facility along with submission of qualification document	M/s Weather Folds Pharmaceuticals have outsourced the LC/MS Facility of every batch like other manufacturers.

Decision of 347th RB meeting:

The Registration Board deferred the case as applicant has not yet applied for “change of source” from “M/s Livzon New North River Pharmaceutical Co., Ltd., China” to “M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China” for Semma 14mg Tablet .

Remarks by BE&R:

The contract acceptor has applied for change of source for their already registered products Semma 7mg and Semma 14mg and both cases are placed above in the instant meeting.

Decision:

The Registration Board approved application for contract manufacturing from M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK with new approved source (M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China) in the instant meeting with following conditions:

- **The manufacturer shall perform identification test for peptide mapping for finished product from any of Government Drug Testing Laboratory for every batch and during the aforesaid period the manufacturer shall install LC/MS in their own facility and inform Registration Board.**
- **The manufacturer shall perform Bioequivalence Studies within six months.**
- **The firm shall perform the post marketing surveillance studies.**
- **The firm shall make arrangements for the ADR reporting as per Rules.**
- **The firm shall submit the quarterly safety Reports to the Registration Board.**

Letter will be issued after submission of following documents;

- **A declaration/undertaking that they shall adopt the same source of drug substance, drug product formulation, specifications and container closure as approved for contract acceptor.**
- **Pre-registration variation fee and revised Module-1 with new approved source of**

semaglutide.

Case#15	
Name, address of Applicant / Importer	M/s Welwink Pharmaceuticals Company Address: G.T Road, Industrial Estate, Gujranwala Cantt, 70 KM G.T Road, Lahore
Status of the applicant	Contract Giver
Name, address of manufacturer(s)	M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK
GMP of manufacturer & Evidence of Section	DML No. 000644 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan Evidence of section biological tablet products (biological) section dated 25th October, 2023 GMP: Last GMP conducted on 12-10-2022 valid up to 1-10-2024
Status of application	Generic Drug Product (GDP)
Intended use of pharmaceutical product	Domestic and Export sales
Dy. No. and Date of submission	Tracking ID: 9XP-WQM-53R2 Application Number: 61885 Date of Receiving: 2025-02-18
Details of fee submitted	Challan Number: 92808290531 Division: Biological Evaluation & Registration Paid Fee: Rs 93,000/- Paid Date: 2024-11-06
The proposed proprietary name / brand name	Semink tablet 7mg
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Semaglutide...7mg
Pharmaceutical form of applied drug	Tablet
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	As per Innovator's Specifications
Proposed Pack size	As per SRO
Proposed unit price	As per SRO
Shelf Life	2 Years
Storage Condition	Store Below 25°C
The status in reference regulatory authorities	Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark
For generic drugs (me-too status)	Rybelsus by Novo Nordisk
Name, address of drug substance	M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One

manufacturer	Road, Qingyuan City, Guangdong Province, China.(rDNA origin)
Data Already Approved on CTD	Yes
Meeting No.	340

Evaluation by BE&R

Observations	Applicant Response
• Status of BE studies for already registered product of contract acceptor. • Evidence of installation of LC-MS for performance of peptide mapping along with qualification documents (IQ/OQ/PQ). • Applicant shall submit a declaration that they will adopt the same source of drug substance, drug product formulation, specifications and container closure. • Applicant shall submit a declaration, in case of any post-registration variation by the contract manufacturer, same shall be immediately applied by the applicant/ registration holder for requisite approval by Registration Board.	Regarding the status of BE studies and installation of LC-MS for peptide mapping along with qualification documents, we would like to clarify that we are the Contract Giver for Semaglutide Tablet on basis of Approved Product by Drug Registration Board, and the question should be directed to the registration holder, M/s Weather Folds Pharmaceuticals, as we act solely as the Contract Giver. We reaffirm our commitment to following the same source of drug substance, drug product formulation, specifications, and container closure system as M/s Weather Folds Pharmaceuticals. Additionally, we would like to highlight that the Contract Application of M/s Jupiter Pharmaceuticals has already been approved of the same product from M/s Weather Folds Pharmaceuticals, and the registration letter has been issued.

Proceeding of the Board:

During the meeting the Registration Board was apprised about the following facts and figures pertinent to the drug product manufacturer:

- i. **The contract acceptor “M/s Weather Folds Pharmaceuticals” has requested for grant of additional source “M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China” in addition to already approved source i.e. “M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One Road, Qingyuan City, Guangdong Province, China (rDNA origin)”.**
- ii. **Moreover, the semaglutide tablet of “M/s Weather Folds Pharmaceuticals” was approved in 340th Meeting with following conditions:**
 - ✓ **The manufacturer shall perform identification test for peptide mapping for finished product from any of Government Drug Testing Laboratory for every batch and during the aforesaid period the manufacturer shall install LC/MS in their own facility and inform Registration Board.**
 - ✓ **The manufacturer shall perform Bioequivalence Studies within six months.**
- iii. **In respect of BE status , the product manufacturer has informed as under:**
 - ✓ **DRAP Vide letter No. F. No. 2412024-DD(RRR) Dated 08th July 2024 Decided as under: In the Light of S.R.O 713(L)/2015 and Requirements for WHO Listed authorities 1.E, In Particular The Maturity Level-T (ML’I) “The Procedures of Regulatory Approval Related to Registration of Generic Drugs, shall be made in line with the Guidelines of International, Regulatory Agencies, for which implementation of Bio-Equivalence study should be initiated. The board decided the Systematic Implementation of Bo-Equivalence Study in accordance with the WHO and International Guidelines**

Therefore, keeping in view the complexity and sensitivity of biological product the Board opined to proceed with change of source instead of additional source subject to provision of requisite documents as per deficiencies highlighted by the BE&R Division.

Decision of 345th Meeting:

The Registration Board deferred the case subject to the decision on the contract acceptor request for grant of change of source from M/s Livzon New North River Pharmaceutical Co., Ltd to “M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China”.

Reply from company

With reference to your above mentioned subject, we would like to submit the shortcoming reply, detail of which is given below,

S.No	Query	Reply from company
i.	Approval of change of source from M/s Livzon New North River Pharmaceutical Co., Ltd to “M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China”.	The Change of Source Application by M/s Weather Folds Pharmaceuticals has been submitted along with all required documents, and any previously conveyed shortcomings have been addressed. We hereby confirm that we shall adopt the same new source, M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China, where M/s Weather Folds Pharmaceuticals is shifting their API procurement from the previous source, M/s Livzon New North River Pharmaceutical Co., Ltd.
ii.	Performance and submission of bioequivalence studies with new source.	M/s Weather Folds Pharmaceuticals has submitted the application for Change of Source. Upon grant of the approval, Bioequivalence (BE) studies will be conducted using a commercial batch manufactured with the API material from the newly approved source
iii.	Installation of LC/MS in their own facility along with submission of qualification document	M/s Weather Folds Pharmaceuticals have outsourced the LC/MS Facility of every batch like other manufacturers.

Decision of 347th RB meeting:

The Registration Board deferred the case as applicant has not yet applied for “change of source” from “M/s Livzon New North River Pharmaceutical Co., Ltd., China” to “M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China” for Semma Tablet 7mg.

Remarks by BE&R:

The contract acceptor has applied for change of source for their already registered products Semma 7mg and Semma 14mg and both cases are placed above in the instant meeting.

Decision:

The Registration Board approved application for contract manufacturing from M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK with new approved source (M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China) in the instant meeting with following conditions:

- **The manufacturer shall perform identification test for peptide mapping for finished product from any of Government Drug Testing Laboratory for every batch and during the aforesaid period the manufacturer shall install LC/MS in their own facility and inform Registration Board.**

- The manufacturer shall perform Bioequivalence Studies within six months.
- The firm shall perform the post marketing surveillance studies.
- The firm shall make arrangements for the ADR reporting as per Rules.
- The firm shall submit the quarterly safety Reports to the Registration Board.

Letter will be issued after submission of following documents;

- A declaration/undertaking that they shall adopt the same source of drug substance, drug product formulation, specifications and container closure as approved for contract acceptor.
- Pre-registration variation fee and revised Module-1 with new approved source of semaglutide.

Case # 16	
Name, address of Applicant / Importer	M/s Welwink Pharmaceuticals Company Address: G.T Road, Industrial Estate, Gujranwala Cantt, 70 KM G.T Road, Lahore
Status of the applicant	Contract Giver
Name, address of manufacturer(s)	M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK
GMP of manufacturer & Evidence of Section	DML No. 000644 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan Evidence of section biological tablet products (biological) section dated 25th October, 2023 GMP: Last GMP conducted on 12-10-2022 valid up to 1-10-2024
Status of application	Generic Drug Product (GDP)
Intended use of pharmaceutical product	Domestic and Export sales
Dy. No. and Date of submission	Tracking ID: UU7-9ZS-255Q Application Number: 61907 Date of Receiving: 2025-02-18
Details of fee submitted	Challan Number: 05640754285 Division: Biological Evaluation & Registration Paid Fee: Rs 93,000/- Paid Date: 2024-11-06
The proposed proprietary name / brand name	Semink tablet 14mg
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Semaglutide...14mg
Pharmaceutical form of applied drug	Tablet
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	As per Innovator's Specifications

Proposed Pack size	As per SRO
Proposed unit price	As per SRO
Shelf Life	2 Years
Storage Condition	Store Below 25°C
The status in reference regulatory authorities	Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark
For generic drugs (me-too status)	Rybelsus by Novo Nordisk
Name, address of drug substance manufacturer	M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One Road, Qingyuan City, Guangdong Province, China.(rDNA origin)
Data Already Approved on CTD	Yes
Meeting No.	340

Evaluation by BE&R

Observations	Applicant Response
• Status of BE studies for already registered product of contract acceptor. • Evidence of installation of LC-MS for performance of peptide mapping along with qualification documents (IQ/OQ/PQ). • Applicant shall submit a declaration that they will adopt the same source of drug substance, drug product formulation, specifications and container closure. • Applicant shall submit a declaration, in case of any post-registration variation by the contract manufacturer, same shall be immediately applied by the applicant/ registration holder for requisite approval by Registration Board.	Regarding the status of BE studies and installation of LC-MS for peptide mapping along with qualification documents, we would like to clarify that we are the Contract Giver for Semaglutide Tablet on basis of Approved Product by Drug Registration Board, and the question should be directed to the registration holder, M/s Weather Folds Pharmaceuticals, as we act solely as the Contract Giver. We reaffirm our commitment to following the same source of drug substance, drug product formulation, specifications, and container closure system as M/s Weather Folds Pharmaceuticals. Additionally, we would like to highlight that the Contract Application of M/s Jupiter Pharmaceuticals has already been approved of the same product from M/s Weather Folds Pharmaceuticals, and the registration letter has been issued.

Proceeding of the Board:

During the meeting the Registration Board was apprised about the following facts and figures pertinent to the drug product manufacturer:

- i. The contract acceptor “M/s Weather Folds Pharmaceuticals” has requested for grant of additional source “M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China” in addition to already approved source i.e. “M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One Road, Qingyuan City, Guangdong Province, China (rDNA origin)”.
- ii. Moreover, the semaglutide tablet of “M/s Weather Folds Pharmaceuticals” was approved in 340th Meeting with following conditions:
 - ✓ The manufacturer shall perform identification test for peptide mapping for finished product from any of Government Drug Testing Laboratory for every batch and during the aforesaid period the manufacturer shall install LC/MS in their own facility and inform Registration Board.
 - ✓ The manufacturer shall perform Bioequivalence Studies within six months.

iii. In respect of BE status , the product manufacturer has informed as under:

- ✓ DRAP Vide letter No. F. No. 2412024-DD(RRR) Dated 08th July 2024 Decided as under:
In the Light of S.R.O 713(L)/2015 and Requirements for WHO Listed authorities 1.E, In Particular The Maturity Level-T (ML'I) "The Procedures of Regulatory Approval Related to Registration of Generic Drugs, shall be made in line with the Guidelines of International, Regulatory Agencies, for which implementation of Bio-Equivalence study should be initiated. The board decided the Systematic Implementation of Bo-Equivalence Study in accordance with the WHO and International Guidelines

Therefore, keeping in view the complexity and sensitivity of biological product the Board opined to proceed with change of source instead of additional source subject to provision of requisite documents as per deficiencies highlighted by the BE&R Division.

Decision of 345th Meeting:

The Registration Board deferred the case subject to the decision on the contract acceptor request for grant of change of source from M/s Livzon New North River Pharmaceutical Co., Ltd to "M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China".

Reply from company

With reference to your above mentioned subject, we would like to submit the shortcoming reply, detail of which is given below,

S.No	Query	Reply from company
i.	Approval of change of source from M/s Livzon New North River Pharmaceutical Co., Ltd to "M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China".	The Change of Source Application by M/s Weather Folds Pharmaceuticals has been submitted along with all required documents, and any previously conveyed shortcomings have been addressed. We hereby confirm that we shall adopt the same new source, M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China, where M/s Weather Folds Pharmaceuticals is shifting their API procurement from the previous source, M/s Livzon New North River Pharmaceutical Co., Ltd.
ii.	Performance and submission of bioequivalence studies with new source.	M/s Weather Folds Pharmaceuticals has submitted the application for Change of Source. Upon grant of the approval, Bioequivalence (BE) studies will be conducted using a commercial batch manufactured with the API material from the newly approved source
iii.	Installation of LC/MS in their own facility along with submission of qualification document	M/s Weather Folds Pharmaceuticals have outsourced the LC/MS Facility of every batch like other manufacturers.

Decision of 347th RB meeting:

The Registration Board deferred the case as manufacturer has not yet applied for "change of source" from "M/s Livzon New North River Pharmaceutical Co., Ltd., China" to "M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China" for Semma tablet 14mg.

Remarks by BE&R:

The contract acceptor has applied for change of source for their already registered products Semma 7mg and Semma 14mg and both cases are placed above in the instant meeting.

Decision:

The Registration Board approved application for contract manufacturing from M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK with new approved source (M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China) in the instant meeting with following conditions:

- The manufacturer shall perform identification test for peptide mapping for finished product from any of Government Drug Testing Laboratory for every batch and during the aforesaid period the manufacturer shall install LC/MS in their own facility and inform Registration Board.
- The manufacturer shall perform Bioequivalence Studies within six months.
- The firm shall perform the post marketing surveillance studies.
- The firm shall make arrangements for the ADR reporting as per Rules.
- The firm shall submit the quarterly safety Reports to the Registration Board.

Letter will be issued after submission of following documents;

- A declaration/undertaking that they shall adopt the same source of drug substance, drug product formulation, specifications and container closure as approved for contract acceptor.
- Pre-registration variation fee and revised Module-1 with new approved source of semaglutide.

Case#17	
Name, address of Applicant / Importer	M/s Wezen Pharmaceuticals Company Address:Plot No. 23 & 24, S-1, RCCI, Industrial Estate, Rawat
Status of the applicant	Contract Giver
Name, address of manufacturer(s)	M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK
GMP of manufacturer & Evidence of Section	DML No. 000644 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan Evidence of section biological tablet products (biological) section dated 25th October, 2023 GMP: Last GMP conducted on 12-10-2022 valid up to 1-10-2024
Status of application	Generic Drug Product (GDP)
Intended use of pharmaceutical product	Domestic and Export sales
Dy. No. and Date of submission	Tracking ID: BS8-TMJ-9VWN Application Number: 61497 Date of Receiving: 2025-02-18
Details of fee submitted	Challan Number: 3033993601 Division: Biological Evaluation & Registration Paid Fee: Rs 93,000/- Paid Date: 2024-11-05
The proposed proprietary name / brand name	Semozen tablet 7mg

Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Semaglutide...7mg
Pharmaceutical form of applied drug	Tablet
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	As per Innovator's Specifications
Proposed Pack size	As per SRO
Proposed unit price	As per SRO
Shelf Life	2 Years
Storage Condition	Store Below 25°C
The status in reference regulatory authorities	Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark
For generic drugs (me-too status)	Rybelsus by Novo Nordisk
Name, address of drug substance manufacturer	M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One Road, Qingyuan City, Guangdong Province, China.(rDNA origin)
Data Already Approved on CTD	Yes
Meeting No.	340

Evaluation by BE&R

Observations	Applicant Response
• Status of BE studies for already registered product of contract acceptor. • Evidence of installation of LC-MS for performance of peptide mapping along with qualification documents (IQ/OQ/PQ). • Applicant shall submit a declaration that they will adopt the same source of drug substance, drug product formulation, specifications and container closure. • Applicant shall submit a declaration, in case of any post-registration variation by the contract manufacturer, same shall be immediately applied by the applicant/ registration holder for requisite approval by Registration Board.	Regarding the status of BE studies and installation of LC-MS for peptide mapping along with qualification documents, we would like to clarify that we are the Contract Giver for Semaglutide Tablet on basis of Approved Product by Drug Registration Board, and the question should be directed to the registration holder, M/s Weather Folds Pharmaceuticals, as we act solely as the Contract Giver. We reaffirm our commitment to following the same source of drug substance, drug product formulation, specifications, and container closure system as M/s Weather Folds Pharmaceuticals. Additionally, we would like to highlight that the Contract Application of M/s Jupiter Pharmaceuticals has already been approved of the same product from M/s Weather Folds Pharmaceuticals, and the registration letter has been issued.

Proceeding of the Board:

During the meeting the Registration Board was apprised about the following facts and figures pertinent to the drug product manufacturer:

- i. The contract acceptor "M/s Weather Folds Pharmaceuticals" has requested for grant of

- additional source “M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China” in addition to already approved source i.e. “M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One Road, Qingyuan City, Guangdong Province, China (rDNA origin)”.
- ii. Moreover, the semaglutide tablet of “M/s Weather Folds Pharmaceuticals” was approved in 340th Meeting with following conditions:
- ✓ The manufacturer shall perform identification test for peptide mapping for finished product from any of Government Drug Testing Laboratory for every batch and during the aforesaid period the manufacturer shall install LC/MS in their own facility and inform Registration Board.
 - ✓ The manufacturer shall perform Bioequivalence Studies within six months.
- iii. In respect of BE status , the product manufacturer has informed as under:
- ✓ DRAP Vide letter No. F. No. 2412024-DD(RRR) Dated 08th July 2024 Decided as under: In the Light of S.R.O 713(L)/2015 and Requirements for WHO Listed authorities 1.E, In Particular The Maturity Level-T (ML’I) “The Procedures of Regulatory Approval Related to Registration of Generic Drugs, shall be made in line with the Guidelines of International, Regulatory Agencies, for which implementation of Bio-Equivalence study should be initiated. The board decided the Systematic Implementation of Bo-Equivalence Study in accordance with the WHO and International Guidelines

Therefore, keeping in view the complexity and sensitivity of biological product the Board opined to proceed with change of source instead of additional source subject to provision of requisite documents as per deficiencies highlighted by the BE&R Division.

Decision of 345th Meeting:

The Registration Board deferred the case subject to the decision on the contract acceptor request for grant of change of source from M/s Livzon New North River Pharmaceutical Co., Ltd to “M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China”.

Reply from company

With reference to your above mentioned subject, we would like to submit the shortcoming reply, detail of which is given below,

S.No	Query	Reply from company
i.	Approval of change of source from M/s Livzon New North River Pharmaceutical Co., Ltd to “M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China”.	The Change of Source Application by M/s Weather Folds Pharmaceuticals has been submitted along with all required documents, and any previously conveyed shortcomings have been addressed. We hereby confirm that we shall adopt the same new source, M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China, where M/s Weather Folds Pharmaceuticals is shifting their API procurement from the previous source, M/s Livzon New North River Pharmaceutical Co., Ltd.
ii.	Performance and submission of bioequivalence studies with new source.	M/s Weather Folds Pharmaceuticals has submitted the application for Change of Source. Upon grant of the approval, Bioequivalence (BE) studies will be conducted using a commercial batch manufactured with the API material from the newly approved source
iii.	Installation of LC/MS in their own facility along with submission of qualification document	M/s Weather Folds Pharmaceuticals have outsourced the LC/MS Facility of every batch like other manufacturers.

Decision:

The Registration Board deferred the case as manufacturer has not yet applied for “change of source” from “M/s Livzon New North River Pharmaceutical Co., Ltd., China” to “M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China” for Semma Tablet 7mg.

Remarks by BE&R:

The contract acceptor has applied for change of source for their already registered products Semma 7mg and Semma 14mg and both cases are placed above in the instant meeting.

Decision:

The Registration Board approved application for contract manufacturing from M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK with new approved source (M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China) in the instant meeting with following conditions:

- **The manufacturer shall perform identification test for peptide mapping for finished product from any of Government Drug Testing Laboratory for every batch and during the aforesaid period the manufacturer shall install LC/MS in their own facility and inform Registration Board.**
- **The manufacturer shall perform Bioequivalence Studies within six months.**
- **The firm shall perform the post marketing surveillance studies.**
- **The firm shall make arrangements for the ADR reporting as per Rules.**
- **The firm shall submit the quarterly safety Reports to the Registration Board.**

Letter will be issued after submission of following documents;

- **A declaration/undertaking that they shall adopt the same source of drug substance, drug product formulation, specifications and container closure as approved for contract acceptor.**
- **Pre-registration variation fee and revised Module-1 with new approved source of semaglutide.**

Case # 18	
Name, address of Applicant / Importer	M/s Wezen Pharmaceuticals Company Address, Plot No. 23 & 24, S-1, RCCI, Industrial Estate, Rawat
Status of the applicant	Contract Giver
Name, address of manufacturer(s)	M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK
GMP of manufacturer & Evidence of Section	DML No. 000644 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan Evidence of section biological tablet products (biological) section dated 25th October, 2023 GMP: Last GMP conducted on 12-10-2022 valid up to 1-10-2024
Status of application	Generic Drug Product (GDP)
Intended use of pharmaceutical product	Domestic and Export sales
Dy. No. and Date of submission	Tracking ID: NDW-AYD-H4ZQ Application Number: 61499 Date of Receiving: 2025-02-18
Details of fee submitted	Challan Number: 9424705537 Division: Biological Evaluation & Registration Paid Fee: Rs 93,000/- Paid Date: 2024-11-05
The proposed proprietary name / brand name	Semozen tablet 14mg
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Semaglutide...14mg
Pharmaceutical form of applied drug	Tablet
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	As per Innovator's Specifications
Proposed Pack size	As per SRO
Proposed unit price	As per SRO
Shelf Life	2 Years
Storage Condition	Store Below 25°C
The status in reference regulatory authorities	Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark
For generic drugs (me-too status)	Rybelsus by Novo Nordisk
Name, address of drug substance manufacturer	M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One Road, Qingyuan City, Guangdong Province, China.(rDNA origin)
Data Already Approved on CTD	Yes
Meeting No.	340
<i>Evaluation by BE&R</i>	

Observations	Applicant Response
• Status of BE studies for already registered product of contract acceptor. • Evidence of installation of LC-MS for performance of peptide mapping along with qualification documents (IQ/OQ/PQ). • Applicant shall submit a declaration that they will adopt the same source of drug substance, drug product formulation, specifications and container closure. • Applicant shall submit a declaration, in case of any post-registration variation by the contract manufacturer, same shall be immediately applied by the applicant/ registration holder for requisite approval by Registration Board.	Regarding the status of BE studies and installation of LC-MS for peptide mapping along with qualification documents, we would like to clarify that we are the Contract Giver for Semaglutide Tablet on basis of Approved Product by Drug Registration Board, and the question should be directed to the registration holder, M/s Weather Folds Pharmaceuticals, as we act solely as the Contract Giver. We reaffirm our commitment to following the same source of drug substance, drug product formulation, specifications, and container closure system as M/s Weather Folds Pharmaceuticals. Additionally, we would like to highlight that the Contract Application of M/s Jupiter Pharmaceuticals has already been approved of the same product from M/s Weather Folds Pharmaceuticals, and the registration letter has been issued.
Proceeding of the Board: During the meeting the Registration Board was apprised about the following facts and figures pertinent to the drug product manufacturer: - The contract acceptor “M/s Weather Folds Pharmaceuticals” has requested for grant of additional source “M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China” in addition to already approved source i.e. “M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One Road, Qingyuan City, Guangdong Province, China (rDNA origin)”. - Moreover, the semaglutide tablet of “M/s Weather Folds Pharmaceuticals” was approved in 340th Meeting with following conditions: ✓ The manufacturer shall perform identification test for peptide mapping for finished product from any of Government Drug Testing Laboratory for every batch and during the aforesaid period the manufacturer shall install LC/MS in their own facility and inform Registration Board. ✓ The manufacturer shall perform Bioequivalence Studies within six months. - In respect of BE status , the product manufacturer has informed as under: ✓ DRAP Vide letter No. F. No. 2412024-DD(RRR) Dated 08th July 2024 Decided as under: In the Light of S.R.O 713(L)/2015 and Requirements for WHO Listed authorities 1.E, In Particular The Maturity Level-T (ML’I) “The Procedures of Regulatory Approval Related to Registration of Generic Drugs, shall be made in line with the Guidelines of International, Regulatory Agencies, for which implementation of Bio-Equivalence study should be initiated. The board decided the Systematic Implementation of Bo-Equivalence Study in accordance with the WHO and International Guidelines Therefore, keeping in view the complexity and sensitivity of biological product the Board opined to proceed with change of source instead of additional source subject to provision of requisite documents as per deficiencies highlighted by the BE&R Division.	
Decision of 345th Meeting: <i>The Registration Board deferred the case subject to the decision on the contract acceptor request for grant of change of source from M/s Livzon New North River Pharmaceutical Co., Ltd to “M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China”.</i>	

Reply from company

With reference to your above mentioned subject, we would like to submit the shortcoming reply, detail of which is given below,

S.No	Query	Reply from company
i.	Approval of change of source from M/s Livzon New North River Pharmaceutical Co., Ltd to “M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China”.	The Change of Source Application by M/s Weather Folds Pharmaceuticals has been submitted along with all required documents, and any previously conveyed shortcomings have been addressed. We hereby confirm that we shall adopt the same new source, M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China, where M/s Weather Folds Pharmaceuticals is shifting their API procurement from the previous source, M/s Livzon New North River Pharmaceutical Co., Ltd.
ii.	Performance and submission of bioequivalence studies with new source.	M/s Weather Folds Pharmaceuticals has submitted the application for Change of Source. Upon grant of the approval, Bioequivalence (BE) studies will be conducted using a commercial batch manufactured with the API material from the newly approved source
iii.	Installation of LC/MS in their own facility along with submission of qualification document	M/s Weather Folds Pharmaceuticals have outsourced the LC/MS Facility of every batch like other manufacturers.

Decision of 347th RB meeting:

The Registration Board deferred the case as manufacturer has not yet applied for “change of source” from “M/s Livzon New North River Pharmaceutical Co., Ltd., China” to “M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China” for Semma Tablet 14mg.

Remarks by BE&R:

The contract acceptor has applied for change of source for their already registered products Semma 7mg and Semma 14mg and both cases are placed above in the instant meeting.

Decision:

The Registration Board approved application for contract manufacturing from M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK with new approved source (M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China) in the instant meeting with following conditions:

- **The manufacturer shall perform identification test for peptide mapping for finished product from any of Government Drug Testing Laboratory for every batch and during the aforesaid period the manufacturer shall install LC/MS in their own facility and inform Registration Board.**
- **The manufacturer shall perform Bioequivalence Studies within six months.**
- **The firm shall perform the post marketing surveillance studies.**
- **The firm shall make arrangements for the ADR reporting as per Rules.**
- **The firm shall submit the quarterly safety Reports to the Registration Board.**

Letter will be issued after submission of following documents;

- A declaration/undertaking that they shall adopt the same source of drug substance, drug product formulation, specifications and container closure as approved for contract acceptor.
- Pre-registration variation fee and revised Module-1 with new approved source of semaglutide.

Agenda Item No. 04. Registration Applications of Imported Semaglutide Products

Case # 01			
Name, address of Applicant / Importer	Name: M/s CCL Pharmaceuticals Company Address: 5-Km Sheikhpura Road Tehsil Muridke District Sheikhpura		
Details of Drug Sale License of importer	License Type: Drug Sale License License Number: 05-354-0077-109178D License Issue Date: 2021-03-20 Validity: 12-10-2028		
Name and address of marketing authorization holder (abroad)	M/s Geropharm LLC 9 ul., Zvenigorodskaya, Saint Petersburg, 191119, Russia.		
Name, address of manufacturer(s)	Manufacturing stage (all participants of manufacturing process)	Name of organisation	Manufacturing site address
	Manufacture of finished dosage form	Limited Liability Company "GEROPHARM" (OOO "GEROPHARM"), Russian Federation	Bldg. 5, Kvartal A area, Obolensk settlement, Serpukhov city district, Moscow region
	Primary packaging	Limited Liability Company "GEROPHARM" (OOO "GEROPHARM"), Russian Federation	Bldg. 5, Kvartal A area, Obolensk settlement, Serpukhov city district, Moscow region
	Secondary packaging	Limited Liability Company "GEROPHARM" (OOO "GEROPHARM"), Russian Federation	Bldg. 5, Kvartal A area, Obolensk settlement, Serpukhov city district, Moscow region Unit 1, bldg. 5, Kvartal A area, Obolensk settlement, Serpukhov city district, Moscow region
	Release quality control	Limited Liability Company "GEROPHARM" (OOO "GEROPHARM"), Russian Federation	Unit 82, bldg. 4, Kvartal A area, Obolensk settlement, Serpukhov city district, Moscow region
Name of exporting country	Russia		
Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	Scanned Translated COPP Certificate No.: 08/2024/0007812 Certifying Authority: Ministry of Industry and Trade of Russian Federation 10, Building 2, Moscow Free sale Status: Yes GMP :Yes Validity:18-03-2027		
Details of letter of authorization / sole agency agreement	Scanned Letter of Authorization Dated 16-01-2025 Agreement is between M/s Geropharm LLC 9 ul., Zvenigorodskaya, Saint Petersburg, 191119, Russia and CCL Pharmaceuticals DSL address. Validity:16-01-2025		

	Status of the applicant	Importer
	Status of application	Biosimilar
	Intended use of pharmaceutical product	Domestic sale
	For imported products, specify one the these	Finished Pharmaceutical product import
	Dy. No. and date of submission	Tracking ID:EB9-3T3-J22A Application Number:83672 Receiving:07-04-2025
	Fee Details	Challan Number: 4161858091 Division: Biological Evaluation & Registration Paid Fee: 300000.0 Paid Date: 2025-02-10
	The proposed proprietary name / brand name	Semavic Injection
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	One pre-filled pen contains: 4 mg semaglutide* in 3 ml solution. Each dose contains 0.5 mg of semaglutide in 0.37 ml solution.
	Indication	Ozempic is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise • as monotherapy when metformin is considered inappropriate due to intolerance or contraindications in addition to other medicinal products for the treatment of diabetes.
	Psology	The starting dose is 0.25 mg semaglutide once weekly. After 4 weeks the dose should be increased to 0.5 mg once weekly. After at least 4 weeks with a dose of 0.5 mg once weekly, the dose can be increased to 1 mg once weekly to further improve glycaemic control. After at least 4 weeks with a dose of 1 mg once weekly, the dose can be increased to 2 mg once weekly to further improve glycaemic control. Semaglutide 0.25 mg is not a maintenance dose. Weekly doses higher than 2 mg are not recommended.
	Dosage form of applied drug	Solution for Injection
	Pharmacotherapeutic Group of (API)	Pharmacotherapeutic group: Drugs used in diabetes, glucagon-like peptide-1 (GLP-1) analogues, ATC code: A10BJ06
	Finished product specifications	As per Innovators Specifications.
	Proposed Pack size	3ml pen with 4 needles.
	Proposed unit price	As per SRO228
	Shelf life	2 years
	Storage conditions	2-8°C
	The status in reference regulatory authorities	OZEMPIC (semaglutide) solution for injection 4 mg/3 ml (USFDA APPROVED) Novo Nordisk A/S Novo Allé DK-2880 Bagsværd Denmark

For generic drugs (me-too status)	Product name: Sem P Company name: Getz Pharma (Pvt.) Limited Distributor Registration no:126126										
Module-II (Quality Overall Summary)	QOS submitted as per ICH.										
Module 3 : Drug Substance Part (Synthetic Source)											
Name, address of drug substance manufacturer	Name: Zhejiang Peptides Biotech Co., Ltd. Address: No.8, Hengyizhi Road, Sanjie Town, Shengzhou City, Shaoxing City, Zhejiang Province, China										
Characterization	<table border="1"> <thead> <tr> <th>Information on medicinal product</th><th>Elucidation procedures</th></tr> </thead> <tbody> <tr> <td>Name: semaglutide Origin: in-house Batch number: G06210801, G06210901, G06210902 Initial composition: KP52701 Origin: Novo Nordisk</td><td>IR-spectrometry UV spectrometry N-terminal peptide sequence analysis Peptide molecular weight analysis by high resolution methods Elemental analysis Amino acids analysis Peptide amino acid D/L-configuration analysis Peptide sequence analysis by mass-spectrometry (Q-ToF) Peptide mapping by UHPLC X-ray diffraction analysis Circular dichroism spectrum analysis Peptide whole-column analysis including capillary isoelectric focusing (cIEF) with photofixation Thermal analysis</td></tr> </tbody> </table> Elucidation of chemical structure was performed on a representative sample of semaglutide using the following test samples:	Information on medicinal product	Elucidation procedures	Name: semaglutide Origin: in-house Batch number: G06210801, G06210901, G06210902 Initial composition: KP52701 Origin: Novo Nordisk	IR-spectrometry UV spectrometry N-terminal peptide sequence analysis Peptide molecular weight analysis by high resolution methods Elemental analysis Amino acids analysis Peptide amino acid D/L-configuration analysis Peptide sequence analysis by mass-spectrometry (Q-ToF) Peptide mapping by UHPLC X-ray diffraction analysis Circular dichroism spectrum analysis Peptide whole-column analysis including capillary isoelectric focusing (cIEF) with photofixation Thermal analysis						
Information on medicinal product	Elucidation procedures										
Name: semaglutide Origin: in-house Batch number: G06210801, G06210901, G06210902 Initial composition: KP52701 Origin: Novo Nordisk	IR-spectrometry UV spectrometry N-terminal peptide sequence analysis Peptide molecular weight analysis by high resolution methods Elemental analysis Amino acids analysis Peptide amino acid D/L-configuration analysis Peptide sequence analysis by mass-spectrometry (Q-ToF) Peptide mapping by UHPLC X-ray diffraction analysis Circular dichroism spectrum analysis Peptide whole-column analysis including capillary isoelectric focusing (cIEF) with photofixation Thermal analysis										
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Accelerated study data is available for 6 months, long term study data is available for 36 months. Results from stability studies are well within the acceptance criteria with no significant variation and trend observed. Therefore, Semaglutide is proposed to be stored in an airtight container, protected from light, at a temperature 2o C-8 o C (as per description in 3.2.S.6). The retest date of Semaglutide is established up to 24 months based on existing 36 months stability data.										
Module-III Drug Product: Semaglutide Injection											
Drug Product Manufacturer	<table border="1"> <thead> <tr> <th>Manufacturing stage</th><th>Business address</th></tr> </thead> <tbody> <tr> <td>Manufacture of the finished dosage form</td><td>Bldg. 5, "Kvartal A" area, Obolensk work settlement, Serpukhov city district, Moscow region</td></tr> <tr> <td>Primary packaging</td><td>Bldg. 5, "Kvartal A" area, Obolensk work settlement, Serpukhov city district, Moscow region</td></tr> <tr> <td>Outer/consumer packaging</td><td>Unit 5, bldg. 1, "Kvartal A" area, Obolensk work settlement, Serpukhov city district, Moscow region</td></tr> <tr> <td>Release quality control</td><td>Unit 82, bldg. 4, "Kvartal A" area, Obolensk work settlement, Serpukhov city district, Moscow region</td></tr> </tbody> </table>	Manufacturing stage	Business address	Manufacture of the finished dosage form	Bldg. 5, "Kvartal A" area, Obolensk work settlement, Serpukhov city district, Moscow region	Primary packaging	Bldg. 5, "Kvartal A" area, Obolensk work settlement, Serpukhov city district, Moscow region	Outer/consumer packaging	Unit 5, bldg. 1, "Kvartal A" area, Obolensk work settlement, Serpukhov city district, Moscow region	Release quality control	Unit 82, bldg. 4, "Kvartal A" area, Obolensk work settlement, Serpukhov city district, Moscow region
Manufacturing stage	Business address										
Manufacture of the finished dosage form	Bldg. 5, "Kvartal A" area, Obolensk work settlement, Serpukhov city district, Moscow region										
Primary packaging	Bldg. 5, "Kvartal A" area, Obolensk work settlement, Serpukhov city district, Moscow region										
Outer/consumer packaging	Unit 5, bldg. 1, "Kvartal A" area, Obolensk work settlement, Serpukhov city district, Moscow region										
Release quality control	Unit 82, bldg. 4, "Kvartal A" area, Obolensk work settlement, Serpukhov city district, Moscow region										
Description	Semavic, solution for subcutaneous injection, 0.25/0.5/1 mg/dose, is a generic of the reference product Ozempic®, solution for subcutaneous injection, 0.25/0.5/1 mg/dose (manufactured by "Novo Nordisk A/S", Denmark)										
Analytical method validation/verification of product	The analytical methods for the assay/related substances, phenol, high molecular weight protein, specific activity, bacterial endotoxin and sterility of Semaglutide Injection were validated/verified with reference.										
Container closure system of the drug product	3 mL in colourless neutral glass cartridges (hydrolytic grade 1) equipped with rubber plungers and sealed with flip-off caps with rubber discs. Each cartridge is installed in a plastic multi-dose disposable pen injector for multiple injections. A label made of polypropylene film is applied to each pen injector. 1 pre-filled multi-dose disposable pen injector for multiple injections and 1 cardboard pack containing 4 or 6										

		disposable needles with a package leaflet including a user's manual for a pen injector and an insert card explaining how to control the product injection are placed in a cardboard package.
	Stability study data of drug product	Injection, 0.25/0.5/1 mg/dose, batches 010623, 020623, 030623, are beyond the standards of the specification when stored for the accelerated stability study at a temperature of (25 ± 2) °C and relative air humidity of (60 ± 5) % during the studied period (6 months). There were deviations in the critical quality parameters ("High molecular weight proteins", "Related substances: Hydrophilic impurities: Any individual impurity", "Related substances: Hydrophobic impurities 1: Any individual impurity", "Related substances: Hydrophobic impurity 2", "Related substances: Total impurities", "Assay: Semaglutide"). The quality parameters of Semavic, solution for subcutaneous injection, 0.25/0.5/1 mg/dose, batches 010623, 020623, 030623, when stored for the long-term stability study at a temperature of (5 ± 3) °C during the studied period (12 months) meet the requirements of the draft RD for Semavic, solution for subcutaneous injection, 0.25/0.5/1 mg/dose, and the acceptance criteria provided in section 3.2.P.5.1 Specification. No adverse trends have been found. The stability studies are ongoing. Submit stability of drug product of commercial batches. In-use stability not submitted by the applicant.
	Module 4 Non Clinical Studies	-
	Module 5 Clinical Studies	-
	Remarks of Evaluator The route of administration mentions oral. Clarification is required. Both drug substance and drug product specification does not include test of peptide mapping and specific activity. Clarification is required. In-use stability studies of drug product not performed by the applicant. Submit stability of drug product of commercial batches till claimed shelf life. Submit sameness studies i.e. synthetic peptide is same to that of rDNA source. Applicant Reponse ii. Both drug substance and drug product specification does not include test of peptide mapping and specific activity. Clarification is required. Answer: The active pharmaceutical ingredient (API) Semaglutide manufactured by Zhejiang Peptides Biotech Co., Ltd. is a substance obtained by chemical synthesis in accordance with the Fmoc strategy of solid-phase peptide synthesis, with a certain amino acid sequence. The API manufacturers have proven that the resulting API has a known and definitely defined structure. All detailed information on the API, including data on the study and confirmation of the structure and properties of the active pharmaceutical ingredient Semaglutide is presented in part 3.2.S. of the registration dossier (sections 3.2.S.1, 3.2.S.3). From the API Semaglutide manufactured by Zhejiang Peptides Biotech Co., Ltd., OOO "GEROPHARM" produced the medicinal product Semavic®, solution for subcutaneous injection, 0.25/0.5/1 mg/dose - a synthetic drug that is an analogue of the original biological drug Ozempic®. Thus, Semavic, solution for subcutaneous injection, 0.25/0.5/1 mg/dose (OOO "GEROPHARM", Russia), is a generic medicinal product for human use similar to original product Ozempic®, solution for subcutaneous injection, 1.34 mg/mL ("Novo Nordisk A/S", Denmark). To date, in accordance with international regulatory requirements for synthetic peptides, OOO "GEROPHARM" has conducted a complete list of comparability studies of medicinal products containing semaglutide as an active pharmaceutical ingredient: Semavic®, OOO "GEROPHARM", Russia, and Ozempic®, "Novo Nordisk A/S", Denmark.	

The bioequivalence of Semavic®, solution for subcutaneous injection, 0.25/0.5/1 mg/dose, to Ozempic®, solution for subcutaneous injection, 1.34 mg/mL (“Novo Nordisk A/S”, Denmark), has been proven at the following levels:

1. Physical and chemical properties of the developed medicinal product were studied comparatively using orthogonal methods (see section 3.2.P.2 Pharmaceutical development).
2. A comparative assessment of biological activity of the developed medicinal product was carried out in vitro using orthogonal methods (see section 3.2.P.2 Pharmaceutical development).
3. Comparative clinical studies of pharmacokinetics/bioequivalence (Clinical Study Authorisation No. 333 dd 27/06/2023) and efficacy/safety/immunogenicity were performed.

In accordance with the regulatory requirements for the conduction of analytical comparability studies, each quality parameter, such as primary structure, higher-order structures, impurities, biological activity, etc., was tested using several complementary orthogonal methods (EMA/CHMP/BWP/247713/2012, 2012). All the methods were verified, validated, and shown to be adequate for the purpose of the analysis.

The assessment of analytical comparability included the analysis of the primary, secondary, and higher-order structures, and the impurity profile. The focus was also on the assessment of the biological activity based on the intracellular signalling mechanism mediated by GLP-1R.

The studies demonstrated a high degree of analytical comparability for Semavic® and Ozempic®. The only difference found was the minor difference in the assay of related substances (lower content of hydrophilic and hydrophobic impurities relative to the acceptable range), which is evidence of a higher purity of Semavic®. Thus, at the analytical level, Semavic® and Ozempic® can be considered comparable. This means that the medicinal products Semavic® and Ozempic®, among other things, have a comparable primary structure and comparable biological activity. Thus, taking into account all of the above, and also that: a) the API Semaglutide is a synthetic substance obtained by chemical synthesis and has a strictly specified structure; b) the API is a small peptide (contains 31 amino acids) with a known and defined amino acid sequence; c) the API production method is controlled chemical synthesis; d) microorganisms that can be sources of variability in the properties of the API are not involved in the production of the API, and therefore the structure, composition and properties of the API are completely stable and unchangeable; c) impurities contained in the API are well studied, and the absence of their effect on the medicinal product has been proven at the level of comparability studies and clinical trials; it can be concluded that, once the manufacturing process is fully validated and established, the peptide mapping results for Semaglutide API remain consistent and do not change unless there is a modification to the process. To confirm this consistency, peptide mapping analysis was performed on process validation batch during the initial validation phase. In routine release testing of the API, peptide mapping is not conducted for every batch. Instead, other identification tests—such as molecular weight determination are performed on every batch to ensure correct identification. The same situation for biological activity, this item is tested for at least 1 batch per year. Therefore, Peptide mapping and biological activity are not included in the specification of Semaglutide API. Taking into account all of the above, as well as the fact that the manufacturing process of the finished dosage form is also tested and stable, and the active pharmaceutical substance is not subject to changes during the manufacturing of the finished dosage form, these indicators “peptide mapping” and “biological activity” are also not included in the routine control (in the specification) of the finished dosage form. iii. In-use stability studies of drug product not performed by the applicant. Answer: The company OOO “GEROPHARM” has conducted an in-use stability study of the medicinal product Semavic® (during use, after opening the primary package) in the conditions of climate zone IVb. Namely, during storage at a temperature of (30±2)°C and humidity of (75±5)% RH for 6 weeks, as well as during storage in a refrigerator at a temperature of (5±3)°C for 6 weeks from the moment of first opening. A report on this study is provided in the Appendix 1 to this letter.

- iv. Submit stability of drug product of commercial batches till claimed shelf life. Answer: All data on the stability of the medicinal product was presented in the registration dossier in section 3.2.P.8.3. The stability study program includes both pilot and commercial batches. According to the study program, full data on the declared shelf life will be available for pilot batches in July 2025. To date, the results before the expiration date of commercial

batches cannot be available due to the production date of these batches - May and July 2024, so at the moment, data for commercial batches are available only for a period of 6 and 9 months. We are attaching this data in Appendix 2 and 3 to this letter. Also, as part of the response to this request, GEROPHARM LLC undertakes to provide full data confirming the shelf life immediately after receiving them. - Submit sameness studies, i.e. synthetic peptide is same to that of rDNA source on attached format Answer: The comparability report “Analytical Comparability Study of Generic Medicinal Product GP40221 (Semaglutide), manufactured by OOO “GEROPHARM”, Russia, and Originator Ozempic®, manufactured by Novo Nordisk, Denmark“ has been submitted in registration dossier (and also is provided in Appendix 4 to this letter). Please see below the fulfilled table with the information regarding the Scientific considerations for ANDAs for proposed synthetic peptides in relation to medicinal product Semavic®.		
Recommendation by BE&R Not recommended till the submission of above cited documents.		
Decision of 347th meeting of RB: <i>The Registration Board deferred the case for the submission of the following documents:</i> • <i>Requisite fee for correction of typographical error.</i> • <i>Inclusion of test of peptide mapping and specific activity in drug substance and drug product specifications.</i> • <i>Performance of test of peptide mapping and specific activity for each batch and submission of evidence.</i> • <i>Stability data of drug product till claimed shelf life.</i>		
Evaluation by BE&R: The firm has submitted a reply as under;		
Shortcomings communicated	Response of the firm	Remarks
Requisite fee for correction of typographical error.	We have submitted the required pre-registration variation fee of 9000/-. dated 05th May 2025. Challan no. 7468819849. Copy of paid challan attached.	Attached
Inclusion of test of peptide mapping and specific activity in drug substance and drug product specifications	Attached as Annex Further, we would like to mention that the same manufacturer of Drug Substance i.e., Zhejiang Peptides Biotech Co Ltd, had already been approved for the same product of M/s BF Biosciences Ltd., Lahore, in 336th meeting of Registration Board.	Not provided
Performance of test of peptide mapping and specific activity for each batch and submission of evidence		
Stability data of drug product till claimed shelf life	We have submitted stability data up to 18 months to date, and the 24-month data is scheduled for submission by July 11, 2025. As the registration letter will only be issued after the inspection of the manufacturer, by which time the 24-month stability data will be available. You are kindly requested either for approval of a shelf life of 18 months or conditional approval of the product for pending submission of the 24-month data by the end of July 2025. We shall be much grateful.	Not provided Stability data of 24 months provided on 30, June 2025.
Concluding remarks by BE&R: The case is still deficient for following; • Inclusion of test of peptide mapping and specific activity in drug substance and drug product specifications. • Stability data of drug product till claimed shelf life.		

Decision of 349th Meeting:

The Registration Board deferred the case for the submission of revised specifications and certificate of analysis including test of identification by peptide mapping (LC-MS) and specific activity in drug substance and drug product specifications.

Case # 02

Name, address of Applicant / Importer	ROSACEAE PHARMA (PRIVATE) LIMITED Company Address: ALTIMI House, Plot No. 21-C, Suite # 301, Khalid Commercial Street # 4, Phase 7 (Ext), D.H.A., Karachi-755350
Details of Drug Sale License of importer	ROSACEAE PHARMA (PRIVATE) LIMITED Company Address: ALTIMI House, Plot No. 21-C, Suite # 301, Khalid Commercial Street # 4, Phase 7 (Ext), D.H.A., Karachi-755350 Site Address: Company City: Karachi License Type: Drug Sale License License Number: 0377 License Issue Date: 2024-11-05
Name and address of marketing authorization holder (abroad)	Name: Loas Alliance Pharmaceutical Group Co. Ltd. Address: Nano Village, Saysettha Development Zone, Saysettha District, Vientiane Capital, Lao PD
Name, address of manufacturer(s)	Name: Loas Alliance Pharmaceutical Group Co. Ltd. Address: Nano Village, Saysettha Development Zone, Saysettha District, Vientiane Capital, Lao PD
Name of exporting country	Lao PDR
Detail of certificates attached (copp, Free sale certificate, GMP certificate)	Not Submitted
Details of letter of authorization / sole agency agreement	We, Lao Alliance Pharmaceutical Group Co., Ltd (Address: NANO VILLAGE SAYSETTHA DISTRICT VTE LAO PDR) declare that we authorize Rosaceae Pharma Private Limited Address: ALTIMI House Plot No. 21-C, Suit # 301, Khalid Commercial Street #4, Phase 7 (Ext), D.H.A. Karachi-755350.) As our cooperated partner exclusively to distribute and register our products with Drug regulatory Authority Ministry of Health-Pakistan. (1) L'OSEM-3 (Semaglutide 3mg) to Pakistan. <u>Scanned Letter of Authorization</u>
Status of the applicant	Importer
Status of application	Biosimilar
Intended use of pharmaceutical product	Domestic sale
For imported products, specify one the these	Finished Pharmaceutical product import
Dy. No. And date of Submission	Tracking ID: NVP-Q6Z-MHXY Application Number: 98809
Fee Details	Challan Number: 28694999608 Division: Biological Evaluation & Registration Paid Fee: 300000.0 Paid Date: 2025-05-08
The proposed proprietary Name / brand name	L'OSEM-3 (3mg) Tablet
Strength / concentration of drug of Active	Each tablet contains Semaglutide..3mg..

	Pharmaceutical ingredient (API) per unit	
	Indication	Ozempic is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise • as monotherapy when metformin is considered inappropriate due to intolerance or contraindications In addition to other medicinal products for the treatment of diabetes.
	Dosage form of applied Drug	Tablet
	Pharmacotherapeutic Group Of (API)	Pharmacotherapeutic group: Drugs used in diabetes, glucagon-like peptide-1 (GLP-1) analogues, ATC code: A10BJ06
	Finished product Specifications	As per Innovators Specifications.
	Proposed Pack size	Box packing of 30's tablets. Alu-Alu blister packing for tablets (10's). Each box packing have 30 tablets (10 in each blister) in it.
	Proposed unit price	As per SRO228
	Shelf life	2 years
	Storage conditions	2-8°C
	The status in reference regulatory authorities	RYBELSUS 3 mg (Semaglutide) Tablet of Novo Nordisk approved by US-FDA
	For generic drugs (me-too Status)	RYBELSUS 3 mg (Semaglutide) Tablet of Novo Nordisk registered by DRAP (Reg. No. 115139)
	Module-II (Quality Overall Summary)	QOS submitted as per WHO which is still incomplete
Module 3 : Drug Substance Part		
	Name, address of drug substance manufacturer	Fujian Genotype Biotechnology Co., Ltd., China Address: No. 288, Xitang St., Hushi Industrial Park, Xiuyu District, Putian City, Fujian Provinc
	Characterization	Not submitted as per CTD.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Not submitted as per CTD.
Module-III Drug Product:		
	Drug Product Manufacturer	Not submitted as per CTD.
	Description	Not submitted as per CTD.
	Analytical method validation/verification of product	Not submitted as per CTD.
	Container closure system of the drug product	Not submitted as per CTD.
	Stability study data of drug product	Not submitted as per CTD.

	Module 4 Non Clinical Studies	Not submitted as per CTD.
	Module 5 Clinical Studies	- Not submitted as per CTD.
Remarks of the Evaluator • Submit Form 5-F as per the attached format, including properly signed commitments from authorized person. • The applicant information on Form 5 F should be filled out by the importer. • Submit original, legalized/apostille and valid COPP. • Submit complete Module 2, replacing any placeholders such as “Information not available, we will submit this to DRAP once received from the manufacturer.” All sections must be completely addressed. • Provide Module 3 in accordance with the Final Guidance for Biological Products, as attached. The currently provided data does not comply with CTD format and needs to be revised. • Specify the source of the Active Ingredient (API): ○ If synthetic, submit sameness studies comparing the synthetic peptide to rDNA which includes the following: A. Active Ingredient Sameness (by Orthogonal Method) (specify) physicochemical Characterization, Primary sequence and physicochemical properties Secondary structure Oligomer/aggregation states biological evaluation .b Impurities peptide-related impurity level of such impurity in the proposed product is the same as or lower than that found in the RLD; any new specified peptide-related impurity ○ Including Bio-equivalence studies. ○ If the product is derived from recombinant DNA (rDNA), submit biosimilarity (comparability) studies. In cases where such data is Not Applicable (NA), provide a scientific justification. Additionally, if the product is administered using the same dose and route as the reference product, include only bioequivalence studies.		
Decision of 345th Meeting: The Registration Board deferred the case for the submission of the following documents: • Submit Form 5-F as per the attached format, including properly signed commitments from authorized person. • The applicant information on Form 5 F should be filled out by the importer. • Submit original, legalized/apostille and valid COPP. • Submit complete Module 2, replacing any placeholders such as “Information not available, we will submit this to DRAP once received from the manufacturer.” All sections must be completely addressed. • Provide Module 3 in accordance with the Final Guidance for Biological Products. • Samness studies for synthetic peptide and biosimilarity studies for rDNA peptide.		

Case # 03		
Name, address of Applicant / Importer	ROSACEAE PHARMA (PRIVATE) LIMITED Company Address: ALTIMI House, Plot No. 21-C, Suite # 301, Khalid Commercial Street # 4, Phase 7 (Ext), D.H.A., Karachi-755350	
Details of Drug SaleLicense of importer	ROSACEAE PHARMA (PRIVATE) LIMITED Company Address: ALTIMI House, Plot No. 21-C, Suite # 301, Khalid Commercial Street # 4, Phase 7 (Ext), D.H.A., Karachi-755350 Site Address:Company City: Karachi License Type: Drug Sale License License Number: 0377 License Issue Date: 2024-11-05	
Name and address of marketing authorizationholder (abroad)	Name: Loas Alliance Pharmaceutical Group Co. Ltd. Address: Nano Village, Saysettha Development Zone, Saysettha District, Vientiane Capital, Loa PD	
Name, address of manufacturer(s)	Name: Loas Alliance Pharmaceutical Group Co. Ltd. Address: Nano Village, Saysettha Development Zone, Saysettha District, Vientiane Capital, Loa PD	
Name of exporting country	Lao PDR	
Detail of certificates attached (copp, Free sale certificate, GMP certificate)	Not Submitted	
Details of letter of authorization / sole agencyagreement	We, Lao Alliance Pharmaceutical Group Co.,Ltd (Address:NANO VILLAGE SAYSETTHA DISTRICT VTE LAO PDR) declare that we authorize Rosaceae Pharma Private Limited Address:ALTIMI House Plot No.21-C, Suit # 301, Khalid Commercial Street #4,Phase 7(Ext),D.H.A. Karachi-755350.) As our cooperated partnerer exclusively to distribute and register our products with Drug regulatory Authority Ministry of Health-Pakistan. (1) L'OSEM-3(Semaglutide 3mg) to Pakistan. <u>Scanned Letter of Authorization</u>	
Status of the applicant	Importer	
Status of application	Biosimilar	
Intended use of pharmaceutical product	Domestic sale	
For imported products, specify one the these	Finished Pharmaceutical product import	
Dy. No. And date of Submission	Tracking ID:DLW-GA1-J1J2 Application Number:98854	
Fee Details	Challan Number: 211673557371 Division: Biological Evaluation & Registration Paid Fee: 300000.0 Paid Date: 2025-05-08	
The proposed proprietary Name / brand name	L'OSEM-7 Tablet	
Strength / concentration ofdrug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains Semaglutide..7mg..	
Indication	Ozempic is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise • as monotherapy when metformin is considered inappropriate due to intolerance or contraindications	

		In addition to other medicinal products for the treatment of diabetes.
	Dosage form of applied Drug	Tablet
	Pharmacotherapeutic Group Of (API)	Pharmacotherapeutic group: Drugs used in diabetes, glucagon-like peptide-1 (GLP-1) analogues, ATC code: A10BJ06
	Finished product Specifications	As per Innovators Specifications.
	Proposed Pack size	Box packing of 30's tablets. Alu-Alu blister packing for tablets (10's). Each box packing have 30 tablets (10 in each blister) in it.
	Proposed unit price	As per SRO228
	Shelf life	2 years
	Storage conditions	2-8°C
	The status in reference regulatory authorities	RYBELSUS 7 mg (Semaglutide) Tablet of Novo Nordisk approved by US-FDA
	For generic drugs (me-too Status)	RYBELSUS 7 mg (Semaglutide) Tablet of Novo Nordisk registered by DRAP (Reg. No. 115139)
	Module-II (Quality OverallSummary)	QOS submitted as per WHO which is still incomplete
Module 3 : Drug Substance Part		
	Name, address of drug substance manufacturer	Fujian Genotype Biotechnology Co., Ltd., China Address: No. 288, Xitang St., Hushi Industrial Park, Xiuyu District, Putian City, Fujian Provinc
	Characterization	Not submitted as per CTD.
	Stability Studies of Drug Substance (Conditions & duration ofStability studies)	Not submitted as per CTD.
Module-III Drug Product:		
	Drug Product Manufacturer	Not submitted as per CTD.
	Description	Not submitted as per CTD.
	Analytical method validation/verification ofproduct	Not submitted as per CTD.
	Container closure system ofthe drug product	Not submitted as per CTD.
	Stability study data of drugproduct	Not submitted as per CTD.
	Module 4 Non Clinical Studies	Not submitted as per CTD.
	Module 5 Clinical Studies	- Not submitted as per CTD.
Remarks of the Evaluator Submit Form 5-F as per the attached format, including properly signed commitments from authorized person.		

- The applicant information on Form 5 F should be filled out by the importer.
- Submit original, legalized/apostille and valid COPP.
- Submit complete Module 2, replacing any placeholders such as “Information not available, we will submit this to DRAP once received from the manufacturer.” All sections must be completely addressed.
- Provide Module 3 in accordance with the Final Guidance for Biological Products, as attached. The currently provided data does not comply with CTD format and needs to be revised.
- Specify the source of the Active Ingredient (API):
 - If synthetic, submit sameness studies comparing the synthetic peptide to rDNA which includes the following:
 - A. Active Ingredient Sameness
(by Orthogonal Method) (specify)
physicochemical Characterization,
Primary sequence and physicochemical properties
Secondary structure
Oligomer/aggregation states
biological evaluation
 - .b Impurities
peptide-related impurity
level of such impurity in the proposed product is the same as or lower than that found in the RLD;
any new specified peptide-related impurity
 - Including Bio-equivalence studies.
 - If the product is derived from recombinant DNA (rDNA), submit biosimilarity (comparability) studies. In cases where such data is Not Applicable (NA), provide a scientific justification. Additionally, if the product is administered using the same dose and route as the reference product, include only bioequivalence studies.

Decision of 345th Meeting:

The Registration Board deferred the case for the submission of the following documents:

- **Submit Form 5-F as per the attached format, including properly signed commitments from authorized person.**
- **The applicant information on Form 5 F should be filled out by the importer.**
- **Submit original, legalized/apostille and valid COPP.**
- **Submit complete Module 2, replacing any placeholders such as “Information not available, we will submit this to DRAP once received from the manufacturer.” All sections must be completely addressed.**
- **Provide Module 3 in accordance with the Final Guidance for Biological Products.**

Samness studies for synthetic peptide and biosimilarity studies for rDNA peptide.

Case # 04		
	Name, address of Applicant / Importer	ROSACEAE PHARMA (PRIVATE) LIMITED Company Address: ALTIMI House, Plot No. 21-C, Suite # 301, Khalid Commercial Street # 4, Phase 7 (Ext), D.H.A., Karachi-755350
	Details of Drug SaleLicense of importer	ROSACEAE PHARMA (PRIVATE) LIMITED Company Address: ALTIMI House, Plot No. 21-C, Suite # 301, Khalid Commercial Street # 4, Phase 7 (Ext), D.H.A., Karachi-755350 Site Address:Company City: Karachi License Type: Drug Sale License License Number: 0377 License Issue Date: 2024-11-05
	Name and address of marketing authorizationholder (abroad)	Name: Loas Alliance Pharmaceutical Group Co. Ltd. Address: Nano Village, Saysettha Development Zone, Saysettha District, Vientiane Capital, Loa PD

Name, address of manufacturer(s)	Name: Loas Alliance Pharmaceutical Group Co. Ltd. Address: Nano Village, Saysettha Development Zone, Saysettha District, Vientiane Capital, Loa PD
Name of exporting country	Lao PDR
Detail of certificates attached (copp, Free sale certificate, GMP certificate)	Not Submitted
Details of letter of authorization / sole agency agreement	We, Lao Alliance Pharmaceutical Group Co., Ltd (Address: NANO VILLAGE SAYSETTHA DISTRICT VTE LAO PDR) declare that we authorize Rosaceae Pharma Private Limited Address: ALTIMI House Plot No.21-C, Suit # 301, Khalid Commercial Street #4, Phase 7(Ext), D.H.A. Karachi-755350.) As our cooperated partner exclusively to distribute and register our products with Drug regulatory Authority Ministry of Health-Pakistan. (1) L'OSEM-3 (Semaglutide 3mg) to Pakistan. <u>Scanned Letter of Authorization</u>
Status of the applicant	Importer
Status of application	Biosimilar
Intended use of pharmaceutical product	Domestic sale
For imported products, specify one the these	Finished Pharmaceutical product import
Dy. No. And date of Submission	Tracking ID: HYE-X6X-SNYU Application Number: 98899
Fee Details	Challan Number: 89285546747 Division: Biological Evaluation & Registration Paid Fee: 300000.0 Paid Date: 2025-05-08
The proposed proprietary Name / brand name	L'OSEM-14 Tablet
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains Semaglutide..14mg..
Indication	Ozempic is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise • as monotherapy when metformin is considered inappropriate due to intolerance or contraindications In addition to other medicinal products for the treatment of diabetes.
Dosage form of applied Drug	Tablet
Pharmacotherapeutic Group Of (API)	Pharmacotherapeutic group: Drugs used in diabetes, glucagon-like peptide-1 (GLP-1) analogues, ATC code: A10BJ06
Finished product Specifications	As per Innovators Specifications.
Proposed Pack size	Box packing of 30's tablets. Alu-Alu blister packing for tablets (10's). Each box packing have 30 tablets (10 in each blister) in it.

Proposed unit price	As per SRO228
Shelf life	2 years
Storage conditions	2-8°C
The status in reference regulatory authorities	RYBELSUS 14 mg (Semaglutide) Tablet of Novo Nordisk approved by US-FDA
For generic drugs (me-too Status)	RYBELSUS 14 mg (Semaglutide) Tablet of Novo Nordisk registered by DRAP (Reg. No. 115139)
Module-II (Quality Overall Summary)	QOS submitted as per WHO which is still incomplete
Module 3 : Drug Substance Part	
Name, address of drug substance manufacturer	Fujian Genotype Biotechnology Co., Ltd., China Address: No. 288, Xitang St., Hushi Industrial Park, Xiuyu District, Putian City, Fujian Provinc
Characterization	Not submitted as per CTD.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Not submitted as per CTD.
Module-III Drug Product:	
Drug Product Manufacturer	Not submitted as per CTD.
Description	Not submitted as per CTD.
Analytical method validation/verification of product	Not submitted as per CTD.
Container closure system of the drug product	Not submitted as per CTD.
Stability study data of drug product	Not submitted as per CTD.
Module 4 Non Clinical Studies	Not submitted as per CTD.
Module 5 Clinical Studies	- Not submitted as per CTD.
Remarks of the Evaluator - Submit Form 5-F as per the attached format, including properly signed commitments from authorized person. - The applicant information on Form 5 F should be filled out by the importer. - Submit original, legalized/apostille and valid COPP. - Submit complete Module 2, replacing any placeholders such as “Information not available, we will submit this to DRAP once received from the manufacturer.” All sections must be completely addressed. - Provide Module 3 in accordance with the Final Guidance for Biological Products, as attached. The currently provided data does not comply with CTD format and needs to be revised. - Specify the source of the Active Ingredient (API): - If synthetic, submit sameness studies comparing the synthetic peptide to rDNA which includes the following: A. Active Ingredient Sameness (by Orthogonal Method) (specify) physicochemical Characterization, Primary sequence and physicochemical properties - Secondary structure - Oligomer/aggregation states	

biological evaluation
 .b Impurities
 peptide-related impurity
 level of such impurity in the proposed product is the same as or lower than that found in the RLD;
 any new specified peptide-related impurity

Including Bio-equivalence studies.

- If the product is derived from recombinant DNA (rDNA), submit biosimilarity (comparability) studies. In cases where such data is Not Applicable (NA), provide a scientific justification. Additionally, if the product is administered using the same dose and route as the reference product, include only bioequivalence studies.

Decision of 345th Meeting:

The Registration Board deferred the case for the submission of the following documents:

- Submit Form 5-F as per the attached format, including properly signed commitments from authorized person.
- The applicant information on Form 5 F should be filled out by the importer.
- Submit original, legalized/apostille and valid COPP.
- Submit complete Module 2, replacing any placeholders such as “Information not available, we will submit this to DRAP once received from the manufacturer.” All sections must be completely addressed.
- Provide Module 3 in accordance with the Final Guidance for Biological Products.

Samness studies for synthetic peptide and biosimilarity studies for rDNA peptide.

Agenda Item No. 05. Registration Applications of Misc. Biological Products

Case#01: Registration Application of Thrombolytic agent (Streptokinase)

Streptokinase is a thrombolytic medication activating plasminogen by non-enzymatic mechanism. It is naturally produced by *Streptococci* spp. Bacteria.

Streptokinase itself is a well-established thrombolytic agent, but differences in manufacturing methods—especially related to recombinant production in *Escherichia coli* versus natural extraction from *Streptococcus*—can lead to variations in potency and immunogenic response.

Recombinant *Streptokinase* is weakly antigenic and may be neutralized by anti-*Streptokinase* antibodies, normally present in the blood as a result of previous streptococcal infections. A fibrinolytic state is initiated when the amount of recombinant *Streptokinase* administered exceeds the anti- *Streptokinase* antibody titre. Thrombolysis commences when recombinant *Streptokinase* activator complex diffuses into the thrombus.

There are no biosimilars of streptokinase approved in Europe. Studies have showed slight differences in the amino acid sequence of the recombinant product in comparison to the native one at the amino terminus and n-terminal sequence of the streptokinase molecule can have significant effect on the activity of this protein.

A particular challenge with recombinant streptokinase, often expressed in *E.coli*, is the potential for incomplete processing of the amino-terminal methionine, which can affect its activity.

Case#01

Name, address of Applicant / Importer	M/s Medicorp Life Sciences, Office No 301, 3rd Floor, Sky Mark tower Plot No A-13, Block 7/8, K.C.H.S Off Sharah-e-Faisal Karachi.
Details of Drug Sale License of importer	License No: 0498 Address: Office No 301, 3rd Floor, Sky Mark tower Plot No A-13, Block 7/8, K.C.H.S Off Sharah-e-Faisal Karachi. Validity: Status: License to sell drugs by way of Whole sale Validity: 30-01-2030.
Name and address of marketing authorization holder (abroad)	M/s. Levim Biotech LLP, NAGARJUNASAGAR, NALGONDA DISTRICT, TELENGANA, 508202,TELANGANA, INDIA.
Name, address of manufacturer(s)	M/s. Levim Biotech LLP, NAGARJUNASAGAR, NALGONDA DISTRICT, TELENGANA, 508202,TELANGANA, INDIA.
Name of exporting country	India
Detail of certificates attached (CoPP, Free Sale certificate, GMP certificate)	CoPP: The firm has submitted copy of CoPP (Certificate No 4271127/TS/2024) by Drug Control Administration, Telangana State India.The certificate confirms that the product is actually on the market in the exporting country and facilities and operations conform to GMP as recommended by WHO. The certificate is valid till 23-01-2027
Details of letter of authorization / sole agency agreement	A copy of product specific Letter of Authorization is attached.
Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☐ Domestic and Export sales (Not provided)
For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Bulk import and local repackaging

	☐ Bulk import and local repackaging for export purpose only
e-app tracking ID and date of receiving	Tracking ID: AWM-1DR-5AUZ Application Number: 81389 Receinig date: 30-04-2025
Details of fee submitted	PKR 300000/- dated: 07-02-2025 Challan Number: 9496405083
The proposed proprietary name / brand name	STREPTOLEV
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Lyophilized vial contains: Recombinant Streptokinase for Injection..... 1500,000IU
Dosage form of applied drug	Lyophilized powder for Solution for Injection
Pharmacotherapeutic Group of (API)	Thrombolytic protein ATC Code: B01AD01
Finished product specifications	Manufacturer's Specifications
Proposed Pack size	1's Vial
Proposed unit price	As per SRO
Shelf Life	24 months
Storage Conditions	Store at 2°C – 8°C
Status in Reference Regulatory Authorities	Streptase by M/s CSL Behring, Germany <i>Streptase®, Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci. So, it is of natural origin while applied product is of rDNA origin.</i>
For generic drugs (me-too status)	Diclair-ST of M/s Gene-Tech Laboratories Karachi Registration No. 059023
Module-II (Quality Overall Summary)	Firm has summarized information related to nomenclature, structure, general properties, manufacturers, Characterization, impurities, specifications, and justification of specification.
Name, address of drug substance manufacturer	M/s Levim Biotech LLP Door No.5, Module No. 501-506, 5th Floor, Ticel

	Biopark Phase II, CSIR Road, Taramani, Chennai 600 113, Tamil Nadu, India.
Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, manufacturers, description of manufacturing process, Characterization, impurities, specification, batch analysis and justification of specification, container closure system, stability.
Stability Studies of Drug Substance	3-month stress, 6 months accelerated and 12 months long term stability data for the following batches are provided; ➤ RSKUF19018 ➤ RSKUF19019 ➤ RSKUF19020 Test conditions and schedule: <u>Stress Stability</u> • Storage conditions: 25±2°C/ 60±5% RH • Test points: Initial ,15 days, 1 month & 3 months <u>Accelerated Stability</u> • Storage conditions: 5±3°C • Test points: Initial ,1,3 & 6 months <u>Long -term stability</u> • Storage conditions: -20±5°C • Test points: Initial,1,3,6,9 &12 months
Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, batch analysis, justification of specifications, container closure system and Stability.
Analytical method Validation / verification of the product	The specifications & analytical procedures are submitted along with validation of Analytical Procedures.
Container closure system of the drug product	The primary container closure system is neutral borosilicate glass vial and bromobutyl rubber stopper.
Stability study data of drug product, shelf life and storage conditions	The stability studies have been conducted for the drug product, Recombinant Streptokinase for Injection 1500000 IU as per the ICH guidelines under accelerated (25±2°C/60±5% RH) at 0,1,2,3,6 months' time interval and real time (5±3°C) storage conditions at 3,6,9,12,18,24 months. stability study data for three batches of Recombinant Streptokinase for Injection 1500000 IU subjected at long term(5±3 °C) and accelerated condition (25° ± 2°C /60±5%RH) is enclosed.
Module-IV Non-Clinical	In order to assess the safety profile of recombinant streptokinase, the following preclinical toxicology studies were carried out with approved protocols. ➤ Acute toxicity studies in rats and mice ➤ Subacute toxicity studies in rats and mice

- Toxicity studies in pregnant rats
- Allergenicity studies in guinea pigs
- Detection of antibodies

Detail of tests are as under;

D. Non-clinical Written and Tabulated Summaries

D.1 Acute Toxicity Study in Swiss Albino Mice

Table 1: Summary of acute toxicity studies in Swiss Albino mice

Treatment Group	No of Animals		Mortality		Clinical Signs of Intoxication	Gross Pathology	Histopathology
	M	F	M	F			
Control	5	5	0	0	Nil	NAD	NAD
0.3mg/kg/day	5	5	0	0	Nil	NAD	NAD
1mg/kg/day	5	5	0	0	Nil	NAD	NAD
3mg/kg/day	5	5	0	0	Nil	NAD	NAD
10mg/kg/day	5	5	0	0	Nil	NAD	NAD

D.2 Acute Toxicity Study in Sprague Dawley Rats

Table 2: Summary of acute toxicity study in Sprague Dawley rats

Treatment Group	No of Animals		Mortality		Clinical Signs of Intoxication	Gross Pathology	Histopathology
	M	F	M	F			
Control	5	5	0	0	Nil	NAD	NAD
0.3mg/kg/day	5	5	0	0	Nil	NAD	NAD
1mg/kg/day	5	5	0	0	Nil	NAD	NAD
3mg/kg/day	5	5	0	0	Nil	NAD	NAD
10mg/kg/day	5	5	0	0	Nil	NAD	NAD

NAD = No Abnormality Detected

D.3 Subacute Toxicity Study in Swiss Albino Mice

Table 3: General Observations

Gr No	Dose mg/kg	No of animals		Mortality		Clinical signs of intoxication	Ophthalmoscopic examination	Gross Histopathology
		M	F	M	F			
I	0	6	6	0	0	Nil	NAD	NAD
II	0 (rev)	6	6	0	0	Nil	NAD	NAD
III	0.3	6	6	0	0	Nil	NAD	NAD
IV	1	6	6	0	0	Nil	NAD	NAD
V	3	6	6	0	0	Nil	NAD	NAD
VI	3(rev)	6	6	0	0	Nil	NAD	NAD

Table 4: Hematology and Biochemical and Urine Analysis

Group No	Dose mg/kg	Hematology	Biochemical analysis	Urine analysis
I	0	Normal	Normal	Normal
II	0(rev)	Normal	Normal	Normal
III	0.3	Normal	Normal	Normal
IV	1	Normal	Normal	Normal
V	3	Marginal increase in MCH levels	Marginal decrease in blood sugar	Normal
VI	3(rev)	Marginal decrease in MCHC levels in females	Normal	Normal

MCH – Mean Corpuscular Hemoglobin

MCHC- Mean Corpuscular Hemoglobin Concentration

D.4 Subacute Toxicity Studies in Sprague Dawley Rats

Table 5: General Observations

Gr No	Dose mg/kg	No of animals		Mortality		Clinical signs of intoxication	Ophthalmoscopic examination	Gross Histopathology
		M	F	M	F			
I	0	6	6	0	0	Nil	NAD	NAD
II	0 (rev)	6	6	0	0	Nil	NAD	NAD
III	0.3	6	6	0	0	Nil	NAD	NAD
IV	1	6	6	0	0	Nil	NAD	NAD
V	3	6	6	0	0	Nil	NAD	NAD
VI	3(rev)	6	6	0	0	Nil	NAD	NAD

NAD = No Abnormality Detected

Table 6: Hematology and Biochemical and Urine Analysis

Group No	Dose mg/kg	Hematology	Biochemical analysis	Urine analysis
I	0	Normal	Normal	Normal
II	0 (rev)	Normal	Normal	Normal
III	0.3	Normal	Normal	Normal
IV	1	Normal	Normal	Normal
V	3	i) Marginal decrease in Hb, total protein and HCT in both sexes ii) In females marginal increase in MCHC levels observed	i) Increase in alkaline phosphatase levels in both sexes ii) Decrease in levels of alanine amino transferase in males	Normal
VI	3 (rev)	Normal	Normal	Normal

Hb - Haemoglobin

HCT- Hematocrit

MCHC- Mean Corpuscular Hemoglobin Concentration

D.5 Developmental Toxicity Study**Table 7: Summary of toxicology studies in pregnant rats**

Treatment Group	No of Animals	Survival at Termination	Clinical Signs of Intoxication	Body Weight (g)	Litter Collection Data			Gross Pathology
					Total	Live	Resorbed	
Control	10	All	Nil	Normal	10.8 ±2.0 4	10.0 ±2.0 5	0.80 ±1.55	NAD
3mg/kg/day	10	All	Nil	Normal	10.7 ±2.1 1	9.9 ±2.6 0	0.80 ±1.03	NAD

D.6 Allergenicity Studies**Table 8: Antibody titers in blood of mice used in subacute toxicity studies**

Group No	Dose Mg/kg	Sex	Antibody titer
I	0	M F	Nil Nil
II	0 (rev)	M F	Nil Nil
III	0.3	M F	5000-10000 10000-50000

Group No	Dose Mg/kg	Sex	Antibody titer
IV	1.0	M F	10000-100000 10000-100000
V	3.0	M F	10000-100000 100000
VI	3.0 (rev)	M F	100000 100000

Detection of Antibodies

Administration of extraneous protein is expected to elicit antibody response. The antibody titers of blood samples collected from mice used in subacute toxicity studies were measured by ELISA.

Module-V Clinical

“Multi-Center, Prospective, Randomized, Parallel Design, Double Blind, Phase III Study to Evaluate the Efficacy and Safety of Streptokinase-A in the Treatment of Acute ST Elevation Myocardial Infarction” is performed.

Hundred and twenty-two (122) patients with certainty of diagnosis of evolving acute myocardial infarction were recruited in the study.

Seven centers enrolled 122 subjects.

Investigational Product: Streptokinase-A (Recombinant Streptokinase)

Comparator Product : Streptase™ (Aventis Pharma)

Conclusion of the study:

From the results obtained, it can be concluded that Streptokinase-A can establish reperfusion without any unexpected side effects and is equivalent to Streptase™ in all the efficacy and safety parameters analysed. Based on the results and the need for the cost-effective thrombolytics such as streptokinase in our country

where the cost of alternative choices of thrombolysis / reperfusion strategies is prohibitive, Streptokinase A will be beneficial to our people.

Following are the serious adverse events:

SYSTEM ORGAN CLASS	PREFERRED TERM	TOTAL		DRUG RELATEDNESS	
		Streptase™	Streptokinase -A	Streptase™	Streptokinase -A
Blood and lymphatic system disorders	Anaemia	1	-	1	-
Cardiac disorders	Accelerated Idioventricular rhythm	-	-	-	-
Cardiac disorders	Acute pulmonary edema	-	3	-	-
	AMI (reinfarction)	2	2	-	1
	Angina	-	1	-	-
	Atrioventricular block	1	2	-	-
	Bradycardia	1	-	-	-
	Cardiac arrest	1	5	-	1
	Cardio-pulmonary failure	2	-	-	-
	Cardiogenic shock	2	-	-	-
	Pericardial effusion	-	1	-	-
	Pericardial haemorrhage	-	1	-	-
	Ventricular Tachycardia	-	1	-	-
Gastrointestinal disorders	Gastroenteritis	1	-	-	-

SYSTEM ORGAN CLASS	PREFERRED TERM	TOTAL		DRUG RELATEDNESS	
		Streptase™	Streptokinase -A	Streptase™	Streptokinase -A
Infections & infestations	Gastroenteritis	-	-	-	-
Investigations	Blood bilirubin increased	-	1	-	1
Neoplasms (incl cysts and polyps)	Renal cell carcinoma	1	-	-	-
Nervous system disorders	Haemorrhage intracranial	-	1	-	1
Renal and urinary disorders	Hematuria	-	1	-	1
Respiratory, thoracic and mediastinal disorders	Renal failure	1	-	-	-
	Dyspnoea	1	-	-	-
Vascular disorders	Hypoxia	1	-	-	-
	Haematoma	1	1	1	1
	Hypotension	2	1	-	-
TOTAL		18	21	2	6

Remarks of Evaluator	• COPP is not legalized. Original legalized COPP is required. • Brand name is not mentioned in COPP. • Original or notarized product specific LOA in hard copy is required. • Module 1.4.1 to 1.4.3 is not provided. • Updated Module 1 as per final guidance document for biological products is required. • Evidence of availability of recombinant streptokinase in any reference country is required. The product “Streptase” mentioned in the application is of natural origin. • All registered streptokinase products with DRAP are natural in origin as per available data. • Proposed Label of the product attached in module 1 does not show recombinant word in composition. • Finished product specifications as per DRAP guidance document. • Stability data of Drug Substance submitted till 12 months however the product shelf life is 24 months. • Process related and host cell related impurity testing is not provided. • Immunogenicity testing is required as recombinant products have a potential to induce an immune response. • GMP of drug substance manufacturer is required. • In-use stability data is required. • Complete Module 4 and Module 5 on CTD format is required including PK and PD studies. • Firm has submitted a comparative phase-III study of the applied product (rDNA origin) with the other product of natural origin. Reference of any international guidelines for acceptance of such kind of study is required.

Concluding remarks of BE&R:

The case is deficient for submission of above cited documents.

Decision:

The Registration Board deferred the case for submission of following documents/clarifications;

- **Original legalized COPP is required as the submitted docummet is not legalized.**
- **Brand name is not mentioned in COPP.**
- **Original or notarized product specific LOA in hard copy is required.**
- **Module 1.4.1 to 1.4.3 is not provided.**
- **Updated Module 1 as per final guidance document for biological products is required.**
- **Evidence of availability of recombinant streptokinase in any reference country is required. The product “Streptase” mentioned in the application as reference is of natural origin.**
- **All registered streptokinase products with DRAP are natural in origin as per available data.**
- **Proposed Label of the product attached in module 1 does not show recombinant word in composition.**
- **Finished product specifications as per DRAP guidance document.**
- **Stability data of Drug Substance submitted till 12 months however the product shelf life is 24 months.**
- **Process related and host cell related impurity testing is not provided.**

- Immunogenicity testing is required as recombinant products have a potential to induce an immune response.
- GMP of drug substance manufacturer is required.
- In-use stability data is required.
- Complete Module 4 and Module 5 on CTD format is required including PK and PD studies.
- Firm has submitted a comparative phase-III study of the applied product (rDNA origin) with the other product of natural origin. Reference of any international guidelines for acceptance of such kind of study is required.

Case#02

1.	Name, address of Applicant / Importer	M/s OBS AGP (Private) Limited. Plot no. B-23-C, 2nd Floor S.I.T.E., Karachi-75700, Pakistan.
	Details of Drug Sale License of importer	License No: 024 Address: OBS AGP PRIVATE LIMITED, PLOT NO. B-23-C, 2nd FLOOR S.I.T.E KARACHI. Address of Godown: Muller & Phipps Pakistan (Private) Limited, plot No. 32-12, Sector 19, K.I.A. Karachi. Status: License to sell, stock & exhibit for sale, distribute and sell drugs by way of whole sale by of manufacturer, importer or indenter Valid Upto: 27-03-2028
	Name and address of marketing authorization holder (abroad)	M/s Bharat Serums and Vaccines Limited Plot No. K-27, K-27 Part and K-27/1, Anand Nagar, Jambivili Village, Additional MIDC, Ambernath (East), Thane 421506, Maharashtra State, India.
	Name, address of manufacturer(s)	M/s Bharat Serums and Vaccines Limited Plot No. K-27, K-27 Part and K-27/1, Anand Nagar, Jambivili Village, Additional MIDC, Ambernath (East), Thane 421506, Maharashtra State, India
	Name of exporting country	INDIA
	Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	CoPP: Firm has attached original, legalized CoPP (No. COPP/CERT/KD/130682/2023/11/47660/229030) dated 20-10-2023 issued by Food & Drug Administration, MS. Bandra (E), Mumbai-400 051, Maharashtra, India. The CoPP confirms free sale status of the product in exporting country as well as GMP status of the manufacturing site through periodic inspection once a year. The COPP is valid upto 29-03-2025.
	Details of letter of authorization / sole agency agreement	Firm has submitted Legalized Letter of Authorization from M/s Bharat Serums and Vaccines Limited issued on 11-12-2023 and valid till 5 years. The letter specifies that the manufacturer appoints M/s OBS AGP Limited to register their products in Pakistan.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Bulk import and local repackaging

	☐ Buk import and local repackaging for export purpose only
E-app Tracking ID and date of submission	E-app Tracking ID: <u>BDW-7PH-1U2Y</u> Application No. 2342 Receiving date: 22-02-2024
Details of fee submitted	Deposit slip# 839319629 dated 07-02-2024 of PKR 300,000/-
The proposed proprietary name / brand name	Foligraf 450 IU (Multidose) Pre Filled pen. (Recombinant Human Follicle Stimulating Hormone Injection IH 450 IU (33.0 µg)/0.75ml
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Prefilled pen containing one 3ml cartridge contains: Recombinant Follitropin Concentrated Solution Ph.Eur.....450 IU (33.0 µg)/0.75 ml
Pharmaceutical form of applied drug	Solution for injection in Prefilled pen –Multidose.
Pharmacotherapeutic Group of (API)	Gonadotropin
Reference to Finished product specifications	In House
Proposed Pack size	1's Pre Filled pen + 7 needles 24 months (2-8°C)
Proposed unit price	As per SRO
The status in reference regulatory authorities	Gonal-F Pen 450 IU (33 ug)/0.75ml Solution for Injection in a pre-filled pen M/s. Merck Serono S.P.A. VIA Delle Magnolie (LOC. FrazioneZona Industriale), Italy.
For generic drugs (me-too status)	Gonal-F Pen 450 IU (33 ug)/0.75ml Solution for Injection in a pre-filled pen Imported by Martin Dow Specialities Pvt.Limited, Karachi.
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Name, address of drug substance manufacturer	M/s Bharat Serums and Vaccines Limited Plot No. K-27, K-27 Part and K-27/1, Anand Nagar, Jambivili Village, Additional MIDC, Ambernath (East) Thane-421506, Maharashtra, India.
Module-III Drug Substance	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.

Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API (BB4019001, BB4020001, BB4020002) conducted at accelerated conditions 5°C ± 3°C RH for 6 months as well as real time conditions. The real time stability data is conducted at -20°C ± 5°C for 36 months.			
Module-III Drug Product	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.			
Analytical method validation/verification of product	The firm informed that “Excipients used in Manufacturing of Foligraf 450 IU I Multidose Pre Filled Pen (Recombinant Human Follicle Stimulating Hormone Injection IH 450 IU (33.0µg) /0.45m) are official in pharmacopeia. Hence it does not necessitate analytical method validation” .			
Container closure system of the drug product	The ‘Foligraf (Multidose) Prefilled Pen’ is filled into clear, colorless USP Type-I siliconized glass cartridges with combiseal, each having a 3 ml geometric volume, and sealed with 10 mm halobutyl cartridge stoppers. This system serves as the primary container packaging for this drug product because of its contact with the packaging material.			
Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches (B24722001, B20720002, B20720003). The accelerated stability study is conducted at 25°C ± 2°C / 60% ± 5%RH at 0, 3 and 6 months’ time interval. The real time stability study is conducted at 5°C ± 3°C at 0, 3, 6, 9 and 12 months. The firm has submitted a statement that they will provide complete data of 24 Months as and when available.			
Biosimilarity data	Firm has claimed the product Biosimilar to “Gonal-F 450 IU” by Merck Serono S.p.A, Italy. The studies provided in module 4 and module 5 are of some other product containing lyophilized powder for injection while the applied product is solution for injection in prefilled pen. The firm has further informed that “The clinical study III with recombinant follicle stimulating hormone prefilled pen device is ongoing”. Bio similarity data as per WHO Bio similarity guidelines in tabular form is required including; ➤ Comparative structural and functional characterization with the Reference product. ➤ Comparative in vitro bioassays for receptor affinity and activation. ➤ Comparative in-vivo potency. ➤ Impurity testing (product related and process related). ➤ Comparative Pharmacokinetic studies ➤ Comparative Toxicology studies (single dose and repeat dose). ➤ Clinical trial data			
<table><tr><td>Shortcomings/Observations</td><td>Reply of the Firm</td><td>Remarks of Evaluator</td></tr></table>		Shortcomings/Observations	Reply of the Firm	Remarks of Evaluator
Shortcomings/Observations	Reply of the Firm	Remarks of Evaluator		

communicated to the firm		
▪ Pack size as per COPP is “Each prefilled pen containing one 3ml cartridge” while the pack size as per application/dossier is “0.75ml x 1’s (One Carton contains one labeled Pen (Multidose) along with 07 needles and one insert.)”	Each prefilled pen contains one 3 ml labeled siliconized sterile glass cartridge, which contains 0.75ml solution for injection i.e (450IU Recombinant human follicle stimulating hormone) 3ml is the size of cartridge. For details see Annex 1-3.2.P.7 “Container Closure System”	
▪ The reference product Gonal F contains Follitropin alpha while the applied product contains follitropin concentrated solution (Ph.Eur). Clarification required.	Our development and clinical development have been in comparison to Gonal-f which is Follitropin Alfa, but not adopted its name. We have adopted the name as per Ph. Eur Follitropin Concentrated Solution.	
▪ Needles details are not mentioned in COPP.	In 450 IU (33.0 gg) / 0.75 ml Solution for Injection Each Carton contains: 1 Foligraf multi-dose prefilled pen, along with 7 sterile pen needles. Needles are provided for 6 different doses, an additional needle is included and needle is considered part of the pen. Since needles are not separate components, their details are not included in the COPP.	
▪ The godown address as per DSL is Muller & Phipps Pakistan (Private) Limited while the same is not mentioned anywhere in application or Form 5-F. Clarification required.	DSL of OBS AGP (Pvt) Ltd. (License No. 024) Provided in section 1.34 of Module 01 Address of godown: Muller & Phipps Pakistan (Private) Limited, Plot No. 32-12 Sector 19 K.I.A Karachi Please find attached revised form 5F as Annex 2	

Finished product specifications in the light of 267th meeting of the Registration Board and in the light of “Guidance document regarding application of drug product specifications” conveyed vide Letter No. 9-2/2022-PEC dated 18-12-2023 is required.	The finished product is not included in any pharmacopeia; hence we submitted the specification as per In-House parameters.	
Analytical method validation of drug product is required.	Analytical method validation of drug product is already provided in section 3.2.P.5.3 of dossier, Please find attached AMV as Annex 3.	The firm has stated that “Analytical Method validation performed on strength Foligraf 300 IU / 1200 IU MD Pen, which are applicable for Strength Foligraf 450 IU Multidose Pre Filled Pen”.
Real time stability data of three commercial batches of drug product till claimed shelf life is required. The data given is till 12 months.	Please find 24 M complete stability data for batches #B24722001, #B24722002, #B24722003 enclosed as Annex 4.	Stability data is submitted.
The firm informed that “<i>The clinical study III with recombinant follicle stimulating hormone prefilled pen device is ongoing</i>”.	Please find phase III clinical study (BSV_rhFSH_20_09) enclosed as Annexure 5.	A Randomized, Parallel-group, Multi-Center, Assessor-blind Phase 3 Study to Compare the Efficacy, Safety and Ease of Use of Two Follicle Stimulating Hormone-Human Recombinant (r-hFSH) 900 IU (66.0 µg) / 1.5mL Solution for Injection in Prefilled Pen (Foligraf®-Manufactured by BSV and Gonaf®-Manufactured by Merck Serono) in 257 Subjects Undergoing Controlled Ovarian Stimulation for Assisted Reproductive Technology. The study was conducted at 18 centers i.e., 14 centers across India and 4 centers across Russia. Test Product: Foligraf® 900 IU (66.0 µg) / 1.5mL Solution for Injection in Prefilled Pen (Follicle Stimulating Hormone-Human Recombinant manufactured by Bharat

		Serums and Vaccines Ltd). Reference Product: Gonal-f® 900 IU (66.0 µg) / 1.5mL Solution for Injection in Prefilled Pen [Follicle Stimulating Hormone (Human Recombinant) manufactured by Merck Serono]. Conclusion: In conclusion, the results of the study demonstrated equivalence and similar safety profiles between Foligraf® and Gonal-f® Pen in women undergoing ovarian stimulation for ART.
▪ Bio similarity data as per WHO Bio similarity guidelines in tabular form is required including; ➤ Comparative structural and functional characterization with the Reference product. ➤ Comparative in vitro bioassays for receptor affinity and activation. ➤ Comparative in-vivo potency. ➤ Impurity testing (product related and process related). ➤ Comparative Pharmacokinetic studies ➤ Comparative Toxicology studies (single dose and repeat dose). ➤ Clinical trial data ➤ Immunogenicity in efficacy studies using validated antibody assays of adequate sensitivity and specificity.	➤ Comparative structural and functional characterization is provided in section 3.2.S.3.I Elucidation of Structure and Other Characteristics. Please find attached the same in Annexure 6. ➤ Comparative in vitro bioassays and in vivo potency is provided in section 3.2.S.3.I Elucidation of Structure and Other Characteristics. Please find attached the same in Annexure 6. ➤ Impurity characterization is provided in section 3.2.P.5.5 Characterization of impurities. Please find attached the same in Annexure 7. ➤ Comparative Pharmacokinetic and toxicology studies is provided in Module	i) “Single dose pharmacokinetic study of r-hFSH in comparison with Gonal-f in wistar rats by subcutaneous route.” The study was conducted to evaluate the pharmacokinetic profile of Recombinant Human Follicle Stimulating Hormone (r-hFSH) product developed by Bharat Serums and Vaccines Ltd in comparison with Gonal –f. Test product is r-hFSH 75 IU /150 IU Lyophilized Powder for Injection. ii) “Acute toxicity study of r-hFSH in comparison with Gonal-f in Swiss albino mice by subcutaneous route.” The study was conducted to evaluate the safety and toxicity profile of Recombinant Human Follicle Stimulating Hormone (r-hFSH) product developed by Bharat Serums and Vaccines Ltd in comparison with Gonal –f.

	4, section 4.2.2 Pharmacokinetics and 4.2.3 Toxicology respectively. Please find attached the same in Annexure 8. ➤ Immunogenicity was tested in BABE (Project No. 21-VIN-0318) and Phase 111 (Bsv_rhFSH_20_09) studies of Foligraf pen 900 IU. These studies confirmed of Foligraf pen having low immunogenicity testing. Please find details of immunogenicity enclosed as Annexure 9 and Phase 1 study enclosed as Annexure 10.	Test product is r-FSH 75IU/150IU Lyophilized Powder for Injection. Conclusion: Present study was conducted to assess the toxicological profile of r-hFSH in comparison with Gonal-f in Swiss albino mice at 1.17, 117.0 and 234.0 IU/mice through subcutaneous route. The study concluded that r-hFSH & Gonal-f is a safe substance for given doses in Swiss albino mice when administered through subcutaneous route. iii) “Repeat dose toxicity and local tolerance study of FOLIGRAF in comparison with reference product (Gonal F) in Wistar rats by subcutaneous route”. The study was conducted to assess the toxicity profile of FOLIGRAF and reference product (Gonal F) in Wistar Rats at dose levels of 9 and 90 IU/kg body weight thrice in a week over a period of 90 day by subcutaneous route. Repeat dose administration did not show any clinical signs and mortality at any of the treated dose groups. Animals injected thrice a week over a 90 days did not show any gross pathological abnormalities as well as hostopathological change at injection site. The test product is Foligraf 75IU (Lyophilized powder for Injection).

Decision of 345th RB meeting: *Registration Board deferred for submission of justification, in the light of*

	<i>reference guidelines, for not performing Toxicity studies in applied product. The data submitted is of Lyophilized powder for Injection while the applied product is pre-filled pen and both products are having different excipients.</i>
Evaluation by BE&R:	The firm has submitted a reply which states that; According to EMA guideline on non-clinical development of similar biological medicinal products containing r-hFSH (EMA/597110/2012), the need for additional toxicology studies should be considered only when novel excipients are introduced. Since active Molecule is well established as non-toxic in Human therapeutic dose point of view and minor difference in the excipients used in both formulations which are Generally Recognized As Safe (GRAS) has no toxicological impact on the formulation, no separate toxicity studies are necessitated. Besides, Bio similarity for the product has been established from Quality comparability and Clinical safety/efficacy point of view based on Phase-III study done between BSV formulation and Gonal F formulation. Firm has also given comparison of the formulation of Lyophilized and Multidose pen formulation and stated that both formulations are same except addition of a preservative metacresol which is a Pharmacopoeial excipient and generally regarded as safe and widely used in multidose formulation.
Decision 347 th RB meeting	<i>Registration Board deferred the case for further deliberation</i>
Remarks of BE&R	The case is placed before the Board for decision.
Decision: Keeping in view legalized CoPP indicating product availability in the country of origin, Registration Board approved the product subject to compliance to current import policy.	

Case#03	
Name, address of Applicant / Importer	M/s OBS AGP (Private) Limited. Plot no. B-23-C, 2nd Floor S.I.T.E., Karachi-75700, Pakistan.
Details of Drug Sale License of importer	License No: 024 Address: OBS AGP PRIVATE LIMITED, PLOT NO. B-23-C, 2nd FLOOR S.I.T.E KARACHI. Address of Godown: Muller & Phipps Pakistan (Private) Limited, plot No. 32-12, Sector 19, K.I.A. Karachi. Status: License to sell, stock & exhibit for sale, distribute and sell drugs by way of whole sale by of manufacturer, importer or indenter Valid Upto: 27-03-2028
Name and address of marketing authorization holder (abroad)	M/s Bharat Serums and Vaccines Limited Plot No. K-27, K-27 Part and K-27/1, Anand Nagar, Jambivili Village, Additional MIDC, Ambernath (East), Thane 421506, Maharashtra State, India.
Name, address of manufacturer(s)	M/s Bharat Serums and Vaccines Limited Plot No. K-27, K-27 Part and K-27/1, Anand Nagar, Jambivili Village, Additional MIDC, Ambernath (East), Thane 421506, Maharashtra State, India

Name of exporting country	INDIA
Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	CoPP: Firm has attached original, legalized CoPP (No. COPP/CERT/KD/130682/2023/11/47660/229035) dated 20-10-2023 issued by Food & Drug Administration, MS. Bandra (E), Mumbai-400 051, Maharashtra, India. The CoPP confirms free sale status of the product in exporting country as well as GMP status of the manufacturing site through periodic inspection once a year. The COPP is valid upto 29-03-2025.
Details of letter of authorization / sole agency agreement	Firm has submitted Legalized Letter of Authorization from M/s Bharat Serums and Vaccines Limited issued on 11-12-2023 and valid till 5 years. The letter specifies that the manufacturer appoints M/s OBS AGP Limited to register their products in Pakistan.
Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
E-app Tracking ID and date of submission	E-app Tracking ID XUE-TE4-1US4 Application No. 2339 Receiving date: 22-02-2024
Details of fee submitted	Deposit slip# 0282783851 dated 10-03-2024 of PKR 300,000/-
The proposed proprietary name / brand name	Foligraf 900 IU (Multidose) Pre Filled pen. (Recombinant Human Follicle Stimulating Hormone Injection IH 900 IU (66.0 µg)/1.5ml
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Prefilled pen containing one 3ml cartridge contains: Recombinant Follitropin Concentrated Solution Ph.Eur.....900 IU (66.0 µg)/1.5 ml
Pharmaceutical form of applied drug	Solution for injection in Prefilled pen –Multidose.
Pharmacotherapeutic Group of (API)	Gonadotropin
Reference to Finished product specifications	In House
Proposed Pack size	1's Pre Filled pen + 14 needles 24 months (2-8°C)

Proposed unit price	As per SRO
The status in reference regulatory authorities	Gonal-F Pen 900 IU (66 ug)/1.5ml Solution for Injection in a pre-filled pen M/s. Merck Serono S.P.A. VIA Delle Magnolie (LOC. Frazione Zona Industriale), Italy.
For generic drugs (me-too status)	Gonal-F Pen 900 IU (66 ug)/1.5ml Solution for Injection in a pre-filled pen Imported by Martin Dow Specialities Pvt.Limited, Karachi.
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Name, address of drug substance manufacturer	M/s Bharat Serums and Vaccines Limited Plot No. K-27, K-27 Part and K-27/1, Anand Nagar, Jambivili Village, Additional MIDC, Ambernath (East) Thane-421506, Maharashtra, India.
Module-III Drug Substance	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of API (BB4019001, BB4020001, BB4020002) conducted at accelerated conditions 5°C ± 3°C RH for 6 months as well as real time conditions. The real time stability data is conducted at -20°C ± 5°C for 36 months.
Module-III Drug Product	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Analytical method validation/verification of product	The firm informed that “Excipients used in Manufacturing of Foligraf 900 IU I Multidose Pre Filled Pen (Recombinant Human Follicle Stimulating Hormone Injection IH 900 IU (66.0µg)

		/1.5ml) are official in pharmacopeia. Hence it does not necessitate analytical method validation".	
	Container closure system of the drug product	The 'Foligraf (Multidose) Prefilled Pen' is filled into clear, colorless USP Type-I siliconized glass cartridges with combiseal, each having a 3 ml geometric volume, and sealed with 10 mm halobutyl cartridge stoppers. This system serves as the primary container packaging for this drug product because of its contact with the packaging material.	
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches (B24822001, B24822002, B24822003). The accelerated stability study is conducted at 25°C ± 2°C / 60% ± 5%RH at 0, 3 and 6 months' time interval. The real time stability study is conducted at 5°C ± 3°C at 0, 3, 6, 9 and 12 months. The firm has submitted a statement that they will provide complete data of 24 Months as and when available.	
	Biosimilarity data	Firm has claimed the product Biosimilar to "Gonal-F 450 IU" by Merck Serono S.p.A, Italy. The studies provided in module 4 and module 5 are of some other product containing lyophilized powder for injection while the applied product is solution for injection in prefilled pen. The firm has further informed that "The clinical study III with recombinant follicle stimulating hormone prefilled pen device is ongoing". Bio similarity data as per WHO Bio similarity guidelines in tabular form is required including; ➤ Comparative structural and functional characterization with the Reference product. ➤ Comparative in vitro bioassays for receptor affinity and activation. ➤ Comparative in-vivo potency. ➤ Impurity testing (product related and process related). ➤ Comparative Pharmacokinetic studies ➤ Comparative Toxicology studies (single dose and repeat dose). ➤ Clinical trial data	
	Shortcomings/Observations communicated to the firm ■ Pack size as per COPP is "Each prefilled pen containing one 3ml cartridge" while the pack size as per application/dossier is "1.5ml x 1's (One Carton contains one labeled Pen (Multidose) along with 14 needles and one insert.)"	Reply of the Firm Each prefilled pen contains one 3 ml labeled siliconized sterile glass cartridge, which contains 1.5ml solution for injection i.e (9001U Recombinant human follicle stimulating hormone) 3ml is the size of cartridge. For details see Annex 1-	Remarks of Evaluator

	3.2.P.7 "Container Closure System"	
The reference product Gonal F contains Follitropin alpha while the applied product contains follitropin concentrated solution (Ph.Eur). Clarification required.	Our development and clinical development have been in comparison to Gonal-f which is Follitropin Alfa, but not adopted its name. We have adopted the name as per Ph. Eur Follitropin Concentrated Solution.	
Needles details are not mentioned in COPP.	In 900 IU / 1.5 ml Solution for Injection Each Carton contains: 1 Foligraf multi-dose prefilled pen, along with 14 sterile pen needles. Needles are provided for 13 different doses, an additional needle is included and needle is considered part of the pen. Since needles are not separate components, their details are not included in the COPP.	
The godown address as per DSL is Muller & Phipps Pakistan (Private) Limited while the same is not mentioned anywhere in application or Form 5-F. Clarification required.	DSL of OBS AGP (Pvt) Ltd. (License No. 024) Provided in section 1.34 of Module 01 Address of godown: Muller & Phipps Pakistan (Private) Limited, Plot No. 32-12 Sector 19 K.I.A Karachi Please find attached revised form 5F as Annex 2	
Finished product specifications in the light of 267th meeting of the Registration Board and in the light of "Guidance document regarding application of drug product specifications" conveyed vide Letter No. 9-2/2022-PEC dated 18-12-2023 is required.	The finished product is not included in any pharmacopeia; hence we submitted the specification as per In-House parameters.	
Analytical method validation of drug product is required.	Analytical method validation of drug product is already provided in section 3.2.P.5.3 of dossier,	The firm has stated that "Analytical Method validation performed on strength Foligraf 300 IU / 1200 IU MD Pen, which

	Please find attached AMV as Annex 3.	are applicable for Strength Foligraf 450 IU Multidose Pre Filled Pen”.
Real time stability data of three commercial batches of drug product till claimed shelf life is required. The data given is till 12 months.	Please find 24 M complete stability data for batches #B24822001, #B24822002, #B24822003 enclosed as Annex 4.	Stability data is submitted.
The firm informed that “<i>The clinical study III with recombinant follicle stimulating hormone prefilled pen device is ongoing</i>”.	Please find phase III clinical study (BSV_rhFSH_20_09) enclosed as Annexure 5.	A Randomized, Parallel-group, Multi-Center, Assessor-blind Phase 3 Study to Compare the Efficacy, Safety and Ease of Use of Two Follicle Stimulating Hormone-Human Recombinant (r-hFSH) 900 IU (66.0 µg) / 1.5mL Solution for Injection in Prefilled Pen (Foligraf®-Manufactured by BSV and Gonal-f® Manufactured by Merck Serono) in 257 Subjects Undergoing Controlled Ovarian Stimulation for Assisted Reproductive Technology. The study was conducted at 18 centers i.e., 14 centers across India and 4 centers across Russia. Test Product: Foligraf® 900 IU (66.0 µg) / 1.5mL Solution for Injection in Prefilled Pen (Follicle Stimulating Hormone-Human Recombinant manufactured by Bharat Serums and Vaccines Ltd). Reference Product: Gonal-f® 900 IU (66.0 µg) / 1.5mL Solution for Injection in Prefilled Pen [Follicle Stimulating Hormone (Human Recombinant) manufactured by Merck Serono]. Conclusion: In conclusion, the results of the study demonstrated

		equivalence and similar safety profiles between Foligraf® and Gonal-f® Pen in women undergoing ovarian stimulation for ART.
▪ Bio similarity data as per WHO Bio similarity guidelines in tabular form is required including; ➤ Comparative structural and functional characterization with the Reference product. ➤ Comparative in vitro bioassays for receptor affinity and activation. ➤ Comparative in-vivo potency. ➤ Impurity testing (product related and process related). ➤ Comparative Pharmacokinetic studies ➤ Comparative Toxicology studies (single dose and repeat dose). ➤ Clinical trial data ➤ Immunogenicity in efficacy studies using validated antibody assays of adequate sensitivity and specificity	➤ Comparative structural and functional characterization is provided in section 3.2.S.3.1 Elucidation of Structure and Other Characteristics. Please find attached the same in Annexure 6. ➤ Comparative in vitro bioassays and in vivo potency is provided in section 3.2.S.3.I Elucidation of Structure and Other Characteristics. Please find attached the same in Annexure 6. ➤ Impurity characterization is provided in section 3.2.P.5.5 Characterization of impurities. Please find attached the same in Annexure 7. ➤ Comparative Pharmacokinetic and toxicology studies is provided in Module 4, section 4.2.2 Pharmacokinetics and 4.2.3 Toxicology respectively. Please find attached the same in Annexure 8. ➤ Immunogenicity was tested in BABE (Project No. 21-VIN-0318) and Phase 111 (Bsv_rhFSH_20_09) studies of Foligraf pen	i) “Single dose pharmacokinetic study of r-hFSH in comparison with Gonal-f in wistar rats by subcutaneous route.” The study was conducted to evaluate the pharmacokinetic profile of Recombinant Human Follicle Stimulating Hormone (r-hFSH) product developed by Bharat Serums and Vaccines Ltd in comparison with Gonal –f. Test product is r-hFSH 75 IU /150 IU Lyophilized Powder for Injection. ii) “Acute toxicity study of r-hFSH in comparison with Gonal-f in Swiss albino mice by subcutaneous route.” The study was conducted to evaluate the safety and toxicity profile of Recombinant Human Follicle Stimulating Hormone (r-hFSH) product developed by Bharat Serums and Vaccines Ltd in comparison with Gonal –f. Test product is r-FSH 75IU/150IU Lyophilized Powder for Injection. Conclusion: Present study was conducted to assess the toxicological profile of r-hFSH in comparison with Gonal-f in Swiss albino mice at 1.17, 117.0 and 234.0 IU/mice through subcutaneous route. The study concluded that r-

		900 IU. These studies confirmed of Foligraf pen having low immunogenicity testing. Please find details of immunogenicity enclosed as Annexure 9 and Phase 1 study enclosed as Annexure 10.	hFSH & Gonal-f is a safe substance for given doses in Swiss albino mice when administered through subcutaneous route. iii) "Repeat dose toxicity and local tolerance study of FOLIGRAF in comparison with reference product (Gonal F) in Wistar rats by subcutaneous route". The study was conducted to assess the toxicity profile of FOLIGRAF and reference product (Gonal F) in Wistar Rats at dose levels of 9 and 90 IU/kg body weight thrice in a week over a period of 90 day by subcutaneous route. Repeat dose administration did not show any clinical signs and mortality at any of the treated dose groups. Animals injected thrice a week over a 90 days did not show any gross pathological abnormalities as well as histopathological change at injection site. The test product is Foligraf 75IU (Lyophilized powder for Injection).	
Decision of 345 th RB meeting:	<i>Registration Board deferred for submission of justification, in the light of reference guidelines, for not performing Toxicity studies in applied product. The data submitted is of Lyophilized powder for Injection while the applied product is pre-filled pen and both products are having different excipients.</i>			
Evaluation by BE&R:	The firm has submitted a reply which states that; According to EMA guideline on non-clinical development of similar biological medicinal products containing r-hFSH (EMA/597110/2012), the need for additional toxicology studies should be considered only when novel excipients are introduced. Since active Molecule is well established as non-toxic in Human therapeutic dose point of view and minor difference in the excipients used in both formulations which are Generally Recognized As Safe (GRAS) has no toxicological impact on the formulation, no separate toxicity studies are necessitated. Besides, Bio similarity for the product has been established from Quality			

	comparability and Clinical safety/efficacy point of view based on Phase-III study done between BSV formulation and Gonal F formulation. Firm has also given comparison of the formulation of Lyophilized and Multidose pen formulation and stated that both formulations are same except addition of a preservative metacresol which is a Pharmacopoeial excipient and generally regarded as safe and widely used in multidose formulation.
Decision of 347 th RB meeting	<i>Registration Board deferred the case for further deliberation.</i>
Evaluation by BE&R	The case is placed before the Board for decision.
Decision: Keeping in view legalized CoPP indicating product availability in the country of origin, Registration Board approved the product subject to compliance to current import policy.	

Case #04		
Name, address of Applicant / Importer	M/s ORGANS PHARMA Address: Block A, 6th Floor, Plot No. FD 35-36-A7, National Industrial Park, Korangi Creek Karachi.	
Details of Drug Sale License of importer	DSL by way of Wholesale M/s ORGANS PHARMA Address: Block A, 6th Floor, Plot No. FD 35-36-A7, National Industrial Park, Korangi Creek Karachi. Address of Godown: Plot no. B-98 Sector 6F 1 st floor Mehran Town, Korangi Industrial Area, Karachi. License No.: 0616 Valid till: 26.09.2028	
Name and address of marketing authorization holder (abroad)	M/s Intas Pharmaceuticals Limited INTAS PHARMACEUTICALS LIMITED Plot No. – 85/87, Kailash Industrial Estate Vill.-Iyava, Tal- Sanand, Dist.- Ahmedabad , Gujarat, India.	
Name, address of manufacturer(s)	M/s Intas Pharmaceuticals Limited INTAS PHARMACEUTICALS LIMITED Plot No. – 85/87, Kailash Industrial Estate Vill.-Iyava, Tal- Sanand, Dist.- Ahmedabad , Gujarat, India. Manufacturer of Diluent: M/s. SOVEREIGN PHARMA PVT. LTD. Survey No .46/1- 4, Kadaiya, Nani Daman – 396210 India.	
Name of exporting country	India	

Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	CoPP: Firm has attached CoPP (MFG/WHO GMP/COPP/2024/3007243197) valid up to 07-08-2025 issued by Food & Drugs Control Administration, Gujarat State, India attested by Ministry of External Affairs . The CoPP specifies that the product is licensed to be placed for use in the exporting country as well as the product is actually in the market in exporting country. The CoPP confirms the GMP status of the manufacturing site through periodic inspection Once a year.
Details of letter of authorization / sole agency agreement	Firm has submitted notarized copy of Letter of Authorization The letter was issued on February 29 th , 2024 and valid for five (5) years from the date of signature.
Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Bulk import and local repackaging ☐ Bulk import and local repackaging for export purpose only
Dy. No. and Date of submission	E-app Tracking ID: MJS-GAW-GB7H Application No: 37478 Receiving Date: 13-09-2024
Details of fee submitted	Deposit Slip No. 051595295335 of Rs.300,000/-dated 11-06-2024
The proposed proprietary name / brand name	CORIOSURGE XP 5000 (Chorionic Gonadotrophin for Injection BP 5000 IU/Vial)
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each combipack contains; A. Chorionic Gonadotrophin for Injection BP 5000 IU/vial, lyophilized B. Sodium Chloride Injection BP 0.9%w/v, 1 ml ampoule
Pharmaceutical form of applied drug	Lyophilized Powder for injection; and solvent for parenteral use Each Vial contains:

	API: Chorionic Gonadotrophin (Refined Powder) 5000 IU (BP) Excipients: Mannitol (BP) Dibasic potassium phosphate (BP) Potassium dihydrogen phosphate (BP) Water for injection (BP) Nitrogen gas (USNF & Ph.Eur.) Each vial of the CORIOSURGE XP 5000 is accompanied by 1 ml ampoule of sodium chloride Injection BP 0.9%w/v.
Pharmacotherapeutic Group of (API)	Hormone. Code ATC: G03GA01.
Reference to Finished product specifications	BP Specifications
Proposed Pack size	1's vial (lyophilized part) + 1's ampoule (solvent)
Proposed unit price	As per latest SRO
Shelf Life	3 years (36 Months)
Storage Condition	Store between 2°C-8°C
The status in reference regulatory authorities	Pregnyl 5000IU of M/s Merk Sharp & Dohme, UK.
For generic drugs (me-too status)	IVF-C 5000 IU (Galaxy Pharma (Pvt) Ltd., Karachi) Reg. No.: 039811
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
Name, address of drug substance manufacturer	Name of manufacturer: Shanghai Techwell Biopharmaceutical Co., Ltd (Herein referred to as "Techwell") Address of manufacturer: No. 4258, Jindu Road, Minhang District, Shanghai 201108, China
Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data as under: Accelerated testing conditions: Batch No: 051101, 051102, 051201 Preserve at 40±2°C, 75%±5%RH for 6 months Long term testing conditions: Batch No: 051101, 051102, 051201 Preserve at 25±2 °C, 60%±5%RH for 60 months.

Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Analytical method validation/verification of product	Firm has performed analytical method validation for Sterility and Bacterial Endotoxin test.
Container closure system of the drug product	CORIOSURGE XP 5000 is supplied as a combipack of Chorionic Gonadotrophin for Injection BP 5000 IU/vial & 1ml ampoule of diluent sodium chloride Inj BP 0.9%w/v. packed in a HIPS tray (vial + Ampoule)
Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 03 batches. Stability studies were conducted on three batches of SHX002, SHX005, SHX010. Accelerated stability at 25°C±2°C/60%± 5%RH for 6 months and Long-term stability at 2 to 8°C for 36 months. For Diluent Sodium Chloride Injection BP (0.9% w/v), 1 mL, Batch Number SP18009, SP18010, SP19010 real time stability at 30 ± 2 °C, 65 ± 5% RH for 48 months and accelerated stability at 40 ± 2 °C, 75 ± 5% RH for 6 months.
Module IV	Literature references and Package insert of Pregnyl 5000IU is attached.
Module V	Literature references and Package insert of Pregnyl 5000IU is attached.
Remarks of Evaluator: - Original Legalized COPP is required in hard copy. - The address of MAH on LOA is different from that on COPP. - Manufacturer of Diluent is M/s. SOVEREIGN PHARMA PVT. LTD. Survey No .46/1-4, Kadaiya, Nani Daman – 396210 India while the same is not mentioned in COPP. - Process development of DS and its validation is not provided. - The label in 3.2.S.6.3 shows to store the DS at 2-8 °C while the stability data at 2-8°C is not provided. - Module 3.2.S.7.3 provided is of Menotropin API. 20% overage is added in the formulation. Proper justification is required in comparison with the innovator. - API manufacturer/vendor mentioned in stability data is M/s Qingdao Kangyuan Pharma instead of M/s Shanghai Techwell. - Diluent stability at 2-8°C is not performed. - GMP certificate of diluent manufacturer is required. - The finished product manufacturer does not have biological section as per GMP certificate. Clarification required. - In-use stability data is not provided. - Module 4 (safety data) and Module 5 (Efficacy data) are not provided.	
Decision of 345th RB meeting: Registration Board deferred for submission of following documents/clarification; Original Legalized COPP in hard copy.	

b) The address of MAH on LOA is different from that on COPP. c) Manufacturer of Diluent is M/s. SOVEREIGN PHARMA PVT. LTD. Survey No .46/1-4, Kadaiya, Nani Daman – 396210 India while the same is not mentioned in COPP. d) Process development of DS and its validation is required. e) The label in 3.2.S.6.3 shows to store the DS at 2-8 °C while the stability data at 2-8 °C is not provided. f) Module 3.2.S.7.3 provided is of Menotropin API. g) 20% overage is added in the formulation. Proper justification is required in comparison with the innovator. h) API manufacturer/vendor mentioned in stability data is M/s Qingdao Kangyuan Pharma instead of M/s Shanghai Techwell. i) Diluent stability at 2-8°C is not performed. j) GMP certificate of diluent manufacturer is required. k) The finished product manufacturer does not have biological section as per GMP certificate. Clarification required. l) In-use stability data is not provided. m) Module 4 (safety data) and Module 5 (Efficacy data) are not provided.				
Evaluation by BE&R: The firm has submitted a reply as under;				
Sr.No.	Clarifications/Shortcomings	Response of the applicant	Remarks evaluator	of
1	Original Legalized COPP in hard copy.	Submitted	Submitted	
2	The address of MAH on LOA is different from that on COPP.	We have noted the comments of authority. We would like to inform the authority that for the LOA we have the details of Marketing Authorization holder (Our Corporate office address) MA Holder: Intas Pharmaceuticals Ltd Corporate House, Nr. Sola Bridge, S. G. Highway, Thaltej, Ahmedabad-380054, INDIA Gujarat, INDIA Whereas the COPP states the details of the Manufacturing site where the product is manufactured: Manufacturer: Intas Pharmaceuticals Ltd., Plot No.: 85/87, Kailash Industrial Estate, Village – Iyava, Tal.: Sanand, Dist.: Ahmedabad	COPP states that manufacturer is the product license holder also. So, in LOA MAH address should be the same as in COPP.	
3	Manufacturer of Diluent is M/s. SOVEREIGN PHARMA PVT. LTD. Survey No .46/1-4, Kadaiya, Nani Daman – 396210 India while the same is not mentioned in COPP.	Please be noted that the COPP is prepared digitally by the Food & Drugs Control Administration, Gujarat State, Jivraj Mehta Bhavan, Block No. 8, 1st Floor, Gandhinagar (INDIA). It is having a Set format and there is no provision to mention the address of M/Sovereign. Whereas the Product permission states the name of the manufacturer of the diluent M/s Sovereign. Please find enclosed the Product permission enclosed as Annexure 1 .	License retention and product list attached.	
4	Process development of DS and its validation is required.	We have noted the comments of authority. We would like to inform the authority that Process development and its validation are described in the restricted part of DMF. API supplier has submitted the restricted part of DMF is enclosed as Annexure II .	Submitted	
5	The label in 3.2.S.6.3 shows	We have noted the comment of the Authority. We	Submitted	

	to store the DS at 2-8 °C while the stability data at 2-8°C is not provided.	would like to inform the Authority that stability data at 2-8 °C was provided in Section 3.2.S.7.3 (on the last page of DMF) of Module 3.																															
6	Module 3.2.S.7.3 provided is of Menotropin API.	We acknowledge the agency’s comment. Herewith we are submitting updated stability Sections as 3.2.S.7.1, 3.2.S.7.2 and 3.2.S.7.3 of Module 3.	Submitted																														
7	20% overage is added in the formulation. Proper justification is required in comparison with the innovator.	We have noted the comment of authority. We would like to inform the authority that during filtration process, the bulk solution of Chorionic Gonadotrophin for Injection directly comes in contact with filter. Hence, adsorption of active (Chorionic Gonadotrophin) from bulk solution of chorionic Gonadotrophin for Injection due to filter need to be study. 0.2µ PES filter, Pall (47mm, Cat. No. FTKEKV) filter and 0.22µ PVDF filter, Millipore (47mm, Item No. GVWP04700) was selected for the adsorption study of active (Chorionic Gonadotrophin) from Bulk solution. 450 mL bulk solution of chorionic Gonadotrophin for Injection was prepared and 25 mL of unfiltered bulk solution keep as control sample. Remaining bulk solution was divided into two parts. First part of bulk solution was filter through 0.2µ PES filter (47mm), Pall filter and second part through 0.2µ PVDF filter (47 mm), Millipore. After filtration, bulk solution (control and test) filled to vial & lyophilized. Lyophilized product was analyzed for Assay and the analytical results are given in following table. Table: Analytical results of Adsorption of Chorionic Gonadotrophin API from bulk solution (Lyophilized Product) <table><tr><td>Product:</td><td colspan="4">Chorionic Gonadotrophin for Injection</td></tr><tr><td>Batch Size:</td><td>450 mL</td><td>Batch No:</td><td colspan="2">INCHGP1004/ INCHGP1004A/INCHGP1004B</td></tr><tr><td colspan="5">Details of Filters used for Aseptic Sterile Filtration</td></tr><tr><td>Material of Construction</td><td>Manufacturer</td><td>Size</td><td>Pore size</td><td>Cat. No / Item No.</td></tr><tr><td>PES</td><td>Pall</td><td>47 mm</td><td>0.2µ</td><td>FTKEKV</td></tr><tr><td>PVDF</td><td>Millipore</td><td>47 mm</td><td>0.22µ</td><td>GVWP04700</td></tr></table>	Product:	Chorionic Gonadotrophin for Injection				Batch Size:	450 mL	Batch No:	INCHGP1004/ INCHGP1004A/INCHGP1004B		Details of Filters used for Aseptic Sterile Filtration					Material of Construction	Manufacturer	Size	Pore size	Cat. No / Item No.	PES	Pall	47 mm	0.2µ	FTKEKV	PVDF	Millipore	47 mm	0.22µ	GVWP04700	
Product:	Chorionic Gonadotrophin for Injection																																
Batch Size:	450 mL	Batch No:	INCHGP1004/ INCHGP1004A/INCHGP1004B																														
Details of Filters used for Aseptic Sterile Filtration																																	
Material of Construction	Manufacturer	Size	Pore size	Cat. No / Item No.																													
PES	Pall	47 mm	0.2µ	FTKEKV																													
PVDF	Millipore	47 mm	0.22µ	GVWP04700																													
		Table: Analytical results of Adsorption of																															

		Chorionic Gonadotrophin API from bulk solution (Lyophilized Product) <table><tr><td colspan="2">Batch No.</td><td>INCHGP1004</td><td>INCHGP1004A</td><td>INCHGP1004C</td></tr><tr><td colspan="2"></td><td>Control Sample</td><td>PES Filtered</td><td>PVDF Filtered</td></tr><tr><td colspan="2">AR No.</td><td></td><td></td><td></td></tr><tr><td>Test Parameters</td><td>Limits</td><td>INHCGP40001</td><td>INHCGP40002</td><td>INHCGP40004</td></tr><tr><td></td><td>Not less than 80 % and not more than 125 % of the stated potency. The fiducial limits of error should not less than 64% and not more than 156% of the stated potency.</td><td></td><td></td><td></td></tr><tr><td>Assay</td><td></td><td>116.01%</td><td>92.44%</td><td>91.71%</td></tr></table> Based on the review of above-mentioned data of Adsorption of active (chorionic Gonadotrophin) from bulk solution was observed due to both types filters (PVDF & PES). So 20% overages need to be added in to bulk solution to compensate loss of active (Chorionic Gonadotrophin) from bulk solution due to filter adsorption. Adsorption of active (Chorionic Gonadotrophin) from bulk solution due to PVDF filter was observed higher compare to PES filter. Hence PES filter was selected for further compatibility study of Chorionic Gonadotrophin for Injection BP 5000 IU/Vial. Herewith we are submitting the updated Process development report as Section 3.2.P.2 in Module 3.	Batch No.		INCHGP1004	INCHGP1004A	INCHGP1004C			Control Sample	PES Filtered	PVDF Filtered	AR No.					Test Parameters	Limits	INHCGP40001	INHCGP40002	INHCGP40004		Not less than 80 % and not more than 125 % of the stated potency. The fiducial limits of error should not less than 64% and not more than 156% of the stated potency.				Assay		116.01%	92.44%	91.71%		
Batch No.		INCHGP1004	INCHGP1004A	INCHGP1004C																														
		Control Sample	PES Filtered	PVDF Filtered																														
AR No.																																		
Test Parameters	Limits	INHCGP40001	INHCGP40002	INHCGP40004																														
	Not less than 80 % and not more than 125 % of the stated potency. The fiducial limits of error should not less than 64% and not more than 156% of the stated potency.																																	
Assay		116.01%	92.44%	91.71%																														
8	API manufacturer/vendor mentioned in stability data is M/s Qingdao Kangyuan Pharma instead of M/s Shanghai Techwell.	We acknowledge the agency’s comment. The initial stability data for Batches SHX002, SHX005 & SHX010 were manufactured using the API from Qingdao. Herewith we are submitting the stability data for the current API manufacturer Techwell as Section 3.2.P.8.3 in Module 3. API manufacturer Qingdao does not support INTAS for registration.																																
9	Diluent stability at 2-8°C is not performed.	We acknowledge the agency’s comment. We would like to inform the authority that the Diluent stability is performed for Long term at 30°C & 75% RH and accelerated at 40°C & 75% RH. The labelled storage condition for diluent is ‘Store below 30°C’. Hence stability at 2-8°C is not required.																																
10	GMP certificate of diluent manufacturer is required.	We acknowledge the agency’s comment. Herewith we are submitting the valid GMP certificate of diluent manufacturer Sovereign Pharm as Annexure III .																																
11	In-use stability data is not provided.	We have noted the comments of authority. We would like to inform agency that the product Chorionic Gonadotrophin for Injection is a single	-																															

		use vial. The Injection is reconstituted with 1ml of Sodium Chloride Injection BP (0.9% w/v) and administered subcutaneously or intramuscularly immediately. Any unused reconstituted material should be discarded. Thus the In-use stability data is not performed as the product is to be used immediately. Moreover the reconstitution data for the product is performed for every batch and is controlled in the finished specification with the Limit of Not more than 180 seconds.		
13	Module 4 (safety data) and Module 5 (Efficacy data) are not provided.	We have noted the comments of the authority. We would like to inform the Authority that Chorionic Gonadotrophin for Injection is a Lyophilized vial. The Injection is reconstituted with 1ml of Sodium Chloride Injection BP (0.9% w/v) and administered subcutaneously or intramuscularly immediately. In reference to the EMEA guidelines Note for guidance on the investigation of bioavailability and bioequivalence" Doc. Ref.: CPMP/EWP/QWP/1401/98 Rev. 1/ Corr 20 January 2010, the BE study is not required for Parenteral preparations. Moreover, the Literature reference for the Clinical study reports are enclosed in Module 4 & 5.	The applied product is not a biosimilar. So, complete module 4 and module 5 are required.	

Concluding remarks by BE&R:

The case is still deficient for the submission of complete Module 4 and Module 5 as per CTD format.

Decision:

Registration Board deferred the case for submission of Module 4 (Non-clinical/safety data) and Module 5 (Clinical/efficacy data) of the applied product.

Case # 05		
	Name, address of Applicant / Importer	M/s ORGANS PHARMA Address: Block A, 6th Floor, Plot No. FD 35-36-A7, National Industrial Park, Korangi Creek Karachi.
	Details of Drug Sale License of importer	DSL by way of Wholesale M/s ORGANS PHARMA Address: Block A, 6th Floor, Plot No. FD 35-36-A7, National Industrial Park, Korangi Creek Karachi. Address of Godown: Plot no. B-98 Sector 6F 1st floor Mehran Town, Korangi Industrial Area, Karachi. License No.: 0616 Valid till: 26.09.2028
	Name and address of	M/s Intas Pharmaceuticals Limited INTAS

marketing authorization holder (abroad)	PHARMACEUTICALS LIMITED Plot No. – 85/87, Kailash Industrial Estate Vill.-Iyava, Tal- Sanand, Dist.- Ahmedabad , Gujarat, India.
Name, address of manufacturer(s)	M/s Intas Pharmaceuticals Limited INTAS PHARMACEUTICALS LIMITED Plot No. – 85/87, Kailash Industrial Estate Vill.-Iyava, Tal- Sanand, Dist.- Ahmedabad , Gujarat, India. Manufacturer of Diluent: M/s. SOVEREIGN PHARMA PVT. LTD. Survey No .46/1-4, Kadaiya, Nani Daman – 396210 India.
Name of exporting country	India
Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	CoPP: Firm has attached CoPP (MFG/WHO GMP/COPP/2024/2550243200) valid up to 07-08-2025 issued by Food & Drugs Control Administration, Gujrat State, India attested by Ministry of External Affairs. The CoPP specifies that the product is licensed to be placed for use in the exporting country as well as the product is actually in the market in exporting country. The CoPP confirms the GMP status of the manufacturing site through periodic inspection Once a year.
Details of letter of authorization / sole agency agreement	Firm has submitted notarized copy of Letter of Authorization The letter was issued on February 29 th , 2024 and valid for five (5) years from the date of signature.
Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Bulk import and local repackaging ☐ Bulk import and local repackaging for export purpose only
Dy. No. and Date of submission	E-app Tracking ID: ENH-836-4TYJ Application No: 37805 Receiving Date: 13-09-2024
Details of fee submitted	Deposit Slip No. 1094220740 of Rs.300,000/-dated 11-06-2024

The proposed proprietary name / brand name	CORIOSURGE XP 10000 (Chorionic Gonadotrophin for Injection BP 10000 IU/Vial)
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Chorionic Gonadotrophin for Injection BP 10000 IU
Pharmaceutical form of applied drug	Lyophilized Powder for injection; and solvent for parenteral use Each Vial contains: API: Chorionic Gonadotrophin (Refined Powder) 10000 IU (BP) Excipients: Mannitol (BP) Dibasic potassium phosphate (BP) Potassium dihydrogen phosphate (BP) Water for injection (BP) Nitrogen gas (USNF & Ph.Eur.) Each vial of the CORIOSURGE XP 10000 is accompanied by 1 ml ampoule of sodium chloride Injection BP 0.9%w/v.
Pharmacotherapeutic Group of (API)	Hormone. Code ATC: G03GA01.
Reference to Finished product specifications	BP Specifications
Proposed Pack size	1's vial (lyophilized part) + 1's ampoule (solvent)
Proposed unit price	As per latest SRO
Shelf Life	3 years (36 Months)
Storage Condition	Store between 2°C-8°C
The status in reference regulatory authorities	Pregnyl 10000IU of M/s Merk Sharp & Dohme, UK.
For generic drugs (me-too status)	Product Name: Pubergen 10000 IU Registration No: 115108 Imported by: Bristol Mayer Biotech Pakistan
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
Name, address of drug substance manufacturer	Name of manufacturer: Shanghai Techwell Biopharmaceutical Co., Ltd (Herein referred to as "Techwell") Address of manufacturer: No. 4258, Jindu Road, Minhang District, Shanghai 201108, China
Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties,

		solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data as under: Accelerated testing conditions: Batch No: 051101, 051102, 051201 Preserve at 40±2°C, 75%±5%RH for 6 months Long term testing conditions: Batch No: 051101, 051102, 051201 Preserve at 25±2 °C, 60%±5%RH for 60 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Analytical method validation/verification of product	Firm has performed analytical method validation for Sterility and Bacterial Endotoxin test.
	Container closure system of the drug product	CORIOSURGE XP 10000 is supplied as a combipack of Chorionic Gonadotrophin for Injection BP 10000 IU/vial & 1ml ampoule of diluent sodium chloride Inj BP 0.9%w/v. packed in a HIPS tray (vial + Ampoule)
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 03 batches. Stability studies were conducted on three batches of Chorionic Gonadotrophin for Injection BP 10000 IU/vial) S2100015, S2100018, S2100026. Accelerated stability at 25°C±2°C/60%± 5%RH for 6 months and Long-term stability at 2 to 8°C for 24 months and further study was under process. For Diluent Sodium Chloride Injection BP (0.9% w/v), 1 mL, Batch Number SP18009, SP18010, SP19010 real time stability at 30 ± 2 °C, 65 ± 5% RH for 48 months and accelerated stability at 40 ± 2 °C, 75 ± 5% RH for 6 months.
	Module IV	Literature references and Package insert of Pregnyl 10000IU is attached.

	Module V	Literature references and Package insert of Pregnyl 10000IU is attached.

Remarks of Evaluator:

- i. The address of Marketing Authorization Holder in LOA is different from that in COPP.
- ii. Process development of DS and its validation is not provided.
- iii. The label in 3.2.S.6.3 shows to store the DS at 2-8 °C while the stability data at 2-8°C is not provided.
- iv. Module 3.2.S.7.3 provided is of Menotropin API.
- v. 20% overage is added in the formulation. Proper justification is required in comparison with the innovator.
- vi. Real time stability data of Drug product is provided till 24 months while the claimed shelf life is 36 months. Stability data till claimed shelf life is required.
- vii. Diluent stability at 2-8°C is not provided.
- viii. GMP certificate of diluent manufacturer is required.
- ix. The finished product manufacturer does not have biological section as per GMP certificate. Clarification required.
- x. In-use stability data is not provided.
- xi. Module 4 (safety data) and Module 5 (Efficacy data) are not provided.

Decision of 345th RB meeting: Registration Board deferred for submission of following documents/clarification;

- a) The address of Marketing Authorization Holder in LOA is different from that in COPP.
- b) Process development of DS and its validation is not provided.
- c) The label in 3.2.S.6.3 shows to store the DS at 2-8 °C while the stability data at 2-8 °C is not provided.
- d) Module 3.2.S.7.3 provided is of Menotropin API.
- e) 20% overage is added in the formulation. Proper justification is required in comparison with the innovator.
- f) Real time stability data of Drug product is provided till 24 months while the claimed shelf life is 36 months. Stability data till claimed shelf life is required.
- g) Diluent stability at 2-8°C is not provided.
- h) GMP certificate of diluent manufacturer is required.
- i) The finished product manufacturer does not have biological section as per GMP certificate. Clarification required.
- j) In-use stability data is not provided.
- k) Module 4 (safety data) and Module 5 (Efficacy data) are not provided.

Evaluation by BE&R:

The firm has submitted a reply as under;

Sr.No.	Clarifications/Shortcomings	Response of the applicant	Remarks of evaluator
1	Original Legalized COPP in hard copy.	Submitted	Submitted
2	The address of MAH on LOA is different from that on COPP.	We have noted the comments of authority. We would like to inform the authority that for the LOA we have the details of Marketing Authorization holder (Our Corporate office address) MA Holder: Intas Pharmaceuticals Ltd Corporate House, Nr. Sola Bridge, S. G. Highway, Thaltej, Ahmedabad-380054, INDIA Gujarat, INDIA Whereas the COPP states the details of the Manufacturing site where the product is	COPP states that manufacturer is the product license holder also. So, in LOA MAH address should be the same as in COPP.

		manufactured: Manufacturer: Intas Pharmaceuticals Ltd., Plot No.: 85/87, Kailash Industrial Estate, Village – Iyava, Tal.: Sanand, Dist.: Ahmedabad	
3	Manufacturer of Diluent is M/s. SOVEREIGN PHARMA PVT. LTD. Survey No .46/1-4, Kadaiya, Nani Daman – 396210 India while the same is not mentioned in COPP.	Please be noted that the COPP is prepared digitally by the Food & Drugs Control Administration, Gujarat State, Jivraj Mehta Bhavan, Block No. 8, 1st Floor, Gandhinagar (INDIA). It is having a Set format and there is no provision to mention the address of M/Sovereign. Whereas the Product permission states the name of the manufacturer of the diluent M/s Sovereign. Please find enclosed the Product permission enclosed as Annexure 1.	License retention and product list attached.
4	Process development of DS and its validation is required.	We have noted the comments of authority. We would like to inform the authority that Process development and its validation are described in the restricted part of DMF. API supplier has submitted the restricted part of DMF is enclosed as Annexure II.	Submitted
5	The label in 3.2.S.6.3 shows to store the DS at 2-8 °C while the stability data at 2-8°C is not provided.	We have noted the comment of the Authority. We would like to inform the Authority that stability data at 2-8 °C was provided in Section 3.2.S.7.3 (on the last page of DMF) of Module 3.	Submitted
6	Module 3.2.S.7.3 provided is of Menotropin API.	We acknowledge the agency's comment. Herewith we are submitting updated stability Sections as 3.2.S.7.1, 3.2.S.7.2 and 3.2.S.7.3 of Module 3.	Submitted
7	20% overage is added in the formulation. Proper justification is required in comparison with the innovator.	We have noted the comment of authority. We would like to inform the authority that during filtration process, the bulk solution of Chorionic Gonadotrophin for Injection directly comes in contact with filter. Hence, adsorption of active (Chorionic Gonadotrophin) from bulk solution of chorionic Gonadotrophin for Injection due to filter need to be study. 0.2µ PES filter, Pall (47mm, Cat. No. FTKEKV) filter and 0.22µ PVDF filter, Millipore (47mm, Item No. GVWP04700) was selected for the adsorption study of active (Chorionic Gonadotrophin) from Bulk solution. 450 mL bulk solution of chorionic Gonadotrophin for Injection was prepared and 25 mL of unfiltered bulk solution keep as control sample. Remaining bulk solution was divided into two parts. First part of bulk solution was filter through 0.2µ PES filter (47mm),	

		Pall filter and second part through 0.2µ PVDF filter (47 mm), Millipore. After filtration, bulk solution (control and test) filled to vial & lyophilized. Lyophilized product was analyzed for Assay and the analytical results are given in following table. Table: Analytical results of Adsorption of Chorionic Gonadotrophin API from bulk solution (Lyophilized Product) <table><tr><td colspan="2">Product:</td><td colspan="3">Chorionic Gonadotrophin for Injection</td></tr><tr><td colspan="2">Batch Size:</td><td>450 mL</td><td>Batch No:</td><td>INCHGP1004/ INCHGP1004A/INCHGP1004B</td></tr><tr><td colspan="5">Details of Filters used for Aseptic Sterile Filtration</td></tr><tr><td>Material of Construction</td><td>Manufacturer</td><td>Size</td><td>Pore size</td><td>Cat. No./ Item No.</td></tr><tr><td>PES</td><td>Pall</td><td>47 mm</td><td>0.2µ</td><td>FTKEKV</td></tr><tr><td>PVDF</td><td>Millipore</td><td>47 mm</td><td>0.22µ</td><td>GVWP04700</td></tr></table> Table: Analytical results of Adsorption of Chorionic Gonadotrophin API from bulk solution (Lyophilized Product) <table><tr><td colspan="2">Batch No.</td><td>INCHGP1004</td><td>INCHGP1004A</td><td>INCHGP1004C</td></tr><tr><td colspan="2"></td><td>Control Sample</td><td>PES Filtered</td><td>PVDF Filtered</td></tr><tr><td colspan="2">AR No.</td><td></td><td></td><td></td></tr><tr><td>Test Parameters</td><td>Limits</td><td>INHCGP40001</td><td>INHCGP40002</td><td>INHCGP40004</td></tr><tr><td></td><td>Not less than 80 % and not more than 125 % of the stated potency. The fiducial limits of error should not less than 64% and not more than 156% of the stated potency.</td><td></td><td></td><td></td></tr><tr><td>Assay</td><td></td><td>116.01%</td><td>92.44%</td><td>91.71%</td></tr></table> Based on the review of above-mentioned data of Adsorption of active (chorionic Gonadotrophin) from bulk solution was observed due to both types filters (PVDF & PES). So 20% overages need to be added in to bulk solution to compensate loss of active (Chorionic Gonadotrophin) from bulk solution due to filter adsorption. Adsorption of active (Chorionic Gonadotrophin) from bulk solution due to PVDF filter was observed higher compare to PES filter. Hence PES filter was selected for further compatibility study of Chorionic Gonadotrophin for Injection BP 5000 IU/Vial. Herewith we are submitting the updated Process development report as Section 3.2.P.2 in Module 3.	Product:		Chorionic Gonadotrophin for Injection			Batch Size:		450 mL	Batch No:	INCHGP1004/ INCHGP1004A/INCHGP1004B	Details of Filters used for Aseptic Sterile Filtration					Material of Construction	Manufacturer	Size	Pore size	Cat. No./ Item No.	PES	Pall	47 mm	0.2µ	FTKEKV	PVDF	Millipore	47 mm	0.22µ	GVWP04700	Batch No.		INCHGP1004	INCHGP1004A	INCHGP1004C			Control Sample	PES Filtered	PVDF Filtered	AR No.					Test Parameters	Limits	INHCGP40001	INHCGP40002	INHCGP40004		Not less than 80 % and not more than 125 % of the stated potency. The fiducial limits of error should not less than 64% and not more than 156% of the stated potency.				Assay		116.01%	92.44%	91.71%
Product:		Chorionic Gonadotrophin for Injection																																																												
Batch Size:		450 mL	Batch No:	INCHGP1004/ INCHGP1004A/INCHGP1004B																																																										
Details of Filters used for Aseptic Sterile Filtration																																																														
Material of Construction	Manufacturer	Size	Pore size	Cat. No./ Item No.																																																										
PES	Pall	47 mm	0.2µ	FTKEKV																																																										
PVDF	Millipore	47 mm	0.22µ	GVWP04700																																																										
Batch No.		INCHGP1004	INCHGP1004A	INCHGP1004C																																																										
		Control Sample	PES Filtered	PVDF Filtered																																																										
AR No.																																																														
Test Parameters	Limits	INHCGP40001	INHCGP40002	INHCGP40004																																																										
	Not less than 80 % and not more than 125 % of the stated potency. The fiducial limits of error should not less than 64% and not more than 156% of the stated potency.																																																													
Assay		116.01%	92.44%	91.71%																																																										
8	API manufacturer/vendor mentioned in stability data is M/s Qingdao Kangyuan Pharma	We acknowledge the agency’s comment. The initial stability data for Batches SHX002, SHX005 & SHX010 were manufactured using the API from Qingdao. Herewith we are submitting the stability data for the																																																												

	instead of M/s Shanghai Techwell.	current API manufacturer Techwell as Section 3.2.P.8.3 in Module 3. API manufacturer Quingdao does not support INTAS for registration.	
9	Diluent stability at 2-8°C is not performed.	We acknowledge the agency's comment. We would like to inform the authority that the Diluent stability is performed for Long term at 30°C & 75% RH and accelerated at 40°C & 75% RH. The labelled storage condition for diluent is 'Store below 30°C'. Hence stability at 2-8°C is not required.	
10	GMP certificate of diluent manufacturer is required.	We acknowledge the agency's comment. Herewith we are submitting the valid GMP certificate of diluent manufacturer Sovereign Pharm as Annexure III .	
11	In-use stability data is not provided.	We have noted the comments of authority. We would like to inform agency that the product Chorionic Gonadotrophin for Injection is a single use vial. The Injection is reconstituted with 1ml of Sodium Chloride Injection BP (0.9% w/v) and administered subcutaneously or intramuscularly immediately. Any unused reconstituted material should be discarded. Thus the In-use stability data is not performed as the product is to be used immediately. Moreover the reconstitution data for the product is performed for every batch and is controlled in the finished specification with the Limit of Not more than 180 seconds.	-
13	Module 4 (safety data) and Module 5 (Efficacy data) are not provided.	We have noted the comments of the authority. We would like to inform the Authority that Chorionic Gonadotrophin for Injection is a Lyophilized vial. The Injection is reconstituted with 1ml of Sodium Chloride Injection BP (0.9% w/v) and administered subcutaneously or intramuscularly immediately. In reference to the EMEA guidelines Note for guidance on the investigation of bioavailability and bioequivalence" Doc. Ref.: CPMP/EWP/QWP/1401/98 Rev. 1/ Corr 20 January 2010, the BE study is not required for Parenteral preparations. Moreover, the Literature reference for the Clinical study reports are enclosed in Module 4 & 5 .	The applied product is not a biosimilar. So, complete module 4 and module 5 are required.
Concluding remarks by BE&R: The case is still deficient for the submission of complete Module 4 and Module 5 as per CTD format.			
Decision: Registration Board deferred the case for submission of Module 4 (Non-clinical/safety data) and Module 5 (Clinical/efficacy data) of the applied product.			

Case # 06	
Name, address of Applicant / Importer	M/s Macter International Limited. F-216, S.I.T.E., Karachi-Pakistan.
Status of Applicant	☒ Manufacturer ☐ Importer ☐ Bulk Import & Local Repack ☐ Is involved in none of the above
Name, address of manufacturer(s)	M/s Macter International Limited. F-216,S.I.T.E., Karachi-Pakistan.
GMP of manufacturer & Evidence of Section	DML No. 000141 Address: F-216,S.I.T.E, Karachi-Pakistan. Evidence of section: Liquid and Lyophilized rDNA Technology Products (Biological) Section (F.2-13/95-Lic (Vol-IV), dated 19-07-2012 GMP: Valid up to 30-06-2027
Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
For imported products, specify one the these	Not Applicable
Dy. No. and date of submission	Tracking ID: 1B9-W8R-26H2 Date of Submission: 30-04-2025
Details of fee submitted	Challan No. 57552277646 Amount: 37,000/- Date of submission: 14-04-2025
The proposed proprietary name / brand name	Hepanox 4000 IU (40 mg) /0.4 ml Solution for Injection in Prefilled syringe
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 0.4 ml single dose prefilled syringe contains: Enoxaparin sodium..... 40 mg
Pharmaceutical form of applied drug	Solution For Injection in PFS
Pharmacotherapeutic Group of (API)	Anticoagulant
Reference to Finished product specifications	European Pharmacopeia's Specification
Proposed Pack size	1's
Proposed unit price	As per SRO

Shelf Life	02 Years
Storage conditions	Store below 25°C
The status in reference regulatory authorities	LOVENOX (Sanofi, USA)
For generic drugs (me-too status)	Clexane 40 mg/0.4 ml of Sanofi Aventis
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, Elucidation of Structure, impurities specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product are submitted.
Name, address of drug substance manufacturer	Name: Hubei Enoray Biopharmaceutical Co., Ltd Address: No.108, Yanjiang Road, Xiaochi Town, Huangemei County, Hubei Province, China.
Module-III Drug Substance:	Firm has submitted drug substance data related to nomenclature, structure, general properties, physical form, manufacturers, description of manufacturing process and controls, elucidation of structure impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of drug substance at long term & accelerated The long-term stability data was conducted at 25°C, 60%RH±5% RH. for 36 months. The accelerated stability was also conducted at 40°C, 75%RH ±5% RH for 06 Months. Batch Numbers for Long-term and accelerated stability studies: ES170201 ES170301 ES170302
Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials,

		container closure system and stability.																
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Comparative Studies are attached.																
	Analytical method validation/verification of product	Method verification studies have submitted including Specificity, precision, intermediate precision, Repeatability solution stability.																
	Container closure system of the drug product	1 ml USP type-1 glass prefilled syringe Clear Glass Barrel, Rubber Plunger																
	Documents for the procurement of API with approval from DRAP	Submitted																
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 03 batches. The accelerated stability study data is conducted at 40°C ± 2°C; 70%RH ± 5%RH for 6 months, for following batches: <table><thead><tr><th>Batch No.</th><th>Batch Size</th></tr></thead><tbody><tr><td>ENPFS-01B</td><td>100 PFS</td></tr><tr><td>ENPFS-02B</td><td>100 PFS</td></tr><tr><td>ENPFS-03B</td><td>100 PFS</td></tr></tbody></table> The real time stability study data is conducted at below 25°C ± 3°C for 24 months for following batches: <table><thead><tr><th>Batch No.</th><th>Batch Size</th></tr></thead><tbody><tr><td>ENPFS-01B</td><td>100 PFS</td></tr><tr><td>ENPFS-02B</td><td>100 PFS</td></tr><tr><td>ENPFS-03B</td><td>100 PFS</td></tr></tbody></table>	Batch No.	Batch Size	ENPFS-01B	100 PFS	ENPFS-02B	100 PFS	ENPFS-03B	100 PFS	Batch No.	Batch Size	ENPFS-01B	100 PFS	ENPFS-02B	100 PFS	ENPFS-03B	100 PFS
Batch No.	Batch Size																	
ENPFS-01B	100 PFS																	
ENPFS-02B	100 PFS																	
ENPFS-03B	100 PFS																	
Batch No.	Batch Size																	
ENPFS-01B	100 PFS																	
ENPFS-02B	100 PFS																	
ENPFS-03B	100 PFS																	
	MODULE- IV	Not provided																
	MODULE- V	Not provided																
Decision: The Registration Board after thorough deliberation approved the case subject to the submission of the data in accordance with the guidelines approved by the Board in 289th meeting and its approval by the Chairman, Registration Board.																		

Case # 07		
	Name, address of Applicant / Importer	M/s Macter International Limited. F-216, S.I.T.E., Karachi-Pakistan.
	Status of Applicant	☒ Manufacturer

	☐ Importer ☐ Bulk Import & Local Repack ☐ Is involved in none of the above
Name, address of manufacturer(s)	M/s Macter International Limited. F-216,S.I.T.E., Karachi-Pakistan.
GMP of manufacturer & Evidence of Section	DML No. 000141 Address: F-216,S.I.T.E, Karachi-Pakistan. Evidence of section: Liquid and Lyophilized rDNA Technology Products (Biological) Section (F.2-13/95-Lic (Vol-IV), dated 19-07-2012 GMP: Valid up to 30-06-2027
Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
For imported products, specify one the these	Not Applicable
Dy. No. and date of submission	Tracking ID: EEV-VLU-Q8XV Date of Submission: 30-04-2025
Details of fee submitted	Challan No. 46952658496 Amount: 37,000/- Date of submission: 14-04-2025
The proposed proprietary name / brand name	Hepanox 6000 IU (60 mg) /0.6 ml Solution for Injection in Prefilled syringe
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 0.6 ml single dose prefilled syringe contains: Enoxaparin sodium..... 60 mg
Pharmaceutical form of applied drug	Solution For Injection in PFS
Pharmacotherapeutic Group of (API)	Anticoagulant
Reference to Finished product specifications	European Pharmacopeia's Specification
Proposed Pack size	1's
Proposed unit price	As per SRO
Shelf Life	02 Years
Storage conditions	Store below 25°C
The status in reference regulatory authorities	LOVENOX (Sanofi, USA)

For generic drugs (me-too status)	Clexane 60 mg/0.6 ml of Sanofi Aventis
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, Elucidation of Structure, impurities specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product are submitted.
Name, address of drug substance manufacturer	Name: Hubei Enoray Biopharmaceutical Co., Ltd Address: No.108, Yanjiang Road, Xiaochi Town, Huangemei County, Hubei Province, China.
Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, physical form, manufacturers, description of manufacturing process and controls, elucidation of structure impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of drug substance at long term & accelerated The long-term stability data was conducted at 25°C, 60%RH±5% RH. for 36 months. The accelerated stability was also conducted at 40°C, 75%RH ±5% RH for 06 Months. Batch Numbers for Long-term and accelerated stability studies: ES170201 ES170301 ES170302
Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Pharmaceutical Equivalence and Comparative Dissolution Profile	Comparative Studies are attached.
Analytical method validation/verification of product	Method verification studies have submitted including Specificity, precision, intermediate precision,

		Repeatability solution stability.																
	Container closure system of the drug product	1 ml USP type-1 glass prefilled syringe Clear Glass Barrel, Rubber Plunger																
	Documents for the procurement of API with approval from DRAP	Submitted																
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 03 batches. The accelerated stability study data is conducted at 40°C ± 2°C; 70%RH ± 5%RH for 6 months, for following batches: <table><thead><tr><th>Batch No.</th><th>Batch Size</th></tr></thead><tbody><tr><td>ENPFS-01C</td><td>100 PFS</td></tr><tr><td>ENPFS-02C</td><td>100 PFS</td></tr><tr><td>ENPFS-03C</td><td>100 PFS</td></tr></tbody></table> The real time stability study data is conducted at below 25°C ± 3°C for 24 months for following batches: <table><thead><tr><th>Batch No.</th><th>Batch Size</th></tr></thead><tbody><tr><td>ENPFS-01C</td><td>100 PFS</td></tr><tr><td>ENPFS-02C</td><td>100 PFS</td></tr><tr><td>ENPFS-03C</td><td>100 PFS</td></tr></tbody></table>	Batch No.	Batch Size	ENPFS-01C	100 PFS	ENPFS-02C	100 PFS	ENPFS-03C	100 PFS	Batch No.	Batch Size	ENPFS-01C	100 PFS	ENPFS-02C	100 PFS	ENPFS-03C	100 PFS
Batch No.	Batch Size																	
ENPFS-01C	100 PFS																	
ENPFS-02C	100 PFS																	
ENPFS-03C	100 PFS																	
Batch No.	Batch Size																	
ENPFS-01C	100 PFS																	
ENPFS-02C	100 PFS																	
ENPFS-03C	100 PFS																	
	MODULE- IV	Not provided																
	MODULE- V	Not provided																
Decision: The Registration Board after thorough deliberation approved the case subject to the submission of the data in accordance with the guidelines approved by the Board in 289th meeting and its approval by the Chairman, Registration Board. .																		

Case # 08		
	Name, address of Applicant / Importer	M/s Macter International Limited. F-216, S.I.T.E., Karachi-Pakistan.
	Status of Applicant	☒ Manufacturer ☐ Importer ☐ Bulk Import & Local Repack ☐ Is involved in none of the above
	Name, address of manufacturer(s)	M/s Macter International Limited. F-216,S.I.T.E., Karachi-Pakistan.

GMP of manufacturer & Evidence of Section	DML No. 000141 Address: F-216,S.I.T.E., Karachi-Pakistan. Evidence of section: Liquid and Lyophilized rDNA Technology Products (Biological) Section (F.2-13/95-Lic (Vol-IV), dated 19-07-2012 GMP: Valid up to 30-06-2027
Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
For imported products, specify one the these	Not Applicable Ready to fill bulk Import, Local Packing
Dy. No. and date of submission	Tracking ID: VU4-HDP-DMRS Date of Submission: 30-04-2025
Details of fee submitted	Challan No. 74412103189 Amount: 300,000/- Date of submission: 30-04-2025
The proposed proprietary name / brand name	Pegstim 6 mg / 0.6 ml single dose solution for injection in a pre-filled syringe
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each pre-filled syringe of 0.6 mL contains: Peg Filgrastim.....6 mg
Pharmaceutical form of applied drug	Solution For Injection in PFS (For Subcutaneous use only)
Pharmacotherapeutic Group of (API)	Anti-neoplastic & immuno-modulator Recombinant human granulocyte colony-stimulating factor (GCSF) ATC Code: L03AA13
Reference to Finished product specifications	As per Innovators Specification
Proposed Pack size	1's
Proposed unit price	As per SRO
Shelf Life	02 Years
Storage conditions	2 – 8 °C
The status in reference regulatory authorities	NEULASTA (Amgen) – EMA, USFDA
For generic drugs (me-too status)	Fulphila Solution for injection by AGP limited
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to

		nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, Elucidation of Structure, impurities specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product are submitted.
	Name, address of drug substance manufacturer	Name: Intas Pharmaceuticals Limited, (IPL) Address: Plot No. 423 / P / A Sarkhej – Bavla Highway Village: Moraiya, Taluka: Sanand Ahmedabad – 382 213 Gujarat, India
	Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, physical form, manufacturers, description of manufacturing process and controls, elucidation of structure impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of drug substance at long term & on-going The long-term stability data was conducted at 2 to 8°C for 24 months. The ongoing stability was also conducted at 2 to 8°C for 24 Months. Batch Numbers for Long-term: BM-0381 BM-0383 BM-0386 Batch Numbers for Ongoing: BM-0001 BM-0002 BM-0003
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Data as per guidelines of 278th meeting of Registration Board; i) For Bulk Concentrate Import, Local formulation Filling	
	The firm shall provide legalized GMP certificate of biological drug substance manufacturer abroad (who will provide	GMP Certificate No. 25035632, valid till 10-09-2025 GMP Issued by: Food & Drugs Control Administration, Gujarat, India

concentrate / ready to fill bulk of biological drug to Pakistani manufacturers for further processing) as an evidence that the manufacturer is an authorized manufacturer of biological drug in the country of origin.	
The firms shall provide legalized free sale certificate/CoPP either from country of origin or by any reference regulatory authority as adopted by Registration Board of finished product as evidence that the final product has been manufactured by same concentrate/ready to fill bulk after submission of data to the concerned regulatory authority.	Not provided
The firm shall provide the lot release certificate of the finished product manufactured by same bulk concentrate/ready to fill from country of export (If applicable).	Not provided
The firm shall provide the 6 months accelerated and real time stability studies for drug substance	Firm has submitted stability study data of drug substance at long term & on-going The long-term stability data was conducted at 5±3°C for 12 months. Accelerated testing at 25±2°C/60±5%RH for 6 months. Batch Numbers for Long-term: BM-0381 BM-0383 BM-0386 Batch Numbers for Ongoing: 201309001 201309002 201309003
The firm shall provide the agreement with the source (of bulk concentrate/ready to fill) that if there shall be any critical change in manufacturing process, biological systems used to manufacture, etc. the firm shall inform DRAP immediately along with relevant documents.	Provided
Regular monitoring through pharmacovigilance reporting system shall be observed through proper pharmacovigilance cell of the	Firm have submitted undertaking & SOP as detailed in 278th meeting of Registration Board by the local manufacturer.

manufacturer and report will be forwarded to the National Pharmacovigilance Centre, Division of Pharmacy Services and Biological Division of DRAP. In case of any severe adverse event, immediate mandatory reporting procedure shall be followed.											
The firm shall inform DRAP if there shall be any adverse event or ADR reporting from the country of manufacture of concentrate/ready to fill bulk and finished product as required vide Rules 30 of Drug (LR&A) Rule.	Firm have submitted undertakings as detailed in 278th meeting of Registration Board by the local manufacturer.										
If any of the conditions is not fulfilled or public health risk reported at any stage, the drug registration shall stand cancelled with immediate effect.	Firm have submitted undertakings as detailed in 278th meeting of Registration Board by the local manufacturer.										
All the provisions as contained in the Drugs Act, 1976 and rules made there under including provisions of Lot Release certification from National Control Laboratory for Biologicals shall be strictly adhered to.	Firm have submitted undertaking as detailed in 278th meeting of Registration Board by the local manufacturer.										
Pharmaceutical Equivalence and Comparative Dissolution Profile	Comparative Studies are attached.										
Analytical method validation/verification of product	Method verification studies have submitted including Specificity, precision, intermediate precision, Repeatability solution stability.										
Container closure system of the drug product	1 ml USP type-1 glass prefilled syringe Clear Glass Barrel, Rubber Plunger										
Documents for the procurement of API with approval from DRAP	Submitted										
Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 03 batches. The accelerated stability study data is conducted at 25°C ± 2°C for 6 months, for following batches: <table><tr><td>Batch No.</td><td>Batch Size</td></tr><tr><td>PGPFS 01</td><td>100 PFS</td></tr><tr><td>PGPFS 02</td><td>100 PFS</td></tr><tr><td>PGPFS 03</td><td>100 PFS</td></tr></table> The real time stability study data is conducted at 5°C ± 3°C for 6 months for following batches: <table><tr><td>Batch No.</td><td>Batch Size</td></tr></table>	Batch No.	Batch Size	PGPFS 01	100 PFS	PGPFS 02	100 PFS	PGPFS 03	100 PFS	Batch No.	Batch Size
Batch No.	Batch Size										
PGPFS 01	100 PFS										
PGPFS 02	100 PFS										
PGPFS 03	100 PFS										
Batch No.	Batch Size										

		PGPFS 01 100 PFS PGPFS 02 100 PFS PGPFS 03 100 PFS
	MODULE- IV	The firm has provided pharmacological, pharmacokinetics and toxicological study reports including the single dose and repeat dose toxicity studies in animals.
	MODULE- V	The firm has provided clinical study reports
Decision: The Registration Board after thorough deliberation deferred the case for the submission of the following documents:		
i. Legalized free sale certificate/CoPP either from country of origin or by any reference regulatory authority as adopted by Registration Board of finished product as evidence that the final product has been manufactured by same concentrate/ready to fill bulk after submission of data to the concerned regulatory authority: ii. Lot release certificate of the finished product manufactured by same bulk concentrate/ ready to fill from country of export (If applicable):		

Case # 09		
	Name, address of Applicant/Importer	M/s Highnoon Laboratories Limited 17.5Km Multan Road, Lahore
	Details of Drug Sale License of importer	License No: 05-352-0066 Address: 17.5Km Multan Road, Lahore Address of Godown: 01. Situated at 18 K.M. Multan Road, Lahore (Behind Highnoon Laboratories Limited, Opposite Star Food Cold Storage) 2. situated at 19 K.M. Multan Road (Din Muhammad Town, Chung) Lahore DSL Issuance Date: 17.01.2023 (Valid till 12-09-2027) Status: License to sell drugs as a distributor
	Name and address of marketing authorization holder (abroad)	Beximco Pharmaceuticals Ltd 19 Dhanmondi R/A, Road No. 7, Dhaka 1205, Bangladesh
	Name, address of manufacturer (s)	Beximco Pharmaceuticals Ltd 126 Kathaldia, Auchpara, Tongi, Gazipur, Bangladesh
	Name of exporting country	Bangladesh
	Detail of certificates attached (CoPP , Free Sale certificate, GMP certificate)	CoPP: Firm has submitted legalized copy of CoPP (No: DA/6-3/96/16910) dated 11-09-2024 issued by Directorate General of Drug Administration, Dhaka, Bangladesh. GMP Certificate: Firm has submitted legalized copy of GMP certificate (DA/6-3/96/22476) dated 19-12-2023 issued by Directorate General of Drug Administration, Dhaka, Bangladesh.

Details of letter of authorization/sole agency agreement	Firm has submitted legalized copy of letter of authorization from Beximco Pharmaceuticals Ltd. , dated 31-10-2024.
Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
For imported products, specify one of these	For imported products, specify one the these ☒ Finished Pharmaceutical product import ☐ Bulk import and local repackaging ☐ Bulk import and local repackaging as for export purpose only
Dy. No. and date of submission	Tracking. No: MEG-AN6-B1NU Date of submission: 11-02-2025
Details of fee submitted	Rs: 300,000 Slip number: 85102296598 Dated : 20-01-2025
The proposed proprietary name/brand name	Cleven 20 Injection
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 0.2mL prefilled syringe contains: Enoxaparin sodium 2,000 IU eq. to Enoxaparin 20mg
Pharmaceutical form of applied drug	Solution for injection
Pharmacotherapeutic Group of (API)	Antithrombotic agent, Heparin group, ATC code: B01A B05
Reference to Finished product specifications	USP
Proposed Pack size	1's x 0.2ml PFS 2's x 0.2ml PFS 5's x 0.2ml PFS 10's x 0.2ml PFS
Proposed unit price	As per SRO
Shelf Life	3 years
Storage Conditions	Do Not Store Above 30°C
The status in reference regulatory authorities	Lovenox (USA) of Sanofi Aventis (US-FDA Approved)
For generic drugs (me-too status)	Reg. No: 017003 Company Name: Clexane 20mg Brand Name: Sanofi Aventis

		Formulation: Each 0.2ml contains:- Enoxaparin Sodium 20 mg Pack Size: 1's
Module-II (Quality Overall Summary)		Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Name, address of drug substance manufacturer		Dongying Tiandong Pharmaceutical Co., Ltd. No.1236, Nan-er Road, Dongying, Shandong Province, 257067, China
Module-III Drug Substance:		Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)		Firm has submitted stability study data of 3 batches KE1-1709035, KE1-1710036 and KE1-1710037 of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C, RH 75% ± 5% for 6 months. The real time stability data is conducted at 25 °C ± 2°C RH 60% ± 5% for 36 months.
Module-III Drug Product:		Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Pharmaceutical Equivalence and Comparative Dissolution Profile		N/A
Analytical method validation/verification of product		Firm has submitted analytical method validation studies for the applied product
Container closure system of the drug product		Enoxaparin Sodium Injection USP 20 mg is packed 1 ml glass barrel Pre-Filled Syringe, sealed with RFU stoppers and finally closed with Plunger Rod.
Stability study data of drug product, shelf life and storage conditions		Firm has submitted stability study data of 3 batches (619004 D, 38100132 and 38200043) The accelerated stability study data is conducted at Temperature at 40°C ± 2°C, RH 75% ± 5% for 6 months. The real time stability study data is conducted Temperature 30°C ± 2°C / RH 75% ± 5% for 36 months as per ICH guidelines.
Module-IV Non-Clinical		Literature References are provided.

	Module – V (Clinical Data)	Not provided
	Decision: The Registration Board after thorough deliberation approved the case subject to the submission of the data in accordance with the guidelines approved by the Board in 289th meeting and its approval by the Chairman, Registration Board. .	

Case # 10		
	Name, address of Applicant/Importer	M/s Highnoon Laboratories Limited 17.5Km Multan Road, Lahore
	Details of Drug Sale License of importer	License No: 05-352-0066 Address: 17.5Km Multan Road, Lahore Address of Godown: 01. Situated at 18 K.M. Multan Road, Lahore (Behind Highnoon Laboratories Limited, Opposite Star Food Cold Storage) 2. situated at 19 K.M. Multan Road (Din Muhammad Town, Chung) Lahore DSL Issuance Date: 17.01.2023 (Valid till 12-09-2027) Status: License to sell drugs as a distributor
	Name and address of marketing authorization holder (abroad)	Beximco Pharmaceuticals Ltd 19 Dhanmondi R/A, Road No. 7, Dhaka 1205, Bangladesh
	Name, address of manufacturer (s)	Beximco Pharmaceuticals Ltd 126 Kathaldia, Auchpara, Tongi, Gazipur, Bangladesh
	Name of exporting country	Bangladesh
	Detail of certificates attached (CoPP , Free Sale certificate, GMP certificate)	CoPP: Firm has submitted legalized copy of CoPP (No: DA/6-3/96/16311) dated 11-09-2024 issued by Directorate General of Drug Administration, Dhaka, Bangladesh. GMP Certificate: Firm has submitted legalized copy of GMP certificate (DA/6-3/96/22476) dated 19-12-2023 issued by Directorate General of Drug Administration, Dhaka, Bangladesh.
	Details of letter of authorization/sole agency agreement	Firm has submitted legalized copy of letter of authorization from Beximco Pharmaceuticals Ltd., dated 31-10-2024.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one of these	For imported products, specify one the these ☒ Finished Pharmaceutical product import ☐ Bulk import and local repackaging ☐ Bulk import and local repackaging as for export purpose only
	Dy. No. and date of submission	Tracking. No: QAT-VLS-SPVT Date of submission: 11-02-2025
	Details of fee submitted	Rs: 300,000 Slip number: 711001566056 Dated : 20-01-2025
	The proposed	Cleven 40 Injection

proprietary name/ brand name	
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 0.4mL prefilled syringe contains: Enoxaparin sodium 4,000 IU eq. to Enoxaparin 40mg
Pharmaceutical form of applied drug	Solution for injection
Pharmacotherapeutic Group of (API)	Antithrombotic agent, Heparin group, ATC code: B01A B05
Reference to Finished product specifications	USP
Proposed Pack size	1's 2's 5's 10's
Proposed unit price	As per SRO
Shelf Life	3 years
Storage Conditions	Do Not Store Above 30°C
The status in reference regulatory authorities	Lovenox (USA) of Sanofi Aventis (US-FDA Approved)
For generic drugs (me- too status)	Reg. No: 017004 Company Name: Clexane 40mg Brand Name: Sanofi Aventis Formulation: Each 0.4ml contains:- Enoxaparin Sodium 40 mg Pack Size: 1's
Module-II (Quality Overall Summary)	Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Name, address of drug substance manufacturer	Dongying Tiandong Pharmaceutical Co., Ltd. No.1236, Nan-er Road, Dongying, Shandong Province, 257067, China
Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches KE1-1709035, KE1-1710036 and KE1-1710037 of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C, RH 75% ± 5% for 6 months. The real time stability data is conducted at 25 °C ± 2°C RH 60% ± 5% for 36 months.

Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Pharmaceutical Equivalence and Comparative Dissolution Profile	N/A
Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product
Container closure system of the drug product	Enoxaparin Sodium Injection USP 20 mg is packed 1 ml glass barrel Pre-Filled Syringe, sealed with RFU stoppers and finally closed with Plunger Rod.
Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches. The accelerated stability study data is conducted at Temperature at 40°C ± 2°C, RH 75% ± 5% for 6 months. The real time stability study data is conducted Temperature 30°C ± 2°C / RH 75% ± 5% for 36 months as per ICH guidelines.
Module-IV Non-Clinical	Literature References are provided.
Module – V (Clinical Data)	Not provided
Decision: The Registration Board after thorough deliberation approved the case subject to the submission of the data in accordance with the guidelines approved by the Board in 289th meeting and its approval by the Chairman, Registration Board.	

Case # 11		
	Name, address of Applicant/Importer	M/s Highnoon Laboratories Limited 17.5Km Multan Road, Lahore
	Details of Drug Sale License of importer	License No: 05-352-0066 Address: 17.5Km Multan Road, Lahore Address of Godown: 01. Situated at 18 K.M. Multan Road, Lahore (Behind Highnoon Laboratories Limited, Opposite Star Food Cold Storage) 2. situated at 19 K.M. Multan Road (Din Muhammad Town, Chung) Lahore DSL Issuance Date: 17.01.2023 (Valid till 12-09-2027) Status: License to sell drugs as a distributor
	Name and address of marketing authorization holder (abroad)	Beximco Pharmaceuticals Ltd 19 Dhanmondi R/A, Road No. 7, Dhaka 1205, Bangladesh
	Name, address of manufacturer (s)	Beximco Pharmaceuticals Ltd 126 Kathaldia, Auchpara, Tongi, Gazipur, Bangladesh
	Name of exporting country	Bangladesh
	Detail of certificates attached (CoPP , Free Sale certificate, GMP certificate)	CoPP: Firm has submitted legalized copy of CoPP (No: DA/6-3/96/16312) dated 11-09-2024 issued by Directorate General of Drug Administration, Dhaka, Bangladesh. GMP Certificate: Firm has submitted legalized copy of GMP certificate (DA/6-3/96/22476) dated 19-12-2023 issued by Directorate General of Drug Administration, Dhaka, Bangladesh.
	Details of letter of authorization/sole agency agreement	Firm has submitted legalized copy of letter of authorization from Beximco Pharmaceuticals Ltd., dated 31-10-2024.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one of these	For imported products, specify one the these ☒ Finished Pharmaceutical product import ☐ Bulk import and local repackaging ☐ Bulk import and local repackaging as for export purpose only
	Dy. No. and date of submission	Tracking. No: VPV-J3M-E4LD Date of submission: 24-01-2025
	Details of fee submitted	Rs: 300,000 Slip number: 695265816923 Dated : 23-01-2025
	The proposed	Cleven 60 Injection

proprietary name/ brand name	
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 0.6mL prefilled syringe contains: Enoxaparin sodium 6,000 IU eq. to Enoxaparin 60mg
Pharmaceutical form of applied drug	Solution for injection
Pharmacotherapeutic Group of (API)	Antithrombotic agent, Heparin group, ATC code: B01A B05
Reference to Finished product specifications	USP
Proposed Pack size	1's 2's 5's 10's
Proposed unit price	As per SRO
Shelf Life	3 years
Storage Conditions	Do Not Store Above 30°C
The status in reference regulatory authorities	Lovenox (USA) of Sanofi Aventis (US-FDA Approved)
For generic drugs (me- too status)	Reg. No: 017809 Company Name: Clexane 60mg Brand Name: Sanofi Aventis Formulation: Each 0.6ml contains:- Enoxaparin Sodium 60 mg Pack Size: 1's
Module-II (Quality Overall Summary)	Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Name, address of drug substance manufacturer	Dongying Tiandong Pharmaceutical Co., Ltd. No.1236, Nan-er Road, Dongying, Shandong Province, 257067, China
Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches KE1-1709035, KE1-1710036 and KE1-1710037 of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C, RH 75% ± 5% for 6 months. The real time stability data is conducted at 25 °C ± 2°C RH 60% ± 5% for 36 months.

Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Pharmaceutical Equivalence and Comparative Dissolution Profile	N/A
Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product
Container closure system of the drug product	Enoxaparin Sodium Injection USP 20 mg is packed 1 ml glass barrel Pre-Filled Syringe, sealed with RFU stoppers and finally closed with Plunger Rod.
Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches. The accelerated stability study data is conducted at Temperature at $40^{\circ}\text{C} \pm 2^{\circ}\text{C}$, RH $75\% \pm 5\%$ for 6 months. The real time stability study data is conducted Temperature $30^{\circ}\text{C} \pm 2^{\circ}\text{C}$ / RH $75\% \pm 5\%$ for 36 months as per ICH guidelines.
Module-IV Non-Clinical	Literature References are provided.
Module – V (Clinical Data)	Not provided
Decision: The Registration Board after thorough deliberation approved the case subject to the submission of the data in accordance with the guidelines approved by the Board in 289th meeting and its approval by the Chairman, Registration Board.	

Case # 12		
	Name, address of Applicant/Importer	M/s Highnoon Laboratories Limited 17.5Km Multan Road, Lahore
	Details of Drug Sale License of importer	License No: 05-352-0066 Address: 17.5Km Multan Road, Lahore Address of Godown: 01. Situated at 18 K.M. Multan Road, Lahore (Behind Highnoon Laboratories Limited, Opposite Star Food Cold Storage) 2. situated at 19 K.M. Multan Road (Din Muhammad Town, Chung) Lahore DSL Issuance Date: 17.01.2023 (Valid till 12-09-2027) Status: License to sell drugs as a distributor
	Name and address of marketing authorization holder (abroad)	Beximco Pharmaceuticals Ltd 19 Dhanmondi R/A, Road No. 7, Dhaka 1205, Bangladesh
	Name, address of manufacturer (s)	Beximco Pharmaceuticals Ltd 126 Kathaldia, Auchpara, Tongi, Gazipur, Bangladesh
	Name of exporting country	Bangladesh
	Detail of certificates attached (CoPP , Free Sale certificate, GMP certificate)	CoPP: Firm has submitted legalized copy of CoPP (No: DA/6-3/96/16313) dated 11-09-2024 issued by Directorate General of Drug Administration, Dhaka, Bangladesh. GMP Certificate: Firm has submitted legalized copy of GMP certificate (DA/6-3/96/22476) dated 19-12-2023 issued by Directorate General of Drug Administration, Dhaka, Bangladesh.
	Details of letter of authorization/sole agency agreement	Firm has submitted legalized copy of letter of authorization from Beximco Pharmaceuticals Ltd., dated 31-10-2024.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one of these	For imported products, specify one the these ☒ Finished Pharmaceutical product import ☐ Bulk import and local repackaging ☐ Bulk import and local repackaging as for export purpose only
	Dy. No. and date of submission	Tracking. No: S9U-L5V-NPL8 Date of submission: 24-01-2025
	Details of fee submitted	Rs: 300,000 Slip number: 597879330894 Dated : 20-01-2025
	The proposed	Cleven 80 Injection

proprietary name/ brand name	
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 0.8mL prefilled syringe contains: Enoxaparin sodium 8,000 IU eq. to Enoxaparin 80mg
Pharmaceutical form of applied drug	Solution for injection
Pharmacotherapeutic Group of (API)	Antithrombotic agent, Heparin group, ATC code: B01A B05
Reference to Finished product specifications	USP
Proposed Pack size	1's 2's 5's 10's
Proposed unit price	As per SRO
Shelf Life	3 years
Storage Conditions	Do Not Store Above 30°C
The status in reference regulatory authorities	Lovenox (USA) of Sanofi Aventis (US-FDA Approved)
For generic drugs (me- too status)	Reg. No: 017810 Company Name: Clexane 80mg Brand Name: Sanofi Aventis Formulation: Each 0.8ml contains:- Enoxaparin Sodium 80 mg Pack Size: 1's
Module-II (Quality Overall Summary)	Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Name, address of drug substance manufacturer	Dongying Tiandong Pharmaceutical Co., Ltd. No.1236, Nan-er Road, Dongying, Shandong Province, 257067, China
Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches KE1-1709035, KE1-1710036 and KE1-1710037 of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C, RH 75% ± 5% for 6 months. The real time stability data is conducted at 25 °C ± 2°C RH 60% ± 5% for 36 months.

Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Pharmaceutical Equivalence and Comparative Dissolution Profile	N/A
Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product
Container closure system of the drug product	Enoxaparin Sodium Injection USP 20 mg is packed 1 ml glass barrel Pre-Filled Syringe, sealed with RFU stoppers and finally closed with Plunger Rod.
Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches. The accelerated stability study data is conducted at Temperature at $40^{\circ}\text{C} \pm 2^{\circ}\text{C}$, RH $75\% \pm 5\%$ for 6 months. The real time stability study data is conducted Temperature $30^{\circ}\text{C} \pm 2^{\circ}\text{C}$ / RH $75\% \pm 5\%$ for 36 months as per ICH guidelines.
Module-IV Non-Clinical	Literature References are provided.
Module – V (Clinical Data)	Not provided
Decision: The Registration Board after thorough deliberation approved the case subject to the submission of the data in accordance with the guidelines approved by the Board in 289th meeting and its approval by the Chairman, Registration Board.	

Case # 13		
	Name, address of Applicant/Importer	M/s Immunonet Pharma Pvt Ltd 12-F1, Johar Town, Lahore, Pakistan.
	Details of Drug Sale License of importer	License No: 05-352-0066 Address: Ground Floor, 14-Airline Society Lahore DSL Issuance Date: 20.02.2023 (Valid till 03-02-2028) Status: License to sell drugs as a distributor
	Name and address of marketing authorization holder (abroad)	M/s Suzhou Erye Pharmaceutical Co., Ltd. No.2, Dongqiao, Anmin Road, Xiangcheng District, Suzhou, Jiangsu, China
	Name, address of manufacturer (s)	M/s Suzhou Erye Pharmaceutical Co., Ltd. No.2, Dongqiao, Anmin Road, Xiangcheng District, Suzhou, Jiangsu, China.
	Name of exporting country	China
	Detail of certificates attached (CoPP , Free Sale certificate, GMP certificate)	CoPP: Firm has submitted legalized copy of CoPP (No: Jiangsu20240360) valid till 29-10-2025 issued by Jiangsu Medical Products Administration, China. GMP Certificate: Firm has submitted legalized copy of GMP certificate (No. 21, 2023) dated 24-02-2024 issued by Jiangsu Medical Products Administration, China
	Details of letter of authorization/sole agency agreement	Firm has submitted Agent and Distribution Agreement between M/s Qingdao JidaBarr International Trading Co. Ltd., No. 2-B-1-4, Heilongjiang South Road, Qingdao City, China, M/s Immunonet Pharma Pvt Ltd., 14-Airline Society Lahore and M/s Suzhou Erye Pharmaceutical Co., Ltd. No.2, Dongqiao, Anmin Road, Xiangcheng District, Suzhou, Jiangsu, China, dated 15-05-2024.
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one of these	For imported products, specify one the these ☒ Finished Pharmaceutical product import ☐ Bulk import and local repackaging ☐ Bulk import and local repackaging as for export purpose only
	Dy. No. and date of submission	Tracking. No: 3NE-XM3-Z276 Date of submission: 28-02-2025
	Details of fee submitted	Rs: 300,000 Slip number: 97353333896 Dated : 15-01-2025
	The proposed proprietary name/ brand name	Enoxaparin Sodium 0.4ml

Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 0.4mL prefilled syringe contains: Enoxaparin sodium 4,000 IU eq. to Enoxaparin 40mg
Pharmaceutical form of applied drug	Lyophilisate and diluent for suspension for injection
Pharmacotherapeutic Group of (API)	Antithrombotic agent, Heparin group, ATC code: B01A B05
Reference to Finished product specifications	B.P
Proposed Pack size	2's
Proposed unit price	As per SRO
Shelf Life	3 years
Storage Conditions	Do Not Store Above 30°C
The status in reference regulatory authorities	Lovenox (USA) of Sanofi Aventis (US-FDA Approved)
For generic drugs (me-too status)	Reg. No: 017004 Company Name: Clexane 40mg Brand Name: Sanofi Aventis Formulation: Each 0.4ml contains:- Enoxaparin Sodium 40 mg Pack Size: 1's
Module-II (Quality Overall Summary)	Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Name, address of drug substance manufacturer	M/s Suzhou Erye Pharmaceutical Co., Ltd. No.2, Dongqiao, Anmin Road, Xiangcheng District, Suzhou, Jiangsu, China.
Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C, RH 75% ± 5% for 6 months. The real time stability data is conducted at 30 °C ± 2°C RH 60% ± 5% for 36 months.
Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference

		standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	N/A
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product
	Container closure system of the drug product	Prefilled syringe assembly (with injection needle)
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches. The accelerated stability study data is conducted at Temperature at 40°C ± 2°C, RH 75% ± 5% for 6 months. The real time stability study data is conducted Temperature 30°C ± 2°C / RH 75% ± 5% for 36 months as per ICH guidelines.
	Module-IV Non-Clinical	Literature References are provided.
	Module – V (Clinical Data)	Not provided
	Decision: The Registration Board after thorough deliberation approved the case subject to the submission of the data in accordance with the guidelines approved by the Board in 289th meeting and its approval by the Chairman, Registration Board.	

Case # 14		
	Name, address of Applicant/Importer	M/s Immunonet Pharma Pvt Ltd 12-F1, Johar Town, Lahore, Pakistan.
	Details of Drug Sale License of importer	License No: 05-352-0066 Address: Ground Floor, 14-Airline Society Lahore DSL Issuance Date: 20.02.2023 (Valid till 03-02-2028) Status: License to sell drugs as a distributor
	Name and address of marketing authorization holder (abroad)	M/s Suzhou Erye Pharmaceutical Co., Ltd. No.2, Dongqiao, Anmin Road, Xiangcheng District, Suzhou, Jiangsu, China
	Name, address of manufacturer (s)	M/s Suzhou Erye Pharmaceutical Co., Ltd. No.2, Dongqiao, Anmin Road, Xiangcheng District, Suzhou, Jiangsu, China.
	Name of exporting country	China
	Detail of certificates attached (CoPP , Free Sale certificate, GMP certificate)	CoPP: Firm has submitted legalized copy of CoPP (No: Jiangsu20240361) valid till 29-10-2025 issued by Jiangsu Medical Products Administration, China. GMP Certificate: Firm has submitted legalized copy of GMP certificate (No. 21, 2023) dated 24-02-2024 issued by Jiangsu

	Medical Products Administration, China
Details of letter of authorization/sole agency agreement	Firm has submitted Agent and Distribution Agreement between M/s Qingdao JidaBarr International Trading Co. Ltd., No. 2-B-1-4, Heilongjiang South Road, Qingdao City, China, M/s Immunonet Pharma Pvt Ltd., 14-Airline Society Lahore and M/s Suzhou Erye Pharmaceutical Co., Ltd. No.2, Dongqiao, Anmin Road, Xiangcheng District, Suzhou, Jiangsu, China, dated 15-05-2024.
Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
For imported products, specify one of these	For imported products, specify one the these ☒ Finished Pharmaceutical product import ☐ Bulk import and local repackaging ☐ Bulk import and local repackaging as for export purpose only
Dy. No. and date of submission	Tracking. No: V3S-WSX-XT87 Date of submission: 28-02-2025
Details of fee submitted	Rs: 300,000 Slip number: 6007244779 Dated : 15-01-2025
The proposed proprietary name/brand name	Enoxaparin Sodium 0.6ml
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 0.6mL prefilled syringe contains: Enoxaparin sodium 6,000 IU eq. to Enoxaparin 60mg
Pharmaceutical form of applied drug	Lyophilisate and diluent for suspension for injection
Pharmacotherapeutic Group of (API)	Antithrombotic agent, Heparin group, ATC code: B01A B05
Reference to Finished product specifications	B.P
Proposed Pack size	2's
Proposed unit price	As per SRO
Shelf Life	3 years
Storage Conditions	Do Not Store Above 30°C
The status in reference regulatory authorities	Lovenox (USA) of Sanofi Aventis (US-FDA Approved)
For generic drugs (me-too status)	Company Name: Clexane 60mg Brand Name: Sanofi Aventis Formulation: Each 0.6ml contains:- Enoxaparin Sodium 60 mg

		Pack Size: 1's
	Module-II (Quality Overall Summary)	Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Name, address of drug substance manufacturer	M/s Suzhou Erye Pharmaceutical Co., Ltd. No.2, Dongqiao, Anmin Road, Xiangcheng District, Suzhou, Jiangsu, China.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C, RH 75% ± 5% for 6 months. The real time stability data is conducted at 30 °C ± 2°C RH 60% ± 5% for 36 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	N/A
	Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product
	Container closure system of the drug product	Prefilled syringe assembly (with injection needle)
	Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches. The accelerated stability study data is conducted at Temperature at 40°C ± 2°C, RH 75% ± 5% for 6 months. The real time stability study data is conducted Temperature 30°C ± 2°C / RH 75% ± 5% for 36 months as per ICH guidelines.
	Module-IV Non-Clinical	Literature References are provided.
	Module – V (Clinical Data)	Not provided

	Decision: The Registration Board after thorough deliberation approved the case subject to the submission of the data in accordance with the guidelines approved by the Board in 289th meeting and its approval by the Chairman, Registration Board. .

Case # 15	
Name, address of Applicant / Importer	M/s SAMI Pharmaceuticals Pvt. Ltd. F-95, Off. Hub River Road, S.I.T.E., Karachi
Status of Applicant	☒ Manufacturer ☐ Importer ☐ Bulk Import & Local Repack ☐ Is involved in none of the above
Name, address of manufacturer(s)	M/s SAMI Pharmaceuticals Pvt. Ltd. F-95, Off. Hub River Road, S.I.T.E., Karachi
GMP of manufacturer & Evidence of Section	DML No. 000072 Address: F-95, Off. Hub River Road, S.I.T.E., Karachi Evidence of section: Biological Section (F.2-9/2007-Lic (Vol-II), dated 13-10-2023 GMP: Expired on 02-08-2024
Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
For imported products, specify one the these	Not Applicable
Dy. No. and date of submission	Tracking ID: ZUG-JJT-GB84 Date of Submission: 05-04-2024
Details of fee submitted	Challan No. 52506959540 Amount: 30,000/- Date of submission: 26-04-2024
The proposed proprietary name / brand name	DENORIN 4000 Anti-Xa IU/0.4ml Injection
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial 4000 anti-Xa IU (0.4mL) contains: Enoxaparin Sodium..... 40mg
Pharmaceutical form of applied drug	Solution For Injection
Pharmacotherapeutic Group of	Anticoagulant

(API)	
Reference to Finished product specifications	European Pharmacopeia's Specification
Proposed Pack size	1's
Proposed unit price	As per SRO
Shelf Life	02 Years
Storage conditions	Store below 25°C
The status in reference regulatory authorities	LOVENOX (Sanofi, USA)
For generic drugs (me-too status)	Clexane 40 mg/0.4 ml of Sanofi Aventis
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, Elucidation of Structure, impurities specifications, analytical procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product are submitted.
Name, address of drug substance manufacturer	Name: Shenzhen Techdow Pharmaceutical Co., Ltd, Address: No.19, Gaoxinhongyi Road, Nanshan District, Shenzhen, Guangdong Province, China.
Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, physical form, manufacturers, description of manufacturing process and controls, elucidation of structure impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of drug substance at long term & accelerated conditions. The long-term stability data was conducted at 30°C, 75%RH±5% RH. for 36 months. The accelerated stability was also conducted at 40°C, 75%RH ±5% RH for 06 Months.
Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.

Pharmaceutical Equivalence and Comparative Dissolution Profile	Comparative Studies are attached.																
Analytical method validation/verification of product	Method verification studies have submitted including Specificity, precision, intermediate precision, Repeatability solution stability.																
Container closure system of the drug product	1 mL, clear glass vial USP Type I, chlorobutyl Rubber Stopper and Aluminium Seal																
Documents for the procurement of API with approval from DRAP	Submitted																
Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 03 batches. The accelerated stability study data is conducted at 40°C ± 2°C; 75%RH ± 5%RH for 6 months, for following batches: <table> <tr> <td>Batch No.</td><td>Batch Size</td></tr> <tr> <td>Lab 1</td><td>750 Vials</td></tr> <tr> <td>Lab 2</td><td>750 Vials</td></tr> <tr> <td>Lab 3</td><td>750 Vials</td></tr> </table> The real time stability study data is conducted at below 30°C ± 2°C; 75%RH ± 5%RH for 24 months for following batches: <table> <tr> <td>Batch No.</td><td>Batch Size</td></tr> <tr> <td>Lab 1</td><td>750 Vials</td></tr> <tr> <td>Lab 2</td><td>750 Vials</td></tr> <tr> <td>Lab 3</td><td>750 Vials</td></tr> </table>	Batch No.	Batch Size	Lab 1	750 Vials	Lab 2	750 Vials	Lab 3	750 Vials	Batch No.	Batch Size	Lab 1	750 Vials	Lab 2	750 Vials	Lab 3	750 Vials
Batch No.	Batch Size																
Lab 1	750 Vials																
Lab 2	750 Vials																
Lab 3	750 Vials																
Batch No.	Batch Size																
Lab 1	750 Vials																
Lab 2	750 Vials																
Lab 3	750 Vials																
MODULE- IV	Literature references and studies have been provided																
MODULE- V	Literature references and studies have been provided																
Decision: The Registration Board after thorough deliberation approved the case subject to the submission of the data in accordance with the guidelines approved by the Board in 289th meeting and its approval by the Chairman, Registration Board.																	

Case # 16	
Name, address of Applicant / Importer	M/s SAMI Pharmaceuticals Pvt. Ltd. F-95, Off. Hub River Road, S.I.T.E., Karachi
Status of Applicant	☒ Manufacturer ☐ Importer ☐ Bulk Import & Local Repack ☐ Is involved in none of the above
Name, address of manufacturer(s)	M/s SAMI Pharmaceuticals Pvt. Ltd. F-95, Off. Hub River Road, S.I.T.E., Karachi

GMP of manufacturer & Evidence of Section	DML No. 000072 Address: F-95, Off. Hub River Road, S.I.T.E., Karachi Evidence of section: Biological Section (F.2-9/2007-Lic (Vol-II), dated 13-10-2023 GMP: Expired on 02-08-2024
Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
For imported products, specify one the these	Not Applicable
Dy. No. and date of submission	Tracking ID: 2V6-27S-N5TT Date of Submission: 06-06-2024
Details of fee submitted	Challan No. 76426913766 Amount: 30,000/- Date of submission: 26-04-2024
The proposed proprietary name / brand name	DENORIN 6000 Anti-Xa IU/0.6ml Injection
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each vial 6000 anti-Xa IU (0.6mL) contains: Enoxaparin Sodium..... 60mg
Pharmaceutical form of applied drug	Solution For Injection
Pharmacotherapeutic Group of (API)	Anticoagulant
Reference to Finished product specifications	European Pharmacopeia's Specification
Proposed Pack size	1's
Proposed unit price	As per SRO
Shelf Life	02 Years
Storage conditions	Store below 25°C
The status in reference regulatory authorities	LOVENOX (Sanofi, USA)
For generic drugs (me-too status)	Clexane 60 mg/0.6 ml of Sanofi Aventis
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, Elucidation of Structure, impurities specifications, analytical

	procedures and its verification, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product are submitted.								
Name, address of drug substance manufacturer	Name: Shenzhen Techdow Pharmaceutical Co., Ltd, Address: No.19, Gaoxinzhongyi Road, Nanshan District, Shenzhen, Guangdong Province, China.								
Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, physical form, manufacturers, description of manufacturing process and controls, elucidation of structure impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.								
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of drug substance at long term & accelerated conditions. The long-term stability data was conducted at 30°C, 75%RH±5% RH. for 36 months. The accelerated stability was also conducted at 40°C, 75%RH ±5% RH for 06 Months.								
Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.								
Pharmaceutical Equivalence and Comparative Dissolution Profile	Comparative Studies are attached.								
Analytical method validation/verification of product	Method verification studies have submitted including Specificity, precision, intermediate precision, Repeatability solution stability.								
Container closure system of the drug product	1 mL, clear glass vial USP Type I, chlorobutyl Rubber Stopper and Aluminum Seal								
Documents for the procurement of API with approval from DRAP	Submitted								
Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 03 batches. The accelerated stability study data is conducted at 40°C ± 2°C; 75%RH ± 5%RH for 6 months, for following batches: <table> <tr> <th>Batch No.</th><th>Batch Size</th></tr> <tr> <td>Lab 1</td><td>750 Vials</td></tr> <tr> <td>Lab 2</td><td>750 Vials</td></tr> <tr> <td>Lab 3</td><td>750 Vials</td></tr> </table> The real time stability study data is conducted at below 30°C	Batch No.	Batch Size	Lab 1	750 Vials	Lab 2	750 Vials	Lab 3	750 Vials
Batch No.	Batch Size								
Lab 1	750 Vials								
Lab 2	750 Vials								
Lab 3	750 Vials								

		$\pm 2^{\circ}\text{C}$: 75%RH $\pm$ 5%RH for 24 months for following batches:								
		<table><tr><th>Batch No.</th><th>Batch Size</th></tr><tr><td>Lab 1</td><td>750 Vials</td></tr><tr><td>Lab 2</td><td>750 Vials</td></tr><tr><td>Lab 3</td><td>750 Vials</td></tr></table>	Batch No.	Batch Size	Lab 1	750 Vials	Lab 2	750 Vials	Lab 3	750 Vials
Batch No.	Batch Size									
Lab 1	750 Vials									
Lab 2	750 Vials									
Lab 3	750 Vials									
	MODULE- IV	Literature references and studies have been provided								
	MODULE- V	Literature references and studies have been provided								
Decision: The Registration Board after thorough deliberation approved the case subject to the submission of the data in accordance with the guidelines approved by the Board in 289th meeting and its approval by the Chairman, Registration Board. .										

Case # 17		
	Name, address of Applicant / Importer	M/s Lab Diagnostic Systems (SMC) Pvt. Ltd. Plot 36-A, PSIC SIE, Taxila Rawalpindi
	Details of Drug Sale License of importer	License No: 01-374-0006-118530D Address: 36-A,PSIC,SIE,Taxila Rawalpindi Validity: 15/08/2029
	Name and address of marketing authorization holder (abroad)	M/s Virchow Healthcare Pvt. Ltd. 901 DLH Park S.V. Road, Goregaon West Mumbai -400062 India.
	Name, address of manufacturer(s)	M/s Virchow Biotech Pvt. Ltd. Located on: Survey No. 172 Part, Gagillapur (V), Dundigal - Gandimaisamma (M), Medchal-Malkajgiri (D), Telangana State- 500043, India
	Name of exporting country	India
	Detail of certificates attached (CoPP, Free Sale certificate, GMP certificate)	Firm has submitted original CoPP having certificate NO. 4299318/TS/2024, valid till 11-12-2025, issued by Drug Control Administration, Telangana, India. The COPP specifies that the product is licensed for sale in country of origin.
	Details of letter of authorization / sole agency agreement	Firm has submitted copy of Letter of Authorization from M/s Virchow Biotech Pvt. Ltd which is valid till 28.02.2029
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Bulk import and local repackaging

	☐ Buk import and local repackaging for export purpose only
Dy. No. and date of submission	Tracking ID: LPR-ST3-P497 Date of Submission: 22-08-2024
Details of fee submitted	Rs: 300,000/- Dated: 19-08-2024 Deposit Slip No. 108382952
The proposed proprietary name / brand name	Peglastim 6mg/0.6ml Solution for Injection
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 0.6ml PFS contains: PEG-Filgrastim (r-DNA origin) IHS.....6mg
Dosage form of applied drug	Solution for Injection in PFS
Pharmacotherapeutic Group of (API)	Anti-neoplastic & immuno-modulator Recombinant human granulocyte colony-stimulating factor (GCSF) ATC Code: L03AA13
Reference to Finished product specifications	United States Pharmacopeia
Proposed Pack size	1's
Proposed unit price	As per SRO
Shelf Life	18 Months
Storage Conditions	Store at 2-8°C.
The status in reference regulatory authorities	Neulasta (Pegfilgrastim) Injection Manufacturer: Amgen Inc. USFDA
For generic drugs (me-too status)	Neulastim Injection 6mg/0.6ml Marketed by: Roche Pakistan Ltd.
Module-II (Quality Overall Summary	Firm has submitted QOS as per ICH guidelines. Firm has summarized information related to general properties, manufacturers, description of manufacturing process and controls, characterization, specifications analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product. The firm has also submitted the non-clinical and clinical overviews and summaries.
Name, address of drug substance manufacturer	M/s Virchow Biotech Pvt. Ltd. Located on: Survey no. 172 Part, Gagillapur (V), Dundigal - Gandimaisamma (M), Medchal-Malkajgiri (D), Telangana State- 500043, India.
Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of three batches at accelerated conditions 25°C±2°C for 6 months. And long -term stability studies of three batches at 5±3 °C for 36 months.

Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Analytical method validation/verification of product	Firm has submitted the details of analytical method validation.
Container closure system of the drug product	Pre-Filled Syringe (PFS) comprising 1 mL USP Type-I glass sterile barrel with needle (27G × ½ inch), PP plunger rod with chloro- butyl rubber stopper and protective needle cap.
Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of three batches at accelerated conditions 25°C±2° C and RH 60±5% for 6 months. And long -term stability studies of three batches at 5±3°C for 24 months. Depicting shelf life of 24 Months.
Module-IV Non-Clinical	Firm has provided non-clinical studies including Single-dose toxicity, Repeat dose toxicity, Genotoxicity, Carcinogenicity, Teratogenicity and local tolerance studies on animals.
Module-V Clinical	Clinical study reports have been provided by the firm.
Decision: Keeping in view submitted CoPP indicating the product availability in country of origin; Registration Board approved the product in compliance of current Import Policy for finished drugs	

Case # 18		
Name, address of Applicant/Importer	M/s HIMMEL PHARMACEUTICALS (PVT.) LTD Ground Floor, 6-Judicial Colony, Phase 1 (Ext.) Shahrah Zazaria e Pakistan Lahore	
Details of Drug Sale License of importer	License No: 05-352-0065 Address: Ground Floor, 6-Judicial Colony, Phase 1 (Ext.) Shahrah Zazaria e Pakistan Lahore DSL Issuance Date: 19-11-2020 Status: License to sell drugs as a distributor	
Name and address of marketing authorization holder (abroad)	M/s Hanlim Pharma Co.Ltd. 2-27, Yeongmun-ro, Cheoin-gu, Yongin-si, Gyeonggi-do, Republic of Korea	
Name, address of manufacturer (s)	M/s Hanlim Pharma Co.Ltd. 2-27, Yeongmun-ro, Cheoin-gu, Yongin-si, Gyeonggi-do, Republic of Korea	
Name of exporting country	South Korea	
Detail of certificates attached (CoPP , Free Sale certificate, GMP certificate)	CoPP: Firm has submitted legalized copy of CoPP (No: 2024-D1-0047) dated 15-01-2024 issued by issued by Ministry of Food and Drug Safety, Republic of Korea. GMP Certificate: Firm has submitted legalized copy of GMP certificate (No. 2024-D1-0047) dated 24-06-2022 valid till 23-06-2025 issued by Ministry of Food and Drug Safety, Republic of Korea	

Details of letter of authorization/sole agency agreement	Firm has submitted Letter of Authorization issued by M/s Hanlim Pharma Co.Ltd., dated 11-01-2024.
Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
For imported products, specify one of these	For imported products, specify one the these ☒ Finished Pharmaceutical product import ☐ Bulk import and local repackaging ☐ Bulk import and local repackaging as for export purpose only
Dy. No. and date of submission	Tracking. No: 3JQ-T5D-JPPV Date of submission: 03-01-2025
Details of fee submitted	Rs: 300,000 Slip number: 941927128 Dated : 03-01-2025
The proposed proprietary name/ brand name	Hanlim Heparin Sodium
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each mL contains: Heparin Sodium..... 5,000 IU
Pharmaceutical form of applied drug	Solution for injection
Pharmacotherapeutic Group of (API)	Antithrombotic agent, Heparin group, ATC code: B01A B05
Reference to Finished product specifications	B.P
Proposed Pack size	5 mL/vial × 10 vials
Proposed unit price	As per SRO
Shelf Life	3 years
Storage Conditions	Do Not Store Above 30°C
The status in reference regulatory authorities	Heparin sodium 25,000 I.U./ml solution for injection or concentrate for solution for infusion by Wockhardt UK Ltd, UK
For generic drugs (me-too status)	PINE 5000IU/5ml injection(Heparin Sodium) by HSC
Module-II (Quality Overall Summary)	Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis

		and justification of specification, reference standard, container closure system and stability studies of drug substance.
Name, address of drug substance manufacturer		M/s Dongying Tiandong Pharmaceutical Co., Ltd. No.1236, Nan-er Road, Dongying City, Shandong, China
Module-III Drug Substance:		Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)		Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C, RH 75% ± 5% for 6 months. The real time stability data is conducted at 30 °C ± 2°C RH 60% ± 5% for 36 months.
Module-III Drug Product:		Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Pharmaceutical Equivalence and Comparative Dissolution Profile		N/A
Analytical method validation/verification of product		Firm has submitted analytical method validation studies for the applied product
Container closure system of the drug product		The primary package is two-layer polyethylene bag which is controlled microbial limit strictly, which is safe to human health, it is closed by fusion, the secondary package is a well-closed aluminum-plastic composite package and the external package is aluminum drum.
Stability study data of drug product, shelf life and storage conditions		Firm has submitted stability study data of 3 batches. The accelerated stability study data is conducted at Temperature at 40°C ± 2°C, RH 75% ± 5% for 6 months. The real time stability study data is conducted Temperature 30°C ± 2°C / RH 75% ± 5% for 36 months as per ICH guidelines.
Module-IV Non-Clinical		Non-clinical study reports including pharmacological and toxicological studies have been provided by the firm.
Module – V (Clinical Data)		Clinical study reports have been provided.
Decision: Keeping in view submitted CoPP indicating the product availability in country of origin; Registration Board approved the product in compliance of current Import Policy for finished		

	drugs

Web Publisher
Web Publisher
Monday, 10 November, 2025, 3:19:4 PM

Web Publisher
Web Publisher
Monday, 10 November, 2025, 3:19:4 PM

Case # 19		
	Name, address of Applicant/Importer	M/s Immunonet Pharma Pvt Ltd 12-F1, Johar Town, Lahore, Pakistan.
	Details of Drug Sale License of importer	License No: 05-352-0066 Address: Ground Floor, 14-Airline Society Lahore DSL Issuance Date: 20.02.2023 (Valid till 03-02-2028) Status: License to sell drugs as a distributor
	Name and address of marketing authorization holder (abroad)	M/s Sinopharm Wuhan Biopharmaceuticals Co.,Ltd No. 1-1, Golden Industrial Park Road, Zhengdian, Jiangxia district, Wuhan, Hubei Province, P.R.China
	Name, address of manufacturer (s)	M/s Sinopharm Wuhan Biopharmaceuticals Co.,Ltd No. 1-1, Golden Industrial Park Road, Zhengdian, Jiangxia district, Wuhan, Hubei Province, P.R.China
	Name of exporting country	China
	Detail of certificates attached (CoPP , Free Sale certificate, GMP certificate)	CoPP: Firm has submitted legalized copy of CoPP (No: Hubei20240093) valid till 23-06-2026 issued by Hubei Medical Products Administration, China.
	Details of letter of authorization/sole agency agreement	Firm has submitted letter of authorization from M/s Sinopharm Wuhan Biopharmaceuticals Co.,Ltd, dated 09-09-2024 valid for 05 years
	Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
	For imported products, specify one of these	For imported products, specify one the these ☒ Finished Pharmaceutical product import ☐ Bulk import and local repackaging ☐ Bulk import and local repackaging as for export purpose only
	Dy. No. and date of submission	Tracking. No: YVG-W3Q-JSVR Date of submission: 25-02-2025
	Details of fee submitted	Rs: 300,000 Slip number: 4016749037 Dated : 20-02-2025
	The proposed proprietary name/ brand name	IVIG Human Immunoglobulin 5% pH4 2.5g 50ML
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per	Human Immunoglobulin Intravenous Injection 5% pH4 2.5g 50ML

unit	
Pharmaceutical form of applied drug	Solution for infusion
Pharmacotherapeutic Group of (API)	Human Immunoglobulin
Reference to Finished product specifications	B.P
Proposed Pack size	2's
Proposed unit price	As per SRO
Shelf Life	36 months
Storage Conditions	2C to 8C
The status in reference regulatory authorities	Intratect by Biotest Pharma, Germany
For generic drugs (me-too status)	
Module-II (Quality Overall Summary)	Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Name, address of drug substance manufacturer	M/s Wuhan Biopharmaceuticals, China
Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 40°C ± 2°C, RH 75% ± 5% for 6 months. The real time stability data is conducted at 30 °C ± 2°C RH 60% ± 5% for 36 months.
Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Pharmaceutical Equivalence and Comparative Dissolution Profile	N/A
Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product

Container closure system of the drug product	Human immunoglobulin (pH4) for intravenous injection is a solution for injection, and the container closure systems consists of: injection bottles made of moulded neutral borosilicate (B20190006263), partially coated teflon membrane bromobutyl rubber stopper for injection (B20190005067) and aluminum-plastic combined caps for infusion bottles(B20190008341)
Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches. The accelerated stability study data is conducted at Temperature at 20~25°C, RH 75% ± 5% for 6 months. The real time stability study data is conducted Temperature 5°C ± 3°C / RH 75% ± 5% for 36 months as per ICH guidelines.
Module-IV Non-Clinical	Non-clinical study reports including pharmacological and toxicological studies have been provided by the firm.
Module – V (Clinical Data)	Clinical study reports have been provided.
Decision: Keeping in view submitted CoPP indicating the product availability in country of origin; Registration Board approved the product in compliance of current Import Policy for finished drugs	

Case # 20	
Name, address of Applicant / Importer	M/s Hakimsons (Impex) (Pvt.) Ltd. Hakimsons Building, 19 West Wharf Road, Karachi 74000, Pakistan.
Details of Drug Sale License of importer	License No: 030 Address: Hakimsons Building, 19 West Wharf Road, Karachi 74000, Pakistan. Address of Godown: Hakimsons Building, 19 T-31 West Wharf Road, Karachi 74000, Pakistan. Status: License to sell drugs as distributor Valid Upto: 19-07-2028
Name and address of marketing authorization holder (abroad)	M/s Firmlink Pvt Limited., J-50 Paschin Vihar, New Delhi India
Name, address of manufacturer(s)	M/s Cadila Pharmaceuticals Limited 1389, Trasad Road, Dholka – 382 225, District: Ahmedabad Gujarat State, INDIA
Name of exporting country	India

Detail of certificates attached (CoPP, Freesale certificate, GMP certificate)	Type of Document: CoPP/FSC/GMP : COPP: Firm has submitted the legalized COPP and Product is available freely in the country of Export [Certificate No. MFG/WHO/GMP COPP/2024/4550243710 Issuance Date: 15-02-2024 Validity: 16.11-2025 Name and address of Issuing Regulatory Authority: Food & Drugs Control Administration, Gujarat State, India] GMP (India) : Firm has submitted the legalized GMP [Certificate No. 22113688 , Issuance Date: 17-11-2022 Validity : 16.11-2025, Name and address of Issuing Regulatory Authority: Food & Drugs Control Administration, Gujarat State, India] GMP (Malaysia) PICs: Firm has submitted the legalized GMP [Certificate No M018/23, Issuance Date: 27-12-2023 Name and address of Issuing Regulatory Authority: National Pharmaceutical Regulatory Agency Ministry of Health Malaysia]
Details of letter of authorization / sole agency agreement	Firm has submitted Legalized letter of distribution certificate from Cadila Pharmaceuticals Limited. The letter species that the manufacturer appoints M/s Hakimsons (Impex) (Pvt.) Ltd. to register their products in Pakistan issued on 03-05-2024
Status of the applicant	☐ Manufacturer ☒ Importer ☐ Is involved in none of the above (contract giver)
Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
Intended use of pharmaceutical product	☒ Domestic sale ☐ Export sale ☐ Domestic and Export sales
For imported products, specify one the these	☒ Finished Pharmaceutical product import ☐ Buk import and local repackaging ☐ Buk import and local repackaging for export purpose only
Dy. No. and date of submission	Tracking ID 32X-P4B-HGQZ , Date: 13-11-2024
Details of fee submitted	Challan No. 363753294885 Amount: 300,000/= Date of submission: 12-11-2024
The proposed proprietary name / brand name	STpase Injection
Strength / concentration of drug of Active Pharmaceutical ingredient (API)	Streptokinase for Injection BP 15,00,000 IU

per unit	
Pharmaceutical form of applied drug	Powder for Infusion
Pharmacotherapeutic Group of (API)	Antithrombotic Agents, Enzymes (B01A D01)
Reference to Finished product specifications	British Pharmacopoeia
Proposed Pack size	1 Vial (15,00,000 IU/10ml)
Proposed unit price	30.5 USD
The status in reference regulatory authorities	Streptokinase Karma 1,500,000 IU Powder for Solution for Infusion 10ml glass Vial with Rubber Closures & Aluminum Seal with plastic flip top Caps Acute MI Intravenous / Intracoronary MAH: Karma Medica GmbH, Germany
For generic drugs (me-too status)	Diclair-ST Gene Tech Laboratories BBT Biotech, Germany Registration No. 059023
Module-II (Quality Overall Summary)	Firm has submitted the Quality Overall Summary WHO QOS-PD Format. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure and Stability of Studies
Name, address of drug substance manufacturer	Cadila Pharmaceuticals Limited Survey No 1389, Trasad Road, Dholka – 387 810, District: Ahmedabad Gujarat State, INDIA
Module-III Drug Substance:	Firm has submitted detailed drug substance data for both sources related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, impurities, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted the 3 batches data 14019, 14020, 14021 Accelerated 2-8 C (6Months) & Long Term (Real Time) Studies -20 C (12Months)

Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Pharmaceutical Equivalence and Comparative Dissolution Profile	Not Required.
Analytical method validation/verification of product	Firm has submitted analytical method validation studies for the applied product.
Container closure system of the drug product	10ml, 20mm Flint Tubular USP Type-I vial 20mm grey sterile rubber stopper 20mm aluminum flip off white seal
Stability study data of drug product, shelf life and storage conditions	Firm has submitted stability study data of 3 batches The accelerated stability study data is conducted at 25°C ± 2°C / 60 % ± 5% RH for 6 months. The real time stability study data is conducted at 5 °C ± 3°C for total 48 Month C the real time stability study data as per ICH guidelines.
Module – IV (Non-clinical)	The firm has provided clarification from the manufacturer
Module – V (Clinical)	The firm has provided clarification from the manufacturer

Evaluator remarks: Previously the case was discussed in 345th meeting of the Board and was decided as under:

Decision: After detailed discussion and deliberation, the Board decided to defer the case for provision of following:

- i. Evidence of approval of biological section from concerned regulatory authority.***
- ii. Documented study reports and non-clinical data of pharmacological, pharmacokinetics, toxicology including single-dose and repeat dose toxicity studies, genotoxicity, carcinogenicity, reproductive and developmental toxicity (including range-finding studies and supportive toxicokinetics evaluations), local tolerance and other toxicological studies:***
- iii. Documented and published clinical studies, In vitro-In vivo Correlation Study Reports, Reports of Bioanalytical and Analytical Methods for Human Studies, Human Pharmacokinetic and Pharmacodynamics studies, Study Reports of Controlled Clinical Studies Pertinent to the claimed indication:***
- iv. Documented and published Clinical trial reports establishing the safety and efficacy of the product:***
- v. Post-marketing surveillance study reports***

Now the firm has submitted the shortcomings vide letter No. Nil, dated 16-06-2025.

Deficiencies	Response of the Firm
Evidence of approval of biological section from concerned regulatory authority.	The firm has provided GMP Certificate (No. M018/23, dated 27-12-2023) from regulatory body of Malaysia however the Biological Section is not mentioned on the said Certificate. The firm has also submitted a clarification letter from the manufacturer which is reproduced as under: <i>"This is with reference to our product Streptokinase Injection BP 1500000 IU which is under Pakistan registration. We would like to clarify that the PICs GMP approval (by NPRA Malaysia) applies to the small volume parenteral production area on the main production Pharma block and Dry Powders injection on the Cephalosporin. Both have separate dedicated facility. The small volume parenteral manufactured in the main Pharma Block includes dry powder and liquid form, in which Streptokinase (STPase) Injection is manufactured.</i> <i>We request you to accept the above mentioned explanation and provide approval on the same.</i> <i>For, Cadila Pharmaceuticals Ltd."</i> Section-wise product list from the Site Master File is also provided by the firm.
Documented study reports and non-clinical data of pharmacological, pharmacokinetics, toxicology including single-dose and repeat dose toxicity studies, genotoxicity, carcinogenicity, reproductive and developmental toxicity (including range-finding studies and supportive toxicokinetics evaluations), local tolerance and other toxicological studies:	The firm has also submitted a clarification letter from the manufacturer which is reproduced as under: <i>This is with reference to our product Streptokinase Injection BP 1500000 IU which is under registration. We would like to clarify that STPase Injection is a well established product and registered under generic/ general category classification in the country of origin. Non-clinical and clinical study was not conducted with reference to under the 'ICH</i>
Documented and published clinical studies, In vitro-In vivo Correlation Study Reports, Reports of Bioanalytical and Analytical Methods for Human Studies, Human Pharmacokinetic and Pharmacodynamics studies, Study Reports of Controlled Clinical Studies Pertinent to the claimed indication:	

Documented and published Clinical trial reports establishing the safety and efficacy of the product:	<i>guideline M4 (R4) on common technical document (CTD) for the registration of pharmaceuticals for human use -organisation of CTD' as it was not part of the registration requirement for a generic drug product.</i> <i>We request you to accept the above mentioned explanation and provide approval on the same.</i> <i>For, Cadila Pharmaceuticals Ltd."</i>
Post-marketing surveillance study reports	The firm has provided Periodic Safety Update Reports (PSURs) of the product.

Decision of 349th Meeting:
The Registration Board after thorough deliberation deferred the case for the submission of the following documents:

- Evidence of approval of biological section from concerned regulatory authority.
- Documented study reports and non-clinical data of pharmacological, pharmacokinetics, toxicology including single-dose and repeat dose toxicity studies, genotoxicity, carcinogenicity, reproductive and developmental toxicity (including range-finding studies and supportive toxicokinetics evaluations), local tolerance and other toxicological studies:
- Documented and published clinical studies, In vitro-In vivo Correlation Study Reports, Reports of Bioanalytical and Analytical Methods for Human Studies, Human Pharmacokinetic and Pharmacodynamics studies, Study Reports of Controlled Clinical Studies Pertinent to the claimed indication:
- Documented and published Clinical trial reports establishing the safety and efficacy of the product:



Drug Regulatory Authority of Pakistan

(Biological Evaluation & Research Division)



Applications submitted on e-App (BE&R)

Sr. No	Title	Description
1	Case Category	Import (Muhammad Ashfaq)
	Name, address of Applicant.	Nawan Laboratories Pvt Ltd Plot No 136-138 , Sector # 15 KIA (000442)
	Application Form Dy. No / Tracking ID & date of submission	(2E9-S72-GBDL, 2025-02-01)
	Detail of Fee Submitted	300000.0, 2025-01-13,
	The proposed proprietary name / brand name	First Defense Tri-Shield® Gel Tube
	Label Claim	Each Single Dose Gel Tube Contains: K99+ E.coli Relative Potency ≥ 1.0 v.s. Unit/Dose Coronavirus Protective Titer $\geq 2.4 \times 10^6$ Unit/Dose Rotavirus Relative Potency ≥ 1.0 v.s. Unit/Dose
	Reference to Finished product specifications	As per Innovators Specification
	Proposed Pack Size	12 Tubes Per Box -De-Controlled
	Shelf Life (Unit)	18 Month(s)Store in Refrigerator at 2°C - 8°C.
	For generic drugs (me-too Status)	Not registered
	Pharmacotherapeutic Group of (API)	Veterinary Immunoglobulins
	Name, address of Manufacturing site:	ImmuCell Corporation-56 Evergreen Drive Portland, ME 04103, USA-United States of America
	Name, address of Marketing Authorization Holder:	ImmuCell Corporation, 56 Evergreen Drive Portland, ME 04103, USA, United States of America
	Details of Certificates (CoPP/FSC/cGMP):	Legalized FSC has been submitted. GMP certificate has not been submitted.
	Details of Authorization Letter :	LOA from MAH has been submitted.
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Stability studies data of three batches has been submitted.
	Evaluation Remarks	
	Following deficiencies have been observed in the application;1. The document attached as MP certificate of manufacturer seems to be establishment license. Valid legalized GMP certificate clearly mentioning current GMP status of the manufacturer, is required.2. Data of Safety & Efficacy studies conducted in target animals, has not been submitted.3. Evidence of approval of me-too, has not been submitted.	
	Decision	
	Deferred	

	The Registration Board referred the case to Expert Working Group on veterinary Drugs for the opinion regarding immunological relevance and need of applied product in Pakistan. The Board further advised DBE&R to ask the firm to submit following: 1. The document attached as GMP certificate of manufacturer seems to be establishment license. Valid legalized GMP certificate clearly mentioning current GMP status of the manufacturer, is required. 2. Data of Safety & Efficacy studies conducted in target animals, has not been submitted. 3. Evidence of approval of me-too, has not been submitted.																																											
2	<table><tr><td>Case Category</td><td>Import (Muhammad Ashfaq)</td></tr><tr><td>Name, address of Applicant.</td><td>MS Enterprises P42/2, Opp Municipal Degree College, Jaranwala Road Fasialabad (06331016811)</td></tr><tr><td>Application Form Dy. No / Tracking ID & date of submission</td><td>(2HE-NW1-BUN1, 2025-05-01)</td></tr><tr><td>Detail of Fee Submitted</td><td>300000.0, 2025-04-16,</td></tr><tr><td>The proposed proprietary name / brand name</td><td>POLIMUN IB H120</td></tr><tr><td>Label Claim</td><td>Each dose contains: Avian Infectious Bronchitis Virus Strain "H-120" ≥ 3.5 lg EID50 obtained on SPF chicken embryos</td></tr><tr><td>Reference to Finished product specifications</td><td>European Pharmacopeia</td></tr><tr><td>Proposed Pack Size</td><td>10 Vials* 5000Doses-De-Controlled</td></tr><tr><td>Shelf Life (Unit)</td><td>18 Month(s)2°C - 8°C</td></tr><tr><td>For generic drugs (me-too Status)</td><td>Product Name:: Bronchipharm Lyophilisate for suspension for chick Registration No: 107933 Company Name: Orient Traders International, Composition: Avian Infectious Bronchitis Virus, live strain H120 ^</td></tr><tr><td>Pharmacotherapeutic Group of (API)</td><td>Veterinary Viral Vaccine</td></tr><tr><td>Name, address of Manufacturing site:</td><td>BIOTESTLAB LLC-57-A Volodymyrska Str. Vasylkiv 08600 Kyiv Region, Ukraine-Ukraine</td></tr><tr><td>Name, address of Marketing Authorization Holder:</td><td>BIOTESTLAB LLC, 08601, City Vasilkiv Volodymirska, Str. 57-A, Ukraine</td></tr><tr><td>Details of Certificates (CoPP/FSC/cGMP):</td><td>Valid legalized FSC has been submitted. Valid legalized GMP certificate has been submitted.</td></tr><tr><td>Details of Authorization Letter :</td><td>LOA from MAH has been submitted.</td></tr><tr><td>Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)</td><td>Stability studies data of three batches has been submitted.</td></tr><tr><td colspan="2">Evaluation Remarks</td></tr><tr><td colspan="2">Following deficiency has been observed in the application;1. Stability studies data of 1000 dose vial has been submitted instead of 5000 dose vial.</td></tr><tr><td colspan="2">Decision</td></tr><tr><td colspan="2">Approved</td></tr><tr><td colspan="2">Keeping in view the legalized FSC indicating product availability in the country of origin, the Registration Board approved the product subject to compliance to the current Import Policy for finished drugs and submission of Stability studies data of 5000 dose vial by the applicant.</td></tr></table>	Case Category	Import (Muhammad Ashfaq)	Name, address of Applicant.	MS Enterprises P42/2, Opp Municipal Degree College, Jaranwala Road Fasialabad (06331016811)	Application Form Dy. No / Tracking ID & date of submission	(2HE-NW1-BUN1, 2025-05-01)	Detail of Fee Submitted	300000.0, 2025-04-16,	The proposed proprietary name / brand name	POLIMUN IB H120	Label Claim	Each dose contains: Avian Infectious Bronchitis Virus Strain "H-120" ≥ 3.5 lg EID50 obtained on SPF chicken embryos	Reference to Finished product specifications	European Pharmacopeia	Proposed Pack Size	10 Vials* 5000Doses-De-Controlled	Shelf Life (Unit)	18 Month(s)2°C - 8°C	For generic drugs (me-too Status)	Product Name:: Bronchipharm Lyophilisate for suspension for chick Registration No: 107933 Company Name: Orient Traders International, Composition: Avian Infectious Bronchitis Virus, live strain H120 ^	Pharmacotherapeutic Group of (API)	Veterinary Viral Vaccine	Name, address of Manufacturing site:	BIOTESTLAB LLC-57-A Volodymyrska Str. Vasylkiv 08600 Kyiv Region, Ukraine-Ukraine	Name, address of Marketing Authorization Holder:	BIOTESTLAB LLC, 08601, City Vasilkiv Volodymirska, Str. 57-A, Ukraine	Details of Certificates (CoPP/FSC/cGMP):	Valid legalized FSC has been submitted. Valid legalized GMP certificate has been submitted.	Details of Authorization Letter :	LOA from MAH has been submitted.	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Stability studies data of three batches has been submitted.	Evaluation Remarks		Following deficiency has been observed in the application;1. Stability studies data of 1000 dose vial has been submitted instead of 5000 dose vial.		Decision		Approved		Keeping in view the legalized FSC indicating product availability in the country of origin, the Registration Board approved the product subject to compliance to the current Import Policy for finished drugs and submission of Stability studies data of 5000 dose vial by the applicant.		
Case Category	Import (Muhammad Ashfaq)																																											
Name, address of Applicant.	MS Enterprises P42/2, Opp Municipal Degree College, Jaranwala Road Fasialabad (06331016811)																																											
Application Form Dy. No / Tracking ID & date of submission	(2HE-NW1-BUN1, 2025-05-01)																																											
Detail of Fee Submitted	300000.0, 2025-04-16,																																											
The proposed proprietary name / brand name	POLIMUN IB H120																																											
Label Claim	Each dose contains: Avian Infectious Bronchitis Virus Strain "H-120" ≥ 3.5 lg EID50 obtained on SPF chicken embryos																																											
Reference to Finished product specifications	European Pharmacopeia																																											
Proposed Pack Size	10 Vials* 5000Doses-De-Controlled																																											
Shelf Life (Unit)	18 Month(s)2°C - 8°C																																											
For generic drugs (me-too Status)	Product Name:: Bronchipharm Lyophilisate for suspension for chick Registration No: 107933 Company Name: Orient Traders International, Composition: Avian Infectious Bronchitis Virus, live strain H120 ^																																											
Pharmacotherapeutic Group of (API)	Veterinary Viral Vaccine																																											
Name, address of Manufacturing site:	BIOTESTLAB LLC-57-A Volodymyrska Str. Vasylkiv 08600 Kyiv Region, Ukraine-Ukraine																																											
Name, address of Marketing Authorization Holder:	BIOTESTLAB LLC, 08601, City Vasilkiv Volodymirska, Str. 57-A, Ukraine																																											
Details of Certificates (CoPP/FSC/cGMP):	Valid legalized FSC has been submitted. Valid legalized GMP certificate has been submitted.																																											
Details of Authorization Letter :	LOA from MAH has been submitted.																																											
Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Stability studies data of three batches has been submitted.																																											
Evaluation Remarks																																												
Following deficiency has been observed in the application;1. Stability studies data of 1000 dose vial has been submitted instead of 5000 dose vial.																																												
Decision																																												
Approved																																												
Keeping in view the legalized FSC indicating product availability in the country of origin, the Registration Board approved the product subject to compliance to the current Import Policy for finished drugs and submission of Stability studies data of 5000 dose vial by the applicant.																																												
3	<table><tr><td>Case Category</td><td>Routine (Muhammad Ashfaq)</td></tr></table>	Case Category	Routine (Muhammad Ashfaq)																																									
Case Category	Routine (Muhammad Ashfaq)																																											

Name, address of Applicant.	INTERVAC (PVT) LTD 18KM SHEIKHUPURA ROAD (000623)
Application Form Dy. No / Tracking ID & date of submission	(674-8P2-5VL5, 2025-02-20)
Detail of Fee Submitted	37000.0, 2025-02-18,
The proposed proprietary name / brand name	INTERVAC LUMPYVAC VACCINE
Label Claim	Each ml Dose Contains: Freeze-dried live attenuated Lumpy Skin Disease Virus (SIS Neethling-type)...10 ⁴ TCID ₅₀
Reference to Finished product specifications	Manufacturer Specification
Proposed Pack Size	100ml-De-Controlled,50ml-De-Controlled
Shelf Life (Unit)	2 Year(s)2-8C
For generic drugs (me-too Status)	LUMPYVAC VACCINE (Huzaiifa International)
Pharmacotherapeutic Group of (API)	
Name, address of Manufacturing site:	--
GMP status of the firm	The firm M/s Intervac (Pvt.) Ltd. 18 Km, Lahore Sheikhpura Road, Sheikhpura was evaluated for facilities like building, flow, HVAC, Water treatment, personnel, Quality Control / Quality Assurance, production operations and facilities, Keeping in view th
Evidence of approval of manufacturing facility	
Evaluation Remarks	
Following deficiencies have been observed in the application;1. Full descriptions of the specifications and analytical methods necessary to assure the identity, strength, quality, purity and homogeneity through out the shelf life of the drug product, is required.2. Stability studies protocol & stability studies data of three trial batches is required.3. The approved section mentioned on the letter of additional section dated 16th March, 2008 submitted, was Viral Vaccine (Poultry) only.4. Evidence of availability of lyophilization facility, is required.5. The detail of diluent to be used with vaccine, has not been provided.6. Multiple Pack sizes have been applied in single application. The required pack size is needed to be specified.	
Decision	
Deferred	
Registration Board deferred the case for submission of following by the applicant:	
1. Full descriptions of the specifications and analytical methods necessary to assure the identity, strength, quality, purity and homogeneity through out the shelf life of the drug product, is required.	
2. Stability studies protocol & stability studies data of three trial batches is required.	
3. The approved section mentioned on the letter of additional section dated 16th March, 2008 submitted, was Viral Vaccine (Poultry) only.	
4. Evidence of availability of lyophilization facility, is required.	
5. The detail of diluent to be used with vaccine, has not been provided.	
6. Multiple Pack sizes have been applied in single application. The required pack size is needed to be specified.	

4	Case Category	Import (Muhammad Ashfaq)
	Name, address of Applicant.	Elahi Traders Office M-1, Mezzanine Floor, Roshan Arcade, Plot SA-2, Sector 5-H, North Karachi (147)
	Application Form Dy. No / Tracking ID & date of submission	(8UG-ZXZ-WSNA, 2025-05-26)
	Detail of Fee Submitted	300000.0, 2025-05-20,
	The proposed proprietary name / brand name	Live Lyophilized Vaccine Against Sheep and Goat Capripoxvirus and Infectious Nodular Dermatitis in Cattle
	Label Claim	Avirulent strain of Sheep Capripoxvirus PKPBA-V-411 > 10 ⁵ TCID ₅₀ /Dose
	Reference to Finished product specifications	Manufacturer Specification
	Proposed Pack Size	10ml-De-Controlled
	Shelf Life (Unit)	1 Year(s)Store in a place protected from light at a temperature from +2 to +8 degrees centigrade
	For generic drugs (me-too Status)	Not registered
	Pharmacotherapeutic Group of (API)	Veterinary Viral Vaccine
	Name, address of Manufacturing site:	BelVitunipharm-Sovetskaya Str. 26-A, 211309, Village Dolzha, Mazolovo Village Council, Vitebsk District, Vitebsk Region, Republic of Belarus.- Belarus
	Name, address of Marketing Authorization Holder:	BelVitunipharm, 210034, Vitebsk, Transportnaya Str. 9, Office 5, Republic of Belarus
	Details of Certificates (CoPP/FSC/cGMP):	FSC submitted has expired. GMP certificate submitted has expired.
	Details of Authorization Letter :	Not submitted. Distribution agreement submitted is without product list.
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Not submitted.
Evaluation Remarks		
Following deficiencies have been observed in application;1. The GMP certificate of the manufacturer & Free sale certificate of product, has expired.2. The product specific Letter of Authorization has not been attached.3. SmPC for conformation of product formulation/strength, has not been attached.4. Copy of valid DSL, has not been attached.5. Information i.e brand name & formulation, regarding me-too already registered in Pakistan, has not been provided.6. The approval status of the formulation in reference regulatory authorities, is also required.7. Justification of use of product in Lumpy Skin Disease is required.8. Safety & efficacy studies data of the product in target animals, has not been provided.9. Method of manufacture has not been submitted.10. A full description of the specifications and analytical methods necessary to assure the identity, strength, quality, purity and homogeneity throughout the shelf life of the drug product, is required11. Labeling and prescribing information (to be mentioned on the pack/leaflet) specimen or draft, is required12- Stability studies data of three batches, is required.13- Detail of persons under whose direct supervision and control the drug applied for registration shall be manufactured, is required14. Detail of equipment that will be used in the manufacture of the applied drug, is required15- Detail of the persons who will be responsible for the quality control of the drug, is required16- Description of the equipment to be used for the quality control of the active raw material and the finished products, is required. 17. As per available record, the me-too of the product is not already registered.		
Decision		

Deferred

Registration Board deferred the case for submission of following by the applicant:

1. The GMP certificate of the manufacturer & Free sale certificate of product, has expired.
2. The product specific Letter of Authorization has not been attached.
3. SmPC for conformation of product formulation/strength, has not been attached.
4. Copy of valid DSL, has not been attached.
5. Information i.e brand name & formulation, regarding me-too already registered in Pakistan, has not been provided.
6. The approval status of the formulation in reference regulatory authorities, is also required.
7. Justification of use of product in Lumpy Skin Disease is required.
8. Safety & efficacy studies data of the product in target animals, has not been provided.
9. Method of manufacture has not been submitted.
10. A full description of the specifications and analytical methods necessary to assure the identity, strength, quality, purity and homogeneity throughout the shelf life of the drug product, is required
11. Labeling and prescribing information (to be mentioned on the pack/leaflet) specimen or draft, is required
- 12- Stability studies data of three batches, is required.
- 13- Detail of persons under whose direct supervision and control the drug applied for registration shall be manufactured, is required
14. Detail of equipment that will be used in the manufacture of the applied drug, is required
- 15- Detail of the persons who will be responsible for the quality control of the drug, is required
- 16- Description of the equipment to be used for the quality control of the active raw material and the finished products, is required.
17. As per available record, the me-too of the product is not already registered.

5	Case Category	Import (Muhammad Ashfaq)
	Name, address of Applicant.	INTERVAC (PVT) LTD 18KM SHEIKHUPURA ROAD (000623)
	Application Form Dy. No / Tracking ID & date of submission	(AR9-GAW-YVLM, 2025-02-20)
	Detail of Fee Submitted	37000.0, 2025-02-18,
	The proposed proprietary name / brand name	INTERVAC ND+IB+H9 VACCINE
	Label Claim	Each ml Contains: Inactivated Newcastle Disease (La-sota strain) virus...10 ^{7.0} EID50, Inactivated Avian Infectious Bronchitis (H-120 strain)

	virus...10 ^{6.5} EID50, Inactivated Avian Influenza (H9N2 strain) virus 10 ^{7.0} EID50
Reference to Finished product specifications	Manufacturer Specification
Proposed Pack Size	300ml-De-Controlled
Shelf Life (Unit)	1 Year(s)2-8C
For generic drugs (me-too Status)	GPVAC ND+IB+H9 (Reg no. 084591) Grand Pharma Pvt. Ltd.
Pharmacotherapeutic Group of (API)	
Name, address of Manufacturing site:	--
Name, address of Marketing Authorization Holder:	, ,
Details of Certificates (CoPP/FSC/cGMP):	The firm M/s Intervac (Pvt.) Ltd. 18 Km, Lahore Sheikhpura Road, Sheikhpura was evaluated for facilities like building, flow, HVAC, Water treatment, personnel, Quality Control / Quality Assurance, production operations and facilities, Keeping in view th
Details of Authorization Letter :	
Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	
Evaluation Remarks	
Following deficiencies have been observed in the application;1. Full descriptions of the specifications and analytical methods necessary to assure the identity, strength, quality, purity and homogeneity through out the shelf life of the drug product, is required.2. The stability studies protocol & stability studies data of three trial batches for six months, is required to be submitted.	
Decision	
Deferred	
Registration Board deferred the case for submission of following by the applicant:	
1. Full descriptions of the specifications and analytical methods necessary to assure the identity, strength, quality, purity and homogeneity through out the shelf life of the drug product, is required.	
2. The stability studies protocol & stability studies data of three trial batches for six months, is required to be submitted.	
6	Case Category
	Import (Muhammad Ashfaq)
	Name, address of Applicant.
	Forward Solutions Plot No. 19-B, Qazalbash, Abdul Sattar Edhi Road, District Lahore (05-352-0066)
	Application Form Dy. No / Tracking ID & date of submission
	(AX9-RQA-DPPR, 2025-03-01)
	Detail of Fee Submitted
	300000.0, 2025-02-10,
	The proposed proprietary name / brand name
	IB-OLVAC
	Label Claim
	Each dose contains: Inactivated Newcastle disease virus (LaSota strain)..... NLT 10 ^{8.5} EID50 Inactivated Infectious bronchitis virus (Massachusetts strain) not less than 3×10 ^{7.5} EID50 (10 ^{7.5} EID50 each strain)
	Reference to Finished product specifications
	European Pharmacopeia
	Proposed Pack Size
	500 ml (1000 doses) -De-Controlled

Shelf Life (Unit)	24 Month(s) 2°C to 8°C																																		
For generic drugs (me-too Status)	Nobilis IB3 + ND																																		
Pharmacotherapeutic Group of (API)	Veterinary Viral Vaccine																																		
Name, address of Manufacturing site:	FATRO S.P.A-Via Molino Emili, 2 - 25030 Macclodio (BS), Italy-Italy																																		
Name, address of Marketing Authorization Holder:	FATRO S.P.A, Via Emilia, 285 - 40064 Ozzano Emilia (Bologna), Italy, Italy																																		
Details of Certificates (CoPP/FSC/cGMP):	Legalized CoPP has been submitted.																																		
Details of Authorization Letter :	LOA from MAH has been submitted.																																		
Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Stability studies data of three batches has been submitted.																																		
Evaluation Remarks																																			
The applicant has submitted the required documents.																																			
Decision																																			
Approved																																			
Keeping in view the legalized CoPP indicating product availability in the country of origin, the Registration Board approved the product subject to compliance to the current Import Policy for finished drugs.																																			
7	<table> <tr> <td>Case Category</td><td>Import (Muhammad Ashfaq)</td></tr> <tr> <td>Name, address of Applicant.</td><td>Inouko Animal Health (Private) Limited 3rd Floor, Plaza No. 3, D-Block, DHA Phase 5, Cantt, District Lahore (05-352-0058)</td></tr> <tr> <td>Application Form Dy. No / Tracking ID & date of submission</td><td>(B3Z-1X2-J513, 2025-05-21)</td></tr> <tr> <td>Detail of Fee Submitted</td><td>225000.0, 2025-03-18,</td></tr> <tr> <td>The proposed proprietary name / brand name</td><td>Newflend ND H9</td></tr> <tr> <td>Label Claim</td><td>One Dose vaccine contains: Cell-associated live recombinant Turkey herpesvirus (rHVT/ND-H9), expressing the fusion protein of Newcastle disease virus and the hemagglutinin H9-subtype of Low Pathogenic Avian Influenza min. 3000PFU*/Dose *PFU: plaque forming unit</td></tr> <tr> <td>Reference to Finished product specifications</td><td>European Pharmacopeia</td></tr> <tr> <td>Proposed Pack Size</td><td>2000 doses & 4000 do-De-Controlled</td></tr> <tr> <td>Shelf Life (Unit)</td><td>24 MonthStore and transport Vaccine in liquid Nitrogen Container</td></tr> <tr> <td>For generic drugs (me-too Status)</td><td>N/A</td></tr> <tr> <td>Pharmacotherapeutic Group of (API)</td><td></td></tr> <tr> <td>Name, address of Manufacturing site:</td><td>Ceva-Phylaxia Veterinary Biologicals Co.Ltd. -1107 Budapest, Szallas u. 5.,-Hungary</td></tr> <tr> <td>Name, address of Marketing Authorization Holder:</td><td>Ceva-Phylaxia Veterinary Biologicals Co.Ltd., 1107 Budapest, Szallas u. 5.,, Hungary</td></tr> <tr> <td>Details of Certificates (CoPP/FSC/cGMP):</td><td></td></tr> <tr> <td>Details of Authorization Letter :</td><td></td></tr> <tr> <td>Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)</td><td></td></tr> <tr> <td colspan="2">Evaluation Remarks</td></tr> </table>	Case Category	Import (Muhammad Ashfaq)	Name, address of Applicant.	Inouko Animal Health (Private) Limited 3rd Floor, Plaza No. 3, D-Block, DHA Phase 5, Cantt, District Lahore (05-352-0058)	Application Form Dy. No / Tracking ID & date of submission	(B3Z-1X2-J513, 2025-05-21)	Detail of Fee Submitted	225000.0, 2025-03-18,	The proposed proprietary name / brand name	Newflend ND H9	Label Claim	One Dose vaccine contains: Cell-associated live recombinant Turkey herpesvirus (rHVT/ND-H9), expressing the fusion protein of Newcastle disease virus and the hemagglutinin H9-subtype of Low Pathogenic Avian Influenza min. 3000PFU*/Dose *PFU: plaque forming unit	Reference to Finished product specifications	European Pharmacopeia	Proposed Pack Size	2000 doses & 4000 do-De-Controlled	Shelf Life (Unit)	24 MonthStore and transport Vaccine in liquid Nitrogen Container	For generic drugs (me-too Status)	N/A	Pharmacotherapeutic Group of (API)		Name, address of Manufacturing site:	Ceva-Phylaxia Veterinary Biologicals Co.Ltd. -1107 Budapest, Szallas u. 5.,-Hungary	Name, address of Marketing Authorization Holder:	Ceva-Phylaxia Veterinary Biologicals Co.Ltd., 1107 Budapest, Szallas u. 5.,, Hungary	Details of Certificates (CoPP/FSC/cGMP):		Details of Authorization Letter :		Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)		Evaluation Remarks	
Case Category	Import (Muhammad Ashfaq)																																		
Name, address of Applicant.	Inouko Animal Health (Private) Limited 3rd Floor, Plaza No. 3, D-Block, DHA Phase 5, Cantt, District Lahore (05-352-0058)																																		
Application Form Dy. No / Tracking ID & date of submission	(B3Z-1X2-J513, 2025-05-21)																																		
Detail of Fee Submitted	225000.0, 2025-03-18,																																		
The proposed proprietary name / brand name	Newflend ND H9																																		
Label Claim	One Dose vaccine contains: Cell-associated live recombinant Turkey herpesvirus (rHVT/ND-H9), expressing the fusion protein of Newcastle disease virus and the hemagglutinin H9-subtype of Low Pathogenic Avian Influenza min. 3000PFU*/Dose *PFU: plaque forming unit																																		
Reference to Finished product specifications	European Pharmacopeia																																		
Proposed Pack Size	2000 doses & 4000 do-De-Controlled																																		
Shelf Life (Unit)	24 MonthStore and transport Vaccine in liquid Nitrogen Container																																		
For generic drugs (me-too Status)	N/A																																		
Pharmacotherapeutic Group of (API)																																			
Name, address of Manufacturing site:	Ceva-Phylaxia Veterinary Biologicals Co.Ltd. -1107 Budapest, Szallas u. 5.,-Hungary																																		
Name, address of Marketing Authorization Holder:	Ceva-Phylaxia Veterinary Biologicals Co.Ltd., 1107 Budapest, Szallas u. 5.,, Hungary																																		
Details of Certificates (CoPP/FSC/cGMP):																																			
Details of Authorization Letter :																																			
Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)																																			
Evaluation Remarks																																			

Following deficiencies have been observed in the application; 1. The sole agency agreement has been signed by Seva Sante Animal Health S.A., France while the product license holder mentioned on the FSC is Ceva-Phylaxia Veterinary Biologicals Co.Ltd., Hungary. 2. The me-too product with the applied formulation is not already registered.

Decision

Deferred

The Registration Board referred the case to Expert Working Group on veterinary drugs for opinion regarding immunological relevance and need of applied product in Pakistan. The Board further advised DBE&R yto ask the firm to submit the following:

1. The sole agency agreement has been signed by Seva Sante Animal Health S.A., France while the product license holder mentioned on the FSC is Ceva-Phylaxia Veterinary Biologicals Co.Ltd., Hungary.

2. The me-too product with the applied formulation is not already registered.

8	Case Category	Import (Muhammad Ashfaq)
	Name, address of Applicant.	tec man international Plot # 276, Bhangril Road, 0.5 Km, T Chowk, Rawat (DHO-ISB-264)
	Application Form Dy. No / Tracking ID & date of submission	(BA1-EAM-P1GQ, 2025-01-14)
	Detail of Fee Submitted	225000.0, 2024-11-14,
	The proposed proprietary name / brand name	PRIMUN GUMBORO
	Label Claim	Each dose contains; Live attenuated infectious bursal disease (IBD) virus, intermediate IBDV-IGS...3.0-4.5 log10EID50
	Reference to Finished product specifications	European Pharmacopeia
	Proposed Pack Size	1000 Doses-De-Controlled
	Shelf Life (Unit)	24 Month(s)(2°C – 8°C)
	For generic drugs (me-too Status)	Not registered
	Pharmacotherapeutic Group of (API)	Live Viral Veterinary Vaccine
	Name, address of Manufacturing site:	LABORATORIOS CALIER, S.A.-Pol. Ind. De Leon. Ed. CEEI - Onzonilla (Leon) - 24231 – Spain-Spain
	Name, address of Marketing Authorization Holder:	LABORATORIOS CALIER, S.A., c/. Barcelones, 26. Les Franqueses del Valles (Barcelona), Spain, Spain
	Details of Certificates (CoPP/FSC/cGMP):	Valid legalized FSC has been submitted. Valid legalized GMP certificate of manufacturer, has not been submitted.
	Details of Authorization Letter :	LOA submitted has expired.
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Stability studies data of three batches has been submitted.
	Evaluation Remarks	
	Following deficiencies have been observed in the application; 1. Evidence of me-too submitted does not contain IBDV-IGS strain. 2. Valid legalized GMP certificate of manufacturer, has not been provided. 3. LOA has expired.	
	Decision	
	Deferred	

Registration Board deferred the case for submission of following by the applicant:

1. Evidence of me-too submitted does not contain IBDV-IGS strain.
2. Valid legalized GMP certificate of manufacturer, has not been provided.
3. LOA has expired.
4. Details of strain in formulation.

9	Case Category	Import (Muhammad Ashfaq)
	Name, address of Applicant.	Inouko Animal Health (Private) Limited 3rd Floor, Plaza No. 3, D-Block, DHA Phase 5, Cantt, District Lahore (05-352-0058)
	Application Form Dy. No / Tracking ID & date of submission	(D7W-7RG-LQV7, 2025-05-13)
	Detail of Fee Submitted	225000.0, 2025-03-18,
	The proposed proprietary name / brand name	Cevac Vitabron L
	Label Claim	One dose of Vaccine contains: New Castle Disease virus strain PHY.LMV.42.....at least 5.5 log10 EID50 Avian infectious bronchitis virus strain H120.....at least 3.3 log10 EID50
	Reference to Finished product specifications	European Pharmacopeia
	Proposed Pack Size	2000 doses-De-Controlled
	Shelf Life (Unit)	18 Month(s)Store at 2-8 C, Protect from Light, don't freeze
	For generic drugs (me-too Status)	N/A
	Pharmacotherapeutic Group of (API)	Veterinary Viral Vaccine
	Name, address of Manufacturing site:	Ceva-Phylaxia Veterinary Biologicals Co.Ltd. -1107 Budapest, Szallas u. 5.,-Hungary
	Name, address of Marketing Authorization Holder:	Ceva-Phylaxia Veterinary Biologicals Co.Ltd., 107 Budapest, Szallas u. 5.,, Hungary
	Details of Certificates (CoPP/FSC/cGMP):	Valid legalized FSC has been submitted. Valid legalized GMP certificate has been submitted.
	Details of Authorization Letter :	Sole agency agreement submitted is with Ceva Sante Animal S.A., France
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Stability studies data of three batches has been submitted.
	Evaluation Remarks	
	Following deficiencies have been observed in the application;1. The sole agency agreement has been signed by Seva Sante Animal Health S.A., France while the product license holder mentioned on the FSC is Ceva-Phylaxia Veterinary Biologicals Co.Ltd., Hungary.2. The me-too product with New Castle Disease virus strain PHY.LMV.42 is not already registered.	
	Decision	
	Deferred	
	The Registration Board referred the case to Expert Working Group on veterinary drugs for the opinion regarding immunological relevance and need of applied product in Pakistan. The Board further advised DBE&R to ask the firm to submit the following:	

1. The sole agency agreement has been signed by Seva Sante Animal Health S.A., France while the product license holder mentioned on the FSC is Ceva-Phylaxia Veterinary Biologicals Co.Ltd., Hungary.

2. The me-too product with New Castle Disease virus strain PHY.LMV.42 is not already registered.

10	Case Category	Import (Muhammad Ashfaq)
	Name, address of Applicant.	Hilton Pharma (Pvt.) Limited Plot No. 13-14 & 43, Sector-15, Korangi Industrial Area Karachi, Pakistan (0647.)
	Application Form Dy. No / Tracking ID & date of submission	(DA5-LX9-875B, 2025-05-16)
	Detail of Fee Submitted	300000.0, 2025-05-16,
	The proposed proprietary name / brand name	Medivac ND G7 Emulsion 0.3
	Label Claim	Each dose contains: Inactivated Newcastle Disease virus of MD15 strain (MD15 strain identical to Genotype VII.2 group) at least 10^7 EID50
	Reference to Finished product specifications	Manufacturer Specification
	Proposed Pack Size	150ml-De-Controlled,300ml-De-Controlled,30ml-De-Controlled,600ml-De-Controlled,75ml-De-Controlled
	Shelf Life (Unit)	18 Month(s)Vaccine is stored on temperature of 2 – 8°C and do not freeze, include temperature on its distribution. Vaccine is protected from heat and direct sunlight.
	For generic drugs (me-too Status)	Hilton Pharma (Pvt) Ltd - Medivac ND G7B Emulsion (Reg No. 084989)
	Pharmacotherapeutic Group of (API)	Veterinary Viral Vaccine
	Name, address of Manufacturing site:	PT MEDION FARMA JAYA-Jl. Raya Batujajar No 29, Cimareme, Ngamprah, Kab Bandung Barat – Indonesia-Indonesia
	Name, address of Marketing Authorization Holder:	PT MEDION FARMA JAYA, Office Address: Jl. Babakan Ciparay No. 282, Babakan Ciparay, Bandung – Indonesia Plant Address: Jl. Raya Batujajar No 29, Cimareme, Ngamprah, Kab Bandung Barat – Indonesia, Indonesia
	Details of Certificates (CoPP/FSC/cGMP):	Valid legalized CoPP has been submitted. Valid legalized GMP certificate of manufacturer has been submitted.
	Details of Authorization Letter :	Legalized Distribution agreement with MAH has been submitted.
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Stability studies data of three batches has been submitted
Evaluation Remarks		
The applicant has submitted required documents. However, multiple pack sizes have been applied on single application.		
Decision		
Approved		
Keeping in view the legalized CoPP indicating product availability in the country of origin, the Registration Board approved the product subject to compliance to the current Import Policy for finished drugs.		

11	Case Category	Routine (Muhammad Ashfaq)
	Name, address of Applicant.	INTERVAC (PVT) LTD 18KM SHEIKHUPURA ROAD (000623)
	Application Form Dy. No / Tracking ID & date of submission	(MNG-38V-HY3M, 2025-02-20)
	Detail of Fee Submitted	37000.0, 2025-02-18,
	The proposed proprietary name / brand name	INTERVAC CAPRINE PLEUROPNEUMONIA VACCINE
	Label Claim	Each Dose Contains: Mycoplasma Mycoides var Capri (PG3 strain)...0.15mg
	Reference to Finished product specifications	Manufacturer Specification
	Proposed Pack Size	100 Doses-De-Controlled,50 Doses-De-Controlled
	Shelf Life (Unit)	12 Month(s)2-8C
	For generic drugs (me-too Status)	Not registered
	Pharmacotherapeutic Group of (API)	
	Name, address of Manufacturing site:	--
	GMP status of the firm	The firm M/s Intervac (Pvt.) Ltd. 18 Km, Lahore Sheikhpura Road, Sheikhpura was evaluated for facilities like building, flow, HVAC, Water treatment, personnel, Quality Control / Quality Assurance, production operations and facilities, Keeping in view th
	Evidence of approval of manufacturing facility	
Evaluation Remarks		
Following deficiencies have been observed in the application;1. Full descriptions of the specifications and analytical methods necessary to assure the identity, strength, quality, purity and homogeneity through out the shelf life of the drug product, is required.2. Stability studies protocol & stability studies data of three trial batches is required.3. The approved section mentioned on the letter of additional section dated 16th March, 2008 submitted, was Viral Vaccine (Poultry) only but the applied vaccine is for goats.4. Evidence of availability of lyophilization facility, is required.5. The detail of diluent to be used with vaccine, has not been provided.6. As per available record, me-too with Mycoplasma Mycoides var Capri (PG3 strain), is not registered.7. Multiple Pack sizes have been applied in single application. The required pack size is needed to be specified.		
Decision		
Deferred		
Registration Board deferred the case for submission of following by the applicant:		
1. Full descriptions of the specifications and analytical methods necessary to assure the identity, strength, quality, purity and homogeneity through out the shelf life of the drug product, is required.		
2. Stability studies protocol & stability studies data of three trial batches is required.		
3. The approved section mentioned on the letter of additional section dated 16th March, 2008 submitted, was Viral Vaccine (Poultry) only but the applied vaccine is for goats.		
4. Evidence of availability of lyophilization facility, is required.		
5. The detail of diluent to be used with vaccine, has not been provided.		

	6. As per available record, me-too with Mycoplasma Mycoides var Capri (PG3 strain), is not registered.	
	7. Multiple Pack sizes have been applied in single application. The required pack size is needed to be specified.	
12	Case Category	Routine (Muhammad Ashfaq)
	Name, address of Applicant.	INTERVAC (PVT) LTD 18KM SHEIKHUPURA ROAD (000623)
	Application Form Dy. No / Tracking ID & date of submission	(MQL-SDY-A6GA, 2025-02-20)
	Detail of Fee Submitted	37000.0, 2025-02-18,
	The proposed proprietary name / brand name	INTERVAC PARVOCURE VACCINE
	Label Claim	Each 1ml Dose Contains: Live attenuated canine parvovirus strain Cornell 780916...10 ^{5.5} CCID50
	Reference to Finished product specifications	Manufacturer Specification
	Proposed Pack Size	1 Dose-De-Controlled, 10 Dose-De-Controlled
	Shelf Life (Unit)	2 Year(s) 2-8C
	For generic drugs (me-too Status)	Not registered
	Pharmaceutical Group of (API)	
	Name, address of Manufacturing site:	--
	GMP status of the firm	The firm M/s Intervac (Pvt.) Ltd. 18 Km, Lahore Sheikhpura Road, Sheikhpura was evaluated for facilities like building, flow, HVAC, Water treatment, personnel, Quality Control / Quality Assurance, production operations and facilities, Keeping in view th
	Evidence of approval of manufacturing facility	
	Evaluation Remarks	
	Following deficiencies have been observed in the application; 1. Full descriptions of the specifications and analytical methods necessary to assure the identity, strength, quality, purity and homogeneity through out the shelf life of the drug product, is required. 2. Stability studies protocol & stability studies data of three trial batches is required. 3. The approved section mentioned on the letter of additional section dated 16th March, 2008 submitted, was Viral Vaccine (Poultry) only but the applied vaccine is for dogs. 4. Evidence of availability of lyophilization facility, is required. 5. The detail of diluent to be used with vaccine, has not been provided. 6. As per available record, me-too with canine parvovirus strain Cornell 780916 is not registered.	
	Decision	
	Deferred	
	Registration Board deferred the case for submission of following by the applicant:	
	1. Full descriptions of the specifications and analytical methods necessary to assure the identity, strength, quality, purity and homogeneity through out the shelf life of the drug product, is required.	
	2. Stability studies protocol & stability studies data of three trial batches is required.	
	3. The approved section mentioned on the letter of additional section dated 16th March, 2008 submitted, was Viral Vaccine (Poultry) only but the applied vaccine is for dogs.	
	4. Evidence of availability of lyophilization facility, is required.	

	5. The detail of diluent to be used with vaccine, has not been provided.	
	6. As per available record, me-too with canine parvovirus strain Cornell 780916 is not registered.	
13	Case Category	Import (Muhammad Ashfaq)
	Name, address of Applicant.	MS Enterprises P42/2, Opp Municipal Degree College, Jaranwala Road Fasialabad (06331016811)
	Application Form Dy. No / Tracking ID & date of submission	(PWX-TNU-1D6T, 2025-05-01)
	Detail of Fee Submitted	300000.0, 2025-04-16,
	The proposed proprietary name / brand name	BOVIMUN LSD – vaccine against lumpy skin disease, live
	Label Claim	One dose (1 ml) contains: Active substances: Lumpy skin disease virus, strain “Neethling” $\geq 10^{3.8}$ TCD50 -or $\geq 10^{4.0}$ TCD50.
	Reference to Finished product specifications	Manufacturer Specification
	Proposed Pack Size	100Doses/100ml-De-Controlled
	Shelf Life (Unit)	24 Month(s) 2°C - 8°C
	For generic drugs (me-too Status)	Strain is already registered
	Pharmacotherapeutic Group of (API)	Veterinary Viral Vaccine
	Name, address of Manufacturing site:	BIOTESTLAB LLC-57-A Volodymyrska Str. Vasylkiv 08600 Kyiv Region, Ukraine-Ukraine
	Name, address of Marketing Authorization Holder:	BIOTESTLAB LLC, 08601, City Vasilkiv Volodymyrska, Str. 57-A, Ukraine
	Details of Certificates (CoPP/FSC/cGMP):	Valid legalized FSC has been submitted. Valid legalized GMP certificate of manufacturer, has been submitted.
	Details of Authorization Letter :	LOA from MAH has been submitted.
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Stability studies data of three batches has been submitted.
	Evaluation Remarks	
	The strength of virus needs clarification since FSC mentions strength as Lumpy skin disease virus, strain “Neethling” $\geq 10^{3.8}$ TCD50 -or $\geq 10^{4.0}$ TCD50 per dose.	
	Decision	
	Deferred	
	Registration Board deferred the case for clarification of strength as FSC mentions strength of virus as Lumpy skin disease virus, strain “Neethling” $\geq 10^{3.8}$ TCD50 -or $\geq 10^{4.0}$ TCD50 per dose.	
14	Case Category	Import (Muhammad Ashfaq)
	Name, address of Applicant.	Nawan Laboratories Pvt Ltd Plot No 136-138 , Sector # 15 KIA (000442)
	Application Form Dy. No / Tracking ID & date of submission	(R85-TVU-9GRA, 2025-02-01)
	Detail of Fee Submitted	300000.0, 2025-01-13,
	The proposed proprietary name / brand name	First Defense® Bolus

Label Claim	Each Single Dose Capsule Contains: K99+ E.coli Relative Potency ≥ 1.0 v.s. Unit/Dose Coronavirus Protective Titer $\geq 2.4 \times 10^6$ Unit/Dose
Reference to Finished product specifications	As per Innovators Specification
Proposed Pack Size	5 Doses Per Box & 30-De-Controlled
Shelf Life (Unit)	24 Month(s)Store at room temperature or at 20°C - 28°C.
For generic drugs (me-too Status)	Not registered
Pharmacotherapeutic Group of (API)	Veterinary Immunoglobulins
Name, address of Manufacturing site:	ImmuCell Corporation-56 Evergreen Drive Portland, ME 04103, USA-United States of America
Name, address of Marketing Authorization Holder:	ImmuCell Corporation, 56 Evergreen Drive Portland, ME 04103, USA, United States of America
Details of Certificates (CoPP/FSC/cGMP):	Legalized FSC has been submitted. GMP certificate has not been submitted.
Details of Authorization Letter :	LOA from MAH has been submitted.
Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Stability studies data submitted is not according to conditions of Zone IVA and does not cover testing points.

Evaluation Remarks

Following deficiencies have been observed in the application;1. The document attached as GMP certificate of manufacturer seems to be establishment license. Valid legalized GMP certificate clearly mentioning current GMP status of the manufacturer, is required.2. Data of Safety & Efficacy studies conducted in target animals, has not been submitted.3. Evidence of approval of me-too, has not been submitted.4. The stability studies data of three batches as per conditions of Zone IVA, is required to be submitted. The submitted data has been generated at 20-280C.5. Justification of product testing during stability studies at 0 & 24 months time points only, is required.

Decision

Deferred

The Registration Board referred the case to Expert Working Group on veterinary Drugs for the opinion regarding immunological relevance and need of applied product in Pakistan. The Board further advised DBE&R to ask the firm to submit following:

1. The document attached as GMP certificate of manufacturer seems to be establishment license. Valid legalized GMP certificate clearly mentioning current GMP status of the manufacturer, is required.
2. Data of Safety & Efficacy studies conducted in target animals, has not been submitted.
3. Evidence of approval of me-too, has not been submitted.
4. The stability studies data of three batches as per conditions of Zone IVA, is required to be submitted. The submitted data has been generated at 20-280C.
5. Justification of product testing during stability studies at 0 & 24 months time points only, is required.

15	Case Category	Import (Muhammad Ashfaq)
	Name, address of Applicant.	Hilton Pharma (Pvt.) Limited Plot No. 13-14 & 43, Sector-15, Korangi Industrial Area Karachi, Pakistan (0647.)

	Application Form Dy. No / Tracking ID & date of submission	(RQT-767-38BD, 2025-05-15)
	Detail of Fee Submitted	300000.0, 2025-05-09,
	The proposed proprietary name / brand name	Medivac ND Clone 45
	Label Claim	Each dose contains: Newcastle Disease Virus, Clone 45 strain at least $10^{7.0}$ EID ₅₀
	Reference to Finished product specifications	Manufacturer Specification
	Proposed Pack Size	5000 doses-De-Controlled
	Shelf Life (Unit)	24 Month(s)2-8C
	For generic drugs (me-too Status)	Hilton Pharma (Pvt) Ltd - Medivac ND Clone 45 Vaccine (Reg. No. 033209)
	Pharmacotherapeutic Group of (API)	Veterinary Viral Vaccine
	Name, address of Manufacturing site:	PT MEDION FARMA JAYA-Jl. Raya Batujajar No 29, Cimareme, Ngamprah, Kab Bandung Barat – Indonesia-Indonesia
	Name, address of Marketing Authorization Holder:	PT MEDION FARMA JAYA, Office Address: Jl. Babakan Ciparay No. 282, Babakan Ciparay, Bandung – Indonesia Plant Address: Jl. Raya Batujajar No 29, Cimareme, Ngamprah, Kab Bandung Barat – Indonesia, Indonesia
	Details of Certificates (CoPP/FSC/cGMP):	Valid Legalized CoPP has been submitted. Valid Legalized GMP certificate of manufacturer has been submitted.
	Details of Authorization Letter :	Legalized Distribution Agreement with MAH has been submitted.
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Stability studies data of three batches has been submitted.
	Evaluation Remarks	
	The applicant has submitted required documents.	
	Decision	
	Approved	
	Keeping in view the legalized CoPP indicating product availability in the country of origin, the Registration Board approved the product subject to compliance to the current Import Policy for finished drugs.	
16	Case Category	Import (Muhammad Ashfaq)
	Name, address of Applicant.	MS Enterprises P42/2, Opp Municipal Degree College, Jaranwala Road Faisalabad (06331016811)
	Application Form Dy. No / Tracking ID & date of submission	(RQU-6M9-EG14, 2025-05-01)
	Detail of Fee Submitted	300000.0, 2025-04-15,
	The proposed proprietary name / brand name	POLIMUN La-Sota + H120 – vaccine against Newcastle disease and avian infectious bronchitis, live
	Label Claim	Active substances per dose (1ml): Newcastle disease virus, strain “La-Sota” $\geq 10^{6.0}$ EID ₅₀ .

	Avian infectious bronchitis virus, strain H-120 $\geq 10^{3.5}$ EID50	
Reference to Finished product specifications	Manufacturer Specification	
Proposed Pack Size	10* 5000 Doses-De-Controlled	
Shelf Life (Unit)	24 Month(s)2°C - 8°C	
For generic drugs (me-too Status)	Product Name:: PoulShot® LaSota + IB Vaccine Registration No: 099503 Company Name: Lucky Core Industries Limited	
Pharmacotherapeutic Group of (API)	Viral Veterinary Vaccine	
Name, address of Manufacturing site:	BIOTESTLAB LLC-57-A Volodymyrska Str. Vasylykiv 08600 Kyiv Region, Ukraine-Ukraine	
Name, address of Marketing Authorization Holder:	BIOTESTLAB LLC, 08601, City Vasilkiv Volodymyrska, Str. 57-A, Ukraine	
Details of Certificates (CoPP/FSC/cGMP):	Valid legalized FSC has bene submitted. Vald legalized GMP certificate has been submitted.	
Details of Authorization Letter :	LOA from MAH has been submitted.	
Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Not Submitted.	
Evaluation Remarks		
Following Deficiency has been observed in the application;1. Only FSC, GMP certificate & LOA has been attached with online application. Remaining application on Form-5(A) alongwith required documents has not been attached.		
Decision		
Deferred		
Registration Board deferred the case for submission of complete application as per Form-5A.		
17	Case Category	Import (Muhammad Ashfaq)
	Name, address of Applicant.	Ghazi Brothers Ghazi House, D-35, KDA Scheme No. 1, Miran Muhammad Shah Road, Karachi-75350, Pakistan. (DHO(East)Dr)
	Application Form Dy. No / Tracking ID & date of submission	(UQZ-Y4Y-1U2V, 2024-04-02)
	Detail of Fee Submitted	75000.0, 2024-02-21,
	The proposed proprietary name / brand name	VAXXON IBD IMC
	Label Claim	Each dose contains: Gumboro disease viral suspension - IBD, Winterfield W2512 strain, sufficient to obtain $\geq 10^{2.5}$ EID50 IBD Antibody Suspension sufficient to obtain ≥ 0.005 UN/ml Solvent (Diluent): Sucrose.....50.50g Potassium phosphate monobasic (KH2PO4)...1.12g Phenol red....0.02g Potassium hydroxide (KOH) q.s....pH adjustment to 7.0 – 7.5 Hydrochloric acid (HCL) q.s. pH adjustment to 7.0 – 7.5 Water for injection q.s. ..1L
	Reference to Finished product specifications	As per Innovators Specification
	Proposed Pack Size	100, 1000, 2000, 250-De-Controlled
	Shelf Life (Unit)	24 Month(s)2-8 °C
	For generic drugs (me-too Status)	Not available

Pharmacotherapeutic Group of (API)	Veterinary Vaccine
Name, address of Manufacturing site:	Laboratorio Biovet Ltda.-Rua Coronel Jose Nunes dos Santos,639, Centro, Zip Code 06730-000-Vargem Grande Paulista/SP, Brazil-Brazil
Name, address of Marketing Authorization Holder:	Laboratorio Biovet Ltda., Rua Coronel Jose Nunes dos Santos,639, Centro, Zip Code 06730-000-Vargem Grande Paulista/SP, Brazil, Brazil
Details of Certificates (CoPP/FSC/cGMP):	FSC & GMP submitted are not legalized.
Details of Authorization Letter :	Notarized POA from MAH has been submitted.
Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Stability studies data of three batches has been submitted.
Evaluation Remarks	
The product was deferred in 347th meeting due to some deficiencies. The response of the applicant is as under;	
Deficiency	Response
Fee of Rs. 300,000/- is required to be deposited as per SRO 1872 (I)/2023 dated 29-12-2023 while the applicant has deposited only Rs. 75,000/- as fee.	As per S.R.O. 496(1)/2024 the required fee for the registration of a new molecule or drug/ not manufactured locally is 75,000/-. Since Vaxxon IBD IMC is biological product (not manufacturing locally), thus challan No. 930228405227 of rupees 75,000/- had already submitted in initial application.
Address of MAH/Manufacturer abroad is required to be updated in online application as per GMP certificate	Kindly consider this address as per GMP Certificate: LABORATORIO BIOVET LTOA, Rua Coronel Jose Nunes dos Santos,639, Centro, Zip Code 06730-000- Vargem Grande Paulista/SP, Brazil
The formulation is required to be corrected as per product license	The formulation mentioned on the e-App is the same as in the product license; it is only a matter of representation in the standard format. However, as per your instruction, please update the formulation in the e-portal as follows:" Gumboro disease viral suspension - IBD, Winterfield W2512 strain, sufficient to obtain ≥ 102.5 EID50/dose IBD antibody suspension sufficient to obtain ≥ 0.005 NU/mL
The FSC & GMP attached are not legalized.	We have requested the supplier to provide legalized FSC & GMP, we shall submit it to your good office once received
Safety and efficacy studies data of the applied product is required	The applicant has submitted safety & efficacy studies data.

Decision

Approved

Keeping in view the copy of FSC indicating product availability in the country of origin, the Registration Board approved the product subject to compliance to the current Import Policy for finished drugs and submission of following:

1. Valid Legalized GMP and FSC?
2. Differential fee of Rs. 225000/-

18	Case Category	Import (Muhammad Ashfaq)
	Name, address of Applicant.	Inouko Animal Health (Private) Limited 3rd Floor, Plaza No. 3, D-Block, DHA Phase 5, Cantt, District Lahore (05-352-0058)
	Application Form Dy. No / Tracking ID & date of submission	(VHQ-E8B-9VZP, 2025-05-12)
	Detail of Fee Submitted	225000.0, 2025-03-18,
	The proposed proprietary name / brand name	Cevac Megamune ND-IB-EDS-SHS K
	Label Claim	Each Dose contains: In activated New Castle Disease Virus, Strain NDV-SZ LaSota min 4log2 HI*titer or min.50 PD50** Avian Infectious Bronchitis virus strain M-41.....min 4.9 log2 HI*titer Avian Infectious Bronchitis virus strain QX Fr.....min 1 RPU*** Inactivated Egg Drop Syndrome virus, strain B8/78.....min 7 log2 HI*titer Inactivated Avian Metapneumovirus strain TRT50 min.20 Antigen ELISA unit *HI-Haemagglutination Inhibition ** PD-Protective Dose *** RPU-Relative Potency Unit
	Reference to Finished product specifications	Manufacturer Specification
	Proposed Pack Size	500ml -De-Controlled
	Shelf Life (Unit)	21 Month(s)Store at 2-8 C, Protect from Light, don't freeze
	For generic drugs (me-too Status)	N/A
	Pharmacotherapeutic Group of (API)	Veterinary Viral Vaccine
	Name, address of Manufacturing site:	Ceva-Phylaxia Veterinary Biologicals Co.Ltd. -1107 Budapest, Szallas u. 5.,-Hungary
	Name, address of Marketing Authorization Holder:	Ceva-Phylaxia Veterinary Biologicals Co.Ltd. , 1107 Budapest, Szallas u. 5.,, Hungary
	Details of Certificates (CoPP/FSC/cGMP):	Valid Legalized FSC has been submitted. Valid legalized GMP certificate has been submitted.
	Details of Authorization Letter :	Sole Agency agreement submitted but the agreement is with Ceva Sante Animal S.A., France.
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Stability Studies data of three batches has been submitted.
	Evaluation Remarks	
	Following deficiencies have been observed in the application;1. The sole agency agreement has been signed by Seva Sante Animal Health S.A., France while the product license holder mentioned on the FSC is Ceva-Phylaxia Veterinary Biologicals Co.Ltd., Hungary.2. The me-too product with the applied formulation is not already registered.	
	Decision	
	Deferred	
	The Registration Board referred the case to Expert Working Group on veterinary drugs for opinion regarding immunological relevance and need of applied product in Pakistan. The Board further advised DBE&R yto ask the firm to submit the following:	

1. The sole agency agreement has been signed by Seva Sante Animal Health S.A., France while the product license holder mentioned on the FSC is Ceva-Phylaxia Veterinary Biologicals Co.Ltd., Hungary.

2. The me-too product with the applied formulation is not already registered.

19	Case Category	Import (Muhammad Ashfaq)
	Name, address of Applicant.	CLOUD AGRI PAKISTAN 45-A2 JOHAR TOWN LAHORE (2029-02)
	Application Form Dy. No / Tracking ID & date of submission	(VZB-3ZZ-6ANM, 2025-05-25)
	Detail of Fee Submitted	300000.0, 2025-03-20,
	The proposed proprietary name / brand name	Bioaftogen O+A+SAT2+Asia1
	Label Claim	Not submitted.
	Reference to Finished product specifications	Manufacturer Specification
	Proposed Pack Size	50 ML-De-Controlled
	Shelf Life (Unit)	24 Month(s)Store and transport between 2°C and 8°C
	For generic drugs (me-too Status)	INOVATOR
	Pharmacotherapeutic Group of (API)	Veterinary Viral Vaccine
	Name, address of Manufacturing site:	BIOGÉNESIS BAGÓ S.A.-RUTA PANAMERICANA, 38.5 KM. (B16191EA) GARIN, BUENOS AIRES, ARGENTINA.- Argentina
	Name, address of Marketing Authorization Holder:	BIOGENESIE BAGO, RUTA PANAMERICANA, 38.5 KM. (B16191EA) GARIN, BUENOS AIRES, ARGENTINA., Argentina
	Details of Certificates (CoPP/FSC/cGMP):	FSC provided mentions that the product is registered for export Valid GMP certificate of manufacturer has been submitted.
	Details of Authorization Letter :	Not Submitted
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Not submitted
Evaluation Remarks		
Following deficiencies have been observed in the application;1. The applicant has not submitted application on Form-5(A) and has just submitted random documents. Complete application with all required attachments has not been submitted.2. LOA submitted does not contain name of product.3. FSC mentions that the product is registered for export purpose.4. The strength of viruses in formulation is not clear.5. Me-too with applied virus strains is not already registered.6. Serotypes of FMD Viruses are not clear.		
Decision		
Deferred		
Registration Board deferred the case for following:		
1. The applicant has not submitted application on Form-5(A) and has just submitted random documents. Complete application with all required attachments has not been submitted.		
2. LOA submitted does not contain name of product.		

3. FSC mentions that the product is registered for export purpose.
4. The strength of viruses in formulation is not clear.
5. Me-too with applied virus strains is not already registered.
6. Serotypes of FMD Viruses are not clear.

20	Case Category	Import (Muhammad Ashfaq)
	Name, address of Applicant.	Hilton Pharma (Pvt.) Limited Plot No. 13-14 & 43, Sector-15, Korangi Industrial Area Karachi, Pakistan (0647.)
	Application Form Dy. No / Tracking ID & date of submission	(WX1-ABD-M8W5, 2025-05-19)
	Detail of Fee Submitted	300000.0, 2025-05-16,
	The proposed proprietary name / brand name	Medivac ND Emulsion 0.3
	Label Claim	Each dose contains: Inactivated Newcastle Disease virus of La Sota strain at least $10^{7.0}$ EID ₅₀
	Reference to Finished product specifications	Manufacturer Specification
	Proposed Pack Size	150ml-De-Controlled,300ml-De-Controlled,30ml-De-Controlled,600ml-De-Controlled,75ml-De-Controlled
	Shelf Life (Unit)	18 Month(s)Vaccine is stored on temperature of 2 – 8°C and do not freeze, include temperature on its distribution. Vaccine is protected from heat and direct sunlight
	For generic drugs (me-too Status)	Hilton Pharma (Pvt) Ltd - Medivac ND Emulsion Vaccine (Reg No. 033211)
	Pharmacotherapeutic Group of (API)	Veterinary Viral Vaccine
	Name, address of Manufacturing site:	PT MEDION FARMA JAYA-Jl. Raya Batujajar No 29, Cimareme, Ngamprah, Kab Bandung Barat – Indonesia-Indonesia
	Name, address of Marketing Authorization Holder:	PT MEDION FARMA JAYA, Office Address: Jl. Babakan Ciparay No. 282, Babakan Ciparay, Bandung – Indonesia Plant Address: Jl. Raya Batujajar No 29, Cimareme, Ngamprah, Kab Bandung Barat – Indonesia, Indonesia
	Details of Certificates (CoPP/FSC/cGMP):	Valid legalized CoPP has been submitted. Valid legalized GMP certificate has been submitted.
	Details of Authorization Letter :	Legalized distribution agreement with MAH has been submitted.
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Stability studies data of three batches has been submitted.
	Evaluation Remarks	
	The applicant has submitted required documents and selected 300ml as pack size.	
	Decision	
	Approved	
	Keeping in view the legalized CoPP indicating product availability in the country of origin, the Registration Board approved the product subject to compliance to the current Import Policy for finished	

	drugs.	
21	Case Category	Import (Muhammad Ashfaq)
	Name, address of Applicant.	QAS INTERNATIONAL PLOT # 153/155, MUSTAFA ABAD TEHSIL KAMOKE (09-341-0134)
	Application Form Dy. No / Tracking ID & date of submission	(XY4-49A-ZEVL, 2025-03-28)
	Detail of Fee Submitted	300000.0, 2025-03-05,
	The proposed proprietary name / brand name	Dou Jing
	Label Claim	Each dose contains; Attenuated goat pox virus strain (CVCC AV41 Strain)...NLT 10 ^{3.5} TCID ₅₀
	Reference to Finished product specifications	Any Other
	Proposed Pack Size	50 ANIMALS/VIAL-De-Controlled
	Shelf Life (Unit)	18 Month(s)Store at 2 ~ 8°C
	For generic drugs (me-too Status)	Not registered
	Pharmacotherapeutic Group of (API)	Veterinary Viral Vaccine
	Name, address of Manufacturing site:	BEIJING SINDER-VET TECHNOLOGY CO, LTD-N0.118, SHUNYU ROAD, BEIJING TIANZHU AIRPORT ECONOMIC DEVELOPMENT ZONE SHUNIYE DISTRICT, BEIJING-China
	Name, address of Marketing Authorization Holder:	BEIJING SINDER-VET TECHNOLOGY CO., LTD, N0.118, SHUNYU ROAD, BEIJING TIANZHU AIRPORT ECONOMIC DEVELOPMENT ZONE SHUNIYE DISTRICT, BEIJING , China
	Details of Certificates (CoPP/FSC/cGMP):	Valid legalized FSC has been submitted. Valid legalized GMP certificate of manufacturer has been submitted.
	Details of Authorization Letter :	LOA from MAH has been submitted
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Stability studies data of three batches has been submitted.
22	Evaluation Remarks	
	As per available record, product with goat pox virus (CVCC AV41 Strain) is not already registered.	
	Decision	
	Deferred	
	The Registration Board referred the case to Expert Working Group on veterinary drugs for opinion regarding immunological relevance and need of applied product in Pakistan.	
	Case Category	Import (Muhammad Ashfaq)
	Name, address of Applicant.	MS Enterprises P42/2, Opp Municipal Degree College, Jaranwala Road Fasialabad (06331016811)
	Application Form Dy. No / Tracking ID & date of submission	(YMR-8EN-B1YL, 2025-04-22)
	Detail of Fee Submitted	300000.0, 2025-04-21,
	The proposed proprietary name / brand name	Premvac Flu H9

	Label Claim	Each Dose Contains; Avian Influenza Viruses (AIV), strain A/Chicken/Egypt/FAO-S/33/2021 (H9N2) of HA antigen titer ranges from 9-10 log ₂ (9 log ₁₀ EID ₅₀ Before inactivation).
	Reference to Finished product specifications	Manufacturer Specification
	Proposed Pack Size	500ML (1000 Doses)-De-Controlled
	Shelf Life (Unit)	24 Month(s) 2°C - 8°C
	For generic drugs (me-too Status)	NOBILIS INFLUENZA H9N2 VACCINE. (Reg No. 052396)
	Pharmacotherapeutic Group of (API)	Inactivated Veterinary Viral Vaccine
	Name, address of Manufacturing site:	Eva Pharma for Pharmaceutical Industries-Plot 27, Polaris International Park, North Expansion of 1st Industrial zone, 6th October of October city, Giza-Egypt
	Name, address of Marketing Authorization Holder:	Eva Pharma for Pharmaceutical Industries, Plot 27, Polaris International Park, North Expansion of 1st Industrial zone, 6th October of October city, Giza, Egypt
	Details of Certificates (CoPP/FSC/cGMP):	Valid Legalized FSC has been submitted. Valid legalized GMP certificate has been submitted.
	Details of Authorization Letter :	LOA form MAH has been submitted.
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Stability studies data of only 12 months has been submitted.
	Evaluation Remarks	
	Following deficiency has been observed in the application.1. Stability studies data of only 12 months has been submitted. Stability studies data of three commercial batches is required. Moreover, the data should include results of physiochemical tests as well as potency of product at different time points covering the complete proposed shelf-life (24 months) of the product.	
	Decision	
	Deferred	
	Registration Board deferred the case for following:	
	1. Stability studies data of only 12 months has been submitted. Stability studies data of three commercial batches is required. Moreover, the data should include results of physiochemical tests as well as potency of product at different time points covering the complete proposed shelf-life (24 months) of the product.	
23	Case Category	Import (Muhammad Ashfaq)
	Name, address of Applicant.	Ghazi Brothers Ghazi House, D-35, KDA Scheme No. 1, Miran Muhammad Shah Road, Karachi-75350, Pakistan. (DHO(East)Dr)
	Application Form Dy. No / Tracking ID & date of submission	(Z19-UPX-2THM, 1970-01-01)
	Detail of Fee Submitted	75000.0, 2024-02-21,
	The proposed proprietary name / brand name	Canglob D Forte
	Label Claim	Each 1 ml contains: Immunoglobulinum anti febris contagiosae canis NLT 320 VNAb50.
	Reference to Finished product specifications	As per Innovators Specification

Proposed Pack Size	5ml-De-Controlled,6ml-De-Controlled														
Shelf Life (Unit)	18 Month(s)2-8 C														
For generic drugs (me-too Status)	Not registered														
Pharmacotherapeutic Group of (API)	Veterinary Immunoglobulins														
Name, address of Manufacturing site:	DYNTEC spol s.r.o-Prazska 328, 411 55 Terezin, Czech Republic -Czechia														
Name, address of Marketing Authorization Holder:	DYNTEC spol s.r.o, Prazska 328, 411 55 Terezin, Czech Republic , Czechia														
Details of Certificates (CoPP/FSC/cGMP):	Valid legalized CoPP has been submitted.														
Details of Authorization Letter :	LOA from MAH has been submitted.														
Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Stability studies data of three batches has been submitted.														
Evaluation Remarks															
The product was deferred in 347th meeting of the Registration Board due to some deficiencies in the application. The response of the applicant is under;															
Deficiency	Response														
Fee of Rs. 300,000/- is required to be deposited as per SRO 1872 (I)/2023 dated 29-12-2023 while the applicant has deposited only Rs. 75,000/- as fee	Since our product is an Innovator product, as per S.R.O. 496(I)/2023 the required fee for the registration of a new molecule or drug/ drug not manufactured locally is 75,000/-.														
The stability studies data submitted shows that the studies have been performed on 8ml vial while the applicant has selected 6ml vial as pack size.	We want to clarify that the filled volume is 6 ml, while the vial size is 8 ml to ensure usability and proper handling throughout its shelf life.														
Safety and efficacy studies data of the applied product has not been submitted, rather, literature has been submitted.	The applicant has submitted the safety & efficacy data.														
Decision															
Approved															
Keeping in view legalized CoPP indicating product availability in the country of origin, the Registration Board approved the product subject to compliance to the current Import Policy for finished drugs and submission of differential fee of Rs. 225000/-.															
24	<table> <tr> <td>Case Category</td><td>Import (Muhammad Ashfaq)</td></tr> <tr> <td>Name, address of Applicant.</td><td>Hilton Pharma (Pvt.) Limited Plot No. 13-14 & 43, Sector-15, Korangi Industrial Area Karachi, Pakistan (0647.)</td></tr> <tr> <td>Application Form Dy. No / Tracking ID & date of submission</td><td>(ZXQ-MND-W75A, 2025-05-16)</td></tr> <tr> <td>Detail of Fee Submitted</td><td>300000.0, 2025-05-16,</td></tr> <tr> <td>The proposed proprietary name / brand name</td><td>Medivac ND-IB S</td></tr> <tr> <td>Label Claim</td><td>Each dose contains: Newcastle Disease Apathogenic enterotropic virus of M225 strain (M225 strain identical to Genotype I.1.1 group) at least 10^7 EID50 Infectious Bronchitis virus of H-120 Massachusetts strain at least $10^{3.5}$ EID50.</td></tr> <tr> <td>Reference to Finished product specifications</td><td>Manufacturer Specification</td></tr> </table>	Case Category	Import (Muhammad Ashfaq)	Name, address of Applicant.	Hilton Pharma (Pvt.) Limited Plot No. 13-14 & 43, Sector-15, Korangi Industrial Area Karachi, Pakistan (0647.)	Application Form Dy. No / Tracking ID & date of submission	(ZXQ-MND-W75A, 2025-05-16)	Detail of Fee Submitted	300000.0, 2025-05-16,	The proposed proprietary name / brand name	Medivac ND-IB S	Label Claim	Each dose contains: Newcastle Disease Apathogenic enterotropic virus of M225 strain (M225 strain identical to Genotype I.1.1 group) at least 10^7 EID50 Infectious Bronchitis virus of H-120 Massachusetts strain at least $10^{3.5}$ EID50.	Reference to Finished product specifications	Manufacturer Specification
Case Category	Import (Muhammad Ashfaq)														
Name, address of Applicant.	Hilton Pharma (Pvt.) Limited Plot No. 13-14 & 43, Sector-15, Korangi Industrial Area Karachi, Pakistan (0647.)														
Application Form Dy. No / Tracking ID & date of submission	(ZXQ-MND-W75A, 2025-05-16)														
Detail of Fee Submitted	300000.0, 2025-05-16,														
The proposed proprietary name / brand name	Medivac ND-IB S														
Label Claim	Each dose contains: Newcastle Disease Apathogenic enterotropic virus of M225 strain (M225 strain identical to Genotype I.1.1 group) at least 10^7 EID50 Infectious Bronchitis virus of H-120 Massachusetts strain at least $10^{3.5}$ EID50.														
Reference to Finished product specifications	Manufacturer Specification														

Proposed Pack Size	100-De-Controlled,1000-De-Controlled,10000-De-Controlled,1500-De-Controlled,200-De-Controlled,2000-De-Controlled,2500-De-Controlled,3000-De-Controlled,4000-De-Controlled,50-De-Controlled,500-De-Controlled,5000-De-Controlled,8000-De-Controlled
Shelf Life (Unit)	24 Month(s)Vaccine is stored on temperature on its distribution 2-8°C, include temperature on its distribution, Vaccine is protected from heat and direct sunlight.
For generic drugs (me-too Status)	Not registered
Pharmacotherapeutic Group of (API)	Veterinary Viral Vaccine
Name, address of Manufacturing site:	PT MEDION FARMA JAYA-Jl. Raya Batujajar No 29, Cimareme, Ngamprah, Kab Bandung Barat – Indonesia-Indonesia
Name, address of Marketing Authorization Holder:	PT MEDION FARMA JAYA, Office Address: Jl. Babakan Ciparay No. 282, Babakan Ciparay, Bandung – Indonesia Plant Address: Jl. Raya Batujajar No 29, Cimareme, Ngamprah, Kab Bandung Barat – Indonesia, Indonesia
Details of Certificates (CoPP/FSC/cGMP):	Valid legalized CoPP has been submitted. Valid legalized GMP certificate has been submitted.
Details of Authorization Letter :	Legalized Distribution agreement with MAH has been submitted.
Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Stability studies data of three batches has been submitted.
Evaluation Remarks	
As per available record, product with Newcastle Disease virus of M225 strain is not already registered.	
Decision	
Deferred	
The Registration Board referred the case to Expert Working Group on veterinary drugs for opinion regarding immunological relevance and need of applied product in Pakistan.	



Drug Regulatory Authority of Pakistan
(Pharmaceutical Evaluation & Registration Division)



Item No. III: Additional/Supplementary Minutes:
Applications submitted on e-App (PE&R)

Sr. No	Title	Description
1	Case Category	Contract Manufacturing (Incharge Evaluation Cell)
	Name, address of Applicant.	Hoechst Pakistan Limited Plot 23, Sector 22, Korangi Industrial Area, (000007)
	Application Form Dy. No / Tracking ID & date of submission	(2VH-RPL-E618, 2025-07-14)
	Detail of Fee Submitted	93000.0, 2025-06-04,
	The proposed proprietary name / brand name	Xirabegron XR 50mg Tablets
	Label Claim	Each film coated extended-release tablet contains: Mirabegron.....50mg
	Reference to Finished product specifications	As per Innovators Specification
	Proposed Pack Size	10's-As per SRO, 20's-As per SRO, 30's-As per SRO
	Shelf Life (Unit)	2 YearStore below 30°C in a cool and dark place
	For generic drugs (me-too Status)	Mirexia XR Tablet 50mg by (Ferozsans Laboratories Limited)
	Pharmacotherapeutic Group of (API)	beta-3 adrenergic agonist
	Name, address of Manufacturing site:	Ferozsans Laboratories Limited-P.O Ferozsans Amangarh, Nowshera Khyber Pakhtunkhwa - Pakistan-
	The status in reference regulatory authorities	MYRBETRIQ XR 50mg tablet - Approved by USFDA
	Detail of previous approval	MIREXIA XR TABLETS 50MG - 295 DRB meeting minutes
	Evaluation Remarks	
	In light of Registration Board's decision taken in its 324th meeting and notified vide F.No.1-2/2022-DMC dated 13th June, 2023, the instant application is being presented for consideration of the Board as an application for cross-reference of already approved data on Form 5F. Applicants need to submit a declaration that they will adopt the same source of drug substance, drug product formulation, specifications and container closure and fulfill other conditions mentioned in the above-mentioned notification. Furthermore, quality agreement under Rule 20-A of the Drugs (LR&A) Rules, 1976 is also needed as part of module-1 of Form 5F.	
	Decision	
	Approved	
2	Case Category	Contract Manufacturing (Incharge Evaluation Cell)
	Name, address of Applicant.	Hoechst Pakistan Limited Plot 23, Sector 22, Korangi Industrial Area, (000007)

Application Form Dy. No / Tracking ID & date of submission	(VNT-3XD-AQD7, 2025-07-14)
Detail of Fee Submitted	93000.0, 2025-06-04,
The proposed proprietary name / brand name	Xirabegron XR 25mg Tablets
Label Claim	Each film coated extended-release tablet contains: Mirabegron.....25mg
Reference to Finished product specifications	As per Innovators Specification
Proposed Pack Size	10's-As per SRO,20's-As per SRO,30's-As per SRO
Shelf Life (Unit)	2 YearStore below 30°C in a cool and dark place
For generic drugs (me-too Status)	Mirexia XR Tablet 25mg by (Ferozsans Laboratories Limited)
Pharmacotherapeutic Group of (API)	beta-3 adrenergic agonist
Name, address of Manufacturing site:	Ferozsans Laboratories Limited-P.O Ferozsans Amangarh, Nowshera Khyber Pakhtunkhwa - Pakistan-
The status in reference regulatory authorities	MYRBETRIQ XR 25mg tablet - Approved by USFDA
Detail of previous approval	MIREXIA XR TABLETS 25MG - 295 DRB meeting minutes
Evaluation Remarks	
In light of Registration Board's decision taken in its 324th meeting and notified vide F.No.1-2/2022-DMC dated 13th June, 2023, the instant application is being presented for consideration of the Board as an application for cross-reference of already approved data on Form 5F. Applicants need to submit a declaration that they will adopt the same source of drug substance, drug product formulation, specifications and container closure and fulfill other conditions mentioned in the above-mentioned notification. Furthermore, quality agreement under Rule 20-A of the Drugs (LR&A) Rules, 1976 is also needed as part of module-1 of Form 5F.	
Decision	
Approved	
3	
Case Category	Export Facilitation (Shahid Nawaz)
Name, address of Applicant.	Getz Pharma (Pvt) Limited 29-30/27,Korangi Industrial Area karachi (000284)
Application Form Dy. No / Tracking ID & date of submission	(E7B-EJ4-HNM6, 2025-04-21)
Detail of Fee Submitted	37000.0, 2025-03-20,
The proposed proprietary name / brand name	SILEXA Tablets 50mg
Label Claim	Each film-coated tablet contains: Sildenafil Citrate equivalent to Sildenafil.....50mg
Reference to Finished product specifications	United States Pharmacopeia
Proposed Pack Size	10's-As per SRO,12's-As per SRO,16's-As per SRO,4's-As per SRO,8's-As per SRO
Shelf Life (Unit)	2 Year(s)Do not store above 30°C.
For generic drugs (me-too Status)	Silagro Tablet 50mg by M/s Nabiqasim Industries (Pvt.) Ltd.
Pharmacotherapeutic Group of (API)	Phosphodiesterase-5 inhibitor (PDE5). ATC code: G04BE03.

Name, address of Manufacturing site:	Self Manufacturing
Name & address of API manufacturer	ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD.
Detail of stability batches of drug product	02 batches having batch size of 5000 tablets each.
Documents for the procurement of API with approval from DRAP (in case of Import)	Firm has submitted copy of Form 6 No. DIL-C-4D7282 dated 09-08-2024 mentioning 4 kg of Sildenafil Citrate USP from M/s Zhejiang Jiuzhou, China. Firm has also submitted Goods Declaration GD-I mentioning sildenafil citrate.
Pharmaceutical Equivalence and Comparative Dissolution Profile	CDP and PE studies are performed against innovator product i.e. Viagra 50mg Tablets, B. No. B838003, Mfg. date 07-2023 manufactured by M/s Fareva Amboise, France. Both test and reference product have shown more than 85% release in pH 1.2 and 4.5 while in pH 6.8 value of F2 is in acceptable range.
Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Stability study data of 3 batches of drug substance as per Zone IV-A is submitted. Accelerated 06 months and real time for 60 months.
The status in reference regulatory authorities	Viagra 25mg, 50mg & 100mg (sildenafil) tablets, USFDA approved.
GMP status of the firm	Firm has submitted copy of GMP Certificate No. 76/2023-DRAP (K) dated 06-12-2023 issued on the basis of inspection conducted on 10-11-2023.
Evidence of approval of manufacturing facility	Firm has submitted copy of letter No. F. 2-5/86-Lic (Vol-II) dated 30-10-2019 mentioning Tablet (General) section.

Evaluation Remarks

Sr. No.	Observations.	Reply submitted by the firm.
1.	At the time of screening, applicable fee was for new molecule i.e. 75000/- while you have submitted fee for me too i.e. 37000/-. Submit differential fee for new molecule.	Firm has submitted differential fee of 38000/- vide slip No. 219896299162 dated 11-07-2025.
2.	Complete CDP studies showing each tablet result shall be submitted.	Firm has submitted complete CDP studies showing each tablet results at different time intervals.
3.	Chromatograms have not mentioned any wavelength.	Firm has submitted that wavelength is mentioned at each chromatogram of the stability data and analytical method. Firm has also provided a sample of chromatograms mentioning wavelength. At the time of evaluation, wavelength was overlooked. Now upon confirming from Module 3, wavelength is mentioned on chromatograms as 290.
4.	Clearance certificate with approval from DRAP shall be submitted.	Firm has once again submitted copy of form 6. However, they now submitted copy of airway bill mentioning Sildenafil, Tadalafil and sterile mixture of Meropenem. Firm has also submitted copy of Good Declaration GD-I mentioning sildenafil citrate.

	Decision	
	Approved	
	Registration letter will be issued after verification of authenticity of submitted data by the panel constituted by the Chairman Registration Board.	
4	Case Category	Export Facilitation (Shahid Nawaz)
	Name, address of Applicant.	Getz Pharma (Pvt) Limited 29-30/27,Korangi Industrial Area karachi (000284)
	Application Form Dy. No / Tracking ID & date of submission	(MP2-WXH-ZDZN, 2025-04-21)
	Detail of Fee Submitted	37000.0, 2025-03-20,
	The proposed proprietary name / brand name	SILEXA Tablets 25mg
	Label Claim	Each film-coated tablet contains: Sildenafil Citrate equivalent to Sildenafil.....25mg
	Reference to Finished product specifications	United States Pharmacopeia
	Proposed Pack Size	10's-As per SRO,12's-As per SRO,16's-As per SRO,4's-As per SRO,8's-As per SRO
	Shelf Life (Unit)	2 Year(s)Do not store above 30°C.
	For generic drugs (me-too Status)	Silagro Tablet 25mg by M/s Nabiqasim Industries (Pvt.) Ltd.
	Pharmacotherapeutic Group of (API)	Phosphodiesterase-5 inhibitor (PDE5). ATC code: G04BE03.
	Name, address of Manufacturing site:	Self Manufacturing
	Name & address of API manufacturer	ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD.
	Detail of stability batches of drug product	02 batches having batch size of 5000 tablets each.
	Documents for the procurement of API with approval from DRAP (in case of Import)	Firm has submitted copy of Form 6 No. DIL-C-4D7282 dated 09-08-2024 mentioning 4 kg of Sildenafil Citrate USP from M/s Zhejiang Jiuzhou, China. Firm has also submitted Goods Declaration GD-I mentioning sildenafil citrate.
	Pharmaceutical Equivalence and Comparative Dissolution Profile	CDP and PE studies are performed against innovator product i.e. Viagra 25mg Tablets, B. No. B592630, Mfg. date 01-2021 manufactured by M/s Fareva Amboise, France. Both test and reference product have shown more than 85%release in pH 1.2 and 4.5 while in pH 6.8 value of F2 is in acceptable range.
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Stability study data of 3 batches of drug substance as per Zone IV-A is submitted. Accelerated 06 months and real time for 60 months.
	The status in reference regulatory authorities	Viagra 25mg, 50mg & 100mg (sildenafil) tablets, USFDA approved.
	GMP status of the firm	Firm has submitted copy of GMP Certificate No. 76/2023-DRAP (K) dated 06-12-2023 issued on the basis of inspection conducted on 10-11-2023.

Evidence of approval of manufacturing facility		Firm has submitted copy of letter No. F. 2-5/86-Lic (Vol-II) dated 30-10-2019 mentioning Tablet (General) section.
Evaluation Remarks		
Sr. No.	Observations.	Reply submitted by the firm.
1.	At the time of screening, applicable fee was for new molecule i.e. 75000/- while you have submitted fee for me too i.e. 37000/-. Submit differential fee for new molecule.	Firm has submitted differential fee of 38000/- vide slip No. 4172182747 dated 11-07-2025.
2.	Complete CDP studies showing each tablet result shall be submitted.	Firm has submitted complete CDP studies showing each tablet results at different time intervals.
3.	Chromatograms have not mentioned any wavelength.	Firm has submitted that wavelength is mentioned at each chromatogram of the stability data and analytical method. Firm has also provided a sample of chromatograms mentioning wavelength. At the time of evaluation, wavelength was overlooked. Now upon confirming from Module 3, wavelength is mentioned on chromatograms as 290.
4.	Clearance certificate with approval from DRAP shall be submitted.	Firm has once again submitted copy of form 6. However, they now submitted copy of airway bill mentioning Sildenafil, Tadalafil and sterile mixture of Meropenem. Firm has also submitted copy of Good Declaration GD-I mentioning sildenafil citrate.
Decision		
Approved		
Registration letter will be issued after verification of authenticity of submitted data by the panel constituted by the Chairman Registration Board.		
5	Case Category	Export Facilitation (Shahid Nawaz)
	Name, address of Applicant.	Getz Pharma (Pvt) Limited 29-30/27,Korangi Industrial Area karachi (000284)
	Application Form Dy. No / Tracking ID & date of submission	(UZS-GU1-R68Q, 2025-04-21)
	Detail of Fee Submitted	37000.0, 2025-03-20,
	The proposed proprietary name / brand name	SILEXA Tablets 100mg
	Label Claim	Each film-coated tablet contains: Sildenafil Citrate equivalent to Sildenafil.....100mg
	Reference to Finished product specifications	United States Pharmacopeia
	Proposed Pack Size	10's-As per SRO,12's-As per SRO,16's-As per SRO,4's-As per SRO,8's-As per SRO
	Shelf Life (Unit)	2 Year(s)Do not store above 30°C.
	For generic drugs (me-too Status)	Silagro Tablet 100mg by M/s Nabiqasim Industries (Pvt.) Ltd.

Pharmacotherapeutic Group of (API)	Phosphodiesterase-5 inhibitor (PDE5). ATC code: G04BE03.
Name, address of Manufacturing site:	Self Manufacturing
Name & address of API manufacturer	ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD.
Detail of stability batches of drug product	02 batches having batch size of 5000 tablets each.
Documents for the procurement of API with approval from DRAP (in case of Import)	Firm has submitted copy of Form 6 No. DIL-C-4D7282 dated 09-08-2024 mentioning 4 kg of Sildenafil Citrate USP from M/s Zhejiang Jiuzhou, China. Firm has also submitted Goods Declaration GD-I mentioning sildenafil citrate.
Pharmaceutical Equivalence and Comparative Dissolution Profile	CDP and PE studies are performed against innovator product i.e. Viagra 100mg Tablets, B. No. B837203, Mfg. date 07-2023 manufactured by M/s Fareva Amboise, France. Both test and reference product have shown more than 85% release in pH 1.2 and 4.5 while in pH 6.8 value of F2 is in acceptable range.
Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Stability study data of 3 batches of drug substance as per Zone IV-A is submitted. Accelerated 06 months and real time for 60 months.
The status in reference regulatory authorities	Viagra 25mg, 50mg & 100mg (sildenafil) tablets, USFDA approved.
GMP status of the firm	Firm has submitted copy of GMP Certificate No. 76/2023-DRAP (K) dated 06-12-2023 issued on the basis of inspection conducted on 10-11-2023.
Evidence of approval of manufacturing facility	Firm has submitted copy of letter No. F. 2-5/86-Lic (Vol-II) dated 30-10-2019 mentioning Tablet (General) section.

Evaluation Remarks

Sr. No.	Observations.	Reply submitted.
1.	At the time of screening, applicable fee was for new molecule i.e. 75000/- while you have submitted fee for me too i.e. 37000/-. Submit differential fee for new molecule.	Firm has submitted differential fee of 38000/- vide slip No. 163736072 dated 11-07-2025.
2.	Complete CDP studies showing each tablet result shall be submitted.	Firm has submitted complete CDP studies showing each tablet results at different time intervals.
3.	Chromatograms have not mentioned any wavelength.	Firm has submitted that wavelength is mentioned at each chromatogram of the stability data and analytical method. Firm has also provided a sample of chromatograms mentioning wavelength. At the time of evaluation, wavelength was overlooked. Now upon confirming from Module 3, wavelength is mentioned on chromatograms as 290.
4.	Clearance certificate with approval from DRAP shall be submitted.	Firm has once again submitted copy of form 6. However, they now submitted copy of airway bill mentioning Sildenafil, Tadalafil and sterile mixture of Meropenem. Firm has also submitted

		copy of Good Declaration GD-I mentioning sildenafil citrate.
Decision		
Approved		
Registration letter will be issued after verification of authenticity of submitted data by the panel constituted by the Chairman Registration Board.		
6	Case Category	Routine (Shahrukh Ali)
	Name, address of Applicant.	Caliph Pharmaceuticals Plot 17, Special Industrial Zone Risalpur, KPK (000748)
	Application Form Dy. No / Tracking ID & date of submission	(68X-V8R-T5ZY, 2024-03-12)
	Detail of Fee Submitted	30000.0, 2024-02-23,
	The proposed proprietary name / brand name	TRILUMA CREAM
	Label Claim	Each gram of cream contains: Hydroquinone 40mg (4%) Fluocinolone acetonide 0.1mg (0.01%) Tretinoin 0.5mg (0.05%)
	Reference to Finished product specifications	As per Innovators Specification
	Proposed Pack Size	As per SRO-Controlled
	Shelf Life (Unit)	2 Year(s)25°C
	For generic drugs (me-too Status)	Lazma cream By M/s Bio-Labs Ltd
	Pharmacotherapeutic Group of (API)	Skin depigmenting agent + topical steroid + retinoid
	Name, address of Manufacturing site:	Self Manufacturing
	Name & address of API manufacturer	
	Detail of stability batches of drug product	3 batches: 400 tubes
	Documents for the procurement of API with approval from DRAP (in case of Import)	Loan from Bio-Lab dated 25-10-2023, clearance certificate of M/s Bio-Lab for all 3 ingredients also submitted
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Clariquin Plus Cream of Martin Dow: Pe studies performed
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	As per Zone IV-A
	The status in reference regulatory authorities	Tri-luma cream By Hill Dermaceuticals, Inc. (USFDA Approved)
	GMP status of the firm	04-05-2023: GMP certificate inspection date F.11-91/2023-DRAP-174
	Evidence of approval of manufacturing facility	17-01-2019: DML grant of additional section specifies cream/ointment/lotion section
	Evaluation Remarks	
	Submit valid GMP certificate of product manufacturer	Firm has submitted GMP certificate No. F.11-91/2023-DRAP-174 dated 4.5.23
	Submit 6th month stability study data	Submitted
	Clarify why intimation of the loan letter was not submitted in R&I DRAP.	We could not submit previously as submission was erroneously missed which we regret but we

		will ensure to submit loan letters to Drap R&I in the future		
Decision				
Approved				
7	Case Category	Routine (Shahrukh Ali)		
	Name, address of Applicant.	Caliph Pharmaceuticals Plot 17, Special Industrial Zone Risalpur, KPK (000748)		
	Application Form Dy. No / Tracking ID & date of submission	(Y3B-LEV-AAX8, 2024-03-19)		
	Detail of Fee Submitted	30000.0, 2024-02-23,		
	The proposed proprietary name / brand name	FLUCICAL 0.025 % W/W CREAM		
	Label Claim	Each gram of cream contains: Fluocinolone acetoneide.....0.25mg		
	Reference to Finished product specifications	United States Pharmacopeia		
	Proposed Pack Size	As per SRO-Controlled		
	Shelf Life (Unit)	2 Year(s)25°C		
	For generic drugs (me-too Status)	Fucin 0.025%w/w Cream By M/s Bio-Labs Pharma		
	Pharmacotherapeutic Group of (API)	Topical steroid		
	Name, address of Manufacturing site:	Self Manufacturing		
	Name & address of API manufacturer	M/s. HUNAN YUXIN PHARMACEUTICAL CO., LTD. Longxutang, Shaoyang City, 422001, Human Province, China		
	Detail of stability batches of drug product	3 batches: 400 tubes		
	Documents for the procurement of API with approval from DRAP (in case of Import)	Loan letter and clearance certificate from BioLabs, 24-10-2023 clearance certificate of Bio Lab is submitted		
	Pharmaceutical Equivalence and Comparative Dissolution Profile	Synalar 0.025% Cream of Pharma Health: PE studies performed		
	Stability Studies of Drug Substance/Product (Conditions & duration of Stability studies)	Zone IV-A		
	The status in reference regulatory authorities	SYNALAR 0.025% Cream (USFDA Approved)		
	GMP status of the firm	F.11-91/2023-DRAP-174 dated 4.5.23: GMP certificate inspection date		
	Evidence of approval of manufacturing facility	17-01-2019: letter for grant of additional section specifies cream / ointment / lotion section.		
	Evaluation Remarks			
	Submit valid GMP certificate of product manufacturer	F.11-91/2023-DRAP-174 dated 4.5.23		
	Clarify why intimation of the loan letter was not submitted in R&I DRAP.	We could not submit previously as submission was erroneously missed which we regret but we will ensure to submit loan letters to Drap R&I in the future		
Decision				
Approved				

Import & Vet-II Section/Human Import

Case No.1: M/S RA HEALTH CARE (SMC-PVT.) LTD, 2ND FLOOR BUILDING NO. 50 MIR ARCADE, MINI COMMERCIAL PHASE 7, BAHRIA TOWN, RAWALPINDI REGARDING FAKE LETTER.

A letter No. NIL dated 22-04-2025 was received from General Headquarters, LS Branch (DGP Army), near 502 Central Base Workshop EME, Main Adyala Road, Rawalpindi, regarding the verification of a firm's registration letter. The details are as follows:

M/s Popular International submitted two different letters for the product Sevoflurane Liquid for Inhalation 250ml under Registration No. 115751, both bearing the same signing date but mentioning different Maximum Retail Prices (MRPs).

The verification status was communicated to GHQ Rawalpindi on 22-04-2025.

Meanwhile, a Show Cause Notice was issued to M/s RA Health Care (SMC-Pvt.) Ltd., 2nd Floor, Building No. 50, Mir Arcade, Mini Commercial, Phase 7, Bahria Town, Rawalpindi. The Registration No. 115751 was issued in your name for the aforementioned product. However, during scrutiny, it was revealed that the MRP on the letter for the said product submitted by M/s Popular International did not match the official records of DRAP. You are hereby directed to clarify your position regarding this discrepancy and submit a written response within seven (07) days from the date of issuance of this notice.

M/s RA Health Care (SMC-Pvt.) Ltd.'s reply dated 20-06-2025 is as under:

- 1) On getting an information that a fake registration letter is circulating in the market showing an exorbitant price of our registered product.
- 2) After getting this information we wrote a letter on April 28, 2025 to the worthy Chief Executive Officer (DRAP) informing him of the information received by us and clarifying that RA Healthcare or its employees are not involved in this case. We also informed that we are going to take legal action against the perpetrators.
- 3) During our further probing of the matter, we got the information that a quotation was submitted at DGP (Army) for sevoflurane Baxter at an exorbitant price by M/s Popular International, at that we immediately contacted our appointed Distributor M/s Popular International (Pvt) Ltd about the quotation. They denied having submitting any quotation to DGP(Army).
- 4) We nevertheless wrote an email to M/s Popular International (Pvt) Ltd, demanding explanation and informing that a legal action may be taken against them if they are not able to provide a satisfactory response.
- 5) M/s Popular International (Pvt) Ltd responded through email and denied that they submitted any quotation at DGP(Army). They informed that another company quoted at DGP(Army) that is identified and they are taking legal action against the culprit. Their request of FIR was denied by the Police; therefore, they submitted two petitions in court of law, one seeking direction to police for registration of FIR and a suite of damages against the perpetrator.
- 6) We also visited DGP(Army) and had a meeting with Col Waqar Abdullah and Lt. Col Salahuddeen and both worthy officers confirmed that they have concluded the investigation and they determined that both RA Healthcare (SMC-Pvt) Ltd and Popular International (Pvt) Ltd are innocent and they have identified that one M/s Popular International Distribution Services is the culprit and they are taking action against the said company under the Army Act.
- 7) We at this time are not importing Sevoflurane as the existing price is much below the import

price and we applied for Hardship and our application of hardship was decided in 62nd DPC and 65th DPC further endorsed its decision made in 62nd DPC.

8) Due to non-approval/issuance of final SRO by FOP we approached the Honorable Islamabad High Court for direction to federal government for approval of DPC recommended price and after insufficient decision by the worthy single bench, we are already in Intra Court Appeal at Honorable Islamabad High Court in order to seek direction to the FOP for issuing of SRO which is already overdue.

9) We also like to submit that at the current MRP the import and sale of Sevoflurane is not possible, we therefore urge DRAP to support us in getting direction to the FOP for early issuance of SRO with DPC approved price to make this critical product available for the patients.

10) We reiterate that neither we M/s RA Healthcare (SMC-Pvt) Ltd, nor our appointed distributor M/s Popular International (Pvt) Ltd have submitted any quotation or any document at DGP (Army).

It is therefore humbly requested that the Show Cause Notice shall be withdrawn and oblige.

A letter for personal hearing was issued to M/s RA Healthcare (SMC-Pvt) Ltd on 09-07-2025, directing them to appear before the Board on 14-07-2025 at 10:00 AM at DRAP Headquarters, Islamabad.

Decision:

The Registration Board decided to refer the case to the Legal Affairs Division for their comments and legal opinion and thereafter the case be placed in the Board.

Export Facilitation Desk

Case No. 01: Registration of Tirzepatide containing formulations.

Division of Pharmaceutical Evaluation & Registration has received multiple applications of different strengths of Tirzepatide Injection.

Tirzepatide, acts in the same way as glucagon-like peptide-1 (GLP1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones are produced in the gut and bind to specific receptors (targets) in the body, such as, among others, the pancreas and brain. This increases the amount of insulin that the pancreas releases in response to food and helps lower blood glucose levels in people with type 2 diabetes. Targeting these receptors also reduces appetite and helps people manage their weight.

Tirzepatide is synthesized using solid-phase peptide synthesis, dissolution and chromatographic purification, isolation and drying concentration and solvent exchange, and using well defined starting materials with acceptable specifications.

Division of PE&R is of the opinion that peptides are sensitive products and require special conditions during manufacturing, hence, these should be manufactured in Bio-tech section and firms having valid Bio-Tech section approval may be granted registration of Tirzepatide.

Decision:

Registration Board deliberated the matter and decided that till finalization of guidelines on registration of Peptide containing formulation, Export only registrations of peptide containing formulations shall only be granted to those firm's having Section approval from Central Licensing Board for bio-tech, r DNA or non-rDNA of DRAP provided that the manufacturer proves contaminations controls including cleaning validation according to relevant guidelines.

Division of Biological Evaluation & Research

Case No: 1

Measles, Mumps and Rubella (MMR)

Combined live vaccine for measles, mumps and rubella (MMR) is used widely for the immunization of children in certain regions of the world because of its advantages over the individual vaccines. Combined vaccine provokes an adequate immune response in children simultaneously for the three infections and facilitates the implementation of current immunization strategies.

Live attenuated measles virus (S-191 strain), mumps virus (S79 strain) and rubella virus (BRDII strain),;

Deferred Case-M-345

Exporting Country (China)

Case No. 01

Name, address of Applicant / Importer	M/s Immuno Well (Pvt) Ltd, Company Address: House No. 473, Street No.7, Block J-2, Johar Town, Lahore
Details of Drug Sale License of importer	License No. 05-352-0066-100098D Address: 473, Street No. 7, Block J-2, Johar Town, Lahore, Pakistan Validity: 17-Nov-2027 Status: License to sell drugs as a distributor. Godown address: Cold Storage Facility of M/S. Hi-Warble Pharmaceuticals (Pvt)Ltd. 44-B-II, Phase-1, Johar Town, Lahore
Name and address of marketing authorization holder (abroad)	M/s. Shanghai Institute of Biological Products Co., Ltd. Address: No. 758 Guangfeng Road, Fengxian District, Shanghai, China
Name, address of manufacturer(s)	M/s. Shanghai Institute of Biological Products Co., Ltd. Address: No. 758 Guangfeng Road, Fengxian District, Shanghai, China
Name of exporting country	China
Detail of certificates attached (CoPP, Free sale certificate, GMP certificate)	Scanned Apostille COPP Certificate No.: No. Shanghai 20220251 Issue Date: 05-12-2022 Certifying Authority: Shanghai Municipal Medical Products Administration, China. Free Sale: Yes GMP: Yes Validity: 04-12-2024
Details of letter of authorization / sole agency agreement	AUTHORIZATION LETTER We (Shanghai Institute of Biological Products Co., Ltd.) hereby authorize Immuno Well (Pvt) Ltd., 25-Rehman Housing Society, Johar Town, Lahore, Pakistan as our exclusive sole agent for Islamic Republic of Pakistan. Immuno Well (Pvt) Ltd., is authorized to represent us, submit documents and dossier of our products "MMRubivac inj. (Measles, Mumps and Rubella Combined Vaccine, Live) & FluLing Quad (Influenza Vaccine (Split Virion), Inactivated, Quadrivalent)" to the health authorities for the purpose of registration and renewal of registration certificate in Islamic Republic of Pakistan.
Status of the applicant	Importer
Status of application	Generic Drug Product (GDP)
Intended use of pharmaceutical product	Domestic sale
For imported products, specify one of these	Finished Pharmaceutical product import
Dy. No. and date of submission	Tracking ID: NXG-JBD-TWJ6 Application Number:31928 Receiving Date: 13-09-2024
Details of fee submitted	Challan Number: 56430199842 Division: Biological Evaluation & Registration Paid Fee: 300000.0 Paid Date: 2024-07-24
The proposed proprietary name / brand name	MMRubivac.
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Live attenuated measles virus (S-191 strain), mumps virus (S79 strain) and rubella virus (BRDII strain),;

	Each 0.5ml of reconstituted vaccine per container 0.5ml per single human dose containing not less than 3.0 lgCCID50 of both live measles virus and rubella virus and 4.3 lgCCID50 of live mumps virus. (Enclosed with 1 ampoule of sterile water for injection as the diluent).
Clinical Indication	Subjects susceptible to MMR above 8 months.
Dosage form of applied drug	Lyophilized injection with diluent
Route of Administration	SC
Pharmacotherapeutic Group of (API)	Vaccine
Finished product specifications	Chinese Pharmacopeia European Pharmacopeia /WHO specification
Proposed Pack size	0.5ml/dose/vial/pack + diluent
Proposed unit price	Rs.2,259/dose/pack
Shelf Life	18 months
Storage Conditions	At 2-8°C. Protect from light.
The status in reference regulatory authorities	Tradename: PRIORIX Manufacturer: GlaxoSmithKline Biologicals SA Indications: For active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age and older. PRIORIX contains the Schwarz strain of live attenuated measles virus, the RIT 4385 strain of live attenuated mumps virus (derived from the Jeryl Lynn strain), both propagated in chick-embryo fibroblasts from embryonated eggs of specific pathogen-free flocks and the Wistar RA 27/3 strain of live attenuated rubella virus propagated in MRC-5 human diploid cells. The 3 virus strains are cultured in media containing amino acids, a small amount of neomycin sulfate and bovine serum albumin and are stabilized after multiple washing steps in media free from antibiotics and albumin. The attenuated measles, mumps and rubella viruses are then mixed with a stabilizer prior to lyophilization. <i>After reconstitution, each approximately 0.5-mL dose contains not less than 3.4 log₁₀ Cell Culture Infective Dose 50% (CCID₅₀) of measles virus, 4.2 log₁₀ CCID₅₀ of mumps virus, and 3.3 log₁₀ CCID₅₀ of rubella virus.</i>
For generic drugs (me-too status)	013272 Measles, Mumps, Rubella Vaccine live, attenuated (freeze-dried) M.M.R, Serum Institute of India Pvt by M/s Amson 115, Industrial Triangle, Kahuta Road, Islamabad The vaccine is prepared from the live, attenuated strains of Edmonston-Zagreb measles virus, Leningrad-Zagreb (L-Z) mumps virus and Wistar RA 27/3 rubella virus.
Drug Substance: (Virus Bulk of Measles Vaccine, Live, Virus Bulk of Mumps Vaccine, Live, and Virus Bulk of Rubella Vaccine, Live	
Name, address of drug substance manufacturer	Manufacture of virus bulks of Measles Vaccine, Live, Mumps Vaccine, Live, and Rubella Vaccine, Live M/s Shanghai Institute of Biological Products Co., Ltd. Measles, Mumps, and Rubella Vaccine Workshop, Building 120, No. 758 Guangfeng Road, Fengxian District, Shanghai, China Control test of virus bulks of Measles Vaccine, Live, Mumps Vaccine, Live, and Rubella Vaccine, Live Shanghai Institute of Biological Products Co., Ltd. QC Laboratory, Building 116, No. 758 Guangfeng Road, Fengxian District, Shanghai, China

General Information	Drug substance name	Virus	Cells for production	Preparation process	Virus titers
	Measles virus bulk	Attenuated measles virus S191 strain	Primary chicken embryo fibroblasts	The virus bulk of Measles Vaccine, Live is prepared by inoculating the attenuated measles virus S191 strain into primary chicken embryo fibroblasts, followed by cell culture, viral harvest, and pooling	5.3-6.5 lg CCID ₅₀ /mL (CCID ₅₀ method)
	Mumps virus bulk	Attenuated mumps virus S ₇₉ strain	Primary chicken embryo fibroblasts	The virus bulk of Mumps Vaccine, Live is prepared by inoculating the attenuated mumps virus S ₇₉ strain into primary chicken embryo fibroblasts, followed by cell culture, viral harvest, and pooling	6.1-7.5 lg CCID ₅₀ /mL (CCID ₅₀ method)
	Rubella virus bulk	Attenuated rubella virus BRD-II strain	Human diploid cell (MRC-5)	The virus bulk of Rubella Vaccine, Live is prepared by inoculating the attenuated rubella virus BRD-II strain into human diploid cells (MRC-5), followed by cell culture, viral harvest, and pooling	4.9-6.5 lg CCID ₅₀ /mL (CCID ₅₀ method)
Specifications	The specifications have been formulated in reference to the Chinese Pharmacopoeia (Volume III)				
Stability Studies of Drug Substance (Conditions & duration of Stability studies)	According to WHO/BS/06.2049, Guideline on stability evaluation of vaccines; ICH Q5C, Quality of biotechnological products: stability testing of biotechnological/biological products, and WHO, considerations for the evaluation of MMR Vaccine. Virus bulk of Measles Vaccine, Live, virus bulk of Mumps Vaccine, Live, and virus bulk of Rubella Vaccine, Live should be stored and transported at below - 60 °C, away from light. The shelf life is 12 months from the date of manufacture. SIBP has conducted accelerated stability, long-term stability, and forced degradation tests on the bulks of measles virus, mumps virus, and rubella virus. The studies showed that the virus bulk of Measles Vaccine, Live, virus bulk of Mumps Vaccine, Live, and virus bulk of Rubella Vaccine, Live was acceptable within the shelf life (-60 °C, 12 months) and complied with the in-house specification.				
Drug Product Part: Measles, Mumps and Rubella Combined Vaccine, Live					
Name, address of drug substance manufacturer	Manufacturing address of drug substance and finished products: Suite of Measles, Mumps and Rubella Combined Vaccine, Live, Building 120, No. 758, Guangfeng Road, Fengxian District, Shanghai Testing address of drug substance and finished products: QC Laboratory, Building 116, No. 758, Guangfeng Road, Fengxian District, Shanghai Packaging address of drug product: Filling Suite, Building 122, No. 758, Guangfeng Road, Fengxian District, Shanghai				
Manufacturing	This product is prepared by following the procedures: primary chicken embryo fibroblasts are inoculated with attenuated measles virus S191 strains and attenuated mumps virus S79 strains, respectively; human diploid cells are inoculated with attenuated rubella virus BRD-II strains (MRC-5 strains); the cultured and harvested virus suspensions are mixed and prepared in a certain ratio, and lyophilized with a suitable stabilizer. The preparation of final bulk and filling of finished products were performed by SIBP at No. 758, Guangfeng Road, Fengxian District, Shanghai. The process validation of 6 batches of commercial batch of Measles, Mumps and Rubella Combined Vaccine, Live fully demonstrated the stability of vaccine manufacturing process and controllable quality				
Container closure system of the drug product	Primary packaging: 1. Injection vial made of middle borosilicate glass tubing and butyl rubber stopper, 1 vial/box; 2. Matching package: One vial of sterile water for injection is attached to each box, 0.5 mL/vial..				
Stability study data of drug product, shelf life and storage conditions	This product should be stored and transported at 2-8 °C, protected from light. The shelf life is 18 months from the date of manufacture.				
Non-Clinical (Module -IV)					
Module 4 (non-clinical/Safety)					
4.2	Study Report				
4.2.1	Pharmacology	Not Applicable			
4.2.2	Pharmacokinetics	Not Applicable			

4.2.3	Toxicology		
4.2.3.1	Single dose Toxicity		Not Applicable
4.2.3.2	Repeat-dose Toxicity		Not applicable.
4.2.3.3	Genotoxicity		Not applicable.
4.2.3.4	Carcinogenicity (including supportive toxicokinetics evaluation)		Not applicable.
4.2.3.5	Reproductive and Developmental Toxicity (including range-finding studies and supportive toxicokinetics evaluations) (if modified study designs are used, following sub-headings should be modified accordingly.)		Not applicable
4.2.3.6	Local Tolerance		The objective of this study is to observe the local irritation reaction of New Zealand rabbits after a single subcutaneous injection of Measles, Mumps and Rubella Combined Vaccine, Live, and to provide animal test data for clinical studies. 12 male New Zealand rabbits were randomly divided into 2 groups (6 rabbits/group). All animals were subcutaneously injected in the back of left nape with the negative control (sodium chloride injection). Animals in Group 1 were subcutaneously injected in the back of right nape with the test article (new process) Measles, Mumps and Rubella Combined Vaccine, Live, and animals in Group 2 were subcutaneously injected in the back of right nape with the control (old process) Measles, Mumps and Rubella Combined Vaccine, Live. Single dose, single-point injection, volume administered of 0.5 mL/animal. The first 3 animals per group were euthanized on D3 and the remaining 3 animals per group were euthanized on D15 and the local administration site were evaluated. During the study, no abnormal symptoms were observed in the clinical observation of animals. During the study, no abnormalities related to the test article/control were observed at the local injection site. No abnormal pathological changes related to treatment were observed in gross observation and microscopic observation of animals euthanized at 48 h (D3) after the last dose and 14 days (D15) after the last dose. Under the conditions of this study, no local irritation was observed in New Zealand rabbits (0.5 mL/rabbit) administered a single subcutaneous dose of the test article Measles, Mumps and Rubella Combined Vaccine, Live, which was consistent with the results of the old process controls.
Clinical (Module-V)			
5.2	Tabular Listing of All Clinical Studies		

Study No. /Title	Design/ Objective	Intervention (N)	Endpoint	Conclusion
R01: Phase I/II/III Clinical Trial of Measles-Mumps-Rubella Combined Attenuated Live Vaccine*	Phases I, II and III Randomized, double-blind (observer blinded), Controlled. Age: 8-18 months Safety and Immunogenicity study	Phase I: SIBP MMR-11+26 Phase II: SIBP MMR- 304 Measles-60 Mumps-61 Rubella-60 Phase III: SIBP MMR- 603 Merck MMR-100 0.5mL of trial vaccine administered subcutaneously	<u>Safety</u> Immediate adverse event Solicited reactions. <u>Immunogenicity</u> Pre and 4 weeks post Micro-hem agglutination-inhibition (HI) test	<u>Safety</u> No difference with control <u>Immunogenicity</u> Measles Conversion- Significant difference GMC-No difference Mumps Conversion- No difference GMC-Significant difference Rubella Conversion- No difference GMC- No difference
R02: Safety Surveillance of Measles Attenuated Live Vaccine and Measles-Mumps-Rubella Combined Attenuated Live Vaccine after Supplementary Immunization	Non-randomized; parallel Age: 8 months to 14 years Measles- kindergartens or living scattered. MMR-Children from primary and secondary schools (students aged 6-14 years)	MMR-977521 Measles-814023 0.5mL of trial vaccine administered subcutaneously	AEFI was divided into adverse reaction (including general reaction and abnormal reaction), psychogenic reaction, immunization accident, vaccine quality accident and coupled	1. The reported rates of common and rare adverse reaction of MMR vaccine were 20.87/100,000 and 3.99/100,000, respectively. 2. The greater proportion of reported AEFI cases happened in the younger group. The reported AEFI were mainly common adverse reactions, such as fever and local swelling. Most of the rare adverse reactions were allergic rash.
Study No. /Title	Design/ Objective	Intervention (N)	Endpoint	Conclusion
Activities (SIA) in Shanghai, 2010	Passive surveillance for safety			3. The vaccination of MMR vaccine in SIA was safe and most adverse reactions were common.
R03: Adverse Reaction Surveillance of Measles-Mumps-Rubella Combined Attenuated Live Vaccine	Randomized Age: 18 -24 months Surveillance for safety	SIBP MMR-229603 GSK MMR-71781 0.5mL of trial vaccine administered subcutaneously	Active surveillance for 1 month Incidence- SIBP MMR-0.08%, GSK MMR-0.15% Passive surveillance by AEFI monitoring over a period of 1 year. Mid- and long-term active monitoring on hospitalized children.	The safety data of large-scale vaccination of SIBP MMR and GSK MMR vaccines indicated that both vaccines had a high safety level, low incidence rate, the reactions were mild, mainly general reaction, and no relevant serious reaction or death were reported.
R04: Immunity comparison of Measles-Mumps-Rubella Combined Attenuated Live Vaccine produced by SIBP and GSK**	Phase IV, Randomized, double blind, comparative. Age: 8 and 12 months Immunogenicity, Persistence of immune response and Safety.	SIBP MMR (8& 18 months)-143 SIBP MMR (12 & 22 months)-220 GSK MMR (12 & 22 months) -217 0.5mL of trial vaccine administered subcutaneously	<u>Immunogenicity</u> Blood samples were collected before, 1 month, 10 months and 3 years after immunization. Serum titers of antibody against measles, mumps and rubella were measured by ELISA.	For this study the non-inferiority comparison was done retrospectively. The results showed that SIBP MMR vaccine was comparable to GSK MMR vaccine in terms of seropositive rate 1 month and 3 years after two doses of the vaccines.
R05: Evaluation of the safety and interaction to immunity of	Phase IV, Randomized, open label. Age: 17 to 23 months	SIBP MMR + SIBP Varicella-160 SIBP MMR-154 SIBP Varicella-141	<u>Immunogenicity</u> Blood samples were collected before and 35-42 days after immunization. Antibody positive conversion rate and GMC to Measles and	For this study non-inferiority was conducted and showed no evidence that co-administration interfered the immunogenicity of individual vaccines.

Study No. /Title	Design/ Objective	Intervention (N)	Endpoint	Conclusion
co-administration with MMR and Varicella Vaccine**	Safety, Immunogenicity, and co-administration with Varicella vaccine	0.5mL of trial vaccine administered subcutaneously	Varicella were detected. Safety Local and systematic reaction of subjects within 30min. 24h, 48h and 72h and day 7, 14 and 30 after vaccination	The adverse reaction was mainly composed of fever and rash, and there was no statistical difference between co-administration subjects and those with either vaccine.
R06: Observation of the lot-to-lot consistency of SIBP MMR**	Phase IV, Randomized, double blind, lot-to-lot consistency study. Age: 8-12 months Safety and Immunogenicity study	SIPB MMR Lot01- 356 SIPB MMR Lot02- 356 SIPB MMR Lot03- 356 0.5mL of trial vaccine administered subcutaneously	Immunogenicity Comparison of geometric mean concentrations (GMCs) of measles, mumps and rubella antibodies in all test groups 42 days post-vaccination. Safety Local 14 days Systemic solicited, 42 days Unsolicited and SAE- 180 days	The immunogenicity of children aged 8-12 months vaccinated with one dose of SIBP MMR reached the lot-to-lot consistency criteria prescribed in the protocol. In addition, the vaccination with SIBP MMR showed good safety and resulted in no additional safety risks.
R07: Observation of the immunity and safety co-administration with MMR and Yellow Fever vaccine, Immunity comparison of MMR Vaccine produced by SIBP and GSK **	Phase III, Multi-Center, Randomized, Observer-Blind, Active Controlled Non-Inferiority Study	SIPB MMR/Yellow Fever- 400 (Group 1) GSK MMR- 400 (Group 2) SIBP MMR + Yellow Fever- 400 (Group 3) 0.5mL of trial vaccine administered subcutaneously	Immunogenicity An evaluation of seropositivity rate to Measles, Mumps and Rubella viruses of SIBP MMR vaccine versus GSK MMR vaccine when measured 42 days after vaccination in seronegative children at baseline. Comparison of GMC for anti-measles/mumps/rubella antibodies and GMT for anti-yellow fever virus antibody before and 42 days after immunization of the Group1 and Group3.	In progress

5.3	Clinical Study Reports		
	5.3.1	Report of Biopharmaceutic Studies	Not Applicable.
	5.3.2	Reports of Studies Pertinent to Pharmacokinetics using Human Biomaterials	Not Applicable.
	5.3.3	Reports of Human Pharmacokinetics (PK) Studies	Not Applicable.
	5.3.4	Reports of Human Pharmacodynamic (PD) Studies	Not Applicable.
	5.3.5	Reports of Efficacy and Safety Studies 5.3.5.2 Study Reports of Uncontrolled Clinical Studies. 5.3.5.3 Reports of Analyses of Data from More Than One Study	There are totally 6 clinical studies conducted to observe the efficacy of SIBP MMR.. Study R01 is a pre-marketing licensure studies consisted of a combined phases I, II and III study designed as a randomized, double-blind, and controlled study in older children and in the targeted population of 8~18 months in China. Study R04 to R07 are postmarketing safety, immunogenicity, co-administration, lot-to-lot and inferiority comparison studies
	5.3.6	Reports of Post-Marketing Experience.	

Table 2.7.4.6.1: Summary of adverse events after immunization of SIBP MMR from 2016-2023																																																											
			<table><tr><th>Age (month)</th><th>Common Adverse Reaction</th><th>Rare Adverse Reaction</th><th>Coincidental Event</th><th>Others</th><th>Total</th><th>Proportion (%)</th></tr><tr><td>≤12</td><td>50927</td><td>9867</td><td>464</td><td>462</td><td>61720</td><td>56.87</td></tr><tr><td>13-15</td><td>1346</td><td>131</td><td>14</td><td>9</td><td>1500</td><td>1.38</td></tr><tr><td>16-24</td><td>34189</td><td>3289</td><td>402</td><td>137</td><td>38017</td><td>35.02</td></tr><tr><td>25≤</td><td>6555</td><td>571</td><td>127</td><td>53</td><td>7306</td><td>6.73</td></tr><tr><td>Unknow</td><td>0</td><td>1</td><td>0</td><td>4</td><td>5</td><td>0.00</td></tr><tr><td>Total</td><td>93017</td><td>13859</td><td>1007</td><td>665</td><td>108548</td><td>100.00</td></tr><tr><td>Proportion (%)</td><td>85.69</td><td>12.77</td><td>0.93</td><td>0.61</td><td>100.00</td><td>/</td></tr></table>	Age (month)	Common Adverse Reaction	Rare Adverse Reaction	Coincidental Event	Others	Total	Proportion (%)	≤12	50927	9867	464	462	61720	56.87	13-15	1346	131	14	9	1500	1.38	16-24	34189	3289	402	137	38017	35.02	25≤	6555	571	127	53	7306	6.73	Unknow	0	1	0	4	5	0.00	Total	93017	13859	1007	665	108548	100.00	Proportion (%)	85.69	12.77	0.93	0.61	100.00	/
Age (month)	Common Adverse Reaction	Rare Adverse Reaction	Coincidental Event	Others	Total	Proportion (%)																																																					
≤12	50927	9867	464	462	61720	56.87																																																					
13-15	1346	131	14	9	1500	1.38																																																					
16-24	34189	3289	402	137	38017	35.02																																																					
25≤	6555	571	127	53	7306	6.73																																																					
Unknow	0	1	0	4	5	0.00																																																					
Total	93017	13859	1007	665	108548	100.00																																																					
Proportion (%)	85.69	12.77	0.93	0.61	100.00	/																																																					
	5.3.7	Case Report Forms and Individual Patient Listing	Submitted																																																								
Evaluation by BE&R																																																											
S. No	Sections	Observations/De ficiencies/ Short- comings	Firms Response																																																								
1.	1.3.4	a) Hard copy of original, legalized and valid COPP mentioning strains of MMR Virus, as provided one is invalid. b) Hard copy of original or notarized sole agency agreement is required. c) The COPP does not include any information on the diluent/combo pack. Clarification is required. d) The address of importer on DSL is different than LOA. Clarification/Just ification is required.	a) For question (a), SIBP will apply for a new CoPP from China National Medical Products Administration (NMPA) follow the WHO format. b) As e-copy of authorization letter has been submitted with CTD Dossier. Hard copy of original authorization letter will be provided along with new valid CoPP. For question ©, NMPA issue the CoPP following the WHO guideline. c) For the WFI, this is the MMR vaccine’s diluent, and does not contain the active ingredients, and already have been marketed in China. According to the Chinese and WHO’s format of CoPP, it is not mandatory to display the diluent information, also there is no applicable section in CoPP to fill in this relevant information. d) The address mentioned on LOA is the Corporate Office address. And address mentioned on DSL is the working office address.																																																								
2.	1.4.1	a) If the Biological Product is a vaccine	The specification and protocol of manufacturing, filling & packaging, release testing, sampling, labeling, shipping and storage of SIBP MMR vaccine follow the Chinese Pharmacopoeia III 2020.																																																								

		manufactured under relevant WHO TRS or is a new vaccine for which WHO TRS is not yet developed. b) A copy of lot summary protocol in compliance with WHO (identified as per specific WHO TRS).	Production and testing facilities, raw materials and excipients, water, equipment, animals, etc. meet the relevant requirements of the "GENERAL NOTICES" of the current edition of the Chinese Pharmacopoeia III. Unless otherwise specified, the testing methods adopted shall be carried out in accordance with the relevant methods in the Appendix of the current edition of Chinese Pharmacopoeia III. Production procedures are consistent with WHO TRS 840 requirements. The relevant files and documents will be provided later.
3.	1.4.2	Documents/evidence for acceptable shipping conditions for both finished product and drug substance and formulated bulk (for importing bulks for filling and domestic production) & proof of shipping validation.	SIBP MMR vaccine has been undergo the stability study before marketing and will also undergo the stability study after marketing follow the relevant guideline, the data of stability study and the protocol of stability study after marketing please refer to the CTD M3. These data can prove that SIBP MMR vaccine meets the requirements under the storage condition. The finished bulk is not suitable for global shipping due to its limited shelf life.
4.	1.5.2	Mention the names of virus strains for each MMR virus and whether these strains are prevalent in Pakistan.	Name: Measles virus: Hu-191, this strain was isolated from a Chinese 2-year-old boy in 1960. Mumps virus: S79, this stain is Jerry-Lyn origin Rubella virus: BRD-II, this strain was from Beijing Institute of Biological Products in 1980s, isolated from a 6-year-old children. For the question "<i>whether these strains are prevalent in Pakistan.</i>". The answer requires data gathered from the citizens, which may not be available by SIBP. Immuno Well shall check the local CDC website or other sources for the information. The strain that SIBP used in MMR vaccine is approved by China NMPA and be known through WHO. Details like history, safety, efficacy and passage etc. of those virus strains are mentioned in M3 and M5. The same strains are prevalent in Pakistan. Please check the already registered product SANVAC in Pakistan mentioned in query No. 7(1.5.2)
5.	1.5.5	Pharmacotherapeutic group of applied vaccine.	Since the Chinese NMPA do not require an ATC for vaccine, the most likely ATC Code: J07BD52
6.	1.5.6	a) Specify the reference to Pharmacopoeial specifications as per Drug Specification Rules 1978 and guidance document regarding application of Drug Product Specifications.	The MMR Vaccine from SIBP is produced and released follow the current edition of Chinese Pharmacopoeia

		b) Tabular Comparison of all the three monographs as mentioned in section 1.5.6.	
7.	1.5.8	The reference of already registered product (with same strains) including the following details needs to be submitted. • Brand name • Manufacturer/Registration holder • Registration number	Brand Name: SANVAC Injection Manufacturer Name: Beijing Institute of Biological Products China Strength: 0.5 ml Per dose Per vial Composition: Measles, Mumps & Rubella Combined Vaccine Live attenuated Registration No.047617 Pack Size: 0.5 ml Per Dose Per vial Per Pack with diluent
8.	1.5.9	a) Evidence of approval / registration / marketing status of the applied formulation in the same composition (strain and strength), salt form and dosage form in one of the reference regulatory authority specified by Registration Board. The name of the reference authority shall be mentioned as adopted by Board currently. b) Evidence of approval / registration / marketing status of the applied formulation with the same clinical indications (above 8 months).	Refer to question 7. SIBP MMR vaccine registered and marketed in China. It's on sale in China now. The authority is: National Medical Products Administration (China) The supporting files and documents are submitted with CTD before. Again please find attached the registration certificate in Chins.
9.	1.5.14	Summary of Product Characteristics (SmPC) of the applied vaccine	SmPC will be provided later. Since SIBP MMR vaccine marketing in China, and China NMPA don't require SmPC for register.

		in one of the reference regulatory authority specified by Registration Board.	In China, NMPA will approval and issue the “ <i>directions for use of Measles, Mumps and Rubella Combined Vaccine, Live.</i> ”. this file is designed for the understanding and use of this vaccine for all users including both the doctors and patients.
10.	3.2.P.1	Final bulk is not assayed for virus content and residual animal serum proteins. Justification is required.	The <i>Chinese Pharmacopoeia III (2020 version)</i> does not require the virus titration and bovine serum albumin residue determination for the final bulk.
11.	3.2.P.5.1	a) A copy of the drug product specification(s) including tests, acceptance criteria and reference to analytical procedure shall be provided. b) Test of ovalbumin not included in the Specifications. Justification is required.	For question (a), the relevant files and documents will be provided later. For question (b), both the <i>Chinese Pharmacopoeia III (2020 version)</i> and WHO TRS 840 do not require the ovalbumin test. Testing and specification of SIBP MMR vaccine are carried out in accordance with the <i>Chinese Pharmacopoeia</i> .
12.	3.2.P.4.5	For excipients of human or animal origin, a certificate shall be provided, confirming that the excipient(s) are free from BSE and TSE.	Refer to attachment 1 The certificate and documents shall be provided later.
13.	3.2.R	Copy of Batch Manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3.	The files and documents shall be provided later.
14.	Module 4 Non-Clinical Data	Proper justification with evidence of reference guidelines were “Not applicable” has been mentioned for non-clinical study reports like	Nonclinical study: 1. Pharmacology: Not Applicable, the WHO guidelines for the non-clinical evaluation of vaccines refer to the safety pharmacology in the non-clinical evaluation of vaccines for the purpose of studying the effects of vaccine candidates on vital function. If non-clinical and/or human clinical study data suggest that a vaccine (such as a vaccine based on a specific toxoid) may affect physiological functions other than the immune system (such as the central nervous system, respiratory, cardiovascular, and renal function), then safety pharmacological studies should be included in the toxicity assessment. The virus strains used in

		pharmacology, Pharmacokinetics, Toxicology, Genotoxicity, Carcinogenicity, Reproductive and Development Toxicity	the live attenuated SIBP MMR vaccine have all been attenuated, and their safety has been demonstrated by a large amount of human clinical data. Pharmacokinetics:
15.	Module 5 Clinical Data	a) Proper justification with evidence of reference guidelines were "Not applicable" has been mentioned for clinical study reports. b) Risk Management Plan (RMP) c) Periodic Safety Update Report (PSUR)/Periodic Benefit-Risk Evaluation Report (PBRER) d) Adverse event following immunization report (summary of annual reports) in the country of origin or any other NRA.	Not Applicable, the WHO guideline for the non-clinical evaluation points out that if determining the concentration of a vaccine component in serum or tissue, pharmacokinetic studies are usually not required. 3. Toxicology The animal safety evaluation including <i>Single-dose Subcutaneous Irritation Test of Measles, Mumps and Rubella Combined Vaccine, Live in New Zealand Rabbits, Active Systemic Anaphylaxis Study of Measles, Mumps and Rubella Combined Vaccine, Live in Guinea Pigs</i> were carried out to demonstrate the safety of SIBP MMR vaccine. 4. Genotoxicity Not Applicable, the WHO guideline for the non-clinical evaluation of the vaccines points out that genotoxicity studies are usually not required for final vaccine formulations. The genotoxicity studies may require only in a situation involving the specific ingredient (like novel adjuvant or additive). SIBP MMR vaccine does not contain novel adjuvant or additive. 5. Carcinogenicity Not Applicable, the WHO guideline for the non-clinical evaluation of the vaccines points out that carcinogenicity study does not require for vaccine antigen. Carcinogenicity study may require for the special ingredients like novel adjuvant or additive, but SIBP MMR vaccine do not contain novel adjuvant or additive. 6. Reproductive and developmental toxicity Not Applicable, the WHO guideline for the non-clinical evaluation of the vaccines points out that reproductive and developmental toxicity generally does not require for the vaccines for the children. Reproductive and developmental toxicity may consider if the vaccines for the pregnant and fertile women, SIBP MMR vaccine's eligible is children aged at 8 months and above, and alert women of childbearing age should avoid pregnancy for at least 3 months after injection of the MMR vaccine. Reference: WHO Technical Report Series, No. 927, 2005 : Annex 1 WHO guidelines on nonclinical evaluation of vaccine

Decision of 345th Meeting:

The Registration Board deferred the case for submission of following requisite documents:

- I. Hard copy of original, legalized and valid COPP mentioning strains of MMR Virus, as provided one is invalid.
- II. Hard copy of original or notarized sole agency agreement is required.
- III. The COPP including details of the diluent/combo pack. A copy of lot summary protocol in compliance with WHO (identified as per specific WHO TRS).
- IV. Documents/evidence for acceptable shipping conditions for finished product & proof of shipping validation.
- V. Data for following strain prevalence (Measles virus: Hu-191, Mumps virus: S79, this strain is Jery-Lyn origin, Rubella virus: BRD-II) in Pakistan.
- VI. Evidence of approval / registration / marketing status of the applied formulation in the same composition (strain and strength), salt form and dosage form in one of the reference regulatory authority specified by Registration Board. The name of the reference authority shall be mentioned as adopted by Board currently.
- VII. Evidence of approval / registration / marketing status of the applied formulation with the same clinical indications (above 8 months).
- VIII. Summary of Product Characteristics (SmPC) of the applied vaccine in one of the reference regulatory authority specified by Registration Board.
- IX. Final bulk should be assayed for virus content and residual animal serum proteins.
- X. Test of ovalbumin to be included in the Specifications.
- XI. For excipients of human or animal origin, a certificate shall be provided, confirming that the excipient(s) are free from BSE and TSE.
- XII. Copy of Batch Manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3.

Sr. No	Observations	Applicant Response	Evaluation
1.	Hard copy of original, legalized and valid COPP mentioning strains of MMR Virus, as provided one is invalid.	Original, and valid CoPP, mentioning MMR virus is being submitted.	Scanned Attached.
2.	Hard copy of original or notarized sole agency agreement is required.	Notarized, Authorization Letter is being submitted	Scanned Attached.
3.	The COPP including details of the diluent/combo pack.	Original, apostilled and valid CoPP is being submitted mentioning the combo pack with diluent	Combo pack scanned COPP has been submitted.
4.	A copy of lot summary protocol in compliance with WHO (identified as per specific WHO TRS).	lot summary product in compliance of WHO (identified as per specific WHO TRS) is being submitted.	Lot summary product in compliance of WHO (identified as per specific WHO TRS) has not been submitted.
5.	Documents/evidence for acceptable shipping conditions for finished product & proof of shipping validation.	Shipping condition validation.	No shipping validation document has been provided.
6.	Data for following strain prevalence (Measles virus: Hu-191, Mumps virus: S79, this strain is Jery-Lyn origin, Rubella virus: BRD-II) in Pakistan.	Measles strains: In Pakistan the main measles strains is genotype 3 which is closely related to strains of neighbouring countries. Measles virus is an enveloped, ribonucleic acid virus of the genus Morbillivirus. Although at least 20 different genotypes have been isolated in various parts of the world, there is only one serotype. Measles is highly contagious, and an infected person will often transmit the virus to over 90% of unprotected close contacts. Mumps strain: Mumps have 12 recognized genotypes of mumps there is only one serotype, means antibody generated in response of one genotype recognize one serotype mumps virus. The WHO has recommended mumps strains for vaccine manufacture including jeryl — lyn, RIT 4385, Leningrad — 3 and Leningrad — Zagreb. Rubella strains: The rubella virus is a single serotype with at least seven genotypes serotypes. The most common genotypes circulating in many regions of world are IE,IG,1J and 2B. As the prevalence of MMR vaccine viruses has single serotype but different genotype which does not affect efficacy and safety of vaccine that is why previous vaccine, Triviritin (Manufactured	No evidence for Data for following strain prevalence (Measles virus: Hu-191, Mumps virus: S79, this strain is Jery-Lyn origin, Rubella virus: BRD-II) in Pakistan. Hu-191 is a recombinant strain engineered for therapeutic purposes, it originates from the Edmonston B strain, which belongs to genotype A.

		in France), Trimovax (Manufactured in Germany), Morupar (Manufactured in Italy, Germany now in India), Sanvac (Manufactured in China) are already registered in Pakistan but only one brand is available.	
7.	Evidence of approval / registration / marketing status of the applied formulation in the same composition Registration Board. The name of the reference authority shall be mentioned as adopted by Board currently. (strain and strength), salt form and dosage form in one of the reference regulatory authority specified by	It is only registered in China.	----
8.	Evidence of approval / registration / marketing status of the applied formulation with the same clinical indications (above 8 months).	All brands manufactured in different countries are recommended at the same age group for vaccination and it is being done from decades, also it is recommended by WHO similar age and is recommended in EPI Pakistan.	---
9.	Summary of Product Characteristics (SmPC) of the applied vaccine in one of the reference regulatory authority specified by Registration Board.	SmPC is being submitted.	SMPC has been provided.
10.	Final bulk should be assayed for virus content and residual animal serum proteins.	The Chinese Pharmacopeia 111 (2020 version) does not require the virus titration and bovine serum albumin residue determination for the final bulk for vaccines.	--
11.	Test of ovalbumin to be included in the Specifications.	Chinese Pharmacopeia III (2020 version) and WHO TRS 840 do not require ovalbumin test. Testing and specification of MMR vaccine are carried in accordance with the Chinese Pharmacopeia.	---
12.	For excipients of human or animal origin, a certificate shall be provided, confirming that the excipient(s) are free from BSE and TSE.	Official Veterinary Bulletin	Declaration submitted by drug product manufacturer.
13.	Copy of Batch Manufacturing Record (BMR) for all the batches of drug product for which stability studies data is provided in Module 3.	BMR is being submitted	BMR of following three batches submitted by the applicant. BMR-S20180314 BMR S20180315 BMRS201180316

Remarks by BE&R

Not recommended as no evidence has been provided regarding the prevalence of these strains in Pakistan; however, they are prevalent in China as per WHO report.
Placed before Board for consideration.

Decision of 347th Meeting:

The Registration Board, keeping in view the absence of substantive data regarding the prevalence of strain in Pakistan, epidemiological relevance and approval of the applied rubella virus strain (BRD II) only in China, decided to forward the matter to the Federal Directorate of Immunization (FDI) for their opinion: -

- Presence, prevalence, and public health relevance of BRD II strain of Rubella Virus in Pakistan
- Whether any MMR vaccines containing BRD II strain has been used in immunization program or otherwise?
- Recommendation of FDI for need of MMR Vaccine containing strain BRD II.

Moreover, the Board also mandated the timely submission of the following documentation:

- ✓ Evidence of approval of “same strains” i.e. measles virus (S-191 strain), mumps virus (S79 strain) and rubella virus (BRDII strain) in reference regulatory authority as approved by Registration Board in its 275th meeting.
- ✓ Evidence of approval of same “clinical indication/target population” i.e. susceptible to MMR above 8 months in reference regulatory authority as approved by Registration Board in its 275th meeting.
- ✓ Proper justification with evidence of reference guidelines were “Not applicable” has been mentioned for non-clinical study reports like repeat dose toxicity studies.
- ✓ Lot summary protocol in compliance to WHO TRS.
- ✓ Evidence of acceptable shipping conditions for finished product.
- ✓ Comprehensive epidemiological evidence establishing the presence, prevalence, and public health relevance of the BRD II strain within target regions.
- ✓ Peer-reviewed scientific publications or technical reports substantiating claims related to the strain's performance and relevance.

Remarks of the Assessor

Sr. No.	Query	Response	Evaluation
1.	Evidence of approval of “same strains” i.e. measles virus (S-191 strain), mumps virus (S79 strain) and rubella virus (BRDII strain) in reference regulatory authority as approved by Registration Board in its 275 th meeting.	MMR from SIBP is in the process of WHO PQ. WHO has already accepted strains of the MMR vaccine used by the Shanghai Institute of Biological Products SIBP for Prequalification.	BRD II not approved in any RRA. Email sent to WHO by SIBP on 2017. Applicant may also submit current status for PQ.
2.	Evidence of approval of same “clinical indication/target population” i.e. susceptible to MMR above 8 months in reference regulatory authority as approved by Registration Board in its 275 th meeting.	MMR Vaccine is being used since more than 50 years in whole world including Pakistan in same age subjects 8 month and above as per WHO recommendations.	No evidence provided.
3.	☐ Proper justification with evidence of reference guidelines were “Not applicable” has been mentioned for non-clinical study reports like repeat dose toxicity studies.	1. Repeated dose toxicity: This refers to identify the toxic reactions, toxic target organs, nature and degree of toxicity reactions, and reversibility of toxicity in experimental animals or humans after administering the test substance (such as viral vaccines) multiple times within a certain period of time. This provides important evidence for the long-term safety of the vaccine. SIBP has conducted multiple animals safety evaluation trials for the MMR vaccine, including rabbit subcutaneous irritation tests and guinea pig active systemic allergic tests, etc. The results of these tests have all confirmed the safety of the vaccine. In addition, the vaccination schedule for the MMR vaccine is to administer two doses at 8 months of age and 18 months of age in China, with an interval of up to 10 months between the two doses. This longer vaccination interval period, combined with the actual usage data of a large number of people, further verifies its safety in long-term use	Multiple-dose safety has been established through local/systemic toxicity tests instead of repeat dose toxicity. Evidence is required in the light of reference guidelines where repeat dose toxicity is not mandatory.

4.	Lot summary protocol in compliance to WHO TRS.		Lot summary submitted.
5.	Evidence of acceptable shipping conditions for finished product.	Declaration from Manufacturer	Data logger data and Cold Chain Insulated Container Verification Protocol and report.
6.	Comprehensive epidemiological evidence establishing the presence, prevalence, and public health relevance of the BRD II strain within target regions	This is an established scientific fact that effectivity of MMR vaccine does not based on the type of strain in any country. It is being used by all over the world for decades regardless of country of manufacturing due to its single / mono serotype nature of all three virus present in MMR vaccine	
7.	Peer-reviewed scientific publications or technical reports substantiating claims related to the strain's performance and relevance	WHO Position Papers on Measles, Mumps, Rubella. Matched Case-Control Study of Effectiveness of Live, Attenuated Molecular evolution of Rubella viruses circulated in the mainland of China and its antigenic difference with Chinese rubella vaccine, safety and Immunogenicity of the Imported and Domestic Measles, Mumps and Rubella. Matched Case-Control Study of Effectiveness of Live, Attenuated S79 Mumps Virus Vaccine against Clinical Mumps	As per WHO position paper comparing RA27/3 with BRD II. Immunogenicity The RA27/3 strain achieves antibody titres that closely resemble those induced by natural infection. In clinical trials, 95–100% of susceptible people aged ≥9 months developed rubella antibodies after a single dose of the vaccine. A meta-analysis of 26 clinical trials showed that 99% (95% CI, 98–99%) of children aged 9–18 months seroconverted after a single dose of RA27/3-containing rubella vaccine. A second dose of rubella vaccine with the RA27/3 strain results in 100% seroconversion (99–100%). ³³ In 2 studies in China, administration of RCV1 containing the BRD II strain at the age of 8 months resulted in 91–94% seroconversion.

Conclusion

The FDI has not yet responded regarding the prevalence of the strain; however, the following information on BRD II has been provided in response to an FDI query to WHO, as outlined in the WHO position paper.

“Please find the information about the Rubella vaccine in the attached WHO position paper.

Globally, several strains of the rubella vaccine are used. The most common strain is the RA 27/3 strain, which is widely used in many countries Other strains include:

Matsuba,DCRB19,Takahashi,Matsuura,TO-336 (primarily used in Japan),BRD-2 (primarily used in China)

These strains are all live, attenuated versions of the rubella virus and are effective in preventing rubella and congenital rubella syndrome”.

Decision of 348th Meeting:

The Registration Board deferred the case for the response of FDI.

Response of applicant vide Tracking ID BH1-3MQ-9Z87 dated 13.07.2025:

This is in reference to our product MMRubivac Measles, Mumps & Rubella Combined Live Vaccine (MMR Vaccine) tracking application No. NXG-JBD-TWJ6, dated: 08-08-2024. Please find below an abstract of a study to compare the reactogenicity and immunogenicity of the BRD-2 and RA27/3 rubella vaccine conducted in China for your perusal. Also, you may find the complete study on link mentioned below.

“A study to compare the reactogenicity and immunogenicity of the BRD-2 and RA27/3 rubella vaccine strains was conducted in GuangXi, China in 1982. Ninety eight susceptible children between two and six years of age, with haemagglutination inhibition (HI) antibody titres of less than 10, were inoculated with RA27/3 vaccine strain. A similar group of 103 children were inoculated with BRD-2 vaccine strain; 110 uninoculated children served as a control group. The percentages of children who had fever reactions were 30.09% for RA27/3, 20.04% for BRD-2, and 24.50% for the uninoculated group. Neither vaccine evoked a high fever reaction. For both vaccines, the seroconversion rates estimated 42 days after immunization were 100%. The geometric mean titre of HI antibody was 144.4 +/- 2.04 for recipients of RA27/3, and 116.1 +/- 2.0 for those vaccinated with BRD-2. The rate of excretion of virus from the nose and throat was 26.67% for the recipients of RA27/3 and 23.08% for those who received BRD-2. No vaccine virus was isolated from the uninoculated susceptibles who were in close contact with the vaccinated children. Furthermore, the latter group remained seronegative when tested after 42 days of contact with the

vaccinated. Hence, it appears that both RA27/3 and BRD-2 vaccine viruses have no capacity for being transmitted to unvaccinated contacts. In susceptible adolescents immunized with the BRD-2 vaccine viruses have no capacity for being transmitted to unvaccinated contacts. In susceptible adolescents immunized with the BRD-2 vaccine strain, a mild febrile reaction was observed (ABSTRACT TRUNCATED AT 250 WORDS)".

Reference: PMID: 6531968 DOI: 10.1016/0264-410x(84)90044-6

WHO position on Rubella Vaccines:

The rubella virus, a togavirus of the genus Rubivirus, is an enveloped single-stranded RNA virus with a single serotype that does not cross-react with other togaviruses. Humans are the only known host, with seasonal epidemics occurring every 5-9 years over a worldwide distribution. Rubella virus is transmitted by the respiratory route and the virus replicates in the nose, throat and the local lymph nodes. The incubation period ranges from 12 to 23 days, with an average of 18 days. Viraemia occurs 5-7 days after exposure and leads to viral spread to different organs.

In pregnant women the virus infects the placenta and the developing fetus. Infection by rubella virus is characterized by a transient rash. Joint pain and arthritis rarely occur in children, but may affect up to 70% of adults. Rubella virus can be found in nose and throat secretions and urine from 1 week before to 2 weeks after rash onset, although infants with congenital rubella may excrete the virus for a year or more in pharyngeal secretions and urine.

Congenital rubella syndrome is caused by infection in early pregnancy; from just before conception and during the first 8-10 weeks of gestation rubella infection may result in multiple fetal defects in up to 90% of cases, affecting many organs and often results in miscarriage or stillbirth. Infants with congenital rubella syndrome that survive may face serious developmental disabilities.

Rubella vaccines

A number of vaccines are available either as single component or combined with either measles vaccine (MR) or measles and mumps vaccines (MMR). Most of the currently licensed vaccines are based on the live, attenuated RA 27/3 strain of rubella virus propagated in human diploid cells. Other attenuated rubella vaccine strains include the Matsuba, DCRB19, Takahashi, Matsuura and TO-336 strains used primarily in Japan, and the BRD-2 strain used primarily in China. Vaccination results in high (>95%) seroconversion rates and protection is generally assumed to be lifelong, although rubella antibodies may fall below detectable levels. Vaccine-induced immunity is generally assumed to be lifelong, although rubella antibodies may fall below detectable levels.

Rubella vaccine standardization

Requirements for rubella vaccines were first adopted in 1977 and amended in 1980. As rubella vaccines are routinely used in multi-antigen combinations with measles and mumps vaccines, WHO updated guidance for the three vaccines in 1992 into a single document which contains the requirements for the three monovalent vaccines and MMR.. In TRS 848 an amendment addressing the safety of the mumps antigen produced with a medium that contains serum was published.

<https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/norms-and-standards/vaccine-standardization/rubella>

Response of Federal Directorate of Immunization:

DRAP Query	Response
Presence, prevalence, and public health relevance of BRD II strain of Rubella Virus in Pakistan	For the Presence, prevalence, and public health relevance of BRD II strain of Rubella Virus in Pakistan, it is recommended that opinion may be taken from National Institute of Health (NIH).
Whether any MMR vaccines containing BRD II strain has been used in immunization program or otherwise?	Currently FDI/EPI program is utilizing MR vaccine and MMR vaccines containing BRD 11 strain has not been used in Pakistan program. However, rubella strains are cross protective and not strain specific according to the WHO position paper attached. The MR vaccine in use in Pakistan are WHO prequalified.
Recommendation of FDI for need of MMR Vaccine containing strain BRD II	Globally, several strains of the rubella vaccine are used. The most common strain is the RA 27/3 strain as per WHO position paper. Other strains in use includes; Matsuba, DCRB19, Takahashi, Matsuura, TO-336 (primarily used in Japan) and BRD-2 (primarily used in China).

Decision of 349th meeting of Registration Board:

Registration Board noted that Rubella Virus has only one serotype and that it has been reported that different strains produce the equivalent immune response. Therefore considering the WHO position paper on Rubella vaccines (July 2020), the Board approved the MMRubivac (MMR Vaccine) in name of M/s Immuno Well (Pvt) Ltd, Lahore, in accordance with the Import Policy for Finished Drugs

Case No: 2

1.	Name, address of Applicant / Marketing Authorization Holder	M/s WEATHER FOLDS PHARMACEUTICAL PLOT NO.69/2, PHASE-2, INDUSTRIAL ESTATE HATTAR
	Name, address of Manufacturing site.	M/s WEATHER FOLDS PHARMACEUTICAL PLOT NO.69/2, PHASE-2, INDUSTRIAL ESTATE HATTAR
	Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
	GMP status of the firm	Firm has submitted copy of GMP certificate dated 17/02/2022 based on inspection conducted on 27/01/2022.
	Evidence of approval of manufacturing facility	Firm has submitted copy of letter of grant of section dated specifying section 05/10/2023.
	Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
	Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
	Dy. No. and date of submission	TID: 84L-NA3-458PDated 10.07.2025
	Details of fee submitted	PKR 37000/- dated 10.07.2025
	The proposed proprietary name / brand name	Semma 0.25mg solution for Injection in Vial.
	Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each Vial Contains: Semaglutide.....4mg vial. (Product complies innovator specs)
	Pharmacotherapeutic Group of (API)	(Semaglutide) Vial, 4mg/3ml indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycemic control as an adjunct to diet and exercise.
	Pharmaceutical form of applied drug	Clear colorless solution filled in Vial.
	Reference to Finished product specifications	Innovator
	Proposed Pack size	As Per SRO
	Proposed unit price	As per SRO
	The status in reference regulatory authorities	4mg/3ml Vial.
	For generic drugs (me-too status)	Seglutide Injection by Macter Pharma
	Name and address of API manufacturer.	Manufacturer Name: Fuxin Long Rui Pharmaceutical CO. Ltd Manufacturing Site: Fluoride Industrial Park, Fumeng Country (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China.
	Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its validation, batch analysis and justification of specification,

		reference standard, container closure system and stability studies of drug substance and drug product.
	Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
	Stability Studies of Drug Substance (Conditions & duration of Stability studies)	Firm has submitted stability study data of 3 batches of drug substance at both accelerated as well as real time conditions. The accelerated stability data is conducted at 25°C ± 2°C / 60% ± 5% RH for 6 months. The real time stability data is conducted at 5°C ± 3°C for 24 months.
	Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
	Pharmaceutical Equivalence	Firm has submitted pharmaceutical equivalence of their product against the reference product.
	Analytical method validation/verification of product	Firm has submitted analytical method validation study reports for drug substance as well as drug product.

Studies conducted by API Manufacturer:

A. ACTIVE INGREDIENT SAMENESS

1. Elucidation of Structure:

Structural confirmation and analysis of IND batches of Semaglutide and Semaglutide Injection are conducted using methods including mass spectrometry molecular weight determination, amino acid composition analysis, peptide mapping coverage analysis, N-terminal and C-terminal amino acid sequence analysis, and circular dichroism analysis. The mass spectrometry molecular weight, peptide mapping coverage, N-terminal and C-terminal amino acid sequence, and modification site confirmation are self-tested. The amino acid composition and circular dichroism are tested by the National Electrochemistry and Spectroscopy Research Analysis Center of Changchun Institute of Applied Chemistry, Chinese Academy of Sciences. The test results showed that the structure of the IND batches of Semaglutide is consistent corresponding original Semaglutide Injection.

Studies conducted on Semaglutide API (Batch No. B065C120220804, B065C120220805 and B065C120220806)		
Studies Performed	Technique	Results
Molecular Weight	High-Resolution Mass Spectrometry	The molecular weight of Semaglutide in the three batches API is consistent with the theoretical molecular weight.
Peptide Coverage	RP-HPLC coupled with Mass Spectrometry	Sequences of the three batches of Semaglutide active substances are consistent with the theoretical sequence.
N-terminal/C-terminal sequence analysis (For analysis the primary higher order structure)	Mass spectrometry	N-terminal/C-terminal sequences of the three batches of the Semaglutide API are consistent with the theoretical sequences

Confirmation of Modification Sites	LC-MS/MS	Modification sites consistent with the theoretical sequence are identified in the MS/MS spectra

Comparative studies conducted on Semaglutide Injection Originator Brand (Semaglutide Injection Batch No. B051Z3202209002, B051Z3202209003 and B051Z3202209004 and Originator Product Batch No (LP57434, LP58404, KP54565))		
Studies Performed	Technique	Results
Molecular Weight Determination	High-Resolution Mass Spectrometry	The molecular weight of Semaglutide in the three batches of in-house Semaglutide Injections is consistent with the theoretical value and the original product.
Peptide Coverage	RP-HPLC coupled with Mass Spectrometry	The results indicate that the sequence of Semaglutide in the three batches of self-made Semaglutide Injection are consistent with theory and the original product.
N-terminal/C-terminal sequence analysis (For analysis the primary higher order structure)	Mass spectrometry	The experimental data indicate that the N-terminal/C-terminal sequences of Semaglutide in the in-house injections are consistent with the theoretical sequences and the original product.
Amino Acid analysis	Amino acid Analysis (Conducted by Changchun Institute of Applied Chemistry, Chinese Academy of Sciences for amino acid composition)	The amino acid composition of Semaglutide in the three batches of in-house injections is consistent with the theoretical values and the original product.
Confirmation of Modification Sites	LC-MS/MS	Modification sites consistent with originator product Sequence, identified in the MS/MS spectra
Circular Dichroism Analysis	CD spectrophotometer (Conducted by Changchun Institute of Applied Chemistry, Chinese Academy of Sciences)	The detection results showed that the secondary structure of Semaglutide in the in-house Semaglutide Injection is consistent with the original product

2. Biological Activity:

The method used is a luciferase reporter gene method for the determination of the specific activity of Semaglutide API and in finished product in comparison with the originator. The manufacturer selected an engineered cell line (HEK293/CRE-Luc/GLP1R) which stably transfected with the glucagon-like peptide-1 receptor (GLP1R) and a luciferase reporter gene plasmid (controlled by a cyclic adenosine monophosphate (cAMP)-inducible promoter). The engineered cell line is incubated with Semaglutide, and the ligand binds to the extracellular domain of GLP-1R, activating the receptor to produce cAMP. The increased level of intracellular cAMP then initiated downstream signaling cascades, leading to the expression of the luciferase reporter gene. By adding the substrate of luciferase to the final system, the enzyme reaction between the

substrate and luciferase is measured to indirectly reflect the activity of Semaglutide. Details can be reviewed in submitted DMF.

Studies conducted on Semaglutide API (Batch No. B065C120220804, B065C120220805 and B065C120220806)		
Studies Performed	Technique	Results
Determination of the specific activity of Semaglutide	Luciferase reporter gene method by using engineered cell line (HEK293/CRE-Luc/GLP1R	The specific activity results of Semaglutide in all three batches of API met the quality standard: 0.7-1.3 units of activity per 1 mg of Semaglutide

Comparative studies conducted on Semaglutide Injection Originator Brand (Semaglutide Injection Batch No. B051Z3202209002, B051Z3202209003 and B051Z3202209004 and Originator Product Batch No (LP57434, LP58404, KP54565)		
Studies Performed	Technique	Results
Determination of the specific activity of Semaglutide in finished product	Luciferase reporter gene method by using engineered cell line (HEK293/CRE-Luc/GLP1R	The specific activity results of the three batches of in-house Semaglutide Injection and three batches of original Semaglutide Injection are complied with the quality standards: calculate the specific activity based on the ratio of activity measurement results to assay measurement results, and the activity of Semaglutide should be 0.7-1.3 units per 1mg.

B. IMPURITIES

Impurities are critical quality attributes of pharmaceutical products that can affect the safety and efficacy of the product. The impurities that may exist in Semaglutide API can be categorized into **organic impurities, inorganic impurities and residual solvents** according to their chemical nature and toxicity.

a. Organic Impurities:

Organic impurities related to Semaglutide can be classified into two categories based on their sources:

- i) Impurities introduced during the manufacturing process;
- ii) Impurities related to the product itself.

i) Impurities introduced during the manufacturing process:

Through the study of the Semaglutide production process, it is found that there are five main types of impurities that are generated or introduced during the process, which may affect the final quality of the active pharmaceutical ingredient (API):

- i) Host cell residues: host proteins, host DNA.
- ii) Intermediate products in the production process: single-chain precursor, peptide main chain GLP-1.
- iii) Residual additives in the production process: Triton X-100, trifluoroacetic acid, acetic acid, recombinant enterokinase (EK), 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride, N,N'-diisopropylcarbodiimide, N-hydroxysuccinimide, N-hydroxysuccinimide sodium salt, fatty acid side chains, dipeptide, antifoaming agents.
- iv) By-products of the production process: triphenylmethanol, tert-butanol.
- v) Endotoxins and microorganisms.

Summary of fermentation-related impurities and purification-related impurities detection data in Semaglutide

Tests	Quality Standards	Results
Host protein residue	The host protein residues in each 1mg should not exceed 100ppm.	1ppm in three batches of API
Host DNA Residual	The residual amount of host DNA in each 1mg of Semaglutide should not exceed 10ng.	Conforms
Main chain residue	The peak area of the peptide main chain in the test solution should not be greater than the peak area of the peptide main chain in the control solution (the concentration of the peptide main chain control sample solution is 100ppm of the concentration of the test sample solution).	Not detected
Triton X-100 residue	The peak area of Triton X-100 in the test solution shall not exceed the peak area of Triton X-100 in the control solution 2, i.e. the residual amount shall not exceed 0.1%.	Not detected
Trifluoroacetic acid residue	According to the area normalization method, the peak area of TFA in the test solution should not exceed the peak area of TFA in the control solution, i.e. the TFA residual amount not higher than 0.3%.	Not detected
Recombinant Intestinal Kinase (EK Enzyme) Residue	The residual amount of EK enzyme in each 1mg should not exceed 10ng.	1ng/mg
(1-Ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride) Residue	The EDC peak area in the test solution should not exceed the peak area of the control solution (the concentration of the control is 0.02% of the concentration of the test).	Not detected
NHS (N-Hydroxysuccinimide) and NHS-S(NHydroxysulfosuccinimide Sodium) Residue	The peak area of NHS and NHS-S in the test solution should not exceed the peak area of NHS and NHS-S in the control solution (the concentration of the control is 0.01% of the concentration of the test).	Not detected
DIC (N,N'-Diisopropylcarbodiimide) Residue	Using the limit method, the peak area of DIC in Semaglutide should not exceed the peak area of the DIC control (the concentration of the control is 0.05% of the concentration of the test) or not be detected.	Not detected
Dipeptide and fatty acid side chain residues	Using the limit method, the peak area of fatty acid and dipeptide in the test solution should not exceed the peak area of each control solution (i.e., the limit is 0.5% for fatty acid, 0.01% for dipeptide)	Not detected
Antifoaming agent residues	The antifoaming agent peak area in the test solution shall not exceed the antifoaming agent peak area of the control solution or shall not be detected (i.e., the residue shall not be more than 0.5%).	Not detected
Triphenylmethane residue	The peak area of triphenylmethanol in the test solution shall not exceed the peak area of triphenylmethanol in the control solution2, i.e. the residue shall not exceed 0.05%.	Not detected
Tert-butanol residue	Using the limit method, the peak area of tert-butanol in Semaglutide should not exceed the peak area of tert-butanol in the control (the	Not detected

	concentration of the control is 0.05% of the concentration of the sample) or not be detected.	
Single chain precursor residue	The peak area of the single-chain precursor in the sample should be no greater than the peak area of the single-chain precursor in the control (the concentration of the single-chain precursor control solution is 10 ppm of the concentration of the sample solution).	Not detected
Dichloromethane residue	The residual amount of dichloromethane should not exceed 0.06%.	Not detected
Bacterial endotoxin	Bacterial endotoxin shall not exceed 10EU/mg.	Not detected
Microbial limit	The total number of aerobic bacteria shall not exceed 102CFU/g.	70CFU/g

ii) Impurities related to the product

Product-related impurities mainly originate from structural changes, molecular conformation changes, polymerization during the preparation of the active ingredient Semaglutide, and impurities generated during the coupling reaction. These impurities may affect the bioactivity of the API to varying degrees, and some impurities may even give rise to immunogenicity. Therefore, controlling the product-related impurities is crucial in quality control of the API. The detection data for polymer proteins and related substances in the API are listed below. Additionally, identification of impurities greater than 0.5% and macromolecular impurities in the accelerated 3M experiment has been performed.

Semaglutide related substances

Comparative table for related substances to multiple batches of Semaglutide API

Quality Indicator	Quality standards	Results		
		B065C1202 20804	B065C1202 20805	B065C1202 20906
Related Substances	In the chromatogram of the test solution, after subtracting the chromatographic peaks from the blank solution and normalizing by area, the Hydrophilic impurities (all peaks eluted before the main peak of Semaglutide) should not exceed 3.4%. Hydrophobic impurity 1 (all peaks eluted during the first isocratic elution after the main peak of Semaglutide) should not exceed 3.1%. Hydrophobic impurity 2 (all peaks eluted during the gradient elution and second isocratic elution after the main peak of Semaglutide) should not exceed 0.3%. The total impurities content should not exceed 5.5%.	Hydrophilic impurity is 0.44%; Hydrophobic impurity 1 is 0.39%; Hydrophobic impurity 2 is 0.03%; Total impurities is 0.86%	Hydrophilic impurity is 0.48%; Hydrophobic impurity 1 is 0.45%; Hydrophobic impurity 2 is 0.02%; Total impurities is 0.95%	Hydrophilic impurity is 0.34%; Hydrophobic impurity 1 is 0.40%; Hydrophobic impurity 2 is 0.04%; Total impurities is 0.78%

Comparative to multiple batches of Semaglutide Injection with Originator batches

Quality Indicator	Quality standards	Results	Results (Originator Product)

		B065C1202 20804	B065C1202 20805	B065C1202 20906	LP57434	KP54565	LP58404
Related Substances	No impurity different from the reference drug and more than 0.1%	Not more than 0.1%			Not more than 0.1%		

Analysis of polymeric impurities of Semaglutide

Tests	Quality Standards	Results
Polymeric protein	The sum of the peak areas of all polymer proteins with retention times less than the main peak of Semaglutide should not exceed 0.3%, calculated by peak area normalization.	Not more than 0.3%

b. Inorganic Impurities

Inorganic impurities in drugs are mostly introduced by the production process, the possibility of introduction in the storage process is relatively small. According to the requirements of ICH (Q3A, Q3D), United States Pharmacopoeia (USP 41) and Chinese Pharmacopoeia (2020 edition), the manufacturer has established the methods for heavy metal and sodium assay detection, and established internal control standards with reference to the pharmacopoeias of various countries and the quality standards of the original product. The analysis of 3 batches of injection solution produced by IND for heavy metal detection and 3 batches of API for sodium assay analysis. The test results were all met the internal control standards. Results can be viewed at provided DMF.

c. Residual Solvents

Residual solvents in drugs are organic solvents used in the manufacture of API or excipients, and in the preparation of formulations, but not completely removed during process operations, and are generally of known toxicity. The organic solvents involved in the manufacturing process of Semaglutide are acetonitrile, isopropanol and ethanol.

Tests	Quality Standards	Results		
		B065C1202 20804	B065C1202 20805	B065C1202 20906
Polymeric protein	The sum of the peak areas of all polymer proteins with retention times less than the main peak of Semaglutide should not exceed 0.3%, calculated by peak area normalization.	Acetonitrile is 0.015%; Isopropanol is not detected; Ethanol is 0.008%;	Acetonitrile is 0.010%; Isopropanol is 0.002%; Ethanol is 0.01%;	Acetonitrile is 0.017%; Isopropanol is 0.005%; Ethanol is 0.01%;

Studies performed by the finished product manufacturer:

1. Pharmaceutical equivalence for following parameters with reference product:

- Description,
- identification,
- pH,
- BET,
- Sterility
- Assay

2. Specifications proposed:

- Description,
- Identification,

3. pH,
4. BET,
5. Sterility
6. Assay

3. Stability Test Details

STABILITY STUDY DATA			
Manufacturer of API	Manufacturer Name: Fuxin Long Rui Pharmaceutical CO. Ltd Manufacturing Site: Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China.		
API Lot No.	H-D01-CP11224001		
Description of Pack (Container closure system)	Clear colourless solution free from particles filled in Vial in Unit carton.		
Stability Storage Condition	Real time: 5°C ± 3°C Accelerated: 25°C ± 2°C / 60% ± 5%RH		
Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	T-55	T-56	T-57
Batch Size	1500 vial	1500 vial	1500 vial
Manufacturing Date	07-2024	07-2024	07-2024
Date of Initiation	20.07.2024	20.07.2024	20.07.2024
No. of Batches	03		

Shortcomings communicated:

Sr. No.	Shortcomings	Reply
1.	Submit Module 1 as per final guidance document for biological products as attached below, including all the commitments and SMPC.	Rectified Attached.
2.	Grant of Additional Section is Biological non-rDNA Liquid Injection Vial and PFS (New). Clarification is required where the sterile batches of biological product of rDNA origin have been manufactured.	According to WHO TRS 999 guidelines, the rDNA products can be manufactured in Non-rDNA facility, hence no separate section required.
3.	Peptide mapping, related substance, HMWP, specific activity not performed on drug substance by drug product manufacturer. Clarification is required.	As stated in our Semaglutide Tablet registration, all required quality control tests are outsourced to a Government Approved Testing Laboratory. Similarly, for Semaglutide Injection, all quality control tests shall also be outsourced to a Government Approved Testing Laboratory
4.	Following tests are not included in drug product specifications identification by peptide mapping, HMWP, impurities, identity of preservative and phenol content and dose accuracy., justification is required.	As stated in our Semaglutide Tablet registration, all required quality control tests are outsourced to a Government Approved Testing Laboratory. Similarly, for Semaglutide Injection, all quality control tests shall also be outsourced to a Government Approved Testing Laboratory
5.	Submit analytical procedures and method validation	Attached

	report	
6.	Details of container closure is required i.e. primary packaging	1's Vial along with Disposable Syringes in Unit Carton Along with Leaflet.
7.	COA of reference standard is required	Attached
8.	Commercial invoice is not attested by DRAP	We imported Semaglutide and cleared via Green Channel. For reference, Goods Declaration is attached and also we have officially intimated to DRAP regarding our materials imported without Clearance Certificate. The Intimation letter with receiving is attached along with.
9.	Include following tests identification by peptide mapping, HMWP, impurities, identity of preservative and phenol content and dose accuracy in the next time point of stability testing. and submit data.	As stated in our Semaglutide Tablet registration, all required quality control tests are outsourced to a Government Approved Testing Laboratory. Similarly, for Semaglutide Injection, all quality control tests shall also be outsourced to a Government Approved Testing Laboratory.
10.	Submit in-use stability studies.	After first opening assay directly performed
11.	Stability protocol of IV-A submitted however stability sheets are of refrigerated conditions. please submit correct protocol.	It was typographical mistake, the conditions are refrigerated as the DATA logger also shows.
12.	The source of semaglutide is rDNA , submit bio similarity studies	API manufacturer and biosimilarity of the API has been as the required tests have already been performed by the established at the Drug Substance stage, these tests are not required to be repeated for the Finished Product.

Decision:

The Registration Board deferred the case for the submission of the following documents:

- Fee for correction in typographical error in storage condition for semaglutide injection, the evidence of cold storage/stability chamber for 2-8C is required.
- The manufacturing of batches is in 2024, whereas section has been granted on 25th June 2025. Clarification is required where the sterile batches of biological product have been manufactured, as no response was submitted earlier.
- Evidence of section approval in which rDNA Prefilled pen/cartidge has been manufactured, as attached evidence is of non r DNA Pre-filled syringe and vial.
- Section 3.2.S.2.2, to 3.2.S.2.3. The description of manufacturing is mandatory to mention. Provide source whether synthetic or rDNA.
- Performance of Peptide mapping, related substance, HMWP, biological activity tests on drug substance by drug product manufacturer.
- The USFDA recommends "Maximum Potency per unit dose" of propylene glycol 1.4%w/v Justification is required along with calculation in % w/v for propylene glycol and evidence of BMR .
- COA of reference standard is required.
- Inclusion of following tests identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy in the next time point of stability testing. Include the following tests in drug product specifications identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy. Also mention content of semaglutide per ml and performance of same tests in batch analysis at release and stability (where applicable).
- Data logger's data for refrigerated condition real time and accelerated condition for 6 months is required.
- The source of semaglutide is rDNA , submit bio similarity studies (Quality Comparison and clinical data/equivalence in comparison to innovator product. Provide justification where studies are "Not applicable".
- In use stability studies of drug product i.e. after first opening.

Submitted please.

Case No. 3

3.	Name, address of Applicant / Marketing Authorization Holder	M/s WEATHER FOLDS PHARMACEUTICAL PLOT NO.69/2, PHASE-2, INDUSTRIAL ESTATE HATTAR

Name, address of Manufacturing site.	M/s WEATHER FOLDS PHARMACEUTICAL PLOT NO.69/2, PHASE-2, INDUSTRIAL ESTATE HATTAR
Status of the applicant	☒ Manufacturer ☐ Importer ☐ Is involved in none of the above (contract giver)
GMP status of the firm	Firm has submitted copy of GMP certificate dated 17/02/2022 based on inspection conducted on 27/01/2022.
Evidence of approval of manufacturing facility	Firm has submitted copy of letter of grant of section dated specifying section 05/10/2023.
Status of application	☐ New Drug Product (NDP) ☒ Generic Drug Product (GDP)
Intended use of pharmaceutical product	☐ Domestic sale ☐ Export sale ☒ Domestic and Export sales
Dy. No. and date of submission	TID: <u>SMQ-ZX5-XQXB</u> Dated 10.07.2025
Details of fee submitted	PKR 37000/- dated 10.07.2025
The proposed proprietary name / brand name	Semma 0.25mg solution for Injection in Vial.
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each 1.5 ml Vial Contains: Semaglutide.....2mg vial. (Product complies innovator specs)
Pharmacotherapeutic Group of (API)	(Semaglutide) Vial, 4mg/3ml indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycemic control as an adjunct to diet and exercise.
Pharmaceutical form of applied drug	Clear colorless solution filled in Vial.
Reference to Finished product specifications	Innovator
Proposed Pack size	As Per SRO
Proposed unit price	As per SRO
The status in reference regulatory authorities	4mg/3ml Vial.
For generic drugs (me-too status)	Seglutide Injection by Macter Pharma
Name and address of API manufacturer.	Manufacturer Name: Fuxin Long Rui Pharmaceutical CO. Ltd Manufacturing Site: Fluoride Industrial Park, Fumeng Country (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China.
Module-II (Quality Overall Summary)	Firm has submitted QOS as per WHO QOS-PD template. Firm has summarized information related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance and drug product.
Module-III Drug Substance:	Firm has submitted detailed drug substance data related to nomenclature, structure, general properties, solubilities, physical form, manufacturers, description of manufacturing process and controls, specifications, analytical procedures and its validation, batch analysis and justification of specification, reference standard, container closure system and stability studies of drug substance.
Stability Studies of Drug Substance	Firm has submitted stability study data of 3 batches of drug substance at

(Conditions & duration of Stability studies)	both accelerated as well as real time conditions. The accelerated stability data is conducted at 25°C ± 2°C / 60% ± 5% RH for 6 months. The real time stability data is conducted at 5°C ± 3°C for 24 months.
Module-III Drug Product:	Firm has submitted data of drug product including its description, composition, pharmaceutical development, manufacture, manufacturing process and process control, process validation protocols, control of excipients, control of drug product, specifications, analytical procedures, validation of analytical procedures, batch analysis, justification of specifications, reference standard or materials, container closure system and stability.
Pharmaceutical Equivalence	Firm has submitted pharmaceutical equivalence of their product against the reference product.
Analytical method validation/verification of product	Firm has submitted analytical method validation study reports for drug substance as well as drug product.

Studies conducted by API Manufacturer:

C. ACTIVE INGREDIENT SAMENESS

1. Elucidation of Structure:

Structural confirmation and analysis of IND batches of Semaglutide and Semaglutide Injection are conducted using methods including mass spectrometry molecular weight determination, amino acid composition analysis, peptide mapping coverage analysis, N-terminal and C-terminal amino acid sequence analysis, and circular dichroism analysis. The mass spectrometry molecular weight, peptide mapping coverage, N-terminal and C-terminal amino acid sequence, and modification site confirmation are self-tested. The amino acid composition and circular dichroism are tested by the National Electrochemistry and Spectroscopy Research Analysis Center of Changchun Institute of Applied Chemistry, Chinese Academy of Sciences. The test results showed that the structure of the IND batches of Semaglutide is consistent corresponding original Semaglutide Injection.

Studies conducted on Semaglutide API (Batch No. B065C120220804, B065C120220805 and B065C120220806)		
Studies Performed	Technique	Results
Molecular Weight	High-Resolution Mass Spectrometry	The molecular weight of Semaglutide in the three batches API is consistent with the theoretical molecular weight.
Peptide Coverage	RP-HPLC coupled with Mass Spectrometry	Sequences of the three batches of Semaglutide active substances are consistent with the theoretical sequence.
N-terminal/C-terminal sequence analysis (For analysis the primary higher order structure)	Mass spectrometry	N-terminal/C-terminal sequences of the three batches of the Semaglutide API are consistent with the theoretical sequences
Confirmation of Modification Sites	LC-MS/MS	Modification sites consistent with the theoretical sequence are identified in the MS/MS spectra

Comparative studies conducted on Semaglutide Injection Originator Brand (Semaglutide Injection Batch No. B051Z3202209002, B051Z3202209003 and B051Z3202209004 and Originator Product Batch No (LP57434, LP58404, KP54565)		
Studies Performed	Technique	Results

Molecular Weight Determination	High-Resolution Mass Spectrometry	The molecular weight of Semaglutide in the three batches of in-house Semaglutide Injections is consistent with the theoretical value and the original product.
Peptide Coverage	RP-HPLC coupled with Mass Spectrometry	The results indicate that the sequence of Semaglutide in the three batches of self-made Semaglutide Injection are consistent with theory and the original product.
N-terminal/C-terminal sequence analysis (For analysis the primary higher order structure)	Mass spectrometry	The experimental data indicate that the N-terminal/C-terminal sequences of Semaglutide in the in-house injections are consistent with the theoretical sequences and the original product.
Amino Acid analysis	Amino acid Analysis (Conducted by Changchun Institute of Applied Chemistry, Chinese Academy of Sciences for amino acid composition)	The amino acid composition of Semaglutide in the three batches of in-house injections is consistent with the theoretical values and the original product.
Confirmation of Modification Sites	LC-MS/MS	Modification sites consistent with originator product Sequence, identified in the MS/MS spectra
Circular Dichroism Analysis	CD spectrophotometer (Conducted by Changchun Institute of Applied Chemistry, Chinese Academy of Sciences)	The detection results showed that the secondary structure of Semaglutide in the in-house Semaglutide Injection is consistent with the original product

2. Biological Activity:

The method used is a luciferase reporter gene method for the determination of the specific activity of Semaglutide API and in finished product in comparison with the originator. The manufacturer selected an engineered cell line (HEK293/CRE-Luc/GLP1R) which stably transfected with the glucagon-like peptide-1 receptor (GLP1R) and a luciferase reporter gene plasmid (controlled by a cyclic adenosine monophosphate (cAMP)-inducible promoter). The engineered cell line is incubated with Semaglutide, and the ligand binded to the extracellular domain of GLP-1R, activating the receptor to produce cAMP. The increased level of intracellular cAMP then initiated downstream signaling cascades, leading to the expression of the luciferase reporter gene. By adding the substrate of luciferase to the final system, the enzyme reaction between the substrate and luciferase is measured to indirectly reflect the activity of Semaglutide. Details can be reviewed in submitted DMF.

Studies conducted on Semaglutide API (Batch No. B065C120220804, B065C120220805 and B065C120220806)		
Studies Performed	Technique	Results
Determination of the specific activity of Semaglutide	Luciferase reporter gene method by using engineered cell line (HEK293/CRE-Luc/GLP1R)	The specific activity results of Semaglutide in all three batches of API met the quality standard: 0.7-1.3 units of activity per 1 mg of Semaglutide

Comparative studies conducted on Semaglutide Injection Originator Brand (Semaglutide Injection Batch No. B051Z3202209002, B051Z3202209003 and B051Z3202209004 and Originator Product Batch No (LP57434, LP58404, KP54565))		
Studies Performed	Technique	Results

Determination of the specific activity of Semaglutide in finished product	Luciferase reporter gene method by using engineered cell line (HEK293/CRE-Luc/GLP1R	The specific activity results of the three batches of in-house Semaglutide Injection and three batches of original Semaglutide Injection are complied with the quality standards: calculate the specific activity based on the ratio of activity measurement results to assay measurement results, and the activity of Semaglutide should be 0.7-1.3 units per 1mg.

D. IMPURITIES

Impurities are critical quality attributes of pharmaceutical products that can affect the safety and efficacy of the product. The impurities that may exist in Semaglutide API can be categorized into **organic impurities, inorganic impurities and residual solvents** according to their chemical nature and toxicity.

d. Organic Impurities:

Organic impurities related to Semaglutide can be classified into two categories based on their sources:

- iii) Impurities introduced during the manufacturing process;
- iv) Impurities related to the product itself.

ii) Impurities introduced during the manufacturing process:

Through the study of the Semaglutide production process, it is found that there are five main types of impurities that are generated or introduced during the process, which may affect the final quality of the active pharmaceutical ingredient (API):

- vi) Host cell residues: host proteins, host DNA.
- vii) Intermediate products in the production process: single-chain precursor, peptide main chain GLP-1.
- viii) Residual additives in the production process: Triton X-100, trifluoroacetic acid, acetic acid, recombinant enterokinase (EK), 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride, N,N'-diisopropylcarbodiimide, N-hydroxysuccinimide, N-hydroxysuccinimide sodium salt, fatty acid side chains, dipeptide, antifoaming agents.
- ix) By-products of the production process: triphenylmethanol, tert-butanol.
- x) Endotoxins and microorganisms.

Summary of fermentation-related impurities and purification-related impurities detection data in Semaglutide

Tests	Quality Standards	Results
Host protein residue	The host protein residues in each 1mg should not exceed 100ppm.	1ppm in three batches of API
Host DNA Residual	The residual amount of host DNA in each 1mg of Semaglutide should not exceed 10ng.	Conforms
Main chain residue	The peak area of the peptide main chain in the test solution should not be greater than the peak area of the peptide main chain in the control solution (the concentration of the peptide main chain control sample solution is 100ppm of the concentration of the test sample solution).	Not detected
Triton X-100 residue	The peak area of Triton X-100 in the test solution shall not exceed the peak area of Triton X-100 in the control solution 2, i.e. the residual amount shall not exceed 0.1%.	Not detected
Trifluoroacetic acid residue	According to the area normalization method, the peak area of TFA in the test solution should	Not detected

	not exceed the peak area of TFA in the control solution, i.e. the TFA residual amount not higher than 0.3%.	
Recombinant Intestinal Kinase (EK Enzyme) Residue	The residual amount of EK enzyme in each 1mg should not exceed 10ng.	1ng/mg
(1-Ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride) Residue	The EDC peak area in the test solution should not exceed the peak area of the control solution (the concentration of the control is 0.02% of the concentration of the test).	Not detected
NHS (N-Hydroxysuccinimide) and NHS-S(N-Hydroxysulfosuccinimide Sodium) Residue	The peak area of NHS and NHS-S in the test solution should not exceed the peak area of NHS and NHS-S in the control solution (the concentration of the control is 0.01% of the concentration of the test).	Not detected
DIC (N,N'-Diisopropylcarbodiimide) Residue	Using the limit method, the peak area of DIC in Semaglutide should not exceed the peak area of the DIC control (the concentration of the control is 0.05% of the concentration of the test) or not be detected.	Not detected
Dipeptide and fatty acid side chain residues	Using the limit method, the peak area of fatty acid and dipeptide in the test solution should not exceed the peak area of each control solution (i.e., the limit is 0.5% for fatty acid, 0.01% for dipeptide)	Not detected
Antifoaming agent residues	The antifoaming agent peak area in the test solution shall not exceed the antifoaming agent peak area of the control solution or shall not be detected (i.e., the residue shall not be more than 0.5%).	Not detected
Triphenylmethane residue	The peak area of triphenylmethanol in the test solution shall not exceed the peak area of triphenylmethanol in the control solution ² , i.e. the residue shall not exceed 0.05%.	Not detected
Tert-butanol residue	Using the limit method, the peak area of tert-butanol in Semaglutide should not exceed the peak area of tert-butanol in the control (the concentration of the control is 0.05% of the concentration of the sample) or not be detected.	Not detected
Single chain precursor residue	The peak area of the single-chain precursor in the sample should be no greater than the peak area of the single-chain precursor in the control (the concentration of the single-chain precursor control solution is 10 ppm of the concentration of the sample solution).	Not detected
Dichloromethane residue	The residual amount of dichloromethane should not exceed 0.06%.	Not detected
Bacterial endotoxin	Bacterial endotoxin shall not exceed 10EU/mg.	Not detected
Microbial limit	The total number of aerobic bacteria shall not exceed 102CFU/g.	70CFU/g

iii) Impurities related to the product

Product-related impurities mainly originate from structural changes, molecular conformation changes, polymerization during the preparation of the active ingredient Semaglutide, and impurities generated during the coupling reaction. These impurities may affect the bioactivity of the API to varying degrees, and some impurities may even give rise to immunogenicity. Therefore, controlling the product-related impurities is crucial in quality control of the API. The

detection data for polymer proteins and related substances in the API are listed below. Additionally, identification of impurities greater than 0.5% and macromolecular impurities in the accelerated 3M experiment has been performed.

Semaglutide related substances

**Comparative table for related substances to multiple batches of
Semaglutide API**

Quality Indicator	Quality standards	Results		
		B065C1202 20804	B065C1202 20805	B065C1202 20906
Related Substances	In the chromatogram of the test solution, after subtracting the chromatographic peaks from the blank solution and normalizing by area, the Hydrophilic impurities (all peaks eluted before the main peak of Semaglutide) should not exceed 3.4%. Hydrophobic impurity 1 (all peaks eluted during the first isocratic elution after the main peak of Semaglutide) should not exceed 3.1%. Hydrophobic impurity 2 (all peaks eluted during the gradient elution and second isocratic elution after the main peak of Semaglutide) should not exceed 0.3%. The total impurities content should not exceed 5.5%.	Hydrophilic impurity is 0.44%; Hydrophobic impurity 1 is 0.39%; Hydrophobic impurity 2 is 0.03%; Total impurities is 0.86%	Hydrophilic impurity is 0.48%; Hydrophobic impurity 1 is 0.45%; Hydrophobic impurity 2 is 0.02%; Total impurities is 0.95%	Hydrophilic impurity is 0.34%; Hydrophobic impurity 1 is 0.40%; Hydrophobic impurity 2 is 0.04%; Total impurities is 0.78%

**Comparative to multiple batches of
Semaglutide Injection with Originator batches**

Quality Indicator	Quality standards	Results			Results (Originator Product)		
		B065C1202 20804	B065C1202 20805	B065C1202 20906	LP57434	KP54565	LP58404
Related Substances	No impurity different from the reference drug and more than 0.1%	Not more than 0.1%			Not more than 0.1%		

Analysis of polymeric impurities of Semaglutide

Tests	Quality Standards	Results
Polymeric protein	The sum of the peak areas of all polymer proteins with retention times less than the main peak of Semaglutide should not exceed 0.3%, calculated by peak area normalization.	Not more than 0.3%

e. Inorganic Impurities

Inorganic impurities in drugs are mostly introduced by the production process, the possibility of introduction in the storage process is relatively small. According to the requirements of ICH (Q3A, Q3D), United States Pharmacopoeia (USP 41) and Chinese Pharmacopoeia (2020 edition), the manufacturer has established the methods for heavy metal and sodium assay detection, and established internal control standards with reference to the pharmacopoeias of various countries and the quality standards of the original product. The analysis of 3 batches of injection solution produced by IND for heavy metal detection and 3 batches of API for sodium assay analysis. The test results were all met the internal control standards. Results can be viewed at provided DMF.

f. Residual Solvents

Residual solvents in drugs are organic solvents used in the manufacture of API or excipients, and in the preparation of formulations, but not completely removed during process operations, and are generally of known toxicity. The organic solvents involved in the manufacturing process of Semaglutide are acetonitrile, isopropanol and ethanol.

Tests	Quality Standards	Results		
		B065C1202 20804	B065C1202 20805	B065C1202 20906
Polymeric protein	The sum of the peak areas of all polymer proteins with retention times less than the main peak of Semaglutide should not exceed 0.3%, calculated by peak area normalization.	Acetonitrile is 0.015%; Isopropanol is not detected; Ethanol is 0.008%;	Acetonitrile is 0.010%; Isopropanol is 0.002%; Ethanol is 0.01%;	Acetonitrile is 0.017%; Isopropanol is 0.005%; Ethanol is 0.01%;

Studies performed by the finished product manufacturer:

1. Pharmaceutical equivalence for following parameters with reference product:

- Description,
- identification,
- pH,
- BET,
- Sterility
- Assay

2. Specifications proposed:

- Description,
- Identification,
- pH,
- BET,
- Sterility
- Assay

3. Stability Test Details

STABILITY STUDY DATA		
Manufacturer of API	Manufacturer Name: Fuxin Long Rui Pharmaceutical CO. Ltd Manufacturing Site: Fluoride Industrial Park, Fumeng County (Yi Ma Tu), Fuxin City, Liaoning Province -123000, China.	
API Lot No.	H-D01-CP11224001	
Description of Pack (Container closure system)	Clear colourless solution free from particles filled in Vial in Unit carton.	
Stability Condition	Storage	Real time: 5°C ± 3°C Accelerated: 25°C ± 2°C / 60% ± 5%RH

Time Period	Real time: 6 months Accelerated: 6 months		
Frequency	Accelerated: 0, 3, 6 (Months) Real Time: 0, 3, 6 (Months)		
Batch No.	T-55	T-56	T-57
Batch Size	1500 vial	1500 vial	1500 vial
Manufacturing Date	07-2024	07-2024	07-2024
Date of Initiation	20.07.2024	20.07.2024	20.07.2024
No. of Batches	03		

Shortcomings communicated:

Sr. No.	Shortcomings	Reply
1.	Submit Module 1 as per final guidance document for biological products as attached below, including all the commitments and SMPC.	Rectified Attached.
2.	Grant of Additional Section is Biological non-rDNA Liquid Injection Vial and PFS (New).Clarification is required where the sterile batches of biological product of rDNA origin have been manufactured.	According to WHO TRS 999 guidelines, the rDNA products can be manufactured in Non-rDNA facility, hence no separate section required.
3.	Peptide mapping, related substance, HMWP, specific activity not performed on drug substance by drug product manufacturer. Clarification is required.	As stated in our Semaglutide Tablet registration, all required quality control tests are outsourced to a Government Approved Testing Laboratory. Similarly, for Semaglutide Injection, all quality control tests shall also be outsourced to a Government Approved Testing Laboratory
4.	Following tests are not included in drug product specifications identification by peptide mapping, HMWP, impurities, identity of preservative and phenol content and dose accuracy., justification is required.	As stated in our Semaglutide Tablet registration, all required quality control tests are outsourced to a Government Approved Testing Laboratory. Similarly, for Semaglutide Injection, all quality control tests shall also be outsourced to a Government Approved Testing Laboratory
5.	Submit analytical procedures and method validation report	Attached
6.	Details of container closure is required i.e. primary packaging	1's Vial along with Disposable Syringes in Unit Carton Along with Leaflet.
7.	COA of reference standard is required	Attached
8.	Commercial invoice is not attested by DRAP	We imported Semaglutide and cleared via Green Channel. For reference, Goods Declaration is attached and also we have officially intimated to DRAP regarding our materials imported without Clearance Certificate. The Intimation letter with receiving is attached along with.
9.	Include following tests identification by peptide mapping, HMWP, impurities, identity of preservative and phenol content and dose accuracy in the next time point of stability testing. and submit data.	As stated in our Semaglutide Tablet registration, all required quality control tests are outsourced to a Government Approved Testing Laboratory. Similarly, for Semaglutide Injection, all quality control tests shall also be outsourced to a Government Approved Testing Laboratory.
10.	Submit in-use stability studies.	After first opening assay directly performed
11.	Stability protocol of IV-A submitted however stability	It was typographical mistake, the conditions are

	sheets are of refrigerated conditions. please submit correct protocol.	refrigerated as the DATA logger also shows.
12.	The source of semaglutide is rDNA , submit bio similarity studies	API manufacturer and biosimilarity of the API has been As the required tests have already been performed by the established at the Drug Substance stage, these tests are not required to be repeated for the Finished Product.

Decision:

The Registration Board deferred the case for the submission of the following documents:

- Fee for correction in typographical error in storage condition for semaglutide injection, the evidence of cold storage/stability chamber for 2-8C is required.
- The manufacturing of batches is in 2024, whereas section has been granted on 25th June 2025. Clarification is required where the sterile batches of biological product have been manufactured, as no response was submitted earlier.
- Evidence of section approval in which rDNA Prefilled pen/cartridge has been manufactured, as attached evidence is of non r DNA Pre-filled syringe and vial.
- Section 3.2.S.2.2, to 3.2.S.2.3. The description of manufacturing is mandatory to mention. Provide source whether synthetic or rDNA.
- Performance of Peptide mapping, related substance, HMWP, biological activity tests on drug substance by drug product manufacturer.
- The USFDA recommends "Maximum Potency per unit dose" of propylene glycol 1.4%w/v Justification is required along with calculation in % w/v for propylene glycol and evidence of BMR .
- COA of reference standard is required.
- Inclusion of following tests identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy in the next time point of stability testing. Include the following tests in drug product specifications identification by peptide mapping, HMWP, impurities, bacterial endotoxins, identity of preservative and phenol content and dose accuracy. Also mention content of semaglutide per ml and performance of same tests in batch analysis at release and stability (where applicable).
- Data logger's data for refrigerated condition real time and accelerated condition for 6 months is required.
- The source of semaglutide is rDNA , submit bio similarity studies (Quality Comparison and clinical data/equivalence in comparison to innovator product. Provide justification where studies are "Not applicable".
- In use stability studies of drug product i.e. after first opening.

Contract manufacturing applications:

Case#1	
Name, address of Applicant / Importer	M/s Wnsfeild Pharmaceuticals Company Address: Plot No.122, Block-A, Phase-V, Industrial Estate, Hattar, KPK
Status of the applicant	Contract Giver
Name, address of manufacturer(s)	M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK
GMP of manufacturer & Evidence of Section	DML No. 000644 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan Evidence of section biological tablet products (biological) section dated 25th October, 2023 GMP: Last GMP conducted on 12-10-2022 valid up to 1-10-2024
Status of application	Generic Drug Product (GDP)
Intended use of pharmaceutical product	Domestic and Export sales
Dy. No. and Date of submission	Tracking ID: 87Z-9ZP-D24P Application Number: 59163

	Date of Receiving: 2025-02-17
Details of fee submitted	Challan Number: 656889537892 Division: Biological Evaluation & Registration Paid Fee: Rs 93,000/- Paid Date: 2024-10-25
The proposed proprietary name / brand name	Semma tablet 3mg
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Semaglutide...3mg
Pharmaceutical form of applied drug	Tablet
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	As per Innovator's Specifications
Proposed Pack size	As per SRO
Proposed unit price	As per SRO
Shelf Life	2 Years
Storage Condition	Store Below 25°C
The status in reference regulatory authorities	Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark
For generic drugs (me-too status)	Rybelsus by Novo Nordisk
Name, address of drug substance manufacturer	M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One Road, Qingyuan City, Guangdong Province, China.(rDNA origin)
Data Already Approved on CTD	Yes
Meeting No.	340

Evaluation by BE&R

Observations	Applicant Response
- Status of BE studies for already registered product of contract acceptor. - Evidence of installation of LC-MS for performance of peptide mapping along with qualification documents (IQ/OQ/PQ). - Applicant shall submit a declaration that they will adopt the same source of drug substance, drug product formulation, specifications and container closure. - Applicant shall submit a declaration, in case of any post-registration variation by the contract manufacturer, same shall	Regarding the status of BE studies and installation of LC-MS for peptide mapping along with qualification documents, we would like to clarify that we are the Contract Giver for Semaglutide Tablet on basis of Approved Product by Drug Registration Board, and the question should be directed to the registration holder, M/s Weather Folds Pharmaceuticals, as we act solely as the Contract Giver. We reaffirm our commitment to following the same source of drug substance, drug product formulation, specifications, and container closure system as M/s Weather Folds Pharmaceuticals.

be immediately applied by the applicant/ registration holder f or requisite approval by Registration Board.	Additionally, we would like to highlight that the Contract Application of M/s Jupiter Pharmaceuticals has already been approved of the same product from M/s Weather Folds Pharmaceuticals, and the registration letter has been issued.

Case#2	
Name, address of Applicant / Importer	M/s Wnsfeild Pharmaceuticals Company Address: Plot No.122, Block-A, Phase-V, Industrial Estate, Hattar, KPK
Status of the applicant	Contract Giver
Name, address of manufacturer(s)	M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK
GMP of manufacturer & Evidence of Section	DML No. 000644 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan Evidence of section biological tablet products (biological) section dated 25th October, 2023 GMP: Last GMP conducted on 12-10-2022 valid up to 1-10-2024
Status of application	Generic Drug Product (GDP)
Intended use of pharmaceutical product	Domestic and Export sales
Dy. No. and Date of submission	Tracking ID: HWY-UB5-VNUM Application Number: 59166 Date of Receiving: 2025-02-17
Details of fee submitted	Challan Number: 29534410754 Division: Biological Evaluation & Registration Paid Fee: Rs 93,000/- Paid Date: 2024-10-25
The proposed proprietary name / brand name	Semma tablet 7mg
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Semaglutide...7mg
Pharmaceutical form of applied drug	Tablet
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	As per Innovator's Specifications
Proposed Pack size	As per SRO
Proposed unit price	As per SRO
Shelf Life	2 Years
Storage Condition	Store Below 25°C
The status in reference regulatory authorities	Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark

For generic drugs (me-too status)	Rybelsus by Novo Nordisk
Name, address of drug substance manufacturer	M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One Road, Qingyuan City, Guangdong Province, China.(rDNA origin)
Data Already Approved on CTD	Yes
Meeting No.	340

Evaluation by BE&R

Observations	Applicant Response
• Status of BE studies for already registered product of contract acceptor. • Evidence of installation of LC-MS for performance of peptide mapping along with qualification documents (IQ/OQ/PQ). • Applicant shall submit a declaration that they will adopt the same source of drug substance, drug product formulation, specifications and container closure. • Applicant shall submit a declaration, in case of any post-registration variation by the contract manufacturer, same shall be immediately applied by the applicant/ registration holder f or requisite approval by Registration Board.	Regarding the status of BE studies and installation of LC-MS for peptide mapping along with qualification documents, we would like to clarify that we are the Contract Giver for Semaglutide Tablet on basis of Approved Product by Drug Registration Board, and the question should be directed to the registration holder, M/s Weather Folds Pharmaceuticals, as we act solely as the Contract Giver. We reaffirm our commitment to following the same source of drug substance, drug product formulation, specifications, and container closure system as M/s Weather Folds Pharmaceuticals. Additionally, we would like to highlight that the Contract Application of M/s Jupiter Pharmaceuticals has already been approved of the same product from M/s Weather Folds Pharmaceuticals, and the registration letter has been issued.

Case#3

Name, address of Applicant / Importer	M/s Wnsfeild Pharmaceuticals Company Address: Plot No.122, Block-A, Phase-V, Industrial Estate, Hattar, KPK
Status of the applicant	Contract Giver
Name, address of manufacturer(s)	M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK
GMP of manufacturer & Evidence of Section	DML No. 000644 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan Evidence of section biological tablet products (biological) section dated 25th October, 2023 GMP: Last GMP conducted on 12-10-2022 valid up to 1-10-2024
Status of application	Generic Drug Product (GDP)
Intended use of pharmaceutical product	Domestic and Export sales

Dy. No. and Date of submission	Tracking ID: G16-N79-HPJ5 Application Number: 59167 Date of Receiving: 2025-02-17
Details of fee submitted	Challan Number: 1627760584 Division: Biological Evaluation & Registration Paid Fee: Rs 93,000/- Paid Date: 2024-10-25
The proposed proprietary name / brand name	Semma tablet 14mg
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Semaglutide...14mg
Pharmaceutical form of applied drug	Tablet
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	As per Innovator's Specifications
Proposed Pack size	As per SRO
Proposed unit price	As per SRO
Shelf Life	2 Years
Storage Condition	Store Below 25°C
The status in reference regulatory authorities	Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark
For generic drugs (me-too status)	Rybelsus by Novo Nordisk
Name, address of drug substance manufacturer	M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One Road, Qingyuan City, Guangdong Province, China.(rDNA origin)
Data Already Approved on CTD	Yes
Meeting No.	340

Evaluation by BE&R

Observations	Applicant Response
- Status of BE studies for already registered product of contract acceptor. - Evidence of installation of LC-MS for performance of peptide mapping along with qualification documents (IQ/OQ/PQ). - Applicant shall submit a declaration that they will adopt the same source of drug substance, drug product formulation, specifications and container closure. - Applicant shall submit a declaration, in case of any post-	Regarding the status of BE studies and installation of LC-MS for peptide mapping along with qualification documents, we would like to clarify that we are the Contract Giver for Semaglutide Tablet on basis of Approved Product by Drug Registration Board, and the question should be directed to the registration holder, M/s Weather Folds Pharmaceuticals, as we act solely as the Contract Giver. We reaffirm our commitment to following the same source of drug substance, drug product formulation, specifications, and container closure system

registration variation by the contract manufacturer, same shall be immediately applied by the applicant/ registration holder f or requisite approval by Registration Board.	as M/s Weather Folds Pharmaceuticals. Additionally, we would like to highlight that the Contract Application of M/s Jupiter Pharmaceuticals has already been approved of the same product from M/s Weather Folds Pharmaceuticals, and the registration letter has been issued.

Case#4	
Name, address of Applicant / Importer	M/s Wenovo Pharmaceuticals Company Address: Plot No. 31-32, Punjab Small Industrial Estate, Taxila.
Status of the applicant	Contract Giver
Name, address of manufacturer(s)	M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK
GMP of manufacturer & Evidence of Section	DML No. 000644 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan Evidence of section biological tablet products (biological) section dated 25th October, 2023 GMP: Last GMP conducted on 12-10-2022 valid up to 1-10-2024
Status of application	Generic Drug Product (GDP)
Intended use of pharmaceutical product	Domestic and Export sales
Dy. No. and Date of submission	Tracking ID: JB2-YSN-5UVR Application Number: 59274 Date of Receiving: 2025-02-17
Details of fee submitted	Challan Number: 5091429670 Division: Biological Evaluation & Registration Paid Fee: Rs 93,000/- Paid Date: 2024-10-25
The proposed proprietary name / brand name	Semkin tablet 3mg
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Semaglutide...3mg
Pharmaceutical form of applied drug	Tablet
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	As per Innovator's Specifications
Proposed Pack size	As per SRO
Proposed unit price	As per SRO
Shelf Life	2 Years
Storage Condition	Store Below 25°C

The status in reference regulatory authorities	Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark
For generic drugs (me-too status)	Rybelsus by Novo Nordisk
Name, address of drug substance manufacturer	M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One Road, Qingyuan City, Guangdong Province, China.(rDNA origin)
Data Already Approved on CTD	Yes
Meeting No.	340

Evaluation by BE&R

Observations	Applicant Response
• Status of BE studies for already registered product of contract acceptor. • Evidence of installation of LC-MS for performance of peptide mapping along with qualification documents (IQ/OQ/PQ). • Applicant shall submit a declaration that they will adopt the same source of drug substance, drug product formulation, specifications and container closure. • Applicant shall submit a declaration, in case of any post-registration variation by the contract manufacturer, same shall be immediately applied by the applicant/ registration holder f or requisite approval by Registration Board.	Regarding the status of BE studies and installation of LC-MS for peptide mapping along with qualification documents, we would like to clarify that we are the Contract Giver for Semaglutide Tablet on basis of Approved Product by Drug Registration Board, and the question should be directed to the registration holder, M/s Weather Folds Pharmaceuticals, as we act solely as the Contract Giver. We reaffirm our commitment to following the same source of drug substance, drug product formulation, specifications, and container closure system as M/s Weather Folds Pharmaceuticals. Additionally, we would like to highlight that the Contract Application of M/s Jupiter Pharmaceuticals has already been approved of the same product from M/s Weather Folds Pharmaceuticals, and the registration letter has been issued.

Case#5

Name, address of Applicant / Importer	M/s Wenovo Pharmaceuticals Company Address: Plot No. 31-32, Punjab Small Industrial Estate, Taxila.
Status of the applicant	Contract Giver
Name, address of manufacturer(s)	M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK
GMP of manufacturer & Evidence of Section	DML No. 000644 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan Evidence of section biological tablet products (biological) section dated 25th October, 2023 GMP: Last GMP conducted on 12-10-2022 valid up to 1-10-2024
Status of application	Generic Drug Product (GDP)

Intended use of pharmaceutical product	Domestic and Export sales
Dy. No. and Date of submission	Tracking ID: NHA-4YB-4MMW Application Number: 59282 Date of Receiving: 2025-02-17
Details of fee submitted	Challan Number: 53296991479 Division: Biological Evaluation & Registration Paid Fee: Rs 93,000/- Paid Date: 2024-10-25
The proposed proprietary name / brand name	Semkin tablet 7mg
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Semaglutide...7mg
Pharmaceutical form of applied drug	Tablet
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	As per Innovator's Specifications
Proposed Pack size	As per SRO
Proposed unit price	As per SRO
Shelf Life	2 Years
Storage Condition	Store Below 25°C
The status in reference regulatory authorities	Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark
For generic drugs (me-too status)	Rybelsus by Novo Nordisk
Name, address of drug substance manufacturer	M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One Road, Qingyuan City, Guangdong Province, China.(rDNA origin)
Data Already Approved on CTD	Yes
Meeting No.	340

=Evaluation by BE&R

Observations	Applicant Response
- Status of BE studies for already registered product of contract acceptor. - Evidence of installation of LC-MS for performance of peptide mapping along with qualification documents (IQ/OQ/PQ). - Applicant shall submit a declaration that they will adopt the same source of drug substance, drug product formulation, specifications and container closure. - Applicant shall submit a declaration, in case of any post-registration variation by the contract manufacturer, same shall be immediately applied by the applicant/ registration holder f or requisite approval by Registration Board.	Regarding the status of BE studies and installation of LC-MS for peptide mapping along with qualification documents, we would like to clarify that we are the Contract Giver for Semaglutide Tablet on basis of Approved Product by Drug Registration Board, and the question should be directed to the registration holder, M/s Weather Folds Pharmaceuticals, as we act solely as the Contract Giver. We reaffirm our commitment to following the same source of drug substance, drug product formulation, specifications, and container closure system as M/s Weather Folds Pharmaceuticals. Additionally, we would like to highlight that the Contract Application of M/s Jupiter Pharmaceuticals has already been approved of the same product from M/s Weather Folds Pharmaceuticals, and the registration letter has been issued.

Case#6

Name, address of Applicant / Importer	M/s Wenovo Pharmaceuticals Company Address: Plot No. 31-32, Punjab Small Industrial Estate, Taxila.
Status of the applicant	Contract Giver
Name, address of manufacturer(s)	M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK
GMP of manufacturer & Evidence of Section	DML No. 000644 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan Evidence of section biological tablet products (biological) section dated 25th October, 2023 GMP: Last GMP conducted on 12-10-2022 valid up to 1-10-2024
Status of application	Generic Drug Product (GDP)
Intended use of pharmaceutical product	Domestic and Export sales
Dy. No. and Date of submission	Tracking ID: 5NG-XWD-2B11 Application Number: 59283 Date of Receiving: 2025-02-17
Details of fee submitted	Challan Number: 516373427 Division: Biological Evaluation & Registration Paid Fee: Rs 93,000/- Paid Date: 2024-10-25

The proposed proprietary name / brand name	Semkin tablet 14mg
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Semaglutide...14mg
Pharmaceutical form of applied drug	Tablet
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	As per Innovator's Specifications
Proposed Pack size	As per SRO
Proposed unit price	As per SRO
Shelf Life	2 Years
Storage Condition	Store Below 25°C
The status in reference regulatory authorities	Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark
For generic drugs (me-too status)	Rybelsus by Novo Nordisk
Name, address of drug substance manufacturer	M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One Road, Qingyuan City, Guangdong Province, China.(rDNA origin)
Data Already Approved on CTD	Yes
Meeting No.	340

Evaluation by BE&R

Observations	Applicant Response
• Status of BE studies for already registered product of contract acceptor. • Evidence of installation of LC-MS for performance of peptide mapping along with qualification documents (IQ/OQ/PQ). • Applicant shall submit a declaration that they will adopt the same source of drug substance, drug product formulation, specifications and container closure. • Applicant shall submit a declaration, in case of any post-registration variation by the contract manufacturer, same shall be immediately applied by the applicant/ registration holder f or requisite approval by Registration Board.	Regarding the status of BE studies and installation of LC-MS for peptide mapping along with qualification documents, we would like to clarify that we are the Contract Giver for Semaglutide Tablet on basis of Approved Product by Drug Registration Board, and the question should be directed to the registration holder, M/s Weather Folds Pharmaceuticals, as we act solely as the Contract Giver. We reaffirm our commitment to following the same source of drug substance, drug product formulation, specifications, and container closure system as M/s Weather Folds Pharmaceuticals. Additionally, we would like to highlight that the Contract Application of M/s Jupiter Pharmaceuticals has already been approved of the same product from M/s Weather Folds Pharmaceuticals, and the registration letter has been issued.

Case#07

Name, address of Applicant / Importer	M/s Welwrd Pharmaceuticals Company Address: Plot No. 3, Block A, Phase I-II, Industrial Estate, Hattar
Status of the applicant	Contract Giver
Name, address of manufacturer(s)	M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK
GMP of manufacturer & Evidence of Section	DML No. 000644 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan Evidence of section biological tablet products (biological) section dated 25th October, 2023 GMP: Last GMP conducted on 12-10-2022 valid up to 1-10-2024
Status of application	Generic Drug Product (GDP)
Intended use of pharmaceutical product	Domestic and Export sales
Dy. No. and Date of submission	Tracking ID: 598-PLU-M319 Application Number: 59875 Date of Receiving: 2024-10-29

Details of fee submitted	Challan Number: 865077738 Division: Biological Evaluation & Registration Paid Fee: Rs 93,000/- Paid Date: 2024-10-29
The proposed proprietary name / brand name	Sempik tablet 3mg
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Semaglutide...3mg
Pharmaceutical form of applied drug	Tablet
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	As per Innovator's Specifications
Proposed Pack size	As per SRO
Proposed unit price	As per SRO
Shelf Life	2 Years
Storage Condition	Store Below 25°C
The status in reference regulatory authorities	Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark
For generic drugs (me-too status)	Rybelsus by Novo Nordisk
Name, address of drug substance manufacturer	M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One Road, Qingyuan City, Guangdong Province, China.(rDNA origin)
Data Already Approved on CTD	Yes
Meeting No.	340

Evaluation by BE&R

Observations	Applicant Response
- Status of BE studies for already registered product of contract acceptor. - Evidence of installation of LC-MS for performance of peptide mapping along with qualification documents (IQ/OQ/PQ). - Applicant shall submit a declaration that they will adopt the same source of drug substance, drug product formulation, specifications and container closure. - Applicant shall submit a declaration, in case of any post-registration variation by the contract manufacturer, same shall be immediately applied by the applicant/ registration holder f or requisite approval by Registration Board.	Regarding the status of BE studies and installation of LC-MS for peptide mapping along with qualification documents, we would like to clarify that we are the Contract Giver for Semaglutide Tablet on basis of Approved Product by Drug Registration Board, and the question should be directed to the registration holder, M/s Weather Folds Pharmaceuticals, as we act solely as the Contract Giver. We reaffirm our commitment to following the same source of drug substance, drug product formulation, specifications, and container closure system as M/s Weather Folds Pharmaceuticals. Additionally, we would like to highlight that the Contract Application of M/s Jupiter Pharmaceuticals has already been approved of the same product from M/s Weather Folds Pharmaceuticals, and the registration letter has been issued.

Case#08

Name, address of Applicant / Importer	M/s Welwrd Pharmaceuticals Company Address: Plot No. 3, Block A, Phase I-II, Industrial Estate, Hattar
Status of the applicant	Contract Giver
Name, address of manufacturer(s)	M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK
GMP of manufacturer & Evidence of Section	DML No. 000644 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan Evidence of section biological tablet products (biological) section dated 25th October, 2023 GMP: Last GMP conducted on 12-10-2022 valid up to 1-10-2024
Status of application	Generic Drug Product (GDP)
Intended use of pharmaceutical product	Domestic and Export sales
Dy. No. and Date of submission	Tracking ID: H8M-W5V-MVA9 Application Number: 59879 Date of Receiving: 2024-10-29
Details of fee submitted	Challan Number: 973953433 Division: Biological Evaluation & Registration Paid Fee: Rs 93,000/- Paid Date: 2024-10-29

The proposed proprietary name / brand name	Sempik tablet 7mg
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Semaglutide...7mg
Pharmaceutical form of applied drug	Tablet
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	As per Innovator's Specifications
Proposed Pack size	As per SRO
Proposed unit price	As per SRO
Shelf Life	2 Years
Storage Condition	Store Below 25°C
The status in reference regulatory authorities	Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark
For generic drugs (me-too status)	Rybelsus by Novo Nordisk
Name, address of drug substance manufacturer	M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One Road, Qingyuan City, Guangdong Province, China.(rDNA origin)
Data Already Approved on CTD	Yes
Meeting No.	340

Evaluation by BE&R

Observations	Applicant Response
- Status of BE studies for already registered product of contract acceptor. - Evidence of installation of LC-MS for performance of peptide mapping along with qualification documents (IQ/OQ/PQ). - Applicant shall submit a declaration that they will adopt the same source of drug substance, drug product formulation, specifications and container closure. - Applicant shall submit a declaration, in case of any post-registration variation by the contract manufacturer, same shall be immediately applied by the applicant/ registration holder f or requisite approval by Registration Board.	Regarding the status of BE studies and installation of LC-MS for peptide mapping along with qualification documents, we would like to clarify that we are the Contract Giver for Semaglutide Tablet on basis of Approved Product by Drug Registration Board, and the question should be directed to the registration holder, M/s Weather Folds Pharmaceuticals, as we act solely as the Contract Giver. We reaffirm our commitment to following the same source of drug substance, drug product formulation, specifications, and container closure system as M/s Weather Folds Pharmaceuticals. Additionally, we would like to highlight that the Contract Application of M/s Jupiter Pharmaceuticals has already been approved of the same product from M/s Weather Folds Pharmaceuticals, and the registration letter has been issued.

Case#09

Name, address of Applicant / Importer	M/s Welwrd Pharmaceuticals Company Address: Plot No. 3, Block A, Phase I-II, Industrial Estate, Hattar
Status of the applicant	Contract Giver
Name, address of manufacturer(s)	M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK
GMP of manufacturer & Evidence of Section	DML No. 000644 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan Evidence of section biological tablet products (biological) section dated 25th October, 2023 GMP: Last GMP conducted on 12-10-2022 valid up to 1-10-2024
Status of application	Generic Drug Product (GDP)
Intended use of pharmaceutical product	Domestic and Export sales
Dy. No. and Date of submission	Tracking ID: YGW-SBQ-YZDX Application Number: 59884 Date of Receiving: 2024-10-29
Details of fee submitted	Challan Number: 21788973065 Division: Biological Evaluation & Registration Paid Fee: Rs 93,000/- Paid Date: 2024-10-29

The proposed proprietary name / brand name	Sempik tablet 14mg
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Semaglutide...14mg
Pharmaceutical form of applied drug	Tablet
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	As per Innovator's Specifications
Proposed Pack size	As per SRO
Proposed unit price	As per SRO
Shelf Life	2 Years
Storage Condition	Store Below 25°C
The status in reference regulatory authorities	Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark
For generic drugs (me-too status)	Rybelsus by Novo Nordisk
Name, address of drug substance manufacturer	M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One Road, Qingyuan City, Guangdong Province, China.(rDNA origin)
Data Already Approved on CTD	Yes
Meeting No.	340

Evaluation by BE&R

Observations	Applicant Response
• Status of BE studies for already registered product of contract acceptor. • Evidence of installation of LC-MS for performance of peptide mapping along with qualification documents (IQ/OQ/PQ). • Applicant shall submit a declaration that they will adopt the same source of drug substance, drug product formulation, specifications and container closure. • Applicant shall submit a declaration, in case of any post-registration variation by the contract manufacturer, same shall be immediately applied by the applicant/ registration holder f or requisite approval by Registration Board.	Regarding the status of BE studies and installation of LC-MS for peptide mapping along with qualification documents, we would like to clarify that we are the Contract Giver for Semaglutide Tablet on basis of Approved Product by Drug Registration Board, and the question should be directed to the registration holder, M/s Weather Folds Pharmaceuticals, as we act solely as the Contract Giver. We reaffirm our commitment to following the same source of drug substance, drug product formulation, specifications, and container closure system as M/s Weather Folds Pharmaceuticals. Additionally, we would like to highlight that the Contract Application of M/s Jupiter Pharmaceuticals has already been approved of the same product from M/s Weather Folds Pharmaceuticals, and the registration letter has been issued.

Case#10

Name, address of Applicant / Importer	M/s Welmark Pharmaceuticals Company Address: Plot No. 122, Bock B, Phase V, Industrial Estate, Hattar
Status of the applicant	Contract Giver
Name, address of manufacturer(s)	M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK
GMP of manufacturer & Evidence of Section	DML No. 000644 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan Evidence of section biological tablet products (biological) section dated 25th October, 2023 GMP: Last GMP conducted on 12-10-2022 valid up to 1-10-2024
Status of application	Generic Drug Product (GDP)
Intended use of pharmaceutical product	Domestic and Export sales
Dy. No. and Date of submission	Tracking ID: 16X-MRX-2PEA Application Number: 60079 Date of Receiving: 2025-02-17

Details of fee submitted	Challan Number: 47863415 Division: Biological Evaluation & Registration Paid Fee: Rs 93,000/- Paid Date: 2024-10-30
The proposed proprietary name / brand name	Semma tablet 3mg
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Semaglutide...3mg
Pharmaceutical form of applied drug	Tablet
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	As per Innovator's Specifications
Proposed Pack size	As per SRO
Proposed unit price	As per SRO
Shelf Life	2 Years
Storage Condition	Store Below 25°C
The status in reference regulatory authorities	Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark
For generic drugs (me-too status)	Rybelsus by Novo Nordisk
Name, address of drug substance manufacturer	M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One Road, Qingyuan City, Guangdong Province, China.(rDNA origin)
Data Already Approved on CTD	Yes
Meeting No.	340

Evaluation by BE&R

Observations	Applicant Response
• Status of BE studies for already registered product of contract acceptor. • Evidence of installation of LC-MS for performance of peptide mapping along with qualification documents (IQ/OQ/PQ). • Applicant shall submit a declaration that they will adopt the same source of drug substance, drug product formulation, specifications and container closure. • Applicant shall submit a declaration, in case of any post-registration variation by the contract manufacturer, same shall be immediately applied by the applicant/ registration holder f or requisite approval by Registration Board.	Regarding the status of BE studies and installation of LC-MS for peptide mapping along with qualification documents, we would like to clarify that we are the Contract Giver for Semaglutide Tablet on basis of Approved Product by Drug Registration Board, and the question should be directed to the registration holder, M/s Weather Folds Pharmaceuticals, as we act solely as the Contract Giver. We reaffirm our commitment to following the same source of drug substance, drug product formulation, specifications, and container closure system as M/s Weather Folds Pharmaceuticals. Additionally, we would like to highlight that the Contract Application of M/s Jupiter Pharmaceuticals has already been approved of the same product from M/s Weather Folds Pharmaceuticals, and the registration letter has been issued.

Case#11

Name, address of Applicant / Importer	M/s Welmark Pharmaceuticals Company Address: Plot No. 122, Bock B, Phase V, Industrial Estate, Hattar
Status of the applicant	Contract Giver
Name, address of manufacturer(s)	M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK
GMP of manufacturer & Evidence of Section	DML No. 000644 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan Evidence of section biological tablet products (biological) section dated 25th October, 2023 GMP: Last GMP conducted on 12-10-2022 valid up to 1-10-2024
Status of application	Generic Drug Product (GDP)
Intended use of pharmaceutical product	Domestic and Export sales
Dy. No. and Date of submission	Tracking ID: QU1-7G8-XS2E Application Number: 60081 Date of Receiving: 2025-02-17
Details of fee submitted	Challan Number: 0800435411 Division: Biological Evaluation & Registration Paid Fee: Rs 93,000/- Paid Date: 2024-10-30

The proposed proprietary name / brand name	Semma tablet 7mg
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Semaglutide...7mg
Pharmaceutical form of applied drug	Tablet
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	As per Innovator's Specifications
Proposed Pack size	As per SRO
Proposed unit price	As per SRO
Shelf Life	2 Years
Storage Condition	Store Below 25°C
The status in reference regulatory authorities	Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark
For generic drugs (me-too status)	Rybelsus by Novo Nordisk
Name, address of drug substance manufacturer	M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One Road, Qingyuan City, Guangdong Province, China.(rDNA origin)
Data Already Approved on CTD	Yes
Meeting No.	340

Evaluation by BE&R

Observations	Applicant Response
• Status of BE studies for already registered product of contract acceptor. • Evidence of installation of LC-MS for performance of peptide mapping along with qualification documents (IQ/OQ/PQ). • Applicant shall submit a declaration that they will adopt the same source of drug substance, drug product formulation, specifications and container closure. • Applicant shall submit a declaration, in case of any post-registration variation by the contract manufacturer, same shall be immediately applied by the applicant/ registration holder f or requisite approval by Registration Board.	Regarding the status of BE studies and installation of LC-MS for peptide mapping along with qualification documents, we would like to clarify that we are the Contract Giver for Semaglutide Tablet on basis of Approved Product by Drug Registration Board, and the question should be directed to the registration holder, M/s Weather Folds Pharmaceuticals, as we act solely as the Contract Giver. We reaffirm our commitment to following the same source of drug substance, drug product formulation, specifications, and container closure system as M/s Weather Folds Pharmaceuticals. Additionally, we would like to highlight that the Contract Application of M/s Jupiter Pharmaceuticals has already been approved of the same product from M/s Weather Folds Pharmaceuticals, and the registration letter has been issued.

Case#12

Name, address of Applicant / Importer	M/s Welmark Pharmaceuticals Company Address: Plot No. 122, Bock B, Phase V, Industrial Estate, Hattar
Status of the applicant	Contract Giver
Name, address of manufacturer(s)	M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK
GMP of manufacturer & Evidence of Section	DML No. 000644 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan Evidence of section biological tablet products (biological) section dated 25th October, 2023 GMP: Last GMP conducted on 12-10-2022 valid up to 1-10-2024
Status of application	Generic Drug Product (GDP)
Intended use of pharmaceutical product	Domestic and Export sales
Dy. No. and Date of submission	Tracking ID: 66E-46V-3SJ7 Application Number: 60083 Date of Receiving: 2025-02-17
Details of fee submitted	Challan Number: 603792092 Division: Biological Evaluation & Registration Paid Fee: Rs 93,000/- Paid Date: 2024-10-30

The proposed proprietary name / brand name	Semma tablet 14mg
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Semaglutide...14mg
Pharmaceutical form of applied drug	Tablet
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	As per Innovator's Specifications
Proposed Pack size	As per SRO
Proposed unit price	As per SRO
Shelf Life	2 Years
Storage Condition	Store Below 25°C
The status in reference regulatory authorities	Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark
For generic drugs (me-too status)	Rybelsus by Novo Nordisk
Name, address of drug substance manufacturer	M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One Road, Qingyuan City, Guangdong Province, China.(rDNA origin)
Data Already Approved on CTD	Yes
Meeting No.	340

Evaluation by BE&R

Observations	Applicant Response
• Status of BE studies for already registered product of contract acceptor. • Evidence of installation of LC-MS for performance of peptide mapping along with qualification documents (IQ/OQ/PQ). • Applicant shall submit a declaration that they will adopt the same source of drug substance, drug product formulation, specifications and container closure. • Applicant shall submit a declaration, in case of any post-registration variation by the contract manufacturer, same shall be immediately applied by the applicant/ registration holder f or requisite approval by Registration Board.	Regarding the status of BE studies and installation of LC-MS for peptide mapping along with qualification documents, we would like to clarify that we are the Contract Giver for Semaglutide Tablet on basis of Approved Product by Drug Registration Board, and the question should be directed to the registration holder, M/s Weather Folds Pharmaceuticals, as we act solely as the Contract Giver. We reaffirm our commitment to following the same source of drug substance, drug product formulation, specifications, and container closure system as M/s Weather Folds Pharmaceuticals. Additionally, we would like to highlight that the Contract Application of M/s Jupiter Pharmaceuticals has already been approved of the same product from M/s Weather Folds Pharmaceuticals, and the registration letter has been issued.

Case#13

Name, address of Applicant / Importer	M/s Wallace Pharma Evolutions Company Address: Kala wala Stop 20-km, Lahore Jaranwala Road, Lahore.
Status of the applicant	Contract Giver
Name, address of manufacturer(s)	M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK
GMP of manufacturer & Evidence of Section	DML No. 000644 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan Evidence of section biological tablet products (biological) section dated 25th October, 2023 GMP: Last GMP conducted on 12-10-2022 valid up to 1-10-2024
Status of application	Generic Drug Product (GDP)
Intended use of pharmaceutical product	Domestic and Export sales
Dy. No. and Date of submission	Tracking ID: YGW-SBQ-YZDX Application Number: 69287 Date of Receiving: 2024-12-11

Details of fee submitted	Challan Number: 58360616569 Division: Biological Evaluation & Registration Paid Fee: Rs 93,000/- Paid Date: 2024-11-20
The proposed proprietary name / brand name	Semwal tablet 3mg
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Semaglutide...3mg
Pharmaceutical form of applied drug	Tablet
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	As per Innovator's Specifications
Proposed Pack size	As per SRO
Proposed unit price	As per SRO
Shelf Life	2 Years
Storage Condition	Store Below 25°C
The status in reference regulatory authorities	Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark
For generic drugs (me-too status)	Rybelsus by Novo Nordisk
Name, address of drug substance manufacturer	M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One Road, Qingyuan City, Guangdong Province, China.(rDNA origin)
Data Already Approved on CTD	Yes
Meeting No.	340

Evaluation by BE&R

Observations	Applicant Response
• Status of BE studies for already registered product of contract acceptor. • Evidence of installation of LC-MS for performance of peptide mapping along with qualification documents (IQ/OQ/PQ). • Applicant shall submit a declaration that they will adopt the same source of drug substance, drug product formulation, specifications and container closure. • Applicant shall submit a declaration, in case of any post-registration variation by the contract manufacturer, same shall be immediately applied by the applicant/ registration holder f or requisite approval by Registration Board.	Regarding the status of BE studies and installation of LC-MS for peptide mapping along with qualification documents, we would like to clarify that we are the Contract Giver for Semaglutide Tablet on basis of Approved Product by Drug Registration Board, and the question should be directed to the registration holder, M/s Weather Folds Pharmaceuticals, as we act solely as the Contract Giver. We reaffirm our commitment to following the same source of drug substance, drug product formulation, specifications, and container closure system as M/s Weather Folds Pharmaceuticals. Additionally, we would like to highlight that the Contract Application of M/s Jupiter Pharmaceuticals has already been approved of the same product from M/s Weather Folds Pharmaceuticals, and the registration letter has been issued.

Case#14

Name, address of Applicant / Importer	M/s Wallace Pharma Evolutions Company Address: Kala wala Stop 20-km, Lahore Jaranwala Road, Lahore.
Status of the applicant	Contract Giver
Name, address of manufacturer(s)	M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK
GMP of manufacturer & Evidence of Section	DML No. 000644 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan Evidence of section biological tablet products (biological) section dated 25th October, 2023 GMP: Last GMP conducted on 12-10-2022 valid up to 1-10-2024
Status of application	Generic Drug Product (GDP)
Intended use of pharmaceutical product	Domestic and Export sales
Dy. No. and Date of submission	Tracking ID: 2HA-3ZY-X3XJ Application Number: 69288 Date of Receiving: 2024-12-11
Details of fee submitted	Challan Number: 18572418 Division: Biological Evaluation & Registration Paid Fee: Rs 93,000/- Paid Date: 2024-11-20

The proposed proprietary name / brand name	Semwal tablet 7mg
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Semaglutide...7mg
Pharmaceutical form of applied drug	Tablet
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	As per Innovator's Specifications
Proposed Pack size	As per SRO
Proposed unit price	As per SRO
Shelf Life	2 Years
Storage Condition	Store Below 25°C
The status in reference regulatory authorities	Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark
For generic drugs (me-too status)	Rybelsus by Novo Nordisk
Name, address of drug substance manufacturer	M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One Road, Qingyuan City, Guangdong Province, China.(rDNA origin)
Data Already Approved on CTD	Yes
Meeting No.	340

Evaluation by BE&R

Observations	Applicant Response
• Status of BE studies for already registered product of contract acceptor. • Evidence of installation of LC-MS for performance of peptide mapping along with qualification documents (IQ/OQ/PQ). • Applicant shall submit a declaration that they will adopt the same source of drug substance, drug product formulation, specifications and container closure. • Applicant shall submit a declaration, in case of any post-registration variation by the contract manufacturer, same shall be immediately applied by the applicant/ registration holder f or requisite approval by Registration Board.	Regarding the status of BE studies and installation of LC-MS for peptide mapping along with qualification documents, we would like to clarify that we are the Contract Giver for Semaglutide Tablet on basis of Approved Product by Drug Registration Board, and the question should be directed to the registration holder, M/s Weather Folds Pharmaceuticals, as we act solely as the Contract Giver. We reaffirm our commitment to following the same source of drug substance, drug product formulation, specifications, and container closure system as M/s Weather Folds Pharmaceuticals. Additionally, we would like to highlight that the Contract Application of M/s Jupiter Pharmaceuticals has already been approved of the same product from M/s Weather Folds Pharmaceuticals, and the registration letter has been issued.

Case#15

Name, address of Applicant / Importer	M/s Wallace Pharma Evolutions Company Address: Kala wala Stop 20-km, Lahore Jaranwala Road, Lahore.
Status of the applicant	Contract Giver
Name, address of manufacturer(s)	M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK
GMP of manufacturer & Evidence of Section	DML No. 000644 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan Evidence of section biological tablet products (biological) section dated 25th October, 2023 GMP: Last GMP conducted on 12-10-2022 valid up to 1-10-2024
Status of application	Generic Drug Product (GDP)
Intended use of pharmaceutical product	Domestic and Export sales
Dy. No. and Date of submission	Tracking ID: RTA-17L-ZAZJ Application Number: 69289 Date of Receiving: 2024-12-11
Details of fee submitted	Challan Number: 9253108245 Division: Biological Evaluation & Registration Paid Fee: Rs 93,000/- Paid Date: 2024-11-20

The proposed proprietary name / brand name	Semwal tablet 14mg
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Semaglutide...14mg
Pharmaceutical form of applied drug	Tablet
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	As per Innovator's Specifications
Proposed Pack size	As per SRO
Proposed unit price	As per SRO
Shelf Life	2 Years
Storage Condition	Store Below 25°C
The status in reference regulatory authorities	Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark
For generic drugs (me-too status)	Rybelsus by Novo Nordisk
Name, address of drug substance manufacturer	M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One Road, Qingyuan City, Guangdong Province, China.(rDNA origin)
Data Already Approved on CTD	Yes
Meeting No.	340

Evaluation by BE&R

Observations	Applicant Response
• Status of BE studies for already registered product of contract acceptor. • Evidence of installation of LC-MS for performance of peptide mapping along with qualification documents (IQ/OQ/PQ). • Applicant shall submit a declaration that they will adopt the same source of drug substance, drug product formulation, specifications and container closure. • Applicant shall submit a declaration, in case of any post-registration variation by the contract manufacturer, same shall be immediately applied by the applicant/ registration holder f or requisite approval by Registration Board.	Regarding the status of BE studies and installation of LC-MS for peptide mapping along with qualification documents, we would like to clarify that we are the Contract Giver for Semaglutide Tablet on basis of Approved Product by Drug Registration Board, and the question should be directed to the registration holder, M/s Weather Folds Pharmaceuticals, as we act solely as the Contract Giver. We reaffirm our commitment to following the same source of drug substance, drug product formulation, specifications, and container closure system as M/s Weather Folds Pharmaceuticals. Additionally, we would like to highlight that the Contract Application of M/s Jupiter Pharmaceuticals has already been approved of the same product from M/s Weather Folds Pharmaceuticals, and the registration letter has been issued.

Case#16

Name, address of Applicant / Importer	M/s Welcome Pakistan Trading Pharma (Pvt) Ltd Company Address: Chakri Interchange, Gangawala
Status of the applicant	Contract Giver
Name, address of manufacturer(s)	M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK
GMP of manufacturer & Evidence of Section	DML No. 000644 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan Evidence of section biological tablet products (biological) section dated 25th October, 2023 GMP: Last GMP conducted on 12-10-2022 valid up to 1-10-2024
Status of application	Generic Drug Product (GDP)
Intended use of pharmaceutical product	Domestic and Export sales
Dy. No. and Date of submission	Tracking ID: 6PA-7Q7-STa1 Application Number: 61137 Date of Receiving: 2025-02-17

Details of fee submitted	Challan Number: 0283486567 Division: Biological Evaluation & Registration Paid Fee: Rs 93,000/- Paid Date: 2024-11-04
The proposed proprietary name / brand name	Semcom tablet 3mg
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Semaglutide...3mg
Pharmaceutical form of applied drug	Tablet
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	As per Innovator's Specifications
Proposed Pack size	As per SRO
Proposed unit price	As per SRO
Shelf Life	2 Years
Storage Condition	Store Below 25°C
The status in reference regulatory authorities	Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark
For generic drugs (me-too status)	Rybelsus by Novo Nordisk
Name, address of drug substance manufacturer	M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One Road, Qingyuan City, Guangdong Province, China.(rDNA origin)
Data Already Approved on CTD	Yes
Meeting No.	340

Evaluation by BE&R

Observations	Applicant Response
- Status of BE studies for already registered product of contract acceptor. - Evidence of installation of LC-MS for performance of peptide mapping along with qualification documents (IQ/OQ/PQ). - Applicant shall submit a declaration that they will adopt the same source of drug substance, drug product formulation, specifications and container closure. - Applicant shall submit a declaration, in case of any post-registration variation by the contract manufacturer, same shall be immediately applied by the applicant/ registration holder f or requisite approval by Registration Board.	Regarding the status of BE studies and installation of LC-MS for peptide mapping along with qualification documents, we would like to clarify that we are the Contract Giver for Semaglutide Tablet on basis of Approved Product by Drug Registration Board, and the question should be directed to the registration holder, M/s Weather Folds Pharmaceuticals, as we act solely as the Contract Giver. We reaffirm our commitment to following the same source of drug substance, drug product formulation, specifications, and container closure system as M/s Weather Folds Pharmaceuticals. Additionally, we would like to highlight that the Contract Application of M/s Jupiter

	Pharmaceuticals has already been approved of the same product from M/s Weather Folds Pharmaceuticals, and the registration letter has been issued.
Case#17	
Name, address of Applicant / Importer	M/s Welcome Pakistan Trading Pharma (Pvt) Ltd Company Address: -Chakri Interchange, Gangawala
Status of the applicant	Contract Giver
Name, address of manufacturer(s)	M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK
GMP of manufacturer & Evidence of Section	DML No. 000644 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan Evidence of section biological tablet products (biological) section dated 25th October, 2023 GMP: Last GMP conducted on 12-10-2022 valid up to 1-10-2024
Status of application	Generic Drug Product (GDP)
Intended use of pharmaceutical product	Domestic and Export sales
Dy. No. and Date of submission	Tracking ID: 1YQ-NGE-9VX3 Application Number: 61138 Date of Receiving: 2025-02-17
Details of fee submitted	Challan Number: 016327004 Division: Biological Evaluation & Registration Paid Fee: Rs 93,000/- Paid Date: 2024-11-04
The proposed proprietary name / brand name	Semcom tablet 7mg
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Semaglutide...7mg
Pharmaceutical form of applied drug	Tablet
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	As per Innovator's Specifications
Proposed Pack size	As per SRO
Proposed unit price	As per SRO
Shelf Life	2 Years
Storage Condition	Store Below 25°C
The status in reference regulatory authorities	Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark
For generic drugs (me-too status)	Rybelsus by Novo Nordisk
Name, address of drug substance manufacturer	M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One Road, Qingyuan City, Guangdong Province, China.(rDNA origin)

Data Already Approved on CTD	Yes
Meeting No.	340
Evaluation by BE&R	
Observations	Applicant Response
- Status of BE studies for already registered product of contract acceptor. - Evidence of installation of LC-MS for performance of peptide mapping along with qualification documents (IQ/OQ/PQ). - Applicant shall submit a declaration that they will adopt the same source of drug substance, drug product formulation, specifications and container closure. - Applicant shall submit a declaration, in case of any post-registration variation by the contract manufacturer, same shall be immediately applied by the applicant/ registration holder f or requisite approval by Registration Board.	Regarding the status of BE studies and installation of LC-MS for peptide mapping along with qualification documents, we would like to clarify that we are the Contract Giver for Semaglutide Tablet on basis of Approved Product by Drug Registration Board, and the question should be directed to the registration holder, M/s Weather Folds Pharmaceuticals, as we act solely as the Contract Giver. We reaffirm our commitment to following the same source of drug substance, drug product formulation, specifications, and container closure system as M/s Weather Folds Pharmaceuticals. Additionally, we would like to highlight that the Contract Application of M/s Jupiter Pharmaceuticals has already been approved of the same product from M/s Weather Folds Pharmaceuticals, and the registration letter has been issued.
Case#18	
Name, address of Applicant / Importer	M/s Welcome Pakistan Trading Pharma (Pvt) Ltd Company Address: Chakri Interchange, Gangawala
Status of the applicant	Contract Giver
Name, address of manufacturer(s)	M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK
GMP of manufacturer & Evidence of Section	DML No. 000644 Address: Plot No 69/2, phase 2, industrial estate Hattar, Pakistan Evidence of section biological tablet products (biological) section dated 25th October, 2023 GMP: Last GMP conducted on 12-10-2022 valid up to 1-10-2024
Status of application	Generic Drug Product (GDP)
Intended use of pharmaceutical product	Domestic and Export sales
Dy. No. and Date of submission	Tracking ID: 4MX-LL5-3EDM Application Number: 61139 Date of Receiving: 2025-02-17
Details of fee submitted	Challan Number: 96881946099 Division: Biological Evaluation & Registration

	Paid Fee: Rs 93,000/- Paid Date: 2024-11-04
The proposed proprietary name / brand name	Semcom tablet 14mg
Strength / concentration of drug of Active Pharmaceutical ingredient (API) per unit	Each tablet contains: Semaglutide...14mg
Pharmaceutical form of applied drug	Tablet
Pharmacotherapeutic Group of (API)	Glucagon-like peptide-1 (GLP-1) analogues ATC Code: A10BJ06
Reference to Finished product specifications	As per Innovator's Specifications
Proposed Pack size	As per SRO
Proposed unit price	As per SRO
Shelf Life	2 Years
Storage Condition	Store Below 25°C
The status in reference regulatory authorities	Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark
For generic drugs (me-too status)	Rybelsus by Novo Nordisk
Name, address of drug substance manufacturer	M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One Road, Qingyuan City, Guangdong Province, China.(rDNA origin)
Data Already Approved on CTD	Yes
Meeting No.	340

Evaluation by BE&R

Observations	Applicant Response
• Status of BE studies for already registered product of contract acceptor. • Evidence of installation of LC-MS for performance of peptide mapping along with qualification documents (IQ/OQ/PQ). • Applicant shall submit a declaration that they will adopt the same source of drug substance, drug product formulation, specifications and container closure. • Applicant shall submit a declaration, in case of any post-registration variation by the contract manufacturer, same shall be immediately applied by the applicant/ registration holder for requisite approval by Registration Board.	Regarding the status of BE studies and installation of LC-MS for peptide mapping along with qualification documents, we would like to clarify that we are the Contract Giver for Semaglutide Tablet on basis of Approved Product by Drug Registration Board, and the question should be directed to the registration holder, M/s Weather Folds Pharmaceuticals, as we act solely as the Contract Giver. We reaffirm our commitment to following the same source of drug substance, drug product formulation, specifications, and container closure system as M/s Weather Folds Pharmaceuticals. Additionally, we would like to highlight that the Contract Application of M/s Jupiter Pharmaceuticals has already been approved of the same product from M/s Weather Folds Pharmaceuticals, and the registration letter has been issued.

(Case#1-18 were considered in 345th meeting of Registration Board. The proceedings of the Board and the decision is as under)

Proceeding of the Board:

During the meeting the Registration Board was apprised about the following facts and figures pertinent to the drug product manufacturer:

- i. The contract acceptor “M/s Weather Folds Pharmaceuticals” has requested for grant of additional source “M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China” in addition to already approved source i.e. “M/s Livzon New North River Pharmaceutical Co., Ltd. Renmin One Road, Qingyuan City, Guangdong Province, China (rDNA origin)”.
- ii. Moreover, the semaglutide tablet of “M/s Weather Folds Pharmaceuticals” was approved in 340th Meeting with following conditions:
 - ✓ The manufacturer shall perform identification test for peptide mapping for finished product from any of Government Drug Testing Laboratory for every batch and during the aforesaid period the manufacturer shall install LC/MS in their own facility and inform Registration Board.
 - ✓ The manufacturer shall perform Bioequivalence Studies within six months.
- iii. In respect of BE status , the product manufacturer has informed as under:
 - ✓ DRAP Vide letter No. F. No. 2412024-DD(RRR) Dated 08th July 2024 Decided as under: In the Light of S.R.O 713(L)/2015 and Requirements for WHO Listed authorities 1.E, In Particular The Maturity Level-T (ML’I) “The Procedures of Regulatory Approval Related to Registration of Generic Drugs, shall be made in line with the Guidelines of International, Regulatory Agencies, for which implementation of Bio-Equivalence study should be initiated. The board decided the Systematic Implementation of Bo-Equivalence Study in accordance with the WHO and International Guidelines

Therefore, keeping in view the complexity and sensitivity of biological product the Board opined to proceed with change of source instead of additional source subject to provision of requisite documents as per deficiencies highlighted by the BE&R Division.

Decision of 345th Meeting:

The Registration Board deferred the case subject to the fulfillment of following conditions by product manufacturer:

- i. Approval of change of source from M/s Livzon New North River Pharmaceutical Co., Ltd to “M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China”.
- ii. Performance and submission of bioequivalence studies with new source.
- iii. Installation of LC/MS in their own facility along with submission of qualification documents (IQ, OQ, PQ).

Remarks of Evaluator:

The Registration Board in its 347th meeting has already approved change of source from existing source “M/s Livzon New North River Pharmaceutical Co., Ltd., China” to “M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China” of semaglutide API for their registered product Semma 3mg Tablet (Reg.No.120558) and API source change application 7mg and 14 mg is also placed in instant meeting for consideration.

Decision of 349th meeting of Registration Board:

The Registration Board approved applications for contract manufacturing (Case#1-18) from M/s Weather Folds Pharmaceuticals Plot No. 69/2, Phase-II, Industrial Estate, Hattar, KPK with new approved source (M/s Fuxin Long Rui Pharmaceutical Co., Ltd., China) with following conditions:

- The manufacturer shall perform identification test for peptide mapping for finished product from any of Government Drug Testing Laboratory for every batch and during the aforesaid period the manufacturer shall install LC/MS in their own facility and inform Registration Board.
- The manufacturer shall perform Bioequivalence Studies within six months.
- The firm will perform the post marketing surveillance studies.
- The firm will make arrangements for the ADR reporting as per Rules.

- The firm will submit the quarterly safety Reports to the Registration Board.

Letter will be issued after submission of following documents;

- A declaration/undertaking that they will adopt the same source of drug substance, drug product formulation, specifications and container closure as approved for contract acceptor.
- Pre-registration variation fee and revised Module-1 with new approved source of semaglutide.

Meeting ended with a vote of thanks to and from the Chair.

-----End of Document-----